<SEC-DOCUMENT>0001477932-23-001497.txt : 20230315
<SEC-HEADER>0001477932-23-001497.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315161807
ACCESSION NUMBER:		0001477932-23-001497
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VOLITIONRX LTD
		CENTRAL INDEX KEY:			0000093314
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				911949078
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36833
		FILM NUMBER:		23735424

	BUSINESS ADDRESS:	
		STREET 1:		1489 WEST WARM SPRINGS ROAD
		STREET 2:		SUITE 110
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89014
		BUSINESS PHONE:		1 (646) 650-1351

	MAIL ADDRESS:	
		STREET 1:		1489 WEST WARM SPRINGS ROAD
		STREET 2:		SUITE 110
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STANDARD CAPITAL CORP
		DATE OF NAME CHANGE:	19990812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vnrx_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:vnrx="http://vnrx.com/20221231"><head><title>vnrx_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-01-01to2022-12-31">0000093314</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2022-01-01to2022-12-31">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2022-01-01to2022-12-31">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2022-01-01to2022-12-31">2022</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">100000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" unitRef="Shares" decimals="0">57873379</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">53772261</ix:nonFraction><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2021-01-01to2021-12-31" unitRef="USD" decimals="0">155803</ix:nonFraction><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-01to2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:SharesWithheldForTax" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfWarrantsOutstandingBeginningBalance" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" unitRef="Shares" decimals="0">485000</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfWarrantsExercised" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfWarrantsExercised" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfWarrantsExpired" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfWarrantsExpired" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:WeightedAverageExercisePriceOutstandingBalanceOne" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" unitRef="USDPShares" decimals="INF">3.88</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfOptionsOutstandingBeginningBalance" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" unitRef="Shares" decimals="0">5027518</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="vnrx:WeightedAverageExercisePriceOutstandingBalance" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" unitRef="USDPShares" decimals="INF">3.87</ix:nonFraction><ix:nonFraction name="vnrx:NumberOfRsusOutstandingBeginingBalance" contextRef="AsOf2021-12-31_vnrx_StockOptionsMember" unitRef="Shares" decimals="0">810750</ix:nonFraction><ix:nonFraction name="vnrx:SharePriceBeginningBalance" contextRef="AsOf2021-12-31_vnrx_StockOptionsMember" unitRef="USDPShares" decimals="INF">3.33</ix:nonFraction><ix:nonFraction name="vnrx:StockCompensationExpenses" contextRef="From2019-01-01to2019-09-30_vnrx_AprilThirteenTwoThousandTwentyMember_vnrx_RestrictedStockUnitsMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonNumeric name="vnrx:MaturityTerm" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">P10Y</ix:nonNumeric><ix:nonNumeric name="vnrx:MaturityTerm" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">P10Y</ix:nonNumeric><ix:nonNumeric name="vnrx:LoanAgreementTerm" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">P3Y5M30D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='vnrx-20221231.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2022-01-01to2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-12_vnrx_RsuVestingEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:RsuVestingEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-01-12_vnrx_RsuVestingEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:RsuVestingEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-02-17_vnrx_CapitalRaiseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CapitalRaiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CapitalRaiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:UniversityOfTaiwanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ClinicalStudyResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:UniversityOfTaiwanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ClinicalStudyResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">vnrx:CollaborativeArrangementCoPromotionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnivercityOfTexasMDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustTenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNinteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">vnrx:CollaborativeArrangementCoPromotionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnivercityOfTexasMDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustTenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnSeptemberSixteenTwohousandtwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:BioinformaticAnalyticsOfCellFreeDNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnSeptemberSixteenTwohousandtwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:BioinformaticAnalyticsOfCellFreeDNAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FiveFebruaryTwoThounsendTwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vnrx:FirstInsuranceFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FiveFebruaryTwoThounsendTwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vnrx:FirstInsuranceFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:NamurInnovationAndGrowthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:NamurInnovationAndGrowthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SixteenAugustTwoThounsendTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SixteenAugustTwoThounsendTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:EighteenNovemberTwoThounsendTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:EighteenNovemberTwoThounsendTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OperatingLeaseRightofUseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vnrx:VestIn2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vnrx:VestIn2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ManagingDirectorsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_ManagingDirectorsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ManagingDirectorsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:BNPParibasLeasingSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:BNPParibasLeasingSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-11-01to2020-11-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_GrantsRepayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:GrantsRepayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OperatingLeaseRightofUseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-27_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-06-15_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-06-15_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-06-13_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2016-08-05_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2016-08-05_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-09-30_vnrx_AprilThirteenTwoThousandTwentyMember_vnrx_RestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-11-01to2022-11-29_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-05-05to2021-05-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilFourTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-05-01to2019-05-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilFourTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-05-05to2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-08-01to2022-08-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-11-01to2022-11-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-04-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-08-01to2021-08-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-04-01to2022-04-04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionFiveteenTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionFourteenTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThirteenTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_vnrx_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:TotalStockOptionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_TotalStockOptionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:TotalStockOptionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OptionFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OptionFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OptionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_OptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2021-12-31_vnrx_OptionFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_OptionFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantsFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_WarrantsFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-02-10_vnrx_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-07-29_vnrx_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilTwentyOneTwentyTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryTwentyTwentyThusandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilTwentyOneTwentyTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryTwentyTwentyThusandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:DecemberFifteenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:NovemberOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OctoberFourTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SeptemberSevenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustThreeTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MayOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MarchTwentyFiveTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustThreeTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:NovemberOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OctoberFourTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SeptemberSevenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:DecemberFifteenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MayOneTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MarchTwentyFiveTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightFebruaryNineTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightFebruaryNineTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryTwoTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryTwoTwentyThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_ForeignMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:ForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_UnitedStateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnitedStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">vnrx:NetDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">vnrx:NetDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MaximumMember_vnrx_PatentsAndIntellectualPropertyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:PatentsAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MinimumMember_vnrx_PatentsAndIntellectualPropertyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:PatentsAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_vnrx_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_vnrx_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_DilutiveWarrantsAndOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vnrx:DilutiveWarrantsAndOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_DilutiveWarrantsAndOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vnrx:DilutiveWarrantsAndOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_UKDepositProtectionSchemeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:UKDepositProtectionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_UKDepositProtectionSchemeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:UKDepositProtectionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_SingaporeDepositInsuranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:SingaporeDepositInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_SingaporeDepositInsuranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:SingaporeDepositInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_vnrx_BelgianDepositGuaranteeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:BelgianDepositGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_vnrx_BelgianDepositGuaranteeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:BelgianDepositGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><img src="vnrx_10kimg1.jpg" alt="vnrx_10kimg1.jpg" />UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fo</strong><strong>r the Fiscal Year Ended <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT </strong><strong>O</strong><strong>F 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fo</strong><strong>r</strong><strong> </strong><strong>t</strong><strong>h</strong><strong>e</strong><strong> </strong><strong>t</strong><strong>rans</strong><strong>iti</strong><strong>o</strong><strong>n</strong><strong> </strong><strong>p</strong><strong>er</strong><strong>i</strong><strong>o</strong><strong>d</strong><strong> </strong><strong>from</strong><strong> _________ </strong><strong>t</strong><strong>o</strong><strong> _________</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Comm</strong><strong>ission File Number: <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-36833</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">VOLITIONRX LIMITED</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">91-1949078</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(State or other jurisdiction of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">incorporation or organization) </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">1489 West Warm Springs Road,</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite 110</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Henderson</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">89014</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">+1 (<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">646</ix:nonNumeric>) <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">650&#8211;1351</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Securities registered pursuant to Section 12(b) of the Act:</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Title of Each Class:</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Trading Symbol(s):</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name of Each Exchange on Which Registered:</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">VNRX</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE American, LLC</ix:nonNumeric></strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Securities registered pursuant to Section 12(g) of the Act: None</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;">Large accelerated filer</td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of June 30, 2022, the last trading day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting common stock held by non-affiliates of the registrant was $<ix:nonFraction contextRef="AsOf2022-06-30" name="dei:EntityPublicFloat" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,353,231</ix:nonFraction> (based upon the $2.05 per share closing price for the registrant&#8217;s common stock as reported by the NYSE American on such date). This calculation does not reflect a determination that persons deemed to be affiliates for this purpose are affiliates for any other purpose.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 8, 2023, there were <ix:nonFraction contextRef="AsOf2023-03-08" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,096,766</ix:nonFraction> shares of the registrant&#8217;s $0.001 par value common stock issued and outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Documents incorporated by reference: </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Portions of the registrant&#8217;s definitive Proxy Statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission on or before May 1, 2023 are incorporated by reference into Part III, Items 10-14 of this Annual Report on Form 10-K.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline"><span id="TOC" class="atag" style="display:inline">Table of Contents</span></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">Page</span></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#P1">PART I</a></strong></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#caution">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I1">Item 1</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I1">BUSINESS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I1A">Item 1A</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I1A">RISK FACTORS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">11</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I1B">Item 1B</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I1B">UNRESOLVED STAFF COMMENTS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I2">Item 2</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I2">PROPERTIES</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I3">Item 3</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I3">LEGAL PROCEEDINGS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I4">Item 4</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I4">MINE SAFETY DISCLOSURES</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#P2">PART II</a></strong></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I5">Item 5</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I5">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I6">Item 6</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I6">RESERVED</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I7">Item 7</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="#I7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ANDRESULTS OF OPERATIONS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">29</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I7A">Item 7A</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I7A">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I8">Item 8</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I8">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">F-35</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I9">Item 9</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I9">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">76</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I9A">Item 9A</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I9A">CONTROLS AND PROCEDURES</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">76</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I9B">Item 9B</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I9B">OTHER INFORMATION</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">77</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I9C">Item 9C</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I9C">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">77</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#P3">PART III</a></strong></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I10">Item 10</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I10">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">78</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I11">Item 11</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I11">EXECUTIVE COMPENSATION</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">78</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I12">Item 12</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I12">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">78</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I13">Item 13</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I13">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">78</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I14">Item 14</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I14">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">78</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#P4">PART IV</a></strong></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I15">Item 15</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I15">EXHIBITS, FINANCIAL STATEMENT SCHEDULES </a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">79</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><a href="#I16">Item 16</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#I16">FORM 10-K SUMMARY&#160;</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">82</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><a href="#SIG">SIGNATURES</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">83</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="caution">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>This Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (this &#8220;Report&#8221;), and the information and documents incorporated by reference in this Report, contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which statements are subject to considerable risks and uncertainties.&#160; These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995.&#160; </em><em>All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements</em><em>.&#160; We have attempted to identify forward-looking statements by using words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate(s),&#8221; &#8220;expect,&#8221; &#8220;forecast(s),&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan(s),&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;will,&#8221;&#160; and other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).&#160; In particular, forward-looking statements contained in this Report, and the information and documents incorporated by reference within this Report, relate to, among other things, our predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy, including regulatory approvals, commercialization and market acceptance; statements concerning industry trends and industry size; statements regarding anticipated demand for our products and market opportunity, or the products of our competitors; statements relating to manufacturing forecasts, and the potential impact of our relationships with contract manufacturers, original equipment manufacturers and distributors on our business; assumptions regarding the future cost and potential benefits of our research and development efforts; the effect of critical accounting policies; forecasts of our liquidity position or available cash resource and financing plans; and statements relating to the assumptions underlying any of the foregoing.&#160; We caution you that the foregoing list may not include all of the forward-looking statements made in this Report and the information and documents incorporated by reference within this Report.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>We have based our forward-looking statements on our current assumptions, expectations and projections about trends affecting our business and industry and other future events.&#160; Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy.&#160; Forward-looking statements are subject to substantial known and unknown risks and uncertainties that could cause our future business, financial condition, results of operations or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report.&#160; </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Some significant factors that may impact our estimates and forward-looking statements include, but are not limited to:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our inability to generate any significant revenue or achieve profitability; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our need to raise additional capital in the future; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our expectations to expand our product development, research and sales and marketing capabilities could give rise to difficulties in managing our growth; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our limited experience with direct sales and marketing; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>The material weaknesses in our internal control over financial reporting that we have identified; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>The possibility that we may not be able to continue to operate, as indicated by the &#8220;going concern&#8221; opinion from our auditors; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our ability to successfully develop, manufacture, market, and sell our future products; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future products; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>The acceptance by the marketplace of our future products; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>The highly competitive and rapidly changing nature of the diagnostics market; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our reliance on third parties to manufacture and supply our intended products, and such manufacturers&#8217; dependence on third party suppliers; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Our dependence on third party distributors; </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Protection of our patents, intellectual property and trade secrets; and </em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><em>Business disruptions and economic and other uncertainties surrounding the COVID-19 pandemic.</em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>For additional information, refer to the section entitled &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Report, and the other documents that we have filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)</em><em>.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>You should read this Report in its entirety, including the documents that we file as exhibits to this Report and the documents we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect.&#160; The forward-looking statements we make speak only as of the date on which they are made.&#160; We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.&#160; If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Use of Terms</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Except as otherwise indicated by the context, references in this Report to &#8220;Company,&#8221; &#8220;VolitionRx,&#8221; &#8220;Volition,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; are references to VolitionRx Limited and its wholly owned subsidiaries, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition Germany GmbH, Volition America, Inc, and Volition Global Services SRL, as well as majority owned subsidiary Volition Veterinary Diagnostics Development LLC.&#160; Additionally, unless otherwise specified, all references to &#8220;$&#8221; refer to the legal currency of the United States of America.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nucleosomics<sup style="vertical-align:super">TM</sup> and Nu.Q<sup style="vertical-align:super">&#174;</sup> and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries.&#160;&#160;All other trademarks, service marks and trade names referred to in this Report are the property of their respective owners.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="P1">PART I</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1">&#160;ITEM 1. BUSINESS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Overview </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Volition is a multi-national epigenetics company powered by Nu.Q<strong><sup style="vertical-align:super">&#174;</sup></strong>, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics&#8482;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have five key&#160;pillars of focus, all of which use the same proprietary Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;platform to commercialize in different areas:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet</strong> <strong>-</strong> cost-effective, easy-to-use cancer screening blood test for dogs and other animals.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs - </strong>monitoring the immune system to save lives.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer - </strong>detecting cancer early to save lives.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Capture</strong> <strong>-</strong> capturing and concentrating samples for more accurate diagnosis.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Discover -</strong> a complete solution to profiling nucleosomes.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our product development and manufacturing activities are centered in Belgium, with innovation and U.S. operations in California, and additional offices in Nevada, London, and Singapore, where we focus on bringing our diagnostic and disease monitoring products to market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Volition&#8217;s </em></strong><strong><em>Solution and the Science Behind It</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics. Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That&#8217;s the world we&#8217;re trying to build by developing our innovative family of simple, easy to use, cost-effective Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;tests.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our patented Nucleosomics&#8482; technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases: as explained below, chromosomes consist of the genetic material (DNA) wrapped in a coat of proteins and other molecules. All the tests in our portfolio detect various characteristic changes in nucleosomes that occur from the earliest stages of disease, potentially enabling early detection and a better way to monitor disease progression and the patient&#8217;s response to treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Unlocking Epigenetics </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We believe epigenetics is the most exciting field in disease detection and management today. Modern genetics - the study of genes and heredity, is underpinned by the linear sequences of molecular &#8220;letters&#8221; present in the DNA double helix of each living cell, many of which encode the genes. It has had an enormous impact on the practice of medicine, revolutionizing the way doctors identify people with inherited conditions, diagnose cancer, and, increasingly, design personalized treatment plans. However, there&#8217;s more to chromosomes than just the DNA sequence; at Volition, we focus on chromosomes&#8217; second epigenetic code, which contains a wealth of additional information about the health and function of the body&#8217;s cells. You can think of the DNA sequence of each cell as the text of an instruction manual, and epigenetics as the formatting. Some parts of the manual are bolded, highlighted, or underlined, telling the cell to emphasize those sections, while others are struck out, telling the cell to ignore those genes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The cells of most bodily organs are continuously replaced by new ones. As they die, many old cells release their nucleosomes into the bloodstream. Our patented Nucleosomics&#8482; technology isolates these circulating nucleosomes from the blood for quantification and analysis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="vnrx_10kimg2.jpg" alt="vnrx_10kimg2.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Chromosome and nucleosome structure represent a major mechanism for epigenetic control. Each chromosome contains one long, single molecule of DNA that is coated by a complex array of proteins, mostly in the form of nucleosomes, giving the stretched-out, unwound DNA/protein core, or chromatin, the appearance of &#8220;beads on a string.&#8221; Unwound chromatin is accessible for reading (or transcribing) and unwound genes may be active. However, genes with coiled or supercoiled nucleosomes are inaccessible and inactive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg3.jpg" alt="vnrx_10kimg3.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Each nucleosome consists of a disc of eight histone proteins wrapped by a short length of DNA. Nucleosome structure has a dual role: first, it allows the compact storage and protection of the genetic material (or DNA), and second, it modulates the epigenetic regulation (transcription) of that DNA. This regulation is achieved through reversible chemical changes to both the DNA and protein components as well as through the binding of specific regulatory proteins to the DNA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Volition&#8217;s Epigenetic Approach </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Through our Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;(short for nucleosome quantification) family of tests in our five key pillars of focus, we aim to offer a new, convenient and cost-effective approach to the detection, diagnosis and monitoring of diverse diseases from a simple blood test.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Highlighting abnormalities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our technology seeks to detect characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and other diseases. Epigenetic changes often occur before the diseased cells themselves become abnormal enough to show up in traditional biopsies, and oftentimes before the first symptoms are felt. We aim to replace unpleasant, invasive, and often expensive screening and diagnostic tests such as colonoscopies and biopsies with Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;blood tests, helping to save lives and to reduce overall healthcare costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have five key&#160;pillars of focus: Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet, Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;NETs, Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer,&#160; Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Capture and Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Discover, all of which use the same proprietary Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;platform to commercialize in different areas.<sup style="vertical-align:super"></sup></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cancer is the most common cause of death in dogs over the age of two years in the United States. Nearly 50% of all dogs over the age of 10 will develop cancer in their lifetime. With approximately 84 million pet dogs in the United States, there are an estimated six million pet dogs diagnosed with cancer each year. As with humans, earlier detection can save lives and can also improve the quality of life of the dog and its owner. Yet, as of today, there are few single assay cancer blood tests on the veterinary market. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming, and painful for the animal. We hope to change this with the introduction of the Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet Cancer&#160; Test: a simple, cost-effective, easy to use enzyme-linked immunosorbent assay (&#8220;ELISA&#8221;) based screening blood test which may help streamline the diagnostic process for older or &#8220;at-risk&#8221; dogs. For example, findings from a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&amp;M University, peer-reviewed and published in August 2022, reflect that Volition&#8217;s Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test detected 76% of systemic cancers ( including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Data presented at the European Society of Veterinary Oncology Congress suggests that Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet may also serve as a more sensitive measurement of both minimal residual disease and remission and could be a useful monitoring test for dogs with cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are currently conducting ongoing research regarding Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Point of Care platform (in partnership with the Heska Corporation),</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Broadening the range of cancers detected,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Differential diagnosis,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Pre-analytics for the use of Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet in the feline population, and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Use of the Nu.Q<sup style="vertical-align:super">&#174;</sup> platform in NETosis in canines.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;NETs - Monitoring the immune system to save lives.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The immune system can be both friend and foe; a potent protective force that sometimes overreacts, damaging the body&#8217;s own cells and tissues in the process. We are working to develop tests that will identify people at high risk of poor outcomes/death caused by an immune system overreaction to sepsis, COVID-19 and other infections. The immune system is comprised of many different types of white blood cells with different functions. The most abundant of these white blood cells are neutrophils, which serve as a first line of defense. When neutrophils detect bacteria, viruses, injuries, or other threats, these cells produce Neutrophil Extracellular Traps (&#8220;NETs&#8221;), which are sticky webs made of long strings of nucleosomes that work to inhibit a perceived threat from spreading through the body.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg4.jpg" alt="vnrx_10kimg4.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Although NETs are an important part of the body&#8217;s response to infection, the presence of too many of them in the blood can tip the immune system&#8217;s delicate balance between reaction and overreaction. Elevated levels of NETs are a complicating factor associated with poor patient outcomes in a range of infectious and non-infectious diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sepsis&#8212;widespread tissue and organ damage triggered by an abnormal immune response to an infection&#8212;is an area of particular focus for our research on NETs. A recent global study estimated that there were approximately 49 million cases and 11 million sepsis-related deaths worldwide in 2017, accounting for approximately 20% of all deaths from the same year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Severe cases of COVID-19 can cause excessive production of NETs in the lungs, which can lead to severe lung impairment or death. Because NETs contain nucleosomes, our proprietary Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;nucleosome assays have been shown to detect NETs. Using our Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;nucleosome assays could enable the stratification of patients with a high level of NETs, allow physicians to rapidly triage these patients, and monitor their disease progression and response to treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In May 2022, our Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs product was CE marked for the detection and evaluation of NETosis on two platforms (ELISA plates and i-10), enabling clinical use in more than 27 countries across Europe.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In August 2022, we appointed Diagnostic Oncology CRO, LLC (&#8220;DXOCRO&#8221;), a contract research organization specializing in the commercialization of diagnostic biomarker technologies, to spearhead our clinical product development and regulatory programs in the United States. DXOCRO is undertaking large-scale finding studies across multiple sites using our Nu.Q&#174; platform to determine clinical utility in sepsis and cancer. We hope the study will support an application to the FDA&#8217;s Breakthrough Device program.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The first phase of the study focused on sepsis has been completed and an application to the FDA&#8217;s Breakthrough Device Program is expected to be submitted in the first half of 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Nu.Q</strong><sup style="vertical-align:super">&#174;</sup><strong>&#160;Cancer - Detecting cancer early to save lives.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are developing a simple, cost-effective blood test for cancer. Cancer is a devastating disease that touches many peoples&#8217; lives, accounting for approximately 10 million deaths worldwide each year. Early diagnosis is the best way to improve someone&#8217;s chances of surviving cancer; however, current population-wide screening tests (such as mammograms and colonoscopies) are often invasive and unpleasant. They can also be expensive, causing many people to miss routine screening. There are no population screening tests at all for some types of cancer, including aggressive forms of the disease such as ovarian or pancreatic cancers. Unfortunately, many patients are therefore diagnosed too late, when their cancer has already spread, and treatment is more difficult. We believe that Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Cancer can become a cost-effective routine blood test for multiple types of cancer, allowing doctors to check off an extra box along with other routine blood tests like cholesterol during an annual wellness visit. Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Cancer tests have further potential applications in clinical oncology beyond cancer detection. Being able to use epigenetic information from tumor cells&#8217; nucleosomes could also help physicians select the best treatment for each patient, monitor their response and the disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are currently investigating the potential use of Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Cancer tests in a range of cancers and clinical settings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Capture - Capturing and concentrating samples for more accurate diagnosis - Locating the needle in a haystack.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Human blood is a mixture of many different cell types floating in a complex soup of proteins and other molecules, including nucleosomes released by cells from all around the body. Detecting a handful of cancerous or other abnormal cells in a patient&#8217;s blood sample has historically been like finding a proverbial needle in a haystack. Volition&#8217;s Nu.Q<strong><sup style="vertical-align:super">&#174;</sup></strong>&#160;Capture program has several strands of technology which either essentially removes background noise, thereby amplifying the signal or looks to identify the signal in a novel way. This sample enrichment tool removes healthy nucleosomes, leaving an enriched sample of abnormal nucleosomes behind for further analysis. These nucleosomes contain tumor-specific DNA &#8220;typos,&#8221; epigenetic changes, and other biomarkers that when analyzed could potentially be used to diagnose a specific type of cancer or other medical condition, guide treatment selection, and monitor disease and treatment progress. Other strands of Nu.Q<strong><sup style="vertical-align:super">&#174;</sup></strong>&#160;Capture technology involve isolating various chromatin fragments including nucleosomes and transcription factors from plasma for analysis by mass spectrometry and next-generation DNA sequencing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Deploying Nu.Q<strong><sup style="vertical-align:super">&#174;</sup></strong>&#160;Capture as the first blood sample processing step could potentially:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Enhance the sensitivity of subsequent Nu.Q<sup style="vertical-align:super">&#174;</sup> immunoassays for diagnosing and monitoring different types of disease using our proprietary Nucleosomics&#8482; platform,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Aid the development of improved diagnostic DNA sequencing methods,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Serve as a quality control tool to reduce the rate of clinical test failure, saving time that is especially valuable for people whose test results are being used to inform their treatment,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Aid the discovery of new biomarkers, and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Allow the complete profiling of nucleosomes.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The use of Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Capture technology in the field of transcription factors has led to the successful isolation of tumor derived transcription factor-DNA complexes from blood samples obtained from cancer patients. As transcription factor binding to DNA is cancer and tissue specific, this technology may, in principle, provide the basis for blood tests for cancer in general as well as blood tests to identify the organ or tissue affected by cancer. Development is ongoing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Another novel method utilizing Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Capture and mass spectrometry was published in 2021 and demonstrated the detection and quantification of histone modifications present in the circulating nucleosomes in the blood of cancer patients. We believe that our work has highlighted for the first time that histone H2A1R3 citrulline is, in plasma, upregulated in colorectal cancer patients and so could be a biomarker we target for future Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;immunoassay development. Furthermore, the use of Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Capture may open up the possibility of using mass spectrometry not only for biomarker discovery as demonstrated in this publication but also as a high throughput platform for screening and/or diagnostics when used in combination with either sequencing and/or our Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;assays.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This technology sheds new light on epigenetic changes that cannot be effectively detected amid the noise left behind when using current testing methods, leading to better clinical tests and potentially improved outcomes in the future. Volition is engaged in multiple research collaborations with academic laboratories working at the cutting edge of their respective fields, to ensure we take advantage of the latest findings and turn them into new clinical tools as quickly as possible.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Discover - A complete solution to profiling nucleosomes.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Discover empowers drug developers and scientists through access to a range of state-of-the-art assays for rapid epigenetic profiling in disease, model development, preclinical testing, and clinical studies - from discovery to market ready.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg5.jpg" alt="vnrx_10kimg5.jpg" /></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg6.jpg" alt="vnrx_10kimg6.jpg" /></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg7.jpg" alt="vnrx_10kimg7.jpg" /></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg8.jpg" alt="vnrx_10kimg8.jpg" /></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="vnrx_10kimg9.jpg" alt="vnrx_10kimg9.jpg" /></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Identify potential drug targets</strong> by measuring levels of specific histone modifications</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Screen and identify lead compounds</strong> that modulate the levels of specific histone modifications</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Monitor changes in histone modification levels to <strong>assess the efficacy and Mechanism of Action (MoA) of compounds</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Monitor target engagement to determine the <strong>pharmaco-dynamics (PD) of drugs in patients</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Support regulatory submissions and help <strong>demonstrate drug safety and efficacy</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Manufacturing Capabilities and Strategy</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our Silver One site in Belgium offers cutting edge, purpose-built manufacturing and processing facilities. We are currently focusing on manufacturing our key components such as the antibodies and positive controls at Silver One, as well as ELISA kits. We have also outsourced a portion of &#160;the production of our ELISA kits to a third-party manufacturer in the U.S. to facilitate logistics and to aim for large-scale production.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Commercialization&#160;Strategy</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are guided by three underlying principles to our commercialization strategy &#8211; ensuring our products:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Result in low capital expenditures for licensors and end users and low operating expenses for Volition,</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Are affordable, and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Are accessible worldwide.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We believe, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;could potentially be used throughout the world.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We aim to remain an IP powerhouse in the Nucleosomics&#8482; space and expect to monetize our IP and technologies through licensing and distribution contracts with companies that have established distribution networks and expertise on a worldwide or regional basis, in both human and animal care across platforms (centralized labs and point-of-care). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To this end, on March 28, 2022, Volition entered into a master license and product supply agreement with Heska Corporation (&#8220;Heska&#8221;), a leading global provider of advanced veterinary diagnostics. In exchange for granting Heska exclusive worldwide rights to sell our Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet Cancer Test at the point of care for companion animals, Volition received a $10.0 million upfront payment upon signing and is eligible to receive up to an additional&#160;$18.0 million based upon the achievement of certain near and mid-term milestones. In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet Cancer Test in kit format for companion animals through Heska&#8217;s network of central reference laboratories. Subsequent to year end, in February 2023 Heska commenced pre-orders of the Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Canine Cancer Screen and Monitor Test to veterinarians at the point of care through Heska.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We also entered into a licensing and supply agreement with IDEXX Laboratories, Inc. (&#8220;IDEXX&#8221;), a global leader in pet healthcare innovation, in October 2022. This contract provides worldwide customer reach through IDEXX&#8217;s global reference laboratory network as we continue to commercialize our transformational Nu.Q&#174; technology within the companion animal healthcare sector and capitalize on the significant opportunities available. Subsequent to year end, IDEXX launched the IDEXX Canine Cancer Test in January 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Further, we engaged with DNAtech, Portugal, and, through our agreement with Heska, with Scil Lab Europe, to launch the Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet Cancer Test to customers in Europe commencing in November 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;<strong><em>Our Market&#160;Opportunity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Volition applies its Nucleosomics&#8482; platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases for both humans and animals including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Given the wide-ranging nature of our products in development we believe that our market opportunity is large.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Based on our calculations, we believe that Volition&#8217;s annual total addressable market (&#8220;TAM&#8221;) is approximately $70 billion (including distributor and vet/clinician margins). Key assumptions for this market forecast include:&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet: opportunity is calculated based on canine and feline populations that are eligible for screening and monitoring.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nu.Q<sup style="vertical-align:super">&#174;</sup> Discover: opportunity is calculated using drug pipeline data (registered clinical trial programs) for relevant epigenetic targets.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs: opportunity is calculated based on average length of stay and estimated hospital admissions and discharges for sepsis.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer: opportunity is calculated based on eligible population for annual screening, target participation rates and incidence/prevalence of specific cancers and risk stratification use cases.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have assumed the following prices per test:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Human: $120 for the U.S., &#8364;45 for Europe, $25 for the rest of the world.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Veterinary: $50 globally.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">To the extent that one or more of our assumptions prove incorrect our calculation could be materially impacted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We anticipate that because of their ease of use and cost efficiency of our tests they have the potential to become the first method of choice for disease detection and monitoring in both humans and animals.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our Competition</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We anticipate facing competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Oncimmune Holdings Plc, Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Technologies Inc., Qiagen Inc., Thermo Fisher, Illumina, Becton Dickinson, BioMerieux, Invitae, Siemens, Gen-Probe Incorporated, EpiGenomics AG, MDxHealth SA, and Roche Diagnostics, and from companies such as PetDx, One Health Company (Fidocure) and Vidium Animal Health focused on the veterinary space. There may also be other companies developing products competitive with ours of which we are unaware.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We predict our future products will have a competitive edge compared to those offered by competitors on the basis that our tests are developed to be accurate, cost-effective, attractive from a government reimbursement perspective, easy to use, non-invasive, technologically advanced, and compatible with immunoassay systems, based on strong intellectual property and to be used for mass screenings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Many of our competitors have substantially greater financial, technical, and other resources and larger, more established marketing, sales and distribution systems than we have. Many of our competitors also offer broad product lines outside of the diagnostic testing market and have brand recognition. Moreover, our competitors may make rapid technological developments that may result in our intended technologies and products becoming obsolete before we are able to enter the market, recover the expenses incurred to develop them or generate significant revenue. Our success will depend, in part, on our ability to develop our intended products in a timely manner, keep our future products current with advancing technologies, achieve market acceptance of our future products, gain name recognition and a positive reputation in the healthcare industry, and establish successful marketing, sales and distribution efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Government Regulations</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The healthcare industry, and thus our business, is subject to extensive federal, state, local and foreign regulation. Some of the pertinent laws and regulations have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations. In addition, these laws and their interpretations are subject to change.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Both United States federal and state governmental agencies continue to subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. As indicated by work plans and reports issued by these agencies, the federal government will continue to scrutinize, among other things, the marketing, labeling, promotion, manufacturing, and export of diagnostic healthcare products. The federal government also has increased funding in recent years to fight healthcare fraud, and various agencies, such as the United States Department of Justice, the Office of Inspector General of the Department of Health and Human Services, and state Medicaid fraud control units, are coordinating their enforcement efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Commercialization of our future products in the clinical in vitro diagnostic (&#8220;IVD&#8221;) market (e.g. for patient diagnosis in hospitals, clinics, etc.) requires government approval (CE marking in Europe, FDA approval in the United States, and Chinese Food and Drug Administration (&#8220;CFDA&#8221;) approval in China). Our diagnostic products fall within the IVD medical device category and are subject to FDA clearance or approval in the United States. We anticipate our tests will have to be cleared through the FDA&#8217;s premarket notification (&#8220;510(k)&#8221;), process, or its premarket approval (&#8220;PMA&#8221;) process. The determination of whether a 510(k) or a PMA is necessary will depend in part on the proposed indications for use and the FDA&#8217;s assessment of the risk associated with the use of the IVD for a particular indication. A similar system operates in China through the CFDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In Europe, since May 2022, IVD medical devices are regulated by the new European In Vitro Diagnostic Regulation 2017/746 (&#8220;EU IVDR&#8221;). The most challenging changes compared to the previous Directive are those regarding the classification of products, which brings almost all IVDs under the direct review and control of designated assessment organizations (&#8220;Notified Bodies&#8221;), and the performance evaluation of IVDs, which requires extensive clinical and analytical performance studies in addition to a demonstration of scientific validity. Additional requirements are now applied to reinforce the safety of the products such as extended responsibilities of the economic actors of the supply chain, increased post marketing surveillance activities, unannounced audits from Notified Bodies, implementation of an improved traceability and transparency of the devices with the introduction of the Unique Device Identification system and an expanded European Database on Medical Devices.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Tailored transitional periods have been introduced for devices that must undergo a conformity assessment involving Notified Bodies for the first time under the EU IVDR. The length of the transitional periods depends on the classification of device.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In practice, the conformity assessment procedure for our products requires a combination of Quality Management System (&#8220;QMS&#8221;) audits and Technical Documentation assessments. The time needed for a Technical Documentation assessment of a device by our Notified Body (&#8220;T&#220;V S&#220;D&#8221;) is expected to last for nine months at a minimum. We have already begun discussions with the T&#220;V S&#220;D and are in the process to ensure compliance with the EU IVDR in 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">To support the conformity to the new IVDR, Belgian Volition has implemented a QMS, conforming to the internationally agreed standard ISO 13485 that sets out the QMS requirements specific to the medical devices industry. Belgian Volition has maintained its ISO certification since 2015.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We will also be required to comply with numerous other federal, state, and local laws relating to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise, which could have a material adverse impact on our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Intellectual Property</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Volition is developing clinical products based on the enrichment and analysis of epigenetically modified circulating nucleosomes using immunoassay, mass spectrometry, DNA sequencing and other methods. We have used this position to build a growing, broad and strong patent portfolio covering the ability to profile the epigenetic environment surrounding circulating chromosome fragments from diseased cells, including the epigenetic signaling status of nucleosomes, DNA, and other epigenetic chromatin proteins.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our patent portfolio includes 34 patent families (plus three in-licensed families) and a total 97 patents granted related to our diagnostic tests (including veterinary applications), with 12 patents granted in the United States, 15 patents granted in Europe, and a further 70 patents granted worldwide. Additionally, we have a total of 122 patent applications currently pending, worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We intend to continue our development of the Nucleosomics&#8482; technologies and will continue to apply for patents for future product developments. Our IP strategy is to protect the technologies and gain market exclusivity with patents in Europe and the United States and in other strategic countries. The patent filings on the technologies underlying our products should provide broad coverage for each product, including protection through at least 2043.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Employees</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, we had 104 full-time equivalent (&#8220;FTE&#8221;) compared to 83 as of December 31, 2021, reflecting the growth in commercial and production activities. We continually assess employee turnover, recruitment initiatives, compensation and benefits programs, safety in performing critical laboratory work, diversity and other matters relevant to human capital management, and we review results with our board of directors on a periodic basis. We aim to offer competitive compensation (including salary, incentive bonus, and equity) and benefits packages in each of our locations and in each of our employee groups at each level around the globe as assessed with internal and external benchmarking data. We aim to build a pipeline for talent to create more opportunities for workplace diversity and to support greater representation within the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Corporate History</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">VolitionRx Limited was originally incorporated on September&#160;24, 1998 in the State of Delaware under the name &#8220;Standard Capital Corporation.&#8221; VolitionRx acquired its wholly owned operating subsidiary, Singapore Volition Pte. Limited, a Singapore registered company (&#8220;Singapore Volition&#8221;) in October 2011. Volition Global Services SRL, a Belgium private limited liability company (&#8220;Volition Global&#8221;), was formed in August 2021, which is a wholly owned operating subsidiary of VolitionRx. Singapore Volition has one subsidiary, Belgian Volition SRL, a Belgium private limited liability company (&#8220;Belgian Volition&#8221;), which it acquired in September 2010. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, a private limited company formed under the laws of England and Wales (&#8220;Volition Diagnostics&#8221;), which was formed in November 2015, Volition America, Inc., a Delaware corporation (&#8220;Volition America&#8221;), which was formed on in February 2017, Volition Veterinary Diagnostics Development LLC, a Texas limited liability company (&#8220;Volition Vet&#8221;), which was formed in June 2019, and Volition Germany GmbH (formerly Octamer GmbH, or &#8220;Octamer&#8221; and now &#8220;Volition Germany&#8221;), a Munich, Germany-based epigenetic reagent company that it acquired in January 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our principal executive office is located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014. Our telephone number is +1 (646) 650-1351.&#160; Our website is located at <em><span style="text-decoration:underline">www.volition.com</span></em>.&#160; The information that can be accessed through our website is not incorporated by reference into this Report and should not be considered to be a part hereof.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Financial Information</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">See our consolidated financial statements and accompanying notes to the consolidated financial statements included in this Report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1A">ITEM 1A. RISK FACTORS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. As a result, investing in our common stock involves substantial risk. Before deciding to purchase, hold or sell our common stock, stockholders, and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in or incorporated by reference into this Report, as well as the other information we file with the SEC. If any of these risks are realized, our business, financial condition, results of operations, and prospects could be materially and adversely affected. In that case, the value of our common stock could decline, and stockholders may lose all or part of their investment. Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Certain statements made in this section constitute &#8220;forward-looking statements,&#8221; which are subject to numerous risks and uncertainties including those described in this section. Refer to the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; within this Report for additional information</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Associated with Our Company</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The summary below, as well as the discussion that follows the summary, highlights some of the risks that may affect future operating results. These are the risks and uncertainties we believe are most important for you to consider. We cannot be certain that we will successfully address these risks. If we are unable to address these risks, among other things, our business may not grow, our stock price may suffer, and we may be unable to stay in business. Additional risks and uncertainties not presently known to us, which we currently deem immaterial, or which are similar to those faced by other companies in our industry or business in general, may also impair our business operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risk Factor Summary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Risks Related to Our Business and Business Strategy</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We have incurred significant losses, and we may never achieve profitability.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We may need to raise additional capital in the future. If we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our plan of operations.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">It is difficult to forecast our future performance, which may cause our financial results to fluctuate unpredictably.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The diagnostics market is highly competitive and subject to rapid technological change; accordingly, we will face fierce competition, including from companies with greater resources and experience than us, and our intended products may not achieve significant market penetration and/or may become obsolete.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our management has broad discretion over the use of our available cash and might not allocate cash in ways that increase the value of your investment.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our future success depends on our ability to retain our officers and directors, scientists, and other key employees and to attract, retain and motivate qualified personnel.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If any of our facilities or our laboratory equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Failure in our information technology, storage systems or our clinical laboratory equipment could significantly disrupt our operations and our research and development efforts.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our business and reputation will suffer if we are unable to establish and comply with stringent quality standards to assure that the highest level of quality is observed in the performance of our tests.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Declining global economic or business conditions may have a negative impact on our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The COVID-19 pandemic could adversely impact our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We may engage in acquisitions that are not successful and which could disrupt our business, cause dilution to our stockholders and reduce our financial resources.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Risks Related to Product Development, Commercialization and Sales of Our Products</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If the marketplace does not accept the products in our development pipeline or any other diagnostic products we might develop, we may be unable to generate sufficient revenue to sustain and grow our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our business is dependent on our ability to successfully develop and commercialize diagnostic products. If we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Failure to successfully develop, manufacture, market, and sell our future products will have a material adverse effect on our business, financial condition, and results of operations.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and our current product candidates may not have favorable results in later studies or trials which, in turn, could have a material adverse effect on our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our research and development efforts will be hindered if we are not able to obtain samples, contract with third parties for access to samples or complete timely enrollment in future clinical trials.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If the third parties on which we increasingly rely to assist us with our current and anticipated pre-clinical development or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We expect to expand our product development, research and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We have limited experience with sales and marketing and any failure to build and manage a sales and marketing team effectively, or to successfully engage and maintain third party providers for such services, could have a material adverse effect on our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We rely on third parties to manufacture and supply our intended products. Any problems experienced by these third parties could result in a delay or interruption in the supply of our intended products to our customers, which could have a material negative effect on our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We depend on third-party distributors to market and sell our products, which will subject us to a number of risks.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The manufacturing operations of our third-party manufacturers will likely be dependent upon third-party suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Defects in our products may subject us to substantial damages which could materially harm our business or financial condition<strong><em>.</em></strong></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Risks Related to Governmental Regulation and Reimbursement</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our failure to obtain necessary regulatory clearances or approvals on a timely basis would significantly impair our ability to distribute and market our future products on the clinical IVD market.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Reductions or changes in reimbursement policies could limit our ability to sell our products.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If we are found to have violated laws concerning the privacy and security of patient health information or other personal information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Risks Related to Our Intellectual Property</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If the patents we rely on to protect our intellectual property prove to be inadequate, our ability to successfully commercialize our products will be harmed and we may never be able to operate our business profitably.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If third parties assert that we have infringed their patents and proprietary rights or challenge the validity of our patents and proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time consuming, and delay or prevent the development or commercialization of our products.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If we are unable to protect our trade secrets, we may be unable to protect our interests in proprietary technology, processes and know-how that is not patentable or for which we have elected not to seek patent protection.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Risks Related to Our Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The market prices and trading volume of our stock may be volatile.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We have identified material weaknesses in our internal control over financial reporting that have not yet been remediated, and although we are working to address such weaknesses, the failure to address these material weaknesses, or the identification of any others, could impact the reliability of our financial reporting and harm investors&#8217; views of us, which could adversely impact our stock price.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We have a &#8220;going concern&#8221; opinion from our auditors, indicating the possibility that we may not be able to continue to operate.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our Second Amended and Restated Certificate of Incorporation exculpates our officers and directors from certain liability to our Company and our stockholders.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Our corporate governance documents, certain corporate laws applicable to us, and share ownership by executive officers and directors, could make a takeover attempt, which may be beneficial to our stockholders, more difficult.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We do not expect to pay dividends in the foreseeable future.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We may in the future issue additional shares of our common stock which would reduce investors&#8217; ownership interests in the Company, and which may cause our stock price to decline.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Future sales of our common stock could depress the market price of our common stock.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If equity research analysts do not publish research or reports about our business, or if they do publish such reports but issue unfavorable commentary or downgrade our common stock, the price and trading volume of our common stock could decline.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">We are a smaller reporting company and a non-accelerated filer, and we cannot be certain if the reduced disclosure requirements applicable to our filing status, as well as the exemption from the requirement to provide an auditor&#8217;s attestation report regarding the effectiveness of our internal controls, will make our common stock less attractive to investors.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Related to Our Business and Business Strategy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We have incurred significant losses, and we may never achieve profitability.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are a clinical stage company and have incurred losses since our formation. As of December 31, 2022, we have an accumulated total deficit of approximately $167.3 million. As we continue the discovery and development of our future diagnostic products, we expect our expenses to increase significantly. Even as we begin to market and sell our intended products, we expect our losses to continue as a result of ongoing research and development expenses, as well as increased manufacturing, sales and marketing expenses. These losses, among other things, have had and will continue to have an adverse effect on our working capital, total assets and stockholders&#8217; equity. Because of the numerous risks and uncertainties associated with our product development and commercialization efforts, we are unable to predict when or if we will become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and then maintain profitability, our business, financial condition and results of operations will be negatively affected, and the market value of our common stock will decline.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We may need to raise additional capital in the future. If we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our plan of operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We will require additional capital to fully fund our current strategic plan, which includes successfully commercializing our Nu.Q<sup style="vertical-align:super">&#174;</sup> pipeline and developing future products. If we incur delays in commencing commercialization of our Nu.Q<sup style="vertical-align:super">&#174;</sup> pipeline or other future products or in achieving significant product revenue, or if we encounter other unforeseen adverse business developments, we may exhaust our capital resources prior to the commencement of commercialization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We cannot be certain that additional capital will be available when needed or that our actual cash requirements will not be greater than anticipated. Financing opportunities may not be available to us, or if available, may not be available on favorable terms. The availability of financing opportunities will depend on various factors, such as market conditions and our financial condition and outlook. In addition, if we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. If we obtain debt financing, a substantial portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, and the terms of the debt securities issued could impose significant restrictions on our operations. If we are unable to obtain financing on terms favorable to us, we may be unable to execute our plan of operations and we may be required to cease or reduce development or commercialization of any future products, sell some or all of our technology or assets or merge with another entity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>It is difficult to forecast our future performance, which may cause our financial results to fluctuate unpredictably.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our limited operating history and the rapid evolution of the market for diagnostic products make it difficult for us to predict our future performance. A number of factors, many of which are outside of our control, may contribute to fluctuations in our financial results, such as:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to develop or procure antibodies for clinical use in our future products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to translate preliminary clinical results to larger prospective symptomatic and screening populations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the demand for our intended products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain any necessary financing;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to market and sell our future products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">market acceptance of our future products and technology;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">performance of any future strategic business partners;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain regulatory clearances or approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our success in collecting payments from third-party payors and customers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changes in technology that may render our future products uncompetitive or obsolete;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">competition with other diagnostics companies; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">adverse changes in the healthcare industry (human and canine).</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>The diagnostics market is highly competitive and subject to rapid technological change; accordingly, we will face fierce competition, including from companies with greater resources and experience than us, and our intended products may not achieve significant market penetration and/or may become obsolete.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The diagnostics market is extremely competitive and characterized by rapidly evolving industry standards and new product enhancements. Our diagnostic tests are technologically innovative and require significant planning, design, development, and testing at the technological, product, and manufacturing process levels. These activities require significant capital commitments and investment. There can be no assurance that our intended products or proprietary technologies will remain competitive following the introduction of new products and technologies by competing companies within the industry. Furthermore, there can be no assurance that our competitors will not develop products that render our future products obsolete or that are more effective, accurate or can be produced at lower costs. There can be no assurance that we will be successful in the face of increasing competition from new technologies or products introduced by existing companies in the industry or by new companies entering the market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large multinational corporations and their operating units, including Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Oncimmune Holdings Plc, Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Technologies Inc., Qiagen Inc., Thermo Fisher, Illumina, Becton Dickinson, BioMerieux, Invitae, Siemens, Gen-Probe Incorporated, EpiGenomics AG, MDxHealth SA, and Roche Diagnostics, and from companies such as PetDx, One Health Company (Fidocure) and Vidium Animal Health focused on the veterinary space. There may also be other companies developing products competitive with ours of which we are unaware. Successful commercialization of our services will require that we satisfactorily address the needs of various medical practitioners that constitute a target market to reach customers and to address potential resistance to recommendations for our services. If we are unable to continue to achieve significant market penetration, we will not be able to generate sufficient revenue to become profitable and our products may become obsolete.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Many of our competitors have greater resources and experience than us and may enjoy several competitive advantages, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">significantly greater name recognition;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">established relationships with healthcare professionals, companies and consumers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives to gain a competitive advantage;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">established supply and distribution networks; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">greater resources for product development, sales and marketing, and intellectual property protection.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Many of these other companies have developed and will continue to develop new products that will compete directly with our future products. In addition, many of our competitors spend significantly greater funds for the research, development, promotion, and sale of new and existing products. These resources may allow them to respond more quickly to new or emerging technologies and changes in consumer requirements. We also face competition in our search for third parties to assist us with sales and marketing of our product candidates, which may negatively impact our ability to enter into favorable sales and marketing arrangements. For all the foregoing reasons, we may not be able to compete successfully against our competitors, which could jeopardize our ability to recoup research and development expenditures, hurt our reputation and harm our business, results of operations and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our management has broad discretion over the use of our available cash and might not allocate cash in ways that increase the value of your investment</em></strong>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, we had approximately $10.9 million in combined cash and cash equivalents compared to approximately $20.6 million as of December 31, 2021. Our management expects to deploy these resources primarily to expand our commercialization activities, to fund our product development efforts and for general corporate and working capital purposes. However, our management has broad discretion to pursue other objectives. Our management might not apply our cash in ways that increase or permit any return of your investment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our future success depends on our ability to retain our officers and directors, scientists, and other key employees and to attract, retain and motivate qualified personnel.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our success depends on our ability to attract, retain and motivate highly qualified management and scientific personnel. In particular, we are highly dependent on Cameron Reynolds, our President and Chief Executive Officer, our other officers and directors, scientists and key employees. The loss of any of these persons or their expertise would be difficult to replace and could have a material adverse effect on our ability to achieve our business goals. In addition, the loss of the services of any one of these persons may impede the achievement of our research, development and commercialization objectives by diverting management&#8217;s attention to the identification of suitable replacements, if any. There can be no assurance that we will be successful in hiring or retaining qualified personnel and our failure to do so could have a material adverse effect on our business, financial condition and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Recruiting and retaining qualified scientific personnel and, in the future, sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among pharmaceutical, biotechnology and diagnostic companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. We do not maintain &#8220;key person&#8221; insurance on any of our employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research, development and commercialization strategies. Our consultants and advisors, however, may have other commitments or employment that may limit their availability to us.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If any of our facilities or our laboratory equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If our present, or any future facilities, were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, storms, tornadoes, earthquakes, other inclement weather events or natural disasters, employee malfeasance, terrorist acts, power outages, or otherwise, it may render it difficult or impossible for us to perform our research and development for some period of time and our business could be severely disrupted. The lead time from ordering to delivery of certain specialized equipment we use can be more than six months and difficult to substitute. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Failure in our information technology, storage systems or our clinical laboratory equipment could significantly disrupt our operations and our research and development efforts.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our information technology (&#8220;IT&#8221;)&#160;systems, which support our operations including our research and development efforts. The integrity and protection of our own data, and that of our customers, clinical trial subjects and employees, is critical to our business. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. IT systems are vulnerable to damage from a variety of sources. High-profile security breaches at other companies and in government agencies have increased in recent years, and cyber-attacks are becoming more sophisticated and frequent, and in some cases have caused significant harm. Computer hackers and others routinely attempt to breach the security of technology products, services and systems, and to fraudulently induce employees, customers, or others to disclose information or unwittingly provide access to systems or data. While we devote significant resources to security measures to protect our systems and data, these measures cannot provide absolute security.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Any breach or interruption of our information technology systems could compromise our networks and the information stored therein could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our IT systems, unauthorized access, loss or disclosure could also disrupt our operations, including our ability to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">provide customer assistance services;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">conduct research and development activities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">collect, process and prepare company financial information;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">provide information about our tests and other patient and healthcare provider education and outreach efforts through our website; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">manage the administrative aspects of our business and damage to our reputation.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the U.S. Health Insurance Portability and Accountability Act of 1996, similar U.S. state data protection regulations, including the California Consumer Privacy Act, the EU&#8217;s General Data Protection Regulation, and other regulations, the breach of which could result in significant penalties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Failure to adequately protect and maintain the integrity of our information systems and data, including as a result of a security breach, may result in significant losses and have a material adverse effect on our financial position, results of operations and cash flows.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our business and reputation will suffer if we are unable to establish and comply with stringent quality standards to assure that the highest level of quality is observed in the performance of our tests.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Inherent risks are involved in providing and marketing diagnostic and monitoring tests and related services. Patients and healthcare providers rely on us to provide accurate clinical and diagnostic information that may be used to make critical healthcare decisions.&#160;Consequently, users of our tests may have a greater sensitivity to errors than users of some other types of products and services. We must maintain high service standards and other quality controls. Performance or accuracy defects, incomplete or improper process controls, excessively slow turnaround times, unanticipated uses of our tests or mishandling of samples or test results (whether by us, patients, healthcare providers, courier delivery services, or others) can lead to adverse outcomes for patients and interruptions to our services.&#160; These events could lead to voluntary or legally mandated safety alerts relating to our tests or our laboratory facilities and could result in the removal of our products and services from the market or the suspension of our laboratories&#8217; operations. Insufficient quality controls and any resulting negative outcomes could result in significant costs and litigation, as well as negative publicity that could reduce demand for our tests and payers&#8217; willingness to cover our tests.&#160;Even if we maintain adequate controls and procedures, damaging and costly errors may occur.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Declining global economic conditions may have a negative impact on our business. </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Concerns over U.S. healthcare reform legislation and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the United States and other countries, and global inflationary pressures may contribute to increased volatility and diminished expectations for the global economy. If the economic climate deteriorates, our business, including our access to the research use only, or clinical IVD markets for diagnostic tests, could be adversely affected, resulting in a negative impact on our business, financial condition and&#160; results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The United Kingdom&#8217;s withdrawal from the European Union became effective in January 2021. Although it is known what the terms of this withdrawal were, it is still possible that greater restrictions on imports and exports between the European Union countries and the United Kingdom and increased regulatory complexities are forthcoming. These changes may adversely affect our ability to market our future products in the United Kingdom which could have an adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In addition, following Russia&#8217;s military invasion of Ukraine in February 2022, NATO deployed additional military forces to Eastern Europe, and the United States, European Union, and other nations announced various sanctions against Russia. The invasion of Ukraine and the retaliatory measures that have been taken, and could be taken in future, by the U.S., NATO, and other countries have created global security concerns that could result in a regional conflict and otherwise have a lasting impact on regional and global economies, any or all of which could adversely affect our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>The COVID-19 pandemic could adversely impact our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As a result of the COVID-19 pandemic and the related responses from government authorities, we have experienced and may continue to experience disruptions that could severely impact our business, strategy, financial performance and financial condition, as well as clinical trials, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">delays or difficulties in enrolling patients in clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of our clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">increased costs in our manufacturing, production and shipping processes;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a slowdown or stoppage in the supply chain of the raw materials, components, and packaging services used to manufacture our products or our inability to secure additional or alternate sources of supplies or services needed to manufacture our products at optimal levels;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">interruptions or delays in global shipping to transport and deliver our products to our distributors and customers; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">fluctuations in foreign currency exchange rates or interest rates resulting from market uncertainties.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets, which increases the cost of, and adversely impacts access to, capital and increases economic uncertainty. This volatility and uncertainty may adversely affect our stock price. The actions that governments and individuals have taken in response to COVID-19 have led to a sharp contraction in many aspects of economies worldwide, including an economic slowdown, and it is possible that it could cause a global recession. If this occurs, it could negatively impact our ability to develop and commercialize our products, among other things. Even after the COVID-19 pandemic has subsided, we may continue to experience material adverse effects to our business as a result of the global economic impact of the pandemic, including local and global inflationary pressures, further or unexpected economic recessionary fears, increased political instability and threats of war, and could suffer from increased borrowing costs that limit discretionary consumer spending, which could hamper demand for our products and delay diagnostic testing and treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Further, the effects of&#160;COVID-19&#160;may exacerbate our other risk factors described in this Report. The degree to which the COVID-19 pandemic may impact our business and clinical trials and development activities will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted with confidence.&#160; Because this situation continues to evolve globally, the ultimate impacts to us of&#160;COVID-19 are uncertain, but such impacts could have a material adverse effect on our business, strategy, financial performance and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We may engage in acquisitions that are not successful and which could disrupt our business, cause dilution to our stockholders and reduce our financial resources.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">From time to time, we may consider opportunities to acquire or invest in other companies, products or technologies that may enhance our product platform or technology, expand the breadth of our markets or customer base, or otherwise advance our business strategies. Potential and completed acquisitions and investments involve numerous risks, including the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">we may be unable to successfully integrate the acquired business (es) into our business;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">we may be unable to realize the anticipated benefits of the acquisition;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the acquisition may not strengthen our competitive position; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our future results may suffer if we do not effectively manage our expanded operations.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We do not know if we will be able to identify future acquisitions or investments we deem suitable, whether we will be able to successfully complete any such acquisitions or investments on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies into our business. Our potential inability to integrate any acquired products or technologies effectively may adversely affect our business, operating results and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Related to Product Development, Commercialization and Sales of Our Products</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If the marketplace does not accept the products in our development pipeline or any other diagnostic products we might develop, we may be unable to generate sufficient revenue to sustain and grow our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our intended products may never gain significant acceptance in the research or clinical marketplace and therefore may never generate substantial revenue or profits. Physicians, hospitals, clinical laboratories, researchers or others in the healthcare industry may not use our future products unless they determine that they are an effective and cost-efficient means of detecting and diagnosing cancer. If our research and studies do not satisfy providers, payors and others as to the reliability and effectiveness, we may experience reluctance or refusal on the part of the physician to use our future products. In addition, we will need to expend a significant amount of resources on marketing and educational efforts to create awareness of our future products and to encourage their acceptance and adoption. If the market for our future products does not develop sufficiently or the products are not accepted, our revenue potential will be harmed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our business is dependent on our ability to successfully develop and commercialize diagnostic products. If we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our current business strategy focuses on discovering, developing and commercializing diagnostic products. The success of our business will depend on our ability to fully develop and commercialize the diagnostic products in our current development pipeline as well as continue the discovery and development of other diagnostics products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prior to commercializing the Nu.Q<sup style="vertical-align:super">&#174;</sup> tests and other diagnostic products, we will be required to undertake time-consuming and costly development activities with uncertain outcomes, including conducting clinical studies and obtaining regulatory clearance or approval in the United States, Asia and in Europe. Delays in obtaining approvals and clearances could have material adverse effects on us and our ability to fully carry out our plan of operations. We have limited experience in taking products through these processes and there are considerable risks involved in these activities. The science and methods that we are employing are innovative and complex, and it is possible that our development programs will ultimately not yield products suitable for commercialization or government approval. Products that appear promising in early development may fail to be validated in subsequent studies, and even if we achieve positive results, we may still fail to obtain the necessary regulatory clearances or approvals. Few research and development projects result in commercial products, and perceived viability in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product, or we may be required to expend considerable resources obtaining additional clinical and nonclinical data, which would adversely impact the timing for generating potential revenue from those products. Further, our ability to develop and launch diagnostic tests is dependent on our receipt of substantial additional funding. If our discovery and development programs yield fewer commercial products than we expect, we may be unable to execute our business plan, and our business, financial condition and results of operations may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Failure to successfully develop, manufacture, market, and sell our future products will have a material adverse effect on our business, financial condition, and results of operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are in the process of developing a suite of diagnostic tests as well as additional products. The successful development and commercialization of our intended products is critical to our future success. Our ability to successfully develop, manufacture, market, and sell our future products is subject to a number of risks, many of which are outside our control. There can be no assurance that we will be able to develop and manufacture products in commercial quantities at acceptable costs, successfully market any products, or generate revenues from the sale of any products. Failure to achieve any of the foregoing would have a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>The results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and our current product candidates may not have favorable results in later studies or trials which, in turn, could have a material adverse effect on our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We must conduct extensive testing of our product candidates and new indications of our marketed products before we can obtain regulatory approval to market and sell them. Success in pre-clinical studies or completed clinical trials does not ensure that later studies or trials, including continuing pre-clinical studies and large-scale clinical trials, will be successful nor does it necessarily predict future results. Favorable results in early studies or trials may not be repeated in later studies or trials, and product candidates in later stage trials may fail to show acceptable safety and efficacy despite having progressed through earlier trials. We may be required to demonstrate through large, long-term outcome trials that our product candidates are safe and effective for use in a broad population prior to obtaining regulatory approval. The failure of clinical trials to demonstrate the safety and effectiveness of our clinical candidates for the desired indication(s) would preclude the successful development of those candidates for such indication(s), in which event our business, prospects, results of operations and financial condition may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our research and development efforts will be hindered if we are not able to obtain samples, contract with third parties for access to samples or complete timely enrollment in future clinical trials.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Access to human and animal sample types, such as blood is necessary for our research and product development. Acquiring samples from individuals / animals with clinical diagnoses or associated clinical outcomes through purchase or clinical studies is necessary. Lack of available samples can delay development timelines and increase costs of development. Generally, the agreements under which we gain access to human and animal samples are non-exclusive. Other companies may compete with us for access. If we are not able to negotiate access to clinical samples with research institutions, hospitals, clinical partners, pharmaceutical companies, or companies developing therapeutics and/or diagnostics on a timely basis, or at all, or if other laboratories or our competitors secure access to these samples before us, our ability to research, develop and commercialize future products will be limited or delayed. Equally, we may not be able to conduct or complete clinical studies in a timely manner if we are unable to enroll sufficient numbers of patients in such studies, which could consequently have an adverse effect on our research and development and product commercialization efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If the third parties on which we increasingly rely to assist us with our current and anticipated pre-clinical development or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As our clinical infrastructure expands, we expect to increasingly rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct some of our current and anticipated&#160;pre-clinical&#160;investigations and clinical trials. For example, we currently rely on DXOCRO to support development and clinical validation studies for our Nu.Q<sup style="vertical-align:super">&#174;</sup> product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs and Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer tests to determine clinical utility in sepsis and non-Hodgkin&#8217;s lymphoma, which we hope to leverage in support of our U.S. commercialization strategy. However, if we are not able to maintain or reach mutually acceptable agreements with DXOCRO or other third parties on a timely basis, these third parties do not successfully carry out their commitments or regulatory obligations or meet expected deadlines, or the quality or accuracy of the data they obtain is compromised due to the failure to adhere to agreed-upon clinical protocols or regulatory requirements or for other reasons, our&#160;pre-clinical&#160;development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory clearance or approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We expect to expand our product development, research and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are focused on developing our pipeline for future products. It is likely that our efforts will result in significant growth in the number of our consultants, advisors, and employees, in addition to the scope of our operations. For example, in connection with the anticipated commercialization of our products, we may add personnel to certain areas of our business including laboratory operations, quality assurance, and compliance. Further, as we build our commercialization efforts and expand research and development activities for new products, the scope and complexity of our operations is increasing significantly. As a result of our growth, our operating expenses and capital requirements have also increased, and we expect that they will continue to increase. Our ability to manage our growth effectively requires us to expend funds to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plan or disrupt our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We have limited experience with sales and marketing and any failure to build and manage a sales and marketing team effectively, or to successfully engage and maintain third party providers for such services, could have a material adverse effect on our business</em></strong>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As an organization we have limited experience with direct sales however we are building a team of experienced individuals in terms of market intelligence, product management and account management in addition to building relationships with market-leading established distributors as commercial partners. For example, subsequent to the fiscal end year ended December 31, 2022, Heska commenced pre-order sales of our Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test for screening and monitoring of cancer in canines to veterinarians worldwide at the point of care pursuant to our exclusive global supply and licensing agreement with Heska. We have also engaged IDEXX to make our Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test available to reference laboratories in the United States. Although we are investing in direct marketing to support these commercial launches, we may rely on third party resources such as Heska&#8217;s global network of veterinarians and IDEXX&#8217;s reference laboratory network to successfully market this test and generate revenue. Any failure to build and manage a sales and marketing team effectively, or to successfully engage and maintain third-party providers for such services, could have a material adverse effect on our business. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our products will require several dynamic and evolving sales models tailored to different worldwide markets, users and products. Our clinical sales strategy is initially focused on the clinical IVD market with the CE marking of our first product in Europe, the Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs test, in May 2022. With this CE marking of our first product in Europe we intend to enter the European markets and, following the completion of any necessary regulatory clearances, certain Asian markets. Even if we receive a CE mark for a certain product, we must still seek regulatory clearance in other jurisdictions. A failure to obtain these regulatory clearances in other jurisdictions could negatively affect our business. Pending completion of our review of the regulatory environment in the United States we may decide to enter the United States market through a Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;), certified laboratory located in the United States. We remain firmly committed to pursuing FDA approval as our primary objective. FDA approval can consist of PMA or 510(k) clearance depending on the test complexity and risk posed to patients. We intend to pursue the most appropriate approval pathway for each individual product developed. We intend to progressively grow to large volumes of tests sold to centralized laboratories and eventually reach the mass diagnostics testing market. The exact nature of the ideal sales strategy will evolve as we continue to develop our intended products and seek entry into the IVD markets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There are significant risks involved in building and managing our sales and marketing organization, as well as identifying and negotiating deals with the right sales and distribution partners, including risks related to our ability to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">identify appropriate partners;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">negotiate beneficial partnership and distribution agreements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">hire qualified individuals as needed;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">generate sufficient leads within our targeted market for our sales force;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">provide adequate training for effective sales and marketing;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">protect intellectual property rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">retain and motivate our direct sales and marketing professionals; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">effectively oversee geographically dispersed sales and marketing teams.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our failure to adequately address these risks could have a material adverse effect on our ability to increase sales and use of our future products, which would cause our revenues to be lower than expected and harm our results of operations. Further, we are required to comply with numerous other federal, state, and local laws relating to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise, which could have a material adverse impact on our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We rely on third parties to manufacture and supply our intended products. Any problems experienced by these third parties could result in a delay or interruption in the supply of our intended products to our customers, which could have a material negative effect on our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We rely on third parties to manufacture and supply our intended products. The manufacture of our intended diagnostic products requires specialized equipment and utilizes complicated production processes that would be difficult, time-consuming and costly to duplicate. If the operations of third-party manufacturers are interrupted or if they are unable to meet our delivery requirements due to capacity limitations or other constraints, we may be limited in our ability to fulfill our future sales orders. Any prolonged disruption in the operations of third-party manufacturers could have a significant negative impact on our ability to sell our future products, could harm our reputation and could cause us to seek other third-party manufacturing contracts, thereby increasing our anticipated development and commercialization costs. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards required by the FDA and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop products or receive approval of any products in a timely manner.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We depend on third-party distributors to market and sell our products, which will subject us to a number of risks.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We depend, and expect to continue to depend, on third-party distributors to market, sell, and service our products in our intended markets. For example, subsequent to the year ended December 31, 2022, Heska commenced pre-order sales of our Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test for screening and monitoring of cancer in canines to veterinarians at the point of care and we engaged IDEXX to make our Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test available to reference laboratories in the United States. Further, we have engaged with others including DNAtech, Portugal, and, through our agreement with Heska, with Scil Lab Europe, to launch the Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;Vet Cancer Test to customers in Europe. We are subject to a number of risks associated with reliance upon these parties and other third-party distributors including the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">lack of day-to-day control over the activities of third-party distributors;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">third-party distributors may not commit the necessary resources to market and sell our products to our level of expectations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">third-party distributors may terminate their arrangements with us on limited or no notice or may change the terms of these arrangements in a manner unfavorable to us; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">disagreements with our distributors could result in costly and time-consuming litigation or arbitration which we could be required to conduct in jurisdictions with which we are not familiar.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If we fail to establish and maintain satisfactory relationships with our third-party distributors, our revenues and market share may not grow as anticipated, and we could be subject to unexpected costs which could harm our results of operations and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>The manufacturing operations of our third-party manufacturers will likely be dependent upon third-party suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The operations of our future third-party manufacturers will likely be dependent upon third-party suppliers. A supply interruption or an increase in demand beyond a supplier&#8217;s capabilities could harm the ability of our future manufacturers to manufacture our intended products until new sources of supply are identified and qualified.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Reliance on these suppliers could subject us to a number of risks that could harm our business, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a lack of long-term supply arrangements for key components with our suppliers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">difficulty and cost associated with locating and qualifying alternative suppliers for components in a timely manner;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">delay in delivery due to suppliers prioritizing other customer orders over ours;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">damage to our brand reputation caused by defective components produced by the suppliers; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">fluctuation in delivery by the suppliers due to changes in demand from us or their other customers.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have implemented certain risk mitigation strategies including the diversification of suppliers by region and the internalization of certain production processes. However, any interruption in the supply of components of our future products or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our future customers, which would have an adverse effect on our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Defects in our products may subject us to substantial damages which could materially harm our business or financial condition.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The products we develop could lead to product liability claims based on allegations that one or more of our products contained a design or manufacturing defect which resulted in the failure to detect the disease for which it was designed. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business or financial condition. We cannot assure you that our product liability insurance would protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Related to Governmental Regulation and Reimbursement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our failure to obtain necessary regulatory clearances or approvals on a timely basis would significantly impair our ability to distribute and market our future products on the clinical IVD market.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to regulation by the FDA in the United States, the CE in Europe, the CFDA in China, and other regulatory bodies in other countries where we intend to sell our future products. Before we are able to place our intended products in the clinical IVD markets in the United States, China and Europe, we will be required to obtain clearance or approval of our future products from the FDA and the CFDA with respect to the United States and China, respectively, and receive a CE mark with respect to Europe. In Europe, since May 2022, IVD medical devices are regulated by the new EU IVDR. The most challenging changes under the EU IVDR as compared to the previous Directive are those regarding the classification of products, which brings almost all IVDs under the direct review and control of Notified Bodies, and the performance evaluation of IVDs, which requires extensive clinical and analytical performance studies in addition to a demonstration of scientific validity. These changes and other additional requirements to obtain a CE mark could result in delays and further expense, in terms of staff costs to us compared to the process under the previous Directive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Additionally, even if we receive the required government clearance or approval of our intended products, we are still subject to continuing regulation and oversight. Under the FDA, diagnostics are considered medical devices and are subject to ongoing controls and regulations, including inspections, compliance with established manufacturing practices, device-tracking, record-keeping, advertising, labeling, packaging, and compliance with other standards. The process of complying with such regulations with respect to current and new products can be costly and time-consuming. Failure to comply with these regulations could jeopardize our ability to sell our products and result in enforcement actions such as fines, civil penalties, injunctions, warning letters, recalls of products, delays in the introduction of products into the market, refusal of the FDA or other regulators to grant future clearances or approvals, delays by the FDA or other regulators in granting clearances or approvals, and the suspension or withdrawal of existing approvals by the FDA or other regulators, any of which could have a material adverse effect on our business, financial condition, and results of operations. Furthermore, any FDA regulations governing our future products are subject to change at any time, which may cause delays and have material adverse effects on our operations. In Europe, IVD companies&#160;are subject to inspection for enforcement, among others things. European national agencies, such as customs authorities and/or the Departments of Health, Industry and Labor, conduct market surveillance to ensure the applicable requirements have been met for products marketed within the European Union.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Reductions or changes in&#160;reimbursement policies could limit our ability to sell our products.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Market acceptance and sales of our products will depend, in part, on reimbursement&#160;policies and may be affected by healthcare reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which products they will pay for and establish reimbursement levels for those products. To manage healthcare costs, many governments and third-party payers in the United States&#160;increasingly scrutinize the pricing of new products and require greater levels of evidence of favorable clinical outcomes and cost-effectiveness before extending coverage. We cannot be sure that reimbursement&#160;will be available for our products and, if&#160;reimbursement&#160;is available, the level of such reimbursement. Reimbursement&#160;may impact the demand for, or the price of, our products. If reimbursement&#160;is not available or is available only at limited levels, we may not be able to successfully commercialize our future products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If we are found to have violated laws concerning the privacy and security of patient health information or other personal information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There are a number of U.S. and international laws protecting the privacy and security of personal information. These laws include the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and related regulations, U.S. state laws (such as the California Consumer Privacy Act (&#8220;CCPA&#8221;) and the California Privacy Rights Act &#160;(&#8220;CPRA&#8221;)), Canada&#8217;s Personal Information and Electronic Documents Act (&#8220;PIPEDA&#8221;) or the applicable provincial alternatives, the EU&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), EU member states directives, or similar applicable laws. These laws place limits on how we may collect, use, share and store medical information and other personal information, and they impose obligations to protect that information against unauthorized access, use, loss, and disclosure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If we, or any of our service providers who have access to the personal data for which we are responsible, are found to be in violation of the privacy or security requirements of HIPAA, PIPEDA, GDPR, or applicable foreign, U.S. state and Canadian provincial laws, we could be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial condition and operating results. In addition, entities operating in the healthcare industry have increasingly become targets for hackers. Although we utilize a variety of measures to secure the data that we control, even compliant entities can experience security breaches or have inadvertent failures despite employing reasonable practices and safeguards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We may also face new risks relating to data privacy and security as the United States, individual U.S. states or Canadian provinces, E.U. member states, and other international jurisdictions adopt or implement new data privacy and security laws and regulations as we continue to commercialize our products worldwide. For example, amendments to privacy and security laws (such as the CCPA and the CPRA) may impose additional requirements on us and increase our regulatory and litigation risk. As we continue to expand, our business will need to adapt to meet these and other similar legal requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Related to Our Intellectual Property</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If the patents we rely on to protect our intellectual property prove to be inadequate, our ability to successfully commercialize our products will be harmed and we may never be able to operate our business profitably.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our success depends, in large part, on our ability to protect proprietary methods, discoveries and technologies that we develop under the patents and intellectual property laws of the United States, Europe and other countries, so that we can seek to prevent others from unlawfully using our inventions and proprietary information.&#160; Our patent portfolio includes 34 patent families (plus three in-licensed families) and a total 97 patents granted related to our diagnostic tests (including veterinary applications), with 12 patents granted in the United States, 15 patents granted in Europe and a further 70 patents granted worldwide. Additionally, we have 122 patent applications pending, worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If we are not able to protect our proprietary technology and information, our competitors may use our inventions to develop competing products. We cannot assure you that any of the pending patent applications will result in patents being issued. In addition, due to technological changes that may affect our products or judicial interpretation of the scope of our patents, our products might not, now or in the future, be adequately covered by our patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If third parties assert that we have infringed their patents and proprietary rights or challenge the validity of our patents and proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time consuming, and delay or prevent the development or commercialization of our products.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our ability to commercialize our products depends on our ability to develop, manufacture, market and sell our products without infringing the proprietary rights of third parties. Third parties may allege that our products or our methods or discoveries infringe their intellectual property rights. Numerous United States and foreign patents and pending patent applications, which are owned by third parties, exist in fields that relate to our products and our underlying methodologies, discoveries and technologies. A third party may sue us for infringing its patent rights. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our ability to successfully commercialize our products depends on our ability to protect our proprietary technology and information. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of third-party proprietary rights. In addition, a third party may claim that we have improperly obtained or used its confidential or proprietary information. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation could divert our management&#8217;s attention from other aspects of our business. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations. Additionally, we cannot be certain of the level of protection, if any that will be provided by our patents if they are challenged in court, where our competitors may raise defenses such as invalidity, unenforceability or possession of a valid license.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If we are found to infringe upon intellectual property rights of third parties, we might be forced to pay damages, potentially including triple damages. In addition to any damages, we might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some or all of our products, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If we are unable to protect our trade secrets, we may be unable to protect our interests in proprietary technology, processes and know-how that is not patentable or for which we have elected not to seek patent protection.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In addition to patented technology, we rely upon trade secret protection to protect our interests in proprietary know-how and for processes for which patents are difficult or impossible to obtain or enforce. We may not be able to protect our trade secrets adequately. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors and outside scientific advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. We rely, in part, on non-disclosure and confidentiality agreements with our employees, consultants and other parties to protect our trade secrets and other proprietary technology. These agreements may be breached, and we may not have adequate remedies for any breach. Moreover, others may independently develop equivalent proprietary information, and third parties may otherwise gain access to our trade secrets and proprietary knowledge. Any disclosure of confidential information into the public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against us, which could adversely affect our competitive advantage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Risks Related to Our Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>The market prices and trading volume of our stock may be volatile.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The market price of our common stock is likely to be highly volatile and the trading volume may fluctuate and cause significant price variation to occur. We cannot assure you that the market prices of our common stock will not fluctuate or decline significantly in the future. Some of the factors that could negatively affect the prices of our shares or result in fluctuations in those prices or in trading volume of our common stock could include the following, many of which will be beyond our control:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">competition;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">comments by securities analysts regarding our business or prospects;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">additions or departures of key personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to execute our business plan;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">issuance of common stock or other securities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">operating results that fall below expectations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">loss of any strategic relationship;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">industry developments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">economic and other external factors; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">period-to-period fluctuations in our financial results.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price and trading volume of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We have identified material weaknesses in our internal control over financial reporting that have not yet been remediated, and </em></strong><strong><em>although we are working to address such weaknesses, the failure to address these material weaknesses, or the identification of any others, could impact the reliability of our financial reporting and harm investors&#8217; views of us, which could adversely impact our stock price.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of assets;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and/or directors; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have determined that we have material weaknesses in our internal control over financial reporting as of December 31, 2022. See Part II, Item 9A<em> </em>of this Report<em> </em>for a complete discussion of these material weaknesses in our internal control over financial reporting and remediation efforts. Although we have taken and continue to take steps to address these material weaknesses, the existence of a material weakness is an indication that there is more than a remote likelihood that a material misstatement of our financial statements will not be prevented or detected in the current or any future period. There can be no assurance that we will be able to fully implement our plans and controls, as further described in Item&#160;9A, to address these material weaknesses, or that the plans and controls, if implemented, will be successful in fully remediating these material weaknesses. In addition, we may in the future identify further material weaknesses in our internal control over financial reporting that we have not discovered to date. If we fail to successfully remediate the identified material weaknesses, or we identify further material weaknesses in our internal controls, the market&#8217;s confidence in our financial statements could decline and the market price of our common stock could be adversely impacted. Additionally, for so long as we remain as a smaller reporting company, under current rules our accounting firm will not be required to provide an opinion regarding our internal controls over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We have a &#8220;going concern&#8221; opinion from our auditors, indicating the possibility that we may not be able to continue to operate.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our independent registered public accountants have expressed substantial doubt about our ability to continue as a going concern. This opinion could materially limit our ability to raise additional funds by issuing new debt or equity securities or otherwise. If we fail to raise sufficient capital when needed, we will not be able to complete our proposed business plan. As a result, we may have to liquidate our business and investors may lose their investments. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish our plan of operations described herein, obtain financing and eventually attain profitable operations. Investors should consider our independent registered public accountant&#8217;s comments when deciding whether to invest in the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our Second Amended and Restated Certificate of Incorporation exculpates our officers and directors from certain liability to our Company and our stockholders.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Second Amended and Restated Certificate of Incorporation contains a provision limiting the liability of our officers and directors for their acts or failures to act, except for acts involving intentional misconduct, fraud or a knowing violation of law. This limitation on liability may reduce the likelihood of derivative litigation against our officers and directors and may discourage or deter our stockholders from suing our officers and directors based upon breaches of their duties to our Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Our corporate governance documents, certain corporate laws applicable to us, and share ownership by executive officers and directors, could make a takeover attempt, which may be beneficial to our stockholders, more difficult.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our board of directors has the power, under our charter documents to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">issue additional shares of common stock without having to obtain stockholder approval for such action;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">fill vacant directorships except for vacancies created by the removal of a director;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">amend our bylaws without stockholder approval subject to certain exceptions; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">require compliance with an advance notice procedure with regard to business to be brought by a stockholder before an annual or special meeting of stockholders and with regard to the nomination by stockholders of candidates for election as directors.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Further, our executive officers and directors beneficially own an amount of our outstanding shares of common stock such that if they were collectively to oppose a third party&#8217;s acquisition proposal for, or a change in control of, the Company, such officers and directors may have sufficient voting power to be able to block or at least delay such an acquisition or change in control from taking place, even if other stockholders would support such a sale or change of control.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">These provisions and circumstances may discourage potential acquisition proposals and could delay or prevent a change of control, including under circumstances in which our stockholders might otherwise receive a premium over the market price of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We do not expect to pay dividends in the foreseeable future.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have never declared or paid cash dividends on our common stock. We do not intend to declare dividends for the foreseeable future, as we anticipate that we will reinvest any future earnings in the development and growth of our business. Therefore, investors will not receive any funds unless they sell their common stock, and stockholders may be unable to sell their shares on favorable terms or at all. We cannot assure you of a positive return on investment or that you will not lose the entire amount of your investment in our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We may in the future issue additional shares of our common stock which would reduce investors&#8217; ownership interests in the Company, and which may cause our stock price to decline.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our Second Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000 shares of common stock, par value $0.001 per share. The future issuance of all or part of our remaining authorized common stock may result in substantial dilution in the percentage of our common stock held by our then existing stockholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the percentage ownership of our stockholders and, depending upon the prices at which such shares are sold or issued, on their investment in our common stock and, therefore, could have an adverse effect on any trading market for our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Future sales of our common stock could depress the market price of our common stock.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales of a substantial number of shares of our common stock in the public market or the perception that large sales of our shares could occur, could cause the market price of our common stock to decline or limit our future ability to raise capital through an offering of equity securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>If equity research analysts do not publish research or reports about our business, or if they do publish such reports but issue unfavorable commentary or downgrade our common stock, the price and trading volume of our common stock could decline.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The trading market for our common stock could be affected by whether and to what extent equity research analysts publish research or reports about us and our business. If one or more equity analysts cover us and publish research reports about our common stock, the price of our stock could decline rapidly if one or more securities analysts downgrade our stock or if those analysts&#8217; issue or offer unfavorable commentary or cease publishing reports about us. If any of these analysts ceases coverage of us, we could lose visibility in the market, which in turn could cause our common stock price or trading volume to decline and our common stock to be less liquid.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We are a smaller reporting company and a non-accelerated filer, and we cannot be certain if the reduced disclosure requirements applicable to our filing status, as well as the exemption from the requirement to provide an auditor&#8217;s attestation report regarding the effectiveness of our internal controls, will make our common stock less attractive to investors.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are a &#8220;smaller reporting company,&#8221; meaning that we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a smaller reporting company and have a public float of less than $250 million measured as of the last business day of our most recently completed second fiscal quarter.&#160; &#8220;Smaller reporting companies&#8221; are able to provide simplified executive compensation disclosures in their filings and have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports.&#160; We are also a &#8220;non-accelerated filer,&#8221; meaning that we have a public float of less than $75 million measured as of the last business day of our most recently completed second fiscal quarter. As a &#8220;non-accelerated filer,&#8221; we are exempt from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting.&#160; Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; and as a &#8220;non-accelerated filer&#8221; may make it harder for investors to analyze our results of operations and financial prospects and may make our common stock a less attractive investment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1B">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I2">ITEM 2. PROPERTIES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Listed below are our current facilities as of December 31, 2022: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Location</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Primary Function </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Approx. Square Feet</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:25%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Leased or Owned</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Namur, Belgium <sup style="vertical-align:super">(1)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Research and development </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">17,300</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Owned </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Namur, Belgium <sup style="vertical-align:super">(2)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Manufacturing</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">9,688</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Owned </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">London, UK <sup style="vertical-align:super">(3)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales and marketing </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">323</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Leased, expiring 2024</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Triple One, Singapore <sup style="vertical-align:super">(4)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales and marketing </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">192</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Leased, expiring 2023</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Henderson, Nevada <sup style="vertical-align:super">(5)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Administration</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">301</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Leased, expiring 2024</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Carlsbad, California <sup style="vertical-align:super">(6)</sup></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Research and development</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">6,645</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Leased, expiring 2027</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(1)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Belgian Volition purchased property located in Namur, Belgium, in October 2016, to be used as a laboratory facility for R&amp;D. The purchase price for the property was &#8364;1.2 million, exclusive of any closing costs.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(2)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Belgian Volition purchased property located in Namur, Belgium, in December 2020, to be used as a manufacturing facility. The purchase price for the property was &#8364;0.6 million, exclusive of any closing costs.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(3)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volition Diagnostics signed a new 24-month lease for this property located at 93-95 Gloucester Place, London, W1U 6JQ, United Kingdom, commencing February 1, 2022 until January 31, 2024, at an annual rent of &#163;64,800 GBP.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(4)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Singapore Volition signed a one-year lease for this property, commencing July 1, 2022, located at 111 Somerset Road, Level 3, Triple One, Somerset, Singapore 238164, at an annual rent of SGD 67,524.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(5)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volition America signed a one-year lease for this property, commencing on April 1, 2022, located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014, at an annual rent of $14,868. Volition America entered into a new one-year lease for this property, commencing April 1, 2023, at an annual rent of $16,308.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><sup style="vertical-align:super">(6)</sup></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volition America signed a sixty-two month lease for this property, commencing on February 1, 2022, located at 6086 Corte Del Cedro, Carlsbad, California 92011 at an annual rent of $91,704.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I3">ITEM 3. LEGAL PROCEEDINGS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In the ordinary course of business, we may be subject to claims, counter claims, suits and other litigation of the type that generally arise from the conduct of our business. We are not aware of any threatened or pending litigation that we expect will have a material adverse effect on our business operations, financial condition or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I4">ITEM 4. MINE SAFETY DISCLOSURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not Applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="P2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I5">ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Market Information </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our common stock is traded on the NYSE American under the symbol &#8220;VNRX&#8221;.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Holders</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 8, 2023, there were 63,096,766 shares of our common stock outstanding held by 148 holders of record, based on information provided by our transfer agent. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Dividends</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have not declared or paid any cash dividends on our common stock since inception and presently anticipate that all earnings, if any, will be retained for development of our business and that no dividends on our common stock will be declared in the foreseeable future. Any future dividends will be subject to the discretion of our board of directors and will depend upon, among other things, future earnings, operating and financial conditions, capital requirements, general business conditions and other pertinent facts. Therefore, there can be no assurance that any dividends on our common stock will be paid in the future. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Securities Authorized for Issuance Under Equity Compensation Plans</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The information required by this item will be set forth in our definitive proxy statement related to our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation 14A, on or before May 1, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Recent Sales of Unregistered Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Repurchase of Equity Securities</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">No equity securities were repurchased during the fourth quarter of 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I6">ITEM 6. RESERVED</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I7">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>The following discussion of our financial condition and results of operations should be read together with our consolidated financial statements in Part II within this Report. This discussion includes an analysis of our financial condition and results of operations for the years ended December 31, 2022 and 2021 and year-over-year comparisons between those periods. Certain statements made in this section constitute &#8220;forward-looking statements,&#8221; which are subject to numerous risks and uncertainties including those described in this section. For additional information, refer to the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; within this Report.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Company Overview </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Volition is a multi-national epigenetics company powered by Nu.Q<sup style="vertical-align:super">&#174;</sup>, its proprietary nucleosome quantification platform.&#160; Through its subsidiaries, Volition is developing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis, such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also improve their quality of life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The tests are based on the science of Nucleosomics&#8482;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids, since changes in these parameters are an indication that disease is present. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;We have five key&#160;pillars of focus, all of which use the same proprietary Nu.Q<sup style="vertical-align:super">&#174;</sup>&#160;platform to commercialize in different areas.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet</strong> - cost-effective, easy-to-use cancer screening blood test for dogs and other animals.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> NETs - </strong>monitoring the immune system to save lives.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Cancer - </strong>detecting cancer early to save lives.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Capture</strong> - capturing and concentrating samples for more accurate diagnosis.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Nu.Q<sup style="vertical-align:super">&#174;</sup> Discover</strong> - a complete solution to profiling nucleosomes.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our research, product development and manufacturing activities are centered in Belgium, with innovation and U.S. operations in California, and additional offices in Nevada, London, and Singapore, where we focus on bringing our diagnostic and disease monitoring products to market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have identified the specific processes and resources required to achieve the near and medium-term objectives of our business plan, including personnel, facilities, equipment, research and testing materials including antibodies and clinical samples, and the protection of intellectual property. To date, operations have proceeded satisfactorily in relation to our business plan. However, it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost. It is also possible that the results of some processes may not be as expected, and that modifications of procedures and materials may be required. Such events could result in delays to the achievement of the near and medium-term objectives of our business plan, in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our future as an operating business will depend on our ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain our operations. Management plans to address the above as needed by: (a) securing additional grant funds; (b) obtaining additional equity or debt financing; (c) granting licenses to third parties in exchange for specified up-front and/or back end payments; and (d) developing and commercializing our products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our ability to continue as a going concern is dependent upon our accomplishment of the plans described in the preceding paragraph and eventually to attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. If we are unable to obtain adequate capital, we could be forced to cease operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Developments&#8212;COVID-19 Pandemic</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Due to the continued evolution of the COVID-19 pandemic since March 2020, we cannot precisely determine or quantify the impacts the pandemic will have on our business, financial conditions or results of operations. For example, although we have worked with clinical trial sites impacted by the pandemic to ensure study continuity, we have experienced and may in the future experience disruptions that could impact our clinical trials, including delays in enrolling patients in clinical trials or in sample collection, and diversion of healthcare resources from the conduct of our clinical trials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The extent of the impact of the COVID-19 pandemic on our business remains uncertain and subject to change. If there is a subsequent outbreak of COVID-19 in the future, we may experience significant delays in our clinical development timelines, which would adversely affect our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Liquidity and Capital Resources</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of December 31, 2022, we had cash and cash equivalents of approximately $10.9 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net cash used in operating activities was $15.3 million and $20.9 million for the years ended December 31, 2022 and December 31, 2021, respectively. The decrease in cash used in operating activities during 2022 when compared to 2021 was primarily due to a $10.0 million payment received pursuant to our master license and product supply agreement with Heska, partly offset by higher payroll costs, and higher amounts paid to suppliers during the period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net cash used in investing activities was $1.6 million and $1.0 million for the years ended December 31, 2022 and December 31, 2021, respectively. The increase in cash used in investing activities during 2022 was primarily due to an increase in purchases of laboratory equipment as compared to 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net cash provided by financing activities after associated costs was $6.9 million and $22.9 million for the years ended December 31, 2022 and December 31, 2021, respectively. The decrease in net cash provided by financing activities for the 2022, when compared to 2021 was primarily due to $18.9 million in net cash received from the issuance of shares of common stock in a registered public offering in February 2021, and an aggregate of $4.6 million in cash received from the issuance of shares of&#160; common stock under our &#8220;at-the-market&#8221; facilities during 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This compares with $6.4 million in net cash received from the issuance of approximately 3.5 million shares of common stock in a registered public offering in August 2022 (before deducting offering expenses of $0.2 million paid by the Company), a $1.1 million loan received in August 2022 from Namur Invest Capital Risk ("Namur Invest"), a $0.5 million loan received in December 2022 from Namur Invest, and an aggregate of&#160;$0.8 million in cash received from the issuance of shares of&#160; common stock under our &#8220;at-the-market&#8221; facilities during&#160;2022 (before deducting offering expenses of $0.2 million).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For additional information on our &#8220;at the market facilities,&#8221; refer to Note 7, <em>Common Stock &#8211; Equity Distribution Agreements, </em>of the Notes to consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes our approximate contractual payments due by year as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Approximate Payments (Including Interest) Due by Year</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2024 - 2027</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2028 + </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Description</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Financing lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541,162</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,534</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating lease liabilities and short-term lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">696,702</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">291,868</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404,834</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Grants repayable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,302</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">149,126</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,893</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Long-term debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,319,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,268,528</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,604,499</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">446,799</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Collaborative agreements obligations&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">879,805</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">798,032</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">81,773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,899,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,465,437</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,471,134</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">963,226</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We intend to use our cash reserves to predominantly fund further research and development activities.&#160; We do not have any substantial source of revenues and expect to rely on additional future financing, through the sale of equity or debt securities, or the sale of licensing or distribution rights, to provide sufficient funding to execute our strategic plan. There is no assurance that we will be successful in raising further funds.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In the event additional financing is delayed, we will prioritize the maintenance of our research and development personnel and facilities, primarily in Belgium, and the maintenance of our patent rights. In such instance, the completion of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD market would be delayed. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors included in their report on our audited financial statements for the year ended December 31, 2022, an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Results of Operations </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Comparison of the Years Ended </span></strong><strong><span style="text-decoration:underline">December 31, 2022 and December 31, 2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table sets forth our results of operations for the years ended on December 31, 2022, and December 31, 2021, respectively (expressed in United Stated Dollars, except outstanding share numbers and percentages). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td></td><td></td><td></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Increase</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>(Decrease)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Percentage Increase</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>(Decrease)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Royalty</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,911</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,911</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">&gt;100</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">&gt;100</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Product</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">210,993</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,035</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">120,958</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">&gt;100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">306,392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">&gt;100</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,572,532</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,022,411</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,550,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,937,686</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,676,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(738,760</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,576,246</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,724,257</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,851,989</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">77</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Operating Expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,086,464</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,423,114</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,663,350</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Grant income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,229,425</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,522,533</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,108</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%)</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Loss on disposal of fixed assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,166</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,166</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">&lt;(100</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Interest income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,265</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,734</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">&gt;100</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(173,087</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(155,803</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,284</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Other Income (Expenses)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,181,603</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,343,298</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(161,695</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30,598,469</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,989,781</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,608,688</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Revenues</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our operations are still transitioning from a research and development stage to a commercialization stage. Revenue for the year ended December 31, 2022 was $306,392 compared with $90,035 for the year ended December 31, 2021. The main source of revenues during the year ended December 31, 2022, was product sales of the Nu.Q&#174;&#160;Vet Cancer Test and services revenue from our Nu.Q<sup style="vertical-align:super">&#174;&#160;</sup> Discover offering. The primary source of revenue during the year ended December 31, 2021, was direct sales of the Nu.Q<sup style="vertical-align:super">&#174;&#160;</sup>Vet Cancer Test through the Gastrointestinal Laboratory at Texas A&amp;M University.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Operating Expenses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Total operating expenses increased to $32.1 million from $28.4 million for the years ended December 31, 2022 and December 31, 2021, respectively, as a result of the factors described below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Research and Development Expenses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Research and development expenses increased to $14.6 million from $13.0 million for the years ended December 31, 2022 and December 31, 2021, respectively. The increase in overall research and development expenditures during 2022 was primarily related to higher personnel expenses offset by a reduction in stock-based compensation expenses. FTE personnel numbers within this division increased by six to sixty-three during 2022 compared to the prior year period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Change</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,125,017</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,335,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,789,684</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">652,653</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,361,989</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(709,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Direct research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,662,957</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,055,411</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">607,546</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">292,292</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">730,491</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(438,199</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">839,613</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">539,187</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">300,426</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,572,532</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,022,411</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,550,121</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>General and Administrative Expenses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">General and administrative expenses decreased to $10.9 million from $11.7 million for the years ended December 31, 2022 and December 31, 2021, respectively. The decrease in overall general and administrative expenditures during 2022 was primarily due to lower stock-based compensation in relation to modification of options, offset by higher personnel expenses. The FTE personnel number within this division increased by nine to twenty-two in 2022 compared to the prior year period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Change</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,047,242</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,944,454</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,102,788</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,393,784</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,984,253</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,590,469</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Legal and professional fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,715,255</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,696,164</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,091</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,486,722</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,477,186</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,536</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">294,683</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">574,389</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(279,706</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total general and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,937,686</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,676,446</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(738,760</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Sales and Marketing Expenses</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales and marketing expenses increased to $6.6 million from $3.7 million for the years ended December 31, 2022 and December 31, 2021, respectively. The increase in overall sales and marketing expenditures was primarily due to increased personnel expenses, stock-based compensation and direct marketing expenses. The FTE personnel number within this division increased by six to nineteen in 2022 compared to the prior year period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Change</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,400,092</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,203,745</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,196,347</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,068,222</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">774,404</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other Sales &amp; Marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,807</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">746,108</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307,699</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total sales and marketing expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,576,246</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,724,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,851,989</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Other Income (Expenses)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the year ended December 31, 2022, other income decreased to approximately $1.2 million compared to other income of approximately $1.3 million for the year ended December 31, 2021. This decrease in other income was primarily due to reduced grant income received of approximately $1.2 million during 2022 compared to $1.5 million in 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Net Loss</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the year ended December 31, 2022, the Company&#8217;s net loss was $30.6 million, an increase of approximately $3.6 million, in comparison to a net loss of $27.0 million for the year ended December 31, 2021. The change was a result of the factors described above.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have not attained profitable operations and are dependent upon obtaining external financing to continue to pursue our operational and strategic plans. For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Off-Balance Sheet Arrangements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Future Equity or Debt Financings</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We may seek to obtain additional capital through the sale of debt or equity securities if we deem it desirable or necessary. These sales may include the sale of equity securities from time to time through our &#8220;at the market facility&#8221; with Jefferies LLC under an equity distribution agreement dated May 20, 2022 (see Note 7, <em>Common Stock &#8211; Equity Distribution Agreements, </em>of the Notes to consolidated financial statements).&#160; However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles, (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We also regularly evaluate estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We base our estimates and assumptions on current facts, historical experiences, information from third party professionals and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from our estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We regularly evaluate the accounting policies that we use to prepare our consolidated financial statements.&#160; A complete summary of these policies is included in the Notes to our consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have determined that for the periods reported in this Report the following accounting policies are critical in understanding our financial condition and results of operations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, &#8220;<em>Compensation &#8211; Stock Compensation&#8221;.</em> Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant, refer to Note 8 of the consolidated financial statements for further details.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Impairment of Long-Lived Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 360, <em>&#8220;Prop</em><em>erty</em><em> Plant and Equipment&#8221;</em>, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Foreign Currency </strong><strong>Translation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has functional currencies in Euros, U.S. Dollars and British Pounds Sterling and its reporting currency is the U.S. Dollar. Management has adopted ASC 830-20, &#8220;<em>Foreign Currency Matters &#8211; Foreign Currency Transactions</em>&#8221; All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in Other Comprehensive Income.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Recently Issued Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I7A">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are a smaller reporting company and are not required to disclose this information.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I8">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="TOCFAN">VOLITIONRX LIMITED</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For the Years Ended December 31, 2022 and 2021</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Index</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#reportt">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">3627</ix:nonNumeric>)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 36</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#BS">Consolidated Balance Sheets</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 38</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#CL">Consolidated Statements of Operations and Comprehensive Loss</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 39</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#SE">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 40</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#CF">Consolidated Statements of Cash Flows</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 41</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="#NOTES">Notes to the Consolidated Financial Statements</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">F - 42</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline"><span id="reportt" class="atag" style="display:inline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">To the Board of Directors and Shareholders of VolitionRx Limited:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="text-decoration:underline">Opinion on the Financial Statements</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have audited the accompanying consolidated balance sheets of VolitionRx Limited (&#8220;the Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations and&#160;comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2022 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="text-decoration:underline">Explanatory Paragraph Regarding Going Concern</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><span style="text-decoration:underline">Basis for Opinion</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Critical Audit Matters</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>License and Supply Agreement with Heska </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As discussed in Note 3 to the consolidated financial statements, in March 2022, the Company entered into a license and supply agreement with Heska Corporation (&#8220;Heska&#8221;). Under the terms of the agreement, the Company granted Heska worldwide exclusive rights to the Nu.Q Vet Cancer Screening Test at the point of care, initially for the screening of lymphoma and hemangiosarcoma in dogs and non-exclusive rights to sell its Nu.Q Vet Cancer Screening Test in kit format through Heska&#8217;s network of central reference laboratories. In addition, the agreement requires the Company to supply required components for point of care testing and for kits used in central laboratories. The Company received an upfront payment of $10 million during 2022 and is eligible to receive additional milestone payments upon certain commercial targets being met. In addition, the Company is eligible to receive per unit consideration for kits and components supplied under this agreement.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have identified the performance obligations, including understanding the nature and significance of the contractual obligations, under the Heska license and supply agreement as a critical audit matter. Determining the distinct performance obligation included in the agreement required management to make judgements with respect to the appropriate application of relevant authoritative accounting guidance. Auditing these management judgements and the resulting impacts on the accounting and deferred revenue recognition for the Heska license and supply agreement required increased auditor effort.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The primary procedures we performed to address this critical audit matter included:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Reading the license and supply agreement with Heska to gain an understanding of the contractual terms and conditions and the commitments being made in the agreement.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Assessing the key terms in the supply and license agreement under the relevant authoritative accounting guidance to evaluate management&#8217;s conclusion that contractual promises made in the license and supply agreement should constitute a single performance obligation.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of management&#8217;s conclusions with respect to the performance obligation identified.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Sadler, Gibb &amp; Associates, LLC</ix:nonNumeric></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">We have served as the Company&#8217;s auditor since 2011.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Draper, UT</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">March 15, 2023</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOL</strong><strong>ITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="BS">Consolidated Balance Sheets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Expressed in United States Dollars, except share numbers)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 28.35pt; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p><strong>$</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2" contextRef="AsOf2022-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,867,050</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,581,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accounts Receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_4" contextRef="AsOf2022-12-31" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,609</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_5" contextRef="AsOf2021-12-31" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,510</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_6" contextRef="AsOf2022-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">784,920</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_7" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">598,367</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8" contextRef="AsOf2022-12-31" name="us-gaap:OtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,566</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9" contextRef="AsOf2021-12-31" name="us-gaap:OtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,642</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Current Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" contextRef="AsOf2022-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,172,145</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11" contextRef="AsOf2021-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,393,012</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_13" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,911,077</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,392</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">383,551</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Intangible assets, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_16" contextRef="AsOf2022-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_17" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,876</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_18" contextRef="AsOf2022-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,295,054</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_19" contextRef="AsOf2021-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,490,336</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_22" contextRef="AsOf2022-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,043,008</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_23" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,542,457</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_24" contextRef="AsOf2022-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,872,247</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_25" contextRef="AsOf2021-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,828,501</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Deferred revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_26" contextRef="AsOf2022-12-31" name="us-gaap:DeferredRevenueCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" contextRef="AsOf2021-12-31" name="us-gaap:DeferredRevenueCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,512</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Management and directors&#8217; fees payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_28" contextRef="AsOf2022-12-31" name="us-gaap:ManagementFeePayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,119</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_29" contextRef="AsOf2021-12-31" name="us-gaap:ManagementFeePayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,303</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion of long-term debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_30" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,700</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" contextRef="AsOf2021-12-31" name="us-gaap:LongTermDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">797,855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion of financing lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" contextRef="AsOf2022-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,958</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion of operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_34" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,163</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_35" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion of grant repayable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_36" contextRef="AsOf2022-12-31" name="vnrx:CurrentPortionOfGrantRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,836</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_37" contextRef="AsOf2021-12-31" name="vnrx:CurrentPortionOfGrantRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,100</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Current Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" contextRef="AsOf2022-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,386,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_39" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,515,852</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Long-term debt, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,779,240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_41" contextRef="AsOf2021-12-31" name="us-gaap:LongTermDebtNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,270,767</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" contextRef="AsOf2022-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,132</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_43" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,086</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_44" contextRef="AsOf2022-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,091</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_45" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,305</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Grant repayable, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_46" contextRef="AsOf2022-12-31" name="vnrx:GrantRepayableNetOfCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,466</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_47" contextRef="AsOf2021-12-31" name="vnrx:GrantRepayableNetOfCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,221</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_48" contextRef="AsOf2022-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,422,016</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_49" contextRef="AsOf2021-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,768,231</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Common Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30px">Authorized: <ix:nonFraction id="fid_69" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000,000</ix:nonFraction> shares of common stock, at $<ix:nonFraction id="fid_71" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value; Issued and outstanding: <ix:nonFraction id="fid_72" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">57,873,379</ix:nonFraction> shares and <ix:nonFraction id="fid_73" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">53,772,261</ix:nonFraction> shares, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_52" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,873</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_53" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,772</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_54" contextRef="AsOf2022-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,397,468</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_55" contextRef="AsOf2021-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,730,938</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accumulated other comprehensive income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_56" contextRef="AsOf2022-12-31" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_57" contextRef="AsOf2021-12-31" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,326</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_58" contextRef="AsOf2022-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">167,257,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_59" contextRef="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">136,988,636</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total VolitionRx Limited Stockholders&#8217; Equity (Deficit)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_60" contextRef="AsOf2022-12-31" name="vnrx:TotalVolitionrxLimitedStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,574,991</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_61" contextRef="AsOf2021-12-31" name="vnrx:TotalVolitionrxLimitedStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,944,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-controlling interest </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_62" contextRef="AsOf2022-12-31" name="vnrx:MinorityInterests" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">551,971</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_63" contextRef="AsOf2021-12-31" name="vnrx:MinorityInterests" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">222,295</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Stockholders&#8217; Equity (Deficit)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_64" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,126,962</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_65" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,722,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Liabilities and Stockholders&#8217; Equity (Deficit)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_66" contextRef="AsOf2022-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,295,054</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_67" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,490,336</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(The accompanying notes are an integral part of these consolidated financial statements)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOL</strong><strong>ITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="CL">Consolidated Statements of Operations and Comprehensive Loss </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Expressed in United States Dollars, except share numbers)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30.35pt; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the year ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Revenues</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Royalty</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_77" contextRef="From2022-01-01to2022-12-31" name="vnrx:RoyaltyRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_78" contextRef="From2021-01-01to2021-12-31" name="vnrx:RoyaltyRevenue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_79" contextRef="From2022-01-01to2022-12-31" name="vnrx:ServiceRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_80" contextRef="From2021-01-01to2021-12-31" name="vnrx:ServiceRevenue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Product</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_81" contextRef="From2022-01-01to2022-12-31" name="vnrx:ProductRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,993</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_82" contextRef="From2021-01-01to2021-12-31" name="vnrx:ProductRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,035</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Revenues</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_83" contextRef="From2022-01-01to2022-12-31" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,392</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_84" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Operating Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_86" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,572,532</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_87" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,022,411</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_88" contextRef="From2022-01-01to2022-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,937,686</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_89" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,676,446</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_90" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SellingAndMarketingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,576,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_91" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SellingAndMarketingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,724,257</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Operating Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_92" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,086,464</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_93" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,423,114</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Operating Loss</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_94" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">31,780,072</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_95" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">28,333,079</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Other Income (Expenses)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Grant income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_97" contextRef="From2022-01-01to2022-12-31" name="vnrx:IncomeFromGrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,229,425</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_98" contextRef="From2021-01-01to2021-12-31" name="vnrx:IncomeFromGrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,522,533</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Loss on disposal of fixed assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_99" contextRef="From2022-01-01to2022-12-31" name="vnrx:LossOnDisposalOfFixedAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_100" contextRef="From2021-01-01to2021-12-31" name="vnrx:LossOnDisposalOfFixedAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,166</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Interest income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_101" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InterestIncomeOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,265</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_102" contextRef="From2021-01-01to2021-12-31" name="us-gaap:InterestIncomeOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,734</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_103" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InterestExpenseOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,087</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(155,803</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Other Income</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_105" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,181,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_106" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343,298</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Loss</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_107" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,598,469</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_108" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,989,781</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Loss attributable to Non-Controlling Interest</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_109" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,676</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_110" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,116</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Loss attributable to VolitionRx Limited Stockholders</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_111" contextRef="From2022-01-01to2022-12-31" name="vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,268,793</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_112" contextRef="From2021-01-01to2021-12-31" name="vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,814,665</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Other Comprehensive Income (Loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Foreign currency translation adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_114" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,771</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_115" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,304</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Comprehensive Loss</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_116" contextRef="From2022-01-01to2022-12-31" name="vnrx:OthersComprehensiveIncomeLossNetOfTax" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,519,698</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_117" contextRef="From2021-01-01to2021-12-31" name="vnrx:OthersComprehensiveIncomeLossNetOfTax" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,781,477</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Loss Per Share &#8211; Basic and Diluted attributable to VolitionRx Limited Stockholders</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_118" contextRef="From2022-01-01to2022-12-31" name="vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.55</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_119" contextRef="From2021-01-01to2021-12-31" name="vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.51</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Weighted Average Shares Outstanding</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"><strong>&#8211; Basic and Diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_121" contextRef="From2022-01-01to2022-12-31" name="vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55,350,401</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_122" contextRef="From2021-01-01to2021-12-31" name="vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,655,885</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(The accompanying notes are an integral part of these consolidated financial statements)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-39</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOL</strong><strong>ITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SE">Consolidated Statement of Stockholders&#8217; Equity</span>&#160;(Deficit)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(Expressed in United States Dollars, except share numbers)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Additional </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Accumulated&#160; Other </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Non </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-in </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Comprehensive</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Controlling </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;#</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Income (Loss)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Interest</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;$</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Balance, December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_360" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,607,017</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_361" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,607</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_362" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,526,239</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_363" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">59,978</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_364" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">110,173,971</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_365" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">47,179</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_366" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,293,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued for cashless exercise of stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_367" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">77,451</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_368" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_369" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">77</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_370" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_371" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_372" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_373" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued for settlement of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_374" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">24,712</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_375" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_376" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">25</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_377" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_378" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_379" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_380" contextRef="From2021-01-01to2021-12-31" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued in public offerings, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_381" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedInPublicOfferingsNetShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,063,081</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_382" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_383" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,214,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_384" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_385" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_386" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_387" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,219,644</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Tax withholdings paid related to stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_388" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_389" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">130,426</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_390" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_391" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_392" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_393" contextRef="From2021-01-01to2021-12-31" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">130,426</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_394" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_395" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,670,297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_397" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_398" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_399" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,670,297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation in relation to modification of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_400" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_401" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_403" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_404" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_405" contextRef="From2021-01-01to2021-12-31" name="vnrx:StockBasedCompensationInRelationToModificationOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_406" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_407" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_409" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_411" contextRef="From2021-01-01to2021-12-31" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss for the Year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_415" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,814,665</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_416" contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">175,116</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_417" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,989,781</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Balance, December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_418" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">53,772,261</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_419" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,772</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_420" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,730,938</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_421" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,326</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_422" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">136,988,636</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_423" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">222,295</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_424" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,722,105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued for settlement of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_425" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,289</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_426" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_427" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">297</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_428" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_429" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_430" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_431" contextRef="From2022-01-01to2022-12-31" name="vnrx:CommonStockIssuedForSettlementOfRsuSAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock issued in public offerings, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_432" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="vnrx:CommonStockIssuedInPublicOfferingsNetShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,803,829</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_433" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,732,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_435" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_438" contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,736,444</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Tax withholdings paid related to stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_440" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">180,472</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_442" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_444" contextRef="From2022-01-01to2022-12-31" name="vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">180,472</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_445" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_446" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,114,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_447" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,114,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Foreign currency translation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_451" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_452" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_453" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,771</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_454" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_456" contextRef="From2022-01-01to2022-12-31" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,771</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss for the Year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_457" contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_458" contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_459" contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_460" contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,268,793</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_461" contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">329,676</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_462" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,598,469</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Balance, December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_463" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">57,873,379</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_464" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,873</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_465" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,397,468</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_466" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,097</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_467" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">167,257,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_468" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">551,971</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_469" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,126,962</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(The accompanying notes are an integral part of these consolidated financial statements)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-40</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOL</strong><strong>ITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="CF">Consolidated Statements of Cash Flows </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the year ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating Activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_226" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,598,469</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_227" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,989,781</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_229" contextRef="From2022-01-01to2022-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">936,084</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_230" contextRef="From2021-01-01to2021-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">945,367</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Amortization of operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_231" contextRef="From2022-01-01to2022-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,864</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_232" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,793</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Loss on disposal of fixed assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_233" contextRef="From2022-01-01to2022-12-31" name="vnrx:OperatingLossOnDisposalOfFixedAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_234" contextRef="From2021-01-01to2021-12-31" name="vnrx:OperatingLossOnDisposalOfFixedAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_235" contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,114,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_236" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,670,297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock-based compensation in relation to modification of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_237" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_238" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_240" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,995</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_241" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">295,189</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_242" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">72,609</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_243" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,510</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_244" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,514</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_245" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">202,801</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Deferred revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_246" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,987,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_247" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,512</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Accounts payable and accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_248" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,611</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_249" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">522,220</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Management and directors&#8217; fees payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_250" contextRef="From2022-01-01to2022-12-31" name="vnrx:ManagementAndDirectorsFeesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">184</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_251" contextRef="From2021-01-01to2021-12-31" name="vnrx:ManagementAndDirectorsFeesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,129</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_252" contextRef="From2022-01-01to2022-12-31" name="vnrx:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">232,695</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_253" contextRef="From2021-01-01to2021-12-31" name="vnrx:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">196,471</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Cash Used In Operating Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_254" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,277,742</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_255" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,853,919</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Investing Activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_257" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,570,182</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_258" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">973,559</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Cash Used In Investing Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_259" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,570,182</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_260" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">973,559</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Financing Activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Net proceeds from issuance of common shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_262" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,736,444</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_263" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,219,644</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Tax withholdings paid related to stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_264" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,472</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_265" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,426</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Proceeds from grants repayable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_266" contextRef="From2022-01-01to2022-12-31" name="vnrx:ProceedsFromGrantsRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,445</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_267" contextRef="From2021-01-01to2021-12-31" name="vnrx:ProceedsFromGrantsRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,631</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Proceeds from long-term debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_268" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_269" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">592,423</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Payments on long-term debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_270" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,268,386</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_271" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">755,721</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Payments on grants repayable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_272" contextRef="From2022-01-01to2022-12-31" name="vnrx:PaymentsOnGrantsRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,664</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_273" contextRef="From2021-01-01to2021-12-31" name="vnrx:PaymentsOnGrantsRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">47,789</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Payments on financing leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_274" contextRef="From2022-01-01to2022-12-31" name="vnrx:PaymentsOnFinancingLeasesLeaseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,433</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_275" contextRef="From2021-01-01to2021-12-31" name="vnrx:PaymentsOnFinancingLeasesLeaseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,210</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net Cash Provided By Financing Activities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,938,032</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_277" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,857,552</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Effect of foreign exchange on cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,502</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Change in Cash and Cash Equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_280" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">9,714,263</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,576</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cash and Cash Equivalents &#8211; Beginning of Year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,581,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_283" contextRef="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,444,737</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Cash and Cash Equivalents &#8211; End of Year</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" contextRef="AsOf2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,867,050</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_285" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,581,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Supplemental Disclosures of Cash Flow Information:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Interest paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_287" contextRef="From2022-01-01to2022-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" contextRef="From2021-01-01to2021-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,803</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Income tax paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxesPaid" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_290" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxesPaid" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-Cash Financing Activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Common Stock issued on exercises of stock options and warrants and settlement of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_292" contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_293" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">102</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Offering costs from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_294" contextRef="From2022-01-01to2022-12-31" name="vnrx:OfferingCostsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,443</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" contextRef="From2021-01-01to2021-12-31" name="vnrx:OfferingCostsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,459</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Non-cash Note Payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2071" contextRef="From2022-01-01to2022-12-31" name="vnrx:NonCashNotePayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,549</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2072" contextRef="From2021-01-01to2021-12-31" name="vnrx:NonCashNotePayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(The accompanying notes are an integral part of these consolidated financial statements)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-41</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="NOTES">Notes to Consolidated Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_305" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NatureOfOperations" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 1 - Nature of Operations </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with the Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of &#8220;VolitionRX Limited&#8221; and the name change became effective on October 11, 2011. On October 7, 2016, the Company amended its Certificate of Incorporation to reflect a name change to &#8220;VolitionRx Limited.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October&#160;6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited, a Singapore corporation incorporated on August 5, 2010 (&#8220;Singapore Volition&#8221;), and the shareholders of Singapore Volition.&#160; Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company.&#160; The issuance was deemed to be a reverse acquisition for accounting purposes and as such, Singapore Volition is regarded as the predecessor of the Company. The number of shares outstanding and per share amounts of the Company have been restated to recognize the foregoing recapitalization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood tests designed to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics<sup style="vertical-align:super">TM</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid &#8211; an indication that disease is present.&#160; The Company has two wholly owned subsidiaries, Volition Global Services SRL (&#8220;Volition Global&#8221;) which was formed in August 2021 and Singapore Volition. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL, a Belgium private limited liability company (&#8220;Belgian Volition&#8221;), which it acquired in September 2010.&#160; Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (&#8220;Volition Diagnostics&#8221;), which was formed in November&#160;2015, Volition America, Inc. (&#8220;Volition America&#8221;), which was formed in February 2017, Volition Germany GmbH (&#8220;Volition Germany&#8221;), which was acquired in January 2020, as well as its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (&#8220;Volition Vet&#8221;), which was formed in June 2019.&#160; Following the acquisition of Singapore Volition in 2011, the Company&#8217;s fiscal year end was changed from August 31 to December 31.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_306" contextRef="From2022-01-01to2022-12-31" name="vnrx:LiquidityAndGoingConcernAssessment" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>No</strong><strong>te 2 </strong><strong>&#8211; Liquidity and </strong><strong>Go</strong><strong>ing Concern Assessment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $<ix:nonFraction id="fid_550" contextRef="From2022-01-01to2022-12-31" name="vnrx:NetIncomeLossSinceInception" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">167.3</ix:nonFraction> million, has negative cash flows from operations, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period at least one year from the date of issuance of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions; (c) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-42</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_296" contextRef="From2022-01-01to2022-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_241816"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Basis of Presentation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_308" contextRef="From2022-01-01to2022-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company&#8217;s fiscal year end is December 31.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Use of Estimates</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_309" contextRef="From2022-01-01to2022-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Principles of Consolidation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_310" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), <em>Commitments and Contingencies &#8211; Other Commitments</em>, for more information regarding Volition Vet, Volition Germany and Volition America. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Reclassification</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative amounts of research and development, sales and marketing and general and administrative expenses to be consistent with the current year classification.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Cash and Cash Equivalents</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_311" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $<ix:nonFraction id="fid_552" contextRef="AsOf2022-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,867,050</ix:nonFraction> and $<ix:nonFraction id="fid_551" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,581,313</ix:nonFraction>, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $<ix:nonFraction id="fid_554" contextRef="AsOf2022-12-31" name="us-gaap:CashFDICInsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,079,089</ix:nonFraction> and $<ix:nonFraction id="fid_553" contextRef="AsOf2021-12-31" name="us-gaap:CashFDICInsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,753,878</ix:nonFraction>, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $<ix:nonFraction id="fid_568" contextRef="AsOf2022-12-31_vnrx_BelgianDepositGuaranteeMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,981</ix:nonFraction> and $<ix:nonFraction id="fid_561" contextRef="AsOf2021-12-31_vnrx_BelgianDepositGuaranteeMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,134</ix:nonFraction>, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $<ix:nonFraction id="fid_563" contextRef="AsOf2022-12-31_vnrx_SingaporeDepositInsuranceMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,601</ix:nonFraction> and $<ix:nonFraction id="fid_562" contextRef="AsOf2021-12-31_vnrx_SingaporeDepositInsuranceMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,514</ix:nonFraction>, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $<ix:nonFraction id="fid_565" contextRef="AsOf2022-12-31_vnrx_UKDepositProtectionSchemeMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,631</ix:nonFraction> and $<ix:nonFraction id="fid_564" contextRef="AsOf2021-12-31_vnrx_UKDepositProtectionSchemeMember" name="us-gaap:CashUninsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,410</ix:nonFraction>, respectively, in its foreign accounts in excess of the UK Deposit insured limits.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Accounts Receivable </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_312" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company&#8217;s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.&#160; The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $<ix:nonFraction id="fid_560" contextRef="AsOf2022-12-31" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,609</ix:nonFraction> and the allowance for doubtful accounts was $nil.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-43</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_241816" continuedAt="cont_aa08df"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Property and Equipment</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_322" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Basic and Diluted Net Loss Per Share</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_315" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company computes net loss per share in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 260, <em>&#8220;Earnings Per Share,&#8221;</em> which requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of December 31, 2022, and December 31, 2021, <ix:nonFraction id="fid_567" contextRef="AsOf2022-12-31_vnrx_DilutiveWarrantsAndOptionsMember" name="vnrx:PotentiallyDilutiveWarrantsAndOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,787,013</ix:nonFraction> and <ix:nonFraction id="fid_566" contextRef="AsOf2021-12-31_vnrx_DilutiveWarrantsAndOptionsMember" name="vnrx:PotentiallyDilutiveWarrantsAndOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,323,268</ix:nonFraction>, respectively, of potential common shares equivalents from stock options, RSUs and warrants were excluded from the diluted EPS calculations as their effect is anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Foreign Currency Translation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_316" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, <em>&#8220;Foreign Currency Matters &#8211; Foreign Currency Transactions&#8221;</em>. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Fair Value Measurements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_323" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to ASC 820, &#8220;<em>Fair Value Measurements and Disclosures,&#8221;</em> an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 1</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 2</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 3</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on &#8220;Level 1&#8221; inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-44</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_aa08df" continuedAt="cont_eb517e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Other Comprehensive Income (Loss)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_324" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASC 220, &#8220;<em>Other Comprehensive Income/(Loss)&#8221;,</em> establishes standards for the reporting and display of other comprehensive loss and its components in the financial statements. As of December 31, 2022, the Company had $<ix:nonFraction id="fid_555" contextRef="AsOf2022-12-31" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,097</ix:nonFraction> of accumulated other comprehensive income, relating to foreign currency translation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Income Taxes</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_331" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, <em>&#8220;Accounting for Income Taxes&#8221;</em> as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Refer to Note 9 for further details.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Revenue Recognition </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_313" contextRef="From2022-01-01to2022-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="cont_8cd9d2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company adopted ASC 606, &#8220;<em>Revenue from Contracts with Customers,&#8221;</em> effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company generates product revenues from the sale of its Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Royalty </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under &#8220;Royalty&#8221; under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Product</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in &#8220;Product&#8221; in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-45</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenue Recognition (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_eb517e" continuedAt="cont_fe56de"><ix:continuation id="cont_8cd9d2" continuedAt="cont_f78af7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Service </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from laboratory services performed in the Company&#8217;s laboratory on behalf of third parties under &#8220;Service&#8221; under the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Licensing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from the licensing of certain rights to third parties in &#8220;Licensing&#8221; in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue from Heska License Agreement </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the &#8220;License Agreement&#8221;) with Heska Corporation (&#8220;Heska&#8221;), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q&#174; Vet Cancer Test at the point of care (&#8220;POC&#8221;) initially for the screening of lymphoma and hemangiosarcoma in dogs (&#8220;Canine Lymphoma &amp; HSA&#8221;), and non-exclusive rights to sell its Nu.Q&#174; Vet Cancer Test in kit format (&#8220;Kits&#8221;) through Heska&#8217;s network of central reference laboratories (&#8220;Central Lab&#8221;) initially for Canine Lymphoma &amp; HSA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under and subject to the terms of the License Agreement, <ix:nonNumeric id="fid_569" contextRef="From2022-01-01to2022-12-31" name="vnrx:TermsOfLicenseAgreement">Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines</ix:nonNumeric>. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well.&#160; Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (&#8220;Key Components&#8221;) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska&#8217;s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.</p></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-46</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenue Recognition (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_fe56de" continuedAt="cont_94fb7f"><ix:continuation id="cont_f78af7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party&#8217;s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of <ix:nonNumeric id="fid_570" contextRef="From2022-01-01to2022-12-31" name="vnrx:InitialTermForPoc" format="ixt-sec:duryear">22</ix:nonNumeric> years for POC and <ix:nonNumeric id="fid_571" contextRef="From2022-01-01to2022-12-31" name="vnrx:InitialTermForCentralLab" format="ixt-sec:duryear">5</ix:nonNumeric> years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">According to ASC Topic 606, &#8220;<em>Revenue from Contracts with Customers</em>&#8221;, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the first quarter of 2022, the Company received a $<ix:nonFraction id="fid_572" contextRef="From2022-01-01to2022-12-31" name="vnrx:UpfrontPayment" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.0</ix:nonFraction> million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $<ix:nonFraction id="fid_573" contextRef="From2022-01-01to2022-12-31" name="vnrx:MilestoneAmountRecognized" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">18.0</ix:nonFraction> million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Deferred Revenue (Contract Liabilities) and Contract Assets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_314" contextRef="From2022-01-01to2022-12-31" name="vnrx:DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $<ix:nonFraction id="fid_574" contextRef="AsOf2022-12-31" name="us-gaap:DeferredRevenue" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.0</ix:nonFraction> million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $<ix:nonFraction id="fid_575" contextRef="AsOf2021-12-31" name="us-gaap:DeferredRevenue" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">12,512</ix:nonFraction> as deferred revenue.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Research and Development</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_317" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $<ix:nonFraction id="fid_556" contextRef="From2022-01-01to2022-12-31" name="vnrx:ResearchAndDevelopmentExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">14.6</ix:nonFraction> million and $<ix:nonFraction id="fid_557" contextRef="From2021-01-01to2021-12-31" name="vnrx:ResearchAndDevelopmentExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.0</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-47</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_94fb7f" continuedAt="cont_3ea22a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_328" contextRef="From2022-01-01to2022-12-31" name="vnrx:ImpairmentofLongLivedAssetsPolixyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 360, <em>&#8220;Property Plant and Equipment&#8221;,</em> the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Stock-Based Compensation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_318" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, &#8220;<em>Compensation &#8211; Stock Compensation&#8221;</em>. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. The estimated fair value of RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation model. Refer to Note 8 for further details.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Leases</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_330" contextRef="From2022-01-01to2022-12-31" name="us-gaap:LessorLeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases.&#8221; The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (&#8220;ROU&#8221;) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (&#8220;IBR&#8221;) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-48</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Note 3 - Summary of Significant Accounting Policies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">&#160;&#160;</p><ix:continuation id="cont_3ea22a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Grant Income&#160; </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_320" contextRef="From2022-01-01to2022-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="cont_4d130c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">COVID-19 Pandemic Impact </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_321" contextRef="From2022-01-01to2022-12-31" name="vnrx:COVID19PandemicImpactPolicyTextblock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company&#8217;s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Recent&#160;Accounting&#160;Pronouncements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline"></span></strong>&#160;</p><ix:continuation id="cont_4d130c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.</p></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline"></span></strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-49</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_298" contextRef="From2022-01-01to2022-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 4 - Property and Equipment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s property and equipment consist of the following amounts as of December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_332" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_508" contextRef="From2022-01-01to2022-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_470" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">656,759</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_482" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">497,306</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_496" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,453</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_509" contextRef="From2022-01-01to2022-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_471" contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,190,289</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_483" contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,951,387</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_497" contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,238,902</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_510" contextRef="From2022-01-01to2022-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_472" contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,575</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_484" contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,436</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_498" contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,139</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_511" contextRef="From2022-01-01to2022-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">30</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_473" contextRef="AsOf2022-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,054,332</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_485" contextRef="AsOf2022-12-31_us-gaap_BuildingMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,397</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_499" contextRef="AsOf2022-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,755,935</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_512" contextRef="From2022-01-01to2022-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric>-<ix:nonNumeric id="fid_513" contextRef="From2022-01-01to2022-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">15</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_474" contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,317,132</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_486" contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,337</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_500" contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">990,795</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_475" contextRef="AsOf2022-12-31_us-gaap_LandMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,788</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_487" contextRef="AsOf2022-12-31_us-gaap_LandMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_501" contextRef="AsOf2022-12-31_us-gaap_LandMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,788</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_530" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,705,875</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_528" contextRef="AsOf2022-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,312,863</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_494" contextRef="AsOf2022-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,393,012</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_514" contextRef="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_531" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,944</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_488" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,169</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_502" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,775</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_515" contextRef="From2021-01-01to2021-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_477" contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,032,108</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_489" contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,434,347</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_503" contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,597,761</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_516" contextRef="From2021-01-01to2021-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_478" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,427</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_490" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,244</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_504" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,183</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_517" contextRef="From2021-01-01to2021-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">30</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_479" contextRef="AsOf2021-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,177,641</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_491" contextRef="AsOf2021-12-31_us-gaap_BuildingMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,750</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_505" contextRef="AsOf2021-12-31_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,933,891</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_518" contextRef="From2021-01-01to2021-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric>-<ix:nonNumeric id="fid_519" contextRef="From2021-01-01to2021-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear">15</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_480" contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,258</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_492" contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,309</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_506" contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,949</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_481" contextRef="AsOf2021-12-31_us-gaap_LandMember" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,518</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_493" contextRef="AsOf2021-12-31_us-gaap_LandMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_507" contextRef="AsOf2021-12-31_us-gaap_LandMember" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,518</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_532" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,532,896</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_529" contextRef="AsOf2021-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,621,819</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_495" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,911,077</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the total capital expenditure was $<ix:nonFraction id="fid_535" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million and $<ix:nonFraction id="fid_536" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.1</ix:nonFraction> million, respectively, the majority of which was from purchases of laboratory equipment. For further details refer to Note 10 (a) for Finance Leases included in <em>Property, Plant and Equipment.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the Company recognized $<ix:nonFraction id="fid_533" contextRef="From2022-01-01to2022-12-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">865,262</ix:nonFraction> and $<ix:nonFraction id="fid_534" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,109</ix:nonFraction>, respectively, in depreciation expense.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-50</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_299" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 5 - Intangible Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets&#8217; estimated useful lives, which range from 8 to 20 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_333" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_539" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,104,103</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_541" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">993,598</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_537" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_540" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,178,135</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_542" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,259</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_538" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,876</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the Company recognized $<ix:nonFraction id="fid_546" contextRef="From2022-01-01to2022-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,558</ix:nonFraction> and $<ix:nonFraction id="fid_547" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,645</ix:nonFraction>, respectively, in amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company amortizes the long-lived assets on a straight-line basis with terms ranging from <ix:nonNumeric id="fid_548" contextRef="From2022-01-01to2022-12-31_srt_MinimumMember_vnrx_PatentsAndIntellectualPropertyMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear">8</ix:nonNumeric> to <ix:nonNumeric id="fid_549" contextRef="From2022-01-01to2022-12-31_srt_MaximumMember_vnrx_PatentsAndIntellectualPropertyMember" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear">20</ix:nonNumeric> years. The annual estimated amortization schedule over the next five years is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_334" contextRef="From2022-01-01to2022-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Remaining Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Amortization</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_543" contextRef="AsOf2022-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,636</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_544" contextRef="AsOf2022-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,869</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Intangible Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_545" contextRef="AsOf2022-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,505</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2022. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2022.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_300" contextRef="From2022-01-01to2022-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 6 - Related Party Transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">See Note 7 for common stock issued to related parties and Note 8 for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under accruals and management and directors&#8217; fees payable (see consolidated balance sheets). </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-51</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_301" contextRef="From2022-01-01to2022-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_cac85a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 7 - Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company was authorized to issue <ix:nonFraction id="fid_763" contextRef="AsOf2022-12-31" name="vnrx:CommonStockShareAuthorized" format="ixt:numdotdecimal" decimals="-6" unitRef="Shares" scale="6">100</ix:nonFraction> million shares of common stock par value $<ix:nonFraction id="fid_761" contextRef="AsOf2022-12-31" name="vnrx:CommonStockPricePerSahres" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share, of which <ix:nonFraction id="fid_752" contextRef="AsOf2022-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">57,873,379</ix:nonFraction> and <ix:nonFraction id="fid_797" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">53,772,261</ix:nonFraction> shares were issued as of December 31, 2022 and December 31, 2021, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Stock Option Exercises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022 no shares of common stock were issued pursuant to the exercise of stock options.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Stock Option Exercises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021 we issued a total of <ix:nonFraction id="fid_799" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">77,451</ix:nonFraction> shares of common stock from the cashless exercise of options, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_347" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 13 - March 19, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_663" contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:StockIncentivePlan">2011</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_630" contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,634</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_683" contextRef="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.35</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_645" contextRef="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">948</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_664" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:StockIncentivePlan">2011</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_631" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_684" contextRef="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_646" contextRef="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,181</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_665" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember" name="vnrx:StockIncentivePlan">2011</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_632" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_685" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_647" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,769</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_666" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember" name="vnrx:StockIncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_633" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_686" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_648" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,446</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8 - February 9, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_667" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:StockIncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_634" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_687" contextRef="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_649" contextRef="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,357</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_668" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:StockIncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_635" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_688" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_650" contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,750</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_636" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionExercisesMember" name="vnrx:CommonStockShareIssuedUponCashlessExercise" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">277,634</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_651" contextRef="AsOf2021-12-31_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">77,451</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-52</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 7 - Common Stock (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_cac85a" continuedAt="cont_f14a26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>RSU Settlements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022 we issued a total of <ix:nonFraction id="fid_800" contextRef="From2022-01-01to2022-12-31_vnrx_UnderwritingAgreementMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,289</ix:nonFraction> shares of common stock from the settlement of RSUs, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_348" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfShareIssuedFromTheSettlementOfRsus" escape="true" continuedAt="cont_e73c23"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 25, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_689" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_652" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 13, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_748" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_706" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.95</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_705" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,712</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,538</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_747" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.79</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">35,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">August 3, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_746" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">230,102</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_714" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.97</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_713" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">191,992</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_712" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,110</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">September 7, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_743" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,038</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_716" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,962</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 4, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_744" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,905</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.46</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,022</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,883</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">November 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_745" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.97</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_725" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,344</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,406</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 15, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_742" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_730" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.97</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_729" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,181</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_728" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">819</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_749" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">377,007</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_659" contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,289</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_733" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember" name="vnrx:SharesWithheldForTax" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">79,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021 we issued a total of <ix:nonFraction id="fid_798" contextRef="From2021-01-01to2021-12-31" name="vnrx:IssuedOfCommonStockFromSettlementOfRSU" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">24,712</ix:nonFraction> shares of common stock from the settlement of RSUs, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_e73c23"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 20, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_734" contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_736" contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember" name="vnrx:SaleOfStockPriceSettledPerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.10</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_738" contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_740" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 21, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_735" contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_737" contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember" name="vnrx:SaleOfStockPriceSettledPerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.44</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_739" contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,712</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_741" contextRef="From2022-01-01to2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,538</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_2073" contextRef="AsOf2022-12-31" name="vnrx:RestrictedStockUnitVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">31,250</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_2074" contextRef="AsOf2022-12-31" name="us-gaap:ExcessStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">24,712</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_2075" contextRef="From2022-01-01to2022-12-31" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,538</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Equity</em></strong><strong><em> </em></strong><strong><em>Capital Raises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On July 29, 2022, the Company entered into an underwriting agreement with Newbridge Securities Corporation (&#8220;Newbridge&#8221;) in connection with an underwritten public offering of <ix:nonFraction id="fid_760" contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,450,000</ix:nonFraction> shares of the Company&#8217;s common stock, which includes Newbridge&#8217;s exercise in full of its overallotment option (of 450,000 shares), pursuant to the Company&#8217;s &#8220;shelf&#8221; registration statement on Form S-3 (declared effective by the SEC on November 8, 2021, File No. 333-259783) (as amended and supplemented from time to time, the &#8220;2021 Form S-3&#8221;). Newbridge purchased the shares from the Company at a weighted average&#160;price of $<ix:nonFraction id="fid_793" contextRef="AsOf2022-07-29_vnrx_UnderwritingAgreementMember" name="vnrx:PurchasePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction> per share.&#160;The offering closed on August 2, 2022. The Company received net proceeds of approximately $<ix:nonFraction id="fid_794" contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">6.4</ix:nonFraction> million from the offering before deducting offering expenses of $<ix:nonFraction id="fid_795" contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember" name="vnrx:OfferingExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million paid by the Company.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-53</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 7 - Common Stock (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_f14a26" continuedAt="cont_eb85c0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Equity</strong><strong> </strong></em><strong><em>Capital Raises </em>(continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 10, 2021, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) in connection with an underwritten public offering of <ix:nonFraction id="fid_801" contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,809,524</ix:nonFraction> shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s &#8220;shelf&#8221; registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248) (the &#8220;2018 Form S-3&#8221;). Cantor purchased the shares from the Company at a price of $<ix:nonFraction id="fid_805" contextRef="AsOf2021-02-10_vnrx_UnderwritingAgreementMember" name="vnrx:PurchasePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.9533</ix:nonFraction> per share, and elected not to exercise an option to purchase up to an additional <ix:nonFraction id="fid_802" contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571,428</ix:nonFraction> shares of common stock at the same price per share. The offering closed on February 12, 2021. The Company received net proceeds of approximately $<ix:nonFraction id="fid_803" contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember" name="vnrx:OfferingExpenses" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">18.9</ix:nonFraction> million from the offering before deducting offering expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Equity</em></strong><strong><em> </em></strong><strong><em>Distribution Agreements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On May 20, 2022, the Company entered into an equity distribution agreement (the &#8220;2022 EDA&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $<ix:nonFraction id="fid_808" contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember" name="vnrx:AggeregateShareOfCommonStockOfferingPrice" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">25.0</ix:nonFraction> million, from time to time through an &#8220;at the market&#8221; offering pursuant to the Company&#8217;s 2021 Form S-3 through Jefferies acting as the Company&#8217;s agent and/or principal.&#160;The Company is not obligated to sell any shares under the 2022 EDA.&#160; As of December 31, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $<ix:nonFraction id="fid_810" contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">0.8</ix:nonFraction> million under the 2022 EDA through the sale of <ix:nonFraction id="fid_809" contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">350,829</ix:nonFraction> shares of common stock, before deducting offering expenses.&#160;See Note 11 for additional details regarding the Company&#8217;s equity distribution agreements subsequent to December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">From January 1, 2022 through May 7, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $<ix:nonFraction id="fid_817" contextRef="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember" name="vnrx:BrokerageFees" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,500</ix:nonFraction> under the 2021 EDA (as defined below) through the sale of <ix:nonFraction id="fid_816" contextRef="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction> shares of its common stock. The Company terminated the 2021 EDA effective May 7, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 24, 2021, the Company entered into an equity distribution agreement (the &#8220;2021 EDA&#8221;) with Cantor and Oppenheimer &amp; Co. Inc. (&#8220;Oppenheimer&#8221;) to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $<ix:nonFraction id="fid_777" contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember" name="vnrx:AggeregateShareOfCommonStockOfferingPrice" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">25.0</ix:nonFraction> million, from time to time through an &#8220;at the market&#8221; offering pursuant to the Company&#8217;s 2021 Form S-3 through Cantor and Oppenheimer acting as the Company&#8217;s agents and/or principals. From the 2021 EDA&#8217;s effectiveness on November 8, 2021 through December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $<ix:nonFraction id="fid_781" contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million through the sale of <ix:nonFraction id="fid_806" contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">190,600</ix:nonFraction> shares of its common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 10, 2020, the Company entered into an equity distribution agreement (the &#8220;2020 EDA&#8221;) with Cantor and Oppenheimer to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $<ix:nonFraction id="fid_778" contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember" name="vnrx:AggeregateShareOfCommonStockOfferingPrice" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">25.0</ix:nonFraction> million, from time to time through an &#8220;at the market&#8221; offering pursuant to the 2018 Form S-3 through Cantor and Oppenheimer acting as the Company&#8217;s agents and/or principals. During the year ended December 31, 2021 (and from inception of the 2020 EDA), the Company raised aggregate net proceeds (net of broker commissions and fees) of $<ix:nonFraction id="fid_782" contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.7</ix:nonFraction> million under the 2020 EDA through the sale of <ix:nonFraction id="fid_771" contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">754,348</ix:nonFraction> shares of its common stock. The Company terminated the 2020 EDA effective November 8, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the &#8220;2018 EDA&#8221;) with Oppenheimer to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $<ix:nonFraction id="fid_779" contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember" name="vnrx:AggeregateShareOfCommonStockOfferingPrice" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.0</ix:nonFraction> million, from time to time through an &#8220;at the market&#8221; offering pursuant to the 2018 Form S-3 through Oppenheimer acting as the Company&#8217;s agent and/or principal. The Company utilized the 2018 EDA in full during the three months ended March 31, 2021, and raised aggregate net proceeds (net of broker commissions and fees) of approximately $<ix:nonFraction id="fid_783" contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">9.7</ix:nonFraction>&#160;million under the 2018 EDA since inception through the sale of&#160;<ix:nonFraction id="fid_772" contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,539,606</ix:nonFraction>&#160;shares of its common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of $<ix:nonFraction id="fid_819" contextRef="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million under the 2018 EDA through the sale of <ix:nonFraction id="fid_818" contextRef="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">308,609</ix:nonFraction> shares of its common stock. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-54</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 7 - Common Stock (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_eb85c0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022 and 2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Issuances Upon Warrant Exercises</em></strong><em>&#160;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the years ended December 31, 2022 and December 31, 2021 no warrants were exercised. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_302" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" escape="true" continuedAt="cont_cb286c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>No</strong><strong>te 8 - </strong><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>a</strong><strong>) Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the changes in warrants outstanding of the Company during the year ended December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_335" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_822" contextRef="From2020-01-01to2020-12-31_vnrx_WarrantsMember" name="vnrx:NumberOfWarrantsOutstandingBeginningBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">175,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_833" contextRef="From2020-01-01to2020-12-31_vnrx_WarrantsMember" name="vnrx:WeightedAverageExercisePriceOutstandingBalanceOne" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_825" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">310,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_834" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_836" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="vnrx:WeightedExercisePriceExercised" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_838" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="vnrx:WeightedExercisePriceExpired" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_829" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="vnrx:NumberOfWarrantsOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">485,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_840" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="vnrx:WeightedAverageExercisePriceEndingBalanceOne" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_826" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_835" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_837" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:WeightedExercisePriceExercised" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_839" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:WeightedExercisePriceExpired" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_830" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:NumberOfWarrantsOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">539,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_841" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:WeightedAverageExercisePriceEndingBalanceOne" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.80</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_831" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:NumberOfWarrantsExercisable" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">485,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_842" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:WeightedAverageExercisePriceExercisable" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective April 4, 2022, the Company granted a warrant to purchase <ix:nonFraction id="fid_1725" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,000</ix:nonFraction> shares of common stock to a Company employee for services to the Company and/or its subsidiaries. <ix:nonNumeric id="fid_1726" contextRef="From2022-01-01to2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription">This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $<ix:nonFraction id="fid_2057" contextRef="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction> per share</ix:nonNumeric>. The Company has calculated the estimated fair market value of this warrant at $<ix:nonFraction id="fid_1727" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,901</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_2061" contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">3.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_2062" contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.95</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_2054" contextRef="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction>, <ix:nonFraction id="fid_2063" contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">71.07</ix:nonFraction>% volatility, <ix:nonFraction id="fid_2064" contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">2.53</ix:nonFraction>% risk-free rate, and no forfeiture rate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2021, the Company granted warrants to purchase <ix:nonFraction id="fid_1590" contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">125,000</ix:nonFraction> shares of common stock to a Company employee for services to the Company. <ix:nonNumeric id="fid_1692" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription">These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share.</ix:nonNumeric> The Company has calculated the estimated fair market value of these warrants at $<ix:nonFraction id="fid_1701" contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,877</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_2044" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">3.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_2036" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.80</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_2038" contextRef="AsOf2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction>, <ix:nonFraction id="fid_2039" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="vnrx:VolatilityRate" decimals="INF" unitRef="Pure" scale="-2">74.53</ix:nonFraction>% volatility, <ix:nonFraction id="fid_2043" contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.50</ix:nonFraction>% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective February 1, 2021, the Company granted warrants to purchase <ix:nonFraction id="fid_1591" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">185,000</ix:nonFraction> shares of common stock to a Company employee for services to the Company. These warrants vested on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $<ix:nonFraction id="fid_2052" contextRef="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.90</ix:nonFraction> per share. The Company has calculated the estimated fair market value of these warrants at $<ix:nonFraction id="fid_1702" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,352</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_2051" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">3.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_1565" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_2049" contextRef="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.90</ix:nonFraction>, <ix:nonFraction id="fid_1575" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">75.03</ix:nonFraction>% volatility, <ix:nonFraction id="fid_1582" contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.59</ix:nonFraction>% risk free rate, and no forfeiture rate. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-55</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>a</strong><strong>) Warrants (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_cb286c" continuedAt="cont_16c24e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the warrants issued and outstanding as of December 31, 2022. The warrants outstanding have a weighted average price of $3.80 per share and an aggregate weighted average remaining contractual life of 3.24 years. The warrants exercisable have a weighted average price of&#160; $3.88 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_336" contextRef="From2022-01-01to2022-12-31" name="vnrx:SummarizingTheWarrantsIssuedAndOutstanding" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Life (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_854" contextRef="AsOf2022-12-31_vnrx_WarrantOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">125,000</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_851" contextRef="AsOf2022-12-31_vnrx_WarrantOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">125,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_869" contextRef="AsOf2022-12-31_vnrx_WarrantOneMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.47</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_846" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">0.15</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_859" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantOneMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">308,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_855" contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_870" contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_847" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">5.76</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_860" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,700</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_856" contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_873" contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_871" contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.45</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_848" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">3.17</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_861" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,500</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_857" contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">125,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_850" contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">125,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_872" contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2027" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">4.01</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_862" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,750</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_876" contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">185,000</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_877" contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">185,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_874" contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.90</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_878" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">4.09</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_875" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong><ix:nonFraction id="fid_858" contextRef="AsOf2022-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">539,000</ix:nonFraction></strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_853" contextRef="AsOf2022-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">485,000</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_863" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,046,200</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to warrants of $<ix:nonFraction id="fid_1728" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,102</ix:nonFraction> and $<ix:nonFraction id="fid_1729" contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">701,781</ix:nonFraction> was recorded for the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately $<ix:nonFraction id="fid_1730" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:CompensationCostRelatedToNonVestedWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,812</ix:nonFraction> and is expected to be recognized over a period of <ix:nonNumeric id="fid_1731" contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember" name="vnrx:MaturityTerm" format="ixt-sec:duryear">1.26</ix:nonNumeric> years. As of December 31, 2022, the total intrinsic value of warrants was $<ix:nonFraction id="fid_1733" contextRef="AsOf2022-12-31_vnrx_WarrantsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) Options</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company currently has options outstanding under both its 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) (for option issuances prior to 2016,) and its 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;) (for option issuances commencing in 2016). Effective as of January 1, 2016, no additional awards were or may be made under the 2011 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The 2015 Plan was adopted by the Board of Directors on August 18, 2015 and approved by the stockholders at an annual meeting held on October 30, 2015. On August 5, 2016, the Board of Directors adopted an amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by <ix:nonFraction id="fid_1677" contextRef="AsOf2016-08-05_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">750,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1678" contextRef="AsOf2016-08-05_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,750,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on October 7, 2016. On June&#160;13, 2017, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by <ix:nonFraction id="fid_2065" contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1680" contextRef="AsOf2017-06-13_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,500,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on September 8, 2017. On June 15, 2018, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by <ix:nonFraction id="fid_1681" contextRef="AsOf2018-06-15_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">750,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1682" contextRef="AsOf2018-06-15_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,250,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on September 7, 2018.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 27, 2019, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by <ix:nonFraction id="fid_1683" contextRef="AsOf2018-03-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1684" contextRef="AsOf2018-03-27_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,250,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on June 14, 2019. On March 31, 2021, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such&#160; Plan by <ix:nonFraction id="fid_2066" contextRef="From2019-05-01to2019-05-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1685" contextRef="AsOf2021-03-31_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,000,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on June 17, 2021.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-56</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b</strong><strong>) Options (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_16c24e" continuedAt="cont_97e438">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On April 4, 2022, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such plan by <ix:nonFraction id="fid_1736" contextRef="From2022-04-01to2022-04-04" name="vnrx:CommonStockAvailable" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,750,000</ix:nonFraction> shares to an aggregate maximum of <ix:nonFraction id="fid_1738" contextRef="From2022-04-01to2022-04-04" name="vnrx:ShareAggregateMaximum" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,750,000</ix:nonFraction> shares, which amendment was approved by the stockholders at an annual meeting held on June 13, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The 2015 Plan permits the grant of incentive stock options, non-statutory stock options, restricted stock awards, stock bonus awards, stock appreciation rights, restricted stock units and performance awards. The primary purpose of the 2015 Plan is to enhance the Company&#8217;s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company&#8217;s business largely depends, and to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company that is tied to the Company&#8217;s performance, thereby giving them an interest in the success and increased value of the Company. &#160;The 2015 Plan is administered by the Compensation Committee comprised solely of members of the Board of Directors or by the Board of Directors as a whole.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the changes in options outstanding of the Company during the years ended December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_337" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfOptionsOutstandingBeginningBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,278,619</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_890" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceOutstandingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_881" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,090,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_892" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceGranted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.41</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_883" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">277,634</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_894" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceExercised" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_885" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfExpiredCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,467</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_896" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.64</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_887" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfOptionOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,027,518</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_900" contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceEndingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.87</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_893" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceGranted" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_895" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceExercised" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_886" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfExpiredCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,413</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_897" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.43</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_888" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfOptionOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,985,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_898" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceEndingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.87</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_889" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfOptionsExercisable" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,495,011</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_899" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageExercisePriceExercisableBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.93</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022, no options were granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 18, 2022, <ix:nonFraction id="fid_1747" contextRef="From2022-08-01to2022-08-18" name="vnrx:OptionGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,515</ix:nonFraction> Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, <ix:nonFraction id="fid_1743" contextRef="From2020-04-01to2020-04-13" name="vnrx:OptionGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> Options previously granted to an employee on April 13, 2020 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, <ix:nonFraction id="fid_1745" contextRef="From2022-11-01to2022-11-18" name="vnrx:OptionGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">32,383</ix:nonFraction> Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, <ix:nonFraction id="fid_1741" contextRef="From2021-08-01to2021-08-03" name="vnrx:OptionGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,515</ix:nonFraction> Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-57</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b</strong><strong>) Options (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:continuation id="cont_97e438" continuedAt="cont_646cd5"><strong><span style="text-decoration:underline">2021</span></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective May 20, 2021, the Company granted stock options to purchase <ix:nonFraction id="fid_1707" contextRef="From2021-01-01to2021-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember" name="vnrx:StockOptionsPurchaseSharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,000</ix:nonFraction> shares of common stock to a Company employee in exchange for services provided to the Company. These options vested on May 20, 2022 and were initially scheduled to expire six years after the grant date, with an exercise price of $<ix:nonFraction id="fid_2048" contextRef="AsOf2022-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction> per share. The Company extended the expiration date to ten years after the original grant date. The Company has calculated the estimated fair market value of these options at $<ix:nonFraction id="fid_1708" contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,641</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_2047" contextRef="From2021-05-05to2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">3.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_1567" contextRef="From2021-05-05to2021-05-20" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_2045" contextRef="AsOf2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction>, <ix:nonFraction id="fid_1577" contextRef="From2021-05-05to2021-05-20" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">76.16</ix:nonFraction>% volatility, <ix:nonFraction id="fid_1584" contextRef="From2021-05-05to2021-05-20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.58</ix:nonFraction>% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021, the Company modified a total of <ix:nonFraction id="fid_1519" contextRef="From2021-01-01to2021-12-31" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,342,518</ix:nonFraction> options to extend their expiration dates to ten years from the original dates of grant. This resulted in $<ix:nonFraction id="fid_1710" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,349</ix:nonFraction> of expense.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the amendments to the expiration dates of various options approved during the year ended December 31, 2021. Except as otherwise noted, the expiration dates for all options in the table below were extended from six years to ten years from the original date of grant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2085" contextRef="From2022-01-01to2022-12-31" name="vnrx:SummaryOfAmendmentsToExpirationDatesOfOptions" escape="true"><table style="border-spacing:0;font-size:10pt;text-align:justify;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:9%;"></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amendment </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>New Expiration </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Option Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Note</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(i)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_959" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Jul 14, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_931" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="vnrx:EquityIncentivePlan">2011</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_902" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">292,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_945" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Jul 23, 2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_973" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Jul 23, 2025</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_917" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">442,273</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_960" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Jul 14, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_932" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="vnrx:EquityIncentivePlan">2011</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_903" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,367</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_946" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Mar 20, 2013</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_974" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Mar 20, 2023</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_918" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,151</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_961" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Jul 14, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_933" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="vnrx:EquityIncentivePlan">2011</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_904" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,151</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_947" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Sep 2, 2013</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_975" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Sep 2, 2023</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_919" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,009</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_962" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Sep 21, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_934" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_905" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">335,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_948" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Apr 13, 2020</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_976" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Apr 13, 2030</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_920" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,945</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_963" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Sep 21, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_935" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_906" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">89,163</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_949" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Jan 23, 2018</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_977" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Jan 23, 2028</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_921" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,194</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_964" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Sep 21, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_936" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_907" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">308,066</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_950" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Feb 13, 2017</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_978" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Feb 13, 2027</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_922" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,719</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_965" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Nov 3, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_937" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_908" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">760,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_951" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Apr 15, 2016</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_979" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Apr 15, 2026</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_923" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984,511</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_966" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Nov 3, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_938" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_909" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_952" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Jun 23, 2016</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_980" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Jun 23, 2026</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_924" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,582</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_967" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Nov 3, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_939" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_910" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_953" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Jan 1, 2017</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_981" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Jan 1, 2027</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_925" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,456</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_968" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Nov 3, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_940" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_911" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">387,934</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_954" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Mar 30, 2017</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_982" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Mar 30, 2027</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_926" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,901</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_969" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Nov 3, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_941" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_912" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">615,837</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_955" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Jan 23, 2018</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_983" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Jan 23, 2028</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_927" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,646</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_970" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Dec 8, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_942" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_913" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">425,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_956" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Apr 13, 2020</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_984" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Apr 13, 2030</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_928" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,267</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_971" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Dec 8, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_943" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_914" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_957" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">Dec 1, 2020</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_985" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">Dec 1, 2030</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_929" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,209</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_972" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="vnrx:stockoptionamendmentdate" format="ixt:datemonthdayyearen">Dec 8, 2021</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_944" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_915" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_958" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="vnrx:StockOptionGrantDate" format="ixt:datemonthdayyearen">May 20, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_986" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:datemonthdayyearen">May 20, 2031</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_930" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,486</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_901" contextRef="From2022-01-01to2022-12-31" name="vnrx:ApprovedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,342,518</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_916" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,349</ix:nonFraction></p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The expiration date of these options were extended from five and a half years to ten years from the original date of grant.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These options were previously amended on December 16, 2019 and amended again on September 21, 2021.</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-58</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) Options (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_646cd5" continuedAt="cont_edd138">Effective August 3, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted stock options to purchase an aggregate of <ix:nonFraction id="fid_1686" contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">926,640</ix:nonFraction> shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with options to purchase up to <ix:nonFraction id="fid_1546" contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:CommonStockSharesIssuableUponExerciseOfStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">463,328</ix:nonFraction> shares vesting on August 3, 2022, and options to purchase up to <ix:nonFraction id="fid_1593" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">463,312</ix:nonFraction> shares vesting on August 3, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $<ix:nonFraction id="fid_1537" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,811,216</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_1560" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">5.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_1568" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_1555" contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction>, <ix:nonFraction id="fid_1578" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">69.13</ix:nonFraction>% volatility, <ix:nonFraction id="fid_1585" contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.19</ix:nonFraction>% risk free rate, and no forfeiture rate. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective September 7, 2021, the Company granted stock options to purchase <ix:nonFraction id="fid_1687" contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction> shares of common stock to two employees in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with <ix:nonFraction id="fid_1547" contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:CommonStockSharesIssuableUponExerciseOfStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,000</ix:nonFraction> shares vesting on September 7, 2022, and <ix:nonFraction id="fid_1594" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,000</ix:nonFraction> shares vesting on September 7, 2023 subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The Company has calculated the estimated fair market value of these options at $<ix:nonFraction id="fid_1538" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,322</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term <ix:nonNumeric id="fid_1561" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">5.5</ix:nonNumeric> years, stock price $<ix:nonFraction id="fid_1569" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.32</ix:nonFraction>, exercise price $<ix:nonFraction id="fid_1556" contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction>, <ix:nonFraction id="fid_1579" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">68.98</ix:nonFraction>% volatility, <ix:nonFraction id="fid_1586" contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.38</ix:nonFraction>% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective October 4, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval the Company granted stock options to purchase <ix:nonFraction id="fid_1688" contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">73,360</ix:nonFraction> shares of common stock to an employee in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with <ix:nonFraction id="fid_1595" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,680</ix:nonFraction> shares vesting on October 4, 2022, and <ix:nonFraction id="fid_2067" contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:NumberOfSharesVesting" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">36,680</ix:nonFraction> shares vesting on October 4, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $<ix:nonFraction id="fid_1539" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,003</ix:nonFraction>, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $<ix:nonFraction id="fid_1570" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction> exercise price $<ix:nonFraction id="fid_1557" contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction>, <ix:nonFraction id="fid_1580" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:Volatility" decimals="INF" unitRef="Pure" scale="-2">68.80</ix:nonFraction>% volatility, <ix:nonFraction id="fid_1587" contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.49</ix:nonFraction>% risk free rate, and no forfeiture rate. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-59</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b</strong><strong>) Options (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_edd138" continuedAt="cont_579f4f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the options issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2011 Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016)and which have a weighted average exercise price of $<ix:nonFraction id="fid_1748" contextRef="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.87</ix:nonFraction> per share and an aggregate weighted average remaining contractual life of <ix:nonNumeric id="fid_1749" contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear">5.22</ix:nonNumeric> years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_338" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;text-align:justify;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>(Years)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_997" contextRef="AsOf2022-12-31_vnrx_OptionsOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">635,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_987" contextRef="AsOf2022-12-31_vnrx_OptionsOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">635,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1017" contextRef="AsOf2022-12-31_vnrx_OptionsOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.25</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1026" contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">2.12</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1007" contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,063,750</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_998" contextRef="AsOf2022-12-31_vnrx_OptionTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,717</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_988" contextRef="AsOf2022-12-31_vnrx_OptionTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,717</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1018" contextRef="AsOf2022-12-31_vnrx_OptionTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.35</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1027" contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">0.67</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1008" contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,102</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_999" contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,022,587</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_989" contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">532,493</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1019" contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1028" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">8.32</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1009" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,476,796</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1000" contextRef="AsOf2022-12-31_vnrx_OptionFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">795,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_990" contextRef="AsOf2022-12-31_vnrx_OptionFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">795,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1020" contextRef="AsOf2022-12-31_vnrx_OptionFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1029" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">6.94</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1010" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,862,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1001" contextRef="AsOf2022-12-31_vnrx_OptionFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,682,837</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_991" contextRef="AsOf2022-12-31_vnrx_OptionFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,682,837</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1021" contextRef="AsOf2022-12-31_vnrx_OptionFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1030" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">3.76</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1011" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,731,348</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1002" contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,801</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_992" contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,801</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1022" contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1031" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">0.44</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1012" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,334</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1003" contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">89,163</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_993" contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">89,163</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1023" contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.38</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1032" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">5.07</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1013" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,534</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1004" contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_994" contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1024" contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1033" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">4.01</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1014" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1005" contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">696,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_995" contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">696,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1025" contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1034" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">4.24</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1015" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,480,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1006" contextRef="AsOf2022-12-31_vnrx_TotalStockOptionOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,985,105</ix:nonFraction></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_996" contextRef="AsOf2022-12-31_vnrx_TotalStockOptionOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,495,011</ix:nonFraction></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1016" contextRef="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,304,864</ix:nonFraction></strong></p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to stock options of $<ix:nonFraction id="fid_1750" contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,127,502</ix:nonFraction> and $<ix:nonFraction id="fid_1713" contextRef="From2021-01-01to2021-12-31_us-gaap_OptionMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,069,605</ix:nonFraction> was recorded for the year ended December 31, 2022 and December 31, 2021 respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately $<ix:nonFraction id="fid_1751" contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:FairValueOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,363</ix:nonFraction> and is expected to be recognized over a period of <ix:nonNumeric id="fid_1752" contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:MaturityTerm" format="ixt-sec:duryear">0.76</ix:nonNumeric> years. As of December 31, 2022, the total intrinsic value of stock options was $nil.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, an aggregate of <ix:nonFraction id="fid_1753" contextRef="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">417,318</ix:nonFraction> shares of common stock remained available for future issuance under the 2015 Plan.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-60</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_579f4f" continuedAt="cont_46b61a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_339" contextRef="From2022-01-01to2022-12-31" name="vnrx:SummarizingTheRsusIssuedAndOutstandingMaturityLife" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" contextRef="AsOf2020-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfRsusOutstandingBeginingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">67,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" contextRef="AsOf2020-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceBeginningBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.47</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1037" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:GrantedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">789,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceGranted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.33</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1050" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfStockVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">31,250</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.55</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1051" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfStockCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember" name="vnrx:Cancelled" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.3</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1041" contextRef="AsOf2021-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfRsusOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">810,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" contextRef="AsOf2021-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceEndingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.33</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:GrantedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,892,102</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceGranted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.64</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1039" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfStockVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">377,007</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1047" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.33</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1040" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfStockCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">62,937</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1048" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember" name="vnrx:Cancelled" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.88</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Outstanding at December 31, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1053" contextRef="AsOf2022-12-31_vnrx_StockOptionsMember" name="vnrx:NumberOfRsusOutstandingEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,262,908</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1057" contextRef="AsOf2022-12-31_vnrx_StockOptionsMember" name="vnrx:SharePriceEndingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.05</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs granted during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan. These RSUs vest equally over periods stated on the dates noted, subject to continued service, and will result in the compensation expense stated. The exception to this is specified in note (iv) which is described in detail below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_355" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfRsusGrantedDuringPeriod" escape="true" continuedAt="cont_9445f2"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Incentive</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Plan</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1143" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1114" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1157" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Feb 8, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1129" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1171" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Feb 8, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1185" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Feb 8, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1196" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,640</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1204" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1203" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1202" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Mar 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1201" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1200" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Mar 1, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1199" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Mar 1, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1197" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,300</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1212" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1211" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">32,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1210" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Apr 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1209" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1208" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Apr 4, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1207" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Apr 4, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1205" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,400</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1220" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1219" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">104,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1218" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Apr 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1217" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseVestingPeriod">36 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1216" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Apr 4, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1215" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Apr 4, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1214" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:ThirdVestingDate" format="ixt:datemonthdayyearen">Apr 4, 2025</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1213" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,800</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1228" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1227" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">33,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1226" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Jun 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1225" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1224" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Jun 1, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1223" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Jun 1, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1221" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,850</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1236" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1235" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">63,102</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1234" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Aug 15, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1233" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1232" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Aug 15, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1231" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Aug 15, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_2028" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,835</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1244" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1243" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1242" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Sep 21, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1241" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1240" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Sep 21, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1239" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Sep 21, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1237" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,250</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1252" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1251" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,144,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1250" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Oct 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1249" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseVestingPeriod">36 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1248" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Oct 4, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1247" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Oct 4, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1246" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:ThirdVestingDate" format="ixt:datemonthdayyearen">Oct 4, 2025</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1245" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,240</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iv)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1260" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1259" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">450,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1258" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Oct 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1834" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember" name="vnrx:CompensationExpenseVestingPeriod">Up to 42 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1253" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,078</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(v)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1268" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1267" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1266" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Nov 29, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1265" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:CompensationExpenseVestingPeriod">36 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1264" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Nov 29, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1263" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Nov 29, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1262" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:ThirdVestingDate" format="ixt:datemonthdayyearen">Nov 29, 2025</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1261" contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,450</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1270" contextRef="From2022-01-01to2022-12-31" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,892,102</ix:nonFraction></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1269" contextRef="From2022-01-01to2022-12-31" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,755,843</ix:nonFraction></strong></p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-61</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs) (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_46b61a" continuedAt="cont_e27da2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These RSUs vest upon the achievement of corporate goals focused around product development and commercialization with further time-based vesting, subject to continued service of the award recipient to the Company through the applicable vesting dates. On October 13, 2022, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals previously established by the Compensation Committee, which resulted in the vesting of the rights with respect to an aggregate of <ix:nonFraction id="fid_1756" contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember" name="vnrx:VestingAggregate" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">198,275</ix:nonFraction> RSUs. The RSUs are further subject to a three-year time based vesting schedule, vesting in three equal installments on the dates set forth in the table above, and conditioned upon the recipient&#8217;s continued service through the applicable vesting date. On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain additional corporate goals, which resulted in the vesting of the rights with respect to an aggregate of an additional <ix:nonFraction id="fid_1758" contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember" name="vnrx:AggregrateAggregate" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">424,875</ix:nonFraction> RSUs, subject to the foregoing time-based vesting and conditioned upon the recipient&#8217;s continued service through the applicable vesting date.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(iv)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These RSUs vest upon the share price closing above $<ix:nonFraction id="fid_1760" contextRef="AsOf2022-12-31_vnrx_RestrictedStockUnitsOneMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction> per share for a minimum of ten consecutive trading days within a period of three years from the date of grant, with further time-based vesting in a single installment six months after the timely achievement of the target, if at all, and subject to continued service. The estimated fair value of the RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation of a Geometric Brownian Motion stock path model and incorporating the probability of vesting occurring. The estimated fair value of these awards will be recognized over the derived service period (as determined by the valuation model), with such recognition occurring regardless of whether the market condition is met.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(v)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company granted an aggregate of <ix:nonFraction id="fid_1763" contextRef="From2022-11-01to2022-11-29_vnrx_RestrictedStockUnitsOneMember" name="vnrx:GrantedAggregate" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction> RSUs on November 29, 2022 as an employment inducement award. These RSUs are subject to time-based vesting and subject to the continued service of each recipient.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Below is a table summarizing the RSUs vested during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_356" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfRsusVestedDuringPeriod" escape="true" continuedAt="cont_bb0cec"><table style="border-spacing:0;font-size:10pt;text-align:justify;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Issued</strong>&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Taxes</strong>&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1271" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1279" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1286" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Mar 25, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1317" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1318" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:RsusHeldForTaxes" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1323" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1322" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,250</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1321" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Apr 13, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1320" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,712</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1319" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,538</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1328" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1327" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1326" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">May 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1325" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">35,000</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1324" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1338" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1337" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">230,102</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1336" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Aug 3, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1335" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">191,992</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1334" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,110</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1343" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1342" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1341" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Sep 7, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1340" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,038</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1339" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,962</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1348" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1347" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,905</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1346" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Oct 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1345" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,022</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1344" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,883</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1353" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1352" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,750</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1351" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Nov 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1350" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,344</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1349" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,406</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1358" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1357" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1356" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Dec 15, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1355" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,181</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1354" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">819</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1362" contextRef="From2022-01-01to2022-12-31" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">377,007</ix:nonFraction></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1361" contextRef="From2022-01-01to2022-12-31" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,289</ix:nonFraction></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1360" contextRef="From2022-01-01to2022-12-31" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,718</ix:nonFraction></strong></p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-62</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs) (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:continuation id="cont_e27da2" continuedAt="cont_719a71"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs cancelled during the year ended December 31, 2022, all of which were originally issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_357" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfRsusCancelledDuringPeriod" escape="true" continuedAt="cont_bbfbd6"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Cancellation </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1410" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1409" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">33,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:23%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1408" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:CancellationDate" format="ixt:datemonthdayyearen">May 31, 2022</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1407" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">33,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1426" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1425" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,365</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1424" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:CancellationDate" format="ixt:datemonthdayyearen">Aug 18, 2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1423" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,365</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1430" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1429" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,572</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1428" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:CancellationDate" format="ixt:datemonthdayyearen">Nov 18, 2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1427" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,572</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1434" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1433" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1432" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:CancellationDate" format="ixt:datemonthdayyearen">Nov 21, 2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1431" contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1439" contextRef="From2022-01-01to2022-12-31" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">62,937</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1440" contextRef="From2022-01-01to2022-12-31" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">62,937</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-63</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs) (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_719a71" continuedAt="cont_d93cd1"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs granted during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_9445f2"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:5%;"></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1442" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1441" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1459" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Jan 1, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1475" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Jan 1, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1491" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,450</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1443" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1452" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1460" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Mar 25, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1468" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1476" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Mar 25, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1483" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Mar 25, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1492" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,700</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1444" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1453" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">150,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1461" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">May 1, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1469" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:CompensationExpenseVestingPeriod">36 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1477" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">May 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1484" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">May 1, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1490" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:ThirdVestingDate" format="ixt:datemonthdayyearen">May 1, 2024</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1493" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,500</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(i)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1445" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1454" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">460,191</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1462" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Aug 3, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1470" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1478" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Aug 3, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1485" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Aug 3, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1494" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,232</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1446" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1455" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1463" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Sep 7, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1471" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1479" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Sep 7, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1486" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Sep 7, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1495" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,160</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(ii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1447" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1456" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">39,809</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1464" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Oct 4, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1472" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1480" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Oct 4, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1487" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Oct 4, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1496" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,019</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1448" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1457" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,500</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1465" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Nov 1, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1473" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1481" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Nov 1, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1488" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Nov 1, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1497" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,685</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1449" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:EquityIncentivePlan">2015</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1458" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1466" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseGrantDate" format="ixt:datemonthdayyearen">Dec 15, 2021</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1474" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:CompensationExpenseVestingPeriod">24 Months</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1482" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:FirstVestingDate" format="ixt:datemonthdayyearen">Dec 15, 2022</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1489" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:SecondVestingDate" format="ixt:datemonthdayyearen">Dec 15, 2023</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1498" contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,740</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1501" contextRef="From2021-01-01to2021-12-31" name="vnrx:CompensationExpenseRsus" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">789,500</ix:nonFraction></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonFraction id="fid_1500" contextRef="From2021-01-01to2021-12-31" name="vnrx:RsuExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,624,486</ix:nonFraction></strong></p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective August 3, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of <ix:nonFraction id="fid_1766" contextRef="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember" name="vnrx:GrantedRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">460,191</ix:nonFraction> shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. <ix:nonNumeric id="fid_1769" contextRef="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember" name="vnrx:DescriptionOfVestingShall">The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232</ix:nonNumeric>.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective October 4, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of <ix:nonFraction id="fid_1771" contextRef="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember" name="vnrx:GrantedRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">39,809</ix:nonFraction> shares of common stock to an employee of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. <ix:nonNumeric id="fid_1772" contextRef="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember" name="vnrx:DescriptionOfVestingShall">These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019</ix:nonNumeric>.</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-64</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs) (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_d93cd1" continuedAt="cont_776ffd">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs vested during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_bb0cec"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2">#</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Issued</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for Taxes</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1499" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1503" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1505" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Jan 1, 2021</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1507" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1509" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1502" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1504" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1506" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentiveVestDate" format="ixt:datemonthdayyearen">Apr 13, 2021</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1508" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,712</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1510" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,538</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1511" contextRef="From2021-01-01to2021-12-31" name="vnrx:EquityIncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">31,250</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1512" contextRef="From2021-01-01to2021-12-31" name="vnrx:IncentiveRsuIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">24,712</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1513" contextRef="From2021-01-01to2021-12-31" name="vnrx:RsusHeldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,538</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs cancelled during the year ended December 31, 2021, all of which were originally issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_bbfbd6"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Equity Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1515" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentivePlan">2015</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2070" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonNumeric id="fid_1517" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:VestDate" format="ixt:datemonthdayyearen">Dec 31, 2020</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1514" contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_2069" contextRef="From2021-01-01to2021-12-31" name="vnrx:IncentiveRsu" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_2068" contextRef="From2021-01-01to2021-12-31" name="vnrx:RsuCancelled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-65</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 8 - Stock-Based Compensation (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs) (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_776ffd">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022 of which the last to vest have a remaining contractual life of 3.26 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_340" contextRef="From2022-01-01to2022-12-31" name="vnrx:summarizingtheRSUsissuedandoutstandingtabletextblock" escape="true"><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>(Years)</strong> </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:31%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1058" contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">450,000</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1066" contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.69</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1073" contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">3.26</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1059" contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,133,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1067" contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.46</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1074" contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">1.76</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1060" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1068" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.69</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1075" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">1.22</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1061" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">63,102</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1069" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.01</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1076" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">1.08</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1062" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1070" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.15</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1077" contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">1.91</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1063" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">33,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1071" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.45</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1078" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.92</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1064" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1072" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.81</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1079" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.67</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1090" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.83</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1088" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.61</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1093" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">136,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1092" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.95</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1091" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.97</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1105" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,904</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1104" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1103" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.38</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1102" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">311,152</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1101" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1100" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.59</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1096" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1095" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.32</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1094" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.68</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1112" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1111" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1110" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.48</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1099" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,750</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1098" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.51</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1097" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.42</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1108" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1107" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember" name="vnrx:SharesPriceRsu" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1106" contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember" name="vnrx:WeightedAverageRemainingContractualLifeYears" format="ixt-sec:duryear">0.23</ix:nonNumeric></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong><ix:nonFraction id="fid_1065" contextRef="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember" name="vnrx:NumberOfStockOutstandingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,262,908</ix:nonFraction></strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to RSUs of $<ix:nonFraction id="fid_1774" contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,903,054</ix:nonFraction> and $<ix:nonFraction id="fid_1773" contextRef="From2021-01-01to2021-12-31_vnrx_RestrictedStockUnitsOneMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,910</ix:nonFraction> was recorded in the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $<ix:nonFraction id="fid_1776" contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember" name="vnrx:UnrecognizedCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,214,593</ix:nonFraction>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-66</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_307" contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 9 - Income Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has estimated net operating losses for the years ended December 31, 2022 and 2021 of $<ix:nonFraction id="fid_628" contextRef="AsOf2022-12-31" name="vnrx:NetOperatingLosses" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">28.6</ix:nonFraction> million and $<ix:nonFraction id="fid_629" contextRef="AsOf2021-12-31" name="vnrx:NetOperatingLosses" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">24.4</ix:nonFraction> million, respectively, available to offset taxable income in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The significant components of deferred income taxes and assets as of December 31, 2022 and December 31, 2021 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_358" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true" continuedAt="cont_6a5109"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net Deferred Tax Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td></td><td></td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Excess of tax over book depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_578" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:ExcessOfTaxOverBookDepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">46,001</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_577" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:ExcessOfTaxOverBookDepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,330</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">ROU Asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_580" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,134</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_579" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,657</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Lease Liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_582" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,279</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_581" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,301</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_584" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,655</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_583" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,199</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Unrealized Gain/Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_585" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:UnrealizedGainLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,106</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Capitalized research expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_599" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:CapitalizedResearchExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,237,122</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_600" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:CapitalizedResearchExpenses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_588" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,956</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_587" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses carry-forward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_590" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,556,992</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_589" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,390,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Research and development tax credits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_592" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,317</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_591" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">606,729</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_594" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,850,186</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_593" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,297,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_596" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,850,186</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_595" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,297,640</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_598" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_597" contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_601" contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember" name="vnrx:ChangeInValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,552,546</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>&#160;</strong></p><ix:continuation id="cont_6a5109"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary Rate Reconciliation</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal statutory rate </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_604" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_603" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;State income taxes, net of federal benefit </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_605" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_606" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Permanent Differences </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_607" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.6</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_608" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" sign="-" scale="-2">4.8</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Stock based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_609" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.3</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_610" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.6</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Research &amp; Development Credits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_612" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" decimals="INF" unitRef="Pure" scale="-2">0.7</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_611" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" decimals="INF" unitRef="Pure" scale="-2">0.5</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Foreign taxes </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_613" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.1</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_614" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" decimals="INF" unitRef="Pure" scale="-2">1.5</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Deferred Rate Decrease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_616" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" decimals="INF" unitRef="Pure" scale="-2">0.5</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_615" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" decimals="INF" unitRef="Pure" sign="-" scale="-2">14.4</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_617" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">21.2</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_618" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">3.2</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_619" contextRef="From2022-01-01to2022-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_620" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Disclosure Amounts</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_624" contextRef="AsOf2022-12-31_vnrx_UnitedStateMember" name="us-gaap:OperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,072,965</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_626" contextRef="AsOf2022-12-31_vnrx_ForeignMember" name="us-gaap:OperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,614,447</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_625" contextRef="AsOf2022-12-31_vnrx_UnitedStateMember" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_627" contextRef="AsOf2022-12-31_vnrx_ForeignMember" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Increase in Valuation Allowance</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_623" contextRef="AsOf2022-12-31" name="vnrx:IncreaseInValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,552,546</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-67</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_303" contextRef="From2022-01-01to2022-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_b8625f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 10 - Commitments and Contingencies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>a) </strong><strong>Finance Lease Obligations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (&#8220;ING&#8221;) to purchase a property located in Belgium for &#8364;1.12 million, maturing <ix:nonNumeric id="fid_1873" contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember" name="vnrx:MaturityDate">May 2031</ix:nonNumeric>, with implicit interest of <ix:nonFraction id="fid_1879" contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember" name="vnrx:FixedInterestRateOnLease" decimals="INF" unitRef="Pure" scale="-2">2.62</ix:nonFraction>%. As of December 31, 2022, the balance payable was $<ix:nonFraction id="fid_1880" contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,146</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for &#8364;<ix:nonFraction id="fid_1872" contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember" name="us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">25,000</ix:nonFraction>, maturing <ix:nonNumeric id="fid_1874" contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember" name="vnrx:MaturityDate">January 2022</ix:nonNumeric>, with implicit interest of <ix:nonFraction id="fid_1875" contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember" name="vnrx:ImplicitInterest" decimals="INF" unitRef="Pure" scale="-2">1.35</ix:nonFraction>%. The leased equipment is amortized on a straight-line basis over <ix:nonNumeric id="fid_1876" contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember" name="vnrx:LeasedEquipmentAmortizedPeriod" format="ixt-sec:duryear">5</ix:nonNumeric> years. As of December 31, 2022, the balance payable was $<ix:nonFraction id="fid_1850" contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember" name="vnrx:AmountPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>. The following is a schedule showing the future minimum lease payments under financing leases by years and the present value of the minimum payments as of December 31, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_341" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1777" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,726</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1778" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,725</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1779" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,725</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1780" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,726</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1781" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,726</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1782" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,534</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1783" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,162</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1784" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="vnrx:LessAmountRepresentingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">59,016</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1785" contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,146</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) </strong><strong>Operating Lease Right-of-Use Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, operating lease right-of-use assets and liabilities arising from operating leases were $<ix:nonFraction id="fid_1963" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeaseRightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,392</ix:nonFraction> and $<ix:nonFraction id="fid_1964" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesLiability1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,254</ix:nonFraction>, respectively. During the year ended December 31, 2022, cash paid for amounts included for the measurement of lease liabilities was $<ix:nonFraction id="fid_1870" contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="us-gaap:ShortTermLeasePayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,354</ix:nonFraction> and the Company recorded operating lease expense of $<ix:nonFraction id="fid_1871" contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="us-gaap:OperatingLeaseExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,434</ix:nonFraction>. Our weighted average discount rate is <ix:nonFraction id="fid_1869" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">2.38</ix:nonFraction>% and the weighted average remaining lease term is 25 months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_342" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1786" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,799</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1787" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,225</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1788" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,209</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1789" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1793" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Operating Lease Obligations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1790" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,633</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1791" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:LessAmountRepresentingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">24,379</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present Value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1792" contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="vnrx:OperatingLeasesFutureMinimumPaymentDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,254</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-68</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) </strong><strong>Operating Lease Right-of-Use Liabilities (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_b8625f" continuedAt="cont_48a094">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s office space leases are short term, and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the year ended December 31, 2022, $<ix:nonFraction id="fid_1965" contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember" name="us-gaap:ShortTermLeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,955</ix:nonFraction> was recognized in short-term lease costs associated with the office space leases in Singapore and Nevada. The annual payments remaining for such short-term office leases as of December 31, 2022, were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_343" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfRecognizedInShortTermLeaseCosts" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1794" contextRef="AsOf2022-12-31" name="vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,069</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1796" contextRef="AsOf2022-12-31" name="vnrx:OperatingLeasesFutureMinimumPaymentDueInTwoYears" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Operating Lease Liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1795" contextRef="AsOf2022-12-31" name="vnrx:OperatingLeasesFutureMinimumLeasePaymentDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,069</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c) Grants Repayable </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#8364;<ix:nonFraction id="fid_2023" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="us-gaap:GrantsReceivableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">1,048,020</ix:nonFraction>. Per the terms of the agreement, &#8364;<ix:nonFraction id="fid_1890" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="vnrx:RepaymentOfGrants" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">314,406</ix:nonFraction> of the grant is to be repaid by installments over the period from June 30, 2014 to June 30, 2023. The Company has recorded the balance of &#8364;<ix:nonFraction id="fid_1966" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">733,614</ix:nonFraction> to other income in previous years as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, <ix:nonNumeric id="fid_1886" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="vnrx:TermsOfAgreementDescription">it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;314,406 and the <ix:nonFraction id="fid_1897" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="vnrx:RoyalityOnRevenuePercentange" decimals="INF" unitRef="Pure" scale="-2">6</ix:nonFraction>% royalty on revenue, is twice the amount of funding received</ix:nonNumeric>. As of December 31, 2022, the grant balance repayable was $<ix:nonFraction id="fid_1882" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member" name="vnrx:AmountRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,831</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#8364;<ix:nonFraction id="fid_1898" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="us-gaap:GrantsReceivableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">605,000</ix:nonFraction>.&#160; Per the terms of the agreement, &#8364;<ix:nonFraction id="fid_1891" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:RepaymentOfGrants" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">181,500</ix:nonFraction> of the grant is to be repaid by instalments <ix:nonNumeric id="fid_1901" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:GrantRepaidByInstallments">over 12 years</ix:nonNumeric> commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, <ix:nonNumeric id="fid_1887" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:TermsOfAgreementDescription">it is due to pay a <ix:nonFraction id="fid_1894" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:RoyalityOnRevenuePercentange" decimals="INF" unitRef="Pure" scale="-2">3.53</ix:nonFraction>% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received</ix:nonNumeric>. As of December 31, 2022, the grant balance repayable was $<ix:nonFraction id="fid_1883" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:AmountRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,280</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#8364;<ix:nonFraction id="fid_1900" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="us-gaap:GrantsReceivableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">495,000</ix:nonFraction>.&#160; Per the terms of the agreement, &#8364;<ix:nonFraction id="fid_1893" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="vnrx:RepaymentOfGrants" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">148,500</ix:nonFraction> of the grant is to be repaid by installments <ix:nonNumeric id="fid_1903" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="vnrx:GrantRepaidByInstallments">over 10 years</ix:nonNumeric> commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, <ix:nonNumeric id="fid_1889" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="vnrx:TermsOfAgreementDescription">it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;148,500 and the <ix:nonFraction id="fid_1896" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="vnrx:RoyalityOnRevenuePercentange" decimals="INF" unitRef="Pure" scale="-2">2.89</ix:nonFraction>% royalty on revenue, is equal to the amount of funding received</ix:nonNumeric>. As of December 31, 2022, the grant balance repayable was $<ix:nonFraction id="fid_1885" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember" name="vnrx:AmountRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,799</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#8364;<ix:nonFraction id="fid_1899" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="us-gaap:GrantsReceivableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">929,433</ix:nonFraction>.&#160; Per the terms of the agreement, &#8364;<ix:nonFraction id="fid_1892" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:RepaymentOfGrants" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">278,830</ix:nonFraction> of the grant is to be repaid by instalments <ix:nonNumeric id="fid_1902" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:GrantRepaidByInstallments">over 15 years</ix:nonNumeric> commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, <ix:nonNumeric id="fid_1888" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:TermsOfAgreementDescription">it is due to pay a <ix:nonFraction id="fid_1895" contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:RoyalityOnRevenuePercentange" decimals="INF" unitRef="Pure" scale="-2">4.34</ix:nonFraction>% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received</ix:nonNumeric>. As of December 31, 2022, the grant balance repayable was $<ix:nonFraction id="fid_1884" contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember" name="vnrx:AmountRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,392</ix:nonFraction>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-69</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c) Grants</strong><strong> Repayable (continued) </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:continuation id="cont_48a094" continuedAt="cont_3a98f8">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, the balance repayable was $<ix:nonFraction id="fid_1857" contextRef="From2022-01-01to2022-12-31" name="vnrx:GrantRepyable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,302</ix:nonFraction> and the annual payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_344" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1797" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,283</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1798" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,541</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1799" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1800" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,026</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1801" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,978</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1802" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,893</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Grants Repayable </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1803" contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember" name="vnrx:GrantsRepayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,302</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>d) Long-Term Debt</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a <ix:nonNumeric id="fid_1934" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">7</ix:nonNumeric>-year loan agreement with Namur Invest for &#8364;<ix:nonFraction id="fid_1923" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">440,000</ix:nonFraction> with a fixed interest rate of <ix:nonFraction id="fid_1913" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.85</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1904" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">December 2023</ix:nonNumeric>. As of December 31, 2022, the principal balance payable was $<ix:nonFraction id="fid_1940" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,659</ix:nonFraction>.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a <ix:nonNumeric id="fid_1933" contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">15</ix:nonNumeric>-year loan agreement with ING for &#8364;<ix:nonFraction id="fid_1922" contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">270,000</ix:nonFraction> with a fixed interest rate of <ix:nonFraction id="fid_1914" contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">2.62</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1905" contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">December 2031</ix:nonNumeric>. As of December 31, 2022, the principal balance payable was $<ix:nonFraction id="fid_1948" contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,806</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2017, the Company entered into a <ix:nonNumeric id="fid_1932" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">7</ix:nonNumeric>-year loan agreement with SOFINEX for up to &#8364;<ix:nonFraction id="fid_1924" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="-6" unitRef="EUR" scale="6">1</ix:nonFraction> million with a fixed interest rate of <ix:nonFraction id="fid_1915" contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.50</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1908" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">September 2024</ix:nonNumeric>.&#160; As of December 31, 2022, &#8364;1 million has been drawn down under this agreement and the principal balance payable was $<ix:nonFraction id="fid_1941" contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,954</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a <ix:nonNumeric id="fid_1936" contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">4</ix:nonNumeric>-year loan agreement with Namur Innovation and Growth for &#8364;<ix:nonFraction id="fid_1925" contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1916" contextRef="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.00</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1907" contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">June 2022</ix:nonNumeric>. As of December 31, 2022, the principal balance payable was $<ix:nonFraction id="fid_1946" contextRef="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2019, the Company entered into a <ix:nonNumeric id="fid_1935" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">4</ix:nonNumeric>-year loan agreement with Namur Innovation and Growth for &#8364;<ix:nonFraction id="fid_1926" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1917" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.80</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1906" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">September 2024</ix:nonNumeric>. As of December 31, 2022, the principal balance payable was $<ix:nonFraction id="fid_1942" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,548</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into a <ix:nonNumeric id="fid_1968" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">10</ix:nonNumeric>-year loan agreement with Namur Invest for a maximum of &#8364;<ix:nonFraction id="fid_1969" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">830,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1970" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">4.00</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1971" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">March 2031</ix:nonNumeric>. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;<ix:nonFraction id="fid_1973" contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:AgreementUnderAmount" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">707,599</ix:nonFraction>, representing a principal balance payable of $<ix:nonFraction id="fid_1972" contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">759,419</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 23, 2021, the Company entered into a 3 &#189; year loan agreement with SOFINEX for a maximum of &#8364;<ix:nonFraction id="fid_1975" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">450,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1919" contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">5.00</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1910" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">June 2025</ix:nonNumeric>. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;<ix:nonFraction id="fid_1950" contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:AgreementUnderAmount" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">450,000</ix:nonFraction>, representing a principal balance payable of $<ix:nonFraction id="fid_1974" contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">442,708</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 5, 2022 the Company entered into a <ix:nonNumeric id="fid_1938" contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:durmonth">9</ix:nonNumeric>-month loan agreement with First Insurance Funding for a maximum of $<ix:nonFraction id="fid_1928" contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,549</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1920" contextRef="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">3.57</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1911" contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">November 2022</ix:nonNumeric>. As of December 31, 2022, the principal balance payable was $<ix:nonFraction id="fid_1976" contextRef="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 16, 2022, the Company entered into a <ix:nonNumeric id="fid_1979" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">4</ix:nonNumeric>-year loan agreement with Namur Invest for a maximum of &#8364;<ix:nonFraction id="fid_1978" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">1,000,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1980" contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">6.00</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1981" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">July 2026</ix:nonNumeric>. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;<ix:nonFraction id="fid_1982" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:AgreementUnderAmount" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">1,000,000</ix:nonFraction>, representing a principal balance payable of $<ix:nonFraction id="fid_1983" contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,073,231</ix:nonFraction>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-70</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>d) Long-Term Debt (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_3a98f8" continuedAt="cont_46b859">&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 18, 2022, the Company entered into a <ix:nonNumeric id="fid_1986" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LoanAgreementTerm" format="ixt-sec:duryear">4</ix:nonNumeric>-year loan agreement with Namur Invest for a maximum of &#8364;<ix:nonFraction id="fid_1985" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction> with fixed interest rate of <ix:nonFraction id="fid_1987" contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:FixedInterestRate" decimals="INF" unitRef="Pure" scale="-2">5.45</ix:nonFraction>%, maturing <ix:nonNumeric id="fid_1988" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:LineOfCreditFacilityExpirationDatesOne">December 2027</ix:nonNumeric>. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;<ix:nonFraction id="fid_1989" contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="vnrx:AgreementUnderAmount" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">500,000</ix:nonFraction>, representing a principal balance payable of $<ix:nonFraction id="fid_1990" contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember" name="us-gaap:OtherNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536,615</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the total balance for long-term debt payable was $<ix:nonFraction id="fid_1858" contextRef="AsOf2022-12-31" name="vnrx:LongTermDebtPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,845,940</ix:nonFraction> and the payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_345" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1804" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,268,528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1805" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,138,227</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1806" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,312</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1807" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,358</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1808" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,602</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1809" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturingInYearsFourAndFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446,799</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1810" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,319,826</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1811" contextRef="AsOf2022-12-31" name="vnrx:LongTermDebtLessAmountRepresentingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">473,886</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Long-Term Debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_1812" contextRef="AsOf2022-12-31" name="us-gaap:LongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,845,940</ix:nonFraction></strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>e) Collaborative Agreement Obligations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a <ix:nonNumeric id="fid_1958" contextRef="From2022-01-01to2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember" name="vnrx:LeaseAgreementExpirePeriod" format="ixt-sec:duryear">3</ix:nonNumeric>-year period for a cost to the Company of up to $<ix:nonFraction id="fid_1961" contextRef="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember" name="vnrx:CollaborativeObligationsAmount" format="ixt:numdotdecimal" decimals="-1" unitRef="USD" scale="3">2.55</ix:nonFraction> million payable over such period. As of December 31, 2022, $<ix:nonFraction id="fid_1955" contextRef="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember" name="vnrx:CollaborativeObligationsAmountDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,000</ix:nonFraction> is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2019, the Company entered into a funded sponsored research agreement with the Texas A&amp;M University (&#8220;TAMU&#8221;) in consideration for the license granted to the Company for a <ix:nonNumeric id="fid_1956" contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember" name="vnrx:LeaseAgreementExpirePeriods">5</ix:nonNumeric>-year period for a cost to the Company of up to $<ix:nonFraction id="fid_1960" contextRef="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember" name="vnrx:CollaborativeObligationsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction> payable over such period. As of December 31, 2022, $<ix:nonFraction id="fid_1953" contextRef="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember" name="vnrx:CollaborativeObligationsAmountDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of &#8364;<ix:nonFraction id="fid_1930" contextRef="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" name="vnrx:RepaymentsOfLongtermLoans" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">54,879</ix:nonFraction>. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of &#8364;<ix:nonFraction id="fid_1947" contextRef="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,236</ix:nonFraction>. In the year ended December 31, 2022, the parties entered into agreements for an additional cost to the Company of &#8364;<ix:nonFraction id="fid_1951" contextRef="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" name="vnrx:AdditionalCostOfCompany" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction>. As of December 31, 2022, $<ix:nonFraction id="fid_2024" contextRef="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" name="vnrx:CollaborativeObligationsAmountDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,018</ix:nonFraction> is still to be paid by the Company under the amended agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 2, 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (&#8220;NETs&#8221;) in cancer patients with sepsis for a cost to the Company of $<ix:nonFraction id="fid_1952" contextRef="From2022-01-01to2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember" name="vnrx:AdditionalCostOfCompany" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,787</ix:nonFraction>. As of December 31, 2022, $<ix:nonFraction id="fid_2025" contextRef="AsOf2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember" name="vnrx:CollaborativeObligationsAmountDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,787</ix:nonFraction> is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the total amount to be paid for future research and collaboration commitments was approximately $<ix:nonFraction id="fid_1855" contextRef="AsOf2022-12-31" name="vnrx:PaymentsForFutureResearchAndCollobration" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,805</ix:nonFraction> and the annual payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_346" contextRef="From2022-01-01to2022-12-31" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1813" contextRef="AsOf2022-12-31" name="vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">798,032</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1815" contextRef="AsOf2022-12-31" name="vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,773</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Collaborative Agreement Obligations&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1814" contextRef="AsOf2022-12-31" name="vnrx:CollaborativeAgreementObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,805</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-71</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_46b859" continuedAt="cont_f59a18"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>f) Other Commitments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition Vet </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 25, 2019, the Company entered into an agreement with TAMU for provision of in-kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of December 31, 2022, TAMU has a 12.5 % equity interest in Volition Vet.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition Germany </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (&#8220;Octamer&#8221;), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or &#8220;Volition Germany&#8221;). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of <ix:nonFraction id="fid_1992" contextRef="From2022-01-01to2022-12-31" name="vnrx:RoyalityOnRevenuePercentange" decimals="INF" unitRef="Pure" scale="-2">6</ix:nonFraction>% of net sales of Volition Germany&#8217;s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, $<ix:nonFraction id="fid_1851" contextRef="AsOf2022-12-31_vnrx_ManagingDirectorsAgreementMember" name="vnrx:AmountPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210</ix:nonFraction> is payable under the <ix:nonFraction id="fid_1878" contextRef="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember" name="vnrx:Royality" decimals="INF" unitRef="Pure" scale="-2">6</ix:nonFraction>% royalty agreement on sales to date towards the Company&#8217;s aggregate minimum royalty obligation of&#160; $<ix:nonFraction id="fid_1877" contextRef="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember" name="us-gaap:PaymentsForRoyalties" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,055</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition America </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 3, 2020, the Company entered into a professional services master agreement (the &#8220;Master Agreement&#8221;) with Diagnostic Oncology CRO, LLC (&#8220;DXOCRO&#8221;) to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. On August 8, 2022, the Company and DXOCRO amended and restated the Master Agreement to expand the scope of DXOCRO&#8217;s consultant services provided thereunder (the &#8220;A&amp;R Master Agreement&#8221;). The A&amp;R Master Agreement requires DXOCRO to support development and clinical validation studies for the Company&#8217;s Nu.Q&#174; product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q&#174; NETs and Nu.Q&#174; Cancer tests to determine clinical utility in sepsis and non-Hodgkin&#8217;s lymphoma. The Company anticipates DXOCRO&#8217;s services <ix:nonNumeric id="fid_1856" contextRef="From2020-11-01to2020-11-03" name="vnrx:AggerateAmountPayableDescription">under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million</ix:nonNumeric>. The Company&#8217;s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days&#8217; prior written notice. Unless earlier terminated, the A&amp;R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of December 31, 2022, $ <ix:nonFraction id="fid_1991" contextRef="AsOf2022-12-31" name="vnrx:AmountPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,692</ix:nonFraction> is payable under the A&amp;R Master Agreement, and up $<ix:nonFraction id="fid_1854" contextRef="AsOf2022-12-31" name="vnrx:PayableByCompanyForServicesRendered" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,435,165</ix:nonFraction> may be payable by Company in future periods for services rendered. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>g) Legal Proceedings</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-72</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_f59a18" continuedAt="cont_b8ed93"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>h) Commitments in Respect of Corporate Goals and Performance-Based Awards</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In August 2021 and October 2021, the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals related to the awards in August 2021 and October 2021 resulting in the payment of the cash bonus awards and the vesting of the remaining rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has paid compensation expense of $<ix:nonFraction id="fid_1868" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SalariesWagesAndOfficersCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">737,137</ix:nonFraction> in relation to the July 1, 2022 specified corporate goals based on the actual outcomes related to the prescribed performance targets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In October 2022, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around product development, manufacturing, financing and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Conditional upon the achievement by January 1, 2023 and July 1, 2023 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has accrued compensation expense of $<ix:nonFraction id="fid_1852" contextRef="AsOf2022-12-31" name="vnrx:AccruedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,856</ix:nonFraction> in relation to the January 1, 2023 and July 1, 2023 specified corporate goals based on the actual outcomes related to the prescribed performance targets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As discussed in detail in Note 8, - <em>Stock-Based Compensation,</em> an aggregate of <ix:nonFraction id="fid_1993" contextRef="From2022-01-01to2022-12-31" name="vnrx:RestrictedStockUnit" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,144,000</ix:nonFraction> RSUs were issued under the 2015 Stock Incentive Plan in connection with the October 2022 grants and an aggregate of <ix:nonFraction id="fid_1867" contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember" name="us-gaap:DilutiveSecurities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction> stock options and <ix:nonFraction id="fid_1866" contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction> RSUs were issued under the 2015 Stock Incentive Plan in connection with the August 2021 and October 2021 grants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized compensation expense of $<ix:nonFraction id="fid_1864" contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,593</ix:nonFraction> in relation to the options vested in 2022 and $630,863 in relation to the options that will vest in 2023. The Company has unrecognized compensation expense of $<ix:nonFraction id="fid_1859" contextRef="From2022-01-01to2022-12-31" name="vnrx:UnrecognizedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,550</ix:nonFraction> to such stock options, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_359" contextRef="From2022-01-01to2022-12-31" name="vnrx:ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" escape="true" continuedAt="cont_5aed5f"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:25%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1816" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,593</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1820" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember" name="vnrx:AmortisedOfOutstandingAward2022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,411</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1821" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember" name="vnrx:AmortisedOfOutstandingAward2021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,182</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1822" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember" name="vnrx:UnAmortisedOfOutstandingAward2023" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1823" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,863</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1824" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember" name="vnrx:AmortisedOfOutstandingAward2022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,090</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1825" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember" name="vnrx:AmortisedOfOutstandingAward2021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,773</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1819" contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember" name="vnrx:UnAmortisedOfOutstandingAward2023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,550</ix:nonFraction></p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-73</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 10 &#8211; Commitments and Contingencies (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_b8ed93"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>h) Commitments in Respect of Corporate Goals and Performance-Based Awards (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized compensation expense of $<ix:nonFraction id="fid_2076" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,149</ix:nonFraction> in relation to the RSUs fully vested in 2022 and $<ix:nonFraction id="fid_2077" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member" name="vnrx:RSuVested" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,930</ix:nonFraction> in relation to RSUs that will vest in 2023. The Company has unrecognized compensation expense of $<ix:nonFraction id="fid_2078" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member" name="vnrx:UnrecognizedCompensationExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,491</ix:nonFraction> to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_5aed5f" continuedAt="cont_7d421a"><table style="border-spacing:0;font-size:10pt;text-align:justify;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:25%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1826" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">822,149</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1828" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:AmortisedOfOutstandingAward2022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,207</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1829" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:AmortisedOfOutstandingAward2021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,942</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1830" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:UnAmortisedOfOutstandingAward2023" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1831" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,930</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1832" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:AmortisedOfOutstandingAward2022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,191</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1833" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:AmortisedOfOutstandingAward2021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,739</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1827" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:UnAmortisedOfOutstandingAward2023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,491</ix:nonFraction> </p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized total compensation expense of $<ix:nonFraction id="fid_2084" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,861</ix:nonFraction> of which $<ix:nonFraction id="fid_2081" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member" name="vnrx:RSuVested" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,087</ix:nonFraction> in relation to RSUs that will vest in 2023, $<ix:nonFraction id="fid_2082" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member" name="vnrx:RSuVestedIn2024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,088</ix:nonFraction> in relation to RSUs that will vest in 2024, and $<ix:nonFraction id="fid_2083" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member" name="vnrx:RSuVestedIn2025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,686</ix:nonFraction> in relation to RSUs that will vest in 2025. The Company has unrecognized compensation expense of $<ix:nonFraction id="fid_2079" contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member" name="vnrx:UnrecognizedCompensationExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,408,319</ix:nonFraction> in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_7d421a"><table style="border-spacing:0;font-size:10pt;text-align:justify;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:34%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Year</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonNumeric id="fid_1835" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:OutstandingAwardVestingPeriod">2023</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1837" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:AmortisedOfOutstandingAwardAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,087</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1839" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember" name="vnrx:UnAmortisedOfOutstandingAward" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,327</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonNumeric id="fid_1840" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:OutstandingAward">2024</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1841" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:AmortisedOfOutstandingAwardAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,088</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1836" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember" name="vnrx:UnAmortisedOfOutstandingAward" format="ixt:numdotdecimal" decimals="0" unitRef="USD">470,244</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><ix:nonNumeric id="fid_1843" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember" name="vnrx:OutstandingAward">2025</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1844" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember" name="vnrx:AmortisedOfOutstandingAwardAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,686</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;<ix:nonFraction id="fid_1845" contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember" name="vnrx:UnAmortisedOfOutstandingAward" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,748</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;<ix:nonFraction id="fid_1847" contextRef="From2022-01-01to2022-12-31" name="vnrx:AmortisedOfOutstandingAwardAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,861</ix:nonFraction> </strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;<ix:nonFraction id="fid_1848" contextRef="From2022-01-01to2022-12-31" name="vnrx:UnAmortisedOfOutstandingAward" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,408,319</ix:nonFraction> </strong></p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-74</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For Years Ended December 31, 2022 and 2021</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>($ expressed in United States Dollars)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_304" contextRef="From2022-01-01to2022-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 11 - Subsequent Events</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Common Stock Issuances and Repurchases</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From January 1 to January 19, 2023, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $<ix:nonFraction id="fid_2016" contextRef="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">656,000</ix:nonFraction> under the 2022 EDA through the sale of <ix:nonFraction id="fid_2019" contextRef="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember" name="vnrx:SaleOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,703</ix:nonFraction> shares of its common stock.&#160; No additional shares have been sold under the 2022 EDA through March 8, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January&#160;5, 2023, the Company purchased from a former officer <ix:nonFraction id="fid_2020" contextRef="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember" name="vnrx:CommonStockSharePurchase" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,264</ix:nonFraction> shares of its common stock at $<ix:nonFraction id="fid_2021" contextRef="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember" name="vnrx:CommonStockPerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.39</ix:nonFraction> per share, for a total cost to the Company of $<ix:nonFraction id="fid_2022" contextRef="From2023-01-01to2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember" name="vnrx:CostOfTheCompany" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,772</ix:nonFraction>.66.&#160; These shares were subsequently retired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>RSU Vesting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals established by the Compensation Committee on October 4, 2022, which resulted in the vesting of rights with respect to an aggregate of <ix:nonFraction id="fid_2012" contextRef="AsOf2023-01-12_vnrx_RsuVestingEventMember" name="vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">424,875</ix:nonFraction> RSUs.&#160; The RSUs are further subject to a <ix:nonNumeric id="fid_2015" contextRef="From2023-01-01to2023-01-12_vnrx_RsuVestingEventMember" name="vnrx:RsuVestingDescription">3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025</ix:nonNumeric>, respectively, and conditioned upon the recipient&#8217;s continued service through the applicable vesting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 8, 2023, <ix:nonFraction id="fid_2002" contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,000</ix:nonFraction> RSUs previously granted to an employee vested and resulted in the issuance of <ix:nonFraction id="fid_2007" contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,369</ix:nonFraction> shares of common stock and the remaining <ix:nonFraction id="fid_2010" contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:CommonStockSharesWithheldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,631</ix:nonFraction> shares of common stock were withheld as taxes and returned to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 1, 2023, <ix:nonFraction id="fid_2001" contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction> RSUs previously granted to employees vested and resulted in the issuance of <ix:nonFraction id="fid_2006" contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,609</ix:nonFraction> shares of common stock. An aggregate of <ix:nonFraction id="fid_2009" contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember" name="vnrx:CommonStockSharesWithheldForTaxes" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,391</ix:nonFraction> shares of common stock were withheld as taxes and returned to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Capital Raise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February&#160;17, 2023, the Company entered into an underwriting agreement with Newbridge in connection with an underwritten public offering of&#160;<ix:nonFraction id="fid_1994" contextRef="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,945,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock, which includes Newbridge&#8217;s exercise in full of its overallotment option, pursuant to the Company&#8217;s 2021 Form S-3. Newbridge purchased the shares from the Company at a price of $<ix:nonFraction id="fid_1995" contextRef="AsOf2023-02-17_vnrx_CapitalRaiseMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.6275</ix:nonFraction> per share.&#160; The offering closed on February 22, 2023. &#160;The Company received net proceeds of approximately $<ix:nonFraction id="fid_1996" contextRef="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">8.0</ix:nonFraction> million from the offering before deducting offering expenses payable by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Commercial Product Launches</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 12, 2023, the Company announced the availability of its Nu.Q&#174; Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 16, 2023, the Company announced that its Nu.Q&#174; Vet Cancer Test was available for pre-order to veterinarians at the point of care through Heska.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>END NOTES TO FINANCIALS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-75</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOCFAN">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9A">ITEM 9A. CONTROLS AND PROCEDURES </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Disclosure Controls and Procedures</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective because of material weakness in our internal control over financial reporting relating to the segregation of duties in some areas of finance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Management&#8217;s Report on Internal Control Over Financial Reporting</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f). The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles U.S. GAAP. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the supervision and with the participation of management, including the Principal Executive Officer and Principal Financial Officer, the Company conducted an evaluation of the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2022, using the criteria established in &#8220;<em>Internal Control - Integrated Framework (2013)</em>&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022, our management, with oversight from our audit committee, implemented the following remediation steps to address and mitigate the underlying deficiencies which gave rise to the material weaknesses and to improve our internal control over financial reporting:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">hired specialists in human resources and information technology to recommend and implement relevant policies and processes that will strengthen the control environment;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changed organizational reporting lines and reallocated certain responsibilities to improve segregation of duties around payroll;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">engaged additional resources to help us assess, document, design and implement control activities related to internal control over financial reporting; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">implemented additional review procedures at each month end close.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2023, we intend to take additional measures to strengthen certain processes we have identified which we believe once implemented in conjunction with the completed actions above will mitigate and remedy this weakness. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">76</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We also intend to take additional steps to continue to strengthen the control environment. Such measures include but may not be limited to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">hiring additional finance resources;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">strengthening our internal processes and reviews, including formal documentation thereof; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">preparation of risk-control matrices to identify key risks and develop and document policies to mitigate those risks.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As we continue to evaluate and test the remediation plan outlined above, we may also identify additional measures to address the material weaknesses or modify certain of the remediation procedures described above. We may also implement additional changes to our internal control over financial reporting as may be appropriate in the course of remediating the material weakness. Management, with the oversight of our audit committee, will continue to take steps necessary to remedy the material weakness to reinforce the overall design and capability of our control environment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Changes in Internal Control over Financial Reporting</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Audit Committee of the Board of Directors meets regularly with our financial management, and with the independent registered public accounting firm engaged by us.&#160;Internal accounting controls and the quality of financial reporting are discussed during these meetings. The Audit Committee has discussed with the independent registered public accounting firm matters required to be discussed by the auditing standards adopted or established by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;). In addition, the Audit Committee and the independent registered public accounting firm have discussed the independent registered public accounting firm&#8217;s independence from&#160;the Company and its management, including the matters in the written disclosures required by PCAOB Rule 3526 <em>&#8220;Communicating with Audit Committees Concerning Independence.&#8221;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, other than those described above.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is not required to include, and does not include an auditor&#8217;s attestation report under SEC Rules. Consequently, the Company&#8217;s registered public accounting firm has not attested to management&#8217;s reports on the Company&#8217;s internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9B">ITEM 9B. OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective March 1, 2023, Singapore Volition entered into an employment agreement with Cameron Reynolds, the Company&#8217;s Chief Executive Officer (the &#8220;Reynolds Employment Agreement&#8221;), which supersedes and replaces in its entirety the Consulting Services Agreement between Singapore Volition and PB Commodities Pte. Ltd., a Singapore corporation (&#8220;PB Commodities&#8221;), dated December 1, 2020, pursuant to which PB Commodities made Mr. Reynolds&#8217; services available to the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Reynolds Employment Agreement continues until terminated by either party providing not less than six months&#8217; prior notice. In exchange for his services, Mr. Reynolds shall receive, among other things, (i) an annual base salary of $450,300 from Singapore Volition, paid in equal monthly installments, and (ii) a lump sum severance payment if terminated by Singapore Volition without cause equal to the salary that he would have received between the date of termination and the completion of a six-month notice period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9C">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">77</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="P3">PART III</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I10">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The information required under this Item is incorporated by reference from our definitive proxy statement related to our 2023 Annual Meeting of Stockholders, or the Proxy Statement, to be filed pursuant to Regulation 14A, on or before May 1, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I11">ITEM 11. EXECUTIVE COMPENSATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The information required under this Item is incorporated herein by reference from the Proxy Statement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I12">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The information required under this Item is incorporated herein by reference from the Proxy Statement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I13">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The information required under this Item is incorporated herein by reference from the Proxy Statement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I14">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The information required under this Item is incorporated herein by reference from the Proxy Statement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">78</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="P4">PART IV</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I15">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">(a)&#160;&#160; The following documents are filed as part of this Report:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Financial Statements. </em>Included in Part II, Item 8 of this Report and are incorporated by reference herein.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Financial Statement Schedules. </em>Financial statement schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Exhibits.</em></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="15"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Incorporated by Reference</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td><td colspan="2" style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>File No.</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filing </strong><strong>Date</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;" colspan="5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filed </strong><strong>Herewith</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212001219/f8ka5050712_ex2z1.htm">2.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212001219/f8ka5050712_ex2z1.htm">Share Purchase Agreement, by and between Singapore Volition and ValiRX, dated September 22, 2010.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K/A</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/8/12</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000060/f8ka2011012_ex10z15.htm">2.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000060/f8ka2011012_ex10z15.htm">Supplementary Agreement to the Share Purchase Agreement, by and between Singapore Volition and ValiRX, dated June 9, 2011.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K/A</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.15</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1/11/12</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000009331411000016/shareexchangeagreement.htm">2.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000009331411000016/shareexchangeagreement.htm">Share Exchange Agreement by and among Standard Capital Corporation, the controlling shareholders of Standard Capital Corporation and Singapore Volition, dated September 26, 2011.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">9/29/11</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000961/f8ka4040412_ex10z28.htm">2.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000961/f8ka4040412_ex10z28.htm">Agreement, Consent and Waiver by and between Standard Capital Corporation and its Shareholders, dated September 27, 2011.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K/A</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.28</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4/5/12</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003598/f8k101116_ex3z1.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003598/f8k101116_ex3z1.htm">Second Amended and Restated Certificate of Incorporation, as currently in effect.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/11/16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878215002010/s8121115_ex4z2.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878215002010/s8121115_ex4z2.htm">Amended and Restated Bylaws, as currently in effect.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-208512</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/11/15</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex4z1.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex4z1.htm">Description of Capital Stock.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-K</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4.1</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/20/20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000537/f8ka3022312_ex10z06.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878212000537/f8ka3022312_ex10z06.htm">Non-Exploitation and Third-Party Patent License Agreement, by and among ValiBio SA, ValiRX and The Walloon Region, dated December 17, 2009.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K/A</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/24/12</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216002414/f10k123115_ex10z24.htm">10.<span style="text-decoration:underline">2</span>#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216002414/f10k123115_ex10z24.htm">Employment Agreement, by and between VolitionRx and Jason Terrell MD, dated December 29, 2015.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.24</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/11/16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">79</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Incorporated by Reference</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exhibit Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>File No.</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exhibit</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing </strong><strong>Date</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filed </strong><strong>Herewith</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/equityincentiveplan_ex4z1.htm">10.<span style="text-decoration:underline">3</span>#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/equityincentiveplan_ex4z1.htm">2011 Equity Incentive Plan dated November&#160;17, 2011.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/18/11</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/samplestockoptionagrmt_ex4z2.htm">10.3(a)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/samplestockoptionagrmt_ex4z2.htm">Form Stock Option Agreement.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/18/11</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/samplestockawardagrmt_ex4z3.htm">10.3(b)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878211003352/samplestockawardagrmt_ex4z3.htm">Form Stock Award Agreement for Restricted Stock under the 2011 Equity Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">000-30402</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4.3</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/18/11</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878219000535/f8k061819_ex10z1.htm">10.<span style="text-decoration:underline">4</span>#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878219000535/f8k061819_ex10z1.htm">2015 Stock Incentive Plan, as amended. </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6/14/22</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z2.htm">10.4(a)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z2.htm">Form of Notice of Stock Option Grant and Stock Option Agreement under the 2015 Stock Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z2.htm">&#160;</a></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.2</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z3.htm">10.4(b)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z3.htm">Form of Notice of Restricted Stock Award and Restricted Stock Agreement under the 2015 Stock Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.3</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z4.htm">10.4(c)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z4.htm">Form of Notice of Stock Bonus Award and Stock Bonus Award Agreement under the 2015 Stock Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.4</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z5.htm">10.4(d)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z5.htm">Form of Notice of Stock Appreciation Right Award and Stock Appreciation Right Award Agreement under the 2015 Stock Incentive Plan.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.5</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z6.htm">10.4(e)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z6.htm">Form of Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the 2015 Stock Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.6</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z7.htm">10.4(f)#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003647/s8101316_ex10z7.htm">Form of Notice of Performance Shares Award and Performance Shares Agreement under the 2015 Stock Incentive Plan.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-8</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">333-214118</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.7</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/14/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878215000744/f10q033115_ex10z33.htm">10.<span style="text-decoration:underline">5</span>#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878215000744/f10q033115_ex10z33.htm">Independent Director Agreement.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.33</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/12/15</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003692/f8k102716_ex10z1.htm">10.<span style="text-decoration:underline">6</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003692/f8k102716_ex10z1.htm">Real Estate Capital Lease Agreement, by and between Belgian Volition and ING Asset Finance Belgium S.A., dated October 4, 2016 (English translation of French original).</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.1</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/31/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003692/f8k102716_ex10z2.htm">10.<span style="text-decoration:underline">7</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878216003692/f8k102716_ex10z2.htm">Deed of Sale to the Sale Agreement, by and between Belgian Volition and Gerard Dekoninck S.A., dated October 25, 2016 (English translation of French original).</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.2</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10/31/16</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217000302/f10k123116_ex10z28.htm">10.<span style="text-decoration:underline">8</span>#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217000302/f10k123116_ex10z28.htm">Employment Agreement, by and between Volition Diagnostics UK Limited and Jacob Micallef, dated March 7, 2017.</a> &#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-K</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.28</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3/10/17</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">80</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="15"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Incorporated by Reference</strong></p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number</strong></p></td><td colspan="2" style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit Description</strong></p></td><td colspan="2" style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td><td colspan="2" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>File No.</strong></p></td><td colspan="2" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td colspan="2" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filing </strong><strong>Date</strong></p></td><td colspan="3" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filed </strong><strong>Herewith</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217000302/f10k123116_ex10z30.htm">10.<span style="text-decoration:underline">9</span>#</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217000302/f10k123116_ex10z30.htm">Employment Agreement, by and between Volition Diagnostics UK and Martin Faulkes, dated March 7, 2017.</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.30</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/10/17</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217001300/f8k092117_ex10z1.htm">10.1<span style="text-decoration:underline">0</span></a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217001300/f8k092117_ex10z1.htm">Unsecured Credit Agreement, by and among VolitionRx, Belgian Volition and SOFINEX (English translation of French original), dated September&#160;20, 2017.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9/21/17</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217001534/f10q093017_ex10z1.htm">10.1<span style="text-decoration:underline">1</span></a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878217001534/f10q093017_ex10z1.htm">Clinical Study Agreement, by and between Volition America and the Regents of the University of Michigan, dated July 17, 2017.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/9/17</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex10z22.htm">10.1<span style="text-decoration:underline">1</span>(a)</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex10z22.htm">Amendment #1 to Clinical Study Agreement, by and between Volition America, Inc. and the Regents of the University of Michigan, dated February 17, 2020.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.22</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2/20/20</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000086/s3020420_ex4z3.htm">10.1<span style="text-decoration:underline">2</span>#</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000086/s3020420_ex4z3.htm">Warrant to Purchase Common Stock, by and between VolitionRx and Jason Terrell MD, dated March 20, 2013; First Amendment to Warrant Agreement, dated February 14, 2017; and Second Amendment to Warrant Agreement, dated July 1, 2019.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">S-3</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">333-236335</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.3</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2/7/20</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000842/f10q093020_ex1z1.htm">10.1<span style="text-decoration:underline">3</span></a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000842/f10q093020_ex1z1.htm">Equity Distribution Agreement, by and among VolitionRx, Oppenheimer &amp; Co. Inc. and Cantor Fitzgerald &amp; Co., dated November 12, 2020.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.1</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/12/20</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000842/f10q093020_ex10z1.htm">10.1<span style="text-decoration:underline">4</span>#</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878220000842/f10q093020_ex10z1.htm">Consulting Services Agreement, by and between Singapore Volition and PB Commodities Pte. Ltd. (Cameron Reynolds), dated December 1, 2020.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.1</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/12/20</p></td><td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z18.htm">10.1<span style="text-decoration:underline">5</span>#&#8224;</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z18.htm">Common Stock Warrant issued by VolitionRx to Gael Forterre, dated January 1, 2021.</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.18</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/22/21</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z19.htm">10.1<span style="text-decoration:underline">6</span>#&#8224;</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z19.htm">Singapore Volition Pte. Limited Employment Agreement, by and between Singapore Volition and Terig Hughes, dated January 27, 2021 and effective February 1, 2021, including the form of Common Stock Warrant attached as Schedule&#160;2.</a></p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.19</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/22/21</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z20.htm">10.<span style="text-decoration:underline">17</span>#&#8224;</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000262/f10k123120_ex10z20.htm">Volition America, Inc. Employment Agreement, by and between Volition America and Gael Forterre, dated February 1, 2021.</a></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">001-36833</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10.20</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3/22/21</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">81</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Incorporated by Reference</strong></p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit Description</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>File No.</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing </strong><strong>Date</strong></p></td><td colspan="2" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filed </strong><strong>Herewith</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000429/f10q033121_ex10z6.htm">10<span style="text-decoration:underline">.18</span><span style="text-decoration:underline">#</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000107878221000429/f10q033121_ex10z6.htm">Volition Veterinary Diagnostics Development, LLC Employment Agreement Chief Executive Officer, by and between Volition Veterinary Diagnostics Development and Salvatore Thomas Butera, dated March 25, 2021.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.6</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/11/21</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221006638/vnrx_ex12.htm">10<span style="text-decoration:underline">.19</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221006638/vnrx_ex12.htm">Equity Distribution Agreement, by and among VolitionRx, Oppenheimer &amp; Co. Inc. and Cantor Fitzgerald &amp; Co., dated September&#160;24, 2021.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">S-3</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">333-259783</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1.2</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">9/24/21</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex101.htm">10.20<span style="text-decoration:underline">#</span></a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex101.htm">Employment Agreement, by and between Volition America and Gaetan Michel, dated September 15, 2021.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.1</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/10/21</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex102.htm">10.21#&#8224;</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex102.htm">Consulting Services Agreement, by and between Volition Global and 3F Management SPRL (Gaetan Michel), dated September&#160;15, 2021.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.2</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/10/21</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex103.htm">10.22#</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793221008003/vnrx_ex103.htm">Employment Agreement, by and between Volition Diagnostics and Nick Plummer, dated August&#160;23, 2021.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.3</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/10/21</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222003197/vnrx_ex101.htm">10.23&#8224;</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222003197/vnrx_ex101.htm">License and Supply Agreement between Belgian Volition and Heska Corporation, dated March 28, 2022.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.1</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/11/22</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222003728/vnrx_ex11.htm">10.24</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222003728/vnrx_ex11.htm">Equity Distribution Agreement, dated May 20, 2022, by and between VolitionRx Limited and Jefferies LLC.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1.1</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/20/22</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222005563/vnrx_ex11.htm">10.25</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793222005563/vnrx_ex11.htm">Underwriting Agreement, dated July&#160;29, 2022, by and between VolitionRx Limited and Newbridge Securities Corporation.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1.1</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8/2/22</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793223001176/vnrx_ex11.htm">10.26</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/93314/000147793223001176/vnrx_ex11.htm">Underwriting Agreement, dated February&#160;17, 2023, by and between VolitionRx Limited and Newbridge Securities Corporation.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">001-36833</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1.1</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2/21/23</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex1027.htm">10.27#</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex1027.htm">Singapore Volition Pte. Limited Employment Agreement &#8211; Group Chief Executive Officer, dated March 13, 2023, by and between Singapore Volition and Cameron Reynolds.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex211.htm">21.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex211.htm">List of Subsidiaries.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex231.htm">23.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex231.htm">Consent of independent registered public accounting firm.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">24.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Power of Attorney (included on the signature page of this Report).&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex311.htm">31.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.&#160;</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex312.htm">31.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.&#160;</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><a href="vnrx_ex321.htm">32.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="vnrx_ex321.htm">Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10.1 INS</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Instance Document</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Taxonomy Extension Schema Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">101.PRE</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">#</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Indicates a management contract or compensatory plan or arrangement.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#8224;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Portions of this exhibit are redacted pursuant to Item 601(a)(6) and/or Item (b)(10)(iv) under Regulation S-K. The registrant agrees to furnish supplementally any omitted schedules to the SEC upon request.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">*</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The certifications attached as Exhibit 32.1 accompany this Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant&#8217;s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="I16">ITEM 16. FORM 10-K SUMMARY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">82</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="SIG">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>VOLITIONRX LIMITED</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dated: March 15, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Cameron Reynolds</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cameron Reynolds</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">President, Chief Executive Officer and Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>POWER OF ATTORNEY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Cameron Reynolds and Rodney Rootsaert, and each or either of them, acting individually, his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form 10-K has been signed below by the following persons in the capacities and on the date indicated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Signature</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:33%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td></tr><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Cameron Reynolds</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">President, Chief Executive Officer and Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cameron Reynolds</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Principal Executive Officer)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>/s/ Terig Hughes</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Chief Financial Officer and Treasurer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Terig Hughes</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Principal Financial and Accounting Officer)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Dr. Martin Faulkes</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dr. Martin Faulkes</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Guy Innes</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Guy Innes</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Dr. Alan Colman</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dr. Alan Colman</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Dr. Phillip Barnes</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dr. Phillip Barnes</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Dr. Edward Futcher</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dr. Edward Futcher</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Kim Nguyen</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Kim Nguyen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Richard Brudnick</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Richard Brudnick</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Mickie Henshall</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Mickie Henshall</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">March 15, 2023</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">83</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>vnrx_ex1027.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT
<TEXT>
<html><head><title>vnrx_ex1027.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.27</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>SINGAPORE VOLITION PTE. LIMITED</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EMPLOYMENT AGREEMENT</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>GROUP CHIEF EXECUTIVE OFFICER</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This Employment Agreement (&#8220;<u>Agreement</u>&#8221;) is dated March 13, 2023 (&#8220;<u>Execution Date&#8221;)</u> and is effective from March 01, 2023 (the &#8220;<u>Effective Date</u>&#8221;) by and between Singapore Volition Pte. Limited, a Singapore corporation (&#8220;<u>Company</u>&#8221; or &#8220;<u>We</u>&#8221;) and Cameron Reynolds (&#8220;<u>Employee</u>&#8221; or &#8220;<u>You</u>&#8221;). The Company and Employee are sometimes referred to herein individually as a &#8220;Party&#8221; or collectively as the &#8220;Parties.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WITNESSETH:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>WHEREAS</strong>, the Company desires that Employee be employed by the Company, and render services to the Company and its subsidiaries and affiliates, and Employee is willing to be so employed and to render such services, all upon the terms and subject to the conditions contained herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>WHEREAS, </strong>in order to ensure a harmonious ongoing business working relationship among themselves with respect to the conduct pursuant to the terms and conditions outlined in this Employment Agreement, the Parties desire to enter into this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AGREEMENT:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>NOW, THEREFORE</strong>, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>1. </strong><strong>EMPLOYMENT</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; This agreement supersedes and replaces in its entirety the existing Consulting Services Agreement between the Company and PB Commodities Pte. Ltd. dated December 1, 2020 (the &#8220;PB Consultancy Agreement&#8221;), which is hereby terminated upon mutual agreement and is of no further force and effect as from the Effective Date (other than the provisions expressly surviving termination under Section 4(e) of the PB Consultancy Agreement).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; Subject to and upon the terms and conditions contained in this Agreement, the Company hereby agrees to employ Employee and Employee agrees to be employed by the Company as of the Effective Date, and, to render to the Company, its affiliates and/or subsidiaries the services described in Section 3 hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>2.</strong> <strong>TERM</strong>. Employee&#8217;s employment under this Agreement shall commence as of the Effective Date hereof and shall continue until terminated in accordance with the provisions of this Agreement (the &#8220;<u>Employment Term&#8221;)</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>3. </strong><strong>DUTIES.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Group Chief Executive Officer</u>. Employee shall serve as the Group Chief Executive Officer of the Company, reporting directly to the Board of Directors (the &#8220;Board&#8221;) of VolitionRx Limited (&#8220;VolitionRx&#8221;). Employee shall be responsible for the performance of such duties, functions and responsibilities as typically carried out by the Chief Executive Officer of a US listed company, as reasonably and lawfully directed by the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Company Policies</u>. Employee agrees to abide by all bylaws and policies of the Company and its affiliates and/or subsidiaries promulgated from time to time by the Company and/or such entities as well as all laws, statutes and regulations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp; <u>Place of Work</u>. The normal place of work for the Employee shall be from his home, or from such other location as mutually agreed upon between the Company and the Employee. The Employee will be required to be available for domestic and international travel as the Company&#8217;s business reasonably requires.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>4. </strong><strong>BEST EFFORTS.</strong> Employee agrees to devote his full business time and attention, as well as his best efforts, energies and skill, to the discharge of the duties and responsibilities attributable to his position.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>5. </strong><strong>COMPENSATION. </strong>For the duration of the Employment Term and as compensation for his services and covenants hereunder, the Employee shall receive:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Salary</u>. Employee&#8217;s base salary shall be Four Hundred and Fifty Thousand Three Hundred U.S. Dollars (US$450,300) per year (&#8220;<u>Base Salary</u>&#8221;). The Base Salary shall be payable in equal monthly instalments in U.S Dollars in accordance with the Company&#8217;s standard payroll practices and policies for employees. The Base Salary shall be reviewed annually, and any increases will be approved by the VolitionRx Board of Directors or its Compensation Committee, and the Board of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Incentive Plans</u>. During the Employment Term, the Employee shall also be eligible to participate in other employee incentive plans of VolitionRx and/or the Company, if any. The criteria for determining the amount of any allocations to the Employee under such incentive plans for employees, including the criteria for determining the amount of any award, and the conditions that must be satisfied to entitle Employee to receive such award for any year during the Employment Term of this Agreement shall be determined, in the sole discretion of the VolitionRx Board of Directors, its Compensation Committee or the Company&#8217;s Board, as applicable.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Health Insurance</u>. During the Employment Term, the Company shall directly pay or reimburse the Employee for the premiums of a health insurance policy for the Employee and his dependents, up to a maximum of One Thousand Five Hundred U.S. Dollars (US$1,500) per month, until such time as the Company establishes a health and medical insurance benefits program in which the Employee is entitled to participate. If Employee&#8217;s employment terminates, with or without any reason, the Company shall have no obligation to continue to directly pay or reimburse the costs of the health insurance policy for the Employee. Reimbursement shall be subject to the production of receipts or other appropriate evidence of payment.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Pension</u>. During the Employment Term, the Company will pay an amount towards the Employee&#8217;s personal pension scheme (currently 3% of the aggregate of the Employee&#8217;s Base Salary and any cash bonus awards) which shall be payable in cash as a separate allowance to be paid together with his monthly salary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>6. </strong><strong>EXPENSES.</strong> Employee shall be reimbursed for business expenses incurred by him which are reasonable and necessary for Employee to perform his duties under this Agreement, subject to the production of receipts or other appropriate evidence of payment. In claiming expenses, the Employee shall comply with the Company&#8217;s Travel and Expenses Policy or any other Expenses Policies implemented by the Company (as amended from time to time), copies of which will be provided.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>7. </strong><strong>EMPLOYEE BENEFITS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Paid Time Off (PTO).</u> Employee shall be entitled to twenty-five (25) days paid vacation (excluding public holidays) on an annual basis in accordance with the Company&#8217;s policies, as may be established from time to time by the Company for its employees, which shall be taken at such time or times as shall be mutually agreed upon by the Parties. The Employee shall not carry forward any accrued but untaken vacation entitlement to a subsequent calendar year, except as set out in the holiday policy of the Company&#8217;s Employee Handbook (as amended from time to time), a copy of which will be provided.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Insurance</u>. During the Employment Term, Employee shall be entitled to participate in such group term insurance, disability insurance, health and medical insurance benefits, life insurance and retirement plans or programs as are from time to time generally made available to executive employees of the Company pursuant to the policies of the Company. The Employee&#8217;s eligibility to participate in the aforementioned schemes is subject to the Employee complying with the conditions attendant to coverage by such plans, and the Employee shall comply with and be entitled to benefits only to the extent former employees are eligible to participate in such arrangements pursuant to the terms of the arrangement, any insurance policy associated therewith and applicable law, and, further, shall be entitled to benefits only in accordance with the terms and conditions of such plans. The Company may withhold from any benefits payable to Employee all taxes and amounts as shall be permitted or required to be withheld pursuant to any applicable law, rule or regulation. Furthermore, the Company may amend, modify or rescind any benefit plan or program and change contribution amounts to benefit costs without notice in its discretion. Employee shall further be subject to the indemnification by-laws policies and/or procedures applicable to senior officers of the Company and shall be included in the Directors &amp; Officers insurance policies maintained by VolitionRx.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>8. </strong><strong>DEATH AND DISABILITY.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Death.</u> The Employment Term shall terminate on the date of Employee&#8217;s death, in which event the Company shall, within thirty (30) days of the date of death, pay to his estate, any unpaid Base Salary earned up to the date of death plus an additional lump-sum payment equal to two (2) monthly payments under his Base Salary, outstanding reimbursable expenses, accrued and unused vacation time, and any vested benefits expressly payable in accordance with the applicable plan or program owing to Employee through to the date of Employee&#8217;s death. Employee will not be entitled to any other compensation upon termination of his employment pursuant to this Section 8(a).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Disability</u>. To the extent permitted by law, the Employment Term shall terminate upon Employee&#8217;s Disability. For purposes of this Agreement, &#8220;<u>Disability</u>&#8221; shall mean that Employee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 6 months, or 150 non-consecutive days in any twelve (12) month period. The existence of a Disability shall be determined by a qualified physician nominated by the Company in consultation with Employee. In case of such termination, Employee shall be entitled to receive his unpaid Base Salary earned up to the date of the Company&#8217;s determination of Employee&#8217;s Disability, outstanding reimbursable expenses and accrued and unused vacation or PTO time, and any vested benefits expressly payable in accordance with the applicable plan or program owing to Employee through the date of termination, which amounts shall be paid within thirty (30) days of the date of the Company&#8217;s determination of Employee&#8217;s Disability. The Employee will not be entitled to any other compensation upon termination of his employment pursuant to this Section 8(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>9. </strong><strong>TERMINATION OF EMPLOYMENT.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; <u>Termination With Cause By Company</u>. The Company may terminate this Agreement at any time during the Employment Term for &#8220;Cause&#8221; upon written notice to Employee, upon which termination shall be effective immediately. For purposes of this Agreement, &#8220;Cause&#8221; means the following:&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:12%;vertical-align:top;"> <p style="text-align:right;margin:0px">&nbsp;i.</p></td> <td style="width:1%;"> <p style="margin:0px">&nbsp;&nbsp;&nbsp;&nbsp; </p></td> <td> <p style="text-align:justify;margin:0px">Willful and material failure to adhere to the Company&#8217;s and/or its affiliates&#8217; and subsidiaries&#8217; bylaws or written policies, or lawful directives of the Board of Directors of VolitionRx, provided Employee shall be given no less than fifteen (15) business days to cure the same after written notice of any failure, if curable in the reasonable discretion of the Company;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:right;margin:0px">&nbsp;ii.</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Misappropriation (or attempted misappropriation) of any non-trivial Company and/or its affiliates and/or subsidiaries property or funds;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:right;margin:0px">iii.</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Conviction of, or the entry of a guilty plea or plea of no contest with respect to, any felony involving moral turpitude; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:right;margin:0px">&nbsp;iv.</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Gross misconduct.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; <u>Other Termination By Company</u>. The Company may terminate this Agreement at any time during the Employment Term without &#8220;Cause&#8221; either (i) upon six (6) months written notice to Employee; or (ii) if less than six (6) months written notice then subject to the payment of a lump sum equal to the balance of the Employee&#8217;s Base Salary that would otherwise have been received between the date of termination and the completion of the six (6) month notice period (which lump sum shall be payable upon receipt by the Company of a satisfactory release from Employee).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Termination By Employee</u>. Employee may terminate this Agreement at any time by providing the Company six (6) months written notice, with or without any reason.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Compensation upon Termination</u>. Upon termination of the Agreement pursuant to this Section 9, Employee shall be entitled to all accrued and unpaid compensation earned as of the date of termination, including Base Salary, outstanding reimbursable expenses, accrued and unused vacation or PTO time, and any vested benefits expressly payable in accordance with the applicable plan or program. Employee shall also receive any awarded and unpaid bonus for a prior completed year, if not yet paid as of the termination date, within 30 days of the termination date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>10. </strong><strong>DISCLOSURE OF TRADE SECRETS AND OTHER PROPRIETARY INFORMATION; RESTRICTIVE COVENANTS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; Employee acknowledges that he is prohibited from directly or indirectly disclosing any confidential information about the Company, its affiliates and/or subsidiaries or companies with whom the Company, its affiliates and/or subsidiaries do business, including but not limited to trade secrets, formulas, and financial information, to any party who is not a director, officer or authorized agent of the Company or its subsidiaries and affiliates. The Company will provide Employee with valuable confidential information belonging to the Company or its subsidiaries or its affiliates above and beyond any confidential information previously received by Employee and will associate Employee with the goodwill of the Company or its subsidiaries or its affiliates above and beyond any prior association of Employee with that goodwill. In return, Employee promises never to disclose or misuse such confidential information and never to misuse such goodwill.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Employee will not, during the Employment Term and for a period of six (6) months thereafter, on his behalf or on behalf of any other business enterprise, directly or indirectly, under any circumstance other than at the direction and for the benefit of the Company, its affiliates and/or subsidiaries, (i) solicit for employment or hire any person employed by the Company or any of its subsidiaries or affiliates, or (ii) call on, solicit, or take away any person or entity who was a customer of the Company or any of its subsidiaries or affiliates during Employee&#8217;s employment with the Company, in either case for a business that is competitive with the business of the Company, its affiliates and/or subsidiaries. This restriction shall not prevent Employee from soliciting or doing business with any customer with whom he had a pre-existing business relationship and which is identified to the Company in a written list provided by Employee at termination of employment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp; It is expressly agreed by Employee that the nature and scope of each of the provisions set forth above are reasonable and necessary. If, for any reason, any aspect of the above provisions as it applies to Employee is determined by a court of competent jurisdiction to be unreasonable or unenforceable under applicable law, the provisions shall be modified to the extent required to make the provisions enforceable. Employee acknowledges and agrees that his services are of unique character and expressly grants to the Company or any subsidiary or affiliate of the Company or any successor of any of them, the right to enforce the above provisions through the use of all remedies available at law or in equity, including, but not limited to, injunctive relief.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>11. </strong><strong>COMPANY PROPERTY.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp; Any patents, inventions, discoveries, applications, processes, models or financial statements designed, devised, planned, applied, created, discovered or invented by Employee during the Employment Term, regardless of when reduced to writing or practice, which pertain to any aspect of the Company&#8217;s or its subsidiaries&#8217; or affiliates&#8217; business as described above shall be the sole and absolute property of the Company, and Employee shall promptly report the same to the Company and promptly execute any and all documents that may from time to time reasonably be requested by the Company to assure the Company the full and complete ownership thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; All records, files, lists, including computer generated lists, drawings, documents, equipment and similar items relating to the Company&#8217;s, its affiliates&#8217; and/or subsidiaries&#8217; business which Employee shall prepare or receive from the Company shall remain the Company&#8217;s, its affiliates&#8217; and/or subsidiaries&#8217; sole and exclusive property. Upon termination of this Agreement, Employee shall promptly return to the Company all property of the Company, its affiliates and/or subsidiaries in his possession. Employee may retain copies of documents evidencing his terms of employment, compensation, or related to his status as an equity holder of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>12. </strong><strong>EQUITABLE RELIEF.</strong> It is mutually understood and agreed that Employee&#8217;s services are special, unique, unusual, extraordinary and of an intellectual character giving them a peculiar value, the loss of which cannot be reasonably or adequately compensated in damages in an action at law. Accordingly, in the event of any breach of this Agreement by Employee, including, but not limited to, the breach of any of the provisions of Sections 10 or 11 hereof, the Company shall be entitled to equitable relief by way of injunction or otherwise in addition to any damages which the Company may be entitled to recover. In the event of any breach of this Agreement by Company the Employee shall be entitled to equitable relief by way of injunction or otherwise in addition to any damages which the Employee may be entitled to recover.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>13. </strong><strong>APPLICABLE LAW AND DISPUTES.</strong> Unless otherwise stated, this Agreement will be governed by and construed in accordance with the laws of the Republic of Singapore. All disputes concerning this Agreement will first be negotiated between the Parties in good faith. If the Parties are unable to settle any difference, dispute, conflict or controversy (a &#8220;<strong>Dispute</strong>&#8221;), which arises out of or in connection with this Agreement or its performance, including without limitation any dispute regarding its existence, validity, termination of rights or obligations of any party, then such Dispute shall be referred to and finally resolved by arbitration in Singapore in accordance with the Arbitration Rules of the Singapore International Arbitration Centre (<strong>&#8220;SIAC&#8221;</strong>) in force at the time of referral of the Dispute (the &#8220;<strong>Rules</strong>&#8221;). The place of arbitration shall be Singapore and the proceedings shall be conducted in the English language. There shall be a single arbitrator and the appointing authority shall be the Chairman of the SIAC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>14. </strong><strong>NOTICE.</strong> Except as otherwise expressly provided, any notice, request, demand or other communication permitted or required to be given under this Agreement shall be in writing, shall be deemed conclusively to have been given: (a) upon receipt, when delivered personally; (b) upon receipt when sent by facsimile or email delivery of a &#8220;.pdf&#8221; format data file (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party; (c) on the third business day following the day timely deposited with Federal Express (or other equivalent international courier), with the cost of delivery prepaid or for the account of the sender; (d) on the seventh business day following the day duly sent by certified or registered mail, postage prepaid; or (e) when otherwise actually received by the addressee on a business day (or on the next business day if received after the close of normal business hours or on any non-business day).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>15. </strong><strong>INTERPRETATION; HEADINGS.</strong> The parties acknowledge and agree that the terms and provisions of this Agreement have been negotiated, shall be construed fairly as to all parties hereto, and shall not be construed in favor of or against any party. The section headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>16. </strong><strong>SUCCESSORS AND ASSIGNS; ASSIGNMENT; INTENDED BENEFICIARIES.</strong> Neither this Agreement, nor any of Employee&#8217;s rights, powers, duties or obligations hereunder, may be assigned by Employee. This Agreement shall be binding upon and inure to the benefit of Employee and his heirs and legal representatives and the Company and its successors. Successors of the Company shall include, without limitation, any corporation or corporations acquiring, directly or indirectly, all or substantially all of the assets of the Company, whether by merger, consolidation, purchase, lease or otherwise, and such successor shall thereafter be deemed &#8220;the Company&#8221; for the purpose hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>17. </strong><strong>NO WAIVER BY ACTION.</strong> Any waiver or consent from the Company respecting any term or provision of this Agreement or any other aspect of the Employee&#8217;s conduct or employment shall be effective only in the specific instance and for the specific purpose for which given and shall not be deemed, regardless of frequency given, to be a further or continuing waiver or consent. The failure or delay of the Company at any time or times to require performance of, or to exercise any of its powers, rights or remedies with respect to, any term or provision of this Agreement or any other aspect of the Employee&#8217;s conduct or employment in no manner (except as otherwise expressly provided herein) shall affect the Company&#8217;s right at a later time to enforce any such term or provision.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>18. </strong><strong>COUNTERPARTS; ELECTRONIC SIGNATURE; JURISDICTION; AMENDMENTS; ENTIRE AGREEMENT; SEVERABILITY; SURVIVAL OF TERMS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed in two (2) counterpart copies, each of which may be executed by one of the Parties hereto, but all of which, when taken together, shall constitute a single agreement binding upon all of the Parties hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp; For convenience, this Agreement may be signed electronically and/or electronically transmitted in Portable Document Format (PDF), in one or more copies, each of which shall be deemed to be an original and all of which shall constitute one and the same instrument. The Parties acknowledge that the exchange of the Agreement signed electronically or signed manually by one or both Parties but transmitted in PDF format shall have the same legal value and probative force as the exchange of original signatures.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp; Each and every modification and amendment of this Agreement shall be in writing and signed by the parties hereto, and any waiver of, or consent to any departure from, any term or provision of this Agreement shall be in writing and signed by each affected party hereto.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement contains the entire agreement of the parties and supersedes all prior representations, agreements and understandings, oral or otherwise, between the parties with respect to the matters contained herein, including but not limited to any written offer letter or letter agreement concerning employment. In the event of any conflict, the terms of this Agreement shall control.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp; The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sections 10 through 19 shall survive any termination of this Agreement and the termination of Employee&#8217;s employment.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>19. TAX AND DEDUCTION.</strong> All payments to Employee pursuant to this Agreement are subject to applicable tax, withholding and deduction requirements based on the country of Employee&#8217;s service.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[Signature page follows.]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6 / 7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>IN WITNESS WHEREOF</strong>, the Parties hereto have executed this Agreement as of the date set forth above.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(&#8220;<strong>COMPANY</strong>&#8221;) </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Singapore Volition Pte. Limited </strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(&#8220;<strong>EMPLOYEE</strong>&#8221;) </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cameron Reynolds</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Jasmine Kway</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"><em>/s/ Cameron Reynolds</em></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By: Jasmine Kway </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By: Cameron Reynolds</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Its: Chief Executive Officer </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Singapore Volition Pte. Limited Employment Agreement &#8211; Group Chief Executive Officer</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7 / 7</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>vnrx_ex211.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<html><head><title>vnrx_ex211.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 21.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SUBSIDIARIES OF VOLITIONRX LIMITED</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Name of Subsidiary</strong></p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:20%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>State or other Jurisdiction of </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Incorporation or Organization</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Singapore Volition Pte. Limited</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of VolitionRx Limited)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Singapore</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Belgian Volition SRL</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of Singapore Volition Pte. Limited)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Belgium</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition Diagnostics UK Limited</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of Belgian Volition SRL)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">United Kingdom</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition America, Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of Belgian Volition SRL)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Delaware</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition Veterinary Diagnostics Development LLC.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(<em>87.5% subsidiary of Belgian Volition SRL)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Texas</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition Germany GmbH</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of Belgian Volition SRL)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Germany</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volition Global Services SRL</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>(100% subsidiary of VolitionRx Limited)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Belgium</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>vnrx_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>vnrx_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">To the Audit Committee</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">VolitionRx Limited</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As independent registered public accountants, we hereby consent to the incorporation by reference of our report dated March 15, 2023, contained in this annual report on Form&nbsp;10-K with respect to the consolidated financial statements of VolitionRx Limited, in its registration statements on Form&nbsp;S-3 (Registration Statement Nos. 333-195213, 333-227248, 333-227731, 333-236335 and 333-259783) and its registration statements on Form&nbsp;S-8 (Registration Statement Nos. 333-208512, 333-214118, 333-221054, 333-227565, 333-236336, 333-258133 and 333-267692).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>/s/ Sadler, Gibb &amp; Associates, LLC</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sadler, Gibb &amp; Associates, LLC</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">March 15, 2023</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>vnrx_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>vnrx_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</strong> </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">I, Cameron Reynolds, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of VolitionRx Limited;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">Date:&nbsp; March 15, 2023</td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ Cameron Reynolds</em></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cameron Reynolds</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">President and Chief Executive Officer </p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>vnrx_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>vnrx_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exhibit&nbsp;31.2</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF CHIEF FINANCIAL OFFICER </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</strong> </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">I, Terig Hughes, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of VolitionRx Limited;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">Date:&nbsp; March 15, 2023</td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ Terig Hughes</em></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Terig Hughes</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Chief Financial Officer and Treasurer </p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>vnrx_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>vnrx_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT&nbsp;32.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO 18 U.S.C. SECTION&nbsp;1350, </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The following certifications are hereby made in connection with the Annual Report on Form 10-K of VolitionRx Limited (the &#8220;Company&#8221;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;):</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">I, Cameron Reynolds, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">Date:&nbsp; March 15, 2023</td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ Cameron Reynolds</em></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cameron Reynolds</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">President and Chief Executive Officer </p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">I, Terig Hughes, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">Date:&nbsp; March 15, 2023</td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"><em>/s/ Terig Hughes</em></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Terig Hughes</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Chief Financial Officer and Treasurer</p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vnrx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/15/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:vnrx="http://vnrx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vnrx.com/20221231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://vnrx.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" id="ConsolidatedStatementOfStockholdersEquityDeficit">
        <link:definition>000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>000007 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" id="LiquidityAndGoingConcernAssessment">
        <link:definition>000008 - Disclosure - Liquidity and Going Concern Assessment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>000010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>000011 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000012 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommonStock" id="CommonStock">
        <link:definition>000013 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>000014 - Disclosure - StockBased Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>000019 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommonStockTables" id="CommonStockTables">
        <link:definition>000020 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>000021 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <link:definition>000022 - Disclosure - StockBased Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000023 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000024 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" id="LiquidityAndGoingConcernAssessmentDetailsNarrative">
        <link:definition>000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000027 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000028 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <link:definition>000029 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
        <link:definition>000030 - Disclosure - Intangible Assets (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
        <link:definition>000031 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000032 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000033 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>000034 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000035 - Disclosure - Income Taxes (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommonStockDetails" id="CommonStockDetails">
        <link:definition>000036 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommonStockDetails1" id="CommonStockDetails1">
        <link:definition>000037 - Disclosure - Common Stock (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommonStockDetailsNarrative" id="CommonStockDetailsNarrative">
        <link:definition>000038 - Disclosure - Common Stock (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails" id="StockbasedCompensationDetails">
        <link:definition>000039 - Disclosure - StockBased Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails1" id="StockbasedCompensationDetails1">
        <link:definition>000040 - Disclosure - StockBased Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails2" id="StockbasedCompensationDetails2">
        <link:definition>000041 - Disclosure - StockBased Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails3" id="StockbasedCompensationDetails3">
        <link:definition>000042 - Disclosure - StockBased Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails4" id="StockbasedCompensationDetails4">
        <link:definition>000043 - Disclosure - StockBased Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails5" id="StockbasedCompensationDetails5">
        <link:definition>000044 - Disclosure - StockBased Compensation (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails6" id="StockbasedCompensationDetails6">
        <link:definition>000045 - Disclosure - StockBased Compensation (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails7" id="StockbasedCompensationDetails7">
        <link:definition>000046 - Disclosure - StockBased Compensation (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails8" id="StockbasedCompensationDetails8">
        <link:definition>000047 - Disclosure - StockBased Compensation (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetails9" id="StockbasedCompensationDetails9">
        <link:definition>000048 - Disclosure - StockBased Compensation (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" id="StockbasedCompensationDetailsNarrative">
        <link:definition>000049 - Disclosure - StockBased Compensation (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000050 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000051 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
        <link:definition>000052 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
        <link:definition>000053 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
        <link:definition>000054 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
        <link:definition>000055 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" id="CommitmentsAndContingenciesDetails6">
        <link:definition>000056 - Disclosure - Commitments and Contingencies (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" id="CommitmentsAndContingenciesDetails7">
        <link:definition>000057 - Disclosure - Commitments and Contingencies (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" id="CommitmentsAndContingenciesDetails8">
        <link:definition>000058 - Disclosure - Commitments and Contingencies (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000059 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://vnrx.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000060 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <element id="vnrx_CurrentPortionOfGrantRepayable" name="CurrentPortionOfGrantRepayable" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantRepayableNetOfCurrentPortion" name="GrantRepayableNetOfCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockAbstract" name="CommonStockAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_TotalVolitionrxLimitedStockholdersEquity" name="TotalVolitionrxLimitedStockholdersEquity" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_MinorityInterests" name="MinorityInterests" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RoyaltyRevenue" name="RoyaltyRevenue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ServiceRevenue" name="ServiceRevenue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ProductRevenue" name="ProductRevenue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncomeFromGrants" name="IncomeFromGrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LossOnDisposalOfFixedAssets" name="LossOnDisposalOfFixedAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" name="IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OthersComprehensiveIncomeLossNetOfTax" name="OthersComprehensiveIncomeLossNetOfTax" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" name="NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" name="WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockIssuedForSettlementOfRsuSShares" name="CommonStockIssuedForSettlementOfRsuSShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockIssuedForSettlementOfRsuSAmount" name="CommonStockIssuedForSettlementOfRsuSAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockIssuedInPublicOfferingsNetShares" name="CommonStockIssuedInPublicOfferingsNetShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" name="TaxWithholdingsPaidRelatedToStockBasedCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_StockBasedCompensationInRelationToModificationOfOptions" name="StockBasedCompensationInRelationToModificationOfOptions" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLossOnDisposalOfFixedAssets" name="OperatingLossOnDisposalOfFixedAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ManagementAndDirectorsFeesPayable" name="ManagementAndDirectorsFeesPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ProceedsFromGrantsRepayable" name="ProceedsFromGrantsRepayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PaymentsOnGrantsRepayable" name="PaymentsOnGrantsRepayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PaymentsOnFinancingLeasesLeaseAmount" name="PaymentsOnFinancingLeasesLeaseAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OfferingCostsFromIssuanceOfCommonStock" name="OfferingCostsFromIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NonCashNotePayable" name="NonCashNotePayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LiquidityAndGoingConcernAssessment" name="LiquidityAndGoingConcernAssessment" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" name="DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock" name="ImpairmentofLongLivedAssetsPolixyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_COVID19PandemicImpactPolicyTextblock" name="COVID19PandemicImpactPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus" name="ScheduleOfShareIssuedFromTheSettlementOfRsus" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SummarizingTheWarrantsIssuedAndOutstanding" name="SummarizingTheWarrantsIssuedAndOutstanding" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife" name="SummarizingTheRsusIssuedAndOutstandingMaturityLife" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock" name="summarizingtheRSUsissuedandoutstandingtabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions" name="SummaryOfAmendmentsToExpirationDatesOfOptions" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfRsusGrantedDuringPeriod" name="ScheduleOfRsusGrantedDuringPeriod" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfRsusVestedDuringPeriod" name="ScheduleOfRsusVestedDuringPeriod" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfRsusCancelledDuringPeriod" name="ScheduleOfRsusCancelledDuringPeriod" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" name="ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" name="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfRecognizedInShortTermLeaseCosts" name="ScheduleOfRecognizedInShortTermLeaseCosts" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" name="ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NetIncomeLossSinceInception" name="NetIncomeLossSinceInception" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_TermsOfLicenseAgreement" name="TermsOfLicenseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_InitialTermForPoc" name="InitialTermForPoc" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_InitialTermForCentralLab" name="InitialTermForCentralLab" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_MilestoneAmountRecognized" name="MilestoneAmountRecognized" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ResearchAndDevelopmentExpenses" name="ResearchAndDevelopmentExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PotentiallyDilutiveWarrantsAndOptions" name="PotentiallyDilutiveWarrantsAndOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" name="ExcessOfTaxOverBookDepreciationAndAmortization" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnrealizedGainLoss" name="UnrealizedGainLoss" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CapitalizedResearchExpenses" name="CapitalizedResearchExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ChangeInValuationAllowance" name="ChangeInValuationAllowance" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncreaseInValuationAllowance" name="IncreaseInValuationAllowance" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NetOperatingLosses" name="NetOperatingLosses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockShareIssuedUponCashlessExercise" name="CommonStockShareIssuedUponCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_StockIncentivePlan" name="StockIncentivePlan" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RestrictedStockUnitsVested" name="RestrictedStockUnitsVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RestrictedStockUnitVested" name="RestrictedStockUnitVested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharesWithheldForTax" name="SharesWithheldForTax" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SaleOfStockPriceSettledPerShare" name="SaleOfStockPriceSettledPerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IssuedOfCommonStockFromSettlementOfRSU" name="IssuedOfCommonStockFromSettlementOfRSU" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockPricePerSahres" name="CommonStockPricePerSahres" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockShareAuthorized" name="CommonStockShareAuthorized" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AggeregateShareOfCommonStockOfferingPrice" name="AggeregateShareOfCommonStockOfferingPrice" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_BrokerageFees" name="BrokerageFees" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PurchasePricePerShare" name="PurchasePricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsOutstandingBeginningBalance" name="NumberOfWarrantsOutstandingBeginningBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsAbstract" name="NumberOfWarrantsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedExercisePriceAbstract" name="WeightedExercisePriceAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsExpired" name="NumberOfWarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsOutstandingEndingBalance" name="NumberOfWarrantsOutstandingEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfWarrantsExercisable" name="NumberOfWarrantsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" name="WeightedAverageExercisePriceOutstandingBalanceOne" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedExercisePriceExercised" name="WeightedExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedExercisePriceExpired" name="WeightedExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceEndingBalanceOne" name="WeightedAverageExercisePriceEndingBalanceOne" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceExercisable" name="WeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfOptionsOutstandingBeginningBalance" name="NumberOfOptionsOutstandingBeginningBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfExpiredCancelled" name="NumberOfExpiredCancelled" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfOptionOutstandingEndingBalance" name="NumberOfOptionOutstandingEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfOptionsExercisable" name="NumberOfOptionsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceOutstandingBalance" name="WeightedAverageExercisePriceOutstandingBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceGranted" name="WeightedAverageExercisePriceGranted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceExercised" name="WeightedAverageExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" name="WeightedAverageExercisePriceExercisedExpiresCancelled" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceEndingBalance" name="WeightedAverageExercisePriceEndingBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageExercisePriceExercisableBalance" name="WeightedAverageExercisePriceExercisableBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ApprovedStockOptions" name="ApprovedStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_EquityIncentivePlan" name="EquityIncentivePlan" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_StockOptionGrantDate" name="StockOptionGrantDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_stockoptionamendmentdate" name="stockoptionamendmentdate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfRsusOutstandingBeginingBalance" name="NumberOfRsusOutstandingBeginingBalance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantedShares" name="GrantedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfStockVested" name="NumberOfStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfStockCancelled" name="NumberOfStockCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfRsusOutstandingEndingBalance" name="NumberOfRsusOutstandingEndingBalance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharePriceBeginningBalance" name="SharePriceBeginningBalance" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharePriceGranted" name="SharePriceGranted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharePriceVested" name="SharePriceVested" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_Cancelled" name="Cancelled" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharePriceEndingBalance" name="SharePriceEndingBalance" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CompensationExpenseRsus" name="CompensationExpenseRsus" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CompensationExpenseGrantDate" name="CompensationExpenseGrantDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CompensationExpenseVestingPeriod" name="CompensationExpenseVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FirstVestingDate" name="FirstVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SecondVestingDate" name="SecondVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ThirdVestingDate" name="ThirdVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RsuExpense" name="RsuExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncentivePlan" name="IncentivePlan" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_EquityIncentiveRsu" name="EquityIncentiveRsu" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncentiveVestDate" name="IncentiveVestDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncentiveRsuIssued" name="IncentiveRsuIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RsusHeldForTaxes" name="RsusHeldForTaxes" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RsuCancelled" name="RsuCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_IncentiveRsu" name="IncentiveRsu" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CancellationDate" name="CancellationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_VestDate" name="VestDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfStockOutstandingBalance" name="NumberOfStockOutstandingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SharesPriceRsu" name="SharesPriceRsu" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_WeightedAverageRemainingContractualLifeYears" name="WeightedAverageRemainingContractualLifeYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockAvailable" name="CommonStockAvailable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ShareAggregateMaximum" name="ShareAggregateMaximum" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OptionGranted" name="OptionGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_NumberOfSharesVesting" name="NumberOfSharesVesting" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FairValueOfOptions" name="FairValueOfOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" name="CommonStockSharesIssuableUponExerciseOfStockOption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_VolatilityRate" name="VolatilityRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_Volatility" name="Volatility" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_VestingAggregate" name="VestingAggregate" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AggregrateAggregate" name="AggregrateAggregate" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantedAggregate" name="GrantedAggregate" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantedRsu" name="GrantedRsu" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_DescriptionOfVestingShall" name="DescriptionOfVestingShall" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_StockCompensationExpenses" name="StockCompensationExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_MaturityTerm" name="MaturityTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_StockOptionsPurchaseSharesOfCommonStock" name="StockOptionsPurchaseSharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CompensationCostRelatedToNonVestedWarrants" name="CompensationCostRelatedToNonVestedWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LessAmountRepresentingInterest" name="LessAmountRepresentingInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" name="OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" name="FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" name="OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" name="OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" name="OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeaseObligations" name="OperatingLeaseObligations" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDue" name="OperatingLeasesFutureMinimumPaymentDue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" name="OperatingLeasesFutureMinimumPaymentDueCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears" name="OperatingLeasesFutureMinimumPaymentDueInTwoYears" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesFutureMinimumLeasePaymentDue" name="OperatingLeasesFutureMinimumLeasePaymentDue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" name="FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantsRepayable" name="GrantsRepayable" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LongTermDebtLessAmountRepresentingInterest" name="LongTermDebtLessAmountRepresentingInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" name="FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" name="FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CollaborativeAgreementObligations" name="CollaborativeAgreementObligations" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AmortisedOfOutstandingAward2022" name="AmortisedOfOutstandingAward2022" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AmortisedOfOutstandingAward2021" name="AmortisedOfOutstandingAward2021" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnAmortisedOfOutstandingAward2023" name="UnAmortisedOfOutstandingAward2023" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OutstandingAwardVestingPeriod" name="OutstandingAwardVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AmortisedOfOutstandingAwardAmount" name="AmortisedOfOutstandingAwardAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnAmortisedOfOutstandingAward" name="UnAmortisedOfOutstandingAward" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OutstandingAward" name="OutstandingAward" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantRepyable" name="GrantRepyable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LongTermDebtPayable" name="LongTermDebtPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PaymentsForFutureResearchAndCollobration" name="PaymentsForFutureResearchAndCollobration" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RoyalityOnRevenuePercentange" name="RoyalityOnRevenuePercentange" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AggerateAmountPayableDescription" name="AggerateAmountPayableDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AmountPayable" name="AmountPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_PayableByCompanyForServicesRendered" name="PayableByCompanyForServicesRendered" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RestrictedStockUnit" name="RestrictedStockUnit" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AccruedCompensationExpense" name="AccruedCompensationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnrecognizedCompensationExpense" name="UnrecognizedCompensationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_MaturityDate" name="MaturityDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ImplicitInterest" name="ImplicitInterest" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LeasedEquipmentAmortizedPeriod" name="LeasedEquipmentAmortizedPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_Royality" name="Royality" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_UnrecognizedCompensationExpenses" name="UnrecognizedCompensationExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RSuVested" name="RSuVested" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RSuVestedIn2024" name="RSuVestedIn2024" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RSuVestedIn2025" name="RSuVestedIn2025" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeaseRightOfUseAssets" name="OperatingLeaseRightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_OperatingLeasesLiability1" name="OperatingLeasesLiability1" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FixedInterestRateOnLease" name="FixedInterestRateOnLease" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RepaymentOfGrants" name="RepaymentOfGrants" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_TermsOfAgreementDescription" name="TermsOfAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AmountRepayable" name="AmountRepayable" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_GrantRepaidByInstallments" name="GrantRepaidByInstallments" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LoanAgreementTerm" name="LoanAgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RepaymentsOfLongtermLoans" name="RepaymentsOfLongtermLoans" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_FixedInterestRate" name="FixedInterestRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LineOfCreditFacilityExpirationDatesOne" name="LineOfCreditFacilityExpirationDatesOne" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AgreementUnderAmount" name="AgreementUnderAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_AdditionalCostOfCompany" name="AdditionalCostOfCompany" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CollaborativeObligationsAmountDue" name="CollaborativeObligationsAmountDue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LeaseAgreementExpirePeriods" name="LeaseAgreementExpirePeriods" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CollaborativeObligationsAmount" name="CollaborativeObligationsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_LeaseAgreementExpirePeriod" name="LeaseAgreementExpirePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_RsuVestingDescription" name="RsuVestingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockSharesWithheldForTaxes" name="CommonStockSharesWithheldForTaxes" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_SaleOfCommonStock" name="SaleOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockSharePurchase" name="CommonStockSharePurchase" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CommonStockPerShare" name="CommonStockPerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="vnrx_CostOfTheCompany" name="CostOfTheCompany" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element name="FebruaryEightTwentyThousandTwentyOneMember" id="vnrx_FebruaryEightTwentyThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionExercisesTwoMember" id="vnrx_StockOptionExercisesTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" id="vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionExercisesMember" id="vnrx_StockOptionExercisesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LaboratoryEquipmentMember" id="vnrx_LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WalloonRegionGovernmentMember" id="vnrx_WalloonRegionGovernmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InTwoThousandsTwentyTwentyMember" id="vnrx_InTwoThousandsTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NamurInvestMember" id="vnrx_NamurInvestMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="In2016Member" id="vnrx_In2016Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LoanAgreementMember" id="vnrx_LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="INGMember" id="vnrx_INGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InTwoThousandNineteenMember" id="vnrx_InTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="In2018Member" id="vnrx_In2018Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NamurInnovationAndGrowthMember" id="vnrx_NamurInnovationAndGrowthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SOFINEXMember" id="vnrx_SOFINEXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="In2017Member" id="vnrx_In2017Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" id="vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FiveFebruaryTwoThounsendTwentyTwentyTwoMember" id="vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FirstInsuranceFundingMember" id="vnrx_FirstInsuranceFundingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OnSeptemberSixteenTwohousandtwentyMember" id="vnrx_OnSeptemberSixteenTwohousandtwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BioinformaticAnalyticsOfCellFreeDNAMember" id="vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnivercityOfTexasMDMember" id="vnrx_UnivercityOfTexasMDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AugustTenTwoThousandTwentyTwoMember" id="vnrx_AugustTenTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InTwoThousandNinteenMember" id="vnrx_InTwoThousandNinteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CollaborativeArrangementCoPromotionMember" id="vnrx_CollaborativeArrangementCoPromotionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UniversityOfTaiwanMember" id="vnrx_UniversityOfTaiwanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InTwoThousandsEightteenMember" id="vnrx_InTwoThousandsEightteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ClinicalStudyResearchAgreementMember" id="vnrx_ClinicalStudyResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="InTwoThousandTwentyMember" id="vnrx_InTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OutstandingAwardThreeMember" id="vnrx_OutstandingAwardThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BNPParibasLeasingSolutionsMember" id="vnrx_BNPParibasLeasingSolutionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FinanceLeaseObligationsMember" id="vnrx_FinanceLeaseObligationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ManagingDirectorsAgreementMember" id="vnrx_ManagingDirectorsAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockIncentivePlanMember" id="vnrx_StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="In2010Member" id="vnrx_In2010Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NamurMember" id="vnrx_NamurMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SixteenAugustTwoThounsendTwentyTwoMember" id="vnrx_SixteenAugustTwoThounsendTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EighteenNovemberTwoThounsendTwentyTwoMember" id="vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CapitalRaiseMember" id="vnrx_CapitalRaiseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RsuVestingEventMember" id="vnrx_RsuVestingEventMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CommonStockIssuancesAndRepurchasesMember" id="vnrx_CommonStockIssuancesAndRepurchasesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AprilFourTwoThousandTwentyTwoMember" id="vnrx_AprilFourTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsMember" id="vnrx_WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnitedStateMember" id="vnrx_UnitedStateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerformanceBasedAwardMember" id="vnrx_PerformanceBasedAwardMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="VestIn2023Member" id="vnrx_VestIn2023Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="VestIn2024Member" id="vnrx_VestIn2024Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PatentsAndIntellectualPropertyMember" id="vnrx_PatentsAndIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BelgianDepositGuaranteeMember" id="vnrx_BelgianDepositGuaranteeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SingaporeDepositInsuranceMember" id="vnrx_SingaporeDepositInsuranceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UKDepositProtectionSchemeMember" id="vnrx_UKDepositProtectionSchemeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DilutiveWarrantsAndOptionsMember" id="vnrx_DilutiveWarrantsAndOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NetDeferredTaxAssetsMember" id="vnrx_NetDeferredTaxAssetsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ForeignMember" id="vnrx_ForeignMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" id="vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FebruaryTwoTwentyThousandTwentyOneMember" id="vnrx_FebruaryTwoTwentyThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionExercisesOneMember" id="vnrx_StockOptionExercisesOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MarchTwentyFiveTwoThousandTwentyTwoMember" id="vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AprilThirteenTwoThousandTwentyTwoMember" id="vnrx_AprilThirteenTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MayOneTwoThousandTwentyTwoMember" id="vnrx_MayOneTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AugustThreeTwoThousandTwentyTwoMember" id="vnrx_AugustThreeTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeptemberSevenTwoThousandTwentyTwoMember" id="vnrx_SeptemberSevenTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberFourTwoThousandTwentyTwoMember" id="vnrx_OctoberFourTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NovemberOneTwoThousandTwentyTwoMember" id="vnrx_NovemberOneTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberFifteenTwoThousandTwentyTwoMember" id="vnrx_DecemberFifteenTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwentyTwentyThusandTwentyOneMember" id="vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RSUSettlementsMember" id="vnrx_RSUSettlementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AprilTwentyOneTwentyTwentyOneMember" id="vnrx_AprilTwentyOneTwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnderwritingAgreementMember" id="vnrx_UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityDistributionAgreementMember" id="vnrx_EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantOneMember" id="vnrx_WarrantOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantTwoMember" id="vnrx_WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantThreeMember" id="vnrx_WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsFourMember" id="vnrx_WarrantsFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsFiveMember" id="vnrx_WarrantsFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionFourMember" id="vnrx_OptionFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentOneMember" id="vnrx_StockOptionsAmendmentOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentTwoMember" id="vnrx_StockOptionsAmendmentTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentThreeMember" id="vnrx_StockOptionsAmendmentThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentFourMember" id="vnrx_StockOptionsAmendmentFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentFiveMember" id="vnrx_StockOptionsAmendmentFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentSixMember" id="vnrx_StockOptionsAmendmentSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentSevenMember" id="vnrx_StockOptionsAmendmentSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentEightMember" id="vnrx_StockOptionsAmendmentEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentNineMember" id="vnrx_StockOptionsAmendmentNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentTenMember" id="vnrx_StockOptionsAmendmentTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentElevenMember" id="vnrx_StockOptionsAmendmentElevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentTwelveMember" id="vnrx_StockOptionsAmendmentTwelveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentThirteenMember" id="vnrx_StockOptionsAmendmentThirteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsAmendmentFourteenMember" id="vnrx_StockOptionsAmendmentFourteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsOneMember" id="vnrx_OptionsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionTwoMember" id="vnrx_OptionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionThreeMember" id="vnrx_StockOptionThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionFiveMember" id="vnrx_OptionFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionSixMember" id="vnrx_StockOptionSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionSevenMember" id="vnrx_StockOptionSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionEightMember" id="vnrx_StockOptionEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionNineMember" id="vnrx_StockOptionNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TotalStockOptionOneMember" id="vnrx_TotalStockOptionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsMember" id="vnrx_StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionTenMember" id="vnrx_StockOptionTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionElevenMember" id="vnrx_StockOptionElevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionTwelveMember" id="vnrx_StockOptionTwelveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionFourteenTenMember" id="vnrx_StockOptionFourteenTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionFiveteenTenMember" id="vnrx_StockOptionFiveteenTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionThirteenTenMember" id="vnrx_StockOptionThirteenTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseNineMember" id="vnrx_CompensationExpenseNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseTenMember" id="vnrx_CompensationExpenseTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanOneMember" id="vnrx_EquityIncentivePlanOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanTwoMember" id="vnrx_EquityIncentivePlanTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanThreeMember" id="vnrx_EquityIncentivePlanThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanFourMember" id="vnrx_EquityIncentivePlanFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanFiveMember" id="vnrx_EquityIncentivePlanFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanSixMember" id="vnrx_EquityIncentivePlanSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanSevenMember" id="vnrx_EquityIncentivePlanSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanEightMember" id="vnrx_EquityIncentivePlanEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseOneMember" id="vnrx_CompensationExpenseOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseTwoMember" id="vnrx_CompensationExpenseTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseThreeMember" id="vnrx_CompensationExpenseThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseFourMember" id="vnrx_CompensationExpenseFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseFiveMember" id="vnrx_CompensationExpenseFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseSixMember" id="vnrx_CompensationExpenseSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseSevenMember" id="vnrx_CompensationExpenseSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CompensationExpenseEightMember" id="vnrx_CompensationExpenseEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoThousandFifteenEquityIncentivePlanMember" id="vnrx_TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FebruaryOneTwoThousandTwentyOneMember" id="vnrx_FebruaryOneTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryOneTwoThousandTwentyOneMember" id="vnrx_JanuaryOneTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AprilThirteenTwoThousandTwentyMember" id="vnrx_AprilThirteenTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStockUnitsMember" id="vnrx_RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OnTwoZeroMayTwoThousandTwentyOneMember" id="vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStockUnitsOneMember" id="vnrx_RestrictedStockUnitsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OperatingLeaseRightofUseObligationsMember" id="vnrx_OperatingLeaseRightofUseObligationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="GrantsRepayableMember" id="vnrx_GrantsRepayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AwardOneMember" id="vnrx_AwardOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OutstandingAwardTwoMember" id="vnrx_OutstandingAwardTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vnrx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03-15-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_bf53b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_bf53b9" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_d5b87d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_d5b87d" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_3d9e98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_3d9e98" xml:lang="en-US">Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_d63bfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_d63bfe" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_c9f254" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_c9f254" xml:lang="en-US">Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_876740" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_876740" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl_4e35e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl_4e35e8" xml:lang="en-US">Other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_de7232" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_de7232" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_8" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_b4f267" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_b4f267" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_38c529" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_38c529" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9df98b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9df98b" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_e699f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_e699f1" xml:lang="en-US">Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_12" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_9ab304" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_9ab304" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_11e20c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_11e20c" xml:lang="en-US">Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_2133ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_2133ae" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_e83952" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_e83952" xml:lang="en-US">Accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl_40222e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl_40222e" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl_4dc85c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl_4dc85c" xml:lang="en-US">Management and directors' fees payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl_47ffa0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl_47ffa0" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_12d75e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_12d75e" xml:lang="en-US">Current portion of financing lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_5df48d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_5df48d" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CurrentPortionOfGrantRepayable" xlink:label="vnrx_CurrentPortionOfGrantRepayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CurrentPortionOfGrantRepayable" xlink:to="vnrx_CurrentPortionOfGrantRepayable_lbl_95f2fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CurrentPortionOfGrantRepayable_lbl_95f2fd" xml:lang="en-US">Current portion of grant repayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_8cc6f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_8cc6f4" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_23" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl_fcddf2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl_fcddf2" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_a16ef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_a16ef7" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_223859" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_223859" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepayableNetOfCurrentPortion" xlink:label="vnrx_GrantRepayableNetOfCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantRepayableNetOfCurrentPortion" xlink:to="vnrx_GrantRepayableNetOfCurrentPortion_lbl_6b3af6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantRepayableNetOfCurrentPortion_lbl_6b3af6" xml:lang="en-US">Grant repayable, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_a71131" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_a71131" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_28" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_3c3591" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_3c3591" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockAbstract" xlink:to="vnrx_CommonStockAbstract_lbl_0160e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_CommonStockAbstract_lbl_0160e8" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockAbstract" xlink:label="vnrx_CommonStockAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockAbstract" xlink:to="vnrx_CommonStockAbstract_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockAbstract_lbl_30" xml:lang="en-US">[Common Stock]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_d03757" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_d03757" xml:lang="en-US">Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 57,873,379 shares and 53,772,261 shares, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_cc23c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_cc23c5" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_c71cf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_c71cf4" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_45dd9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_45dd9d" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TotalVolitionrxLimitedStockholdersEquity" xlink:to="vnrx_TotalVolitionrxLimitedStockholdersEquity_lbl_34fc84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="vnrx_TotalVolitionrxLimitedStockholdersEquity_lbl_34fc84" xml:lang="en-US">Total VolitionRx Limited Stockholders' Equity (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalVolitionrxLimitedStockholdersEquity" xlink:label="vnrx_TotalVolitionrxLimitedStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TotalVolitionrxLimitedStockholdersEquity" xlink:to="vnrx_TotalVolitionrxLimitedStockholdersEquity_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TotalVolitionrxLimitedStockholdersEquity_lbl_35" xml:lang="en-US">[Total VolitionRx Limited Stockholders' Equity (Deficit)]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MinorityInterests" xlink:label="vnrx_MinorityInterests" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MinorityInterests" xlink:to="vnrx_MinorityInterests_lbl_bbb05a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MinorityInterests_lbl_bbb05a" xml:lang="en-US">Non-controlling interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_d5f302" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_d5f302" xml:lang="en-US">Total Stockholders' Equity (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_37" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_06b6b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_06b6b7" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_38" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_3691bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_3691bf" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_61a32a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_61a32a" xml:lang="en-US">Common Stock, Shares Par Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_15e07f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_15e07f" xml:lang="en-US">Common Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_89189a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_89189a" xml:lang="en-US">Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_3a7997" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_3a7997" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl_3c1dd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl_3c1dd1" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyaltyRevenue" xlink:label="vnrx_RoyaltyRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RoyaltyRevenue" xlink:to="vnrx_RoyaltyRevenue_lbl_26ff69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RoyaltyRevenue_lbl_26ff69" xml:lang="en-US">Royalty</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ServiceRevenue" xlink:label="vnrx_ServiceRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ServiceRevenue" xlink:to="vnrx_ServiceRevenue_lbl_5ba560" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ServiceRevenue_lbl_5ba560" xml:lang="en-US">Service</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProductRevenue" xlink:label="vnrx_ProductRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ProductRevenue" xlink:to="vnrx_ProductRevenue_lbl_cb1620" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ProductRevenue_lbl_cb1620" xml:lang="en-US">Product</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_b2758b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl_b2758b" xml:lang="en-US">Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_6" xml:lang="en-US">[Revenues]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_d730be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_d730be" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_724b6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_724b6f" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_f7af91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_f7af91" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl_57dbc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl_57dbc9" xml:lang="en-US">Sales and marketing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_45af59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_45af59" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_11" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_626ca8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_626ca8" xml:lang="en-US">Operating Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_12" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl_b0aa0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl_b0aa0a" xml:lang="en-US">Other Income (Expenses)</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeFromGrants" xlink:label="vnrx_IncomeFromGrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncomeFromGrants" xlink:to="vnrx_IncomeFromGrants_lbl_5ba43a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncomeFromGrants_lbl_5ba43a" xml:lang="en-US">Grant income</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LossOnDisposalOfFixedAssets" xlink:label="vnrx_LossOnDisposalOfFixedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LossOnDisposalOfFixedAssets" xlink:to="vnrx_LossOnDisposalOfFixedAssets_lbl_7fd8f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LossOnDisposalOfFixedAssets_lbl_7fd8f3" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl_c55283" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl_c55283" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl_253503" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl_253503" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl_17" xml:lang="en-US">[Interest Expense, Other]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_3fe153" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherIncome_lbl_3fe153" xml:lang="en-US">Total Other Income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl_18" xml:lang="en-US">[Other Income]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_caad33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_caad33" xml:lang="en-US">Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_19" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_lbl_4f6c92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_lbl_4f6c92" xml:lang="en-US">Net Loss attributable to Non-Controlling Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:to="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_lbl_183f78" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_lbl_183f78" xml:lang="en-US">Net Loss attributable to VolitionRx Limited Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:label="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:to="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_lbl_21" xml:lang="en-US">[Net Loss attributable to VolitionRx Limited Stockholders]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl_11d034" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl_11d034" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_a944ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl_a944ef" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OthersComprehensiveIncomeLossNetOfTax" xlink:to="vnrx_OthersComprehensiveIncomeLossNetOfTax_lbl_0b188a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="vnrx_OthersComprehensiveIncomeLossNetOfTax_lbl_0b188a" xml:lang="en-US">Net Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OthersComprehensiveIncomeLossNetOfTax" xlink:label="vnrx_OthersComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OthersComprehensiveIncomeLossNetOfTax" xlink:to="vnrx_OthersComprehensiveIncomeLossNetOfTax_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OthersComprehensiveIncomeLossNetOfTax_lbl_24" xml:lang="en-US">[Net Comprehensive Loss]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" xlink:label="vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" xlink:to="vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited_lbl_f0b113" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited_lbl_f0b113" xml:lang="en-US">Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_5fed7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_5fed7c" xml:lang="en-US">Weighted Average Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" xlink:label="vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" xlink:to="vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted_lbl_24e984" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted_lbl_24e984" xml:lang="en-US">- Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_76bee2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_76bee2" xml:lang="en-US">Consolidated Statement of Stockholders Equity (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_64287d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_64287d" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_5feb48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_5feb48" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_da87d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_da87d6" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_7d9357" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_7d9357" xml:lang="en-US">Common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_928458" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_928458" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_83236b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl_83236b" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_3a28d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_3a28d7" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl_c58968" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl_c58968" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_30fe6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_30fe6a" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_617831" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_617831" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_beae4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_beae4e" xml:lang="en-US">Common stock issued for cashless exercise of stock options, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_93ca50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_93ca50" xml:lang="en-US">Common stock issued for cashless exercise of stock options, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSShares" xlink:label="vnrx_CommonStockIssuedForSettlementOfRsuSShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockIssuedForSettlementOfRsuSShares" xlink:to="vnrx_CommonStockIssuedForSettlementOfRsuSShares_lbl_cfb343" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockIssuedForSettlementOfRsuSShares_lbl_cfb343" xml:lang="en-US">Common stock issued for settlement of RSUs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSAmount" xlink:label="vnrx_CommonStockIssuedForSettlementOfRsuSAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockIssuedForSettlementOfRsuSAmount" xlink:to="vnrx_CommonStockIssuedForSettlementOfRsuSAmount_lbl_b3e8e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockIssuedForSettlementOfRsuSAmount_lbl_b3e8e4" xml:lang="en-US">Common stock issued for settlement of RSUs, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedInPublicOfferingsNetShares" xlink:label="vnrx_CommonStockIssuedInPublicOfferingsNetShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockIssuedInPublicOfferingsNetShares" xlink:to="vnrx_CommonStockIssuedInPublicOfferingsNetShares_lbl_814840" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockIssuedInPublicOfferingsNetShares_lbl_814840" xml:lang="en-US">Common stock issued in public offerings, net, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_60ebb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_60ebb4" xml:lang="en-US">Common stock issued in public offerings, net, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" xlink:label="vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" xlink:to="vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation_lbl_af1c9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation_lbl_af1c9b" xml:lang="en-US">Tax withholdings paid related to stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl_9ff9c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl_9ff9c0" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockBasedCompensationInRelationToModificationOfOptions" xlink:label="vnrx_StockBasedCompensationInRelationToModificationOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockBasedCompensationInRelationToModificationOfOptions" xlink:to="vnrx_StockBasedCompensationInRelationToModificationOfOptions_lbl_e14a31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockBasedCompensationInRelationToModificationOfOptions_lbl_e14a31" xml:lang="en-US">Stock-based compensation in relation to modification of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl_5d1f64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl_5d1f64" xml:lang="en-US">Foreign currency translation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_d4d460" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_d4d460" xml:lang="en-US">Net loss for the Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_78662b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_78662b" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_0ab529" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_0ab529" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_3c848c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_3c848c" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_8b7a1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_8b7a1e" xml:lang="en-US">Operating Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_2c686e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_2c686e" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e19a82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e19a82" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_a4bbd3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_a4bbd3" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_159885" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_159885" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLossOnDisposalOfFixedAssets" xlink:to="vnrx_OperatingLossOnDisposalOfFixedAssets_lbl_93e2da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLossOnDisposalOfFixedAssets_lbl_93e2da" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLossOnDisposalOfFixedAssets" xlink:label="vnrx_OperatingLossOnDisposalOfFixedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLossOnDisposalOfFixedAssets" xlink:to="vnrx_OperatingLossOnDisposalOfFixedAssets_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLossOnDisposalOfFixedAssets_lbl_7" xml:lang="en-US">[Loss on disposal of fixed assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl_001e45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl_001e45" xml:lang="en-US">Stock based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_2788a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_2788a3" xml:lang="en-US">Stock-based compensation in relation to modification of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_9" xml:lang="en-US">[Share-Based Payment Arrangement, Noncash Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_13d4aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_13d4aa" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_c3cc6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_c3cc6a" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_f97121" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_f97121" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl_4de8e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl_4de8e1" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl_13" xml:lang="en-US">[Increase (Decrease) in Other Current Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl_92f346" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl_92f346" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl_14" xml:lang="en-US">[Increase (Decrease) in Deferred Revenue]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_d61ca4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_d61ca4" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ManagementAndDirectorsFeesPayable" xlink:to="vnrx_ManagementAndDirectorsFeesPayable_lbl_b73e88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_ManagementAndDirectorsFeesPayable_lbl_b73e88" xml:lang="en-US">Management and directors' fees payable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagementAndDirectorsFeesPayable" xlink:label="vnrx_ManagementAndDirectorsFeesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ManagementAndDirectorsFeesPayable" xlink:to="vnrx_ManagementAndDirectorsFeesPayable_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ManagementAndDirectorsFeesPayable_lbl_16" xml:lang="en-US">[Management and directors' fees payable]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="vnrx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl_e9ed3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl_e9ed3b" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_cf2b25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_cf2b25" xml:lang="en-US">Net Cash Used In Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_a024ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_a024ce" xml:lang="en-US">Investing Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_eea347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_eea347" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_6de15c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_6de15c" xml:lang="en-US">Net Cash Used In Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_aaef4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_aaef4e" xml:lang="en-US">Financing Activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_28e7a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_28e7a8" xml:lang="en-US">Net proceeds from issuance of common shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_252b88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_252b88" xml:lang="en-US">Tax withholdings paid related to stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_24" xml:lang="en-US">[Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProceedsFromGrantsRepayable" xlink:label="vnrx_ProceedsFromGrantsRepayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ProceedsFromGrantsRepayable" xlink:to="vnrx_ProceedsFromGrantsRepayable_lbl_cbcd0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ProceedsFromGrantsRepayable_lbl_cbcd0f" xml:lang="en-US">Proceeds from grants repayable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl_23d306" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl_23d306" xml:lang="en-US">Proceeds from long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_lbl_6c1283" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_lbl_6c1283" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnGrantsRepayable" xlink:label="vnrx_PaymentsOnGrantsRepayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PaymentsOnGrantsRepayable" xlink:to="vnrx_PaymentsOnGrantsRepayable_lbl_6c688a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PaymentsOnGrantsRepayable_lbl_6c688a" xml:lang="en-US">Payments on grants repayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PaymentsOnFinancingLeasesLeaseAmount" xlink:to="vnrx_PaymentsOnFinancingLeasesLeaseAmount_lbl_30bc32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_PaymentsOnFinancingLeasesLeaseAmount_lbl_30bc32" xml:lang="en-US">Payments on financing leases</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnFinancingLeasesLeaseAmount" xlink:label="vnrx_PaymentsOnFinancingLeasesLeaseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PaymentsOnFinancingLeasesLeaseAmount" xlink:to="vnrx_PaymentsOnFinancingLeasesLeaseAmount_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PaymentsOnFinancingLeasesLeaseAmount_lbl_29" xml:lang="en-US">[Payments on financing leases]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_d6685b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_d6685b" xml:lang="en-US">Net Cash Provided By Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_e2bf0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_e2bf0f" xml:lang="en-US">Effect of foreign exchange on cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_f71e2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_f71e2a" xml:lang="en-US">Net Change in Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_32" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_fb177b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_fb177b" xml:lang="en-US">Cash and Cash Equivalents - Beginning of Year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_33" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_169fc1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_169fc1" xml:lang="en-US">Cash and Cash Equivalents - End of Year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_1d3f18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_1d3f18" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_934cb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_934cb4" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl_7b42d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl_7b42d4" xml:lang="en-US">Income tax paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_51d4e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_51d4e8" xml:lang="en-US">Non-Cash Financing Activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_bfa545" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_bfa545" xml:lang="en-US">Common Stock issued on exercises of stock options and warrants and settlement of RSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OfferingCostsFromIssuanceOfCommonStock" xlink:label="vnrx_OfferingCostsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OfferingCostsFromIssuanceOfCommonStock" xlink:to="vnrx_OfferingCostsFromIssuanceOfCommonStock_lbl_ffefef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OfferingCostsFromIssuanceOfCommonStock_lbl_ffefef" xml:lang="en-US">Offering costs from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NonCashNotePayable" xlink:label="vnrx_NonCashNotePayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NonCashNotePayable" xlink:to="vnrx_NonCashNotePayable_lbl_4e45f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NonCashNotePayable_lbl_4e45f6" xml:lang="en-US">Non-cash Note Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_2af5c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_2af5c9" xml:lang="en-US">Nature of Operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl_c2fc7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl_c2fc7c" xml:lang="en-US">Nature of Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl_2" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl_06ce11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl_06ce11" xml:lang="en-US">Liquidity and Going Concern Assessment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LiquidityAndGoingConcernAssessment" xlink:to="vnrx_LiquidityAndGoingConcernAssessment_lbl_704749" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_LiquidityAndGoingConcernAssessment_lbl_704749" xml:lang="en-US">Liquidity and Going Concern Assessment</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LiquidityAndGoingConcernAssessment" xlink:label="vnrx_LiquidityAndGoingConcernAssessment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LiquidityAndGoingConcernAssessment" xlink:to="vnrx_LiquidityAndGoingConcernAssessment_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LiquidityAndGoingConcernAssessment_lbl_2" xml:lang="en-US">[Liquidity and Going Concern Assessment]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_1d43ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_1d43ad" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_5c4b37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_5c4b37" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_709179" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_709179" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_95ffba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_95ffba" xml:lang="en-US">Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_4e528e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_4e528e" xml:lang="en-US">Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_b4ce3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_b4ce3a" xml:lang="en-US">Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_4ec212" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_4ec212" xml:lang="en-US">Related Party Transactions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_840991" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_840991" xml:lang="en-US">Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_eded45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_eded45" xml:lang="en-US">Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_275098" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_275098" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl_ff8def" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl_ff8def" xml:lang="en-US">StockBased Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl_35d139" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl_35d139" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl_5fe6c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl_5fe6c8" xml:lang="en-US">Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_062d71" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_062d71" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_c35afb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_c35afb" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_056a26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_056a26" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_23cf8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_23cf8f" xml:lang="en-US">Subsequent Events</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_8c8c9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_8c8c9d" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_2ef5b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_2ef5b5" xml:lang="en-US">Basis Of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_3e5394" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_3e5394" xml:lang="en-US">Use Of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_a56d7e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_a56d7e" xml:lang="en-US">Principles Of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_2e45b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_2e45b8" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl_055f91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl_055f91" xml:lang="en-US">Accounts Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_d51947" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_d51947" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_7" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_42203f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_42203f" xml:lang="en-US">Basic And Diluted Net Loss Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_d04581" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_d04581" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl_321cb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl_321cb9" xml:lang="en-US">Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_c0c0c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_c0c0c3" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_11" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_8f5b74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_8f5b74" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_12" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_789548" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_789548" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" xlink:label="vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" xlink:to="vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock_lbl_1fcddf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock_lbl_1fcddf" xml:lang="en-US">Deferred Revenue (contract Liabilities) And Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_4e7926" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_4e7926" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock" xlink:label="vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock" xlink:to="vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock_lbl_9882fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock_lbl_9882fb" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_3d8819" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_3d8819" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_17" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl_a04b91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl_a04b91" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_COVID19PandemicImpactPolicyTextblock" xlink:label="vnrx_COVID19PandemicImpactPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_COVID19PandemicImpactPolicyTextblock" xlink:to="vnrx_COVID19PandemicImpactPolicyTextblock_lbl_fedf79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_COVID19PandemicImpactPolicyTextblock_lbl_fedf79" xml:lang="en-US">Covid-19 Pandemic Impact</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_db34be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_db34be" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_bba8ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl_bba8ad" xml:lang="en-US">Schedule Of Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:to="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_lbl_6286ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_lbl_6286ee" xml:lang="en-US">Schedule Of share issued from the cashless exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus" xlink:label="vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus" xlink:to="vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus_lbl_ac573b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus_lbl_ac573b" xml:lang="en-US">Schedule Of share issued from the settlement of RSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_ce0ebd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_ce0ebd" xml:lang="en-US">Schedule Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl_9b5577" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl_9b5577" xml:lang="en-US">Schedule Of Annual Estimated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_e5c3d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_e5c3d8" xml:lang="en-US">Summary Of Changes In Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummarizingTheWarrantsIssuedAndOutstanding" xlink:label="vnrx_SummarizingTheWarrantsIssuedAndOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SummarizingTheWarrantsIssuedAndOutstanding" xlink:to="vnrx_SummarizingTheWarrantsIssuedAndOutstanding_lbl_0c6c67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SummarizingTheWarrantsIssuedAndOutstanding_lbl_0c6c67" xml:lang="en-US">Summarizing The Warrants Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d18592" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d18592" xml:lang="en-US">Summarizes The Changes In Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl_9c4f73" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl_9c4f73" xml:lang="en-US">Summarizing The Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife" xlink:label="vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife" xlink:to="vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife_lbl_dcb005" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife_lbl_dcb005" xml:lang="en-US">Summarizing The Rsus Issued And Outstanding Maturity Life</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock" xlink:label="vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock" xlink:to="vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock_lbl_5e8959" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock_lbl_5e8959" xml:lang="en-US">summarizing the RSUs issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions" xlink:label="vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions" xlink:to="vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions_lbl_36efdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions_lbl_36efdf" xml:lang="en-US">Summary of Amendments to Expiration Dates of Options</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusGrantedDuringPeriod" xlink:label="vnrx_ScheduleOfRsusGrantedDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfRsusGrantedDuringPeriod" xlink:to="vnrx_ScheduleOfRsusGrantedDuringPeriod_lbl_a73dd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfRsusGrantedDuringPeriod_lbl_a73dd8" xml:lang="en-US">Schedule of RSUs granted during period</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusVestedDuringPeriod" xlink:label="vnrx_ScheduleOfRsusVestedDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfRsusVestedDuringPeriod" xlink:to="vnrx_ScheduleOfRsusVestedDuringPeriod_lbl_8d153f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfRsusVestedDuringPeriod_lbl_8d153f" xml:lang="en-US">Schedule of RSUs vested during period</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusCancelledDuringPeriod" xlink:label="vnrx_ScheduleOfRsusCancelledDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfRsusCancelledDuringPeriod" xlink:to="vnrx_ScheduleOfRsusCancelledDuringPeriod_lbl_1f42a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfRsusCancelledDuringPeriod_lbl_1f42a8" xml:lang="en-US">Schedule of RSUs cancelled during period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl_e8455a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl_e8455a" xml:lang="en-US">Shedule of components of deferred income taxes and assets</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" xlink:label="vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" xlink:to="vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock_lbl_279dd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock_lbl_279dd8" xml:lang="en-US">Schedule Of Future Minimum Lease Payments Under Financing Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:label="vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl_9fb8e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl_9fb8e6" xml:lang="en-US">Schedule Of Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRecognizedInShortTermLeaseCosts" xlink:label="vnrx_ScheduleOfRecognizedInShortTermLeaseCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfRecognizedInShortTermLeaseCosts" xlink:to="vnrx_ScheduleOfRecognizedInShortTermLeaseCosts_lbl_2e1bfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfRecognizedInShortTermLeaseCosts_lbl_2e1bfe" xml:lang="en-US">Schedule Of Recognized In Short-term Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl_1c9aad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl_1c9aad" xml:lang="en-US">Schedule Of Grants Repayable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl_6ba98a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl_6ba98a" xml:lang="en-US">Schedule Of Long-term Debt Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl_b214b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl_b214b6" xml:lang="en-US">Schedule of annual payments Of Collaborative Agreement Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" xlink:label="vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" xlink:to="vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets_lbl_041c01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets_lbl_041c01" xml:lang="en-US">Schedule of outcomes related to the prescribed performance targets</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetIncomeLossSinceInception" xlink:label="vnrx_NetIncomeLossSinceInception" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NetIncomeLossSinceInception" xlink:to="vnrx_NetIncomeLossSinceInception_lbl_414889" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NetIncomeLossSinceInception_lbl_414889" xml:lang="en-US">Net Loss Since Inception</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyAxis_lbl_c4be5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl_c4be5e" xml:lang="en-US">Regulatory Agency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_a5165a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_a5165a" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BelgianDepositGuaranteeMember" xlink:label="vnrx_BelgianDepositGuaranteeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_BelgianDepositGuaranteeMember" xlink:to="vnrx_BelgianDepositGuaranteeMember_lbl_87d014" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_BelgianDepositGuaranteeMember_lbl_87d014" xml:lang="en-US">Belgian Deposit Guarantee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SingaporeDepositInsuranceMember" xlink:label="vnrx_SingaporeDepositInsuranceMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SingaporeDepositInsuranceMember" xlink:to="vnrx_SingaporeDepositInsuranceMember_lbl_07d3f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SingaporeDepositInsuranceMember_lbl_07d3f0" xml:lang="en-US">Singapore Deposit Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UKDepositProtectionSchemeMember" xlink:label="vnrx_UKDepositProtectionSchemeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UKDepositProtectionSchemeMember" xlink:to="vnrx_UKDepositProtectionSchemeMember_lbl_0486a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UKDepositProtectionSchemeMember_lbl_0486a5" xml:lang="en-US">UK Deposit Protection Scheme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DilutiveWarrantsAndOptionsMember" xlink:label="vnrx_DilutiveWarrantsAndOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_DilutiveWarrantsAndOptionsMember" xlink:to="vnrx_DilutiveWarrantsAndOptionsMember_lbl_a0bf11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_DilutiveWarrantsAndOptionsMember_lbl_a0bf11" xml:lang="en-US">Warrants And Options [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_4dcb22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_4dcb22" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfLicenseAgreement" xlink:label="vnrx_TermsOfLicenseAgreement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TermsOfLicenseAgreement" xlink:to="vnrx_TermsOfLicenseAgreement_lbl_ce3d48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TermsOfLicenseAgreement_lbl_ce3d48" xml:lang="en-US">Terms of license Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForPoc" xlink:label="vnrx_InitialTermForPoc" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InitialTermForPoc" xlink:to="vnrx_InitialTermForPoc_lbl_4f72d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InitialTermForPoc_lbl_4f72d6" xml:lang="en-US">Initial term for POC</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForCentralLab" xlink:label="vnrx_InitialTermForCentralLab" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InitialTermForCentralLab" xlink:to="vnrx_InitialTermForCentralLab_lbl_1c693b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InitialTermForCentralLab_lbl_1c693b" xml:lang="en-US">Initial term for Central Lab</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UpfrontPayment" xlink:label="vnrx_UpfrontPayment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UpfrontPayment" xlink:to="vnrx_UpfrontPayment_lbl_9a32be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UpfrontPayment_lbl_9a32be" xml:lang="en-US">Upfront payment</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MilestoneAmountRecognized" xlink:label="vnrx_MilestoneAmountRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MilestoneAmountRecognized" xlink:to="vnrx_MilestoneAmountRecognized_lbl_d1998e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MilestoneAmountRecognized_lbl_d1998e" xml:lang="en-US">Milestone amount recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl_8e8557" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl_8e8557" xml:lang="en-US">Amount in excess of FDIC limit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_a4379f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl_a4379f" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ResearchAndDevelopmentExpenses" xlink:label="vnrx_ResearchAndDevelopmentExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ResearchAndDevelopmentExpenses" xlink:to="vnrx_ResearchAndDevelopmentExpenses_lbl_b88fdd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ResearchAndDevelopmentExpenses_lbl_b88fdd" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl_7fea9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl_7fea9f" xml:lang="en-US">Impairment losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_d93484" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_d93484" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl_9a65a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl_9a65a7" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl_13" xml:lang="en-US">[Deferred Revenue]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl_b078a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl_b078a8" xml:lang="en-US">Deposits/cash in excess of insured limits</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PotentiallyDilutiveWarrantsAndOptions" xlink:label="vnrx_PotentiallyDilutiveWarrantsAndOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PotentiallyDilutiveWarrantsAndOptions" xlink:to="vnrx_PotentiallyDilutiveWarrantsAndOptions_lbl_51bc89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PotentiallyDilutiveWarrantsAndOptions_lbl_51bc89" xml:lang="en-US">Potentially dilutive securities excluded from the computation of EPS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_25ad13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_25ad13" xml:lang="en-US">Property Plant And Equipment By Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_de82e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_de82e5" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_ff2f9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_ff2f9b" xml:lang="en-US">Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl_a11f58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl_a11f58" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LaboratoryEquipmentMember" xlink:label="vnrx_LaboratoryEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LaboratoryEquipmentMember" xlink:to="vnrx_LaboratoryEquipmentMember_lbl_af43af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LaboratoryEquipmentMember_lbl_af43af" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl_79f59e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl_79f59e" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl_95f291" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl_95f291" xml:lang="en-US">Buildings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl_9a77a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl_9a77a0" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl_cbd438" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl_cbd438" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_3af9ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_3af9ac" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_b5621b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_b5621b" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_110a8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_110a8c" xml:lang="en-US">Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_cac923" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_cac923" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_1dfd04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_1dfd04" xml:lang="en-US">Net Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl_85f956" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl_85f956" xml:lang="en-US">Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_cd0bf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_cd0bf9" xml:lang="en-US">Depreciation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl_a54b8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl_a54b8a" xml:lang="en-US">Capital expenditure</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_dd1369" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_dd1369" xml:lang="en-US">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl_f27898" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl_f27898" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_058c29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_058c29" xml:lang="en-US">Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Assets, Gross]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_0ad301" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_0ad301" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9dcabb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9dcabb" xml:lang="en-US">Net Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_fbbb80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_fbbb80" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_adc911" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_adc911" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_73aab5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_73aab5" xml:lang="en-US">Total Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl_304477" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl_304477" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_5a4f95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl_5a4f95" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PatentsAndIntellectualPropertyMember" xlink:label="vnrx_PatentsAndIntellectualPropertyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PatentsAndIntellectualPropertyMember" xlink:to="vnrx_PatentsAndIntellectualPropertyMember_lbl_16a10c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PatentsAndIntellectualPropertyMember_lbl_16a10c" xml:lang="en-US">Patents And Intellectual Property [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_42e3e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl_42e3e3" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_8eea0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_8eea0f" xml:lang="en-US">Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl_7513ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl_7513ee" xml:lang="en-US">Amortization Of Long-lived Asset On Straight Line Basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl_8d077f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl_8d077f" xml:lang="en-US">Tax Credit Carryforward Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetDeferredTaxAssetsMember" xlink:label="vnrx_NetDeferredTaxAssetsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NetDeferredTaxAssetsMember" xlink:to="vnrx_NetDeferredTaxAssetsMember_lbl_f8c1fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NetDeferredTaxAssetsMember_lbl_f8c1fd" xml:lang="en-US">Net Deferred Tax Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl_1606ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl_1606ee" xml:lang="en-US">Net deferred tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" xlink:label="vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" xlink:to="vnrx_ExcessOfTaxOverBookDepreciationAndAmortization_lbl_726442" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ExcessOfTaxOverBookDepreciationAndAmortization_lbl_726442" xml:lang="en-US">Excess of tax over book depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_3a867d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_3a867d" xml:lang="en-US">ROU Asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_4" xml:lang="en-US">[Finance Lease, Right-of-Use Asset, after Accumulated Amortization]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_e9e27e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_e9e27e" xml:lang="en-US">Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_lbl_ff7c0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_lbl_ff7c0e" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrealizedGainLoss" xlink:label="vnrx_UnrealizedGainLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnrealizedGainLoss" xlink:to="vnrx_UnrealizedGainLoss_lbl_908a10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnrealizedGainLoss_lbl_908a10" xml:lang="en-US">Unrealized Gain/Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalizedResearchExpenses" xlink:label="vnrx_CapitalizedResearchExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CapitalizedResearchExpenses" xlink:to="vnrx_CapitalizedResearchExpenses_lbl_b34412" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CapitalizedResearchExpenses_lbl_b34412" xml:lang="en-US">Capitalized research expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl_67814d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl_67814d" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl_9" xml:lang="en-US">[Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_f6d1ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_f6d1ca" xml:lang="en-US">Net Operating Losses carry-forward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl_492d87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl_492d87" xml:lang="en-US">Research and development tax credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_86ea4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_86ea4c" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_55d890" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_55d890" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_13" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_82684b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_82684b" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ChangeInValuationAllowance" xlink:label="vnrx_ChangeInValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ChangeInValuationAllowance" xlink:to="vnrx_ChangeInValuationAllowance_lbl_5e3675" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ChangeInValuationAllowance_lbl_5e3675" xml:lang="en-US">Change in Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl_e4ab06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl_e4ab06" xml:lang="en-US">Summary Rate Reconciliation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_f75582" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_f75582" xml:lang="en-US">Federal statutory rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl_6b86f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl_6b86f7" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_a3542c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_a3542c" xml:lang="en-US">Permanent Differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_0df380" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_0df380" xml:lang="en-US">Stock based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl_6" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl_0dc4e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl_0dc4e4" xml:lang="en-US">Federal Research &amp;amp;amp; Development Credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl_903376" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl_903376" xml:lang="en-US">Foreign taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl_fbe92d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl_fbe92d" xml:lang="en-US">Federal Deferred Rate Decrease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_beb9d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_beb9d8" xml:lang="en-US">Change in Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_10" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_ea7316" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_ea7316" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_11" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Percent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl_afa652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl_afa652" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnitedStateMember" xlink:label="vnrx_UnitedStateMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnitedStateMember" xlink:to="vnrx_UnitedStateMember_lbl_0b729d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnitedStateMember_lbl_0b729d" xml:lang="en-US">United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ForeignMember" xlink:label="vnrx_ForeignMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ForeignMember" xlink:to="vnrx_ForeignMember_lbl_f52a16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ForeignMember_lbl_f52a16" xml:lang="en-US">Foreign [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseInValuationAllowance" xlink:label="vnrx_IncreaseInValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncreaseInValuationAllowance" xlink:to="vnrx_IncreaseInValuationAllowance_lbl_b5d537" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncreaseInValuationAllowance_lbl_b5d537" xml:lang="en-US">Increase in Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl_5e072c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl_5e072c" xml:lang="en-US">Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl_6502d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl_6502d9" xml:lang="en-US">Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetOperatingLosses" xlink:label="vnrx_NetOperatingLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NetOperatingLosses" xlink:to="vnrx_NetOperatingLosses_lbl_030424" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NetOperatingLosses_lbl_030424" xml:lang="en-US">Net operating losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_1c4ec9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_1c4ec9" xml:lang="en-US">Award Date Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_43ea55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_43ea55" xml:lang="en-US">Derivative Instrument Risk Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightTwentyThousandTwentyOneMember" xlink:label="vnrx_FebruaryEightTwentyThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FebruaryEightTwentyThousandTwentyOneMember" xlink:to="vnrx_FebruaryEightTwentyThousandTwentyOneMember_lbl_868789" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FebruaryEightTwentyThousandTwentyOneMember_lbl_868789" xml:lang="en-US">February 8, 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesTwoMember" xlink:label="vnrx_StockOptionExercisesTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionExercisesTwoMember" xlink:to="vnrx_StockOptionExercisesTwoMember_lbl_038de1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionExercisesTwoMember_lbl_038de1" xml:lang="en-US">Stock Option Exercises Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" xlink:label="vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" xlink:to="vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_lbl_793925" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_lbl_793925" xml:lang="en-US">February 8 - February 9, 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesMember" xlink:label="vnrx_StockOptionExercisesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionExercisesMember" xlink:to="vnrx_StockOptionExercisesMember_lbl_90be5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionExercisesMember_lbl_90be5c" xml:lang="en-US">Stock Option Exercises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" xlink:label="vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" xlink:to="vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_lbl_f10725" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_lbl_f10725" xml:lang="en-US">January 13 - March 19, 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryTwoTwentyThousandTwentyOneMember" xlink:label="vnrx_FebruaryTwoTwentyThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FebruaryTwoTwentyThousandTwentyOneMember" xlink:to="vnrx_FebruaryTwoTwentyThousandTwentyOneMember_lbl_f8fe3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FebruaryTwoTwentyThousandTwentyOneMember_lbl_f8fe3c" xml:lang="en-US">February 2, 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesOneMember" xlink:label="vnrx_StockOptionExercisesOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionExercisesOneMember" xlink:to="vnrx_StockOptionExercisesOneMember_lbl_249d54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionExercisesOneMember_lbl_249d54" xml:lang="en-US">Stock Option Exercises 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" xlink:label="vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" xlink:to="vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember_lbl_cdb134" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember_lbl_cdb134" xml:lang="en-US">March 25, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyTwoMember" xlink:label="vnrx_AprilThirteenTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AprilThirteenTwoThousandTwentyTwoMember" xlink:to="vnrx_AprilThirteenTwoThousandTwentyTwoMember_lbl_2e6fa2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AprilThirteenTwoThousandTwentyTwoMember_lbl_2e6fa2" xml:lang="en-US">April 13, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MayOneTwoThousandTwentyTwoMember" xlink:label="vnrx_MayOneTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MayOneTwoThousandTwentyTwoMember" xlink:to="vnrx_MayOneTwoThousandTwentyTwoMember_lbl_1d1c32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MayOneTwoThousandTwentyTwoMember_lbl_1d1c32" xml:lang="en-US">May 1, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustThreeTwoThousandTwentyTwoMember" xlink:label="vnrx_AugustThreeTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AugustThreeTwoThousandTwentyTwoMember" xlink:to="vnrx_AugustThreeTwoThousandTwentyTwoMember_lbl_a6ca8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AugustThreeTwoThousandTwentyTwoMember_lbl_a6ca8f" xml:lang="en-US">August 3, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SeptemberSevenTwoThousandTwentyTwoMember" xlink:label="vnrx_SeptemberSevenTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SeptemberSevenTwoThousandTwentyTwoMember" xlink:to="vnrx_SeptemberSevenTwoThousandTwentyTwoMember_lbl_113707" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SeptemberSevenTwoThousandTwentyTwoMember_lbl_113707" xml:lang="en-US">September 7, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OctoberFourTwoThousandTwentyTwoMember" xlink:label="vnrx_OctoberFourTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OctoberFourTwoThousandTwentyTwoMember" xlink:to="vnrx_OctoberFourTwoThousandTwentyTwoMember_lbl_718d0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OctoberFourTwoThousandTwentyTwoMember_lbl_718d0e" xml:lang="en-US">October 4, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NovemberOneTwoThousandTwentyTwoMember" xlink:label="vnrx_NovemberOneTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NovemberOneTwoThousandTwentyTwoMember" xlink:to="vnrx_NovemberOneTwoThousandTwentyTwoMember_lbl_ff23b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NovemberOneTwoThousandTwentyTwoMember_lbl_ff23b0" xml:lang="en-US">November 1, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DecemberFifteenTwoThousandTwentyTwoMember" xlink:label="vnrx_DecemberFifteenTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_DecemberFifteenTwoThousandTwentyTwoMember" xlink:to="vnrx_DecemberFifteenTwoThousandTwentyTwoMember_lbl_c50258" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_DecemberFifteenTwoThousandTwentyTwoMember_lbl_c50258" xml:lang="en-US">December 15, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareIssuedUponCashlessExercise" xlink:label="vnrx_CommonStockShareIssuedUponCashlessExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockShareIssuedUponCashlessExercise" xlink:to="vnrx_CommonStockShareIssuedUponCashlessExercise_lbl_06bf25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockShareIssuedUponCashlessExercise_lbl_06bf25" xml:lang="en-US">Common stock, share issued upon cashless exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl_d1d1c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl_d1d1c8" xml:lang="en-US">Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlan" xlink:label="vnrx_StockIncentivePlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockIncentivePlan" xlink:to="vnrx_StockIncentivePlan_lbl_ea9f62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockIncentivePlan_lbl_ea9f62" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_06df77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_06df77" xml:lang="en-US">Price per shares</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsVested" xlink:label="vnrx_RestrictedStockUnitsVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitsVested" xlink:to="vnrx_RestrictedStockUnitsVested_lbl_997fc3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RestrictedStockUnitsVested_lbl_997fc3" xml:lang="en-US">Restricted Stock Units Vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitVested" xlink:to="vnrx_RestrictedStockUnitVested_lbl_705539" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_RestrictedStockUnitVested_lbl_705539" xml:lang="en-US">Restricted Stock Units Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitVested" xlink:label="vnrx_RestrictedStockUnitVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitVested" xlink:to="vnrx_RestrictedStockUnitVested_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RestrictedStockUnitVested_lbl_7" xml:lang="en-US">[Restricted Stock Units Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharesWithheldForTax" xlink:to="vnrx_SharesWithheldForTax_lbl_5a7d56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_SharesWithheldForTax_lbl_5a7d56" xml:lang="en-US">Shares Withheld for Tax</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesWithheldForTax" xlink:label="vnrx_SharesWithheldForTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharesWithheldForTax" xlink:to="vnrx_SharesWithheldForTax_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharesWithheldForTax_lbl_8" xml:lang="en-US">[Shares Withheld for Tax]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl_8c9010" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl_8c9010" xml:lang="en-US">Shares Withheld for Tax</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_e933f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_e933f0" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" xlink:label="vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" xlink:to="vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_lbl_631faf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_lbl_631faf" xml:lang="en-US">January 20, 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSUSettlementsMember" xlink:label="vnrx_RSUSettlementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RSUSettlementsMember" xlink:to="vnrx_RSUSettlementsMember_lbl_f4de99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RSUSettlementsMember_lbl_f4de99" xml:lang="en-US">RSU Settlements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilTwentyOneTwentyTwentyOneMember" xlink:label="vnrx_AprilTwentyOneTwentyTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AprilTwentyOneTwentyTwentyOneMember" xlink:to="vnrx_AprilTwentyOneTwentyTwentyOneMember_lbl_d97582" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AprilTwentyOneTwentyTwentyOneMember_lbl_d97582" xml:lang="en-US">April 21, 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitVested" xlink:to="vnrx_RestrictedStockUnitVested_lbl_c7be53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vnrx_RestrictedStockUnitVested_lbl_c7be53" xml:lang="en-US">Restricted Stock Units Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfStockPriceSettledPerShare" xlink:label="vnrx_SaleOfStockPriceSettledPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SaleOfStockPriceSettledPerShare" xlink:to="vnrx_SaleOfStockPriceSettledPerShare_lbl_1a390e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SaleOfStockPriceSettledPerShare_lbl_1a390e" xml:lang="en-US">Price Settled Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl_bcc625" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl_bcc625" xml:lang="en-US">Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl_a230b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl_a230b6" xml:lang="en-US">Shares Withheld for tax</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_2b5b5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_2b5b5f" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnderwritingAgreementMember" xlink:label="vnrx_UnderwritingAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnderwritingAgreementMember" xlink:to="vnrx_UnderwritingAgreementMember_lbl_3fc2cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnderwritingAgreementMember_lbl_3fc2cc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityDistributionAgreementMember" xlink:label="vnrx_EquityDistributionAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityDistributionAgreementMember" xlink:to="vnrx_EquityDistributionAgreementMember_lbl_190d53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityDistributionAgreementMember_lbl_190d53" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_550f1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_550f1b" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IssuedOfCommonStockFromSettlementOfRSU" xlink:label="vnrx_IssuedOfCommonStockFromSettlementOfRSU" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IssuedOfCommonStockFromSettlementOfRSU" xlink:to="vnrx_IssuedOfCommonStockFromSettlementOfRSU_lbl_7d858c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IssuedOfCommonStockFromSettlementOfRSU_lbl_7d858c" xml:lang="en-US">Issued of common stock from settlement of RSU</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_fb40ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_fb40ff" xml:lang="en-US">Issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPricePerSahres" xlink:label="vnrx_CommonStockPricePerSahres" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockPricePerSahres" xlink:to="vnrx_CommonStockPricePerSahres_lbl_681cfc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockPricePerSahres_lbl_681cfc" xml:lang="en-US">Common stock price per sahres</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareAuthorized" xlink:label="vnrx_CommonStockShareAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockShareAuthorized" xlink:to="vnrx_CommonStockShareAuthorized_lbl_398a8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockShareAuthorized_lbl_398a8c" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_0e650c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_0e650c" xml:lang="en-US">Common stock shares sold</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggeregateShareOfCommonStockOfferingPrice" xlink:label="vnrx_AggeregateShareOfCommonStockOfferingPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AggeregateShareOfCommonStockOfferingPrice" xlink:to="vnrx_AggeregateShareOfCommonStockOfferingPrice_lbl_a09a3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AggeregateShareOfCommonStockOfferingPrice_lbl_a09a3f" xml:lang="en-US">Aggeregate share of common stock offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BrokerageFees" xlink:label="vnrx_BrokerageFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_BrokerageFees" xlink:to="vnrx_BrokerageFees_lbl_783a52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_BrokerageFees_lbl_783a52" xml:lang="en-US">Brokerage fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl_848a9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl_848a9d" xml:lang="en-US">Commissions and fee</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PurchasePricePerShare" xlink:label="vnrx_PurchasePricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PurchasePricePerShare" xlink:to="vnrx_PurchasePricePerShare_lbl_028dd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PurchasePricePerShare_lbl_028dd0" xml:lang="en-US">Purchase price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl_d08b56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl_d08b56" xml:lang="en-US">Proceeds from Issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OfferingExpenses" xlink:label="vnrx_OfferingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OfferingExpenses" xlink:to="vnrx_OfferingExpenses_lbl_873797" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OfferingExpenses_lbl_873797" xml:lang="en-US">offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="vnrx_WarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantsMember" xlink:to="vnrx_WarrantsMember_lbl_718d27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantsMember_lbl_718d27" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingBeginningBalance" xlink:label="vnrx_NumberOfWarrantsOutstandingBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsOutstandingBeginningBalance" xlink:to="vnrx_NumberOfWarrantsOutstandingBeginningBalance_lbl_6afc23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsOutstandingBeginningBalance_lbl_6afc23" xml:lang="en-US">Number of warrants Outstanding beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsAbstract" xlink:label="vnrx_NumberOfWarrantsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsAbstract" xlink:to="vnrx_NumberOfWarrantsAbstract_lbl_1e4d5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsAbstract_lbl_1e4d5b" xml:lang="en-US">Number of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceAbstract" xlink:label="vnrx_WeightedExercisePriceAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedExercisePriceAbstract" xlink:to="vnrx_WeightedExercisePriceAbstract_lbl_31ed1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedExercisePriceAbstract_lbl_31ed1d" xml:lang="en-US">Weighted Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_20184f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_20184f" xml:lang="en-US">Number of warrants granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsExercised" xlink:to="vnrx_NumberOfWarrantsExercised_lbl_da67be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_NumberOfWarrantsExercised_lbl_da67be" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercised" xlink:label="vnrx_NumberOfWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsExercised" xlink:to="vnrx_NumberOfWarrantsExercised_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsExercised_lbl_6" xml:lang="en-US">[Number of warrants exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsExpired" xlink:to="vnrx_NumberOfWarrantsExpired_lbl_5644e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_NumberOfWarrantsExpired_lbl_5644e3" xml:lang="en-US">Number of warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExpired" xlink:label="vnrx_NumberOfWarrantsExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsExpired" xlink:to="vnrx_NumberOfWarrantsExpired_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsExpired_lbl_7" xml:lang="en-US">[Number of warrants Expired]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingEndingBalance" xlink:label="vnrx_NumberOfWarrantsOutstandingEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsOutstandingEndingBalance" xlink:to="vnrx_NumberOfWarrantsOutstandingEndingBalance_lbl_95dad3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsOutstandingEndingBalance_lbl_95dad3" xml:lang="en-US">Number of warrants outstanding ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercisable" xlink:label="vnrx_NumberOfWarrantsExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfWarrantsExercisable" xlink:to="vnrx_NumberOfWarrantsExercisable_lbl_233118" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfWarrantsExercisable_lbl_233118" xml:lang="en-US">Number of Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" xlink:label="vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" xlink:to="vnrx_WeightedAverageExercisePriceOutstandingBalanceOne_lbl_305e95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceOutstandingBalanceOne_lbl_305e95" xml:lang="en-US">Weighted Average Exercise Price Outstanding balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_87826d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_87826d" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExercised" xlink:label="vnrx_WeightedExercisePriceExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedExercisePriceExercised" xlink:to="vnrx_WeightedExercisePriceExercised_lbl_84de61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedExercisePriceExercised_lbl_84de61" xml:lang="en-US">Weighted Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExpired" xlink:label="vnrx_WeightedExercisePriceExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedExercisePriceExpired" xlink:to="vnrx_WeightedExercisePriceExpired_lbl_105e74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedExercisePriceExpired_lbl_105e74" xml:lang="en-US">Weighted Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalanceOne" xlink:label="vnrx_WeightedAverageExercisePriceEndingBalanceOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceEndingBalanceOne" xlink:to="vnrx_WeightedAverageExercisePriceEndingBalanceOne_lbl_41cbee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceEndingBalanceOne_lbl_41cbee" xml:lang="en-US">Weighted Average Exercise Price ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisable" xlink:label="vnrx_WeightedAverageExercisePriceExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceExercisable" xlink:to="vnrx_WeightedAverageExercisePriceExercisable_lbl_285f64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceExercisable_lbl_285f64" xml:lang="en-US">Weighted Average Exercise Price exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantOneMember" xlink:label="vnrx_WarrantOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantOneMember" xlink:to="vnrx_WarrantOneMember_lbl_6f8515" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantOneMember_lbl_6f8515" xml:lang="en-US">Warrant One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantTwoMember" xlink:label="vnrx_WarrantTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantTwoMember" xlink:to="vnrx_WarrantTwoMember_lbl_2cbaaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantTwoMember_lbl_2cbaaa" xml:lang="en-US">Warrant Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantThreeMember" xlink:label="vnrx_WarrantThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantThreeMember" xlink:to="vnrx_WarrantThreeMember_lbl_04047b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantThreeMember_lbl_04047b" xml:lang="en-US">Warrant Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFourMember" xlink:label="vnrx_WarrantsFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantsFourMember" xlink:to="vnrx_WarrantsFourMember_lbl_ae5ab5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantsFourMember_lbl_ae5ab5" xml:lang="en-US">Warrants Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFiveMember" xlink:label="vnrx_WarrantsFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WarrantsFiveMember" xlink:to="vnrx_WarrantsFiveMember_lbl_f9a7bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WarrantsFiveMember_lbl_f9a7bc" xml:lang="en-US">Warrants Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_2a6b82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_2a6b82" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_335458" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_335458" xml:lang="en-US">Number Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_4e96f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_4e96f8" xml:lang="en-US">Number Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_deb3a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_deb3a8" xml:lang="en-US">Proceeds to Company if Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExercisePrice" xlink:label="vnrx_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ExercisePrice" xlink:to="vnrx_ExercisePrice_lbl_b65d0c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ExercisePrice_lbl_b65d0c" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="vnrx_OptionFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OptionFourMember" xlink:to="vnrx_OptionFourMember_lbl_e78194" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OptionFourMember_lbl_e78194" xml:lang="en-US">Option Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsOutstandingBeginningBalance" xlink:label="vnrx_NumberOfOptionsOutstandingBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfOptionsOutstandingBeginningBalance" xlink:to="vnrx_NumberOfOptionsOutstandingBeginningBalance_lbl_5229c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfOptionsOutstandingBeginningBalance_lbl_5229c6" xml:lang="en-US">Number of options outstanding beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_551fed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_551fed" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_eaa2e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_eaa2e8" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_lbl_4" xml:lang="en-US">[Exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfExpiredCancelled" xlink:to="vnrx_NumberOfExpiredCancelled_lbl_e00222" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_NumberOfExpiredCancelled_lbl_e00222" xml:lang="en-US">Number of Expired/Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfExpiredCancelled" xlink:label="vnrx_NumberOfExpiredCancelled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfExpiredCancelled" xlink:to="vnrx_NumberOfExpiredCancelled_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfExpiredCancelled_lbl_5" xml:lang="en-US">[Number of Expired/Cancelled]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionOutstandingEndingBalance" xlink:label="vnrx_NumberOfOptionOutstandingEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfOptionOutstandingEndingBalance" xlink:to="vnrx_NumberOfOptionOutstandingEndingBalance_lbl_063db4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfOptionOutstandingEndingBalance_lbl_063db4" xml:lang="en-US">Number of option outstanding ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsExercisable" xlink:label="vnrx_NumberOfOptionsExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfOptionsExercisable" xlink:to="vnrx_NumberOfOptionsExercisable_lbl_56d395" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfOptionsExercisable_lbl_56d395" xml:lang="en-US">Number of options exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceOutstandingBalance" xlink:to="vnrx_WeightedAverageExercisePriceOutstandingBalance_lbl_a69f3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_WeightedAverageExercisePriceOutstandingBalance_lbl_a69f3d" xml:lang="en-US">Weighted Average Exercise Price Outstanding balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalance" xlink:label="vnrx_WeightedAverageExercisePriceOutstandingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceOutstandingBalance" xlink:to="vnrx_WeightedAverageExercisePriceOutstandingBalance_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceOutstandingBalance_lbl_8" xml:lang="en-US">[Weighted Average Exercise Price Outstanding balance]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceGranted" xlink:to="vnrx_WeightedAverageExercisePriceGranted_lbl_37331f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_WeightedAverageExercisePriceGranted_lbl_37331f" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceGranted" xlink:label="vnrx_WeightedAverageExercisePriceGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceGranted" xlink:to="vnrx_WeightedAverageExercisePriceGranted_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceGranted_lbl_9" xml:lang="en-US">[Weighted Average Exercise Price Granted]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercised" xlink:label="vnrx_WeightedAverageExercisePriceExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceExercised" xlink:to="vnrx_WeightedAverageExercisePriceExercised_lbl_d67417" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceExercised_lbl_d67417" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" xlink:label="vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" xlink:to="vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled_lbl_535fb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled_lbl_535fb3" xml:lang="en-US">Weighted Average Exercise Price expires/cancelled</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceEndingBalance" xlink:to="vnrx_WeightedAverageExercisePriceEndingBalance_lbl_0e530e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_WeightedAverageExercisePriceEndingBalance_lbl_0e530e" xml:lang="en-US">Weighted Average Exercise Price ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalance" xlink:label="vnrx_WeightedAverageExercisePriceEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceEndingBalance" xlink:to="vnrx_WeightedAverageExercisePriceEndingBalance_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceEndingBalance_lbl_12" xml:lang="en-US">[Weighted Average Exercise Price ending balance]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisableBalance" xlink:label="vnrx_WeightedAverageExercisePriceExercisableBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageExercisePriceExercisableBalance" xlink:to="vnrx_WeightedAverageExercisePriceExercisableBalance_lbl_1f9a27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageExercisePriceExercisableBalance_lbl_1f9a27" xml:lang="en-US">Weighted Average Exercise Price exercisable balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentOneMember" xlink:label="vnrx_StockOptionsAmendmentOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentOneMember" xlink:to="vnrx_StockOptionsAmendmentOneMember_lbl_7d002d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentOneMember_lbl_7d002d" xml:lang="en-US">Stock Options Amendment One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwoMember" xlink:label="vnrx_StockOptionsAmendmentTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentTwoMember" xlink:to="vnrx_StockOptionsAmendmentTwoMember_lbl_9928f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentTwoMember_lbl_9928f5" xml:lang="en-US">Stock Options Amendment Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThreeMember" xlink:label="vnrx_StockOptionsAmendmentThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentThreeMember" xlink:to="vnrx_StockOptionsAmendmentThreeMember_lbl_5cb08c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentThreeMember_lbl_5cb08c" xml:lang="en-US">Stock Options Amendment Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourMember" xlink:label="vnrx_StockOptionsAmendmentFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentFourMember" xlink:to="vnrx_StockOptionsAmendmentFourMember_lbl_34dcaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentFourMember_lbl_34dcaa" xml:lang="en-US">Stock Options Amendment Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFiveMember" xlink:label="vnrx_StockOptionsAmendmentFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentFiveMember" xlink:to="vnrx_StockOptionsAmendmentFiveMember_lbl_01dd52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentFiveMember_lbl_01dd52" xml:lang="en-US">Stock Options Amendment Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSixMember" xlink:label="vnrx_StockOptionsAmendmentSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentSixMember" xlink:to="vnrx_StockOptionsAmendmentSixMember_lbl_7d84aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentSixMember_lbl_7d84aa" xml:lang="en-US">Stock Options Amendment Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSevenMember" xlink:label="vnrx_StockOptionsAmendmentSevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentSevenMember" xlink:to="vnrx_StockOptionsAmendmentSevenMember_lbl_0a0b23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentSevenMember_lbl_0a0b23" xml:lang="en-US">Stock Options Amendment Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentEightMember" xlink:label="vnrx_StockOptionsAmendmentEightMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentEightMember" xlink:to="vnrx_StockOptionsAmendmentEightMember_lbl_5efefb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentEightMember_lbl_5efefb" xml:lang="en-US">Stock Options Amendment Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentNineMember" xlink:label="vnrx_StockOptionsAmendmentNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentNineMember" xlink:to="vnrx_StockOptionsAmendmentNineMember_lbl_9bd01f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentNineMember_lbl_9bd01f" xml:lang="en-US">Stock Options Amendment Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTenMember" xlink:label="vnrx_StockOptionsAmendmentTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentTenMember" xlink:to="vnrx_StockOptionsAmendmentTenMember_lbl_3b8ecf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentTenMember_lbl_3b8ecf" xml:lang="en-US">Stock Options Amendment Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentElevenMember" xlink:label="vnrx_StockOptionsAmendmentElevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentElevenMember" xlink:to="vnrx_StockOptionsAmendmentElevenMember_lbl_9ce36f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentElevenMember_lbl_9ce36f" xml:lang="en-US">Stock Options Amendment Eleven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwelveMember" xlink:label="vnrx_StockOptionsAmendmentTwelveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentTwelveMember" xlink:to="vnrx_StockOptionsAmendmentTwelveMember_lbl_43b0e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentTwelveMember_lbl_43b0e3" xml:lang="en-US">Stock Options Amendment Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThirteenMember" xlink:label="vnrx_StockOptionsAmendmentThirteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentThirteenMember" xlink:to="vnrx_StockOptionsAmendmentThirteenMember_lbl_f2832a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentThirteenMember_lbl_f2832a" xml:lang="en-US">Stock Options Amendment Thirteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourteenMember" xlink:label="vnrx_StockOptionsAmendmentFourteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsAmendmentFourteenMember" xlink:to="vnrx_StockOptionsAmendmentFourteenMember_lbl_c8d77a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsAmendmentFourteenMember_lbl_c8d77a" xml:lang="en-US">Stock Options Amendment Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ApprovedStockOptions" xlink:label="vnrx_ApprovedStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ApprovedStockOptions" xlink:to="vnrx_ApprovedStockOptions_lbl_a344b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ApprovedStockOptions_lbl_a344b7" xml:lang="en-US">Approved Stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl_f55883" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl_f55883" xml:lang="en-US">Option expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlan" xlink:label="vnrx_EquityIncentivePlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlan" xlink:to="vnrx_EquityIncentivePlan_lbl_704702" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlan_lbl_704702" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionGrantDate" xlink:label="vnrx_StockOptionGrantDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionGrantDate" xlink:to="vnrx_StockOptionGrantDate_lbl_228537" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionGrantDate_lbl_228537" xml:lang="en-US">Stock option grant date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_stockoptionamendmentdate" xlink:label="vnrx_stockoptionamendmentdate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_stockoptionamendmentdate" xlink:to="vnrx_stockoptionamendmentdate_lbl_5a22b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_stockoptionamendmentdate_lbl_5a22b2" xml:lang="en-US">Stock option amendment date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl_b2665a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl_b2665a" xml:lang="en-US">Stock option expiration date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionsOneMember" xlink:label="vnrx_OptionsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OptionsOneMember" xlink:to="vnrx_OptionsOneMember_lbl_3f7b55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OptionsOneMember_lbl_3f7b55" xml:lang="en-US">Options One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionTwoMember" xlink:label="vnrx_OptionTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OptionTwoMember" xlink:to="vnrx_OptionTwoMember_lbl_210d1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OptionTwoMember_lbl_210d1b" xml:lang="en-US">Option Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThreeMember" xlink:label="vnrx_StockOptionThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionThreeMember" xlink:to="vnrx_StockOptionThreeMember_lbl_1c6663" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionThreeMember_lbl_1c6663" xml:lang="en-US">Option Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFiveMember" xlink:label="vnrx_OptionFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OptionFiveMember" xlink:to="vnrx_OptionFiveMember_lbl_1a3e8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OptionFiveMember_lbl_1a3e8f" xml:lang="en-US">Option Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSixMember" xlink:label="vnrx_StockOptionSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionSixMember" xlink:to="vnrx_StockOptionSixMember_lbl_f8dd50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionSixMember_lbl_f8dd50" xml:lang="en-US">Option Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSevenMember" xlink:label="vnrx_StockOptionSevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionSevenMember" xlink:to="vnrx_StockOptionSevenMember_lbl_84c907" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionSevenMember_lbl_84c907" xml:lang="en-US">Option Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionEightMember" xlink:label="vnrx_StockOptionEightMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionEightMember" xlink:to="vnrx_StockOptionEightMember_lbl_1a2d38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionEightMember_lbl_1a2d38" xml:lang="en-US">Option Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionNineMember" xlink:label="vnrx_StockOptionNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionNineMember" xlink:to="vnrx_StockOptionNineMember_lbl_1cedc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionNineMember_lbl_1cedc5" xml:lang="en-US">Option Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalStockOptionOneMember" xlink:label="vnrx_TotalStockOptionOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TotalStockOptionOneMember" xlink:to="vnrx_TotalStockOptionOneMember_lbl_4def84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TotalStockOptionOneMember_lbl_4def84" xml:lang="en-US">Total Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_4c96d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_4c96d3" xml:lang="en-US">Number Exercisable, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_c42ee5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_c42ee5" xml:lang="en-US">Number Outstanding, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_4d4563" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_4d4563" xml:lang="en-US">Proceeds to Company if Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_4" xml:lang="en-US">[Proceeds from Stock Options Exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_4839de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_4839de" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_477061" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_477061" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl_66356d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl_66356d" xml:lang="en-US">Financial Instrument Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsMember" xlink:label="vnrx_StockOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsMember" xlink:to="vnrx_StockOptionsMember_lbl_f1a61c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsMember_lbl_f1a61c" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfRsusOutstandingBeginingBalance" xlink:to="vnrx_NumberOfRsusOutstandingBeginingBalance_lbl_ab5ee6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="vnrx_NumberOfRsusOutstandingBeginingBalance_lbl_ab5ee6" xml:lang="en-US">Number of RSUs outstanding begining balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingBeginingBalance" xlink:label="vnrx_NumberOfRsusOutstandingBeginingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfRsusOutstandingBeginingBalance" xlink:to="vnrx_NumberOfRsusOutstandingBeginingBalance_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfRsusOutstandingBeginingBalance_lbl_2" xml:lang="en-US">[Number of RSUs outstanding begining balance]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantedShares" xlink:to="vnrx_GrantedShares_lbl_695d2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_GrantedShares_lbl_695d2f" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedShares" xlink:label="vnrx_GrantedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantedShares" xlink:to="vnrx_GrantedShares_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantedShares_lbl_3" xml:lang="en-US">[Granted]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfStockVested" xlink:to="vnrx_NumberOfStockVested_lbl_9b1547" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_NumberOfStockVested_lbl_9b1547" xml:lang="en-US">Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockVested" xlink:label="vnrx_NumberOfStockVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfStockVested" xlink:to="vnrx_NumberOfStockVested_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfStockVested_lbl_4" xml:lang="en-US">[Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfStockCancelled" xlink:to="vnrx_NumberOfStockCancelled_lbl_3da8da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="vnrx_NumberOfStockCancelled_lbl_3da8da" xml:lang="en-US">Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockCancelled" xlink:label="vnrx_NumberOfStockCancelled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfStockCancelled" xlink:to="vnrx_NumberOfStockCancelled_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfStockCancelled_lbl_5" xml:lang="en-US">[Cancelled]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfRsusOutstandingEndingBalance" xlink:to="vnrx_NumberOfRsusOutstandingEndingBalance_lbl_ef27a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="vnrx_NumberOfRsusOutstandingEndingBalance_lbl_ef27a1" xml:lang="en-US">Number of RSUs outstanding ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingEndingBalance" xlink:label="vnrx_NumberOfRsusOutstandingEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfRsusOutstandingEndingBalance" xlink:to="vnrx_NumberOfRsusOutstandingEndingBalance_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfRsusOutstandingEndingBalance_lbl_6" xml:lang="en-US">[Number of RSUs outstanding ending balance]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceBeginningBalance" xlink:to="vnrx_SharePriceBeginningBalance_lbl_40da95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="vnrx_SharePriceBeginningBalance_lbl_40da95" xml:lang="en-US">Share price beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceBeginningBalance" xlink:label="vnrx_SharePriceBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceBeginningBalance" xlink:to="vnrx_SharePriceBeginningBalance_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharePriceBeginningBalance_lbl_7" xml:lang="en-US">[Share price beginning balance]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceGranted" xlink:label="vnrx_SharePriceGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceGranted" xlink:to="vnrx_SharePriceGranted_lbl_652840" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharePriceGranted_lbl_652840" xml:lang="en-US">Share price granted</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceVested" xlink:label="vnrx_SharePriceVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceVested" xlink:to="vnrx_SharePriceVested_lbl_2e5135" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharePriceVested_lbl_2e5135" xml:lang="en-US">Share price vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Cancelled" xlink:label="vnrx_Cancelled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_Cancelled" xlink:to="vnrx_Cancelled_lbl_346bd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_Cancelled_lbl_346bd1" xml:lang="en-US">Cancelled net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceEndingBalance" xlink:to="vnrx_SharePriceEndingBalance_lbl_7eef9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="vnrx_SharePriceEndingBalance_lbl_7eef9f" xml:lang="en-US">Share price ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceEndingBalance" xlink:label="vnrx_SharePriceEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharePriceEndingBalance" xlink:to="vnrx_SharePriceEndingBalance_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharePriceEndingBalance_lbl_11" xml:lang="en-US">[Share price ending balance]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseNineMember" xlink:label="vnrx_CompensationExpenseNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseNineMember" xlink:to="vnrx_CompensationExpenseNineMember_lbl_4f89b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseNineMember_lbl_4f89b3" xml:lang="en-US">Compensation Expense Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTenMember" xlink:label="vnrx_CompensationExpenseTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseTenMember" xlink:to="vnrx_CompensationExpenseTenMember_lbl_33d168" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseTenMember_lbl_33d168" xml:lang="en-US">Compensation Expense Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseOneMember" xlink:label="vnrx_CompensationExpenseOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseOneMember" xlink:to="vnrx_CompensationExpenseOneMember_lbl_a93b91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseOneMember_lbl_a93b91" xml:lang="en-US">Compensation Expense One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTwoMember" xlink:label="vnrx_CompensationExpenseTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseTwoMember" xlink:to="vnrx_CompensationExpenseTwoMember_lbl_a1d07b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseTwoMember_lbl_a1d07b" xml:lang="en-US">Compensation Expense Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseThreeMember" xlink:label="vnrx_CompensationExpenseThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseThreeMember" xlink:to="vnrx_CompensationExpenseThreeMember_lbl_7dd3f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseThreeMember_lbl_7dd3f9" xml:lang="en-US">Compensation Expense Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFourMember" xlink:label="vnrx_CompensationExpenseFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseFourMember" xlink:to="vnrx_CompensationExpenseFourMember_lbl_a31fef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseFourMember_lbl_a31fef" xml:lang="en-US">Compensation Expense Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFiveMember" xlink:label="vnrx_CompensationExpenseFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseFiveMember" xlink:to="vnrx_CompensationExpenseFiveMember_lbl_ad36a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseFiveMember_lbl_ad36a5" xml:lang="en-US">Compensation Expense Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSixMember" xlink:label="vnrx_CompensationExpenseSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseSixMember" xlink:to="vnrx_CompensationExpenseSixMember_lbl_252246" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseSixMember_lbl_252246" xml:lang="en-US">Compensation Expense Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSevenMember" xlink:label="vnrx_CompensationExpenseSevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseSevenMember" xlink:to="vnrx_CompensationExpenseSevenMember_lbl_247102" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseSevenMember_lbl_247102" xml:lang="en-US">Compensation Expense Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseEightMember" xlink:label="vnrx_CompensationExpenseEightMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseEightMember" xlink:to="vnrx_CompensationExpenseEightMember_lbl_c54ed8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseEightMember_lbl_c54ed8" xml:lang="en-US">Compensation Expense Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseRsus" xlink:label="vnrx_CompensationExpenseRsus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseRsus" xlink:to="vnrx_CompensationExpenseRsus_lbl_6bb4c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseRsus_lbl_6bb4c6" xml:lang="en-US">Compensation Expense RSUs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlan" xlink:to="vnrx_EquityIncentivePlan_lbl_21b43d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_EquityIncentivePlan_lbl_21b43d" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseGrantDate" xlink:label="vnrx_CompensationExpenseGrantDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseGrantDate" xlink:to="vnrx_CompensationExpenseGrantDate_lbl_036292" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseGrantDate_lbl_036292" xml:lang="en-US">Compensation Expense grant date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseVestingPeriod" xlink:label="vnrx_CompensationExpenseVestingPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationExpenseVestingPeriod" xlink:to="vnrx_CompensationExpenseVestingPeriod_lbl_33acbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationExpenseVestingPeriod_lbl_33acbf" xml:lang="en-US">Compensation Expense Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstVestingDate" xlink:label="vnrx_FirstVestingDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FirstVestingDate" xlink:to="vnrx_FirstVestingDate_lbl_b8cf8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FirstVestingDate_lbl_b8cf8a" xml:lang="en-US">First Vesting date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SecondVestingDate" xlink:label="vnrx_SecondVestingDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SecondVestingDate" xlink:to="vnrx_SecondVestingDate_lbl_93cced" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SecondVestingDate_lbl_93cced" xml:lang="en-US">Second vesting date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ThirdVestingDate" xlink:label="vnrx_ThirdVestingDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ThirdVestingDate" xlink:to="vnrx_ThirdVestingDate_lbl_d29a67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ThirdVestingDate_lbl_d29a67" xml:lang="en-US">Third vesting date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuExpense" xlink:label="vnrx_RsuExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RsuExpense" xlink:to="vnrx_RsuExpense_lbl_b63ae4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RsuExpense_lbl_b63ae4" xml:lang="en-US">RSU Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanOneMember" xlink:label="vnrx_EquityIncentivePlanOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanOneMember" xlink:to="vnrx_EquityIncentivePlanOneMember_lbl_c8d48f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanOneMember_lbl_c8d48f" xml:lang="en-US">Equity Incentive Plan One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanTwoMember" xlink:label="vnrx_EquityIncentivePlanTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanTwoMember" xlink:to="vnrx_EquityIncentivePlanTwoMember_lbl_bc5ffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanTwoMember_lbl_bc5ffd" xml:lang="en-US">Equity Incentive Plan Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanThreeMember" xlink:label="vnrx_EquityIncentivePlanThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanThreeMember" xlink:to="vnrx_EquityIncentivePlanThreeMember_lbl_875898" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanThreeMember_lbl_875898" xml:lang="en-US">Equity Incentive Plan Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFourMember" xlink:label="vnrx_EquityIncentivePlanFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanFourMember" xlink:to="vnrx_EquityIncentivePlanFourMember_lbl_d5b90f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanFourMember_lbl_d5b90f" xml:lang="en-US">Equity Incentive Plan Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFiveMember" xlink:label="vnrx_EquityIncentivePlanFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanFiveMember" xlink:to="vnrx_EquityIncentivePlanFiveMember_lbl_c5aeb7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanFiveMember_lbl_c5aeb7" xml:lang="en-US">Equity Incentive Plan Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSixMember" xlink:label="vnrx_EquityIncentivePlanSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanSixMember" xlink:to="vnrx_EquityIncentivePlanSixMember_lbl_1713aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanSixMember_lbl_1713aa" xml:lang="en-US">Equity Incentive Plan Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSevenMember" xlink:label="vnrx_EquityIncentivePlanSevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanSevenMember" xlink:to="vnrx_EquityIncentivePlanSevenMember_lbl_a75b69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanSevenMember_lbl_a75b69" xml:lang="en-US">Equity Incentive Plan Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanEightMember" xlink:label="vnrx_EquityIncentivePlanEightMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentivePlanEightMember" xlink:to="vnrx_EquityIncentivePlanEightMember_lbl_c2105a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentivePlanEightMember_lbl_c2105a" xml:lang="en-US">Equity Incentive Plan Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentivePlan" xlink:label="vnrx_IncentivePlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncentivePlan" xlink:to="vnrx_IncentivePlan_lbl_19f43c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncentivePlan_lbl_19f43c" xml:lang="en-US">Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentiveRsu" xlink:label="vnrx_EquityIncentiveRsu" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EquityIncentiveRsu" xlink:to="vnrx_EquityIncentiveRsu_lbl_1d61f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EquityIncentiveRsu_lbl_1d61f6" xml:lang="en-US">Equity Incentive RSU</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveVestDate" xlink:label="vnrx_IncentiveVestDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncentiveVestDate" xlink:to="vnrx_IncentiveVestDate_lbl_179999" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncentiveVestDate_lbl_179999" xml:lang="en-US">Incentive Vest Date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsuIssued" xlink:label="vnrx_IncentiveRsuIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncentiveRsuIssued" xlink:to="vnrx_IncentiveRsuIssued_lbl_f7e5c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncentiveRsuIssued_lbl_f7e5c4" xml:lang="en-US">Incentive RSU Issued</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsusHeldForTaxes" xlink:label="vnrx_RsusHeldForTaxes" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RsusHeldForTaxes" xlink:to="vnrx_RsusHeldForTaxes_lbl_06d242" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RsusHeldForTaxes_lbl_06d242" xml:lang="en-US">RSUs Held for Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuCancelled" xlink:label="vnrx_RsuCancelled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RsuCancelled" xlink:to="vnrx_RsuCancelled_lbl_b6266b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RsuCancelled_lbl_b6266b" xml:lang="en-US">RSU Cancelled</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncentivePlan" xlink:to="vnrx_IncentivePlan_lbl_ac9101" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_IncentivePlan_lbl_ac9101" xml:lang="en-US">Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsu" xlink:label="vnrx_IncentiveRsu" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_IncentiveRsu" xlink:to="vnrx_IncentiveRsu_lbl_650204" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_IncentiveRsu_lbl_650204" xml:lang="en-US">Incentive RSU</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CancellationDate" xlink:label="vnrx_CancellationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CancellationDate" xlink:to="vnrx_CancellationDate_lbl_59e963" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CancellationDate_lbl_59e963" xml:lang="en-US">Cancellation Date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestDate" xlink:label="vnrx_VestDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_VestDate" xlink:to="vnrx_VestDate_lbl_e87349" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_VestDate_lbl_e87349" xml:lang="en-US">Vest date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTenMember" xlink:label="vnrx_StockOptionTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionTenMember" xlink:to="vnrx_StockOptionTenMember_lbl_3c5f76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionTenMember_lbl_3c5f76" xml:lang="en-US">Option Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionElevenMember" xlink:label="vnrx_StockOptionElevenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionElevenMember" xlink:to="vnrx_StockOptionElevenMember_lbl_5af172" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionElevenMember_lbl_5af172" xml:lang="en-US">Option Eleven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTwelveMember" xlink:label="vnrx_StockOptionTwelveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionTwelveMember" xlink:to="vnrx_StockOptionTwelveMember_lbl_500d23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionTwelveMember_lbl_500d23" xml:lang="en-US">Option Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFourteenTenMember" xlink:label="vnrx_StockOptionFourteenTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionFourteenTenMember" xlink:to="vnrx_StockOptionFourteenTenMember_lbl_d556af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionFourteenTenMember_lbl_d556af" xml:lang="en-US">Option Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFiveteenTenMember" xlink:label="vnrx_StockOptionFiveteenTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionFiveteenTenMember" xlink:to="vnrx_StockOptionFiveteenTenMember_lbl_d09bd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionFiveteenTenMember_lbl_d09bd7" xml:lang="en-US">Option Fiveteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThirteenTenMember" xlink:label="vnrx_StockOptionThirteenTenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionThirteenTenMember" xlink:to="vnrx_StockOptionThirteenTenMember_lbl_841667" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionThirteenTenMember_lbl_841667" xml:lang="en-US">Option Thirteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockOutstandingBalance" xlink:label="vnrx_NumberOfStockOutstandingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfStockOutstandingBalance" xlink:to="vnrx_NumberOfStockOutstandingBalance_lbl_2deb32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfStockOutstandingBalance_lbl_2deb32" xml:lang="en-US">Number of stock Outstanding balance</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesPriceRsu" xlink:label="vnrx_SharesPriceRsu" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SharesPriceRsu" xlink:to="vnrx_SharesPriceRsu_lbl_6943c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SharesPriceRsu_lbl_6943c8" xml:lang="en-US">Share price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageRemainingContractualLifeYears" xlink:label="vnrx_WeightedAverageRemainingContractualLifeYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WeightedAverageRemainingContractualLifeYears" xlink:to="vnrx_WeightedAverageRemainingContractualLifeYears_lbl_ae0fc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WeightedAverageRemainingContractualLifeYears_lbl_ae0fc5" xml:lang="en-US">Weighted average remaining contractual life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilFourTwoThousandTwentyTwoMember" xlink:label="vnrx_AprilFourTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AprilFourTwoThousandTwentyTwoMember" xlink:to="vnrx_AprilFourTwoThousandTwentyTwoMember_lbl_af028e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AprilFourTwoThousandTwentyTwoMember_lbl_af028e" xml:lang="en-US">April 4, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl_4d5ce0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl_4d5ce0" xml:lang="en-US">Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="vnrx_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="vnrx_TwoThousandFifteenEquityIncentivePlanMember_lbl_581917" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TwoThousandFifteenEquityIncentivePlanMember_lbl_581917" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryOneTwoThousandTwentyOneMember" xlink:label="vnrx_FebruaryOneTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FebruaryOneTwoThousandTwentyOneMember" xlink:to="vnrx_FebruaryOneTwoThousandTwentyOneMember_lbl_c4a26e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FebruaryOneTwoThousandTwentyOneMember_lbl_c4a26e" xml:lang="en-US">February 1, 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryOneTwoThousandTwentyOneMember" xlink:label="vnrx_JanuaryOneTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_JanuaryOneTwoThousandTwentyOneMember" xlink:to="vnrx_JanuaryOneTwoThousandTwentyOneMember_lbl_afb378" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_JanuaryOneTwoThousandTwentyOneMember_lbl_afb378" xml:lang="en-US">January 01, 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyMember" xlink:label="vnrx_AprilThirteenTwoThousandTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AprilThirteenTwoThousandTwentyMember" xlink:to="vnrx_AprilThirteenTwoThousandTwentyMember_lbl_e869cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AprilThirteenTwoThousandTwentyMember_lbl_e869cf" xml:lang="en-US">April 13,2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsMember" xlink:label="vnrx_RestrictedStockUnitsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitsMember" xlink:to="vnrx_RestrictedStockUnitsMember_lbl_fcff69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RestrictedStockUnitsMember_lbl_fcff69" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" xlink:label="vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" xlink:to="vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_lbl_d6205f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_lbl_d6205f" xml:lang="en-US">On 20, May 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsOneMember" xlink:label="vnrx_RestrictedStockUnitsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnitsOneMember" xlink:to="vnrx_RestrictedStockUnitsOneMember_lbl_86dab2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RestrictedStockUnitsOneMember_lbl_86dab2" xml:lang="en-US">Restricted Stock Units [Member] | One</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockAvailable" xlink:label="vnrx_CommonStockAvailable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockAvailable" xlink:to="vnrx_CommonStockAvailable_lbl_700a46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockAvailable_lbl_700a46" xml:lang="en-US">Common stock available</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareAggregateMaximum" xlink:label="vnrx_ShareAggregateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ShareAggregateMaximum" xlink:to="vnrx_ShareAggregateMaximum_lbl_900d08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ShareAggregateMaximum_lbl_900d08" xml:lang="en-US">Share aggregate maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionGranted" xlink:label="vnrx_OptionGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OptionGranted" xlink:to="vnrx_OptionGranted_lbl_0154d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OptionGranted_lbl_0154d0" xml:lang="en-US">Option Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ApprovedStockOptions" xlink:to="vnrx_ApprovedStockOptions_lbl_abb54b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_ApprovedStockOptions_lbl_abb54b" xml:lang="en-US">Stock options approved amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfSharesVesting" xlink:label="vnrx_NumberOfSharesVesting" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NumberOfSharesVesting" xlink:to="vnrx_NumberOfSharesVesting_lbl_f56fab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NumberOfSharesVesting_lbl_f56fab" xml:lang="en-US">Shares vesting</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FairValueOfOptions" xlink:label="vnrx_FairValueOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FairValueOfOptions" xlink:to="vnrx_FairValueOfOptions_lbl_9e0d04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FairValueOfOptions_lbl_9e0d04" xml:lang="en-US">Fair value of options</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" xlink:label="vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" xlink:to="vnrx_CommonStockSharesIssuableUponExerciseOfStockOption_lbl_d790df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockSharesIssuableUponExerciseOfStockOption_lbl_d790df" xml:lang="en-US">Common stock shares issuable upon exercise of stock option</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ExercisePrice" xlink:to="vnrx_ExercisePrice_lbl_b7af80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_ExercisePrice_lbl_b7af80" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl_874f19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl_874f19" xml:lang="en-US">Maturity Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_590920" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_590920" xml:lang="en-US">Common stock available for issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_eaa8f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_eaa8f4" xml:lang="en-US">Stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VolatilityRate" xlink:label="vnrx_VolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_VolatilityRate" xlink:to="vnrx_VolatilityRate_lbl_7ba87e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_VolatilityRate_lbl_7ba87e" xml:lang="en-US">Volatility rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_72ff6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_72ff6a" xml:lang="en-US">Warrants exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Volatility" xlink:label="vnrx_Volatility" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_Volatility" xlink:to="vnrx_Volatility_lbl_53077f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_Volatility_lbl_53077f" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_2b49d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_2b49d1" xml:lang="en-US">Risk free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_1cd33d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_1cd33d" xml:lang="en-US">Stock option purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestingAggregate" xlink:label="vnrx_VestingAggregate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_VestingAggregate" xlink:to="vnrx_VestingAggregate_lbl_f03b9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_VestingAggregate_lbl_f03b9e" xml:lang="en-US">Vesting aggregate</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggregrateAggregate" xlink:label="vnrx_AggregrateAggregate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AggregrateAggregate" xlink:to="vnrx_AggregrateAggregate_lbl_233d4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AggregrateAggregate_lbl_233d4c" xml:lang="en-US">Aggregrate aggregate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_8d59f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl_8d59f2" xml:lang="en-US">share price</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedAggregate" xlink:label="vnrx_GrantedAggregate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantedAggregate" xlink:to="vnrx_GrantedAggregate_lbl_ff966d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantedAggregate_lbl_ff966d" xml:lang="en-US">Granted aggregate</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedRsu" xlink:label="vnrx_GrantedRsu" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantedRsu" xlink:to="vnrx_GrantedRsu_lbl_f4f564" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantedRsu_lbl_f4f564" xml:lang="en-US">Granted RSU</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DescriptionOfVestingShall" xlink:label="vnrx_DescriptionOfVestingShall" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_DescriptionOfVestingShall" xlink:to="vnrx_DescriptionOfVestingShall_lbl_d07582" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_DescriptionOfVestingShall_lbl_d07582" xml:lang="en-US">Description of vesting shall</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_7453dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_7453dc" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationCost" xlink:label="vnrx_UnrecognizedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnrecognizedCompensationCost" xlink:to="vnrx_UnrecognizedCompensationCost_lbl_a7766e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnrecognizedCompensationCost_lbl_a7766e" xml:lang="en-US">unrecognized compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_a262d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_a262d6" xml:lang="en-US">Intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockCompensationExpenses" xlink:label="vnrx_StockCompensationExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockCompensationExpenses" xlink:to="vnrx_StockCompensationExpenses_lbl_a1484c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockCompensationExpenses_lbl_a1484c" xml:lang="en-US">Stock compensation expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityTerm" xlink:label="vnrx_MaturityTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MaturityTerm" xlink:to="vnrx_MaturityTerm_lbl_797546" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MaturityTerm_lbl_797546" xml:lang="en-US">Vesting term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_3b0218" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_3b0218" xml:lang="en-US">Common stock shares reserved for future issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" xlink:label="us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" xlink:to="us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription_lbl_650e5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription_lbl_650e5b" xml:lang="en-US">Expire description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl_fd3b54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl_fd3b54" xml:lang="en-US">Warrant expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsPurchaseSharesOfCommonStock" xlink:label="vnrx_StockOptionsPurchaseSharesOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockOptionsPurchaseSharesOfCommonStock" xlink:to="vnrx_StockOptionsPurchaseSharesOfCommonStock_lbl_e5596c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockOptionsPurchaseSharesOfCommonStock_lbl_e5596c" xml:lang="en-US">Stock options purchase shares of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl_bcf944" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl_bcf944" xml:lang="en-US">Fair market value of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_87231a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_87231a" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationCostRelatedToNonVestedWarrants" xlink:label="vnrx_CompensationCostRelatedToNonVestedWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CompensationCostRelatedToNonVestedWarrants" xlink:to="vnrx_CompensationCostRelatedToNonVestedWarrants_lbl_0e40dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CompensationCostRelatedToNonVestedWarrants_lbl_0e40dc" xml:lang="en-US">Compensation cost related to non-vested warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl_98d3ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl_98d3ef" xml:lang="en-US">Longterm Debt Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FinanceLeaseObligationsMember" xlink:label="vnrx_FinanceLeaseObligationsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FinanceLeaseObligationsMember" xlink:to="vnrx_FinanceLeaseObligationsMember_lbl_ede5a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FinanceLeaseObligationsMember_lbl_ede5a6" xml:lang="en-US">Finance Lease Obligations [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_a17fe5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_a17fe5" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_718382" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_718382" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Two]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_7c4237" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_7c4237" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_97f77d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_97f77d" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_0d3c92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_0d3c92" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_995b22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_995b22" xml:lang="en-US">Greater than 5 years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_87bff7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_87bff7" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_8" xml:lang="en-US">[Finance Lease, Liability, to be Paid]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LessAmountRepresentingInterest" xlink:label="vnrx_LessAmountRepresentingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LessAmountRepresentingInterest" xlink:to="vnrx_LessAmountRepresentingInterest_lbl_9eaf89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LessAmountRepresentingInterest_lbl_9eaf89" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_9a1e21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl_9a1e21" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl_66e811" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl_66e811" xml:lang="en-US">Other Commitments Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightofUseObligationsMember" xlink:label="vnrx_OperatingLeaseRightofUseObligationsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeaseRightofUseObligationsMember" xlink:to="vnrx_OperatingLeaseRightofUseObligationsMember_lbl_7c8bd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeaseRightofUseObligationsMember_lbl_7c8bd0" xml:lang="en-US">Operating Lease Right of Use Obligations [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_lbl_fcaba6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_lbl_fcaba6" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_lbl_2" xml:lang="en-US">[2023]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" xlink:to="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo_lbl_93b0e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo_lbl_93b0e4" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" xlink:label="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" xlink:to="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo_lbl_3" xml:lang="en-US">[2024]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour_lbl_c86e02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour_lbl_c86e02" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour_lbl_4" xml:lang="en-US">[2025]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive_lbl_29329a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive_lbl_29329a" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive_lbl_5" xml:lang="en-US">[2026]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_lbl_3f5fe0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_lbl_3f5fe0" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_lbl_6" xml:lang="en-US">[2027]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseObligations" xlink:label="vnrx_OperatingLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeaseObligations" xlink:to="vnrx_OperatingLeaseObligations_lbl_559031" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeaseObligations_lbl_559031" xml:lang="en-US">Total Operating Lease Obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LessAmountRepresentingInterest" xlink:to="vnrx_LessAmountRepresentingInterest_lbl_9a64f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_LessAmountRepresentingInterest_lbl_9a64f5" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDue" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDue_lbl_885f4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDue_lbl_885f4d" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDue" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDue" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDue_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDue_lbl_9" xml:lang="en-US">[Present value of minimum lease payments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl_b8c847" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl_b8c847" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl_2" xml:lang="en-US">[2023 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:to="vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl_af8ebd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl_af8ebd" xml:lang="en-US">2024 - 2027</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumLeasePaymentDue" xlink:label="vnrx_OperatingLeasesFutureMinimumLeasePaymentDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesFutureMinimumLeasePaymentDue" xlink:to="vnrx_OperatingLeasesFutureMinimumLeasePaymentDue_lbl_f01166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesFutureMinimumLeasePaymentDue_lbl_f01166" xml:lang="en-US">Total Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayableMember" xlink:label="vnrx_GrantsRepayableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantsRepayableMember" xlink:to="vnrx_GrantsRepayableMember_lbl_62f34f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantsRepayableMember_lbl_62f34f" xml:lang="en-US">Grants Repayable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_lbl_d60fb6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_lbl_d60fb6" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_lbl_2" xml:lang="en-US">[2023 2]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_lbl_ff049b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_lbl_ff049b" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_lbl_3" xml:lang="en-US">[2024 1]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_lbl_ea984c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_lbl_ea984c" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_lbl_4" xml:lang="en-US">[2025 1]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_lbl_7464ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_lbl_7464ad" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_lbl_5" xml:lang="en-US">[2026 1]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_lbl_a79d2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_lbl_a79d2e" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_lbl_6" xml:lang="en-US">[2027 1]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_lbl_581118" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_lbl_581118" xml:lang="en-US">Greater than 5 years</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" xlink:to="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_lbl_7" xml:lang="en-US">[Greater than 5 years]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayable" xlink:label="vnrx_GrantsRepayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantsRepayable" xlink:to="vnrx_GrantsRepayable_lbl_0e578b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantsRepayable_lbl_0e578b" xml:lang="en-US">Total Grants Repayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_5f5c99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_5f5c99" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl_2" xml:lang="en-US">[Long-Term Debt, Maturity, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_c42c62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_c42c62" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl_3" xml:lang="en-US">[Long-Term Debt, Maturity, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_e50b37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_e50b37" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl_4" xml:lang="en-US">[Long-Term Debt, Maturity, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_6b301b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_6b301b" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl_5" xml:lang="en-US">[Long-Term Debt, Maturity, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl_185d39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl_185d39" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl_6" xml:lang="en-US">[Long-Term Debt, Maturity, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:to="us-gaap_LongTermDebtMaturingInYearsFourAndFive_lbl_78b75a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturingInYearsFourAndFive_lbl_78b75a" xml:lang="en-US">Greater than 5 years</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="us-gaap_LongTermDebtMaturingInYearsFourAndFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:to="us-gaap_LongTermDebtMaturingInYearsFourAndFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturingInYearsFourAndFive_lbl_7" xml:lang="en-US">[Long-Term Debt, Maturity, Year Four and Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_d9a06c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_d9a06c" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl_8" xml:lang="en-US">[Long-Term Debt, Maturity, after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LongTermDebtLessAmountRepresentingInterest" xlink:to="vnrx_LongTermDebtLessAmountRepresentingInterest_lbl_772c92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_LongTermDebtLessAmountRepresentingInterest_lbl_772c92" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LongTermDebtLessAmountRepresentingInterest" xlink:label="vnrx_LongTermDebtLessAmountRepresentingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LongTermDebtLessAmountRepresentingInterest" xlink:to="vnrx_LongTermDebtLessAmountRepresentingInterest_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LongTermDebtLessAmountRepresentingInterest_lbl_9" xml:lang="en-US">[Less: Amount representing interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl_d06ca1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl_d06ca1" xml:lang="en-US">Total Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" xlink:label="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" xlink:to="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour_lbl_e09b25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour_lbl_e09b25" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" xlink:to="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_lbl_e12f40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_lbl_e12f40" xml:lang="en-US">2024 - 2027</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" xlink:label="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" xlink:to="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_lbl_3" xml:lang="en-US">[2024 - 2027]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeAgreementObligations" xlink:label="vnrx_CollaborativeAgreementObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CollaborativeAgreementObligations" xlink:to="vnrx_CollaborativeAgreementObligations_lbl_5c2652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CollaborativeAgreementObligations_lbl_5c2652" xml:lang="en-US">Total Collaborative Agreement Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl_7bf306" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl_7bf306" xml:lang="en-US">Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="vnrx_AwardOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AwardOneMember" xlink:to="vnrx_AwardOneMember_lbl_41dbb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AwardOneMember_lbl_41dbb3" xml:lang="en-US">Outstanding Award 1</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="vnrx_OutstandingAwardTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAwardTwoMember" xlink:to="vnrx_OutstandingAwardTwoMember_lbl_0bd84c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OutstandingAwardTwoMember_lbl_0bd84c" xml:lang="en-US">Outstanding Award 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl_6e3ce0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl_6e3ce0" xml:lang="en-US">Outstanding award</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2022" xlink:label="vnrx_AmortisedOfOutstandingAward2022" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAward2022" xlink:to="vnrx_AmortisedOfOutstandingAward2022_lbl_34533c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AmortisedOfOutstandingAward2022_lbl_34533c" xml:lang="en-US">Amortised of outstanding award 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2021" xlink:label="vnrx_AmortisedOfOutstandingAward2021" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAward2021" xlink:to="vnrx_AmortisedOfOutstandingAward2021_lbl_5f1b5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AmortisedOfOutstandingAward2021_lbl_5f1b5c" xml:lang="en-US">Amortised of outstanding award 2021</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward2023" xlink:label="vnrx_UnAmortisedOfOutstandingAward2023" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnAmortisedOfOutstandingAward2023" xlink:to="vnrx_UnAmortisedOfOutstandingAward2023_lbl_45e16a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnAmortisedOfOutstandingAward2023_lbl_45e16a" xml:lang="en-US">Un-amortised of outstanding award 2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl_97a8e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl_97a8e2" xml:lang="en-US">Restricted stock option</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AwardOneMember" xlink:to="vnrx_AwardOneMember_lbl_656008" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_AwardOneMember_lbl_656008" xml:lang="en-US">Outstanding Award 1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAwardTwoMember" xlink:to="vnrx_OutstandingAwardTwoMember_lbl_c4356a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OutstandingAwardTwoMember_lbl_c4356a" xml:lang="en-US">Outstanding Award 2</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl_43c645" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl_43c645" xml:lang="en-US">Outstanding award</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAward2022" xlink:to="vnrx_AmortisedOfOutstandingAward2022_lbl_0d94aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_AmortisedOfOutstandingAward2022_lbl_0d94aa" xml:lang="en-US">Amortised of outstanding award 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAward2021" xlink:to="vnrx_AmortisedOfOutstandingAward2021_lbl_96c860" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_AmortisedOfOutstandingAward2021_lbl_96c860" xml:lang="en-US">Amortised of outstanding award 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnAmortisedOfOutstandingAward2023" xlink:to="vnrx_UnAmortisedOfOutstandingAward2023_lbl_37f058" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_UnAmortisedOfOutstandingAward2023_lbl_37f058" xml:lang="en-US">Un-amortised of outstanding award 2023</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardThreeMember" xlink:label="vnrx_OutstandingAwardThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAwardThreeMember" xlink:to="vnrx_OutstandingAwardThreeMember_lbl_df84bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OutstandingAwardThreeMember_lbl_df84bf" xml:lang="en-US">Outstanding Award 3</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardVestingPeriod" xlink:label="vnrx_OutstandingAwardVestingPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAwardVestingPeriod" xlink:to="vnrx_OutstandingAwardVestingPeriod_lbl_bd0ec2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OutstandingAwardVestingPeriod_lbl_bd0ec2" xml:lang="en-US">Vesting period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAwardAmount" xlink:to="vnrx_AmortisedOfOutstandingAwardAmount_lbl_301f83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_AmortisedOfOutstandingAwardAmount_lbl_301f83" xml:lang="en-US">Amortised of outstanding award 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAwardAmount" xlink:label="vnrx_AmortisedOfOutstandingAwardAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmortisedOfOutstandingAwardAmount" xlink:to="vnrx_AmortisedOfOutstandingAwardAmount_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AmortisedOfOutstandingAwardAmount_lbl_3" xml:lang="en-US">[Amortised of outstanding award 2022]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward" xlink:label="vnrx_UnAmortisedOfOutstandingAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnAmortisedOfOutstandingAward" xlink:to="vnrx_UnAmortisedOfOutstandingAward_lbl_52d1fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnAmortisedOfOutstandingAward_lbl_52d1fb" xml:lang="en-US">Un-amortised of outstanding award</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAward" xlink:to="vnrx_OutstandingAward_lbl_9486ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_OutstandingAward_lbl_9486ce" xml:lang="en-US">Outstanding award</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAward" xlink:label="vnrx_OutstandingAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OutstandingAward" xlink:to="vnrx_OutstandingAward_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OutstandingAward_lbl_5" xml:lang="en-US">[Outstanding award]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_40d7eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_40d7eb" xml:lang="en-US">Title Of Individual Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl_5753c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl_5753c3" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others By Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_06ff98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_06ff98" xml:lang="en-US">Related Party Transaction Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis" xlink:label="us-gaap_CollectiveBargainingArrangementAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollectiveBargainingArrangementAxis" xlink:to="us-gaap_CollectiveBargainingArrangementAxis_lbl_fa682e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollectiveBargainingArrangementAxis_lbl_fa682e" xml:lang="en-US">Collective Bargaining Arrangement Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl_f2cf8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl_f2cf8d" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WalloonRegionGovernmentMember" xlink:label="vnrx_WalloonRegionGovernmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_WalloonRegionGovernmentMember" xlink:to="vnrx_WalloonRegionGovernmentMember_lbl_da818f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_WalloonRegionGovernmentMember_lbl_da818f" xml:lang="en-US">Walloon Region Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsTwentyTwentyMember" xlink:label="vnrx_InTwoThousandsTwentyTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandsTwentyTwentyMember" xlink:to="vnrx_InTwoThousandsTwentyTwentyMember_lbl_932dba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InTwoThousandsTwentyTwentyMember_lbl_932dba" xml:lang="en-US">In 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFundingAgreementTermsMember" xlink:to="us-gaap_AdditionalFundingAgreementTermsMember_lbl_6400df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFundingAgreementTermsMember_lbl_6400df" xml:lang="en-US">Colorectal Cancer Research Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInvestMember" xlink:label="vnrx_NamurInvestMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NamurInvestMember" xlink:to="vnrx_NamurInvestMember_lbl_7eca49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NamurInvestMember_lbl_7eca49" xml:lang="en-US">Namur Invest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2016Member" xlink:label="vnrx_In2016Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_In2016Member" xlink:to="vnrx_In2016Member_lbl_deb518" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_In2016Member_lbl_deb518" xml:lang="en-US">In 2016 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl_f70b1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMember_lbl_f70b1e" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementMember" xlink:label="vnrx_LoanAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LoanAgreementMember" xlink:to="vnrx_LoanAgreementMember_lbl_c56293" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LoanAgreementMember_lbl_c56293" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_INGMember" xlink:label="vnrx_INGMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_INGMember" xlink:to="vnrx_INGMember_lbl_936c4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_INGMember_lbl_936c4b" xml:lang="en-US">ING [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNineteenMember" xlink:label="vnrx_InTwoThousandNineteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandNineteenMember" xlink:to="vnrx_InTwoThousandNineteenMember_lbl_be3a8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InTwoThousandNineteenMember_lbl_be3a8b" xml:lang="en-US">In 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2018Member" xlink:label="vnrx_In2018Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_In2018Member" xlink:to="vnrx_In2018Member_lbl_069d60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_In2018Member_lbl_069d60" xml:lang="en-US">In 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInnovationAndGrowthMember" xlink:label="vnrx_NamurInnovationAndGrowthMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NamurInnovationAndGrowthMember" xlink:to="vnrx_NamurInnovationAndGrowthMember_lbl_3ad939" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NamurInnovationAndGrowthMember_lbl_3ad939" xml:lang="en-US">Namur Innovation and Growth [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SOFINEXMember" xlink:label="vnrx_SOFINEXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SOFINEXMember" xlink:to="vnrx_SOFINEXMember_lbl_5691e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SOFINEXMember_lbl_5691e9" xml:lang="en-US">SOFINEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2017Member" xlink:label="vnrx_In2017Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_In2017Member" xlink:to="vnrx_In2017Member_lbl_f9745a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_In2017Member_lbl_f9745a" xml:lang="en-US">In 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" xlink:label="vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" xlink:to="vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_lbl_92108d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_lbl_92108d" xml:lang="en-US">November 23, 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" xlink:label="vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" xlink:to="vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_lbl_41c9f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_lbl_41c9f4" xml:lang="en-US">February 5, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstInsuranceFundingMember" xlink:label="vnrx_FirstInsuranceFundingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FirstInsuranceFundingMember" xlink:to="vnrx_FirstInsuranceFundingMember_lbl_68d53c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FirstInsuranceFundingMember_lbl_68d53c" xml:lang="en-US">First Insurance Funding [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnSeptemberSixteenTwohousandtwentyMember" xlink:label="vnrx_OnSeptemberSixteenTwohousandtwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OnSeptemberSixteenTwohousandtwentyMember" xlink:to="vnrx_OnSeptemberSixteenTwohousandtwentyMember_lbl_1016b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OnSeptemberSixteenTwohousandtwentyMember_lbl_1016b5" xml:lang="en-US">On September 16, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" xlink:label="vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" xlink:to="vnrx_BioinformaticAnalyticsOfCellFreeDNAMember_lbl_72747f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_BioinformaticAnalyticsOfCellFreeDNAMember_lbl_72747f" xml:lang="en-US">Bioinformatic Analytics Of Cell Free DNA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnivercityOfTexasMDMember" xlink:label="vnrx_UnivercityOfTexasMDMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnivercityOfTexasMDMember" xlink:to="vnrx_UnivercityOfTexasMDMember_lbl_d2fdb2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnivercityOfTexasMDMember_lbl_d2fdb2" xml:lang="en-US">Univercity Of Texas MD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustTenTwoThousandTwentyTwoMember" xlink:label="vnrx_AugustTenTwoThousandTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AugustTenTwoThousandTwentyTwoMember" xlink:to="vnrx_AugustTenTwoThousandTwentyTwoMember_lbl_baf6ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AugustTenTwoThousandTwentyTwoMember_lbl_baf6ad" xml:lang="en-US">August Ten Two Thousand Twenty Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandNinteenMember" xlink:to="vnrx_InTwoThousandNinteenMember_lbl_fe9a5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_InTwoThousandNinteenMember_lbl_fe9a5d" xml:lang="en-US">In 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNinteenMember" xlink:label="vnrx_InTwoThousandNinteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandNinteenMember" xlink:to="vnrx_InTwoThousandNinteenMember_lbl_203" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InTwoThousandNinteenMember_lbl_203" xml:lang="en-US">[In 2019 [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeArrangementCoPromotionMember" xlink:label="vnrx_CollaborativeArrangementCoPromotionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CollaborativeArrangementCoPromotionMember" xlink:to="vnrx_CollaborativeArrangementCoPromotionMember_lbl_88d634" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CollaborativeArrangementCoPromotionMember_lbl_88d634" xml:lang="en-US">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UniversityOfTaiwanMember" xlink:label="vnrx_UniversityOfTaiwanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UniversityOfTaiwanMember" xlink:to="vnrx_UniversityOfTaiwanMember_lbl_70ff5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UniversityOfTaiwanMember_lbl_70ff5b" xml:lang="en-US">University of Taiwan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandsEightteenMember" xlink:to="vnrx_InTwoThousandsEightteenMember_lbl_6a2e5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_InTwoThousandsEightteenMember_lbl_6a2e5a" xml:lang="en-US">In 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsEightteenMember" xlink:label="vnrx_InTwoThousandsEightteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandsEightteenMember" xlink:to="vnrx_InTwoThousandsEightteenMember_lbl_206" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InTwoThousandsEightteenMember_lbl_206" xml:lang="en-US">[In 2018 [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ClinicalStudyResearchAgreementMember" xlink:label="vnrx_ClinicalStudyResearchAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ClinicalStudyResearchAgreementMember" xlink:to="vnrx_ClinicalStudyResearchAgreementMember_lbl_a12375" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ClinicalStudyResearchAgreementMember_lbl_a12375" xml:lang="en-US">Clinical Study Research Agreement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandTwentyMember" xlink:to="vnrx_InTwoThousandTwentyMember_lbl_fcf102" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_InTwoThousandTwentyMember_lbl_fcf102" xml:lang="en-US">In 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandTwentyMember" xlink:label="vnrx_InTwoThousandTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_InTwoThousandTwentyMember" xlink:to="vnrx_InTwoThousandTwentyMember_lbl_208" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_InTwoThousandTwentyMember_lbl_208" xml:lang="en-US">[In 2020 [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BNPParibasLeasingSolutionsMember" xlink:label="vnrx_BNPParibasLeasingSolutionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_BNPParibasLeasingSolutionsMember" xlink:to="vnrx_BNPParibasLeasingSolutionsMember_lbl_f88584" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_BNPParibasLeasingSolutionsMember_lbl_f88584" xml:lang="en-US">BNP Paribas leasing solutions [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FinanceLeaseObligationsMember" xlink:to="vnrx_FinanceLeaseObligationsMember_lbl_fa053f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_FinanceLeaseObligationsMember_lbl_fa053f" xml:lang="en-US">Finance Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagingDirectorsAgreementMember" xlink:label="vnrx_ManagingDirectorsAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ManagingDirectorsAgreementMember" xlink:to="vnrx_ManagingDirectorsAgreementMember_lbl_0042bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ManagingDirectorsAgreementMember_lbl_0042bc" xml:lang="en-US">Managing Director's Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlanMember" xlink:label="vnrx_StockIncentivePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_StockIncentivePlanMember" xlink:to="vnrx_StockIncentivePlanMember_lbl_e80b22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_StockIncentivePlanMember_lbl_e80b22" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2010Member" xlink:label="vnrx_In2010Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_In2010Member" xlink:to="vnrx_In2010Member_lbl_b8324e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_In2010Member_lbl_b8324e" xml:lang="en-US">In 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurMember" xlink:label="vnrx_NamurMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_NamurMember" xlink:to="vnrx_NamurMember_lbl_6b3dfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_NamurMember_lbl_6b3dfe" xml:lang="en-US">Namur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SixteenAugustTwoThounsendTwentyTwoMember" xlink:label="vnrx_SixteenAugustTwoThounsendTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SixteenAugustTwoThounsendTwentyTwoMember" xlink:to="vnrx_SixteenAugustTwoThounsendTwentyTwoMember_lbl_dbd7f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SixteenAugustTwoThounsendTwentyTwoMember_lbl_dbd7f9" xml:lang="en-US">August 16, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" xlink:label="vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" xlink:to="vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_lbl_7c538a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_lbl_7c538a" xml:lang="en-US">November 18, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PerformanceBasedAwardMember" xlink:label="vnrx_PerformanceBasedAwardMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PerformanceBasedAwardMember" xlink:to="vnrx_PerformanceBasedAwardMember_lbl_078ff4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PerformanceBasedAwardMember_lbl_078ff4" xml:lang="en-US">Performance Based Award [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2023Member" xlink:label="vnrx_VestIn2023Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_VestIn2023Member" xlink:to="vnrx_VestIn2023Member_lbl_3ae8bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_VestIn2023Member_lbl_3ae8bb" xml:lang="en-US">Vest In 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2024Member" xlink:label="vnrx_VestIn2024Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_VestIn2024Member" xlink:to="vnrx_VestIn2024Member_lbl_c5cbaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_VestIn2024Member_lbl_c5cbaf" xml:lang="en-US">Vest In 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepyable" xlink:label="vnrx_GrantRepyable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantRepyable" xlink:to="vnrx_GrantRepyable_lbl_4376f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantRepyable_lbl_4376f2" xml:lang="en-US">Grant Repyable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LongTermDebtPayable" xlink:label="vnrx_LongTermDebtPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LongTermDebtPayable" xlink:to="vnrx_LongTermDebtPayable_lbl_374d64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LongTermDebtPayable_lbl_374d64" xml:lang="en-US">Long-term debt payable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsForFutureResearchAndCollobration" xlink:label="vnrx_PaymentsForFutureResearchAndCollobration" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PaymentsForFutureResearchAndCollobration" xlink:to="vnrx_PaymentsForFutureResearchAndCollobration_lbl_f958ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PaymentsForFutureResearchAndCollobration_lbl_f958ad" xml:lang="en-US">Payments For Future Research And Collobration</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyalityOnRevenuePercentange" xlink:label="vnrx_RoyalityOnRevenuePercentange" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RoyalityOnRevenuePercentange" xlink:to="vnrx_RoyalityOnRevenuePercentange_lbl_28b576" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RoyalityOnRevenuePercentange_lbl_28b576" xml:lang="en-US">RoyalityOnRevenuePercentange</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggerateAmountPayableDescription" xlink:label="vnrx_AggerateAmountPayableDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AggerateAmountPayableDescription" xlink:to="vnrx_AggerateAmountPayableDescription_lbl_4117dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AggerateAmountPayableDescription_lbl_4117dd" xml:lang="en-US">Aggerate Amount Payable, Description</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountPayable" xlink:label="vnrx_AmountPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmountPayable" xlink:to="vnrx_AmountPayable_lbl_2e05d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AmountPayable_lbl_2e05d4" xml:lang="en-US">Amount payable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PayableByCompanyForServicesRendered" xlink:label="vnrx_PayableByCompanyForServicesRendered" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_PayableByCompanyForServicesRendered" xlink:to="vnrx_PayableByCompanyForServicesRendered_lbl_84e107" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_PayableByCompanyForServicesRendered_lbl_84e107" xml:lang="en-US">Payable By Company For Services Rendered</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnit" xlink:label="vnrx_RestrictedStockUnit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RestrictedStockUnit" xlink:to="vnrx_RestrictedStockUnit_lbl_293673" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RestrictedStockUnit_lbl_293673" xml:lang="en-US">Restricted stock unit</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AccruedCompensationExpense" xlink:label="vnrx_AccruedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AccruedCompensationExpense" xlink:to="vnrx_AccruedCompensationExpense_lbl_7cbb59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AccruedCompensationExpense_lbl_7cbb59" xml:lang="en-US">Accrued compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpense" xlink:label="vnrx_UnrecognizedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnrecognizedCompensationExpense" xlink:to="vnrx_UnrecognizedCompensationExpense_lbl_1eeca4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnrecognizedCompensationExpense_lbl_1eeca4" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:to="us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_lbl_9e193b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_lbl_9e193b" xml:lang="en-US">Purchase Price For The Property</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityDate" xlink:label="vnrx_MaturityDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_MaturityDate" xlink:to="vnrx_MaturityDate_lbl_a8f6c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_MaturityDate_lbl_a8f6c4" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ImplicitInterest" xlink:label="vnrx_ImplicitInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ImplicitInterest" xlink:to="vnrx_ImplicitInterest_lbl_d9dbef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ImplicitInterest_lbl_d9dbef" xml:lang="en-US">Implicit Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeasedEquipmentAmortizedPeriod" xlink:label="vnrx_LeasedEquipmentAmortizedPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LeasedEquipmentAmortizedPeriod" xlink:to="vnrx_LeasedEquipmentAmortizedPeriod_lbl_54960a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LeasedEquipmentAmortizedPeriod_lbl_54960a" xml:lang="en-US">Leased Equipment Amortized Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl_7021c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl_7021c9" xml:lang="en-US">Royalty Payment</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Royality" xlink:label="vnrx_Royality" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_Royality" xlink:to="vnrx_Royality_lbl_8399d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_Royality_lbl_8399d3" xml:lang="en-US">Royality</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnrecognizedCompensationExpenses" xlink:to="vnrx_UnrecognizedCompensationExpenses_lbl_95f592" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_UnrecognizedCompensationExpenses_lbl_95f592" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpenses" xlink:label="vnrx_UnrecognizedCompensationExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_UnrecognizedCompensationExpenses" xlink:to="vnrx_UnrecognizedCompensationExpenses_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_UnrecognizedCompensationExpenses_lbl_18" xml:lang="en-US">[Unrecognized compensation expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVested" xlink:label="vnrx_RSuVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RSuVested" xlink:to="vnrx_RSuVested_lbl_8ad56d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RSuVested_lbl_8ad56d" xml:lang="en-US">RSu Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2024" xlink:label="vnrx_RSuVestedIn2024" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RSuVestedIn2024" xlink:to="vnrx_RSuVestedIn2024_lbl_bf05f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RSuVestedIn2024_lbl_bf05f1" xml:lang="en-US">RSu Vested in 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2025" xlink:label="vnrx_RSuVestedIn2025" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RSuVestedIn2025" xlink:to="vnrx_RSuVestedIn2025_lbl_b0802a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RSuVestedIn2025_lbl_b0802a" xml:lang="en-US">RSu Vested in 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightOfUseAssets" xlink:label="vnrx_OperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeaseRightOfUseAssets" xlink:to="vnrx_OperatingLeaseRightOfUseAssets_lbl_13657a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeaseRightOfUseAssets_lbl_13657a" xml:lang="en-US">Operating Lease Right-of-use Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesLiability1" xlink:label="vnrx_OperatingLeasesLiability1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_OperatingLeasesLiability1" xlink:to="vnrx_OperatingLeasesLiability1_lbl_8651cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_OperatingLeasesLiability1_lbl_8651cf" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_03629c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_03629c" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl_177e9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl_177e9b" xml:lang="en-US">Payment Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl_08840d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl_08840d" xml:lang="en-US">Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl_8f3776" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl_8f3776" xml:lang="en-US">Short Term Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_60050c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_60050c" xml:lang="en-US">Stock Option Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl_b0506a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl_b0506a" xml:lang="en-US">Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl_77ef3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl_77ef3f" xml:lang="en-US">Total Of Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl_a705ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl_a705ed" xml:lang="en-US">Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRateOnLease" xlink:label="vnrx_FixedInterestRateOnLease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FixedInterestRateOnLease" xlink:to="vnrx_FixedInterestRateOnLease_lbl_85ec00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FixedInterestRateOnLease_lbl_85ec00" xml:lang="en-US">Fixed Interest Rate On Lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_4d2b9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_4d2b9b" xml:lang="en-US">Lease Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentOfGrants" xlink:label="vnrx_RepaymentOfGrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RepaymentOfGrants" xlink:to="vnrx_RepaymentOfGrants_lbl_627bec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RepaymentOfGrants_lbl_627bec" xml:lang="en-US">Repayment Of Grants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_d40101" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncome_lbl_d40101" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfAgreementDescription" xlink:label="vnrx_TermsOfAgreementDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TermsOfAgreementDescription" xlink:to="vnrx_TermsOfAgreementDescription_lbl_b24619" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_TermsOfAgreementDescription_lbl_b24619" xml:lang="en-US">Terms Of Agreement Description</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountRepayable" xlink:label="vnrx_AmountRepayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AmountRepayable" xlink:to="vnrx_AmountRepayable_lbl_1bc0a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AmountRepayable_lbl_1bc0a7" xml:lang="en-US">Amount Repayable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl_0d6313" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl_0d6313" xml:lang="en-US">Grant Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepaidByInstallments" xlink:label="vnrx_GrantRepaidByInstallments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_GrantRepaidByInstallments" xlink:to="vnrx_GrantRepaidByInstallments_lbl_55b8d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_GrantRepaidByInstallments_lbl_55b8d5" xml:lang="en-US">Grant Repaid By Installments</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementTerm" xlink:label="vnrx_LoanAgreementTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LoanAgreementTerm" xlink:to="vnrx_LoanAgreementTerm_lbl_765cf3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LoanAgreementTerm_lbl_765cf3" xml:lang="en-US">Loan Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentsOfLongtermLoans" xlink:label="vnrx_RepaymentsOfLongtermLoans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RepaymentsOfLongtermLoans" xlink:to="vnrx_RepaymentsOfLongtermLoans_lbl_963cca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RepaymentsOfLongtermLoans_lbl_963cca" xml:lang="en-US">Repayment Of Long-term Loan Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRate" xlink:label="vnrx_FixedInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_FixedInterestRate" xlink:to="vnrx_FixedInterestRate_lbl_c996f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_FixedInterestRate_lbl_c996f1" xml:lang="en-US">Fixed Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LineOfCreditFacilityExpirationDatesOne" xlink:to="vnrx_LineOfCreditFacilityExpirationDatesOne_lbl_568b53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_LineOfCreditFacilityExpirationDatesOne_lbl_568b53" xml:lang="en-US">Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LineOfCreditFacilityExpirationDatesOne" xlink:label="vnrx_LineOfCreditFacilityExpirationDatesOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LineOfCreditFacilityExpirationDatesOne" xlink:to="vnrx_LineOfCreditFacilityExpirationDatesOne_lbl_44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LineOfCreditFacilityExpirationDatesOne_lbl_44" xml:lang="en-US">[Maturity Date]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_b8de3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl_b8de3c" xml:lang="en-US">Total Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable" xlink:label="us-gaap_OtherNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl_ca9d8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl_ca9d8b" xml:lang="en-US">Principal Balance Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AgreementUnderAmount" xlink:label="vnrx_AgreementUnderAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AgreementUnderAmount" xlink:to="vnrx_AgreementUnderAmount_lbl_432963" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AgreementUnderAmount_lbl_432963" xml:lang="en-US">Agreement Under Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AdditionalCostOfCompany" xlink:label="vnrx_AdditionalCostOfCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_AdditionalCostOfCompany" xlink:to="vnrx_AdditionalCostOfCompany_lbl_e0b4d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_AdditionalCostOfCompany_lbl_e0b4d7" xml:lang="en-US">Additional Cost Of Company</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmountDue" xlink:label="vnrx_CollaborativeObligationsAmountDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CollaborativeObligationsAmountDue" xlink:to="vnrx_CollaborativeObligationsAmountDue_lbl_145749" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CollaborativeObligationsAmountDue_lbl_145749" xml:lang="en-US">Collaborative Obligations Amount Due</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriods" xlink:label="vnrx_LeaseAgreementExpirePeriods" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LeaseAgreementExpirePeriods" xlink:to="vnrx_LeaseAgreementExpirePeriods_lbl_fd4e83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LeaseAgreementExpirePeriods_lbl_fd4e83" xml:lang="en-US">Lease Agreement Expire Period</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmount" xlink:label="vnrx_CollaborativeObligationsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CollaborativeObligationsAmount" xlink:to="vnrx_CollaborativeObligationsAmount_lbl_08ab1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CollaborativeObligationsAmount_lbl_08ab1d" xml:lang="en-US">Collaborative Obligations Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LeaseAgreementExpirePeriod" xlink:to="vnrx_LeaseAgreementExpirePeriod_lbl_105690" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_LeaseAgreementExpirePeriod_lbl_105690" xml:lang="en-US">Lease Agreement Expire Period</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriod" xlink:label="vnrx_LeaseAgreementExpirePeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_LeaseAgreementExpirePeriod" xlink:to="vnrx_LeaseAgreementExpirePeriod_lbl_52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_LeaseAgreementExpirePeriod_lbl_52" xml:lang="en-US">[Lease Agreement Expire Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl_fce177" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OptionMember_lbl_fce177" xml:lang="en-US">Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="vnrx_TwoThousandFifteenEquityIncentivePlanMember_lbl_401ef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="vnrx_TwoThousandFifteenEquityIncentivePlanMember_lbl_401ef7" xml:lang="en-US">2015 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalRaiseMember" xlink:label="vnrx_CapitalRaiseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CapitalRaiseMember" xlink:to="vnrx_CapitalRaiseMember_lbl_95398d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CapitalRaiseMember_lbl_95398d" xml:lang="en-US">Capital Raise [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingEventMember" xlink:label="vnrx_RsuVestingEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RsuVestingEventMember" xlink:to="vnrx_RsuVestingEventMember_lbl_e4b77e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RsuVestingEventMember_lbl_e4b77e" xml:lang="en-US">RSU Vesting [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuancesAndRepurchasesMember" xlink:label="vnrx_CommonStockIssuancesAndRepurchasesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockIssuancesAndRepurchasesMember" xlink:to="vnrx_CommonStockIssuancesAndRepurchasesMember_lbl_845940" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockIssuancesAndRepurchasesMember_lbl_845940" xml:lang="en-US">Common Stock Issuances And Repurchases [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_7542e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_7542e9" xml:lang="en-US">Shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_b15ca3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl_b15ca3" xml:lang="en-US">Share price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_99e3df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_99e3df" xml:lang="en-US">Proceed from sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:to="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl_23699d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl_23699d" xml:lang="en-US">RSUs, vested</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingDescription" xlink:label="vnrx_RsuVestingDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_RsuVestingDescription" xlink:to="vnrx_RsuVestingDescription_lbl_55af1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_RsuVestingDescription_lbl_55af1d" xml:lang="en-US">Description of rsu vesting</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_100c93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_100c93" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesWithheldForTaxes" xlink:label="vnrx_CommonStockSharesWithheldForTaxes" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockSharesWithheldForTaxes" xlink:to="vnrx_CommonStockSharesWithheldForTaxes_lbl_9cbd4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockSharesWithheldForTaxes_lbl_9cbd4d" xml:lang="en-US">Common stock, shares withheld for taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_f21cd9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl_f21cd9" xml:lang="en-US">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfCommonStock" xlink:label="vnrx_SaleOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_SaleOfCommonStock" xlink:to="vnrx_SaleOfCommonStock_lbl_4f4569" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_SaleOfCommonStock_lbl_4f4569" xml:lang="en-US">Sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharePurchase" xlink:label="vnrx_CommonStockSharePurchase" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockSharePurchase" xlink:to="vnrx_CommonStockSharePurchase_lbl_3bec81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockSharePurchase_lbl_3bec81" xml:lang="en-US">Common stock, share purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPerShare" xlink:label="vnrx_CommonStockPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CommonStockPerShare" xlink:to="vnrx_CommonStockPerShare_lbl_30519c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CommonStockPerShare_lbl_30519c" xml:lang="en-US">Common stock, per share</link:label>
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CostOfTheCompany" xlink:label="vnrx_CostOfTheCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vnrx_CostOfTheCompany" xlink:to="vnrx_CostOfTheCompany_lbl_f865fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vnrx_CostOfTheCompany_lbl_f865fc" xml:lang="en-US">Total cost of the company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="vnrx_ExercisePrice" xlink:to="vnrx_ExercisePrice_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="vnrx_ExercisePrice_d">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:to="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_d">Number of non-option equity instruments exercised by participants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="vnrx_MaturityTerm" xlink:to="vnrx_MaturityTerm_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="vnrx_MaturityTerm_d">Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen da</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="vnrx_CompensationCostRelatedToNonVestedWarrants" xlink:to="vnrx_CompensationCostRelatedToNonVestedWarrants_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="vnrx_CompensationCostRelatedToNonVestedWarrants_d">Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="vnrx_GrantsRepayable" xlink:to="vnrx_GrantsRepayable_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="vnrx_GrantsRepayable_d">Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>vnrx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03-15-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/NatureOfOperations" xlink:href="vnrx-20221231.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipment" xlink:href="vnrx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssets" xlink:href="vnrx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/RelatedPartyTransactions" xlink:href="vnrx-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStock" xlink:href="vnrx-20221231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensation" xlink:href="vnrx-20221231.xsd#StockbasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxes" xlink:href="vnrx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingencies" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEvents" xlink:href="vnrx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnrx-20221231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockTables" xlink:href="vnrx-20221231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsTables" xlink:href="vnrx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationTables" xlink:href="vnrx-20221231.xsd#StockbasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesTables" xlink:href="vnrx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails1" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails2" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails" xlink:href="vnrx-20221231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails1" xlink:href="vnrx-20221231.xsd#CommonStockDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:href="vnrx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CurrentPortionOfGrantRepayable" xlink:label="loc_vnrxCurrentPortionOfGrantRepayable" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_vnrxCurrentPortionOfGrantRepayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepayableNetOfCurrentPortion" xlink:label="loc_vnrxGrantRepayableNetOfCurrentPortion" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_vnrxGrantRepayableNetOfCurrentPortion" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalVolitionrxLimitedStockholdersEquity" xlink:label="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_vnrxTotalVolitionrxLimitedStockholdersEquity" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MinorityInterests" xlink:label="loc_vnrxMinorityInterests" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_vnrxMinorityInterests" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyaltyRevenue" xlink:label="loc_vnrxRoyaltyRevenue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_vnrxRoyaltyRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ServiceRevenue" xlink:label="loc_vnrxServiceRevenue" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_vnrxServiceRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProductRevenue" xlink:label="loc_vnrxProductRevenue" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_vnrxProductRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeFromGrants" xlink:label="loc_vnrxIncomeFromGrants" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherIncome" xlink:to="loc_vnrxIncomeFromGrants" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LossOnDisposalOfFixedAssets" xlink:label="loc_vnrxLossOnDisposalOfFixedAssets" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherIncome" xlink:to="loc_vnrxLossOnDisposalOfFixedAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherIncome" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherIncome" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OthersComprehensiveIncomeLossNetOfTax" xlink:label="loc_vnrxOthersComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxOthersComprehensiveIncomeLossNetOfTax" xlink:to="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnrxOthersComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_vnrxIncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_vnrxIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagementAndDirectorsFeesPayable" xlink:label="loc_vnrxManagementAndDirectorsFeesPayable" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_vnrxManagementAndDirectorsFeesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProceedsFromGrantsRepayable" xlink:label="loc_vnrxProceedsFromGrantsRepayable" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_vnrxProceedsFromGrantsRepayable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfOtherLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnGrantsRepayable" xlink:label="loc_vnrxPaymentsOnGrantsRepayable" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_vnrxPaymentsOnGrantsRepayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnFinancingLeasesLeaseAmount" xlink:label="loc_vnrxPaymentsOnFinancingLeasesLeaseAmount" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_vnrxPaymentsOnFinancingLeasesLeaseAmount" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/NatureOfOperations" xlink:title="000007 - Disclosure - Nature of Operations" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:title="000008 - Disclosure - Liquidity and Going Concern Assessment" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - Summary of Significant Accounting Policies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipment" xlink:title="000010 - Disclosure - Property and Equipment" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssets" xlink:title="000011 - Disclosure - Intangible Assets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/RelatedPartyTransactions" xlink:title="000012 - Disclosure - Related Party Transactions" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStock" xlink:title="000013 - Disclosure - Common Stock" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensation" xlink:title="000014 - Disclosure - StockBased Compensation" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxes" xlink:title="000015 - Disclosure - Income Taxes" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEvents" xlink:title="000017 - Disclosure - Subsequent Events" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:title="000019 - Disclosure - Property and Equipment (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockTables" xlink:title="000020 - Disclosure - Common Stock (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsTables" xlink:title="000021 - Disclosure - Intangible Assets (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationTables" xlink:title="000022 - Disclosure - StockBased Compensation (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesTables" xlink:title="000023 - Disclosure - Income Taxes (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:title="000024 - Disclosure - Commitments and Contingencies (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:title="000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:title="000027 - Disclosure - Property and Equipment (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000028 - Disclosure - Property and Equipment (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails" xlink:title="000029 - Disclosure - Intangible Assets (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:title="000030 - Disclosure - Intangible Assets (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Intangible Assets (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails" xlink:title="000032 - Disclosure - Income Taxes (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails1" xlink:title="000033 - Disclosure - Income Taxes (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails2" xlink:title="000034 - Disclosure - Income Taxes (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="000035 - Disclosure - Income Taxes (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails" xlink:title="000036 - Disclosure - Common Stock (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails1" xlink:title="000037 - Disclosure - Common Stock (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:title="000038 - Disclosure - Common Stock (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails" xlink:title="000039 - Disclosure - StockBased Compensation (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:title="000040 - Disclosure - StockBased Compensation (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:title="000041 - Disclosure - StockBased Compensation (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:title="000042 - Disclosure - StockBased Compensation (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:title="000043 - Disclosure - StockBased Compensation (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:title="000044 - Disclosure - StockBased Compensation (Details 5)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:title="000045 - Disclosure - StockBased Compensation (Details 6)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:title="000046 - Disclosure - StockBased Compensation (Details 7)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:title="000047 - Disclosure - StockBased Compensation (Details 8)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:title="000048 - Disclosure - StockBased Compensation (Details 9)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000049 - Disclosure - StockBased Compensation (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - Commitments and Contingencies (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - Commitments and Contingencies (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:title="000052 - Disclosure - Commitments and Contingencies (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:title="000053 - Disclosure - Commitments and Contingencies (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:title="000054 - Disclosure - Commitments and Contingencies (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:title="000055 - Disclosure - Commitments and Contingencies (Details 5)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:title="000056 - Disclosure - Commitments and Contingencies (Details 6)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:title="000057 - Disclosure - Commitments and Contingencies (Details 7)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:title="000058 - Disclosure - Commitments and Contingencies (Details 8)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000059 - Disclosure - Commitments and Contingencies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:title="000060 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vnrx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03-15-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/NatureOfOperations" xlink:href="vnrx-20221231.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipment" xlink:href="vnrx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssets" xlink:href="vnrx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/RelatedPartyTransactions" xlink:href="vnrx-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStock" xlink:href="vnrx-20221231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensation" xlink:href="vnrx-20221231.xsd#StockbasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxes" xlink:href="vnrx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingencies" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEvents" xlink:href="vnrx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnrx-20221231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockTables" xlink:href="vnrx-20221231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsTables" xlink:href="vnrx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationTables" xlink:href="vnrx-20221231.xsd#StockbasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesTables" xlink:href="vnrx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails1" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails2" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails" xlink:href="vnrx-20221231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails1" xlink:href="vnrx-20221231.xsd#CommonStockDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:href="vnrx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_c4d20e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_56ae9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_c4d20e" xlink:to="loc_us-gaapAssetsAbstract_56ae9a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_611e16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_56ae9a" xlink:to="loc_us-gaapAssetsCurrentAbstract_611e16" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_fefb7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_fefb7b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_a50ee8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_a50ee8" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_4c935a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapPrepaidExpenseCurrent_4c935a" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_d176f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapOtherAssetsCurrent_d176f6" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_fb173e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapAssetsCurrent_fb173e" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_cd5608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_cd5608" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_7dc89a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_7dc89a" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_49b72b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_49b72b" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_329a29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapAssets_329a29" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_a27a2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_611e16" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_a27a2d" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_a27a2d" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_f690e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapAccountsPayableCurrent_f690e6" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_5be55e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_5be55e" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_58e239" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapDeferredRevenueCurrent_58e239" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_feea0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapManagementFeePayable_feea0d" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent_454e89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapLongTermDebtCurrent_454e89" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_662328" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_662328" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_7dc8a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_7dc8a9" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CurrentPortionOfGrantRepayable" xlink:label="loc_vnrxCurrentPortionOfGrantRepayable_e98dd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_vnrxCurrentPortionOfGrantRepayable_e98dd8" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_d7f9d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapLiabilitiesCurrent_d7f9d9" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_73be8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapLongTermDebtNoncurrent_73be8a" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_569b0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_569b0d" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_230d78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_230d78" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepayableNetOfCurrentPortion" xlink:label="loc_vnrxGrantRepayableNetOfCurrentPortion_3c3c5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_vnrxGrantRepayableNetOfCurrentPortion_3c3c5a" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_726f2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapLiabilities_726f2c" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_b875b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_0c7de2" xlink:to="loc_us-gaapStockholdersEquityAbstract_b875b7" order="28" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockAbstract" xlink:label="loc_vnrxCommonStockAbstract_20fbb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_b875b7" xlink:to="loc_vnrxCommonStockAbstract_20fbb7" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_6cc151" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapCommonStockValue_6cc151" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_9b6313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapAdditionalPaidInCapital_9b6313" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_859312" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_859312" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_5cab03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_5cab03" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalVolitionrxLimitedStockholdersEquity" xlink:label="loc_vnrxTotalVolitionrxLimitedStockholdersEquity_0775bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_vnrxTotalVolitionrxLimitedStockholdersEquity_0775bd" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MinorityInterests" xlink:label="loc_vnrxMinorityInterests_29b7ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_vnrxMinorityInterests_29b7ee" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_58a524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapStockholdersEquity_58a524" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_963e5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxCommonStockAbstract_20fbb7" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_963e5b" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_9ee96f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_251be8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_9ee96f" xlink:to="loc_us-gaapCommonStockSharesAuthorized_251be8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_e748e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_9ee96f" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_e748e9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_944e0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_9ee96f" xlink:to="loc_us-gaapCommonStockSharesIssued_944e0f" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_55a7c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_9ee96f" xlink:to="loc_us-gaapCommonStockSharesOutstanding_55a7c3" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_1519b9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_cec8bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_1519b9" xlink:to="loc_us-gaapRevenuesAbstract_cec8bf" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyaltyRevenue" xlink:label="loc_vnrxRoyaltyRevenue_bf3d35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_cec8bf" xlink:to="loc_vnrxRoyaltyRevenue_bf3d35" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ServiceRevenue" xlink:label="loc_vnrxServiceRevenue_ef1d11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_cec8bf" xlink:to="loc_vnrxServiceRevenue_ef1d11" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProductRevenue" xlink:label="loc_vnrxProductRevenue_6ac6d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_cec8bf" xlink:to="loc_vnrxProductRevenue_6ac6d9" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_a3b618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_cec8bf" xlink:to="loc_us-gaapRevenues_a3b618" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_78bae7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_cec8bf" xlink:to="loc_us-gaapOperatingExpensesAbstract_78bae7" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_b9fe6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_b9fe6a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_7418f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_7418f5" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_37d3c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapSellingAndMarketingExpense_37d3c0" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_fb8371" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapOperatingExpenses_fb8371" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_39bfb1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapOperatingIncomeLoss_39bfb1" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_78bae7" xlink:to="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeFromGrants" xlink:label="loc_vnrxIncomeFromGrants_66bc60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_vnrxIncomeFromGrants_66bc60" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LossOnDisposalOfFixedAssets" xlink:label="loc_vnrxLossOnDisposalOfFixedAssets_94b83f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_vnrxLossOnDisposalOfFixedAssets_94b83f" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_c216a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapInterestIncomeOther_c216a9" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_073980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapInterestExpenseOther_073980" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_ebd4fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapOtherIncome_ebd4fc" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_361236" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapNetIncomeLoss_361236" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest_243494" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest_243494" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_d8150d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_vnrxIncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest_d8150d" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_6d73b9" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2846d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2846d0" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OthersComprehensiveIncomeLossNetOfTax" xlink:label="loc_vnrxOthersComprehensiveIncomeLossNetOfTax_bf8477" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" xlink:to="loc_vnrxOthersComprehensiveIncomeLossNetOfTax_bf8477" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited" xlink:label="loc_vnrxNetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited_dc8f26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" xlink:to="loc_vnrxNetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited_dc8f26" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_c431fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract_77dad0" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_c431fe" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted" xlink:label="loc_vnrxWeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted_088657" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_c431fe" xlink:to="loc_vnrxWeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted_088657" order="26" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_c62b5d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_647f66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_c62b5d" xlink:to="loc_us-gaapStatementTable_647f66" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1adc49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_647f66" xlink:to="loc_us-gaapStatementLineItems_1adc49" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_8f6add" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_647f66" xlink:to="loc_us-gaapStatementEquityComponentsAxis_8f6add" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_dc7fa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_8f6add" xlink:to="loc_us-gaapEquityComponentDomain_dc7fa0" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_5a1035" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dc7fa0" xlink:to="loc_us-gaapCommonStockMember_5a1035" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_4a9bed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dc7fa0" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_4a9bed" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_dcb7b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dc7fa0" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_dcb7b0" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_d3559d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dc7fa0" xlink:to="loc_us-gaapRetainedEarningsMember_d3559d" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_5aeeee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dc7fa0" xlink:to="loc_us-gaapNoncontrollingInterestMember_5aeeee" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_222b63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapSharesIssued_222b63" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_28b6bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapStockholdersEquity_28b6bb" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6849f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_6849f4" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_bddcb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_bddcb9" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSShares" xlink:label="loc_vnrxCommonStockIssuedForSettlementOfRsuSShares_77cfd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_vnrxCommonStockIssuedForSettlementOfRsuSShares_77cfd8" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSAmount" xlink:label="loc_vnrxCommonStockIssuedForSettlementOfRsuSAmount_08685e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_vnrxCommonStockIssuedForSettlementOfRsuSAmount_08685e" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedInPublicOfferingsNetShares" xlink:label="loc_vnrxCommonStockIssuedInPublicOfferingsNetShares_63ebe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_vnrxCommonStockIssuedInPublicOfferingsNetShares_63ebe5" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_e72b3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_e72b3a" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" xlink:label="loc_vnrxTaxWithholdingsPaidRelatedToStockBasedCompensation_d31354" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_vnrxTaxWithholdingsPaidRelatedToStockBasedCompensation_d31354" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_a56a91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_a56a91" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockBasedCompensationInRelationToModificationOfOptions" xlink:label="loc_vnrxStockBasedCompensationInRelationToModificationOfOptions_f31294" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_vnrxStockBasedCompensationInRelationToModificationOfOptions_f31294" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:label="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments_5c2866" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments_5c2866" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_276137" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapNetIncomeLoss_276137" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_91a05f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapSharesIssued_91a05f" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_e8bdd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1adc49" xlink:to="loc_us-gaapStockholdersEquity_e8bdd5" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_66bb71" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_468b53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_66bb71" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_468b53" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_206792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_468b53" xlink:to="loc_us-gaapNetIncomeLoss_206792" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_468b53" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_96faf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_us-gaapDepreciationAndAmortization_96faf1" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_9f243c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_9f243c" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLossOnDisposalOfFixedAssets" xlink:label="loc_vnrxOperatingLossOnDisposalOfFixedAssets_4fdfbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_vnrxOperatingLossOnDisposalOfFixedAssets_4fdfbc" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_d4e0d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_d4e0d7" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_0deb98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_us-gaapShareBasedCompensation_0deb98" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b910eb" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_e62bf2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_e62bf2" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_63849d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_63849d" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets_06e6df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets_06e6df" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue_731c44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue_731c44" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_840237" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_840237" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagementAndDirectorsFeesPayable" xlink:label="loc_vnrxManagementAndDirectorsFeesPayable_e77bd4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_vnrxManagementAndDirectorsFeesPayable_e77bd4" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_vnrxIncreaseDecreaseInOperatingLeaseLiabilities_33e3eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_vnrxIncreaseDecreaseInOperatingLeaseLiabilities_33e3eb" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_ba5c5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_ba5c5d" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e9c820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_429cfd" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e9c820" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_20e72f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e9c820" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_20e72f" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_c0d7db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e9c820" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_c0d7db" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e9c820" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_6bd629" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_6bd629" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_442eaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_442eaa" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ProceedsFromGrantsRepayable" xlink:label="loc_vnrxProceedsFromGrantsRepayable_ed6877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_vnrxProceedsFromGrantsRepayable_ed6877" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt_77fb11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapProceedsFromShortTermDebt_77fb11" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfOtherLongTermDebt_611589" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapProceedsFromRepaymentsOfOtherLongTermDebt_611589" order="26" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnGrantsRepayable" xlink:label="loc_vnrxPaymentsOnGrantsRepayable_7fb12c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_vnrxPaymentsOnGrantsRepayable_7fb12c" order="27" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsOnFinancingLeasesLeaseAmount" xlink:label="loc_vnrxPaymentsOnFinancingLeasesLeaseAmount_58fc78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_vnrxPaymentsOnFinancingLeasesLeaseAmount_58fc78" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_afe744" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_afe744" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae55f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae55f7" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e036c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e036c" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_027e7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_027e7d" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231e14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231e14" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_dccc64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_fa5c9f" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_dccc64" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_9341e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_dccc64" xlink:to="loc_us-gaapInterestPaidNet_9341e8" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_1f3025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_dccc64" xlink:to="loc_us-gaapIncomeTaxesPaid_1f3025" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_960817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_dccc64" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_960817" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_754e3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_960817" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_754e3f" order="38" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OfferingCostsFromIssuanceOfCommonStock" xlink:label="loc_vnrxOfferingCostsFromIssuanceOfCommonStock_972463" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_960817" xlink:to="loc_vnrxOfferingCostsFromIssuanceOfCommonStock_972463" order="39" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NonCashNotePayable" xlink:label="loc_vnrxNonCashNotePayable_aea5af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_960817" xlink:to="loc_vnrxNonCashNotePayable_aea5af" order="40" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/NatureOfOperations" xlink:title="000007 - Disclosure - Nature of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5308dc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations_4f3ef8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5308dc" xlink:to="loc_us-gaapNatureOfOperations_4f3ef8" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:title="000008 - Disclosure - Liquidity and Going Concern Assessment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract_2c720c" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LiquidityAndGoingConcernAssessment" xlink:label="loc_vnrxLiquidityAndGoingConcernAssessment_638154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_2c720c" xlink:to="loc_vnrxLiquidityAndGoingConcernAssessment_638154" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_aa12a2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fd1e60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_aa12a2" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fd1e60" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipment" xlink:title="000010 - Disclosure - Property and Equipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_5c20a5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_cac74d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_5c20a5" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_cac74d" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssets" xlink:title="000011 - Disclosure - Intangible Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_547f24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_84fcf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_547f24" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_84fcf1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/RelatedPartyTransactions" xlink:title="000012 - Disclosure - Related Party Transactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_7f1f39" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ba6a7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_7f1f39" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_ba6a7e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStock" xlink:title="000013 - Disclosure - Common Stock">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_3b221e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_c60eca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_3b221e" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_c60eca" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensation" xlink:title="000014 - Disclosure - StockBased Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_0c5399" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_ef8dd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_0c5399" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_ef8dd5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxes" xlink:title="000015 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_cf9093" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_6c6c80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_cf9093" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_6c6c80" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ea78e0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_eaf1dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ea78e0" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_eaf1dd" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEvents" xlink:title="000017 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_70c7a8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_6002c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_70c7a8" xlink:to="loc_us-gaapSubsequentEventsTextBlock_6002c4" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_556242" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_556242" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_b2aecd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapUseOfEstimates_b2aecd" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_07de04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_07de04" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_bcf65a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_bcf65a" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_5de838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_5de838" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_063643" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_063643" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_f20fdf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_f20fdf" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_bf2ebb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_bf2ebb" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock_f77467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock_f77467" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_946f03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_946f03" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_93d760" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_93d760" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_ff895e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_ff895e" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock" xlink:label="loc_vnrxDeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock_016179" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_vnrxDeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock_016179" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_447166" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_447166" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock" xlink:label="loc_vnrxImpairmentofLongLivedAssetsPolixyTextBlock_61b3ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_vnrxImpairmentofLongLivedAssetsPolixyTextBlock_61b3ff" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_abb5e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_abb5e1" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock_c42243" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock_c42243" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_COVID19PandemicImpactPolicyTextblock" xlink:label="loc_vnrxCOVID19PandemicImpactPolicyTextblock_c10d58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_vnrxCOVID19PandemicImpactPolicyTextblock_c10d58" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_7b23d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5eb8c5" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_7b23d8" order="19" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:title="000019 - Disclosure - Property and Equipment (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_de5844" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_975533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_de5844" xlink:to="loc_us-gaapScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_975533" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockTables" xlink:title="000020 - Disclosure - Common Stock (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_e90ccb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:label="loc_us-gaapScheduleOfOptionsIndexedToIssuersEquityTextBlock_4335ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_e90ccb" xlink:to="loc_us-gaapScheduleOfOptionsIndexedToIssuersEquityTextBlock_4335ea" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus" xlink:label="loc_vnrxScheduleOfShareIssuedFromTheSettlementOfRsus_b92eb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_e90ccb" xlink:to="loc_vnrxScheduleOfShareIssuedFromTheSettlementOfRsus_b92eb0" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsTables" xlink:title="000021 - Disclosure - Intangible Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_4c1f3a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_434278" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_4c1f3a" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_434278" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_25f8b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_4c1f3a" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_25f8b4" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationTables" xlink:title="000022 - Disclosure - StockBased Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_88a47a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_88a47a" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummarizingTheWarrantsIssuedAndOutstanding" xlink:label="loc_vnrxSummarizingTheWarrantsIssuedAndOutstanding_c972a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxSummarizingTheWarrantsIssuedAndOutstanding_c972a3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3e9b52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3e9b52" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9d6bab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9d6bab" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife" xlink:label="loc_vnrxSummarizingTheRsusIssuedAndOutstandingMaturityLife_ff4024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxSummarizingTheRsusIssuedAndOutstandingMaturityLife_ff4024" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock" xlink:label="loc_vnrxsummarizingtheRSUsissuedandoutstandingtabletextblock_746b3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxsummarizingtheRSUsissuedandoutstandingtabletextblock_746b3e" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions" xlink:label="loc_vnrxSummaryOfAmendmentsToExpirationDatesOfOptions_513e20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxSummaryOfAmendmentsToExpirationDatesOfOptions_513e20" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusGrantedDuringPeriod" xlink:label="loc_vnrxScheduleOfRsusGrantedDuringPeriod_eb875f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxScheduleOfRsusGrantedDuringPeriod_eb875f" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusVestedDuringPeriod" xlink:label="loc_vnrxScheduleOfRsusVestedDuringPeriod_7dac8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxScheduleOfRsusVestedDuringPeriod_7dac8e" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRsusCancelledDuringPeriod" xlink:label="loc_vnrxScheduleOfRsusCancelledDuringPeriod_a1b958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_43905c" xlink:to="loc_vnrxScheduleOfRsusCancelledDuringPeriod_a1b958" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesTables" xlink:title="000023 - Disclosure - Income Taxes (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_1542e5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c97180" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1542e5" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c97180" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:title="000024 - Disclosure - Commitments and Contingencies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock" xlink:label="loc_vnrxScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock_7f3a21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_vnrxScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock_7f3a21" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:label="loc_vnrxScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_335ab4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_vnrxScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_335ab4" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfRecognizedInShortTermLeaseCosts" xlink:label="loc_vnrxScheduleOfRecognizedInShortTermLeaseCosts_060ff6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_vnrxScheduleOfRecognizedInShortTermLeaseCosts_060ff6" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock_190e7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock_190e7a" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7ab4f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7ab4f1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_5d6d5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_5d6d5f" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets" xlink:label="loc_vnrxScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets_3f045d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_815207" xlink:to="loc_vnrxScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets_3f045d" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:title="000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract_11d8ff" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetIncomeLossSinceInception" xlink:label="loc_vnrxNetIncomeLossSinceInception_f55789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_11d8ff" xlink:to="loc_vnrxNetIncomeLossSinceInception_f55789" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_f85eda" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_dbb1d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f85eda" xlink:to="loc_us-gaapStatementTable_dbb1d0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_42c733" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dbb1d0" xlink:to="loc_us-gaapStatementLineItems_42c733" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="loc_us-gaapRegulatoryAgencyAxis_8370f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dbb1d0" xlink:to="loc_us-gaapRegulatoryAgencyAxis_8370f4" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaapRegulatoryAgencyDomain_062438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAgencyAxis_8370f4" xlink:to="loc_us-gaapRegulatoryAgencyDomain_062438" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a8ffd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dbb1d0" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a8ffd" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_8c7e72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a8ffd" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_8c7e72" order="40" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BelgianDepositGuaranteeMember" xlink:label="loc_vnrxBelgianDepositGuaranteeMember_175e3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAgencyDomain_062438" xlink:to="loc_vnrxBelgianDepositGuaranteeMember_175e3b" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SingaporeDepositInsuranceMember" xlink:label="loc_vnrxSingaporeDepositInsuranceMember_d5e58a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAgencyDomain_062438" xlink:to="loc_vnrxSingaporeDepositInsuranceMember_d5e58a" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UKDepositProtectionSchemeMember" xlink:label="loc_vnrxUKDepositProtectionSchemeMember_8f9f95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAgencyDomain_062438" xlink:to="loc_vnrxUKDepositProtectionSchemeMember_8f9f95" order="43" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DilutiveWarrantsAndOptionsMember" xlink:label="loc_vnrxDilutiveWarrantsAndOptionsMember_6c6199" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_8c7e72" xlink:to="loc_vnrxDilutiveWarrantsAndOptionsMember_6c6199" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_b5b214" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_b5b214" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfLicenseAgreement" xlink:label="loc_vnrxTermsOfLicenseAgreement_93e000" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxTermsOfLicenseAgreement_93e000" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForPoc" xlink:label="loc_vnrxInitialTermForPoc_de5d80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxInitialTermForPoc_de5d80" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForCentralLab" xlink:label="loc_vnrxInitialTermForCentralLab_862a0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxInitialTermForCentralLab_862a0e" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UpfrontPayment" xlink:label="loc_vnrxUpfrontPayment_a27b73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxUpfrontPayment_a27b73" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MilestoneAmountRecognized" xlink:label="loc_vnrxMilestoneAmountRecognized_3d1719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxMilestoneAmountRecognized_3d1719" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_7a726d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapCashFDICInsuredAmount_7a726d" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_83d12b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_83d12b" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ResearchAndDevelopmentExpenses" xlink:label="loc_vnrxResearchAndDevelopmentExpenses_2b944a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxResearchAndDevelopmentExpenses_2b944a" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_f84bbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapGoodwillImpairmentLoss_f84bbc" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_a3d1c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_a3d1c8" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_5d9ee5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapDeferredRevenue_5d9ee5" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_f75fcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_us-gaapCashUninsuredAmount_f75fcd" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PotentiallyDilutiveWarrantsAndOptions" xlink:label="loc_vnrxPotentiallyDilutiveWarrantsAndOptions_536b2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_42c733" xlink:to="loc_vnrxPotentiallyDilutiveWarrantsAndOptions_536b2f" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:title="000027 - Disclosure - Property and Equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_474f9f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0e64ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_474f9f" xlink:to="loc_us-gaapStatementTable_0e64ba" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_17ce4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e64ba" xlink:to="loc_us-gaapStatementLineItems_17ce4f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_9b9f67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e64ba" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_9b9f67" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_9b9f67" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_17681f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e64ba" xlink:to="loc_srtProductOrServiceAxis_17681f" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_772d37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_17681f" xlink:to="loc_srtProductsAndServicesDomain_772d37" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_e51218" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e64ba" xlink:to="loc_srtRangeAxis_e51218" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_011e16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_e51218" xlink:to="loc_srtRangeMember_011e16" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_ac6d67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" xlink:to="loc_us-gaapComputerEquipmentMember_ac6d67" order="61" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LaboratoryEquipmentMember" xlink:label="loc_vnrxLaboratoryEquipmentMember_5a6396" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" xlink:to="loc_vnrxLaboratoryEquipmentMember_5a6396" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_d1ac72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" xlink:to="loc_us-gaapOfficeEquipmentMember_d1ac72" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_b70651" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" xlink:to="loc_us-gaapBuildingMember_b70651" order="64" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember_edb5b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_79f976" xlink:to="loc_us-gaapBuildingImprovementsMember_edb5b2" order="65" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember_cb7278" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_772d37" xlink:to="loc_us-gaapLandMember_cb7278" order="66" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_e2e3ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_011e16" xlink:to="loc_srtMinimumMember_e2e3ad" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_1d35f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_011e16" xlink:to="loc_srtMaximumMember_1d35f9" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_f25b65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_17ce4f" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_f25b65" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_737060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_17ce4f" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_737060" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_e5802f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_17ce4f" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_e5802f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_ed0c9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_17ce4f" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_ed0c9c" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000028 - Disclosure - Property and Equipment (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_3645b5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_9f5893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_3645b5" xlink:to="loc_us-gaapDepreciation_9f5893" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid_00a116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_3645b5" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid_00a116" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails" xlink:title="000029 - Disclosure - Intangible Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f588cd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_95849f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f588cd" xlink:to="loc_us-gaapStatementTable_95849f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_887d7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_95849f" xlink:to="loc_us-gaapStatementLineItems_887d7f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_dc1157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_95849f" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_dc1157" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_6f186d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_dc1157" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_6f186d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_b8aaa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_6f186d" xlink:to="loc_us-gaapPatentsMember_b8aaa2" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_98cf51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_887d7f" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_98cf51" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_5d5af0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_887d7f" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_5d5af0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_4d1616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_887d7f" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_4d1616" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:title="000030 - Disclosure - Intangible Assets (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_92f662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4abc6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_92f662" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4abc6d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5090eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_92f662" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5090eb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_535090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_92f662" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_535090" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Intangible Assets (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_6ce719" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_219c7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_6ce719" xlink:to="loc_us-gaapStatementTable_219c7c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_827ca4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_219c7c" xlink:to="loc_us-gaapStatementLineItems_827ca4" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_475dda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_219c7c" xlink:to="loc_srtRangeAxis_475dda" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_965d46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_475dda" xlink:to="loc_srtRangeMember_965d46" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_4ef213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_219c7c" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_4ef213" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_b9cd0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_4ef213" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_b9cd0b" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_cab62c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_965d46" xlink:to="loc_srtMinimumMember_cab62c" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PatentsAndIntellectualPropertyMember" xlink:label="loc_vnrxPatentsAndIntellectualPropertyMember_e6dc6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_b9cd0b" xlink:to="loc_vnrxPatentsAndIntellectualPropertyMember_e6dc6e" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_976077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_965d46" xlink:to="loc_srtMaximumMember_976077" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_6b1a47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_827ca4" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_6b1a47" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_37e7ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_827ca4" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_37e7ee" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails" xlink:title="000032 - Disclosure - Income Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_9fe931" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c6db3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9fe931" xlink:to="loc_us-gaapStatementTable_c6db3b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6c9952" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c6db3b" xlink:to="loc_us-gaapStatementLineItems_6c9952" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis_50dcdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c6db3b" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis_50dcdd" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_b6d14b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis_50dcdd" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_b6d14b" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetDeferredTaxAssetsMember" xlink:label="loc_vnrxNetDeferredTaxAssetsMember_9e42d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain_b6d14b" xlink:to="loc_vnrxNetDeferredTaxAssetsMember_9e42d6" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6c9952" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" xlink:label="loc_vnrxExcessOfTaxOverBookDepreciationAndAmortization_d798d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_vnrxExcessOfTaxOverBookDepreciationAndAmortization_d798d2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_b9e224" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_b9e224" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_7131a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapFinanceLeaseLiability_7131a4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_a8e32b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals_a8e32b" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrealizedGainLoss" xlink:label="loc_vnrxUnrealizedGainLoss_00b26a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_vnrxUnrealizedGainLoss_00b26a" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalizedResearchExpenses" xlink:label="loc_vnrxCapitalizedResearchExpenses_f0556c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_vnrxCapitalizedResearchExpenses_f0556c" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_6ea7cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_6ea7cc" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_c95fab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_c95fab" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_0f79b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_0f79b4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_40adac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsGross_40adac" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_284ab5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_284ab5" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_669643" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_us-gaapDeferredTaxAssetsNet_669643" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ChangeInValuationAllowance" xlink:label="loc_vnrxChangeInValuationAllowance_9c904d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_d987fb" xlink:to="loc_vnrxChangeInValuationAllowance_9c904d" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails1" xlink:title="000033 - Disclosure - Income Taxes (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_b750fb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b750fb" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a99985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a99985" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6c036f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6c036f" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d310a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d310a3" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_08e48e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_08e48e" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch_27d41a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch_27d41a" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_6c8f6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_6c8f6b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5ca0a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5ca0a3" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_238611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_238611" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_916045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ef5304" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_916045" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails2" xlink:title="000034 - Disclosure - Income Taxes (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_b40cdd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5d7e86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b40cdd" xlink:to="loc_us-gaapStatementTable_5d7e86" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_595b98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5d7e86" xlink:to="loc_us-gaapStatementLineItems_595b98" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis_057039" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5d7e86" xlink:to="loc_srtStatementGeographicalAxis_057039" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_389240" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis_057039" xlink:to="loc_srtSegmentGeographicalDomain_389240" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnitedStateMember" xlink:label="loc_vnrxUnitedStateMember_946034" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain_389240" xlink:to="loc_vnrxUnitedStateMember_946034" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ForeignMember" xlink:label="loc_vnrxForeignMember_e1f1c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain_389240" xlink:to="loc_vnrxForeignMember_e1f1c0" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseInValuationAllowance" xlink:label="loc_vnrxIncreaseInValuationAllowance_1fd82a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_595b98" xlink:to="loc_vnrxIncreaseInValuationAllowance_1fd82a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_6805ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_595b98" xlink:to="loc_us-gaapOperatingLossCarryforwards_6805ae" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards_6ebfa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_595b98" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards_6ebfa6" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="000035 - Disclosure - Income Taxes (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_3546a5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetOperatingLosses" xlink:label="loc_vnrxNetOperatingLosses_65fe94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_3546a5" xlink:to="loc_vnrxNetOperatingLosses_65fe94" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails" xlink:title="000036 - Disclosure - Common Stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_27c29c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d587ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_27c29c" xlink:to="loc_us-gaapStatementTable_d587ff" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f7f910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d587ff" xlink:to="loc_us-gaapStatementLineItems_f7f910" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_8a7d8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d587ff" xlink:to="loc_us-gaapAwardDateAxis_8a7d8a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_b1080a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_8a7d8a" xlink:to="loc_us-gaapAwardDateDomain_b1080a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_a399a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d587ff" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_a399a7" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_e1f2d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_a399a7" xlink:to="loc_us-gaapDerivativeContractTypeDomain_e1f2d2" order="40" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryEightTwentyThousandTwentyOneMember_d62f24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxFebruaryEightTwentyThousandTwentyOneMember_d62f24" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesTwoMember" xlink:label="loc_vnrxStockOptionExercisesTwoMember_b460fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_e1f2d2" xlink:to="loc_vnrxStockOptionExercisesTwoMember_b460fc" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryEightFebruaryNineTwentyThousandTwentyOneMember_81c799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxFebruaryEightFebruaryNineTwentyThousandTwentyOneMember_81c799" order="43" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesMember" xlink:label="loc_vnrxStockOptionExercisesMember_d6a590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_e1f2d2" xlink:to="loc_vnrxStockOptionExercisesMember_d6a590" order="44" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" xlink:label="loc_vnrxJanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_328926" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxJanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_328926" order="45" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryTwoTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryTwoTwentyThousandTwentyOneMember_1c1aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxFebruaryTwoTwentyThousandTwentyOneMember_1c1aae" order="46" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesOneMember" xlink:label="loc_vnrxStockOptionExercisesOneMember_7d92bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_e1f2d2" xlink:to="loc_vnrxStockOptionExercisesOneMember_7d92bd" order="47" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" xlink:label="loc_vnrxMarchTwentyFiveTwoThousandTwentyTwoMember_d4c741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxMarchTwentyFiveTwoThousandTwentyTwoMember_d4c741" order="48" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAprilThirteenTwoThousandTwentyTwoMember_fd8d33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxAprilThirteenTwoThousandTwentyTwoMember_fd8d33" order="49" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MayOneTwoThousandTwentyTwoMember" xlink:label="loc_vnrxMayOneTwoThousandTwentyTwoMember_824eea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxMayOneTwoThousandTwentyTwoMember_824eea" order="50" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustThreeTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAugustThreeTwoThousandTwentyTwoMember_47f88e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxAugustThreeTwoThousandTwentyTwoMember_47f88e" order="51" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SeptemberSevenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxSeptemberSevenTwoThousandTwentyTwoMember_522023" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxSeptemberSevenTwoThousandTwentyTwoMember_522023" order="52" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OctoberFourTwoThousandTwentyTwoMember" xlink:label="loc_vnrxOctoberFourTwoThousandTwentyTwoMember_cd0af8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxOctoberFourTwoThousandTwentyTwoMember_cd0af8" order="53" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NovemberOneTwoThousandTwentyTwoMember" xlink:label="loc_vnrxNovemberOneTwoThousandTwentyTwoMember_d3874b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxNovemberOneTwoThousandTwentyTwoMember_d3874b" order="54" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DecemberFifteenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxDecemberFifteenTwoThousandTwentyTwoMember_ce5f9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_b1080a" xlink:to="loc_vnrxDecemberFifteenTwoThousandTwentyTwoMember_ce5f9d" order="55" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareIssuedUponCashlessExercise" xlink:label="loc_vnrxCommonStockShareIssuedUponCashlessExercise_85eee3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_vnrxCommonStockShareIssuedUponCashlessExercise_85eee3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued_a7e15e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_us-gaapExcessStockSharesIssued_a7e15e" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlan" xlink:label="loc_vnrxStockIncentivePlan_46c693" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_vnrxStockIncentivePlan_46c693" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_28a785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_us-gaapSharePrice_28a785" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsVested" xlink:label="loc_vnrxRestrictedStockUnitsVested_2c479e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_vnrxRestrictedStockUnitsVested_2c479e" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitVested" xlink:label="loc_vnrxRestrictedStockUnitVested_4c39fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_vnrxRestrictedStockUnitVested_4c39fb" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesWithheldForTax" xlink:label="loc_vnrxSharesWithheldForTax_1e1229" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_vnrxSharesWithheldForTax_1e1229" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_bfd474" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f7f910" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_bfd474" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails1" xlink:title="000037 - Disclosure - Common Stock (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2b1d99" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2e57d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2b1d99" xlink:to="loc_us-gaapStatementTable_2e57d0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_24c703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e57d0" xlink:to="loc_us-gaapStatementLineItems_24c703" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_58ab92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e57d0" xlink:to="loc_us-gaapAwardDateAxis_58ab92" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_de2862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_58ab92" xlink:to="loc_us-gaapAwardDateDomain_de2862" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_a6c8f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e57d0" xlink:to="loc_us-gaapAwardTypeAxis_a6c8f8" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e8565" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_a6c8f8" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e8565" order="30" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" xlink:label="loc_vnrxJanuaryTwentyTwentyThusandTwentyOneMember_08cea0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_de2862" xlink:to="loc_vnrxJanuaryTwentyTwentyThusandTwentyOneMember_08cea0" order="31" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSUSettlementsMember" xlink:label="loc_vnrxRSUSettlementsMember_ad9fbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e8565" xlink:to="loc_vnrxRSUSettlementsMember_ad9fbc" order="32" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilTwentyOneTwentyTwentyOneMember" xlink:label="loc_vnrxAprilTwentyOneTwentyTwentyOneMember_6d2961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_de2862" xlink:to="loc_vnrxAprilTwentyOneTwentyTwentyOneMember_6d2961" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitVested" xlink:label="loc_vnrxRestrictedStockUnitVested_b35572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_24c703" xlink:to="loc_vnrxRestrictedStockUnitVested_b35572" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfStockPriceSettledPerShare" xlink:label="loc_vnrxSaleOfStockPriceSettledPerShare_90fe9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_24c703" xlink:to="loc_vnrxSaleOfStockPriceSettledPerShare_90fe9f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued_926f35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_24c703" xlink:to="loc_us-gaapExcessStockSharesIssued_926f35" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_367e22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_24c703" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_367e22" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:title="000038 - Disclosure - Common Stock (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_ccbe4c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c36c18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_ccbe4c" xlink:to="loc_us-gaapStatementTable_c36c18" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b3525b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c36c18" xlink:to="loc_us-gaapStatementLineItems_b3525b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_c1aa4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c36c18" xlink:to="loc_us-gaapPlanNameAxis_c1aa4b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_ffcab0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_c1aa4b" xlink:to="loc_us-gaapPlanNameDomain_ffcab0" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnderwritingAgreementMember" xlink:label="loc_vnrxUnderwritingAgreementMember_0640c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_ffcab0" xlink:to="loc_vnrxUnderwritingAgreementMember_0640c3" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityDistributionAgreementMember" xlink:label="loc_vnrxEquityDistributionAgreementMember_bc1a8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_ffcab0" xlink:to="loc_vnrxEquityDistributionAgreementMember_bc1a8a" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_8b533d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_us-gaapCommonStockSharesIssued_8b533d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IssuedOfCommonStockFromSettlementOfRSU" xlink:label="loc_vnrxIssuedOfCommonStockFromSettlementOfRSU_228990" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxIssuedOfCommonStockFromSettlementOfRSU_228990" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_e6475b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_e6475b" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPricePerSahres" xlink:label="loc_vnrxCommonStockPricePerSahres_b6de8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxCommonStockPricePerSahres_b6de8e" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareAuthorized" xlink:label="loc_vnrxCommonStockShareAuthorized_2aa5a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxCommonStockShareAuthorized_2aa5a5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_0af3f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_0af3f5" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggeregateShareOfCommonStockOfferingPrice" xlink:label="loc_vnrxAggeregateShareOfCommonStockOfferingPrice_a4d699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxAggeregateShareOfCommonStockOfferingPrice_a4d699" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BrokerageFees" xlink:label="loc_vnrxBrokerageFees_cc37dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxBrokerageFees_cc37dd" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_896acd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_us-gaapSalesCommissionsAndFees_896acd" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PurchasePricePerShare" xlink:label="loc_vnrxPurchasePricePerShare_bd364a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxPurchasePricePerShare_bd364a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_041d9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_041d9d" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OfferingExpenses" xlink:label="loc_vnrxOfferingExpenses_21f161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b3525b" xlink:to="loc_vnrxOfferingExpenses_21f161" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails" xlink:title="000039 - Disclosure - StockBased Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_e45906" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1ce67a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_e45906" xlink:to="loc_us-gaapStatementTable_1ce67a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_603efd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ce67a" xlink:to="loc_us-gaapStatementLineItems_603efd" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_10cee4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1ce67a" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_10cee4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_eebddc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_10cee4" xlink:to="loc_us-gaapDerivativeContractTypeDomain_eebddc" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember_48258b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eebddc" xlink:to="loc_vnrxWarrantsMember_48258b" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingBeginningBalance" xlink:label="loc_vnrxNumberOfWarrantsOutstandingBeginningBalance_a8850f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_603efd" xlink:to="loc_vnrxNumberOfWarrantsOutstandingBeginningBalance_a8850f" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsAbstract" xlink:label="loc_vnrxNumberOfWarrantsAbstract_c8b8b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_603efd" xlink:to="loc_vnrxNumberOfWarrantsAbstract_c8b8b8" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceAbstract" xlink:label="loc_vnrxWeightedExercisePriceAbstract_c0742e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxNumberOfWarrantsAbstract_c8b8b8" xlink:to="loc_vnrxWeightedExercisePriceAbstract_c0742e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c68235" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c68235" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercised" xlink:label="loc_vnrxNumberOfWarrantsExercised_09854e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxNumberOfWarrantsExercised_09854e" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExpired" xlink:label="loc_vnrxNumberOfWarrantsExpired_56dd88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxNumberOfWarrantsExpired_56dd88" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfWarrantsOutstandingEndingBalance_631259" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxNumberOfWarrantsOutstandingEndingBalance_631259" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercisable" xlink:label="loc_vnrxNumberOfWarrantsExercisable_88c669" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxNumberOfWarrantsExercisable_88c669" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" xlink:label="loc_vnrxWeightedAverageExercisePriceOutstandingBalanceOne_c7f4d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxWeightedAverageExercisePriceOutstandingBalanceOne_c7f4d2" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b16bda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b16bda" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExercised" xlink:label="loc_vnrxWeightedExercisePriceExercised_febda9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxWeightedExercisePriceExercised_febda9" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExpired" xlink:label="loc_vnrxWeightedExercisePriceExpired_db754b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxWeightedExercisePriceExpired_db754b" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalanceOne" xlink:label="loc_vnrxWeightedAverageExercisePriceEndingBalanceOne_95c5b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxWeightedAverageExercisePriceEndingBalanceOne_95c5b8" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisable" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisable_1c0bde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnrxWeightedExercisePriceAbstract_c0742e" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisable_1c0bde" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:title="000040 - Disclosure - StockBased Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_7090df" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7604ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_7090df" xlink:to="loc_us-gaapStatementTable_7604ee" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_832f94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7604ee" xlink:to="loc_us-gaapStatementLineItems_832f94" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_aa998e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7604ee" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_aa998e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_eac7f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_aa998e" xlink:to="loc_us-gaapDerivativeContractTypeDomain_eac7f6" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember_5c9fa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantsMember_5c9fa3" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantOneMember" xlink:label="loc_vnrxWarrantOneMember_718a26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantOneMember_718a26" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantTwoMember" xlink:label="loc_vnrxWarrantTwoMember_2f71e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantTwoMember_2f71e6" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantThreeMember" xlink:label="loc_vnrxWarrantThreeMember_231bec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantThreeMember_231bec" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFourMember" xlink:label="loc_vnrxWarrantsFourMember_307b12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantsFourMember_307b12" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFiveMember" xlink:label="loc_vnrxWarrantsFiveMember_615f42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_eac7f6" xlink:to="loc_vnrxWarrantsFiveMember_615f42" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a29566" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_832f94" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a29566" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a64fe0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_832f94" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a64fe0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_832f94" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263c6" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_23160b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_832f94" xlink:to="loc_us-gaapProceedsFromWarrantExercises_23160b" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExercisePrice" xlink:label="loc_vnrxExercisePrice_a8e761" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_832f94" xlink:to="loc_vnrxExercisePrice_a8e761" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:title="000041 - Disclosure - StockBased Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_f0d2c5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_73e364" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_f0d2c5" xlink:to="loc_us-gaapStatementTable_73e364" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c3701c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_73e364" xlink:to="loc_us-gaapStatementLineItems_c3701c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_3dd0f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_73e364" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_3dd0f1" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_a23113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_3dd0f1" xlink:to="loc_us-gaapDerivativeContractTypeDomain_a23113" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember_9fb375" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_a23113" xlink:to="loc_vnrxOptionFourMember_9fb375" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsOutstandingBeginningBalance" xlink:label="loc_vnrxNumberOfOptionsOutstandingBeginningBalance_daa815" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxNumberOfOptionsOutstandingBeginningBalance_daa815" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_a80de0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_a80de0" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_4a8b4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised_4a8b4e" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfExpiredCancelled" xlink:label="loc_vnrxNumberOfExpiredCancelled_3009b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxNumberOfExpiredCancelled_3009b9" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfOptionOutstandingEndingBalance_030a74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxNumberOfOptionOutstandingEndingBalance_030a74" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsExercisable" xlink:label="loc_vnrxNumberOfOptionsExercisable_f474ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxNumberOfOptionsExercisable_f474ff" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceOutstandingBalance_d711bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceOutstandingBalance_d711bd" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceGranted" xlink:label="loc_vnrxWeightedAverageExercisePriceGranted_f11021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceGranted_f11021" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercised" xlink:label="loc_vnrxWeightedAverageExercisePriceExercised_e44769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceExercised_e44769" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisedExpiresCancelled_4b7fa7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisedExpiresCancelled_4b7fa7" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceEndingBalance_502ed0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceEndingBalance_502ed0" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisableBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisableBalance_65ce9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c3701c" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisableBalance_65ce9f" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:title="000042 - Disclosure - StockBased Compensation (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_c8db6e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_9bb3e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_c8db6e" xlink:to="loc_us-gaapStatementTable_9bb3e0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_57d005" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_9bb3e0" xlink:to="loc_us-gaapStatementLineItems_57d005" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_7c6a63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_9bb3e0" xlink:to="loc_us-gaapAwardTypeAxis_7c6a63" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_7c6a63" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentOneMember" xlink:label="loc_vnrxStockOptionsAmendmentOneMember_788137" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentOneMember_788137" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwoMember" xlink:label="loc_vnrxStockOptionsAmendmentTwoMember_da8160" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentTwoMember_da8160" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThreeMember" xlink:label="loc_vnrxStockOptionsAmendmentThreeMember_761ee2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentThreeMember_761ee2" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourMember" xlink:label="loc_vnrxStockOptionsAmendmentFourMember_761895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentFourMember_761895" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFiveMember" xlink:label="loc_vnrxStockOptionsAmendmentFiveMember_eb0d97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentFiveMember_eb0d97" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSixMember" xlink:label="loc_vnrxStockOptionsAmendmentSixMember_681607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentSixMember_681607" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSevenMember" xlink:label="loc_vnrxStockOptionsAmendmentSevenMember_eae758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentSevenMember_eae758" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentEightMember" xlink:label="loc_vnrxStockOptionsAmendmentEightMember_70c9fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentEightMember_70c9fb" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentNineMember" xlink:label="loc_vnrxStockOptionsAmendmentNineMember_938031" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentNineMember_938031" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTenMember" xlink:label="loc_vnrxStockOptionsAmendmentTenMember_0805a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentTenMember_0805a9" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentElevenMember" xlink:label="loc_vnrxStockOptionsAmendmentElevenMember_a1525d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentElevenMember_a1525d" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwelveMember" xlink:label="loc_vnrxStockOptionsAmendmentTwelveMember_76026a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentTwelveMember_76026a" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThirteenMember" xlink:label="loc_vnrxStockOptionsAmendmentThirteenMember_34e3b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentThirteenMember_34e3b2" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourteenMember" xlink:label="loc_vnrxStockOptionsAmendmentFourteenMember_8f7d15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_949cb9" xlink:to="loc_vnrxStockOptionsAmendmentFourteenMember_8f7d15" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ApprovedStockOptions" xlink:label="loc_vnrxApprovedStockOptions_927c30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_vnrxApprovedStockOptions_927c30" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_3751af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_3751af" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlan" xlink:label="loc_vnrxEquityIncentivePlan_715005" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_vnrxEquityIncentivePlan_715005" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionGrantDate" xlink:label="loc_vnrxStockOptionGrantDate_bbef34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_vnrxStockOptionGrantDate_bbef34" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_stockoptionamendmentdate" xlink:label="loc_vnrxstockoptionamendmentdate_a7c61f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_vnrxstockoptionamendmentdate_a7c61f" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_cb3d41" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57d005" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_cb3d41" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:title="000043 - Disclosure - StockBased Compensation (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_f03a10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5c9b8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_f03a10" xlink:to="loc_us-gaapStatementTable_5c9b8d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f3f3b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5c9b8d" xlink:to="loc_us-gaapStatementLineItems_f3f3b3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_4341b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5c9b8d" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_4341b4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_7a7d72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_4341b4" xlink:to="loc_us-gaapDerivativeContractTypeDomain_7a7d72" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember_7c380d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxOptionFourMember_7c380d" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionsOneMember" xlink:label="loc_vnrxOptionsOneMember_200056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxOptionsOneMember_200056" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionTwoMember" xlink:label="loc_vnrxOptionTwoMember_19c51c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxOptionTwoMember_19c51c" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThreeMember" xlink:label="loc_vnrxStockOptionThreeMember_174198" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxStockOptionThreeMember_174198" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFiveMember" xlink:label="loc_vnrxOptionFiveMember_97f373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxOptionFiveMember_97f373" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSixMember" xlink:label="loc_vnrxStockOptionSixMember_86c21c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxStockOptionSixMember_86c21c" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSevenMember" xlink:label="loc_vnrxStockOptionSevenMember_8bac56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxStockOptionSevenMember_8bac56" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionEightMember" xlink:label="loc_vnrxStockOptionEightMember_e1e2fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxStockOptionEightMember_e1e2fa" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionNineMember" xlink:label="loc_vnrxStockOptionNineMember_515f35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxStockOptionNineMember_515f35" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalStockOptionOneMember" xlink:label="loc_vnrxTotalStockOptionOneMember_ecb05c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_7a7d72" xlink:to="loc_vnrxTotalStockOptionOneMember_ecb05c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a26176" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f3f3b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a26176" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f695ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f3f3b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f695ab" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_1063c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f3f3b3" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_1063c1" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b331ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f3f3b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b331ba" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c2e290" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f3f3b3" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c2e290" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:title="000044 - Disclosure - StockBased Compensation (Details 5)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_332608" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_43c56b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_332608" xlink:to="loc_us-gaapStatementTable_43c56b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_31f60c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_43c56b" xlink:to="loc_us-gaapStatementLineItems_31f60c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_aec979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_43c56b" xlink:to="loc_us-gaapFinancialInstrumentAxis_aec979" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f35cde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_aec979" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f35cde" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsMember" xlink:label="loc_vnrxStockOptionsMember_1edc78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f35cde" xlink:to="loc_vnrxStockOptionsMember_1edc78" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingBeginingBalance" xlink:label="loc_vnrxNumberOfRsusOutstandingBeginingBalance_ff3dd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxNumberOfRsusOutstandingBeginingBalance_ff3dd7" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedShares" xlink:label="loc_vnrxGrantedShares_d32c1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxGrantedShares_d32c1c" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockVested" xlink:label="loc_vnrxNumberOfStockVested_f677ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxNumberOfStockVested_f677ec" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockCancelled" xlink:label="loc_vnrxNumberOfStockCancelled_e4709a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxNumberOfStockCancelled_e4709a" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfRsusOutstandingEndingBalance_79b675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxNumberOfRsusOutstandingEndingBalance_79b675" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceBeginningBalance" xlink:label="loc_vnrxSharePriceBeginningBalance_172541" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxSharePriceBeginningBalance_172541" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceGranted" xlink:label="loc_vnrxSharePriceGranted_52001b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxSharePriceGranted_52001b" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceVested" xlink:label="loc_vnrxSharePriceVested_b2018d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxSharePriceVested_b2018d" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Cancelled" xlink:label="loc_vnrxCancelled_5f1b28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxCancelled_5f1b28" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceEndingBalance" xlink:label="loc_vnrxSharePriceEndingBalance_5af495" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_31f60c" xlink:to="loc_vnrxSharePriceEndingBalance_5af495" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:title="000045 - Disclosure - StockBased Compensation (Details 6)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_aaccf7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ad2970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_aaccf7" xlink:to="loc_us-gaapStatementTable_ad2970" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8b220b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ad2970" xlink:to="loc_us-gaapStatementLineItems_8b220b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_95e1c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ad2970" xlink:to="loc_us-gaapAwardTypeAxis_95e1c4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_95e1c4" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseNineMember" xlink:label="loc_vnrxCompensationExpenseNineMember_7d6510" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseNineMember_7d6510" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTenMember" xlink:label="loc_vnrxCompensationExpenseTenMember_4392f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseTenMember_4392f5" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseOneMember" xlink:label="loc_vnrxCompensationExpenseOneMember_15c3e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseOneMember_15c3e9" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTwoMember" xlink:label="loc_vnrxCompensationExpenseTwoMember_8224bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseTwoMember_8224bf" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseThreeMember" xlink:label="loc_vnrxCompensationExpenseThreeMember_c1f6f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseThreeMember_c1f6f1" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFourMember" xlink:label="loc_vnrxCompensationExpenseFourMember_435d5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseFourMember_435d5d" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFiveMember" xlink:label="loc_vnrxCompensationExpenseFiveMember_52c7c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseFiveMember_52c7c8" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSixMember" xlink:label="loc_vnrxCompensationExpenseSixMember_c79ec8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseSixMember_c79ec8" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSevenMember" xlink:label="loc_vnrxCompensationExpenseSevenMember_84616c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseSevenMember_84616c" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseEightMember" xlink:label="loc_vnrxCompensationExpenseEightMember_94f62d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c00d20" xlink:to="loc_vnrxCompensationExpenseEightMember_94f62d" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseRsus" xlink:label="loc_vnrxCompensationExpenseRsus_496524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxCompensationExpenseRsus_496524" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlan" xlink:label="loc_vnrxEquityIncentivePlan_76a302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxEquityIncentivePlan_76a302" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseGrantDate" xlink:label="loc_vnrxCompensationExpenseGrantDate_c3a1e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxCompensationExpenseGrantDate_c3a1e1" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseVestingPeriod" xlink:label="loc_vnrxCompensationExpenseVestingPeriod_5006e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxCompensationExpenseVestingPeriod_5006e5" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstVestingDate" xlink:label="loc_vnrxFirstVestingDate_0fddeb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxFirstVestingDate_0fddeb" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SecondVestingDate" xlink:label="loc_vnrxSecondVestingDate_6e615f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxSecondVestingDate_6e615f" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ThirdVestingDate" xlink:label="loc_vnrxThirdVestingDate_b3fb37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxThirdVestingDate_b3fb37" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuExpense" xlink:label="loc_vnrxRsuExpense_11dcd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8b220b" xlink:to="loc_vnrxRsuExpense_11dcd6" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:title="000046 - Disclosure - StockBased Compensation (Details 7)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_da1440" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_4fac6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_da1440" xlink:to="loc_us-gaapStatementTable_4fac6b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_018f34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4fac6b" xlink:to="loc_us-gaapStatementLineItems_018f34" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_bcbf19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4fac6b" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_bcbf19" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_34a559" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_bcbf19" xlink:to="loc_us-gaapDerivativeContractTypeDomain_34a559" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanOneMember" xlink:label="loc_vnrxEquityIncentivePlanOneMember_ff16d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanOneMember_ff16d8" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanTwoMember" xlink:label="loc_vnrxEquityIncentivePlanTwoMember_d850ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanTwoMember_d850ab" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanThreeMember" xlink:label="loc_vnrxEquityIncentivePlanThreeMember_f479b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanThreeMember_f479b1" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFourMember" xlink:label="loc_vnrxEquityIncentivePlanFourMember_f5651e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanFourMember_f5651e" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFiveMember" xlink:label="loc_vnrxEquityIncentivePlanFiveMember_59d1f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanFiveMember_59d1f3" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSixMember" xlink:label="loc_vnrxEquityIncentivePlanSixMember_3bfe59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanSixMember_3bfe59" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSevenMember" xlink:label="loc_vnrxEquityIncentivePlanSevenMember_80ebc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanSevenMember_80ebc9" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanEightMember" xlink:label="loc_vnrxEquityIncentivePlanEightMember_d0398e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_34a559" xlink:to="loc_vnrxEquityIncentivePlanEightMember_d0398e" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentivePlan" xlink:label="loc_vnrxIncentivePlan_5e06a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_018f34" xlink:to="loc_vnrxIncentivePlan_5e06a6" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentiveRsu" xlink:label="loc_vnrxEquityIncentiveRsu_137a4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_018f34" xlink:to="loc_vnrxEquityIncentiveRsu_137a4c" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveVestDate" xlink:label="loc_vnrxIncentiveVestDate_076dc6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_018f34" xlink:to="loc_vnrxIncentiveVestDate_076dc6" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsuIssued" xlink:label="loc_vnrxIncentiveRsuIssued_8d79c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_018f34" xlink:to="loc_vnrxIncentiveRsuIssued_8d79c1" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsusHeldForTaxes" xlink:label="loc_vnrxRsusHeldForTaxes_2bcf8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_018f34" xlink:to="loc_vnrxRsusHeldForTaxes_2bcf8d" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:title="000047 - Disclosure - StockBased Compensation (Details 8)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_b64e96" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_735b93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_b64e96" xlink:to="loc_us-gaapStatementTable_735b93" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ed41db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_735b93" xlink:to="loc_us-gaapStatementLineItems_ed41db" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_e3ed9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_735b93" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_e3ed9d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_282d91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_e3ed9d" xlink:to="loc_us-gaapDerivativeContractTypeDomain_282d91" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanOneMember" xlink:label="loc_vnrxEquityIncentivePlanOneMember_cbdf1b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_282d91" xlink:to="loc_vnrxEquityIncentivePlanOneMember_cbdf1b" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanTwoMember" xlink:label="loc_vnrxEquityIncentivePlanTwoMember_b472b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_282d91" xlink:to="loc_vnrxEquityIncentivePlanTwoMember_b472b3" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanThreeMember" xlink:label="loc_vnrxEquityIncentivePlanThreeMember_040a21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_282d91" xlink:to="loc_vnrxEquityIncentivePlanThreeMember_040a21" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFourMember" xlink:label="loc_vnrxEquityIncentivePlanFourMember_312b45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_282d91" xlink:to="loc_vnrxEquityIncentivePlanFourMember_312b45" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuCancelled" xlink:label="loc_vnrxRsuCancelled_4375f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed41db" xlink:to="loc_vnrxRsuCancelled_4375f9" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentivePlan" xlink:label="loc_vnrxIncentivePlan_4f5650" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed41db" xlink:to="loc_vnrxIncentivePlan_4f5650" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsu" xlink:label="loc_vnrxIncentiveRsu_8520d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed41db" xlink:to="loc_vnrxIncentiveRsu_8520d8" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CancellationDate" xlink:label="loc_vnrxCancellationDate_5556b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed41db" xlink:to="loc_vnrxCancellationDate_5556b7" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestDate" xlink:label="loc_vnrxVestDate_ea184a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed41db" xlink:to="loc_vnrxVestDate_ea184a" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:title="000048 - Disclosure - StockBased Compensation (Details 9)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_8552c8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5ebc2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_8552c8" xlink:to="loc_us-gaapStatementTable_5ebc2e" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4380b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ebc2e" xlink:to="loc_us-gaapStatementLineItems_4380b8" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_28305d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ebc2e" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_28305d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_b29883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_28305d" xlink:to="loc_us-gaapDerivativeContractTypeDomain_b29883" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember_7cfc91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxOptionFourMember_7cfc91" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionsOneMember" xlink:label="loc_vnrxOptionsOneMember_b34556" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxOptionsOneMember_b34556" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionTwoMember" xlink:label="loc_vnrxOptionTwoMember_335ab7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxOptionTwoMember_335ab7" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThreeMember" xlink:label="loc_vnrxStockOptionThreeMember_4b068f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionThreeMember_4b068f" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFiveMember" xlink:label="loc_vnrxOptionFiveMember_7cd9c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxOptionFiveMember_7cd9c3" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSixMember" xlink:label="loc_vnrxStockOptionSixMember_b92db7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionSixMember_b92db7" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSevenMember" xlink:label="loc_vnrxStockOptionSevenMember_929b01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionSevenMember_929b01" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionEightMember" xlink:label="loc_vnrxStockOptionEightMember_ca60f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionEightMember_ca60f2" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionNineMember" xlink:label="loc_vnrxStockOptionNineMember_126aaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionNineMember_126aaa" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalStockOptionOneMember" xlink:label="loc_vnrxTotalStockOptionOneMember_57764e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxTotalStockOptionOneMember_57764e" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTenMember" xlink:label="loc_vnrxStockOptionTenMember_8de907" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionTenMember_8de907" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionElevenMember" xlink:label="loc_vnrxStockOptionElevenMember_50583f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionElevenMember_50583f" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTwelveMember" xlink:label="loc_vnrxStockOptionTwelveMember_e8daf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionTwelveMember_e8daf3" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFourteenTenMember" xlink:label="loc_vnrxStockOptionFourteenTenMember_846238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionFourteenTenMember_846238" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFiveteenTenMember" xlink:label="loc_vnrxStockOptionFiveteenTenMember_eebd20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionFiveteenTenMember_eebd20" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThirteenTenMember" xlink:label="loc_vnrxStockOptionThirteenTenMember_b2ae49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_b29883" xlink:to="loc_vnrxStockOptionThirteenTenMember_b2ae49" order="26" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockOutstandingBalance" xlink:label="loc_vnrxNumberOfStockOutstandingBalance_fc04a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4380b8" xlink:to="loc_vnrxNumberOfStockOutstandingBalance_fc04a0" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesPriceRsu" xlink:label="loc_vnrxSharesPriceRsu_36af9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4380b8" xlink:to="loc_vnrxSharesPriceRsu_36af9f" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageRemainingContractualLifeYears" xlink:label="loc_vnrxWeightedAverageRemainingContractualLifeYears_b31e69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4380b8" xlink:to="loc_vnrxWeightedAverageRemainingContractualLifeYears_b31e69" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000049 - Disclosure - StockBased Compensation (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_10bcc3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_28e4e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_10bcc3" xlink:to="loc_us-gaapStatementTable_28e4e2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a2562e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapStatementLineItems_a2562e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_1eafb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapAwardDateAxis_1eafb4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_774965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_1eafb4" xlink:to="loc_us-gaapAwardDateDomain_774965" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_c63219" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_c63219" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_11b40a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_c63219" xlink:to="loc_us-gaapDerivativeContractTypeDomain_11b40a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_54b249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapFinancialInstrumentAxis_54b249" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b80d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_54b249" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b80d1" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_ae2f1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapPlanNameAxis_ae2f1d" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_b1af7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_ae2f1d" xlink:to="loc_us-gaapPlanNameDomain_b1af7d" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_8c2e45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_us-gaapAwardTypeAxis_8c2e45" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372e2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_8c2e45" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372e2e" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_428c65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_28e4e2" xlink:to="loc_srtRangeAxis_428c65" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_77ad4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_428c65" xlink:to="loc_srtRangeMember_77ad4f" order="60" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember_45725a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_11b40a" xlink:to="loc_vnrxWarrantsMember_45725a" order="61" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilFourTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAprilFourTwoThousandTwentyTwoMember_475d65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_774965" xlink:to="loc_vnrxAprilFourTwoThousandTwentyTwoMember_475d65" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_3f535e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b80d1" xlink:to="loc_us-gaapOptionMember_3f535e" order="63" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember_c6e4e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b1af7d" xlink:to="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember_c6e4e0" order="64" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryOneTwoThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryOneTwoThousandTwentyOneMember_49a1dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_774965" xlink:to="loc_vnrxFebruaryOneTwoThousandTwentyOneMember_49a1dd" order="65" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryOneTwoThousandTwentyOneMember" xlink:label="loc_vnrxJanuaryOneTwoThousandTwentyOneMember_14ec10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_774965" xlink:to="loc_vnrxJanuaryOneTwoThousandTwentyOneMember_14ec10" order="66" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyMember" xlink:label="loc_vnrxAprilThirteenTwoThousandTwentyMember_0fb827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_774965" xlink:to="loc_vnrxAprilThirteenTwoThousandTwentyMember_0fb827" order="67" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsMember" xlink:label="loc_vnrxRestrictedStockUnitsMember_938667" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372e2e" xlink:to="loc_vnrxRestrictedStockUnitsMember_938667" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_7b2d02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_77ad4f" xlink:to="loc_srtMaximumMember_7b2d02" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" xlink:label="loc_vnrxOnTwoZeroMayTwoThousandTwentyOneMember_068ba1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_774965" xlink:to="loc_vnrxOnTwoZeroMayTwoThousandTwentyOneMember_068ba1" order="70" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsOneMember" xlink:label="loc_vnrxRestrictedStockUnitsOneMember_645a70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372e2e" xlink:to="loc_vnrxRestrictedStockUnitsOneMember_645a70" order="71" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockAvailable" xlink:label="loc_vnrxCommonStockAvailable_bf4673" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxCommonStockAvailable_bf4673" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareAggregateMaximum" xlink:label="loc_vnrxShareAggregateMaximum_8c4d1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxShareAggregateMaximum_8c4d1c" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionGranted" xlink:label="loc_vnrxOptionGranted_affe55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxOptionGranted_affe55" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ApprovedStockOptions" xlink:label="loc_vnrxApprovedStockOptions_d2abde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxApprovedStockOptions_d2abde" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfSharesVesting" xlink:label="loc_vnrxNumberOfSharesVesting_c69409" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxNumberOfSharesVesting_c69409" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FairValueOfOptions" xlink:label="loc_vnrxFairValueOfOptions_0209ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxFairValueOfOptions_0209ba" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" xlink:label="loc_vnrxCommonStockSharesIssuableUponExerciseOfStockOption_e0d28d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxCommonStockSharesIssuableUponExerciseOfStockOption_e0d28d" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExercisePrice" xlink:label="loc_vnrxExercisePrice_fd8118" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxExercisePrice_fd8118" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_2eb243" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapDebtInstrumentTerm_2eb243" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_0bd3ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_0bd3ab" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_bfe291" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_bfe291" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VolatilityRate" xlink:label="loc_vnrxVolatilityRate_2ff2e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxVolatilityRate_2ff2e2" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e7d27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e7d27" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Volatility" xlink:label="loc_vnrxVolatility_a9ca9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxVolatility_a9ca9b" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6b2580" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6b2580" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d1dfde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d1dfde" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestingAggregate" xlink:label="loc_vnrxVestingAggregate_8339b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxVestingAggregate_8339b9" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggregrateAggregate" xlink:label="loc_vnrxAggregrateAggregate_2a8fb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxAggregrateAggregate_2a8fb9" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_9e1672" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapSharePrice_9e1672" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedAggregate" xlink:label="loc_vnrxGrantedAggregate_329fa9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxGrantedAggregate_329fa9" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedRsu" xlink:label="loc_vnrxGrantedRsu_8872a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxGrantedRsu_8872a4" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DescriptionOfVestingShall" xlink:label="loc_vnrxDescriptionOfVestingShall_786b72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxDescriptionOfVestingShall_786b72" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_b26ee6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapShareBasedCompensation_b26ee6" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationCost" xlink:label="loc_vnrxUnrecognizedCompensationCost_5ef8e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxUnrecognizedCompensationCost_5ef8e9" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_46a6d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_46a6d9" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockCompensationExpenses" xlink:label="loc_vnrxStockCompensationExpenses_e01126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxStockCompensationExpenses_e01126" order="26" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityTerm" xlink:label="loc_vnrxMaturityTerm_781bb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxMaturityTerm_781bb7" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_af6371" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_af6371" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" xlink:label="loc_us-gaapMultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription_75604c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapMultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription_75604c" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_024d46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_024d46" order="30" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsPurchaseSharesOfCommonStock" xlink:label="loc_vnrxStockOptionsPurchaseSharesOfCommonStock_849d2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxStockOptionsPurchaseSharesOfCommonStock_849d2d" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_099b0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_099b0c" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_7cb61c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_7cb61c" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationCostRelatedToNonVestedWarrants" xlink:label="loc_vnrxCompensationCostRelatedToNonVestedWarrants_116969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a2562e" xlink:to="loc_vnrxCompensationCostRelatedToNonVestedWarrants_116969" order="34" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c1fbc5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a94cff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c1fbc5" xlink:to="loc_us-gaapStatementTable_a94cff" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_47a5cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a94cff" xlink:to="loc_us-gaapStatementLineItems_47a5cb" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis_487ecc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a94cff" xlink:to="loc_us-gaapLongtermDebtTypeAxis_487ecc" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_665ebd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis_487ecc" xlink:to="loc_us-gaapLongtermDebtTypeDomain_665ebd" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FinanceLeaseObligationsMember" xlink:label="loc_vnrxFinanceLeaseObligationsMember_3e3c8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain_665ebd" xlink:to="loc_vnrxFinanceLeaseObligationsMember_3e3c8f" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d39b66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d39b66" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_73a047" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_73a047" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8dace2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8dace2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_af09bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_af09bd" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_eba6d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_eba6d5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_96e7eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_96e7eb" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_f8cd8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_f8cd8a" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LessAmountRepresentingInterest" xlink:label="loc_vnrxLessAmountRepresentingInterest_49b6fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_vnrxLessAmountRepresentingInterest_49b6fd" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_83d723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_47a5cb" xlink:to="loc_us-gaapFinanceLeaseLiability_83d723" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - Commitments and Contingencies (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a43804" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b4cc50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a43804" xlink:to="loc_us-gaapStatementTable_b4cc50" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_edb447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4cc50" xlink:to="loc_us-gaapStatementLineItems_edb447" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_472d17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4cc50" xlink:to="loc_us-gaapOtherCommitmentsAxis_472d17" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_9dccc6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_472d17" xlink:to="loc_us-gaapOtherCommitmentsDomain_9dccc6" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightofUseObligationsMember" xlink:label="loc_vnrxOperatingLeaseRightofUseObligationsMember_40804c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_9dccc6" xlink:to="loc_vnrxOperatingLeaseRightofUseObligationsMember_40804c" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_ea4cea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearTwo_ea4cea" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" xlink:label="loc_vnrxFiniteLivedIntangibleAssetAmortizationExpenseYearTwo_9ec07b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxFiniteLivedIntangibleAssetAmortizationExpenseYearTwo_9ec07b" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFour_b12db6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFour_b12db6" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFive_b0ec1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFive_b0ec1d" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_14f998" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentsDueInRollingYearSix_14f998" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseObligations" xlink:label="loc_vnrxOperatingLeaseObligations_5c5c08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeaseObligations_5c5c08" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LessAmountRepresentingInterest" xlink:label="loc_vnrxLessAmountRepresentingInterest_cc4fce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxLessAmountRepresentingInterest_cc4fce" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDue" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDue_39580f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_edb447" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDue_39580f" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:title="000052 - Disclosure - Commitments and Contingencies (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c601a3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueCurrent_2d10b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c601a3" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueCurrent_2d10b1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInTwoYears_103a29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c601a3" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInTwoYears_103a29" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumLeasePaymentDue" xlink:label="loc_vnrxOperatingLeasesFutureMinimumLeasePaymentDue_8ab85d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c601a3" xlink:to="loc_vnrxOperatingLeasesFutureMinimumLeasePaymentDue_8ab85d" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:title="000053 - Disclosure - Commitments and Contingencies (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_97b230" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e40a4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_97b230" xlink:to="loc_us-gaapStatementTable_e40a4e" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_757b97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e40a4e" xlink:to="loc_us-gaapStatementLineItems_757b97" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_7672ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e40a4e" xlink:to="loc_us-gaapOtherCommitmentsAxis_7672ed" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_40aeed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_7672ed" xlink:to="loc_us-gaapOtherCommitmentsDomain_40aeed" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayableMember" xlink:label="loc_vnrxGrantsRepayableMember_b93319" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_40aeed" xlink:to="loc_vnrxGrantsRepayableMember_b93319" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_8af1fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree_8af1fe" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_0476b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour_0476b4" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_c824c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive_c824c9" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_b4a29f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix_b4a29f" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_3ba633" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven_3ba633" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_f98726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter_f98726" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayable" xlink:label="loc_vnrxGrantsRepayable_e1c8b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_757b97" xlink:to="loc_vnrxGrantsRepayable_e1c8b1" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:title="000054 - Disclosure - Commitments and Contingencies (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_745370" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_745370" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9308ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9308ad" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8654a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8654a5" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3c67d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3c67d0" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b48131" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b48131" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="loc_us-gaapLongTermDebtMaturingInYearsFourAndFive_3f3257" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturingInYearsFourAndFive_3f3257" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cec260" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cec260" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LongTermDebtLessAmountRepresentingInterest" xlink:label="loc_vnrxLongTermDebtLessAmountRepresentingInterest_be6d47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_vnrxLongTermDebtLessAmountRepresentingInterest_be6d47" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_ea5f67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_eeacea" xlink:to="loc_us-gaapLongTermDebt_ea5f67" order="9" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:title="000055 - Disclosure - Commitments and Contingencies (Details 5)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_75a2cf" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour" xlink:label="loc_vnrxFutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour_da647f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_75a2cf" xlink:to="loc_vnrxFutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour_da647f" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive" xlink:label="loc_vnrxFutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_6e4f5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_75a2cf" xlink:to="loc_vnrxFutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive_6e4f5d" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeAgreementObligations" xlink:label="loc_vnrxCollaborativeAgreementObligations_ef0b1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_75a2cf" xlink:to="loc_vnrxCollaborativeAgreementObligations_ef0b1a" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:title="000056 - Disclosure - Commitments and Contingencies (Details 6)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_941870" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_356803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_941870" xlink:to="loc_us-gaapStatementTable_356803" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_306fc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_356803" xlink:to="loc_us-gaapStatementLineItems_306fc7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_f6e0d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_356803" xlink:to="loc_us-gaapFinancialInstrumentAxis_f6e0d2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f809d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_f6e0d2" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f809d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_741a7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_356803" xlink:to="loc_us-gaapOtherCommitmentsAxis_741a7e" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_530be2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_741a7e" xlink:to="loc_us-gaapOtherCommitmentsDomain_530be2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0f3149" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f809d" xlink:to="loc_us-gaapStockOptionMember_0f3149" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember_1a45d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_530be2" xlink:to="loc_vnrxAwardOneMember_1a45d0" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember_2c5247" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_530be2" xlink:to="loc_vnrxOutstandingAwardTwoMember_2c5247" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_577946" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_306fc7" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_577946" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2022" xlink:label="loc_vnrxAmortisedOfOutstandingAward2022_e40ff6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_306fc7" xlink:to="loc_vnrxAmortisedOfOutstandingAward2022_e40ff6" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2021" xlink:label="loc_vnrxAmortisedOfOutstandingAward2021_de89f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_306fc7" xlink:to="loc_vnrxAmortisedOfOutstandingAward2021_de89f4" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward2023" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward2023_0de305" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_306fc7" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward2023_0de305" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:title="000057 - Disclosure - Commitments and Contingencies (Details 7)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a37d9f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_722703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a37d9f" xlink:to="loc_us-gaapStatementTable_722703" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_db1145" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_722703" xlink:to="loc_us-gaapStatementLineItems_db1145" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_ba2a24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_722703" xlink:to="loc_us-gaapAwardTypeAxis_ba2a24" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ca191" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_ba2a24" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ca191" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_3f440d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_722703" xlink:to="loc_us-gaapOtherCommitmentsAxis_3f440d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_7433ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_3f440d" xlink:to="loc_us-gaapOtherCommitmentsDomain_7433ca" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_394634" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ca191" xlink:to="loc_us-gaapRestrictedStockMember_394634" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember_d3cd13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_7433ca" xlink:to="loc_vnrxAwardOneMember_d3cd13" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember_ad01d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_7433ca" xlink:to="loc_vnrxOutstandingAwardTwoMember_ad01d3" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_5e6562" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_db1145" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_5e6562" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2022" xlink:label="loc_vnrxAmortisedOfOutstandingAward2022_8a227b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_db1145" xlink:to="loc_vnrxAmortisedOfOutstandingAward2022_8a227b" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2021" xlink:label="loc_vnrxAmortisedOfOutstandingAward2021_d6279f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_db1145" xlink:to="loc_vnrxAmortisedOfOutstandingAward2021_d6279f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward2023" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward2023_cfea42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_db1145" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward2023_cfea42" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:title="000058 - Disclosure - Commitments and Contingencies (Details 8)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_cf2220" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c0ce60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_cf2220" xlink:to="loc_us-gaapStatementTable_c0ce60" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_086802" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c0ce60" xlink:to="loc_us-gaapStatementLineItems_086802" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_57560f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c0ce60" xlink:to="loc_us-gaapAwardTypeAxis_57560f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f664c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_57560f" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f664c" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_bff7d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c0ce60" xlink:to="loc_us-gaapOtherCommitmentsAxis_bff7d6" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_45f56f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_bff7d6" xlink:to="loc_us-gaapOtherCommitmentsDomain_45f56f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_730142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f664c" xlink:to="loc_us-gaapRestrictedStockMember_730142" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember_efade4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_45f56f" xlink:to="loc_vnrxAwardOneMember_efade4" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember_6f38f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_45f56f" xlink:to="loc_vnrxOutstandingAwardTwoMember_6f38f4" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardThreeMember" xlink:label="loc_vnrxOutstandingAwardThreeMember_763771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_45f56f" xlink:to="loc_vnrxOutstandingAwardThreeMember_763771" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardVestingPeriod" xlink:label="loc_vnrxOutstandingAwardVestingPeriod_22ee63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_086802" xlink:to="loc_vnrxOutstandingAwardVestingPeriod_22ee63" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAwardAmount" xlink:label="loc_vnrxAmortisedOfOutstandingAwardAmount_eb64f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_086802" xlink:to="loc_vnrxAmortisedOfOutstandingAwardAmount_eb64f3" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward_374dde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_086802" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward_374dde" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAward" xlink:label="loc_vnrxOutstandingAward_28954d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_086802" xlink:to="loc_vnrxOutstandingAward_28954d" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000059 - Disclosure - Commitments and Contingencies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_392290" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f50036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_392290" xlink:to="loc_us-gaapStatementTable_f50036" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4d2e5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapStatementLineItems_4d2e5d" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_89ea6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_srtTitleOfIndividualAxis_89ea6a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_89ea6a" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_876c69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapAwardDateAxis_876c69" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_2c321e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_876c69" xlink:to="loc_us-gaapAwardDateDomain_2c321e" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b89a9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b89a9c" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a115ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b89a9c" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a115ce" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_e793b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapFinancialInstrumentAxis_e793b4" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bbc9b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_e793b4" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bbc9b5" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_38b33b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapPlanNameAxis_38b33b" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_1e3a14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_38b33b" xlink:to="loc_us-gaapPlanNameDomain_1e3a14" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis_121299" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapOtherCommitmentsAxis_121299" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_4f3db7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis_121299" xlink:to="loc_us-gaapOtherCommitmentsDomain_4f3db7" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_dfe42b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_dfe42b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_6d2604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_dfe42b" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_6d2604" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis_2e5fc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_srtStatementGeographicalAxis_2e5fc3" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_bc0c2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis_2e5fc3" xlink:to="loc_srtSegmentGeographicalDomain_bc0c2a" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis" xlink:label="loc_us-gaapCollectiveBargainingArrangementAxis_fc3358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapCollectiveBargainingArrangementAxis_fc3358" order="130" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain" xlink:label="loc_us-gaapCollectiveBargainingArrangementDomain_9ba740" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollectiveBargainingArrangementAxis_fc3358" xlink:to="loc_us-gaapCollectiveBargainingArrangementDomain_9ba740" order="130" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_73b6b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_73b6b3" order="140" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_901dd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_73b6b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_901dd0" order="140" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis_3bab8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapLongtermDebtTypeAxis_3bab8b" order="150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_f425d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis_3bab8b" xlink:to="loc_us-gaapLongtermDebtTypeDomain_f425d1" order="150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_5aacfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapAwardTypeAxis_5aacfe" order="160" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577e68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_5aacfe" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577e68" order="160" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis_de578f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f50036" xlink:to="loc_us-gaapVestingAxis_de578f" order="180" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_5b1807" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis_de578f" xlink:to="loc_us-gaapVestingDomain_5b1807" order="180" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightofUseObligationsMember" xlink:label="loc_vnrxOperatingLeaseRightofUseObligationsMember_93a780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_4f3db7" xlink:to="loc_vnrxOperatingLeaseRightofUseObligationsMember_93a780" order="181" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WalloonRegionGovernmentMember" xlink:label="loc_vnrxWalloonRegionGovernmentMember_b44c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxWalloonRegionGovernmentMember_b44c66" order="182" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsTwentyTwentyMember" xlink:label="loc_vnrxInTwoThousandsTwentyTwentyMember_9d58b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxInTwoThousandsTwentyTwentyMember_9d58b0" order="183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="loc_us-gaapAdditionalFundingAgreementTermsMember_149743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a115ce" xlink:to="loc_us-gaapAdditionalFundingAgreementTermsMember_149743" order="184" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInvestMember" xlink:label="loc_vnrxNamurInvestMember_c2eac2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxNamurInvestMember_c2eac2" order="185" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2016Member" xlink:label="loc_vnrxIn2016Member_65d8de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxIn2016Member_65d8de" order="186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember_4ee70e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bbc9b5" xlink:to="loc_us-gaapLongTermDebtMember_4ee70e" order="187" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementMember" xlink:label="loc_vnrxLoanAgreementMember_6ec2c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1e3a14" xlink:to="loc_vnrxLoanAgreementMember_6ec2c0" order="188" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_INGMember" xlink:label="loc_vnrxINGMember_ee801b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxINGMember_ee801b" order="189" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNineteenMember" xlink:label="loc_vnrxInTwoThousandNineteenMember_92d7ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxInTwoThousandNineteenMember_92d7ec" order="190" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2018Member" xlink:label="loc_vnrxIn2018Member_d8778f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxIn2018Member_d8778f" order="191" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInnovationAndGrowthMember" xlink:label="loc_vnrxNamurInnovationAndGrowthMember_a6a3a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain_4f3db7" xlink:to="loc_vnrxNamurInnovationAndGrowthMember_a6a3a9" order="192" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SOFINEXMember" xlink:label="loc_vnrxSOFINEXMember_ac9195" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxSOFINEXMember_ac9195" order="193" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2017Member" xlink:label="loc_vnrxIn2017Member_08ed18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxIn2017Member_08ed18" order="194" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" xlink:label="loc_vnrxTwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_4d22dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxTwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_4d22dc" order="195" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" xlink:label="loc_vnrxFiveFebruaryTwoThounsendTwentyTwentyTwoMember_e6f333" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxFiveFebruaryTwoThounsendTwentyTwentyTwoMember_e6f333" order="196" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstInsuranceFundingMember" xlink:label="loc_vnrxFirstInsuranceFundingMember_e983fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_6d2604" xlink:to="loc_vnrxFirstInsuranceFundingMember_e983fe" order="197" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnSeptemberSixteenTwohousandtwentyMember" xlink:label="loc_vnrxOnSeptemberSixteenTwohousandtwentyMember_f8c03b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxOnSeptemberSixteenTwohousandtwentyMember_f8c03b" order="198" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" xlink:label="loc_vnrxBioinformaticAnalyticsOfCellFreeDNAMember_11904c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1e3a14" xlink:to="loc_vnrxBioinformaticAnalyticsOfCellFreeDNAMember_11904c" order="199" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnivercityOfTexasMDMember" xlink:label="loc_vnrxUnivercityOfTexasMDMember_157c84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain_bc0c2a" xlink:to="loc_vnrxUnivercityOfTexasMDMember_157c84" order="200" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustTenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAugustTenTwoThousandTwentyTwoMember_905fac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxAugustTenTwoThousandTwentyTwoMember_905fac" order="201" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNinteenMember" xlink:label="loc_vnrxInTwoThousandNinteenMember_ec5b4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxInTwoThousandNinteenMember_ec5b4c" order="202" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeArrangementCoPromotionMember" xlink:label="loc_vnrxCollaborativeArrangementCoPromotionMember_a3493c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollectiveBargainingArrangementDomain_9ba740" xlink:to="loc_vnrxCollaborativeArrangementCoPromotionMember_a3493c" order="203" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UniversityOfTaiwanMember" xlink:label="loc_vnrxUniversityOfTaiwanMember_095ad3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxUniversityOfTaiwanMember_095ad3" order="204" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsEightteenMember" xlink:label="loc_vnrxInTwoThousandsEightteenMember_07d940" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxInTwoThousandsEightteenMember_07d940" order="205" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ClinicalStudyResearchAgreementMember" xlink:label="loc_vnrxClinicalStudyResearchAgreementMember_42f05c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1e3a14" xlink:to="loc_vnrxClinicalStudyResearchAgreementMember_42f05c" order="206" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandTwentyMember" xlink:label="loc_vnrxInTwoThousandTwentyMember_12c6b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxInTwoThousandTwentyMember_12c6b0" order="207" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BNPParibasLeasingSolutionsMember" xlink:label="loc_vnrxBNPParibasLeasingSolutionsMember_c7466f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_901dd0" xlink:to="loc_vnrxBNPParibasLeasingSolutionsMember_c7466f" order="208" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FinanceLeaseObligationsMember" xlink:label="loc_vnrxFinanceLeaseObligationsMember_f91c8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain_f425d1" xlink:to="loc_vnrxFinanceLeaseObligationsMember_f91c8b" order="209" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagingDirectorsAgreementMember" xlink:label="loc_vnrxManagingDirectorsAgreementMember_8b256b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1e3a14" xlink:to="loc_vnrxManagingDirectorsAgreementMember_8b256b" order="210" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlanMember" xlink:label="loc_vnrxStockIncentivePlanMember_fe6981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1e3a14" xlink:to="loc_vnrxStockIncentivePlanMember_fe6981" order="211" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2010Member" xlink:label="loc_vnrxIn2010Member_9404ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxIn2010Member_9404ec" order="212" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurMember" xlink:label="loc_vnrxNamurMember_e47dee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_6e44a5" xlink:to="loc_vnrxNamurMember_e47dee" order="213" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SixteenAugustTwoThounsendTwentyTwoMember" xlink:label="loc_vnrxSixteenAugustTwoThounsendTwentyTwoMember_468ced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxSixteenAugustTwoThounsendTwentyTwoMember_468ced" order="214" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" xlink:label="loc_vnrxEighteenNovemberTwoThounsendTwentyTwoMember_0f1617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2c321e" xlink:to="loc_vnrxEighteenNovemberTwoThounsendTwentyTwoMember_0f1617" order="215" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PerformanceBasedAwardMember" xlink:label="loc_vnrxPerformanceBasedAwardMember_1ee4f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577e68" xlink:to="loc_vnrxPerformanceBasedAwardMember_1ee4f3" order="216" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2023Member" xlink:label="loc_vnrxVestIn2023Member_5e84ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain_5b1807" xlink:to="loc_vnrxVestIn2023Member_5e84ee" order="217" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2024Member" xlink:label="loc_vnrxVestIn2024Member_3bbdac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain_5b1807" xlink:to="loc_vnrxVestIn2024Member_3bbdac" order="218" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepyable" xlink:label="loc_vnrxGrantRepyable_5196ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxGrantRepyable_5196ad" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LongTermDebtPayable" xlink:label="loc_vnrxLongTermDebtPayable_64f9dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLongTermDebtPayable_64f9dd" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsForFutureResearchAndCollobration" xlink:label="loc_vnrxPaymentsForFutureResearchAndCollobration_216ad0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxPaymentsForFutureResearchAndCollobration_216ad0" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyalityOnRevenuePercentange" xlink:label="loc_vnrxRoyalityOnRevenuePercentange_a0f8ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRoyalityOnRevenuePercentange_a0f8ac" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggerateAmountPayableDescription" xlink:label="loc_vnrxAggerateAmountPayableDescription_f8191a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAggerateAmountPayableDescription_f8191a" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountPayable" xlink:label="loc_vnrxAmountPayable_85e9e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAmountPayable_85e9e9" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PayableByCompanyForServicesRendered" xlink:label="loc_vnrxPayableByCompanyForServicesRendered_352b31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxPayableByCompanyForServicesRendered_352b31" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnit" xlink:label="loc_vnrxRestrictedStockUnit_f8a636" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRestrictedStockUnit_f8a636" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AccruedCompensationExpense" xlink:label="loc_vnrxAccruedCompensationExpense_57373a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAccruedCompensationExpense_57373a" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpense" xlink:label="loc_vnrxUnrecognizedCompensationExpense_0bd223" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxUnrecognizedCompensationExpense_0bd223" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="loc_us-gaapBusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_852b5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapBusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments_852b5a" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityDate" xlink:label="loc_vnrxMaturityDate_4c89a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxMaturityDate_4c89a4" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ImplicitInterest" xlink:label="loc_vnrxImplicitInterest_eb8c8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxImplicitInterest_eb8c8a" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeasedEquipmentAmortizedPeriod" xlink:label="loc_vnrxLeasedEquipmentAmortizedPeriod_79ce5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLeasedEquipmentAmortizedPeriod_79ce5f" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_616c75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapPaymentsForRoyalties_616c75" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Royality" xlink:label="loc_vnrxRoyality_a05614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRoyality_a05614" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpenses" xlink:label="loc_vnrxUnrecognizedCompensationExpenses_a7b80e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxUnrecognizedCompensationExpenses_a7b80e" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVested" xlink:label="loc_vnrxRSuVested_19f1f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRSuVested_19f1f0" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2024" xlink:label="loc_vnrxRSuVestedIn2024_6b3686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRSuVestedIn2024_6b3686" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2025" xlink:label="loc_vnrxRSuVestedIn2025_714532" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRSuVestedIn2025_714532" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_934321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapShareBasedCompensation_934321" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightOfUseAssets" xlink:label="loc_vnrxOperatingLeaseRightOfUseAssets_fe3a69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxOperatingLeaseRightOfUseAssets_fe3a69" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesLiability1" xlink:label="loc_vnrxOperatingLeasesLiability1_2f1c54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxOperatingLeasesLiability1_2f1c54" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_925588" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_925588" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments_c8eca3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapShortTermLeasePayments_c8eca3" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_6644da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapOperatingLeaseExpense_6644da" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_87b31a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapShortTermLeaseCost_87b31a" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_09d897" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapCostsAndExpenses_09d897" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1b3baa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1b3baa" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaapDilutiveSecurities_8ebc1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapDilutiveSecurities_8ebc1d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_a8f878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_a8f878" order="31" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRateOnLease" xlink:label="loc_vnrxFixedInterestRateOnLease_bae266" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxFixedInterestRateOnLease_bae266" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_7c26fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_7c26fe" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentOfGrants" xlink:label="loc_vnrxRepaymentOfGrants_8c4e2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRepaymentOfGrants_8c4e2b" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_632c16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapOtherIncome_632c16" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfAgreementDescription" xlink:label="loc_vnrxTermsOfAgreementDescription_c9ed79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxTermsOfAgreementDescription_c9ed79" order="36" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountRepayable" xlink:label="loc_vnrxAmountRepayable_fd8012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAmountRepayable_fd8012" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent_a0852e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapGrantsReceivableCurrent_a0852e" order="38" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepaidByInstallments" xlink:label="loc_vnrxGrantRepaidByInstallments_830b29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxGrantRepaidByInstallments_830b29" order="39" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementTerm" xlink:label="loc_vnrxLoanAgreementTerm_83fd76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLoanAgreementTerm_83fd76" order="40" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentsOfLongtermLoans" xlink:label="loc_vnrxRepaymentsOfLongtermLoans_035868" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxRepaymentsOfLongtermLoans_035868" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRate" xlink:label="loc_vnrxFixedInterestRate_17a899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxFixedInterestRate_17a899" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LineOfCreditFacilityExpirationDatesOne" xlink:label="loc_vnrxLineOfCreditFacilityExpirationDatesOne_cb069a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLineOfCreditFacilityExpirationDatesOne_cb069a" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_817c45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapOtherLongTermDebt_817c45" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable_a5664c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_us-gaapOtherNotesPayable_a5664c" order="45" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AgreementUnderAmount" xlink:label="loc_vnrxAgreementUnderAmount_54e1b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAgreementUnderAmount_54e1b5" order="46" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AdditionalCostOfCompany" xlink:label="loc_vnrxAdditionalCostOfCompany_f5f5a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxAdditionalCostOfCompany_f5f5a9" order="47" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmountDue" xlink:label="loc_vnrxCollaborativeObligationsAmountDue_f419b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxCollaborativeObligationsAmountDue_f419b9" order="48" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriods" xlink:label="loc_vnrxLeaseAgreementExpirePeriods_d13328" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLeaseAgreementExpirePeriods_d13328" order="49" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmount" xlink:label="loc_vnrxCollaborativeObligationsAmount_9e9c26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxCollaborativeObligationsAmount_9e9c26" order="50" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriod" xlink:label="loc_vnrxLeaseAgreementExpirePeriod_2ce31b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d2e5d" xlink:to="loc_vnrxLeaseAgreementExpirePeriod_2ce31b" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:title="000060 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_f1344f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a7188d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_f1344f" xlink:to="loc_us-gaapStatementTable_a7188d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4d7eaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a7188d" xlink:to="loc_us-gaapStatementLineItems_4d7eaa" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_2af915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a7188d" xlink:to="loc_us-gaapPlanNameAxis_2af915" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_9defdb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_2af915" xlink:to="loc_us-gaapPlanNameDomain_9defdb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_cc53e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a7188d" xlink:to="loc_us-gaapFinancialInstrumentAxis_cc53e9" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c26f66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_cc53e9" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c26f66" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_91a82c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c26f66" xlink:to="loc_us-gaapOptionMember_91a82c" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember_380a2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_9defdb" xlink:to="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember_380a2a" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalRaiseMember" xlink:label="loc_vnrxCapitalRaiseMember_6db22c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_9defdb" xlink:to="loc_vnrxCapitalRaiseMember_6db22c" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingEventMember" xlink:label="loc_vnrxRsuVestingEventMember_88ae3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_9defdb" xlink:to="loc_vnrxRsuVestingEventMember_88ae3c" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuancesAndRepurchasesMember" xlink:label="loc_vnrxCommonStockIssuancesAndRepurchasesMember_9e350b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_9defdb" xlink:to="loc_vnrxCommonStockIssuancesAndRepurchasesMember_9e350b" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_49c13b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_49c13b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_da79ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_us-gaapSharePrice_da79ba" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_985698" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_985698" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:label="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_c94e2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_c94e2f" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingDescription" xlink:label="loc_vnrxRsuVestingDescription_f450b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxRsuVestingDescription_f450b0" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_5a1aed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_us-gaapCommonStockSharesIssued_5a1aed" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesWithheldForTaxes" xlink:label="loc_vnrxCommonStockSharesWithheldForTaxes_409354" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxCommonStockSharesWithheldForTaxes_409354" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_636d05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_us-gaapRevenues_636d05" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfCommonStock" xlink:label="loc_vnrxSaleOfCommonStock_b81600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxSaleOfCommonStock_b81600" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharePurchase" xlink:label="loc_vnrxCommonStockSharePurchase_e7c3e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxCommonStockSharePurchase_e7c3e6" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPerShare" xlink:label="loc_vnrxCommonStockPerShare_a219ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxCommonStockPerShare_a219ed" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CostOfTheCompany" xlink:label="loc_vnrxCostOfTheCompany_8a04c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4d7eaa" xlink:to="loc_vnrxCostOfTheCompany_8a04c4" order="12" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>vnrx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03-15-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20221231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="vnrx-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="vnrx-20221231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/NatureOfOperations" xlink:href="vnrx-20221231.xsd#NatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipment" xlink:href="vnrx-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssets" xlink:href="vnrx-20221231.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/RelatedPartyTransactions" xlink:href="vnrx-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStock" xlink:href="vnrx-20221231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensation" xlink:href="vnrx-20221231.xsd#StockbasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxes" xlink:href="vnrx-20221231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingencies" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEvents" xlink:href="vnrx-20221231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnrx-20221231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockTables" xlink:href="vnrx-20221231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsTables" xlink:href="vnrx-20221231.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationTables" xlink:href="vnrx-20221231.xsd#StockbasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesTables" xlink:href="vnrx-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="vnrx-20221231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:href="vnrx-20221231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails1" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetails2" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="vnrx-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails" xlink:href="vnrx-20221231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetails1" xlink:href="vnrx-20221231.xsd#CommonStockDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:href="vnrx-20221231.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="vnrx-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:href="vnrx-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSShares" xlink:label="loc_vnrxCommonStockIssuedForSettlementOfRsuSShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockIssuedForSettlementOfRsuSShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedForSettlementOfRsuSAmount" xlink:label="loc_vnrxCommonStockIssuedForSettlementOfRsuSAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockIssuedForSettlementOfRsuSAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuedInPublicOfferingsNetShares" xlink:label="loc_vnrxCommonStockIssuedInPublicOfferingsNetShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockIssuedInPublicOfferingsNetShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation" xlink:label="loc_vnrxTaxWithholdingsPaidRelatedToStockBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxTaxWithholdingsPaidRelatedToStockBasedCompensation" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockBasedCompensationInRelationToModificationOfOptions" xlink:label="loc_vnrxStockBasedCompensationInRelationToModificationOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxStockBasedCompensationInRelationToModificationOfOptions" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:label="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityForeignCurrencyTranslationAdjustments" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/NatureOfOperations" xlink:title="000007 - Disclosure - Nature of Operations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessment" xlink:title="000008 - Disclosure - Liquidity and Going Concern Assessment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - Summary of Significant Accounting Policies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipment" xlink:title="000010 - Disclosure - Property and Equipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssets" xlink:title="000011 - Disclosure - Intangible Assets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/RelatedPartyTransactions" xlink:title="000012 - Disclosure - Related Party Transactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStock" xlink:title="000013 - Disclosure - Common Stock" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensation" xlink:title="000014 - Disclosure - StockBased Compensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxes" xlink:title="000015 - Disclosure - Income Taxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - Commitments and Contingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEvents" xlink:title="000017 - Disclosure - Subsequent Events" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentTables" xlink:title="000019 - Disclosure - Property and Equipment (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockTables" xlink:title="000020 - Disclosure - Common Stock (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsTables" xlink:title="000021 - Disclosure - Intangible Assets (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationTables" xlink:title="000022 - Disclosure - StockBased Compensation (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesTables" xlink:title="000023 - Disclosure - Income Taxes (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesTables" xlink:title="000024 - Disclosure - Commitments and Contingencies (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative" xlink:title="000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="loc_us-gaapRegulatoryAgencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRegulatoryAgencyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaapRegulatoryAgencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegulatoryAgencyAxis" xlink:to="loc_us-gaapRegulatoryAgencyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaapRegulatoryAgencyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRegulatoryAgencyAxis" xlink:to="loc_us-gaapRegulatoryAgencyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BelgianDepositGuaranteeMember" xlink:label="loc_vnrxBelgianDepositGuaranteeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegulatoryAgencyDomain" xlink:to="loc_vnrxBelgianDepositGuaranteeMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SingaporeDepositInsuranceMember" xlink:label="loc_vnrxSingaporeDepositInsuranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegulatoryAgencyDomain" xlink:to="loc_vnrxSingaporeDepositInsuranceMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UKDepositProtectionSchemeMember" xlink:label="loc_vnrxUKDepositProtectionSchemeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegulatoryAgencyDomain" xlink:to="loc_vnrxUKDepositProtectionSchemeMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DilutiveWarrantsAndOptionsMember" xlink:label="loc_vnrxDilutiveWarrantsAndOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_vnrxDilutiveWarrantsAndOptionsMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfLicenseAgreement" xlink:label="loc_vnrxTermsOfLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxTermsOfLicenseAgreement" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForPoc" xlink:label="loc_vnrxInitialTermForPoc" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxInitialTermForPoc" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InitialTermForCentralLab" xlink:label="loc_vnrxInitialTermForCentralLab" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxInitialTermForCentralLab" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UpfrontPayment" xlink:label="loc_vnrxUpfrontPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUpfrontPayment" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MilestoneAmountRecognized" xlink:label="loc_vnrxMilestoneAmountRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxMilestoneAmountRecognized" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ResearchAndDevelopmentExpenses" xlink:label="loc_vnrxResearchAndDevelopmentExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxResearchAndDevelopmentExpenses" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PotentiallyDilutiveWarrantsAndOptions" xlink:label="loc_vnrxPotentiallyDilutiveWarrantsAndOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxPotentiallyDilutiveWarrantsAndOptions" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetails" xlink:title="000027 - Disclosure - Property and Equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LaboratoryEquipmentMember" xlink:label="loc_vnrxLaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_vnrxLaboratoryEquipmentMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaapBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingImprovementsMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLandMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000028 - Disclosure - Property and Equipment (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails" xlink:title="000029 - Disclosure - Intangible Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetails1" xlink:title="000030 - Disclosure - Intangible Assets (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000031 - Disclosure - Intangible Assets (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PatentsAndIntellectualPropertyMember" xlink:label="loc_vnrxPatentsAndIntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_vnrxPatentsAndIntellectualPropertyMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails" xlink:title="000032 - Disclosure - Income Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NetDeferredTaxAssetsMember" xlink:label="loc_vnrxNetDeferredTaxAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_vnrxNetDeferredTaxAssetsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExcessOfTaxOverBookDepreciationAndAmortization" xlink:label="loc_vnrxExcessOfTaxOverBookDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxExcessOfTaxOverBookDepreciationAndAmortization" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrealizedGainLoss" xlink:label="loc_vnrxUnrealizedGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnrealizedGainLoss" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalizedResearchExpenses" xlink:label="loc_vnrxCapitalizedResearchExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCapitalizedResearchExpenses" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ChangeInValuationAllowance" xlink:label="loc_vnrxChangeInValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxChangeInValuationAllowance" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails1" xlink:title="000033 - Disclosure - Income Taxes (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetails2" xlink:title="000034 - Disclosure - Income Taxes (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnitedStateMember" xlink:label="loc_vnrxUnitedStateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_vnrxUnitedStateMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ForeignMember" xlink:label="loc_vnrxForeignMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_vnrxForeignMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncreaseInValuationAllowance" xlink:label="loc_vnrxIncreaseInValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncreaseInValuationAllowance" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="000035 - Disclosure - Income Taxes (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails" xlink:title="000036 - Disclosure - Common Stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryEightTwentyThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxFebruaryEightTwentyThousandTwentyOneMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesTwoMember" xlink:label="loc_vnrxStockOptionExercisesTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionExercisesTwoMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryEightFebruaryNineTwentyThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxFebruaryEightFebruaryNineTwentyThousandTwentyOneMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesMember" xlink:label="loc_vnrxStockOptionExercisesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionExercisesMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" xlink:label="loc_vnrxJanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxJanuaryThirteenMarchNinteenTwoThousandTwentyOneMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryTwoTwentyThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryTwoTwentyThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxFebruaryTwoTwentyThousandTwentyOneMember" order="46" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionExercisesOneMember" xlink:label="loc_vnrxStockOptionExercisesOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionExercisesOneMember" order="47" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember" xlink:label="loc_vnrxMarchTwentyFiveTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxMarchTwentyFiveTwoThousandTwentyTwoMember" order="48" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAprilThirteenTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAprilThirteenTwoThousandTwentyTwoMember" order="49" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MayOneTwoThousandTwentyTwoMember" xlink:label="loc_vnrxMayOneTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxMayOneTwoThousandTwentyTwoMember" order="50" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustThreeTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAugustThreeTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAugustThreeTwoThousandTwentyTwoMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SeptemberSevenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxSeptemberSevenTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxSeptemberSevenTwoThousandTwentyTwoMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OctoberFourTwoThousandTwentyTwoMember" xlink:label="loc_vnrxOctoberFourTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxOctoberFourTwoThousandTwentyTwoMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NovemberOneTwoThousandTwentyTwoMember" xlink:label="loc_vnrxNovemberOneTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxNovemberOneTwoThousandTwentyTwoMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DecemberFifteenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxDecemberFifteenTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxDecemberFifteenTwoThousandTwentyTwoMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareIssuedUponCashlessExercise" xlink:label="loc_vnrxCommonStockShareIssuedUponCashlessExercise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockShareIssuedUponCashlessExercise" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlan" xlink:label="loc_vnrxStockIncentivePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxStockIncentivePlan" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsVested" xlink:label="loc_vnrxRestrictedStockUnitsVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRestrictedStockUnitsVested" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitVested" xlink:label="loc_vnrxRestrictedStockUnitVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRestrictedStockUnitVested" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesWithheldForTax" xlink:label="loc_vnrxSharesWithheldForTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharesWithheldForTax" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetails1" xlink:title="000037 - Disclosure - Common Stock (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryTwentyTwentyThusandTwentyOneMember" xlink:label="loc_vnrxJanuaryTwentyTwentyThusandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxJanuaryTwentyTwentyThusandTwentyOneMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSUSettlementsMember" xlink:label="loc_vnrxRSUSettlementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxRSUSettlementsMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilTwentyOneTwentyTwentyOneMember" xlink:label="loc_vnrxAprilTwentyOneTwentyTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAprilTwentyOneTwentyTwentyOneMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitVested" xlink:label="loc_vnrxRestrictedStockUnitVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRestrictedStockUnitVested" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfStockPriceSettledPerShare" xlink:label="loc_vnrxSaleOfStockPriceSettledPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSaleOfStockPriceSettledPerShare" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommonStockDetailsNarrative" xlink:title="000038 - Disclosure - Common Stock (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnderwritingAgreementMember" xlink:label="loc_vnrxUnderwritingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxUnderwritingAgreementMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityDistributionAgreementMember" xlink:label="loc_vnrxEquityDistributionAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxEquityDistributionAgreementMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IssuedOfCommonStockFromSettlementOfRSU" xlink:label="loc_vnrxIssuedOfCommonStockFromSettlementOfRSU" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIssuedOfCommonStockFromSettlementOfRSU" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPricePerSahres" xlink:label="loc_vnrxCommonStockPricePerSahres" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockPricePerSahres" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockShareAuthorized" xlink:label="loc_vnrxCommonStockShareAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockShareAuthorized" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggeregateShareOfCommonStockOfferingPrice" xlink:label="loc_vnrxAggeregateShareOfCommonStockOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAggeregateShareOfCommonStockOfferingPrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BrokerageFees" xlink:label="loc_vnrxBrokerageFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxBrokerageFees" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PurchasePricePerShare" xlink:label="loc_vnrxPurchasePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxPurchasePricePerShare" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OfferingExpenses" xlink:label="loc_vnrxOfferingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOfferingExpenses" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails" xlink:title="000039 - Disclosure - StockBased Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingBeginningBalance" xlink:label="loc_vnrxNumberOfWarrantsOutstandingBeginningBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsOutstandingBeginningBalance" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsAbstract" xlink:label="loc_vnrxNumberOfWarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsAbstract" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceAbstract" xlink:label="loc_vnrxWeightedExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedExercisePriceAbstract" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercised" xlink:label="loc_vnrxNumberOfWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsExercised" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExpired" xlink:label="loc_vnrxNumberOfWarrantsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsExpired" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfWarrantsOutstandingEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsOutstandingEndingBalance" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfWarrantsExercisable" xlink:label="loc_vnrxNumberOfWarrantsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfWarrantsExercisable" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalanceOne" xlink:label="loc_vnrxWeightedAverageExercisePriceOutstandingBalanceOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceOutstandingBalanceOne" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExercised" xlink:label="loc_vnrxWeightedExercisePriceExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedExercisePriceExercised" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedExercisePriceExpired" xlink:label="loc_vnrxWeightedExercisePriceExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedExercisePriceExpired" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalanceOne" xlink:label="loc_vnrxWeightedAverageExercisePriceEndingBalanceOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceEndingBalanceOne" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisable" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisable" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails1" xlink:title="000040 - Disclosure - StockBased Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantOneMember" xlink:label="loc_vnrxWarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantOneMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantTwoMember" xlink:label="loc_vnrxWarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantThreeMember" xlink:label="loc_vnrxWarrantThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantThreeMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFourMember" xlink:label="loc_vnrxWarrantsFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantsFourMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsFiveMember" xlink:label="loc_vnrxWarrantsFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantsFiveMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExercisePrice" xlink:label="loc_vnrxExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxExercisePrice" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails2" xlink:title="000041 - Disclosure - StockBased Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionFourMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsOutstandingBeginningBalance" xlink:label="loc_vnrxNumberOfOptionsOutstandingBeginningBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfOptionsOutstandingBeginningBalance" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" xlink:label="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfExpiredCancelled" xlink:label="loc_vnrxNumberOfExpiredCancelled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfExpiredCancelled" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfOptionOutstandingEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfOptionOutstandingEndingBalance" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfOptionsExercisable" xlink:label="loc_vnrxNumberOfOptionsExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfOptionsExercisable" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceOutstandingBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceOutstandingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceOutstandingBalance" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceGranted" xlink:label="loc_vnrxWeightedAverageExercisePriceGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceGranted" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercised" xlink:label="loc_vnrxWeightedAverageExercisePriceExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceExercised" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisedExpiresCancelled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisedExpiresCancelled" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceEndingBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceEndingBalance" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageExercisePriceExercisableBalance" xlink:label="loc_vnrxWeightedAverageExercisePriceExercisableBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageExercisePriceExercisableBalance" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails3" xlink:title="000042 - Disclosure - StockBased Compensation (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentOneMember" xlink:label="loc_vnrxStockOptionsAmendmentOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentOneMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwoMember" xlink:label="loc_vnrxStockOptionsAmendmentTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentTwoMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThreeMember" xlink:label="loc_vnrxStockOptionsAmendmentThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentThreeMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourMember" xlink:label="loc_vnrxStockOptionsAmendmentFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentFourMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFiveMember" xlink:label="loc_vnrxStockOptionsAmendmentFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentFiveMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSixMember" xlink:label="loc_vnrxStockOptionsAmendmentSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentSixMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentSevenMember" xlink:label="loc_vnrxStockOptionsAmendmentSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentSevenMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentEightMember" xlink:label="loc_vnrxStockOptionsAmendmentEightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentEightMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentNineMember" xlink:label="loc_vnrxStockOptionsAmendmentNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentNineMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTenMember" xlink:label="loc_vnrxStockOptionsAmendmentTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentTenMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentElevenMember" xlink:label="loc_vnrxStockOptionsAmendmentElevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentElevenMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentTwelveMember" xlink:label="loc_vnrxStockOptionsAmendmentTwelveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentTwelveMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentThirteenMember" xlink:label="loc_vnrxStockOptionsAmendmentThirteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentThirteenMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsAmendmentFourteenMember" xlink:label="loc_vnrxStockOptionsAmendmentFourteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxStockOptionsAmendmentFourteenMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ApprovedStockOptions" xlink:label="loc_vnrxApprovedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxApprovedStockOptions" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlan" xlink:label="loc_vnrxEquityIncentivePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxEquityIncentivePlan" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionGrantDate" xlink:label="loc_vnrxStockOptionGrantDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxStockOptionGrantDate" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_stockoptionamendmentdate" xlink:label="loc_vnrxstockoptionamendmentdate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxstockoptionamendmentdate" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails4" xlink:title="000043 - Disclosure - StockBased Compensation (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionFourMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionsOneMember" xlink:label="loc_vnrxOptionsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionsOneMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionTwoMember" xlink:label="loc_vnrxOptionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThreeMember" xlink:label="loc_vnrxStockOptionThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionThreeMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFiveMember" xlink:label="loc_vnrxOptionFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionFiveMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSixMember" xlink:label="loc_vnrxStockOptionSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionSixMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSevenMember" xlink:label="loc_vnrxStockOptionSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionSevenMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionEightMember" xlink:label="loc_vnrxStockOptionEightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionEightMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionNineMember" xlink:label="loc_vnrxStockOptionNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionNineMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalStockOptionOneMember" xlink:label="loc_vnrxTotalStockOptionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxTotalStockOptionOneMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails5" xlink:title="000044 - Disclosure - StockBased Compensation (Details 5)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsMember" xlink:label="loc_vnrxStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_vnrxStockOptionsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingBeginingBalance" xlink:label="loc_vnrxNumberOfRsusOutstandingBeginingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfRsusOutstandingBeginingBalance" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedShares" xlink:label="loc_vnrxGrantedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantedShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockVested" xlink:label="loc_vnrxNumberOfStockVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfStockVested" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockCancelled" xlink:label="loc_vnrxNumberOfStockCancelled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfStockCancelled" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfRsusOutstandingEndingBalance" xlink:label="loc_vnrxNumberOfRsusOutstandingEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfRsusOutstandingEndingBalance" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceBeginningBalance" xlink:label="loc_vnrxSharePriceBeginningBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharePriceBeginningBalance" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceGranted" xlink:label="loc_vnrxSharePriceGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharePriceGranted" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceVested" xlink:label="loc_vnrxSharePriceVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharePriceVested" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Cancelled" xlink:label="loc_vnrxCancelled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCancelled" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharePriceEndingBalance" xlink:label="loc_vnrxSharePriceEndingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharePriceEndingBalance" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails6" xlink:title="000045 - Disclosure - StockBased Compensation (Details 6)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseNineMember" xlink:label="loc_vnrxCompensationExpenseNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseNineMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTenMember" xlink:label="loc_vnrxCompensationExpenseTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseTenMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseOneMember" xlink:label="loc_vnrxCompensationExpenseOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseOneMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseTwoMember" xlink:label="loc_vnrxCompensationExpenseTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseTwoMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseThreeMember" xlink:label="loc_vnrxCompensationExpenseThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseThreeMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFourMember" xlink:label="loc_vnrxCompensationExpenseFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseFourMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseFiveMember" xlink:label="loc_vnrxCompensationExpenseFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseFiveMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSixMember" xlink:label="loc_vnrxCompensationExpenseSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseSixMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseSevenMember" xlink:label="loc_vnrxCompensationExpenseSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseSevenMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseEightMember" xlink:label="loc_vnrxCompensationExpenseEightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxCompensationExpenseEightMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseRsus" xlink:label="loc_vnrxCompensationExpenseRsus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCompensationExpenseRsus" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlan" xlink:label="loc_vnrxEquityIncentivePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxEquityIncentivePlan" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseGrantDate" xlink:label="loc_vnrxCompensationExpenseGrantDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCompensationExpenseGrantDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationExpenseVestingPeriod" xlink:label="loc_vnrxCompensationExpenseVestingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCompensationExpenseVestingPeriod" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstVestingDate" xlink:label="loc_vnrxFirstVestingDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFirstVestingDate" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SecondVestingDate" xlink:label="loc_vnrxSecondVestingDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSecondVestingDate" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ThirdVestingDate" xlink:label="loc_vnrxThirdVestingDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxThirdVestingDate" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuExpense" xlink:label="loc_vnrxRsuExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRsuExpense" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails7" xlink:title="000046 - Disclosure - StockBased Compensation (Details 7)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanOneMember" xlink:label="loc_vnrxEquityIncentivePlanOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanOneMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanTwoMember" xlink:label="loc_vnrxEquityIncentivePlanTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanTwoMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanThreeMember" xlink:label="loc_vnrxEquityIncentivePlanThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanThreeMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFourMember" xlink:label="loc_vnrxEquityIncentivePlanFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanFourMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFiveMember" xlink:label="loc_vnrxEquityIncentivePlanFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanFiveMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSixMember" xlink:label="loc_vnrxEquityIncentivePlanSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanSixMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanSevenMember" xlink:label="loc_vnrxEquityIncentivePlanSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanSevenMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanEightMember" xlink:label="loc_vnrxEquityIncentivePlanEightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanEightMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentivePlan" xlink:label="loc_vnrxIncentivePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncentivePlan" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentiveRsu" xlink:label="loc_vnrxEquityIncentiveRsu" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxEquityIncentiveRsu" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveVestDate" xlink:label="loc_vnrxIncentiveVestDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncentiveVestDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsuIssued" xlink:label="loc_vnrxIncentiveRsuIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncentiveRsuIssued" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsusHeldForTaxes" xlink:label="loc_vnrxRsusHeldForTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRsusHeldForTaxes" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails8" xlink:title="000047 - Disclosure - StockBased Compensation (Details 8)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanOneMember" xlink:label="loc_vnrxEquityIncentivePlanOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanOneMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanTwoMember" xlink:label="loc_vnrxEquityIncentivePlanTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanTwoMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanThreeMember" xlink:label="loc_vnrxEquityIncentivePlanThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanThreeMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EquityIncentivePlanFourMember" xlink:label="loc_vnrxEquityIncentivePlanFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxEquityIncentivePlanFourMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuCancelled" xlink:label="loc_vnrxRsuCancelled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRsuCancelled" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentivePlan" xlink:label="loc_vnrxIncentivePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncentivePlan" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_IncentiveRsu" xlink:label="loc_vnrxIncentiveRsu" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxIncentiveRsu" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CancellationDate" xlink:label="loc_vnrxCancellationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCancellationDate" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestDate" xlink:label="loc_vnrxVestDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxVestDate" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetails9" xlink:title="000048 - Disclosure - StockBased Compensation (Details 9)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFourMember" xlink:label="loc_vnrxOptionFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionFourMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionsOneMember" xlink:label="loc_vnrxOptionsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionsOneMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionTwoMember" xlink:label="loc_vnrxOptionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThreeMember" xlink:label="loc_vnrxStockOptionThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionThreeMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionFiveMember" xlink:label="loc_vnrxOptionFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxOptionFiveMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSixMember" xlink:label="loc_vnrxStockOptionSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionSixMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionSevenMember" xlink:label="loc_vnrxStockOptionSevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionSevenMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionEightMember" xlink:label="loc_vnrxStockOptionEightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionEightMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionNineMember" xlink:label="loc_vnrxStockOptionNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionNineMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TotalStockOptionOneMember" xlink:label="loc_vnrxTotalStockOptionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxTotalStockOptionOneMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTenMember" xlink:label="loc_vnrxStockOptionTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionTenMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionElevenMember" xlink:label="loc_vnrxStockOptionElevenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionElevenMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionTwelveMember" xlink:label="loc_vnrxStockOptionTwelveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionTwelveMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFourteenTenMember" xlink:label="loc_vnrxStockOptionFourteenTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionFourteenTenMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionFiveteenTenMember" xlink:label="loc_vnrxStockOptionFiveteenTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionFiveteenTenMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionThirteenTenMember" xlink:label="loc_vnrxStockOptionThirteenTenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxStockOptionThirteenTenMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfStockOutstandingBalance" xlink:label="loc_vnrxNumberOfStockOutstandingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfStockOutstandingBalance" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SharesPriceRsu" xlink:label="loc_vnrxSharesPriceRsu" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSharesPriceRsu" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WeightedAverageRemainingContractualLifeYears" xlink:label="loc_vnrxWeightedAverageRemainingContractualLifeYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxWeightedAverageRemainingContractualLifeYears" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000049 - Disclosure - StockBased Compensation (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WarrantsMember" xlink:label="loc_vnrxWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_vnrxWarrantsMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilFourTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAprilFourTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAprilFourTwoThousandTwentyTwoMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FebruaryOneTwoThousandTwentyOneMember" xlink:label="loc_vnrxFebruaryOneTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxFebruaryOneTwoThousandTwentyOneMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_JanuaryOneTwoThousandTwentyOneMember" xlink:label="loc_vnrxJanuaryOneTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxJanuaryOneTwoThousandTwentyOneMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AprilThirteenTwoThousandTwentyMember" xlink:label="loc_vnrxAprilThirteenTwoThousandTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAprilThirteenTwoThousandTwentyMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsMember" xlink:label="loc_vnrxRestrictedStockUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxRestrictedStockUnitsMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnTwoZeroMayTwoThousandTwentyOneMember" xlink:label="loc_vnrxOnTwoZeroMayTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxOnTwoZeroMayTwoThousandTwentyOneMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnitsOneMember" xlink:label="loc_vnrxRestrictedStockUnitsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxRestrictedStockUnitsOneMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockAvailable" xlink:label="loc_vnrxCommonStockAvailable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockAvailable" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareAggregateMaximum" xlink:label="loc_vnrxShareAggregateMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxShareAggregateMaximum" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OptionGranted" xlink:label="loc_vnrxOptionGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOptionGranted" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ApprovedStockOptions" xlink:label="loc_vnrxApprovedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxApprovedStockOptions" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NumberOfSharesVesting" xlink:label="loc_vnrxNumberOfSharesVesting" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxNumberOfSharesVesting" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FairValueOfOptions" xlink:label="loc_vnrxFairValueOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFairValueOfOptions" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesIssuableUponExerciseOfStockOption" xlink:label="loc_vnrxCommonStockSharesIssuableUponExerciseOfStockOption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockSharesIssuableUponExerciseOfStockOption" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ExercisePrice" xlink:label="loc_vnrxExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VolatilityRate" xlink:label="loc_vnrxVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxVolatilityRate" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Volatility" xlink:label="loc_vnrxVolatility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxVolatility" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestingAggregate" xlink:label="loc_vnrxVestingAggregate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxVestingAggregate" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggregrateAggregate" xlink:label="loc_vnrxAggregrateAggregate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAggregrateAggregate" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedAggregate" xlink:label="loc_vnrxGrantedAggregate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantedAggregate" order="20" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantedRsu" xlink:label="loc_vnrxGrantedRsu" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantedRsu" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_DescriptionOfVestingShall" xlink:label="loc_vnrxDescriptionOfVestingShall" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxDescriptionOfVestingShall" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationCost" xlink:label="loc_vnrxUnrecognizedCompensationCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnrecognizedCompensationCost" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="25" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockCompensationExpenses" xlink:label="loc_vnrxStockCompensationExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxStockCompensationExpenses" order="26" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityTerm" xlink:label="loc_vnrxMaturityTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxMaturityTerm" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" xlink:label="loc_us-gaapMultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" order="30" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockOptionsPurchaseSharesOfCommonStock" xlink:label="loc_vnrxStockOptionsPurchaseSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxStockOptionsPurchaseSharesOfCommonStock" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CompensationCostRelatedToNonVestedWarrants" xlink:label="loc_vnrxCompensationCostRelatedToNonVestedWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCompensationCostRelatedToNonVestedWarrants" order="34" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FinanceLeaseObligationsMember" xlink:label="loc_vnrxFinanceLeaseObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_vnrxFinanceLeaseObligationsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LessAmountRepresentingInterest" xlink:label="loc_vnrxLessAmountRepresentingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLessAmountRepresentingInterest" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="9" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - Commitments and Contingencies (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightofUseObligationsMember" xlink:label="loc_vnrxOperatingLeaseRightofUseObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOperatingLeaseRightofUseObligationsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearTwo" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo" xlink:label="loc_vnrxFiniteLivedIntangibleAssetAmortizationExpenseYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFiniteLivedIntangibleAssetAmortizationExpenseYearTwo" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFour" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDueInRollingYearFive" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentsDueInRollingYearSix" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseObligations" xlink:label="loc_vnrxOperatingLeaseObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeaseObligations" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LessAmountRepresentingInterest" xlink:label="loc_vnrxLessAmountRepresentingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLessAmountRepresentingInterest" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesFutureMinimumPaymentDue" xlink:label="loc_vnrxOperatingLeasesFutureMinimumPaymentDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesFutureMinimumPaymentDue" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails2" xlink:title="000052 - Disclosure - Commitments and Contingencies (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails3" xlink:title="000053 - Disclosure - Commitments and Contingencies (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayableMember" xlink:label="loc_vnrxGrantsRepayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxGrantsRepayableMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" xlink:label="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantsRepayable" xlink:label="loc_vnrxGrantsRepayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantsRepayable" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails4" xlink:title="000054 - Disclosure - Commitments and Contingencies (Details 4)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails5" xlink:title="000055 - Disclosure - Commitments and Contingencies (Details 5)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails6" xlink:title="000056 - Disclosure - Commitments and Contingencies (Details 6)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxAwardOneMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOutstandingAwardTwoMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2022" xlink:label="loc_vnrxAmortisedOfOutstandingAward2022" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmortisedOfOutstandingAward2022" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2021" xlink:label="loc_vnrxAmortisedOfOutstandingAward2021" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmortisedOfOutstandingAward2021" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward2023" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward2023" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward2023" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails7" xlink:title="000057 - Disclosure - Commitments and Contingencies (Details 7)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxAwardOneMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOutstandingAwardTwoMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2022" xlink:label="loc_vnrxAmortisedOfOutstandingAward2022" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmortisedOfOutstandingAward2022" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAward2021" xlink:label="loc_vnrxAmortisedOfOutstandingAward2021" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmortisedOfOutstandingAward2021" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward2023" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward2023" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward2023" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetails8" xlink:title="000058 - Disclosure - Commitments and Contingencies (Details 8)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AwardOneMember" xlink:label="loc_vnrxAwardOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxAwardOneMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardTwoMember" xlink:label="loc_vnrxOutstandingAwardTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOutstandingAwardTwoMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardThreeMember" xlink:label="loc_vnrxOutstandingAwardThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOutstandingAwardThreeMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAwardVestingPeriod" xlink:label="loc_vnrxOutstandingAwardVestingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOutstandingAwardVestingPeriod" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmortisedOfOutstandingAwardAmount" xlink:label="loc_vnrxAmortisedOfOutstandingAwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmortisedOfOutstandingAwardAmount" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnAmortisedOfOutstandingAward" xlink:label="loc_vnrxUnAmortisedOfOutstandingAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnAmortisedOfOutstandingAward" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OutstandingAward" xlink:label="loc_vnrxOutstandingAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOutstandingAward" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000059 - Disclosure - Commitments and Contingencies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="120" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="120" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" order="130" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementAxis" xlink:label="loc_us-gaapCollectiveBargainingArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCollectiveBargainingArrangementAxis" order="130" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain" xlink:label="loc_us-gaapCollectiveBargainingArrangementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCollectiveBargainingArrangementAxis" xlink:to="loc_us-gaapCollectiveBargainingArrangementDomain" order="140" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollectiveBargainingArrangementDomain" xlink:label="loc_us-gaapCollectiveBargainingArrangementDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapCollectiveBargainingArrangementAxis" xlink:to="loc_us-gaapCollectiveBargainingArrangementDomain_10" order="150" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="140" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="160" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="160" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" order="170" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="160" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="170" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="180" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="180" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="190" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" order="200" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightofUseObligationsMember" xlink:label="loc_vnrxOperatingLeaseRightofUseObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxOperatingLeaseRightofUseObligationsMember" order="181" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_WalloonRegionGovernmentMember" xlink:label="loc_vnrxWalloonRegionGovernmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxWalloonRegionGovernmentMember" order="182" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsTwentyTwentyMember" xlink:label="loc_vnrxInTwoThousandsTwentyTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxInTwoThousandsTwentyTwentyMember" order="183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember" xlink:label="loc_us-gaapAdditionalFundingAgreementTermsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapAdditionalFundingAgreementTermsMember" order="184" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInvestMember" xlink:label="loc_vnrxNamurInvestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxNamurInvestMember" order="185" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2016Member" xlink:label="loc_vnrxIn2016Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxIn2016Member" order="186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapLongTermDebtMember" order="187" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementMember" xlink:label="loc_vnrxLoanAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxLoanAgreementMember" order="188" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_INGMember" xlink:label="loc_vnrxINGMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxINGMember" order="189" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNineteenMember" xlink:label="loc_vnrxInTwoThousandNineteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxInTwoThousandNineteenMember" order="190" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2018Member" xlink:label="loc_vnrxIn2018Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxIn2018Member" order="191" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurInnovationAndGrowthMember" xlink:label="loc_vnrxNamurInnovationAndGrowthMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_vnrxNamurInnovationAndGrowthMember" order="192" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SOFINEXMember" xlink:label="loc_vnrxSOFINEXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxSOFINEXMember" order="193" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2017Member" xlink:label="loc_vnrxIn2017Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxIn2017Member" order="194" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" xlink:label="loc_vnrxTwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxTwentyTreeNovemberTwoThounsendTwentyTwentyOneMember" order="195" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember" xlink:label="loc_vnrxFiveFebruaryTwoThounsendTwentyTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxFiveFebruaryTwoThounsendTwentyTwentyTwoMember" order="196" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FirstInsuranceFundingMember" xlink:label="loc_vnrxFirstInsuranceFundingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_vnrxFirstInsuranceFundingMember" order="197" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OnSeptemberSixteenTwohousandtwentyMember" xlink:label="loc_vnrxOnSeptemberSixteenTwohousandtwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxOnSeptemberSixteenTwohousandtwentyMember" order="198" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BioinformaticAnalyticsOfCellFreeDNAMember" xlink:label="loc_vnrxBioinformaticAnalyticsOfCellFreeDNAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxBioinformaticAnalyticsOfCellFreeDNAMember" order="199" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnivercityOfTexasMDMember" xlink:label="loc_vnrxUnivercityOfTexasMDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_vnrxUnivercityOfTexasMDMember" order="200" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AugustTenTwoThousandTwentyTwoMember" xlink:label="loc_vnrxAugustTenTwoThousandTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxAugustTenTwoThousandTwentyTwoMember" order="201" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandNinteenMember" xlink:label="loc_vnrxInTwoThousandNinteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxInTwoThousandNinteenMember" order="202" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeArrangementCoPromotionMember" xlink:label="loc_vnrxCollaborativeArrangementCoPromotionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollectiveBargainingArrangementDomain" xlink:to="loc_vnrxCollaborativeArrangementCoPromotionMember" order="203" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UniversityOfTaiwanMember" xlink:label="loc_vnrxUniversityOfTaiwanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxUniversityOfTaiwanMember" order="204" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandsEightteenMember" xlink:label="loc_vnrxInTwoThousandsEightteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxInTwoThousandsEightteenMember" order="205" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ClinicalStudyResearchAgreementMember" xlink:label="loc_vnrxClinicalStudyResearchAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxClinicalStudyResearchAgreementMember" order="206" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_InTwoThousandTwentyMember" xlink:label="loc_vnrxInTwoThousandTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxInTwoThousandTwentyMember" order="207" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_BNPParibasLeasingSolutionsMember" xlink:label="loc_vnrxBNPParibasLeasingSolutionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_vnrxBNPParibasLeasingSolutionsMember" order="208" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FinanceLeaseObligationsMember" xlink:label="loc_vnrxFinanceLeaseObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_vnrxFinanceLeaseObligationsMember" order="209" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ManagingDirectorsAgreementMember" xlink:label="loc_vnrxManagingDirectorsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxManagingDirectorsAgreementMember" order="210" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_StockIncentivePlanMember" xlink:label="loc_vnrxStockIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxStockIncentivePlanMember" order="211" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_In2010Member" xlink:label="loc_vnrxIn2010Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxIn2010Member" order="212" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_NamurMember" xlink:label="loc_vnrxNamurMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_vnrxNamurMember" order="213" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SixteenAugustTwoThounsendTwentyTwoMember" xlink:label="loc_vnrxSixteenAugustTwoThounsendTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxSixteenAugustTwoThounsendTwentyTwoMember" order="214" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_EighteenNovemberTwoThounsendTwentyTwoMember" xlink:label="loc_vnrxEighteenNovemberTwoThounsendTwentyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_vnrxEighteenNovemberTwoThounsendTwentyTwoMember" order="215" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PerformanceBasedAwardMember" xlink:label="loc_vnrxPerformanceBasedAwardMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vnrxPerformanceBasedAwardMember" order="216" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2023Member" xlink:label="loc_vnrxVestIn2023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_vnrxVestIn2023Member" order="217" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_VestIn2024Member" xlink:label="loc_vnrxVestIn2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_vnrxVestIn2024Member" order="218" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepyable" xlink:label="loc_vnrxGrantRepyable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantRepyable" order="1" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LongTermDebtPayable" xlink:label="loc_vnrxLongTermDebtPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLongTermDebtPayable" order="2" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PaymentsForFutureResearchAndCollobration" xlink:label="loc_vnrxPaymentsForFutureResearchAndCollobration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxPaymentsForFutureResearchAndCollobration" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RoyalityOnRevenuePercentange" xlink:label="loc_vnrxRoyalityOnRevenuePercentange" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRoyalityOnRevenuePercentange" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AggerateAmountPayableDescription" xlink:label="loc_vnrxAggerateAmountPayableDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAggerateAmountPayableDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountPayable" xlink:label="loc_vnrxAmountPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmountPayable" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_PayableByCompanyForServicesRendered" xlink:label="loc_vnrxPayableByCompanyForServicesRendered" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxPayableByCompanyForServicesRendered" order="7" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RestrictedStockUnit" xlink:label="loc_vnrxRestrictedStockUnit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRestrictedStockUnit" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AccruedCompensationExpense" xlink:label="loc_vnrxAccruedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAccruedCompensationExpense" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpense" xlink:label="loc_vnrxUnrecognizedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnrecognizedCompensationExpense" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" xlink:label="loc_us-gaapBusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_MaturityDate" xlink:label="loc_vnrxMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxMaturityDate" order="12" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ImplicitInterest" xlink:label="loc_vnrxImplicitInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxImplicitInterest" order="13" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeasedEquipmentAmortizedPeriod" xlink:label="loc_vnrxLeasedEquipmentAmortizedPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLeasedEquipmentAmortizedPeriod" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" order="15" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_Royality" xlink:label="loc_vnrxRoyality" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRoyality" order="16" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_UnrecognizedCompensationExpenses" xlink:label="loc_vnrxUnrecognizedCompensationExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxUnrecognizedCompensationExpenses" order="17" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVested" xlink:label="loc_vnrxRSuVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRSuVested" order="18" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2024" xlink:label="loc_vnrxRSuVestedIn2024" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRSuVestedIn2024" order="19" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RSuVestedIn2025" xlink:label="loc_vnrxRSuVestedIn2025" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRSuVestedIn2025" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeaseRightOfUseAssets" xlink:label="loc_vnrxOperatingLeaseRightOfUseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeaseRightOfUseAssets" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_OperatingLeasesLiability1" xlink:label="loc_vnrxOperatingLeasesLiability1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxOperatingLeasesLiability1" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeasePayments" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaapDilutiveSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDilutiveSecurities" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" order="31" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRateOnLease" xlink:label="loc_vnrxFixedInterestRateOnLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFixedInterestRateOnLease" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" order="33" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentOfGrants" xlink:label="loc_vnrxRepaymentOfGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRepaymentOfGrants" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherIncome" order="35" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TermsOfAgreementDescription" xlink:label="loc_vnrxTermsOfAgreementDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxTermsOfAgreementDescription" order="36" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AmountRepayable" xlink:label="loc_vnrxAmountRepayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAmountRepayable" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrantsReceivableCurrent" order="38" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_GrantRepaidByInstallments" xlink:label="loc_vnrxGrantRepaidByInstallments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxGrantRepaidByInstallments" order="39" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LoanAgreementTerm" xlink:label="loc_vnrxLoanAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLoanAgreementTerm" order="40" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RepaymentsOfLongtermLoans" xlink:label="loc_vnrxRepaymentsOfLongtermLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRepaymentsOfLongtermLoans" order="41" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_FixedInterestRate" xlink:label="loc_vnrxFixedInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxFixedInterestRate" order="42" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LineOfCreditFacilityExpirationDatesOne" xlink:label="loc_vnrxLineOfCreditFacilityExpirationDatesOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLineOfCreditFacilityExpirationDatesOne" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLongTermDebt" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNotesPayable" order="45" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AgreementUnderAmount" xlink:label="loc_vnrxAgreementUnderAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAgreementUnderAmount" order="46" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_AdditionalCostOfCompany" xlink:label="loc_vnrxAdditionalCostOfCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxAdditionalCostOfCompany" order="47" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmountDue" xlink:label="loc_vnrxCollaborativeObligationsAmountDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCollaborativeObligationsAmountDue" order="48" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriods" xlink:label="loc_vnrxLeaseAgreementExpirePeriods" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLeaseAgreementExpirePeriods" order="49" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CollaborativeObligationsAmount" xlink:label="loc_vnrxCollaborativeObligationsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCollaborativeObligationsAmount" order="50" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_LeaseAgreementExpirePeriod" xlink:label="loc_vnrxLeaseAgreementExpirePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxLeaseAgreementExpirePeriod" order="51" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/SubsequentEventsDetailsNarrative" xlink:title="000060 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxTwoThousandFifteenEquityIncentivePlanMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CapitalRaiseMember" xlink:label="loc_vnrxCapitalRaiseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxCapitalRaiseMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingEventMember" xlink:label="loc_vnrxRsuVestingEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxRsuVestingEventMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockIssuancesAndRepurchasesMember" xlink:label="loc_vnrxCommonStockIssuancesAndRepurchasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_vnrxCommonStockIssuancesAndRepurchasesMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="3" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:label="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" order="4" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_RsuVestingDescription" xlink:label="loc_vnrxRsuVestingDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxRsuVestingDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="6" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharesWithheldForTaxes" xlink:label="loc_vnrxCommonStockSharesWithheldForTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockSharesWithheldForTaxes" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="8" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_SaleOfCommonStock" xlink:label="loc_vnrxSaleOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxSaleOfCommonStock" order="9" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockSharePurchase" xlink:label="loc_vnrxCommonStockSharePurchase" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockSharePurchase" order="10" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CommonStockPerShare" xlink:label="loc_vnrxCommonStockPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCommonStockPerShare" order="11" />
    <link:loc xlink:type="locator" xlink:href="vnrx-20221231.xsd#vnrx_CostOfTheCompany" xlink:label="loc_vnrxCostOfTheCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_vnrxCostOfTheCompany" order="12" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vnrx_10kimg4.jpg
<TEXT>
begin 644 vnrx_10kimg4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %3 EH# 2(  A$! Q$!_\0
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MT 1[:-M2;:-M $>VG;:DVT;: (]M&VI-M&V@"';1MJ;;3=M $>VF[:FVT;:
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M&[:=MIVVG;: &[:=MIVVG;: (]M.VT[;3MM R/;3MM.VT[;0!'MHVU)MHVT
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M:HVJ1D;5&U2-4;51F1M4+5,U1M0!"U1M4S5&U B%JC:IFJ-JHDC:H^:D:FT
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ME-R1&$ISI4E"6Z'4ZFT5D=HZG4VB@D=1110 M%)10 4444 %-HHH&%-HIO-
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M:HVH)(VJ-JD:FM0(A:FM4C5&U401M4;5,U1M0!"U-J2FTR326G+3E6G*M0;
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MW_?Q:FBU!E_YEEE_X$K57M(]A^^4;;PUIL5Q')J%RVMWB_ZM65=J_P# 5_\
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MVO\ OJKVVF[:D?.4OLJT?9U_NU=Q3>:"N<J^0J_PK1Y6W^%:M<TV@.8K[/\
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MGT>?63Y]'GT<I7,:WGT>?67Y]'GT6#F-3SJ//K+\^CSZ.4.8U//IOGUF^?\
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M06.I:** )*6BB@!U/HHH *=1104/HHHH *?112 ;3]Q]:**"AU%%% #J***
M"BBB@!]%%% #:DHHH **** "HZ** '4VBB@ HHHH **** $HHHH *;110 E-
MHHI@%-HHH)"BBB@!**** &4VBB@!U1T44$A2444 ,HHHH ;3:** "DHHH("F
*444 -HHHK0#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vnrx_10kimg2.jpg
<TEXT>
begin 644 vnrx_10kimg2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $1 >4# 2(  A$! Q$!_\0
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M&K?]<Y*TYP]Q]3+DL;YEVQ_>_P!E:KM!=Q_\?$;;:VFEO(&_>6,O_?O=5?\
MM-=S>8NW_>W57,/DO\)@W,BM')&J_>_O+NK+GT'39]S;?LR[=S;6^7_OFNNG
MNK9O^6$;5ERW5HWRM9JO^[5<QC*E(P8_!UC/&LBZA*T;+N7;MK1TW0;2Q;SX
M[8R2?WI6W,M2K+8QJJQ[E5?X:D^U0;?_ +*G[IE[.9<99%95C5E;;]Y::OVF
M-?+C9E_X%38]25?O1[F_O*RU(M] S;F62J%RR".ZOF_=KN6/;_=J16G^])N:
M1O[U-:^MMOR^;_W[J-;RVW?O))/^^6H#E+2^>K,R[?+V_P!WYMU.C:15W-NW
M-]ZH?[0L8XUVLS57;4VW,L:Q_P# J!V-C[4RKN9?+JC>--+MDL]K3;MVW:OS
M?\"K/CGD:9FN)U9?X5W5I+>0;?\ 61K_ ,"HVES"M]DZ/3]+T.^\,QV7DRMX
MJ\YI(Y9G/ER1_P#/-?X<[?X?[U836K1M]Y8V7Y?[M4UNEBD9OMS,K?\ +/=N
MK2:>3Q,W[M9%UJ-?EW?=OE_^/?\ H7^]]ZS",73]"OM^;=N;=4GG>5\WF5A^
M5J#-)M61=S?-NH6"[V_-&K?\"J.8WY3>MKZ#R_+N)/,D_O,NVI)VM)8]O^L5
MOO;:YMFV_>@96_V6IWVF?R]JKM_X%1S$\II2;5;]W&VW_:IT6Y59F^5MM9JR
MS_\ /55_X%3OM#1_ZR?=1S%<LCOK.3S+&W;^]&M6-U9>BRK+HMNRM_#M_P#'
MJT-U<4CFD2;J;NINZC=0 [=1NJ/=1NH))-U%1[J-U $FZBH]U% &IY34>4U;
MBV/^S4BZ:S?PU/,=/LS!\FG>570+I4C?\LZL+HLC?PU-RN0Y?R&9MNW[U<3Y
MD\=JUC))\T=RS21LOW6VLO\ [-]ZO9(M";S%W55UKP/_ &MH=XMK#&-0?;Y4
MC*N[Y?X=W^U3W^$J,XP]V>QX/J5FT$=K'I<DL]K=+YGR_>C;^)?\_P!ZH;K[
M3!'';+Y\$C?--YW^L9?[J_W:UK5;F.WDG:QE^R[O.61E^ZV[[J_^.U)IUK/>
M7BV,S1M"R^9'YC?=V_PJW^UMJN:6QI]5I_%$Y_\ L>[OF5O(6>W^]M63Y6_N
MJVW[ORU+I]]?Z=K<D'F10".RD:.%?W:JWW?X=W\-=/9^'K&.^:2:TB\MONJS
M;O+_ -W^]6Q'9Z?;6LDEC8[5W?OF_P!7_P!\UHU*4;R.F'+'W4>=ZGX.U*SD
MM5TV&2Y6XC\Z16^7[/N_A9FVU)'X3:SDM_[:D9O.;_CWM6_]":O2+6.?R6:\
M7]Y-(S;O^>G^U3=R^9\VUFK2/PF,DN;4IQV<&D6+1Z38Q+M;_5JVUF_X%_>H
M:U:76(=0:>16CCVM"OW:M3QSR0LMO(L<S?=9EW+5>*VGBN&D7RVC;YF;;M9F
MK0S-!=JR-(S-N9=OWJJW-M'<JRR1[EJO=6=S<S*WVZ6"-?X8_P"]_O5<6!EA
M_B5=WWO[S4%$?VM8+=I6W?W?N[JL7FH6UK:P^=&S>9(L?[O^%F_B_P!VJL2R
M*K-(NUE^5MOW=U58UN=TGVB1656;R]J_PT!'^\=1X9F6V\36T;-^YN=UK)_N
MR?+_ .A;:Z*\D6*2%I/O,OER?[R_+7!VT[6S1R+NW1LK;O\ =KUC4-)AF623
M;E3*TJ_\"^:LJOPG+)<M7U.+GU!8V95_AJC+J;5U,_AV*21JI2>%U;[K5Q<Q
MT\IRLE](U5VG9OXJZ:3PG)_#(M4Y/"=]_"RT[Q#D9A[Z=YE7G\+ZHOW5JO)X
M?U9?^6&ZJO$/9,A\RCS*:VE:M'_R[-4+6NI1_>MG_P"^:KF)]E(L>93MU9[+
M=K]Z!O\ OFH_-F7[RM03R2-3?_M4V18Y%VR*K?[R[JS?M4B_PT?;&_NT#LRP
MVF:;)]ZQB^;_ &:IR>'-'E_Y=F7_ '9&J3[8W]VC[=_LU7,'O%%_"&GR?ZNY
MGC7^[\K55D\%K_RSU)O^!0UL?;J=]NHYI#YIG-R>"[M?]7J$3?[T;+4;>$=6
M7[LULW_ F_\ B:ZC[<M.^W+5>TD5SS./_P"$9UZ-OECC;_=FJ.30_$"_\NDC
M?[LBUVGVQ:/MBT>TD'-(X5M)\0+_ ,N,_P#X[3?[/UW_ *!]S_W[KOOMBT?:
ME_O4>T#VLNQYZUGK*_>T^Y_[\TW['JW\6GW/_?FO1/M2_P!ZG?:E_O4>T#VK
M['G/V35/^?&?_OS4T$&J?*WV:Y7_ &EC:O0/M2_WJ/M"_P!ZCV@<_P#=,7R+
M[Q%&S>1.NM1K\W[O:M\O][_KM_Z%_O?>PY+'5&^[:7/_ 'S7;+=;6W+)\RUI
M)-/KU]'';P)]N:-FD;=M6;;\V[_>_P#0JKGN8JK*'H>6MH^NNWRV-S_P*F_\
M(_KNW<VGR[?]Y:],DBN8_+W02?O%61=J_P![_P#:6K$EG?1K^\MI-VUF9=K;
MEV_>W4<TBOK)YC%X:UN7_ET:/_KI(JU87PAK,GWO(C_WI*]$:UNU5F:TG55C
M\SYHV^[_ 'JL+INI-(T:Z?<LR[=R^2WR[J.:1'UEF#HNGR:;I,=I,RM(K-\R
M_=K2VU,T$\<:R2021QLVU69:;MK,Q^+WB';1MJQMH\N@97VT58\NCRZ *]-J
MUY5'E4$<I5HJQY-% 'M$>CK_ ':MII"_W:Z)8UJ98UH]F>=+&S,!-(7^[4ZZ
M4O\ =K<5%J146JY3GEBYF*FFKN^[5F.P58S\O>M,*M.^4 ^QS6M.)SRQ$I'S
M%/Y#6[0-M:/YE9:YF?2+&/S&MVEDF9?EC9JU?$GE6/B[4=)\W;+#/*?+7^)=
MU002+'MW,NYJJ43[&A4YH1D9=C'/8R22?9IUMU_A5=J[JUK.\@NHYHV_=[5^
M;YJN2LLENT;1_NV^5EK+72H%AF:%9%F;[WF-NW5E:2.CFCS%JVO/,:3Y=JQJ
MJP_-N_=__%?WJ=+;077E_:(]WEMN7YMNUJKP6S01[=VYMVYMM6EDVU<(V1E/
MXBTL?S+_ '?[M1RP1M<1W/W9HU95^;Y=O^[4?VF3S(U55\O^+<WS5GW-S<OJ
M$<$;-!#]YI%9?WG^S\U*<K$I$>I:DUC_ *=(L[6OW=JLJKNV_P"[6+?>*(X-
M0W6<\JMN5EM[CY5:-OE^;^[\U9^M+)<PPQPWT]VT,C1R;?[VW=]W_*UQ^H%X
MFC:\B'[QOEAW?*WW=S+_ +S5[6#P4*T.:4C@KXF496BCTY?$#1W4UHS*T>W<
MRJW[M6W?+\WW?]G_ +ZK2W+'^[:=I&6-9)&;_:^;_OG;7D-C>>5<33QLW^TK
M+N5O[J_\!KTJSN6:UC@;]W?36R_:)/O?95V_W?X6VUQXW#.A)=CMPE;VL7S$
MFD26+6]U'9M.T>YFW3?Q;O[M?2,,2_8T7;]U47_QQ:^2O#/B6[N_&MGH$49N
MX+B_CM463_6*K-M^]7U]/MR0OW26K@G\)P8F:=1<I3:)=WW:8T4?]VIVIK+7
M("D5?(3^[2?9X_[M6,4W%(TYI$#6T?\ =J-K:/\ NU9Q28I:E<TBJUM'_=IK
M6L?_ #SJYMHVTB^>1GMI\+?\L%_[YJ-M&LG^]:1_]\UK;:=MJA>UD8+>'M+?
M[UC'_P!\U$WA/1W_ .7&.NGVT[91RD^V9Q[>"]%D_P"73_OEJA;P)HK?\L'7
M_@5=OLHV5?*+V[.";X>Z0WW?.7_@50M\.=-;[L\RUZ)Y='ETA>W/-F^'5I_#
M=R?]\U$WPXB_AO6_[YKTS93?+H*]N>7M\.6_AO5_[YJ-OAW<_P -W'_WS7J?
MEBD\N@KVYY.WP_OO^?F*HV\ :E_#)%_WU7K/EK2>305[8\C;P'JB_P#/)O\
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M6UV[O)CW,W_ ?[JK_%7I&AZGX9E\6O'KEC+::;Y;+-=23-)+NV_*J[5W;?\
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B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>vnrx_10kimg1.jpg
<TEXT>
begin 644 vnrx_10kimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  "  (# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>vnrx_10kimg5.jpg
<TEXT>
begin 644 vnrx_10kimg5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !* ',# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z4\?>-M)\
M ^$Y-<U0/(N\1PP1XWS2'HHSQT!)]@:\"N/VK-9:8M:^$[6.+LLETSD?B%'\
MJWOVJ9)!X?\ #L(8^6UU(Q7L2$X/ZG\Z^5*\[$5IQGRQ9]1EF7T:M'VE17;/
MHC_AJCQ%_P!"U9?]_P!Z/^&J/$7_ $+5E_W_ 'KYWHKF^L5.YZG]EX?^4^B/
M^&IO$7_0MV'_ '_>D_X:F\1?]"O8_P#?]Z^>*W1X-\7FU%T/"NKFW*>8)?[/
MFV%<9W9VXQCG--5ZKU3)EE^%A\44OF>T_P##57B+_H6['_O^]._X:H\1?]"U
M9?\ ?]Z^=Z*7UBIW*_LS"_RGT/\ \-4^(_\ H6;'_O\ O1_PU3XC_P"A9L?^
M_P"]?/%%'UBIW#^S,+_*?1'_  U1XB_Z%JR_[_O1_P -4>(O^A:LO^_[U\[T
M4?6*G<K^R\+_ "GT/_PU-XA_Z%RR_P"_[UTG@W]IBUU;7K72?$FA#3$N7$:W
MD-QO1&) 7>K ;5]6R<>F,D?*E'0Y'6J6(J)[G%5RZCRNT;'Z;+-\HHJK9MNL
M8&]8U_E17N6/F.5'S[^U=_R!O#?_ %\2_P#H(KY5KZJ_:N_Y WAO_KXE_P#0
M17RK7AXG^(S[#*/]WC\PHJ[I>G-JVL6>EK=0V[W4JPK+/NV*Q.!G:K'K@< U
MI6_A6[O/&L/@^RU"QGO)KH6:S^8T<!?H?FD53P<C[N2>%#$@'!0D[6ZGISK0
MA?F=K*Y@5W7DZL?@VNL"&\*#7/-^V;'V@^6$W>9_O_+G/WN.M</(ACD:-NJD
MJ<4L,,MQ<PVT$;233.L4:*,EV8X51ZDD@5<&TG%+?_,X*[C5Y9722U_ ]ET7
MX>Z?=V_AL7WA&[F$U_IBW,]BMSY<MM/#(SLT[$HV'5"WE(JHK*HD8MN7+\/^
M'=)U1M5O)OA^T\-EJ$MK-9)%J,\H6*-#Y:>2?EG+,=QF*(<KMV[7 X"QT.YU
M"_33XIX4N_.DCDA8.3!'&F^29BJD;%4.>"6^0X4Y7=K7$]CX;@AT]K?PYXF+
M?Z5'=1?:<P[U7"DJ8@QP <.K%>5.,%1U^Z_><;(\EJ7-RPJ-OMJOU-9]#T&'
MX9OKS:#>7=^WG2/+%;R"WM)TN,"UDE^T HIB4?+Y?F,95*R=A5^*5LEI\2-5
MA@TR.PM=W^CB)9%2:+HLB[R<@@<%<+QP*XVXN)KN[FNKF0RSS.9)';JS$Y)/
MXU.VGRP@&\D2S\RU6ZA\T,?/5B-H7:#RP.X$X&!UY&>>?OQ5HVL=]"/L:G/.
MIS-WT^:*=%%%<Y[7-$****$<F)_AGZ76G_'C!_US7^5%%I_QXP?]<U_E17O'
MP;W/GO\ :N_Y OAS_KXE_P#017RK7U5^U=_R!?#G_7Q+_P"@BOE6O*Q/\1GV
M.3_[O'YFMX;DM;?Q5I5Q>W26UM#=1RR2R*[*BJP8\(K,>G8&O3/"_BK0]%\0
MS75GXPBTHKXD6_NKF**Y"ZG8'!\H%(M^4/F?NW 4^:3DX%>:Z'X9UCQ&[II,
M,$C+(D6)KJ*#?(^=D:>8R[W;:V%7).#Q5U? ?BQM*AU1M(,5K<6CWT!FFCC>
MX@0$N\:,P:3 &XA02%*MT9273E4@KJ/]:!BX8>M)QJ5+/:UT=-!XFTJS\'IH
MMA?:.K+<21W"W4%Y-Y[_ &KS$NUC/[AEV>6"9(_-"HRA6!"UN77CK39/$U[J
MA\7+-:V_BJQU/3H8(9XREH&?[1Y:^6JH627#C@N5D)W9!;A]+\$S3>#-:\1:
MIOM1;6,=W8Q":$/,&N%B+O&6\T)@G:VS:W7<, -1ATW2[KP.VH6EK?SZU;:@
MEO<(DRF(Q2*YB*ILW!B4=<EB,J/[X W52HFM%IK^)Y7L:5G[S:O;IV/4-*\:
M6-K&C3?$**.[2XU5FN(X[X22I<6Z) 7<0;G*R*#EB2H1,?=4# F\3:;)I.D1
M+XHBBUQ=&>T_M:WCN(VLYA=M*=[K$)-TD;E3(@9BV[<<.S'C[GPS-J#ZEJ7A
MN!6T:W:;R/M5_!YTJ0H'D91\C284ASL0[0PSGJ=/Q)X+;2[>2]T>PU2_TR2/
M3Q;WL@5"9I[83-'Y:AB['(PJL=G );<II\U1QO;:Q*HX=32YW=Z]/N.BT?Q%
MI7]BZU;ZAXRMC<:L^HQW:30W4%O,TUML2=(H(2LA,W.9<;5W$1*YS3M0\66>
MK>$=034/%R7<MQX7L[%;.Z6X><7<30M(JR&)E3>8WRROAB4+= 5Y[4OAW>:?
MX=T>3?&VK7MW>PW,)O;8P6Z0(C\R+(50A68OO*[<8( &YJ<7P_\ $$UEK,H^
MQK<:8]M%]G6\AD>X>X7?%Y05_P!YN7!7;G>3A<D-A<]7X>7:WY![/#RO)S>_
MEW.S7QEX>@\7:9<1ZY#=:/'K=M?V,5Q9R,-$LTC;S;?8T; $YC15AW*#$'RI
M -<CXLUZ'6/#&GP7/B"'5M2M-5O"L:1RKY-JZQB/9NC55CS&Q$:XVAU^4<A8
M#X'\07VL:I8Z7HTD;V%R]LUK/>0M+YJ@EHD/R^?( ,E8P3RO'S#-5?!?BYM+
MAU1M(,5K<6CWT!FFCC>X@0$N\:,P9\ ;B%!(4JW1E)QG*I*+3CH=U*%&,XRC
M4U7FCGZ***Y$>CB/X1^E5G_QX6__ %S7^5%+:?\ 'C!_US7^5%>Z?$/<^?OV
MKO\ D#>&_P#KXE_]!%?*M?57[5W_ "!O#G_7Q+_Z"*^5:\O$_P 1GUV4?[O'
MYG8>!_&5GX/N6NY-)GN+L7,%Q%<VEXMM*JQEBT19HI#Y;YPP386&020<"Y:^
M-M!LY]%\CPWJ'V?2]-N]-5'U1"TBS^;\VX6X *B>3MS\O3!W<'14>WJ6Y;G1
M/+\/.;G*.K\V=BOC:UDT&>TNM#E;4I]$BT62[@O%CA98F1HI?)\HG<!%&K /
M@A3C:3FL+1M:GT4W_DP13"\M6MF$H)\L[E=)%]'1T1E/M[FLNBDZLW+F;U-8
M8.C"+C&.C_0[3PSXRTO0O#]QI=QHEY)+<BZBGGLK]+8W,4T'E>7)NA=F5>75
M0P3=M8J2,G2O/B-IOD0MI'AVYM+Z"?2[B*:ZOTN(PUBNR/*"%"0RDY^8<X(Q
MC%><T57UBHK*_;\#!Y9AY2<I1U?F^IZ$OCOPS"MO%;^#;C[/!?7=\L4^I1S*
MC3Q",A0UMM^38A3>'Q@Y!.&6O>>.-)U)]9%]H^JW$.K0Z>LKSZLLEP9;2-HU
MD:4P?-O5OF!7.[)S@X'"T4?6*BZB_LRA_+^+/1)_B99W&N76J/X=<S1ZR^NZ
M9_IH_P!%N'5-ZRXC_?1EXT8 ;& !&[G-4-/\<:;:C06N-#O+B33-+N]-E9=0
M1/M!G\S=(!Y)V8\^7"_-_!S\IW<512]O4M:X++<.G?E_%B#.!NY/J.*6BBL4
M57_A'Z56?_'A;_\ 7-?Y44MGG[!;_P#7-?Y45[2/BGN>8_'+X?ZAX\\%Q0Z*
MJ/J5A/\ :(8W(7SAM(9 QX!.01GC*@<9R/DN;X<_$"WG>&3P3KA9#@F/3Y77
M\"JD'\*_0<]:GC^X*FK2C*6I."S2K27)%*Q^=G_"O_'G_0DZ]_X+)O\ XFC_
M (5_X\_Z$G7O_!9-_P#$U^B]-KE]C$]?^VJW\J/SJ_X5_P"//^A)U[_P63?_
M !-'_"O_ !Y_T).O?^"R;_XFOT5HI^QB/^VJW\J/SJ_X5_X\_P"A)U[_ ,%D
MW_Q-)_PK_P >?]"/KW_@LF_^)K]&**/8Q#^VJW\J/SH_X5_X\_Z$G7O_  63
M?_$T?\*_\>?]"3KW_@LF_P#B:_16BE[*(?VU6_E1^=7_  K_ ,>_]"1K_P#X
M+)O_ (FD_P"%?^.O^A(U[_P63?\ Q-?HQ3:?L8A_;5;^5'YT_P#"O_'G_0DZ
M]_X+)O\ XFNI\&_!?QQXDUVVM[[0;W2=.$@-S<WT+0[$SSM5L%B1TP.OIUK[
AMJ.3H*N%&*9PXG-ZTHM))$\<:K&JXZ"BI1THKO/,N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>vnrx_10kimg6.jpg
<TEXT>
begin 644 vnrx_10kimg6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !* ',# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z,^(GQ$TG
MX<^'1JFI1O<32MY=O:QD!IGQGJ>BCN>WN2 ?!YOVJ-;:9C;^%[2.(_=5[EW(
M^I &?RJ[^U@[?;?"L>[Y-MT<>^8J^:*\RO7G&?+%GU>6Y=1JT54J*[9]$?\
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MG )P. 3Q7TS^UA_R$?"O_7.Z_G%7S17FUI<M3F/KLNCSX6,7UN=_XBNO"O\
MPL8>*O[:@UC3Y-4AN)-/MX+A9'A#AG#^;&BXVJ1@,<D@=,D:3>+K*X\5W&H-
MXNLH+N'3FAM;RU.I11W+?:%D5)IG\RZ'&[(3;\N$$@'!\NHI*M)6LMM366!4
M_BD]K=-CVC1?%^@:7XTU+4=/\81:4C^*CJ<]Q%#<*NI:<Q#B$;(B^8R9 8W
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M6E&4M1X/-*M.G[.*5C\Z/^%?^//^A)U[_P %DW_Q-'_"O_'G_0DZ]_X+)O\
MXFOT7IM<_LHGH_VQ6[(_.K_A7_CW_H2-?_\ !9-_\31_PK_Q[_T)&O\ _@LF
M_P#B:_16BCV,2O[:K?RH_.K_ (5_X]_Z$C7_ /P63?\ Q-'_  K_ ,>_]"1K
M_P#X+)O_ (FOT5HH]C$/[:K?RH_.K_A7_CW_ *$C7_\ P63?_$T?\*_\>_\
M0D:__P""R;_XFOT5HH]C$/[:K?RH_.K_ (5_X]_Z$C7_ /P63?\ Q-'_  K_
M ,=?]"/KW_@MF_\ B:_16BCV,0_MJM_*C\Z?^%?^//\ H2=>_P#!9-_\37<_
M#?X,^,M<\6:=<:MH-SI.D6TZ37,E]$8F=5;.Q4;#$MC&<8&<^@/V[3)>HJZ=
:&*D<6)S>LX-))7)57:H7THJ8=**[SR[G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>vnrx_10kimg7.jpg
<TEXT>
begin 644 vnrx_10kimg7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !* 'L# 2(  A$! Q$!_\0
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M_H6K+_O^]?.]%'UBIW#^R\+_ "GT1_PU/XB_Z%FR_P"_[T?\-3^(O^A9LO\
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MA(R4.X#YEZ'&1D<$CFHJ5@5:,E=!7Z:6/_(.M_\ KFO\J_,NOTTL?^0=;_\
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*>1C<74JR3D?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>vnrx_10kimg8.jpg
<TEXT>
begin 644 vnrx_10kimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !+ 'D# 2(  A$! Q$!_\0
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M<?[Q\CYF_:N_Y!_AC_KI/_)*^7*^H_VKO^0?X7_ZZS_R2OERN3$_Q&?193_
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M ,!7_P *_2?RH_[@H\J/^X/RK#ZFNYT?VW/^7\3\V/\ A'/$/_0!U'_P%?\
MPH_X1SQ#_P! '4?_  %?_"OTG\J/^X*/*C_N"CZFNX?VW/\ E_$_-C_A'/$/
M_0!U'_P%?_"C_A'/$/\ T =1_P# 5_\ "OTG\J/^X*/*C_N"CZFNX?VW/^7\
M3\V/^$<\0_\ 0!U'_P !7_PH_P"$<\0_] '4?_ 5_P#"OTG\J/\ N"CRH_[@
MH^IKN']MS_E_$_-C_A'/$/\ T =1_P# 5_\ "C_A'/$/_0!U'_P%?_"OTG\N
M/^Z*/*C_ +@H^IKN']MS_E_$_-C_ (1SQ#_T =1_\!7_ ,*/^$<\0_\ 0!U'
M_P !7_PK])_*C_N"CRH_[@H^IKN']MS_ )?Q/ES]G7X;^(M+\27/BS7M-GTV
M!+9K>VBN4,<DCLPRVT\@ *1R.=W'2OJ3RZBMO]2:GKMITU"-D>-B<1*I4<F?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>vnrx_10kimg9.jpg
<TEXT>
begin 644 vnrx_10kimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !* '<# 2(  A$! Q$!_\0
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F=1E$TT*D,(E PJ9'!(Y)(XR<<XR2O8A_JQ175&"L>%6Q$W-L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>vnrx_10kimg3.jpg
<TEXT>
begin 644 vnrx_10kimg3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $4 >L# 2(  A$! Q$!_\0
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MQ)YMXR^9<R;FVM)_LUY=6M>!SVE%ZD7D>)UE58[JVD7/S/)]UOF_NJN[[O\
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M9%9MW]W;68C1K,U+5(]+A622-I)&^[&OWF_O-_NK6)_;&K:X\^GZ99"W:/\
MUUPLZ_N?F^[]W[WW6_W:NZ1X4MH7DN]2ABN+J1OE4[I%A7^ZK-][[WWJKE)]
MU?$48+&]\02"_P!06*WMU;9#&K>8RJK?ZQ6_VO[W]VNQCC6.-8T7:BKM"_W1
M4BQ[5VJORT[;3&Y7&T[;_P "IVVC;01<\[UKX7V.L6NH,VJ7<>H74[72S*_[
MJ.3^']W]W:NU?]JLG3?A&T-O;7/_  DEY;7WELLK0C;\S?>V_-7K>TT>56CJ
M2<>60XU)1ZG(>'/!=AH0GCVK<&259$>3[R[:ZXYIWET[969,I\SNR/FFU-LH
MV5(N8K[:"M3;*-E!7,5RM-9:L[*3RZ"N8ILE0M'6AY51M%0',9K1U"T=:S05
M"UM0!DR157DBK::V:H6M?]F@HPY(JJR15O26M5Y+5O[M &#)%5=HZW)+-JKR
M6;?W: ,-EJ-EK6DLV_NU5DM6_NU9)FLM0M6A) W]VJ[1-_=H#E*++4>VKC)4
M?ET$\IU"Q5(L56%2I%CJ#0KK%4BQ5:6.I%BH JK%4BQ5<6"IE@H HK%4BQ5>
M6"I%MJ **Q5(L5:"V]2+#_LT 9JPU(L5:2P4Y8:">8SUAIRQ5H>32^30'/$I
M+%3EAJ]Y-.\JCE)]H4?)IWE5<\JG>71RD^T*>RH;FSANK.:TN%W0S1M'(O\
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/HV8T44 -9VIN]J** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192706752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VOLITIONRX LIMITED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000093314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,096,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,353,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1949078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Icfr Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">1489 West Warm Springs Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Henderson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">89014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">650&#8211;1351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">3627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Sadler, Gibb & Associates, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Draper, UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193594848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,867,050<span></span>
</td>
<td class="nump">$ 20,581,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable</a></td>
<td class="nump">72,609<span></span>
</td>
<td class="nump">12,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">784,920<span></span>
</td>
<td class="nump">598,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">447,566<span></span>
</td>
<td class="nump">786,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">12,172,145<span></span>
</td>
<td class="nump">21,978,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,393,012<span></span>
</td>
<td class="nump">4,911,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">619,392<span></span>
</td>
<td class="nump">383,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">110,505<span></span>
</td>
<td class="nump">216,876<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,295,054<span></span>
</td>
<td class="nump">27,490,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,043,008<span></span>
</td>
<td class="nump">1,542,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,872,247<span></span>
</td>
<td class="nump">3,828,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Management and directors' fees payable</a></td>
<td class="nump">71,119<span></span>
</td>
<td class="nump">71,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,066,700<span></span>
</td>
<td class="nump">797,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of financing lease liabilities</a></td>
<td class="nump">46,014<span></span>
</td>
<td class="nump">48,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">245,163<span></span>
</td>
<td class="nump">171,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CurrentPortionOfGrantRepayable', window );">Current portion of grant repayable</a></td>
<td class="nump">41,836<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">17,386,087<span></span>
</td>
<td class="nump">6,515,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">2,779,240<span></span>
</td>
<td class="nump">2,270,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">436,132<span></span>
</td>
<td class="nump">511,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">400,091<span></span>
</td>
<td class="nump">217,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantRepayableNetOfCurrentPortion', window );">Grant repayable, net of current portion</a></td>
<td class="nump">420,466<span></span>
</td>
<td class="nump">253,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">21,422,016<span></span>
</td>
<td class="nump">9,768,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 57,873,379 shares and 53,772,261 shares, respectively</a></td>
<td class="nump">57,873<span></span>
</td>
<td class="nump">53,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">164,397,468<span></span>
</td>
<td class="nump">154,730,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">227,097<span></span>
</td>
<td class="nump">148,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,257,429)<span></span>
</td>
<td class="num">(136,988,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TotalVolitionrxLimitedStockholdersEquity', window );">Total VolitionRx Limited Stockholders' Equity (Deficit)</a></td>
<td class="num">(2,574,991)<span></span>
</td>
<td class="nump">17,944,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MinorityInterests', window );">Non-controlling interest</a></td>
<td class="num">(551,971)<span></span>
</td>
<td class="num">(222,295)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="num">(3,126,962)<span></span>
</td>
<td class="nump">17,722,105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 18,295,054<span></span>
</td>
<td class="nump">$ 27,490,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CurrentPortionOfGrantRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CurrentPortionOfGrantRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantRepayableNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantRepayableNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_MinorityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_MinorityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_TotalVolitionrxLimitedStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_TotalVolitionrxLimitedStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192570832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Shares Par Value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">57,873,379<span></span>
</td>
<td class="nump">53,772,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">57,873,379<span></span>
</td>
<td class="nump">53,772,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192514208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyaltyRevenue', window );">Royalty</a></td>
<td class="nump">$ 2,911<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ServiceRevenue', window );">Service</a></td>
<td class="nump">92,488<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ProductRevenue', window );">Product</a></td>
<td class="nump">210,993<span></span>
</td>
<td class="nump">90,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">306,392<span></span>
</td>
<td class="nump">90,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">14,572,532<span></span>
</td>
<td class="nump">13,022,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,937,686<span></span>
</td>
<td class="nump">11,676,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">6,576,246<span></span>
</td>
<td class="nump">3,724,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">32,086,464<span></span>
</td>
<td class="nump">28,423,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(31,780,072)<span></span>
</td>
<td class="num">(28,333,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income (Expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncomeFromGrants', window );">Grant income</a></td>
<td class="nump">1,229,425<span></span>
</td>
<td class="nump">1,522,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LossOnDisposalOfFixedAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">125,265<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="num">(173,087)<span></span>
</td>
<td class="num">(155,803)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Total Other Income</a></td>
<td class="nump">1,181,603<span></span>
</td>
<td class="nump">1,343,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(30,598,469)<span></span>
</td>
<td class="num">(26,989,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Net Loss attributable to Non-Controlling Interest</a></td>
<td class="nump">329,676<span></span>
</td>
<td class="nump">175,116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest', window );">Net Loss attributable to VolitionRx Limited Stockholders</a></td>
<td class="num">(30,268,793)<span></span>
</td>
<td class="num">(26,814,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">78,771<span></span>
</td>
<td class="nump">208,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OthersComprehensiveIncomeLossNetOfTax', window );">Net Comprehensive Loss</a></td>
<td class="num">$ (30,519,698)<span></span>
</td>
<td class="num">$ (26,781,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited', window );">Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="nump">55,350,401<span></span>
</td>
<td class="nump">52,655,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LossOnDisposalOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LossOnDisposalOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OthersComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OthersComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192759808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,607,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td>
<td class="nump">$ 16,293,718<span></span>
</td>
<td class="nump">$ 48,607<span></span>
</td>
<td class="nump">$ 126,526,239<span></span>
</td>
<td class="num">$ (59,978)<span></span>
</td>
<td class="num">$ (110,173,971)<span></span>
</td>
<td class="num">$ (47,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cashless exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued for cashless exercise of stock options, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedForSettlementOfRsuSShares', window );">Common stock issued for settlement of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedForSettlementOfRsuSAmount', window );">Common stock issued for settlement of RSUs, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedInPublicOfferingsNetShares', window );">Common stock issued in public offerings, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,063,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in public offerings, net, amount</a></td>
<td class="nump">23,219,644<span></span>
</td>
<td class="nump">$ 5,063<span></span>
</td>
<td class="nump">23,214,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation', window );">Tax withholdings paid related to stock-based compensation</a></td>
<td class="num">(130,426)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(130,426)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">2,670,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,670,297<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockBasedCompensationInRelationToModificationOfOptions', window );">Stock-based compensation in relation to modification of options</a></td>
<td class="nump">2,450,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,450,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation</a></td>
<td class="nump">208,304<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">208,304<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the Year</a></td>
<td class="num">(26,989,781)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,814,665)<span></span>
</td>
<td class="num">(175,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,772,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2021</a></td>
<td class="nump">17,722,105<span></span>
</td>
<td class="nump">$ 53,772<span></span>
</td>
<td class="nump">154,730,938<span></span>
</td>
<td class="nump">148,326<span></span>
</td>
<td class="num">(136,988,636)<span></span>
</td>
<td class="num">(222,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedForSettlementOfRsuSShares', window );">Common stock issued for settlement of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedForSettlementOfRsuSAmount', window );">Common stock issued for settlement of RSUs, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockIssuedInPublicOfferingsNetShares', window );">Common stock issued in public offerings, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in public offerings, net, amount</a></td>
<td class="nump">6,736,444<span></span>
</td>
<td class="nump">$ 3,804<span></span>
</td>
<td class="nump">6,732,640<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation', window );">Tax withholdings paid related to stock-based compensation</a></td>
<td class="num">(180,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(180,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">3,114,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,114,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation</a></td>
<td class="nump">78,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">78,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the Year</a></td>
<td class="num">(30,598,469)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,268,793)<span></span>
</td>
<td class="num">(329,676)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,873,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="num">$ (3,126,962)<span></span>
</td>
<td class="nump">$ 57,873<span></span>
</td>
<td class="nump">$ 164,397,468<span></span>
</td>
<td class="nump">$ 227,097<span></span>
</td>
<td class="num">$ (167,257,429)<span></span>
</td>
<td class="num">$ (551,971)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockIssuedForSettlementOfRsuSAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockIssuedForSettlementOfRsuSAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockIssuedForSettlementOfRsuSShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockIssuedForSettlementOfRsuSShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockIssuedInPublicOfferingsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockIssuedInPublicOfferingsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_StockBasedCompensationInRelationToModificationOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_StockBasedCompensationInRelationToModificationOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193363168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (30,598,469)<span></span>
</td>
<td class="num">$ (26,989,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">936,084<span></span>
</td>
<td class="nump">945,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">253,864<span></span>
</td>
<td class="nump">199,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLossOnDisposalOfFixedAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">3,114,659<span></span>
</td>
<td class="nump">2,670,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation in relation to modification of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,450,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">433,995<span></span>
</td>
<td class="num">(295,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(72,609)<span></span>
</td>
<td class="num">(12,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">351,514<span></span>
</td>
<td class="num">(202,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">9,987,488<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">548,611<span></span>
</td>
<td class="nump">522,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ManagementAndDirectorsFeesPayable', window );">Management and directors' fees payable</a></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">16,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(232,695)<span></span>
</td>
<td class="num">(196,471)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(15,277,742)<span></span>
</td>
<td class="num">(20,853,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,570,182)<span></span>
</td>
<td class="num">(973,559)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(1,570,182)<span></span>
</td>
<td class="num">(973,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares</a></td>
<td class="nump">6,736,444<span></span>
</td>
<td class="nump">23,219,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings paid related to stock-based compensation</a></td>
<td class="num">(180,472)<span></span>
</td>
<td class="num">(130,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ProceedsFromGrantsRepayable', window );">Proceeds from grants repayable</a></td>
<td class="nump">218,445<span></span>
</td>
<td class="nump">37,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">1,523,098<span></span>
</td>
<td class="nump">592,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="num">(1,268,386)<span></span>
</td>
<td class="num">(755,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PaymentsOnGrantsRepayable', window );">Payments on grants repayable</a></td>
<td class="num">(45,664)<span></span>
</td>
<td class="num">(47,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PaymentsOnFinancingLeasesLeaseAmount', window );">Payments on financing leases</a></td>
<td class="num">(45,433)<span></span>
</td>
<td class="num">(58,210)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">6,938,032<span></span>
</td>
<td class="nump">22,857,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange on cash and cash equivalents</a></td>
<td class="nump">195,629<span></span>
</td>
<td class="nump">106,502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash and Cash Equivalents</a></td>
<td class="num">(9,714,263)<span></span>
</td>
<td class="nump">1,136,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - Beginning of Year</a></td>
<td class="nump">20,581,313<span></span>
</td>
<td class="nump">19,444,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - End of Year</a></td>
<td class="nump">10,867,050<span></span>
</td>
<td class="nump">20,581,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">173,087<span></span>
</td>
<td class="nump">155,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common Stock issued on exercises of stock options and warrants and settlement of RSUs</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OfferingCostsFromIssuanceOfCommonStock', window );">Offering costs from issuance of common stock</a></td>
<td class="nump">$ 427,443<span></span>
</td>
<td class="nump">$ 218,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NonCashNotePayable', window );">Non-cash Note Payable</a></td>
<td class="nump">$ 620,549<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from other long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=128088960&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126965701&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ManagementAndDirectorsFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ManagementAndDirectorsFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NonCashNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NonCashNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OfferingCostsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OfferingCostsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLossOnDisposalOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLossOnDisposalOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PaymentsOnFinancingLeasesLeaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PaymentsOnFinancingLeasesLeaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PaymentsOnGrantsRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PaymentsOnGrantsRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ProceedsFromGrantsRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ProceedsFromGrantsRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197676432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 1 - Nature of Operations </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with the Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of &#8220;VolitionRX Limited&#8221; and the name change became effective on October 11, 2011. On October 7, 2016, the Company amended its Certificate of Incorporation to reflect a name change to &#8220;VolitionRx Limited.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October&#160;6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited, a Singapore corporation incorporated on August 5, 2010 (&#8220;Singapore Volition&#8221;), and the shareholders of Singapore Volition.&#160; Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company.&#160; The issuance was deemed to be a reverse acquisition for accounting purposes and as such, Singapore Volition is regarded as the predecessor of the Company. The number of shares outstanding and per share amounts of the Company have been restated to recognize the foregoing recapitalization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood tests designed to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics<sup style="vertical-align:super">TM</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid &#8211; an indication that disease is present.&#160; The Company has two wholly owned subsidiaries, Volition Global Services SRL (&#8220;Volition Global&#8221;) which was formed in August 2021 and Singapore Volition. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL, a Belgium private limited liability company (&#8220;Belgian Volition&#8221;), which it acquired in September 2010.&#160; Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (&#8220;Volition Diagnostics&#8221;), which was formed in November&#160;2015, Volition America, Inc. (&#8220;Volition America&#8221;), which was formed in February 2017, Volition Germany GmbH (&#8220;Volition Germany&#8221;), which was acquired in January 2020, as well as its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (&#8220;Volition Vet&#8221;), which was formed in June 2019.&#160; Following the acquisition of Singapore Volition in 2011, the Company&#8217;s fiscal year end was changed from August 31 to December 31.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230196408592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern Assessment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Liquidity and Going Concern Assessment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LiquidityAndGoingConcernAssessment', window );">Liquidity and Going Concern Assessment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>No</strong><strong>te 2 </strong><strong>&#8211; Liquidity and </strong><strong>Go</strong><strong>ing Concern Assessment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $167.3 million, has negative cash flows from operations, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period at least one year from the date of issuance of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions; (c) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LiquidityAndGoingConcernAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LiquidityAndGoingConcernAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230200542560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 3 - Summary of Significant Accounting Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Basis of Presentation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company&#8217;s fiscal year end is December 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Use of Estimates</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Principles of Consolidation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), <em>Commitments and Contingencies &#8211; Other Commitments</em>, for more information regarding Volition Vet, Volition Germany and Volition America. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Reclassification</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative amounts of research and development, sales and marketing and general and administrative expenses to be consistent with the current year classification.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Cash and Cash Equivalents</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Accounts Receivable </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company&#8217;s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.&#160; The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Property and Equipment</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Basic and Diluted Net Loss Per Share</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company computes net loss per share in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 260, <em>&#8220;Earnings Per Share,&#8221;</em> which requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of December 31, 2022, and December 31, 2021, 7,787,013 and 6,323,268, respectively, of potential common shares equivalents from stock options, RSUs and warrants were excluded from the diluted EPS calculations as their effect is anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Foreign Currency Translation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, <em>&#8220;Foreign Currency Matters &#8211; Foreign Currency Transactions&#8221;</em>. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Fair Value Measurements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to ASC 820, &#8220;<em>Fair Value Measurements and Disclosures,&#8221;</em> an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 1</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 2</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 3</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on &#8220;Level 1&#8221; inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Other Comprehensive Income (Loss)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASC 220, &#8220;<em>Other Comprehensive Income/(Loss)&#8221;,</em> establishes standards for the reporting and display of other comprehensive loss and its components in the financial statements. As of December 31, 2022, the Company had $227,097 of accumulated other comprehensive income, relating to foreign currency translation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Income Taxes</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, <em>&#8220;Accounting for Income Taxes&#8221;</em> as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Refer to Note 9 for further details.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Revenue Recognition </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company adopted ASC 606, &#8220;<em>Revenue from Contracts with Customers,&#8221;</em> effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company generates product revenues from the sale of its Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Royalty </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under &#8220;Royalty&#8221; under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Product</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in &#8220;Product&#8221; in the consolidated statements of operations and comprehensive loss.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Service </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from laboratory services performed in the Company&#8217;s laboratory on behalf of third parties under &#8220;Service&#8221; under the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Licensing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from the licensing of certain rights to third parties in &#8220;Licensing&#8221; in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue from Heska License Agreement </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the &#8220;License Agreement&#8221;) with Heska Corporation (&#8220;Heska&#8221;), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q&#174; Vet Cancer Test at the point of care (&#8220;POC&#8221;) initially for the screening of lymphoma and hemangiosarcoma in dogs (&#8220;Canine Lymphoma &amp; HSA&#8221;), and non-exclusive rights to sell its Nu.Q&#174; Vet Cancer Test in kit format (&#8220;Kits&#8221;) through Heska&#8217;s network of central reference laboratories (&#8220;Central Lab&#8221;) initially for Canine Lymphoma &amp; HSA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well.&#160; Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (&#8220;Key Components&#8221;) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska&#8217;s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party&#8217;s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">According to ASC Topic 606, &#8220;<em>Revenue from Contracts with Customers</em>&#8221;, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Deferred Revenue (Contract Liabilities) and Contract Assets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Research and Development</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 360, <em>&#8220;Property Plant and Equipment&#8221;,</em> the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Stock-Based Compensation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, &#8220;<em>Compensation &#8211; Stock Compensation&#8221;</em>. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. The estimated fair value of RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation model. Refer to Note 8 for further details.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Leases</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases.&#8221; The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (&#8220;ROU&#8221;) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (&#8220;IBR&#8221;) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Grant Income&#160; </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">COVID-19 Pandemic Impact </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company&#8217;s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Recent&#160;Accounting&#160;Pronouncements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline"/></strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197534320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property And Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 4 - Property and Equipment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s property and equipment consist of the following amounts as of December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;3 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">656,759</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">497,306</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,190,289</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,951,387</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,238,902</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">358,575</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">239,436</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">119,139</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;30 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,054,332</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">298,397</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,755,935</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5-15 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,317,132</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">326,337</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">990,795</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">128,788</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">128,788</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">8,705,875</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,312,863</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">5,393,012</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;3 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">599,944</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">474,169</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,775</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,032,108</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,434,347</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,597,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">293,427</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">213,244</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">80,183</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;30 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,177,641</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">243,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,933,891</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5-15 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,293,258</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">256,309</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,036,949</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">136,518</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">136,518</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">7,532,896</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2,621,819</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4,911,077</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the total capital expenditure was $1.6 million and $1.1 million, respectively, the majority of which was from purchases of laboratory equipment. For further details refer to Note 10 (a) for Finance Leases included in <em>Property, Plant and Equipment.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the Company recognized $865,262 and $812,109, respectively, in depreciation expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192672112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 5 - Intangible Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets&#8217; estimated useful lives, which range from 8 to 20 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,104,103</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">993,598</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">110,505</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,178,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">961,259</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">216,876</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the years ended December 31, 2022 and December 31, 2021, the Company recognized $75,558 and $91,645, respectively, in amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Remaining Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Amortization</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,636</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,869</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Intangible Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>110,505</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2022. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230196564944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 6 - Related Party Transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">See Note 7 for common stock issued to related parties and Note 8 for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under accruals and management and directors&#8217; fees payable (see consolidated balance sheets). </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197570256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 7 - Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which 57,873,379 and 53,772,261 shares were issued as of December 31, 2022 and December 31, 2021, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Stock Option Exercises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022 no shares of common stock were issued pursuant to the exercise of stock options.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Stock Option Exercises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021 we issued a total of 77,451 shares of common stock from the cashless exercise of options, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 13 - March 19, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,634</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">948</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,181</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,769</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8 - February 9, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,750</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">277,634</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">77,451</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>RSU Settlements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022 we issued a total of 297,289 shares of common stock from the settlement of RSUs, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 25, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 13, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">August 3, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,992</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">September 7, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,962</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 4, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,905</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,883</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">November 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,406</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 15, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,181</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">819</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">377,007</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297,289</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,718</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021 we issued a total of 24,712 shares of common stock from the settlement of RSUs, as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 20, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 21, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;31,250</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;24,712</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;6,538</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Equity</em></strong><strong><em> </em></strong><strong><em>Capital Raises</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On July 29, 2022, the Company entered into an underwriting agreement with Newbridge Securities Corporation (&#8220;Newbridge&#8221;) in connection with an underwritten public offering of 3,450,000 shares of the Company&#8217;s common stock, which includes Newbridge&#8217;s exercise in full of its overallotment option (of 450,000 shares), pursuant to the Company&#8217;s &#8220;shelf&#8221; registration statement on Form S-3 (declared effective by the SEC on November 8, 2021, File No. 333-259783) (as amended and supplemented from time to time, the &#8220;2021 Form S-3&#8221;). Newbridge purchased the shares from the Company at a weighted average&#160;price of $1.87 per share.&#160;The offering closed on August 2, 2022. The Company received net proceeds of approximately $6.4 million from the offering before deducting offering expenses of $0.2 million paid by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Equity</strong><strong> </strong></em><strong><em>Capital Raises </em>(continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 10, 2021, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) in connection with an underwritten public offering of 3,809,524 shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s &#8220;shelf&#8221; registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248) (the &#8220;2018 Form S-3&#8221;). Cantor purchased the shares from the Company at a price of $4.9533 per share, and elected not to exercise an option to purchase up to an additional 571,428 shares of common stock at the same price per share. The offering closed on February 12, 2021. The Company received net proceeds of approximately $18.9 million from the offering before deducting offering expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Equity</em></strong><strong><em> </em></strong><strong><em>Distribution Agreements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On May 20, 2022, the Company entered into an equity distribution agreement (the &#8220;2022 EDA&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#8220;at the market&#8221; offering pursuant to the Company&#8217;s 2021 Form S-3 through Jefferies acting as the Company&#8217;s agent and/or principal.&#160;The Company is not obligated to sell any shares under the 2022 EDA.&#160; As of December 31, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.8 million under the 2022 EDA through the sale of 350,829 shares of common stock, before deducting offering expenses.&#160;See Note 11 for additional details regarding the Company&#8217;s equity distribution agreements subsequent to December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">From January 1, 2022 through May 7, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $9,500 under the 2021 EDA (as defined below) through the sale of 3,000 shares of its common stock. The Company terminated the 2021 EDA effective May 7, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 24, 2021, the Company entered into an equity distribution agreement (the &#8220;2021 EDA&#8221;) with Cantor and Oppenheimer &amp; Co. Inc. (&#8220;Oppenheimer&#8221;) to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#8220;at the market&#8221; offering pursuant to the Company&#8217;s 2021 Form S-3 through Cantor and Oppenheimer acting as the Company&#8217;s agents and/or principals. From the 2021 EDA&#8217;s effectiveness on November 8, 2021 through December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.7 million through the sale of 190,600 shares of its common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 10, 2020, the Company entered into an equity distribution agreement (the &#8220;2020 EDA&#8221;) with Cantor and Oppenheimer to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#8220;at the market&#8221; offering pursuant to the 2018 Form S-3 through Cantor and Oppenheimer acting as the Company&#8217;s agents and/or principals. During the year ended December 31, 2021 (and from inception of the 2020 EDA), the Company raised aggregate net proceeds (net of broker commissions and fees) of $2.7 million under the 2020 EDA through the sale of 754,348 shares of its common stock. The Company terminated the 2020 EDA effective November 8, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the &#8220;2018 EDA&#8221;) with Oppenheimer to sell shares of the Company&#8217;s common stock, with an aggregate offering price of up to $10.0 million, from time to time through an &#8220;at the market&#8221; offering pursuant to the 2018 Form S-3 through Oppenheimer acting as the Company&#8217;s agent and/or principal. The Company utilized the 2018 EDA in full during the three months ended March 31, 2021, and raised aggregate net proceeds (net of broker commissions and fees) of approximately $9.7&#160;million under the 2018 EDA since inception through the sale of&#160;2,539,606&#160;shares of its common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of $1.2 million under the 2018 EDA through the sale of 308,609 shares of its common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022 and 2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Issuances Upon Warrant Exercises</em></strong><em>&#160;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the years ended December 31, 2022 and December 31, 2021 no warrants were exercised. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197510272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>StockBased Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>No</strong><strong>te 8 - </strong><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>a</strong><strong>) Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the changes in warrants outstanding of the Company during the year ended December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">310,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">485,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">539,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">485,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective April 4, 2022, the Company granted a warrant to purchase 54,000 shares of common stock to a Company employee for services to the Company and/or its subsidiaries. This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share. The Company has calculated the estimated fair market value of this warrant at $80,901, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $2.95, exercise price $3.05, 71.07% volatility, 2.53% risk-free rate, and no forfeiture rate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective January 1, 2021, the Company granted warrants to purchase 125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share. The Company has calculated the estimated fair market value of these warrants at $242,877, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.80, exercise price $3.95, 74.53% volatility, 0.50% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vested on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.80, exercise price $4.90, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the warrants issued and outstanding as of December 31, 2022. The warrants outstanding have a weighted average price of $3.80 per share and an aggregate weighted average remaining contractual life of 3.24 years. The warrants exercisable have a weighted average price of&#160; $3.88 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Life (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">125,000</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">125,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">2.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">0.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">308,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">54,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.05</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">164,700</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">50,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.45</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.17</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">172,500</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">125,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">125,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.95</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.01</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">493,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">185,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.90</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">906,500</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>539,000</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong>485,000</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong>2,046,200</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to warrants of $84,102 and $701,781 was recorded for the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately $35,812 and is expected to be recognized over a period of 1.26 years. As of December 31, 2022, the total intrinsic value of warrants was $0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) Options</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company currently has options outstanding under both its 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) (for option issuances prior to 2016,) and its 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;) (for option issuances commencing in 2016). Effective as of January 1, 2016, no additional awards were or may be made under the 2011 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The 2015 Plan was adopted by the Board of Directors on August 18, 2015 and approved by the stockholders at an annual meeting held on October 30, 2015. On August 5, 2016, the Board of Directors adopted an amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 1,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on October 7, 2016. On June&#160;13, 2017, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 2,500,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 8, 2017. On June 15, 2018, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 3,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 7, 2018.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 27, 2019, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 1,000,000 shares to an aggregate maximum of 4,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 14, 2019. On March 31, 2021, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such&#160; Plan by 1,750,000 shares to an aggregate maximum of 6,000,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 17, 2021.</p>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On April 4, 2022, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such plan by 1,750,000 shares to an aggregate maximum of 7,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 13, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The 2015 Plan permits the grant of incentive stock options, non-statutory stock options, restricted stock awards, stock bonus awards, stock appreciation rights, restricted stock units and performance awards. The primary purpose of the 2015 Plan is to enhance the Company&#8217;s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company&#8217;s business largely depends, and to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company that is tied to the Company&#8217;s performance, thereby giving them an interest in the success and increased value of the Company. &#160;The 2015 Plan is administered by the Compensation Committee comprised solely of members of the Board of Directors or by the Board of Directors as a whole.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the changes in options outstanding of the Company during the years ended December 31, 2022 and December 31, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,278,619</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,090,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(277,634</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(63,467</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.64</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,027,518</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,413</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.43</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,985,105</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,495,011</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.93</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2022, no options were granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, 5,000 Options previously granted to an employee on April 13, 2020 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, 32,383 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.</p><strong><span style="text-decoration:underline">2021</span></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective May 20, 2021, the Company granted stock options to purchase 40,000 shares of common stock to a Company employee in exchange for services provided to the Company. These options vested on May 20, 2022 and were initially scheduled to expire six years after the grant date, with an exercise price of $3.60 per share. The Company extended the expiration date to ten years after the original grant date. The Company has calculated the estimated fair market value of these options at $73,641, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.50, exercise price $3.60, 76.16% volatility, 0.58% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the year ended December 31, 2021, the Company modified a total of 3,342,518 options to extend their expiration dates to ten years from the original dates of grant. This resulted in $2,450,349 of expense.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the amendments to the expiration dates of various options approved during the year ended December 31, 2021. Except as otherwise noted, the expiration dates for all options in the table below were extended from six years to ten years from the original date of grant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:9%;"/><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amendment </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>New Expiration </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Option Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Note</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(i)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">292,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 23, 2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 23, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">442,273</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,367</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 20, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 20, 2023</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,151</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8,151</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 2, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 2, 2023</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,009</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">335,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">163,945</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2018</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2028</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24,194</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">308,066</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 13, 2017</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 13, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">127,719</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">760,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 15, 2016</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 15, 2026</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">984,511</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 23, 2016</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 23, 2026</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,582</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2017</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">32,456</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">387,934</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 30, 2017</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 30, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">224,901</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">615,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2018</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2028</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">213,646</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">425,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">180,267</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 1, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 1, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,209</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">40,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 20, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 20, 2031</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,486</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,342,518</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,450,349</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The expiration date of these options were extended from five and a half years to ten years from the original date of grant.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These options were previously amended on December 16, 2019 and amended again on September 21, 2021.</p></td></tr></tbody></table>Effective August 3, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted stock options to purchase an aggregate of 926,640 shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with options to purchase up to 463,328 shares vesting on August 3, 2022, and options to purchase up to 463,312 shares vesting on August 3, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $1,811,216, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.31, exercise price $3.40, 69.13% volatility, 1.19% risk free rate, and no forfeiture rate. <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective September 7, 2021, the Company granted stock options to purchase 50,000 shares of common stock to two employees in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 25,000 shares vesting on September 7, 2022, and 25,000 shares vesting on September 7, 2023 subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The Company has calculated the estimated fair market value of these options at $98,322, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.32, exercise price $3.40, 68.98% volatility, 1.38% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Effective October 4, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval the Company granted stock options to purchase 73,360 shares of common stock to an employee in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 36,680 shares vesting on October 4, 2022, and 36,680 shares vesting on October 4, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $128,003, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.04 exercise price $3.40, 68.80% volatility, 1.49% risk free rate, and no forfeiture rate. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the options issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2011 Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016)and which have a weighted average exercise price of $3.87 per share and an aggregate weighted average remaining contractual life of 5.22 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>(Years)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">635,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">635,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.25</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.12</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,063,750</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,717</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,717</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.35</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">0.67</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">9,102</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,022,587</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">532,493</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.40</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8.32</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,476,796</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">795,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">795,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.60</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6.94</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,862,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,682,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,682,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.00</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.76</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,731,348</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">11,801</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">11,801</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.35</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">0.44</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">51,334</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.38</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5.07</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">390,534</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.80</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.01</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">240,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">696,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">696,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5.00</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.24</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,480,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>4,985,105</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>4,495,011</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>19,304,864</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to stock options of $1,127,502 and $1,069,605 was recorded for the year ended December 31, 2022 and December 31, 2021 respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately $287,363 and is expected to be recognized over a period of 0.76 years. As of December 31, 2022, the total intrinsic value of stock options was $nil.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, an aggregate of 417,318 shares of common stock remained available for future issuance under the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c</strong><strong>) Restricted Stock Units (RSUs)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">789,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(31,250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">810,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,892,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(377,007</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,937</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Outstanding at December 31, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2,262,908</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2.05</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2022</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs granted during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan. These RSUs vest equally over periods stated on the dates noted, subject to continued service, and will result in the compensation expense stated. The exception to this is specified in note (iv) which is described in detail below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Incentive</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Plan</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">22,640</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">30,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">84,300</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">32,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">94,400</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">104,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">306,800</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">33,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">80,850</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">63,102</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">126,835</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">42,250</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,144,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,670,240</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iv)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">450,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Up to 42 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">321,078</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(v)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,450</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>1,892,102</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,755,843</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These RSUs vest upon the achievement of corporate goals focused around product development and commercialization with further time-based vesting, subject to continued service of the award recipient to the Company through the applicable vesting dates. On October 13, 2022, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals previously established by the Compensation Committee, which resulted in the vesting of the rights with respect to an aggregate of 198,275 RSUs. The RSUs are further subject to a three-year time based vesting schedule, vesting in three equal installments on the dates set forth in the table above, and conditioned upon the recipient&#8217;s continued service through the applicable vesting date. On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain additional corporate goals, which resulted in the vesting of the rights with respect to an aggregate of an additional 424,875 RSUs, subject to the foregoing time-based vesting and conditioned upon the recipient&#8217;s continued service through the applicable vesting date.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(iv)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">These RSUs vest upon the share price closing above $5.00 per share for a minimum of ten consecutive trading days within a period of three years from the date of grant, with further time-based vesting in a single installment six months after the timely achievement of the target, if at all, and subject to continued service. The estimated fair value of the RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation of a Geometric Brownian Motion stock path model and incorporating the probability of vesting occurring. The estimated fair value of these awards will be recognized over the derived service period (as determined by the valuation model), with such recognition occurring regardless of whether the market condition is met.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(v)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company granted an aggregate of 3,000 RSUs on November 29, 2022 as an employment inducement award. These RSUs are subject to time-based vesting and subject to the continued service of each recipient.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Below is a table summarizing the RSUs vested during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Issued</strong>&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Taxes</strong>&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">26,250</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,712</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,538</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">35,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">230,102</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">191,992</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">38,110</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">12,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7,038</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,962</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,905</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">13,022</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,883</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,750</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">12,344</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">9,406</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,181</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">819</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>377,007</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>297,289</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>79,718</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs cancelled during the year ended December 31, 2022, all of which were originally issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Cancellation </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;">33,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:23%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;">33,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,365</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 18, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,365</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">17,572</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 18, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">17,572</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 21, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>62,937</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>62,937</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">2021</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs granted during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:5%;"/><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,450</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">30,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">107,700</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">150,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">496,500</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(i)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">460,191</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,523,232</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">38,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">126,160</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(ii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">39,809</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">121,019</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">43,500</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">152,685</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">77,740</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>789,500</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,624,486</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective August 3, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 460,191 shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective October 4, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 39,809 shares of common stock to an employee of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019.</p></td></tr></tbody></table>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs vested during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">#</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Issued</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for Taxes</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">26,250</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">21,712</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4,538</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>31,250</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>24,712</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>6,538</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs cancelled during the year ended December 31, 2021, all of which were originally issued pursuant to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Equity Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;text-align:right;">15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:bottom;text-align:right;">15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>15,000</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>15,000</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022 of which the last to vest have a remaining contractual life of 3.26 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>(Years)</strong> </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:31%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450,000</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;">0.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;">3.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,133,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.46</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">25,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.22</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">63,102</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.01</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.08</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.15</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.91</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">33,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.45</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.92</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">30,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.81</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.61</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">136,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.95</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.97</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">19,904</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.04</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">311,152</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.31</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.32</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.68</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.48</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">21,750</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.51</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.42</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">0.23</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>2,262,908</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock-based compensation expense related to RSUs of $1,903,054 and $898,910 was recorded in the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $2,214,593.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197570256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 9 - Income Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has estimated net operating losses for the years ended December 31, 2022 and 2021 of $28.6 million and $24.4 million, respectively, available to offset taxable income in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The significant components of deferred income taxes and assets as of December 31, 2022 and December 31, 2021 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net Deferred Tax Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td/><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Excess of tax over book depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(46,001</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,330</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">ROU Asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(117,134</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,657</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Lease Liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,279</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,301</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,655</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Unrealized Gain/Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,106</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Capitalized research expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,237,122</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses carry-forward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,556,992</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,390,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Research and development tax credits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">769,317</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">606,729</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,850,186</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,297,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,850,186</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,297,640</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,552,546</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>&#160;</strong></p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary Rate Reconciliation</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal statutory rate </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;State income taxes, net of federal benefit </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Permanent Differences </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Stock based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Research &amp; Development Credits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Foreign taxes </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Deferred Rate Decrease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3.2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Disclosure Amounts</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,072,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,614,447</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">769,317</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Increase in Valuation Allowance</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,552,546</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197448064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments And Contingencies</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 10 - Commitments and Contingencies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>a) </strong><strong>Finance Lease Obligations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (&#8220;ING&#8221;) to purchase a property located in Belgium for &#8364;1.12 million, maturing May 2031, with implicit interest of 2.62%. As of December 31, 2022, the balance payable was $482,146.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for &#8364;25,000, maturing January 2022, with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of December 31, 2022, the balance payable was $0. The following is a schedule showing the future minimum lease payments under financing leases by years and the present value of the minimum payments as of December 31, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,725</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,725</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,534</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541,162</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,016</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>482,146</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>b) </strong><strong>Operating Lease Right-of-Use Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, operating lease right-of-use assets and liabilities arising from operating leases were $619,392 and $645,254, respectively. During the year ended December 31, 2022, cash paid for amounts included for the measurement of lease liabilities was $245,354 and the Company recorded operating lease expense of $267,434. Our weighted average discount rate is 2.38% and the weighted average remaining lease term is 25 months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,799</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,225</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,209</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Operating Lease Obligations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">669,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,379</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present Value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>645,254</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s office space leases are short term, and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the year ended December 31, 2022, $76,955 was recognized in short-term lease costs associated with the office space leases in Singapore and Nevada. The annual payments remaining for such short-term office leases as of December 31, 2022, were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,069</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Operating Lease Liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>27,069</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>c) Grants Repayable </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#8364;1,048,020. Per the terms of the agreement, &#8364;314,406 of the grant is to be repaid by installments over the period from June 30, 2014 to June 30, 2023. The Company has recorded the balance of &#8364;733,614 to other income in previous years as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;314,406 and the 6% royalty on revenue, is twice the amount of funding received. As of December 31, 2022, the grant balance repayable was $26,831. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#8364;605,000.&#160; Per the terms of the agreement, &#8364;181,500 of the grant is to be repaid by instalments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $107,280. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#8364;495,000.&#160; Per the terms of the agreement, &#8364;148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $97,799. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#8364;929,433.&#160; Per the terms of the agreement, &#8364;278,830 of the grant is to be repaid by instalments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $230,392.</p>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2022, the balance repayable was $462,302 and the annual payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,541</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,581</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,026</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,978</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">263,893</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Grants Repayable </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>462,302</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>d) Long-Term Debt</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a 7-year loan agreement with Namur Invest for &#8364;440,000 with a fixed interest rate of 4.85%, maturing December 2023. As of December 31, 2022, the principal balance payable was $82,659.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2016, the Company entered into a 15-year loan agreement with ING for &#8364;270,000 with a fixed interest rate of 2.62%, maturing December 2031. As of December 31, 2022, the principal balance payable was $188,806. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to &#8364;1 million with a fixed interest rate of 4.50%, maturing September 2024.&#160; As of December 31, 2022, &#8364;1 million has been drawn down under this agreement and the principal balance payable was $482,954. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for &#8364;500,000 with fixed interest rate of 4.00%, maturing June 2022. As of December 31, 2022, the principal balance payable was $0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for &#8364;500,000 with fixed interest rate of 4.80%, maturing September 2024. As of December 31, 2022, the principal balance payable was $279,548.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of &#8364;830,000 with fixed interest rate of 4.00%, maturing March 2031. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;707,599, representing a principal balance payable of $759,419.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 23, 2021, the Company entered into a 3 &#189; year loan agreement with SOFINEX for a maximum of &#8364;450,000 with fixed interest rate of 5.00%, maturing June 2025. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;450,000, representing a principal balance payable of $442,708.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 5, 2022 the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $620,549 with fixed interest rate of 3.57%, maturing November 2022. As of December 31, 2022, the principal balance payable was $0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 16, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of &#8364;1,000,000 with fixed interest rate of 6.00%, maturing July 2026. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;1,000,000, representing a principal balance payable of $1,073,231.</p>&#160; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 18, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of &#8364;500,000 with fixed interest rate of 5.45%, maturing December 2027. As of December 31, 2022, the amount that has been drawn down under this agreement was &#8364;500,000, representing a principal balance payable of $536,615.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the total balance for long-term debt payable was $3,845,940 and the payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,268,528</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,138,227</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">704,312</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,358</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">281,602</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">446,799</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,319,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(473,886</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Long-Term Debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>3,845,940</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>e) Collaborative Agreement Obligations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a 3-year period for a cost to the Company of up to $2.55 million payable over such period. As of December 31, 2022, $510,000 is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2019, the Company entered into a funded sponsored research agreement with the Texas A&amp;M University (&#8220;TAMU&#8221;) in consideration for the license granted to the Company for a 5-year period for a cost to the Company of up to $400,000 payable over such period. As of December 31, 2022, $0 is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of &#8364;54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of &#8364;100,236. In the year ended December 31, 2022, the parties entered into agreements for an additional cost to the Company of &#8364;39,000. As of December 31, 2022, $23,018 is still to be paid by the Company under the amended agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On August 2, 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (&#8220;NETs&#8221;) in cancer patients with sepsis for a cost to the Company of $346,787. As of December 31, 2022, $346,787 is still to be paid by the Company under this agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the total amount to be paid for future research and collaboration commitments was approximately $879,805 and the annual payments remaining were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">798,032</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">81,773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Collaborative Agreement Obligations&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">879,805</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>f) Other Commitments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition Vet </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 25, 2019, the Company entered into an agreement with TAMU for provision of in-kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of December 31, 2022, TAMU has a 12.5 % equity interest in Volition Vet.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition Germany </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (&#8220;Octamer&#8221;), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or &#8220;Volition Germany&#8221;). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany&#8217;s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, $210 is payable under the 6% royalty agreement on sales to date towards the Company&#8217;s aggregate minimum royalty obligation of&#160; $118,055.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Volition America </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 3, 2020, the Company entered into a professional services master agreement (the &#8220;Master Agreement&#8221;) with Diagnostic Oncology CRO, LLC (&#8220;DXOCRO&#8221;) to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. On August 8, 2022, the Company and DXOCRO amended and restated the Master Agreement to expand the scope of DXOCRO&#8217;s consultant services provided thereunder (the &#8220;A&amp;R Master Agreement&#8221;). The A&amp;R Master Agreement requires DXOCRO to support development and clinical validation studies for the Company&#8217;s Nu.Q&#174; product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q&#174; NETs and Nu.Q&#174; Cancer tests to determine clinical utility in sepsis and non-Hodgkin&#8217;s lymphoma. The Company anticipates DXOCRO&#8217;s services under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million. The Company&#8217;s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days&#8217; prior written notice. Unless earlier terminated, the A&amp;R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of December 31, 2022, $ 264,692 is payable under the A&amp;R Master Agreement, and up $3,435,165 may be payable by Company in future periods for services rendered. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>g) Legal Proceedings</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>h) Commitments in Respect of Corporate Goals and Performance-Based Awards</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In August 2021 and October 2021, the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals related to the awards in August 2021 and October 2021 resulting in the payment of the cash bonus awards and the vesting of the remaining rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has paid compensation expense of $737,137 in relation to the July 1, 2022 specified corporate goals based on the actual outcomes related to the prescribed performance targets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In October 2022, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around product development, manufacturing, financing and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Conditional upon the achievement by January 1, 2023 and July 1, 2023 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has accrued compensation expense of $905,856 in relation to the January 1, 2023 and July 1, 2023 specified corporate goals based on the actual outcomes related to the prescribed performance targets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As discussed in detail in Note 8, - <em>Stock-Based Compensation,</em> an aggregate of 1,144,000 RSUs were issued under the 2015 Stock Incentive Plan in connection with the October 2022 grants and an aggregate of 1,000,000 stock options and 500,000 RSUs were issued under the 2015 Stock Incentive Plan in connection with the August 2021 and October 2021 grants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized compensation expense of $969,593 in relation to the options vested in 2022 and $630,863 in relation to the options that will vest in 2023. The Company has unrecognized compensation expense of $270,550 to such stock options, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:25%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">969,593</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">580,411</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">389,182</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">630,863</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450,090</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">180,773</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">270,550</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>h) Commitments in Respect of Corporate Goals and Performance-Based Awards (continued)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized compensation expense of $822,149 in relation to the RSUs fully vested in 2022 and $530,930 in relation to RSUs that will vest in 2023. The Company has unrecognized compensation expense of $228,491 to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:25%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;822,149 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;493,207</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;328,942 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;530,930 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;379,191 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;151,739 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;228,491 </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of December 31, 2022, the Company has recognized total compensation expense of $245,861 of which $134,087 in relation to RSUs that will vest in 2023, $65,088 in relation to RSUs that will vest in 2024, and $46,686 in relation to RSUs that will vest in 2025. The Company has unrecognized compensation expense of $1,408,319 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:34%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Year</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;134,087 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;417,327 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2024</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;65,088 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;470,244 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2025</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;46,686 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;520,748 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;245,861 </strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;1,408,319 </strong></p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197539808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Note 11 - Subsequent Events</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Common Stock Issuances and Repurchases</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From January 1 to January 19, 2023, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $656,000 under the 2022 EDA through the sale of 279,703 shares of its common stock.&#160; No additional shares have been sold under the 2022 EDA through March 8, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January&#160;5, 2023, the Company purchased from a former officer 13,264 shares of its common stock at $2.39 per share, for a total cost to the Company of $31,772.66.&#160; These shares were subsequently retired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>RSU Vesting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals established by the Compensation Committee on October 4, 2022, which resulted in the vesting of rights with respect to an aggregate of 424,875 RSUs.&#160; The RSUs are further subject to a 3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively, and conditioned upon the recipient&#8217;s continued service through the applicable vesting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 8, 2023, 4,000 RSUs previously granted to an employee vested and resulted in the issuance of 2,369 shares of common stock and the remaining 1,631 shares of common stock were withheld as taxes and returned to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 1, 2023, 15,000 RSUs previously granted to employees vested and resulted in the issuance of 9,609 shares of common stock. An aggregate of 5,391 shares of common stock were withheld as taxes and returned to the 2015 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Capital Raise</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February&#160;17, 2023, the Company entered into an underwriting agreement with Newbridge in connection with an underwritten public offering of&#160;4,945,000&#160;shares of the Company&#8217;s common stock, which includes Newbridge&#8217;s exercise in full of its overallotment option, pursuant to the Company&#8217;s 2021 Form S-3. Newbridge purchased the shares from the Company at a price of $1.6275 per share.&#160; The offering closed on February 22, 2023. &#160;The Company received net proceeds of approximately $8.0 million from the offering before deducting offering expenses payable by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Commercial Product Launches</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 12, 2023, the Company announced the availability of its Nu.Q&#174; Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 16, 2023, the Company announced that its Nu.Q&#174; Vet Cancer Test was available for pre-order to veterinarians at the point of care through Heska.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192961808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis Of Presentation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company&#8217;s fiscal year end is December 31.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles Of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), <em>Commitments and Contingencies &#8211; Other Commitments</em>, for more information regarding Volition Vet, Volition Germany and Volition America. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivables</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company&#8217;s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.&#160; The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic And Diluted Net Loss Per Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company computes net loss per share in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 260, <em>&#8220;Earnings Per Share,&#8221;</em> which requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of December 31, 2022, and December 31, 2021, 7,787,013 and 6,323,268, respectively, of potential common shares equivalents from stock options, RSUs and warrants were excluded from the diluted EPS calculations as their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, <em>&#8220;Foreign Currency Matters &#8211; Foreign Currency Transactions&#8221;</em>. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to ASC 820, &#8220;<em>Fair Value Measurements and Disclosures,&#8221;</em> an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 1</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 2</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Level 3</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on &#8220;Level 1&#8221; inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">ASC 220, &#8220;<em>Other Comprehensive Income/(Loss)&#8221;,</em> establishes standards for the reporting and display of other comprehensive loss and its components in the financial statements. As of December 31, 2022, the Company had $227,097 of accumulated other comprehensive income, relating to foreign currency translation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, <em>&#8220;Accounting for Income Taxes&#8221;</em> as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Refer to Note 9 for further details.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company adopted ASC 606, &#8220;<em>Revenue from Contracts with Customers,&#8221;</em> effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company generates product revenues from the sale of its Nu.Q<sup style="vertical-align:super">&#174;</sup> Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Royalty </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under &#8220;Royalty&#8221; under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Product</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in &#8220;Product&#8221; in the consolidated statements of operations and comprehensive loss.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Service </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from laboratory services performed in the Company&#8217;s laboratory on behalf of third parties under &#8220;Service&#8221; under the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Licensing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company includes revenue recognized from the licensing of certain rights to third parties in &#8220;Licensing&#8221; in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue from Heska License Agreement </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the &#8220;License Agreement&#8221;) with Heska Corporation (&#8220;Heska&#8221;), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q&#174; Vet Cancer Test at the point of care (&#8220;POC&#8221;) initially for the screening of lymphoma and hemangiosarcoma in dogs (&#8220;Canine Lymphoma &amp; HSA&#8221;), and non-exclusive rights to sell its Nu.Q&#174; Vet Cancer Test in kit format (&#8220;Kits&#8221;) through Heska&#8217;s network of central reference laboratories (&#8220;Central Lab&#8221;) initially for Canine Lymphoma &amp; HSA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well.&#160; Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (&#8220;Key Components&#8221;) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska&#8217;s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party&#8217;s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">According to ASC Topic 606, &#8220;<em>Revenue from Contracts with Customers</em>&#8221;, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock', window );">Deferred Revenue (contract Liabilities) And Contract Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research And Development</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC 360, <em>&#8220;Property Plant and Equipment&#8221;,</em> the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company records stock-based compensation in accordance with ASC 718, &#8220;<em>Compensation &#8211; Stock Compensation&#8221;</em>. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. The estimated fair value of RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation model. Refer to Note 8 for further details.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company accounts for leases in accordance with ASC Topic 842, &#8220;Leases.&#8221; The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (&#8220;ROU&#8221;) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (&#8220;IBR&#8221;) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_COVID19PandemicImpactPolicyTextblock', window );">Covid-19 Pandemic Impact</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company&#8217;s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_COVID19PandemicImpactPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_COVID19PandemicImpactPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197645440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule Of Property And Equipment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;3 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">656,759</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">497,306</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,190,289</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,951,387</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,238,902</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">358,575</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">239,436</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">119,139</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;30 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,054,332</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">298,397</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,755,935</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5-15 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,317,132</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">326,337</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">990,795</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">128,788</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">128,788</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">8,705,875</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3,312,863</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">5,393,012</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Depreciation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Useful Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Computer hardware and software</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;3 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">599,944</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">474,169</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,775</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Laboratory equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,032,108</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,434,347</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,597,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Office furniture and equipment</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">293,427</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">213,244</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">80,183</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Buildings</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;30 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,177,641</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">243,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,933,891</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Building improvements</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;5-15 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,293,258</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">256,309</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,036,949</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Land</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;Not amortized</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">136,518</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">136,518</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">7,532,896</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2,621,819</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4,911,077</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192714640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock', window );">Schedule Of share issued from the cashless exercise of options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 13 - March 19, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,634</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">948</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,181</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,769</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8 - February 9, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 8, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,750</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">277,634</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">77,451</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus', window );">Schedule Of share issued from the settlement of RSUs</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 25, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 13, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.79</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">August 3, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,992</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,110</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">September 7, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,038</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,962</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 4, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,905</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,883</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">November 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,344</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,406</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 15, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,181</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">819</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">377,007</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">297,289</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,718</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Restricted Stock Units Vested</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price Settled</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares Withheld for Tax</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 20, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">April 21, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;31,250</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;24,712</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;6,538</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90193-114008<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 55<br> -Paragraph 63<br> -URI https://asc.fasb.org/extlink&amp;oid=126970277&amp;loc=d3e23176-110880<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90198-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230200345824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Of Intangible Assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,104,103</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">993,598</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">110,505</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 31, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Net Carrying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Cost</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Value</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,178,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">961,259</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">216,876</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule Of Annual Estimated Amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Remaining Life</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Amortization</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,636</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,869</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Intangible Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>110,505</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192997136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>StockBased Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary Of Changes In Warrants Outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">310,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">485,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">539,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">485,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SummarizingTheWarrantsIssuedAndOutstanding', window );">Summarizing The Warrants Issued And Outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Life (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">125,000</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">125,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">2.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">0.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;">308,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">54,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.05</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">164,700</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">50,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.45</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.17</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">172,500</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">125,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">125,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.95</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.01</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">493,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">185,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.90</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">906,500</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>539,000</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong>485,000</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><strong>2,046,200</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes The Changes In Options Outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,278,619</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,090,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(277,634</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(63,467</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.64</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,027,518</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Expired/Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,413</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.43</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,985,105</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.87</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,495,011</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.93</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summarizing The Options Issued And Outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:19%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Proceeds to</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Company if</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Price</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercised </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercisable</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>($)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>(Years)</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">635,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">635,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.25</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.12</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,063,750</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,717</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,717</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.35</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">0.67</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">9,102</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,022,587</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">532,493</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.40</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8.32</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,476,796</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">795,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">795,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.60</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6.94</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,862,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,682,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,682,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.00</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.76</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,731,348</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">11,801</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">11,801</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.35</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">0.44</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">51,334</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.38</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5.07</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">390,534</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.80</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.01</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">240,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">696,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">696,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5.00</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4.24</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,480,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>4,985,105</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>4,495,011</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>19,304,864</strong></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife', window );">Summarizing The Rsus Issued And Outstanding Maturity Life</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Exercise Price </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">789,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(31,250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">810,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,892,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(377,007</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,937</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.88</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Outstanding at December 31, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2,262,908</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2.05</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock', window );">summarizing the RSUs issued and outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Remaining </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Fair Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Contractual Life</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>(Years)</strong> </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:31%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450,000</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;">0.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;">3.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,133,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.46</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">25,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.22</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">63,102</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.01</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.08</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.15</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.91</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">33,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.45</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.92</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">30,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.81</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.61</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">136,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.95</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.97</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">19,904</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.04</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">311,152</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.31</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.32</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.68</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,000</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.48</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">21,750</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.51</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.42</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">0.23</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>2,262,908</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions', window );">Summary of Amendments to Expiration Dates of Options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:9%;"/><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amendment </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Stock Options</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>New Expiration </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:13%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Option Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Note</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(i)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">292,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 23, 2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 23, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">442,273</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,367</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 20, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 20, 2023</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,151</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jul 14, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2011</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8,151</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 2, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 2, 2023</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,009</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">335,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">163,945</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">89,163</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2018</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2028</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24,194</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(ii)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Sep 21, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">308,066</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 13, 2017</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 13, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">127,719</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">760,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 15, 2016</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 15, 2026</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">984,511</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 23, 2016</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 23, 2026</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,582</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2017</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">32,456</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">387,934</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 30, 2017</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 30, 2027</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">224,901</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 3, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">615,837</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2018</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 23, 2028</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">213,646</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">425,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">180,267</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 1, 2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 1, 2030</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,209</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 8, 2021</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">40,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 20, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 20, 2031</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,486</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,342,518</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,450,349</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfRsusGrantedDuringPeriod', window );">Schedule of RSUs granted during period</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Incentive</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Plan</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Feb 8, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">22,640</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">30,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">84,300</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">32,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">94,400</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">104,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 4, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">306,800</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">33,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jun 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">80,850</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">63,102</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 15, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">126,835</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 21, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">42,250</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,144,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,670,240</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(iv)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">450,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Up to 42 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">Variable</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">321,078</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">(v)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 29, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,450</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>1,892,102</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,755,843</strong></p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:5%;"/><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Grant </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>First Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Second Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Third Vesting </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSU Expense</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Note</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Period</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,450</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">30,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">107,700</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">150,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">36 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">496,500</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(i)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">460,191</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,523,232</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">38,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">126,160</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(ii)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">39,809</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">121,019</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">43,500</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">152,685</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24 Months</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2023</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">N/A</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">77,740</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>789,500</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,624,486</strong></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfRsusVestedDuringPeriod', window );">Schedule of RSUs vested during period</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="width:19%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Plan</strong>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Issued</strong>&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Taxes</strong>&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Mar 25, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">26,250</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,712</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,538</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">50,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">35,000</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">230,102</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 3, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">191,992</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">38,110</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">12,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Sep 7, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7,038</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4,962</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19,905</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Oct 4, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">13,022</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6,883</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">21,750</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 1, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">12,344</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">9,406</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 15, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1,181</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">819</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>377,007</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>297,289</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>79,718</strong></p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">#</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Issued</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Shares&#160;Withheld for Taxes</strong>&#160;</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">5,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Jan 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">26,250</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Apr 13, 2021</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">21,712</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4,538</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>31,250</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>24,712</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>6,538</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfRsusCancelledDuringPeriod', window );">Schedule of RSUs cancelled during period</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Equity Incentive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Cancellation </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<strong>Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:24%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;">33,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:23%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;">33,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,365</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Aug 18, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,365</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">17,572</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 18, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">17,572</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Nov 21, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">11,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>62,937</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>62,937</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Equity Incentive Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>#</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vest Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>RSUs Cancelled</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2015</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;text-align:right;">15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;Dec 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:bottom;text-align:right;">15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>15,000</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong>15,000</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfRsusCancelledDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfRsusCancelledDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfRsusGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfRsusGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfRsusVestedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfRsusVestedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SummarizingTheWarrantsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SummarizingTheWarrantsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197658544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Shedule of components of deferred income taxes and assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net Deferred Tax Liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td/><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Excess of tax over book depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(46,001</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,330</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">ROU Asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(117,134</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,657</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Lease Liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,279</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,301</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,655</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Unrealized Gain/Loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,106</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Capitalized research expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,237,122</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses carry-forward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,556,992</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,390,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px">Research and development tax credits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">769,317</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">606,729</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,850,186</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,297,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,850,186</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,297,640</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,552,546</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Summary Rate Reconciliation</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>%</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal statutory rate </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;State income taxes, net of federal benefit </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Permanent Differences </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Stock based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Research &amp; Development Credits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.7</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Foreign taxes </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Federal Deferred Rate Decrease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;Change in Valuation Allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3.2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Disclosure Amounts</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>December 31, 2022</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,072,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net Operating Losses - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,614,447</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - United States </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Credit Carryforward - Foreign</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">769,317</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Increase in Valuation Allowance</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,552,546</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192583632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock', window );">Schedule Of Future Minimum Lease Payments Under Financing Leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,725</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,725</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,726</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,534</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541,162</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,016</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>482,146</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock', window );">Schedule Of Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,799</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,225</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,209</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Operating Lease Obligations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">669,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(24,379</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Present Value of minimum lease payments</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>645,254</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfRecognizedInShortTermLeaseCosts', window );">Schedule Of Recognized In Short-term Lease Costs</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,069</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Operating Lease Liabilities</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>27,069</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule Of Grants Repayable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,541</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,581</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,026</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,978</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">263,893</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Grants Repayable </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>462,302</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule Of Long-term Debt Payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,268,528</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,138,227</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">704,312</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,358</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">281,602</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Greater than 5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">446,799</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,319,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: Amount representing interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(473,886</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Total Long-Term Debt</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>3,845,940</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of annual payments Of Collaborative Agreement Obligations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">798,032</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024 - 2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">81,773</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total Collaborative Agreement Obligations&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">879,805</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets', window );">Schedule of outcomes related to the prescribed performance targets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:25%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">969,593</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">580,411</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">389,182</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">630,863</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450,090</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">180,773</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">270,550</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Total </strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:24%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:25%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Award</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2021</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;822,149 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;493,207</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;328,942 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;530,930 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;379,191 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;151,739 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;228,491 </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"><tbody><tr style="height:15px"><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Vesting</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Amortised</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:34%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;Year</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2022</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>Un-Amortised</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>$</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2023</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;134,087 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;417,327 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2024</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;65,088 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;470,244 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2025</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;46,686 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">&#160;520,748 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;245,861 </strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>&#160;1,408,319 </strong></p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ScheduleOfRecognizedInShortTermLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ScheduleOfRecognizedInShortTermLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197094128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern Assessment (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Liquidity and Going Concern Assessment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NetIncomeLossSinceInception', window );">Net Loss Since Inception</a></td>
<td class="nump">$ 167.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NetIncomeLossSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NetIncomeLossSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230194339104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,867,050<span></span>
</td>
<td class="nump">$ 20,581,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TermsOfLicenseAgreement', window );">Terms of license Agreement</a></td>
<td class="text">Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_InitialTermForPoc', window );">Initial term for POC</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_InitialTermForCentralLab', window );">Initial term for Central Lab</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MilestoneAmountRecognized', window );">Milestone amount recognized</a></td>
<td class="nump">18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount in excess of FDIC limit</a></td>
<td class="nump">10,079,089<span></span>
</td>
<td class="nump">19,753,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">227,097<span></span>
</td>
<td class="nump">148,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">14,600,000<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">72,609<span></span>
</td>
<td class="nump">12,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 12,512,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vnrx_DilutiveWarrantsAndOptionsMember', window );">Warrants And Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PotentiallyDilutiveWarrantsAndOptions', window );">Potentially dilutive securities excluded from the computation of EPS</a></td>
<td class="nump">7,787,013<span></span>
</td>
<td class="nump">6,323,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryAgencyAxis=vnrx_BelgianDepositGuaranteeMember', window );">Belgian Deposit Guarantee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Deposits/cash in excess of insured limits</a></td>
<td class="nump">$ 1,725,981<span></span>
</td>
<td class="nump">$ 134,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryAgencyAxis=vnrx_SingaporeDepositInsuranceMember', window );">Singapore Deposit Insurance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Deposits/cash in excess of insured limits</a></td>
<td class="nump">100,601<span></span>
</td>
<td class="nump">102,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryAgencyAxis=vnrx_UKDepositProtectionSchemeMember', window );">UK Deposit Protection Scheme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Deposits/cash in excess of insured limits</a></td>
<td class="nump">$ 326,631<span></span>
</td>
<td class="nump">$ 142,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_InitialTermForCentralLab">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_InitialTermForCentralLab</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_InitialTermForPoc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_InitialTermForPoc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_MilestoneAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_MilestoneAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PotentiallyDilutiveWarrantsAndOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PotentiallyDilutiveWarrantsAndOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_TermsOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_TermsOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vnrx_DilutiveWarrantsAndOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vnrx_DilutiveWarrantsAndOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=vnrx_BelgianDepositGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=vnrx_BelgianDepositGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=vnrx_SingaporeDepositInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=vnrx_SingaporeDepositInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=vnrx_UKDepositProtectionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=vnrx_UKDepositProtectionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193615920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 8,705,875<span></span>
</td>
<td class="nump">$ 7,532,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">3,312,863<span></span>
</td>
<td class="nump">2,621,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">5,393,012<span></span>
</td>
<td class="nump">4,911,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">128,788<span></span>
</td>
<td class="nump">136,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">128,788<span></span>
</td>
<td class="nump">136,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Hardware And Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">656,759<span></span>
</td>
<td class="nump">599,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">497,306<span></span>
</td>
<td class="nump">474,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 159,453<span></span>
</td>
<td class="nump">$ 125,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 4,190,289<span></span>
</td>
<td class="nump">$ 3,032,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">1,951,387<span></span>
</td>
<td class="nump">1,434,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 2,238,902<span></span>
</td>
<td class="nump">$ 1,597,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 358,575<span></span>
</td>
<td class="nump">$ 293,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">239,436<span></span>
</td>
<td class="nump">213,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 119,139<span></span>
</td>
<td class="nump">$ 80,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 2,054,332<span></span>
</td>
<td class="nump">$ 2,177,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">298,397<span></span>
</td>
<td class="nump">243,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 1,755,935<span></span>
</td>
<td class="nump">$ 1,933,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 1,317,132<span></span>
</td>
<td class="nump">$ 1,293,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">326,337<span></span>
</td>
<td class="nump">256,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 990,795<span></span>
</td>
<td class="nump">$ 1,036,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vnrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192443088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 865,262<span></span>
</td>
<td class="nump">$ 812,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditure</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192581200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 110,505<span></span>
</td>
<td class="nump">$ 216,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">1,104,103<span></span>
</td>
<td class="nump">1,178,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">993,598<span></span>
</td>
<td class="nump">961,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 110,505<span></span>
</td>
<td class="nump">$ 216,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230198562896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">$ 85,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">24,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total Intangible Assets</a></td>
<td class="nump">$ 110,505<span></span>
</td>
<td class="nump">$ 216,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230198551072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization Expense</a></td>
<td class="nump">$ 75,558<span></span>
</td>
<td class="nump">$ 91,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patents And Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization Of Long-lived Asset On Straight Line Basis</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Patents And Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization Of Long-lived Asset On Straight Line Basis</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_PatentsAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_PatentsAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192487344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Net Deferred Tax Assets [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Net deferred tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExcessOfTaxOverBookDepreciationAndAmortization', window );">Excess of tax over book depreciation and amortization</a></td>
<td class="num">$ (46,001)<span></span>
</td>
<td class="num">$ (8,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">ROU Asset</a></td>
<td class="num">(117,134)<span></span>
</td>
<td class="num">(28,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Lease Liability</a></td>
<td class="nump">122,279<span></span>
</td>
<td class="nump">47,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">5,655<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnrealizedGainLoss', window );">Unrealized Gain/Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CapitalizedResearchExpenses', window );">Capitalized research expenses</a></td>
<td class="nump">1,237,122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock-based compensation</a></td>
<td class="nump">321,956<span></span>
</td>
<td class="nump">186,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Losses carry-forward</a></td>
<td class="nump">28,556,992<span></span>
</td>
<td class="nump">24,390,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">769,317<span></span>
</td>
<td class="nump">606,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">30,850,186<span></span>
</td>
<td class="nump">25,297,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(30,850,186)<span></span>
</td>
<td class="num">(25,297,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ChangeInValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="num">$ (5,552,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CapitalizedResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CapitalizedResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ExcessOfTaxOverBookDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ExcessOfTaxOverBookDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=vnrx_NetDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=vnrx_NetDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192519040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Summary Rate Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent Differences</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal Research &amp;amp;amp; Development Credits</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign', window );">Foreign taxes</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal Deferred Rate Decrease</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(14.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="num">(21.20%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192725216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncreaseInValuationAllowance', window );">Increase in Valuation Allowance</a></td>
<td class="nump">$ 5,552,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vnrx_UnitedStateMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">35,072,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit Carryforward</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vnrx_ForeignMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">90,614,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit Carryforward</a></td>
<td class="nump">$ 769,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vnrx_UnitedStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vnrx_UnitedStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vnrx_ForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vnrx_ForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230195936656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NetOperatingLosses', window );">Net operating losses</a></td>
<td class="nump">$ 2,860<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230189760384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">24,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">6,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesMember', window );">Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">297,289<span></span>
</td>
<td class="nump">77,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">377,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesWithheldForTax', window );">Shares Withheld for Tax</a></td>
<td class="nump">79,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightTwentyThousandTwentyOneMember', window );">February 8, 2021 | Stock Option Exercises Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightTwentyThousandTwentyOneMember', window );">February 8, 2021 | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightTwentyThousandTwentyOneMember', window );">February 8, 2021 | Stock Option Exercises 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember', window );">February 8 - February 9, 2021 | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember', window );">January 13 - March 19, 2021 | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryTwoTwentyThousandTwentyOneMember', window );">February 2, 2021 | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareIssuedUponCashlessExercise', window );">Common stock, share issued upon cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockIncentivePlan', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember', window );">March 25, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitsVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesWithheldForTax', window );">Shares Withheld for Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyTwoMember', window );">April 13, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">21,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_MayOneTwoThousandTwentyTwoMember', window );">May 1, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AugustThreeTwoThousandTwentyTwoMember', window );">August 3, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">191,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">230,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">38,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_SeptemberSevenTwoThousandTwentyTwoMember', window );">September 7, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">7,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">4,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_OctoberFourTwoThousandTwentyTwoMember', window );">October 4, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">13,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">19,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_NovemberOneTwoThousandTwentyTwoMember', window );">November 1, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">12,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">21,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">9,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_DecemberFifteenTwoThousandTwentyTwoMember', window );">December 15, 2022 [Member] | Stock Option Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per shares</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for Tax</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockShareIssuedUponCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockShareIssuedUponCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RestrictedStockUnitVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RestrictedStockUnitVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RestrictedStockUnitsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RestrictedStockUnitsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharesWithheldForTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharesWithheldForTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_StockIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_StockIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightTwentyThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_FebruaryEightTwentyThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionExercisesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_FebruaryTwoTwentyThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_FebruaryTwoTwentyThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_MayOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_MayOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AugustThreeTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AugustThreeTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_SeptemberSevenTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_SeptemberSevenTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_OctoberFourTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_OctoberFourTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_NovemberOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_NovemberOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_DecemberFifteenTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_DecemberFifteenTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192870240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">31,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">24,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for tax</a></td>
<td class="nump">6,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_JanuaryTwentyTwentyThusandTwentyOneMember', window );">January 20, 2021 | RSU Settlements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SaleOfStockPriceSettledPerShare', window );">Price Settled Per Share | $ / shares</a></td>
<td class="nump">$ 4.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for tax</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AprilTwentyOneTwentyTwentyOneMember', window );">April 21, 2021 | RSU Settlements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnitVested', window );">Restricted Stock Units Vested</a></td>
<td class="nump">26,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SaleOfStockPriceSettledPerShare', window );">Price Settled Per Share | $ / shares</a></td>
<td class="nump">$ 3.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares Issued</a></td>
<td class="nump">21,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares Withheld for tax</a></td>
<td class="nump">4,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RestrictedStockUnitVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RestrictedStockUnitVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SaleOfStockPriceSettledPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SaleOfStockPriceSettledPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_JanuaryTwentyTwentyThusandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_JanuaryTwentyTwentyThusandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_RSUSettlementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_RSUSettlementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AprilTwentyOneTwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AprilTwentyOneTwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230194296832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 07, 2022</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Sep. 07, 2018</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
<th class="th"><div>May 20, 2022</div></th>
<th class="th"><div>Sep. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,873,379<span></span>
</td>
<td class="nump">53,772,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IssuedOfCommonStockFromSettlementOfRSU', window );">Issued of common stock from settlement of RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockPricePerSahres', window );">Common stock price per sahres</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockShareAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PurchasePricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Proceeds from Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OfferingExpenses', window );">offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,348<span></span>
</td>
<td class="nump">2,539,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,829<span></span>
</td>
<td class="nump">190,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AggeregateShareOfCommonStockOfferingPrice', window );">Aggeregate share of common stock offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000.0<span></span>
</td>
<td class="nump">$ 2,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_BrokerageFees', window );">Brokerage fees</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commissions and fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AggeregateShareOfCommonStockOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AggeregateShareOfCommonStockOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_BrokerageFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_BrokerageFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockPricePerSahres">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockPricePerSahres</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IssuedOfCommonStockFromSettlementOfRSU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IssuedOfCommonStockFromSettlementOfRSU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193359520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details) - Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfWarrantsOutstandingBeginningBalance', window );">Number of warrants Outstanding beginning balance</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedExercisePriceAbstract', window );"><strong>Weighted Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of warrants granted</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfWarrantsExpired', window );">Number of warrants Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfWarrantsOutstandingEndingBalance', window );">Number of warrants outstanding ending balance</a></td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfWarrantsExercisable', window );">Number of Warrants Exercisable</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceOutstandingBalanceOne', window );">Weighted Average Exercise Price Outstanding balance</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">3.05<span></span>
</td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedExercisePriceExercised', window );">Weighted Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedExercisePriceExpired', window );">Weighted Exercise Price Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceEndingBalanceOne', window );">Weighted Average Exercise Price ending balance</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceExercisable', window );">Weighted Average Exercise Price exercisable</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfWarrantsOutstandingBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfWarrantsOutstandingBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfWarrantsOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfWarrantsOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceEndingBalanceOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceEndingBalanceOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceOutstandingBalanceOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceOutstandingBalanceOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230194210096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">485,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 2,046,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 308,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 164,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 172,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFourMember', window );">Warrants Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 493,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFiveMember', window );">Warrants Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable</a></td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding</a></td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 906,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230194436896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 2) - Option Four [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfOptionsOutstandingBeginningBalance', window );">Number of options outstanding beginning balance</a></td>
<td class="nump">5,027,518<span></span>
</td>
<td class="nump">4,278,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,090,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(277,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfExpiredCancelled', window );">Number of Expired/Cancelled</a></td>
<td class="num">$ (42,413)<span></span>
</td>
<td class="num">$ (63,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfOptionOutstandingEndingBalance', window );">Number of option outstanding ending balance</a></td>
<td class="nump">4,985,105<span></span>
</td>
<td class="nump">5,027,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfOptionsExercisable', window );">Number of options exercisable</a></td>
<td class="nump">4,495,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceOutstandingBalance', window );">Weighted Average Exercise Price Outstanding balance</a></td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceGranted', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled', window );">Weighted Average Exercise Price expires/cancelled</a></td>
<td class="nump">3.43<span></span>
</td>
<td class="nump">3.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceEndingBalance', window );">Weighted Average Exercise Price ending balance</a></td>
<td class="nump">3.87<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageExercisePriceExercisableBalance', window );">Weighted Average Exercise Price exercisable balance</a></td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfExpiredCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfExpiredCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfOptionOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfOptionOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfOptionsOutstandingBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfOptionsOutstandingBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceExercisableBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceExercisableBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageExercisePriceOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageExercisePriceOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230189450848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">3,342,518<span></span>
</td>
<td class="nump">3,342,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 2,450,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentOneMember', window );">Stock Options Amendment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 442,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Jul. 23,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Jul. 14,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Jul. 23,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwoMember', window );">Stock Options Amendment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">6,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 4,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Mar. 20,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Jul. 14,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Mar. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThreeMember', window );">Stock Options Amendment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">8,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 6,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Sep.  02,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Jul. 14,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Sep.  02,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourMember', window );">Stock Options Amendment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 163,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Apr. 13,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Sep. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Apr. 13,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFiveMember', window );">Stock Options Amendment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">89,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 24,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Jan. 23,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Sep. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Jan. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSixMember', window );">Stock Options Amendment Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">308,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 127,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Feb. 13,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Sep. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Feb. 13,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSevenMember', window );">Stock Options Amendment Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 984,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Apr. 15,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Apr. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentEightMember', window );">Stock Options Amendment Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 19,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Jun. 23,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Jun. 23,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentNineMember', window );">Stock Options Amendment Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 32,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Jan.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Jan.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTenMember', window );">Stock Options Amendment Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">387,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 224,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Mar. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Mar. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentElevenMember', window );">Stock Options Amendment Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">615,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 213,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Jan. 23,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Nov.  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Jan. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwelveMember', window );">Stock Options Amendment Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 180,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Apr. 13,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Dec.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Apr. 13,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThirteenMember', window );">Stock Options Amendment Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 5,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">Dec.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Dec.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">Dec.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourteenMember', window );">Stock Options Amendment Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Approved Stock options</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Option expenses</a></td>
<td class="nump">$ 21,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionGrantDate', window );">Stock option grant date</a></td>
<td class="text">May 20,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_stockoptionamendmentdate', window );">Stock option amendment date</a></td>
<td class="text">Dec.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock option expiration date</a></td>
<td class="text">May 20,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ApprovedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ApprovedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_EquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_EquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_StockOptionGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_StockOptionGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_stockoptionamendmentdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_stockoptionamendmentdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_StockOptionsAmendmentFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230194372176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 4)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember', window );">Option Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">795,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">795,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 2,862,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">6 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember', window );">Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">635,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 2,063,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember', window );">Option Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">2,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">2,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 9,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember', window );">Option Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">532,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">1,022,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 3,476,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember', window );">Option Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">1,682,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">1,682,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 6,731,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember', window );">Option Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">11,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">11,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 51,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">5 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember', window );">Option Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">89,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">89,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 390,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">5 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember', window );">Option Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember', window );">Option Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">696,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 3,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember', window );">Total Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable, shares</a></td>
<td class="nump">4,495,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, shares</a></td>
<td class="nump">4,985,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds to Company if Exercised | $</a></td>
<td class="nump">$ 19,304,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192872096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 5) - Stock Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfRsusOutstandingBeginingBalance', window );">Number of RSUs outstanding begining balance</a></td>
<td class="nump">810,750<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantedShares', window );">Granted</a></td>
<td class="nump">1,892,102<span></span>
</td>
<td class="nump">789,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockVested', window );">Vested</a></td>
<td class="num">(377,007)<span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockCancelled', window );">Cancelled</a></td>
<td class="num">(62,937)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfRsusOutstandingEndingBalance', window );">Number of RSUs outstanding ending balance</a></td>
<td class="nump">2,262,908<span></span>
</td>
<td class="nump">810,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharePriceBeginningBalance', window );">Share price beginning balance</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharePriceGranted', window );">Share price granted</a></td>
<td class="nump">1.64<span></span>
</td>
<td class="nump">3.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharePriceVested', window );">Share price vested</a></td>
<td class="nump">3.33<span></span>
</td>
<td class="nump">3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Cancelled', window );">Cancelled net</a></td>
<td class="nump">2.88<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharePriceEndingBalance', window );">Share price ending balance</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_Cancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_Cancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfRsusOutstandingBeginingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfRsusOutstandingBeginingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfRsusOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfRsusOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfStockCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfStockCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharePriceBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharePriceBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharePriceEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharePriceEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=vnrx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=vnrx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230190191264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 6) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">1,892,102<span></span>
</td>
<td class="nump">789,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 2,755,843<span></span>
</td>
<td class="nump">$ 2,624,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseNineMember', window );">Compensation Expense Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Oct.  04,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">Up to 42 Months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 321,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTenMember', window );">Compensation Expense Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Nov. 29,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">36 Months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Nov. 29,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Nov. 29,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ThirdVestingDate', window );">Third vesting date</a></td>
<td class="text">Nov. 29,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 6,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseOneMember', window );">Compensation Expense One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Feb.  08,  2022<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Feb.  08,  2023<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Feb.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 22,640<span></span>
</td>
<td class="nump">$ 19,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTwoMember', window );">Compensation Expense Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Mar.  01,  2022<span></span>
</td>
<td class="text">Mar. 25,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Mar.  01,  2023<span></span>
</td>
<td class="text">Mar. 25,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">Mar. 25,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 84,300<span></span>
</td>
<td class="nump">$ 107,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseThreeMember', window );">Compensation Expense Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Apr.  04,  2022<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">36 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Apr.  04,  2023<span></span>
</td>
<td class="text">May  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Apr.  04,  2024<span></span>
</td>
<td class="text">May  01,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ThirdVestingDate', window );">Third vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 94,400<span></span>
</td>
<td class="nump">$ 496,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFourMember', window );">Compensation Expense Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">460,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Apr.  04,  2022<span></span>
</td>
<td class="text">Aug.  03,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">36 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Apr.  04,  2023<span></span>
</td>
<td class="text">Aug.  03,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Apr.  04,  2024<span></span>
</td>
<td class="text">Aug.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ThirdVestingDate', window );">Third vesting date</a></td>
<td class="text">Apr.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 306,800<span></span>
</td>
<td class="nump">$ 1,523,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFiveMember', window );">Compensation Expense Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Jun.  01,  2022<span></span>
</td>
<td class="text">Sep.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Jun.  01,  2023<span></span>
</td>
<td class="text">Sep.  07,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="text">Sep.  07,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 80,850<span></span>
</td>
<td class="nump">$ 126,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSixMember', window );">Compensation Expense Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">63,102<span></span>
</td>
<td class="nump">39,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Aug. 15,  2022<span></span>
</td>
<td class="text">Oct.  04,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Aug. 15,  2023<span></span>
</td>
<td class="text">Oct.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Aug. 15,  2024<span></span>
</td>
<td class="text">Oct.  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 126,835<span></span>
</td>
<td class="nump">$ 121,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSevenMember', window );">Compensation Expense Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">43,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Sep. 21,  2022<span></span>
</td>
<td class="text">Nov.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">24 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Sep. 21,  2023<span></span>
</td>
<td class="text">Nov.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Sep. 21,  2024<span></span>
</td>
<td class="text">Nov.  01,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 42,250<span></span>
</td>
<td class="nump">$ 152,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseEightMember', window );">Compensation Expense Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseRsus', window );">Compensation Expense RSUs</a></td>
<td class="nump">1,144,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentivePlan', window );">Equity Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseGrantDate', window );">Compensation Expense grant date</a></td>
<td class="text">Oct.  04,  2022<span></span>
</td>
<td class="text">Dec. 15,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationExpenseVestingPeriod', window );">Compensation Expense Vesting Period</a></td>
<td class="text">36 Months<span></span>
</td>
<td class="text">24 Months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FirstVestingDate', window );">First Vesting date</a></td>
<td class="text">Oct.  04,  2023<span></span>
</td>
<td class="text">Dec. 15,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SecondVestingDate', window );">Second vesting date</a></td>
<td class="text">Oct.  04,  2024<span></span>
</td>
<td class="text">Dec. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ThirdVestingDate', window );">Third vesting date</a></td>
<td class="text">Oct.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuExpense', window );">RSU Expense</a></td>
<td class="nump">$ 1,670,240<span></span>
</td>
<td class="nump">$ 77,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CompensationExpenseGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CompensationExpenseGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CompensationExpenseRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CompensationExpenseRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CompensationExpenseVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CompensationExpenseVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_EquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_EquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FirstVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FirstVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RsuExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RsuExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SecondVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SecondVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ThirdVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ThirdVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_CompensationExpenseEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_CompensationExpenseEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193647296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 7) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">377,007<span></span>
</td>
<td class="nump">31,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">297,289<span></span>
</td>
<td class="nump">24,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 79,718<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember', window );">Equity Incentive Plan One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Mar. 25,  2022<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember', window );">Equity Incentive Plan Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">26,250<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Apr. 13,  2022<span></span>
</td>
<td class="text">Apr. 13,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">21,712<span></span>
</td>
<td class="nump">21,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 4,538<span></span>
</td>
<td class="nump">$ 4,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember', window );">Equity Incentive Plan Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">May  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember', window );">Equity Incentive Plan Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">230,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Aug.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">191,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 38,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFiveMember', window );">Equity Incentive Plan Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Sep.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">7,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 4,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSixMember', window );">Equity Incentive Plan Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">19,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Oct.  04,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">13,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSevenMember', window );">Equity Incentive Plan Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">21,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Nov.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">12,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 9,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanEightMember', window );">Equity Incentive Plan Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_EquityIncentiveRsu', window );">Equity Incentive RSU</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveVestDate', window );">Incentive Vest Date</a></td>
<td class="text">Dec. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsuIssued', window );">Incentive RSU Issued</a></td>
<td class="nump">1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsusHeldForTaxes', window );">RSUs Held for Taxes</a></td>
<td class="nump">$ 819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_EquityIncentiveRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_EquityIncentiveRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncentiveRsuIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncentiveRsuIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncentiveVestDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncentiveVestDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RsusHeldForTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RsusHeldForTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192890256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 8) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuCancelled', window );">RSU Cancelled</a></td>
<td class="nump">62,937<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsu', window );">Incentive RSU</a></td>
<td class="nump">62,937<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember', window );">Equity Incentive Plan One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuCancelled', window );">RSU Cancelled</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsu', window );">Incentive RSU</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CancellationDate', window );">Cancellation Date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_VestDate', window );">Vest date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember', window );">Equity Incentive Plan Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuCancelled', window );">RSU Cancelled</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsu', window );">Incentive RSU</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CancellationDate', window );">Cancellation Date</a></td>
<td class="text">Aug. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember', window );">Equity Incentive Plan Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuCancelled', window );">RSU Cancelled</a></td>
<td class="nump">17,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsu', window );">Incentive RSU</a></td>
<td class="nump">17,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CancellationDate', window );">Cancellation Date</a></td>
<td class="text">Nov. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember', window );">Equity Incentive Plan Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuCancelled', window );">RSU Cancelled</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentivePlan', window );">Incentive Plan</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_IncentiveRsu', window );">Incentive RSU</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CancellationDate', window );">Cancellation Date</a></td>
<td class="text">Nov. 21,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CancellationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CancellationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_IncentiveRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_IncentiveRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RsuCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RsuCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_VestDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_VestDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_EquityIncentivePlanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192835888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 9)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember', window );">Option Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">63,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">1 year 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember', window );">Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember', window );">Option Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">1,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember', window );">Option Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 1.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">1 year 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember', window );">Option Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">1 year 10 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember', window );">Option Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember', window );">Option Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">8 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember', window );">Option Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">7 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember', window );">Option Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">11 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember', window );">Total Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">2,262,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTenMember', window );">Option Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">19,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">4 months 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionElevenMember', window );">Option Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">311,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTwelveMember', window );">Option Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">8 months 4 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFourteenTenMember', window );">Option Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">21,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">5 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFiveteenTenMember', window );">Option Fiveteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">2 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThirteenTenMember', window );">Option Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfStockOutstandingBalance', window );">Number of stock Outstanding balance</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SharesPriceRsu', window );">Share price | $ / shares</a></td>
<td class="nump">$ 3.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_WeightedAverageRemainingContractualLifeYears', window );">Weighted average remaining contractual life (Years)</a></td>
<td class="text">5 months 23 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfStockOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfStockOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SharesPriceRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SharesPriceRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_WeightedAverageRemainingContractualLifeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_WeightedAverageRemainingContractualLifeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_OptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_TotalStockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFourteenTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFourteenTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFiveteenTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionFiveteenTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThirteenTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_StockOptionThirteenTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230184662720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2022</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Nov. 18, 2022</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>May 20, 2021</div></th>
<th class="th"><div>May 27, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 15, 2018</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
<th class="th"><div>Jun. 13, 2017</div></th>
<th class="th"><div>Aug. 05, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockAvailable', window );">Common stock available</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ShareAggregateMaximum', window );">Share aggregate maximum</a></td>
<td class="nump">7,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OptionGranted', window );">Option Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,383<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ApprovedStockOptions', window );">Stock options approved amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,342,518<span></span>
</td>
<td class="nump">3,342,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,736,444<span></span>
</td>
<td class="nump">$ 23,219,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Volatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,450,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_RestrictedStockUnitsOneMember', window );">Restricted Stock Units [Member] | One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_VestingAggregate', window );">Vesting aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AggregrateAggregate', window );">Aggregrate aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantedAggregate', window );">Granted aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantedRsu', window );">Granted RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_DescriptionOfVestingShall', window );">Description of vesting shall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,903,054<span></span>
</td>
<td class="nump">898,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnrecognizedCompensationCost', window );">unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,214,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127,502<span></span>
</td>
<td class="nump">1,069,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | 2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_NumberOfSharesVesting', window );">Shares vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FairValueOfOptions', window );">Fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,003<span></span>
</td>
<td class="nump">$ 98,322<span></span>
</td>
<td class="nump">$ 1,811,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockSharesIssuableUponExerciseOfStockOption', window );">Common stock shares issuable upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">463,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Volatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.80%<span></span>
</td>
<td class="nump">68.98%<span></span>
</td>
<td class="nump">69.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.49%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">1.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,680<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">463,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MaturityTerm', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,360<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">926,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | 2015 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">4,250,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,102<span></span>
</td>
<td class="nump">$ 701,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MaturityTerm', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CompensationCostRelatedToNonVestedWarrants', window );">Compensation cost related to non-vested warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AprilFourTwoThousandTwentyTwoMember', window );">April 4, 2022 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Volatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FebruaryOneTwoThousandTwentyOneMember', window );">February 1, 2021 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Volatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription', window );">Expire description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share<span></span>
</td>
<td class="text">These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_JanuaryOneTwoThousandTwentyOneMember', window );">January 01, 2021 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_VolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,901<span></span>
</td>
<td class="nump">$ 242,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair market value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyMember', window );">April 13,2020 [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockCompensationExpenses', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_OnTwoZeroMayTwoThousandTwentyOneMember', window );">On 20, May 2021 [Member] | Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_StockOptionsPurchaseSharesOfCommonStock', window );">Stock options purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the significant collective-bargaining arrangements within the range of expiration dates for collective-bargaining arrangements requiring contributions to a multiemployer plan as well as other information to help investors understand the significance of the collective-bargaining agreements and when they expire. A multiemployer plan is a pension or postretirement benefit plan to which two or more unrelated employers contribute where assets contributed by one participating employer may be used to provide benefits to employees of other participating employers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450657-114947<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AggregrateAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AggregrateAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ApprovedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ApprovedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockSharesIssuableUponExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockSharesIssuableUponExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CompensationCostRelatedToNonVestedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CompensationCostRelatedToNonVestedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_DescriptionOfVestingShall">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_DescriptionOfVestingShall</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantedAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantedAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantedRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantedRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_MaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen da</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_MaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_NumberOfSharesVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_NumberOfSharesVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ShareAggregateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ShareAggregateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_StockCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_StockCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_StockOptionsPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_StockOptionsPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_VestingAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_VestingAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_Volatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_Volatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_VolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_VolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_RestrictedStockUnitsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_RestrictedStockUnitsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=vnrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AprilFourTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AprilFourTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_FebruaryOneTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_FebruaryOneTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_JanuaryOneTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_JanuaryOneTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AprilThirteenTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_OnTwoZeroMayTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_OnTwoZeroMayTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230198479760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Finance Lease Obligations [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 57,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">57,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">57,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">57,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">57,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Greater than 5 years</a></td>
<td class="nump">252,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">541,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LessAmountRepresentingInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(59,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 482,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LessAmountRepresentingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LessAmountRepresentingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230198562896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - Operating Lease Right of Use Obligations [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">$ 264,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">164,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour', window );">2025</a></td>
<td class="nump">120,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive', window );">2026</a></td>
<td class="nump">94,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix', window );">2027</a></td>
<td class="nump">25,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeaseObligations', window );">Total Operating Lease Obligations</a></td>
<td class="nump">669,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LessAmountRepresentingInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(24,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDue', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 645,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LessAmountRepresentingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LessAmountRepresentingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197589168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent', window );">2023</a></td>
<td class="nump">$ 27,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears', window );">2024 - 2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesFutureMinimumLeasePaymentDue', window );">Total Operating Lease Liabilities</a></td>
<td class="nump">$ 27,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumLeasePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumLeasePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230198517984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - Grants Repayable [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree', window );">2023</a></td>
<td class="nump">$ 49,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour', window );">2024</a></td>
<td class="nump">26,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive', window );">2025</a></td>
<td class="nump">34,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix', window );">2026</a></td>
<td class="nump">42,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven', window );">2027</a></td>
<td class="nump">45,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter', window );">Greater than 5 years</a></td>
<td class="nump">263,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantsRepayable', window );">Total Grants Repayable</a></td>
<td class="nump">$ 462,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantsRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantsRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_GrantsRepayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_GrantsRepayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230196213808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,268,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,138,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">704,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">480,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">281,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturingInYearsFourAndFive', window );">Greater than 5 years</a></td>
<td class="nump">446,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Total</a></td>
<td class="nump">4,319,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LongTermDebtLessAmountRepresentingInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(473,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Long-Term Debt</a></td>
<td class="nump">$ 3,845,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturingInYearsFourAndFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturingInYearsFourAndFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LongTermDebtLessAmountRepresentingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LongTermDebtLessAmountRepresentingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230197509712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour', window );">2022</a></td>
<td class="nump">$ 798,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive', window );">2024 - 2027</a></td>
<td class="nump">81,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeAgreementObligations', window );">Total Collaborative Agreement Obligations</a></td>
<td class="nump">$ 879,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CollaborativeAgreementObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CollaborativeAgreementObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193378000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 6) - Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Outstanding Award 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding award</a></td>
<td class="nump">$ 969,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2022', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">580,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2021', window );">Amortised of outstanding award 2021</a></td>
<td class="nump">389,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward2023', window );">Un-amortised of outstanding award 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Outstanding Award 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding award</a></td>
<td class="nump">630,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2022', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">450,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2021', window );">Amortised of outstanding award 2021</a></td>
<td class="nump">180,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward2023', window );">Un-amortised of outstanding award 2023</a></td>
<td class="nump">$ 270,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmortisedOfOutstandingAward2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmortisedOfOutstandingAward2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmortisedOfOutstandingAward2022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmortisedOfOutstandingAward2022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnAmortisedOfOutstandingAward2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnAmortisedOfOutstandingAward2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193380128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 7) - Restricted stock option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Outstanding Award 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding award</a></td>
<td class="nump">$ 822,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2022', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">493,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2021', window );">Amortised of outstanding award 2021</a></td>
<td class="nump">328,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward2023', window );">Un-amortised of outstanding award 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Outstanding Award 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding award</a></td>
<td class="nump">530,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2022', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">379,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAward2021', window );">Amortised of outstanding award 2021</a></td>
<td class="nump">151,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward2023', window );">Un-amortised of outstanding award 2023</a></td>
<td class="nump">$ 228,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmortisedOfOutstandingAward2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmortisedOfOutstandingAward2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmortisedOfOutstandingAward2022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmortisedOfOutstandingAward2022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnAmortisedOfOutstandingAward2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnAmortisedOfOutstandingAward2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230192808544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 8)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAwardAmount', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">$ 245,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward', window );">Un-amortised of outstanding award</a></td>
<td class="nump">$ 1,408,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock option | Outstanding Award 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OutstandingAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAwardAmount', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">$ 134,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward', window );">Un-amortised of outstanding award</a></td>
<td class="nump">417,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock option | Outstanding Award 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAwardAmount', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">65,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward', window );">Un-amortised of outstanding award</a></td>
<td class="nump">$ 470,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OutstandingAward', window );">Outstanding award</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock option | Outstanding Award 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmortisedOfOutstandingAwardAmount', window );">Amortised of outstanding award 2022</a></td>
<td class="nump">$ 46,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnAmortisedOfOutstandingAward', window );">Un-amortised of outstanding award</a></td>
<td class="nump">$ 520,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OutstandingAward', window );">Outstanding award</a></td>
<td class="text">2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmortisedOfOutstandingAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmortisedOfOutstandingAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OutstandingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OutstandingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OutstandingAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OutstandingAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnAmortisedOfOutstandingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnAmortisedOfOutstandingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_AwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OutstandingAwardThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230182245264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 03, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantRepyable', window );">Grant Repyable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LongTermDebtPayable', window );">Long-term debt payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PaymentsForFutureResearchAndCollobration', window );">Payments For Future Research And Collobration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 879,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyalityOnRevenuePercentange', window );">RoyalityOnRevenuePercentange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AggerateAmountPayableDescription', window );">Aggerate Amount Payable, Description</a></td>
<td class="text">under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountPayable', window );">Amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_PayableByCompanyForServicesRendered', window );">Payable By Company For Services Rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,435,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RestrictedStockUnit', window );">Restricted stock unit | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AccruedCompensationExpense', window );">Accrued compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 905,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,450,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">737,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,181,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,343,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_PerformanceBasedAwardMember', window );">Performance Based Award [Member] | Vest In 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnrecognizedCompensationExpenses', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RSuVested', window );">RSu Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnrx_PerformanceBasedAwardMember', window );">Performance Based Award [Member] | Vest In 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_UnrecognizedCompensationExpenses', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RSuVested', window );">RSu Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RSuVestedIn2024', window );">RSu Vested in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RSuVestedIn2025', window );">RSu Vested in 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember', window );">Finance Lease Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Lease Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember', window );">Operating Lease Right of Use Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeaseRightOfUseAssets', window );">Operating Lease Right-of-use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_OperatingLeasesLiability1', window );">Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Payment Of Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short Term Lease Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_ManagingDirectorsAgreementMember', window );">Managing Director's Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountPayable', window );">Amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_Royality', window );">Royality</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_StockIncentivePlanMember', window );">Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Stock Option Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 969,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Total Of Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_In2018Member', window );">In 2018 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 2022<span></span>
</td>
<td class="text">June 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Total Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember', window );">February 5, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | First Insurance Funding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">November 2022<span></span>
</td>
<td class="text">November 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_OnSeptemberSixteenTwohousandtwentyMember', window );">On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 54,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Total Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AdditionalCostOfCompany', window );">Additional Cost Of Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmountDue', window );">Collaborative Obligations Amount Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_AugustTenTwoThousandTwentyTwoMember', window );">August Ten Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AdditionalCostOfCompany', window );">Additional Cost Of Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmountDue', window );">Collaborative Obligations Amount Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandNinteenMember', window );">In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmountDue', window );">Collaborative Obligations Amount Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LeaseAgreementExpirePeriods', window );">Lease Agreement Expire Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5<span></span>
</td>
<td class="text">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmount', window );">Collaborative Obligations Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandsEightteenMember', window );">In 2018 [Member] | BNP Paribas leasing solutions [Member] | Finance Lease Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountPayable', window );">Amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments', window );">Purchase Price For The Property | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 2022<span></span>
</td>
<td class="text">January 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ImplicitInterest', window );">Implicit Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LeasedEquipmentAmortizedPeriod', window );">Leased Equipment Amortized Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember', window );">Walloon Region Government [Member] | In 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyalityOnRevenuePercentange', window );">RoyalityOnRevenuePercentange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentOfGrants', window );">Repayment Of Grants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 148,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TermsOfAgreementDescription', window );">Terms Of Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountRepayable', window );">Amount Repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant Receivable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantRepaidByInstallments', window );">Grant Repaid By Installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">over 10 years<span></span>
</td>
<td class="text">over 10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember', window );">Walloon Region Government [Member] | In 2020 [Member] | Colorectal Cancer Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyalityOnRevenuePercentange', window );">RoyalityOnRevenuePercentange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentOfGrants', window );">Repayment Of Grants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TermsOfAgreementDescription', window );">Terms Of Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountRepayable', window );">Amount Repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant Receivable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantRepaidByInstallments', window );">Grant Repaid By Installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">over 15 years<span></span>
</td>
<td class="text">over 15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember', window );">Walloon Region Government [Member] | In 2018 [Member] | Colorectal Cancer Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyalityOnRevenuePercentange', window );">RoyalityOnRevenuePercentange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentOfGrants', window );">Repayment Of Grants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TermsOfAgreementDescription', window );">Terms Of Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountRepayable', window );">Amount Repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant Receivable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_GrantRepaidByInstallments', window );">Grant Repaid By Installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">over 12 years<span></span>
</td>
<td class="text">over 12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember', window );">Walloon Region Government [Member] | In 2010 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RoyalityOnRevenuePercentange', window );">RoyalityOnRevenuePercentange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentOfGrants', window );">Repayment Of Grants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_TermsOfAgreementDescription', window );">Terms Of Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;314,406 and the 6% royalty on revenue, is twice the amount of funding received<span></span>
</td>
<td class="text">it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#8364;314,406 and the 6% royalty on revenue, is twice the amount of funding received<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AmountRepayable', window );">Amount Repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant Receivable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,048,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_NamurInvestMember', window );">Namur Invest [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 2023<span></span>
</td>
<td class="text">December 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Total Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_NamurInvestMember', window );">Namur Invest [Member] | In 2019 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September 2024<span></span>
</td>
<td class="text">September 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Total Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_NamurInvestMember', window );">Namur Invest [Member] | In 2020 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 2031<span></span>
</td>
<td class="text">March 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AgreementUnderAmount', window );">Agreement Under Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 707,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_INGMember', window );">ING [Member] | In 2016 [Member] | Long-term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_MaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 2031<span></span>
</td>
<td class="text">May 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRateOnLease', window );">Fixed Interest Rate On Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Lease Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_INGMember', window );">ING [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 2031<span></span>
</td>
<td class="text">December 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_SOFINEXMember', window );">SOFINEX [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September 2024<span></span>
</td>
<td class="text">September 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Total Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_SOFINEXMember', window );">SOFINEX [Member] | November 23, 2021 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 30 days<span></span>
</td>
<td class="text">3 years 5 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 2025<span></span>
</td>
<td class="text">June 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AgreementUnderAmount', window );">Agreement Under Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_UniversityOfTaiwanMember', window );">University of Taiwan [Member] | In 2018 [Member] | Clinical Study Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmountDue', window );">Collaborative Obligations Amount Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CollaborativeObligationsAmount', window );">Collaborative Obligations Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LeaseAgreementExpirePeriod', window );">Lease Agreement Expire Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_NamurMember', window );">Namur [Member] | August 16, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 2026<span></span>
</td>
<td class="text">July 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,073,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AgreementUnderAmount', window );">Agreement Under Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vnrx_NamurMember', window );">Namur [Member] | November 18, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LoanAgreementTerm', window );">Loan Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RepaymentsOfLongtermLoans', window );">Repayment Of Long-term Loan Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_FixedInterestRate', window );">Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_LineOfCreditFacilityExpirationDatesOne', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 2027<span></span>
</td>
<td class="text">December 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Principal Balance Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_AgreementUnderAmount', window );">Agreement Under Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AccruedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AccruedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AdditionalCostOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AdditionalCostOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AggerateAmountPayableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AggerateAmountPayableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AgreementUnderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AgreementUnderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_AmountRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_AmountRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CollaborativeObligationsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CollaborativeObligationsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CollaborativeObligationsAmountDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CollaborativeObligationsAmountDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_FixedInterestRateOnLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_FixedInterestRateOnLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantRepaidByInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantRepaidByInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_GrantRepyable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_GrantRepyable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ImplicitInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ImplicitInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LeaseAgreementExpirePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LeaseAgreementExpirePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LeaseAgreementExpirePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LeaseAgreementExpirePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LeasedEquipmentAmortizedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LeasedEquipmentAmortizedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LineOfCreditFacilityExpirationDatesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LineOfCreditFacilityExpirationDatesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LoanAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LoanAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_LongTermDebtPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_LongTermDebtPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_OperatingLeasesLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_OperatingLeasesLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PayableByCompanyForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PayableByCompanyForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_PaymentsForFutureResearchAndCollobration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_PaymentsForFutureResearchAndCollobration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RSuVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RSuVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RSuVestedIn2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RSuVestedIn2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RSuVestedIn2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RSuVestedIn2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RepaymentOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RepaymentOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RepaymentsOfLongtermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RepaymentsOfLongtermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_Royality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_Royality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RoyalityOnRevenuePercentange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RoyalityOnRevenuePercentange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_TermsOfAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_TermsOfAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_UnrecognizedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_UnrecognizedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnrx_PerformanceBasedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnrx_PerformanceBasedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vnrx_VestIn2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vnrx_VestIn2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vnrx_VestIn2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vnrx_VestIn2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=vnrx_FinanceLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_OperatingLeaseRightofUseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_ManagingDirectorsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_ManagingDirectorsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_In2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_In2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vnrx_NamurInnovationAndGrowthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vnrx_NamurInnovationAndGrowthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vnrx_FirstInsuranceFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vnrx_FirstInsuranceFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_OnSeptemberSixteenTwohousandtwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_OnSeptemberSixteenTwohousandtwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_BioinformaticAnalyticsOfCellFreeDNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_BioinformaticAnalyticsOfCellFreeDNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_AugustTenTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_AugustTenTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vnrx_UnivercityOfTexasMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vnrx_UnivercityOfTexasMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandNinteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_InTwoThousandNinteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollectiveBargainingArrangementAxis=vnrx_CollaborativeArrangementCoPromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollectiveBargainingArrangementAxis=vnrx_CollaborativeArrangementCoPromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandsEightteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_InTwoThousandsEightteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_BNPParibasLeasingSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vnrx_BNPParibasLeasingSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_WalloonRegionGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandsTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_InTwoThousandsTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_In2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_In2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_NamurInvestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_NamurInvestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_In2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_In2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_InTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_InTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_InTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_INGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_INGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_SOFINEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_SOFINEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_In2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_In2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_UniversityOfTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_UniversityOfTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_ClinicalStudyResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_ClinicalStudyResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vnrx_NamurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vnrx_NamurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_SixteenAugustTwoThounsendTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_SixteenAugustTwoThounsendTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vnrx_EighteenNovemberTwoThounsendTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vnrx_EighteenNovemberTwoThounsendTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140230193013072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Jan. 05, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,873,379<span></span>
</td>
<td class="nump">53,772,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,392<span></span>
</td>
<td class="nump">$ 90,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan [Member] | Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested', window );">RSUs, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockSharesWithheldForTaxes', window );">Common stock, shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,391<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_CapitalRaiseMember', window );">Capital Raise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceed from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_RsuVestingEventMember', window );">RSU Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested', window );">RSUs, vested</a></td>
<td class="nump">424,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_RsuVestingDescription', window );">Description of rsu vesting</a></td>
<td class="text">3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnrx_CommonStockIssuancesAndRepurchasesMember', window );">Common Stock Issuances And Repurchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_SaleOfCommonStock', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockSharePurchase', window );">Common stock, share purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CommonStockPerShare', window );">Common stock, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vnrx_CostOfTheCompany', window );">Total cost of the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockSharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockSharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CommonStockSharesWithheldForTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CommonStockSharesWithheldForTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_CostOfTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_CostOfTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_RsuVestingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_RsuVestingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_SaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_SaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_CapitalRaiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_CapitalRaiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_RsuVestingEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_RsuVestingEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnrx_CommonStockIssuancesAndRepurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnrx_CommonStockIssuancesAndRepurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>vnrx_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:vnrx="http://vnrx.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnrx-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CommonStockIssuancesAndRepurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-19</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-12_vnrx_RsuVestingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:RsuVestingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-12_vnrx_RsuVestingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:RsuVestingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-12</instant>
        </period>
    </context>
    <context id="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-08</instant>
        </period>
    </context>
    <context id="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="AsOf2023-02-17_vnrx_CapitalRaiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CapitalRaiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:CapitalRaiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:UniversityOfTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ClinicalStudyResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:UniversityOfTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ClinicalStudyResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNinteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">vnrx:CollaborativeArrangementCoPromotionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnivercityOfTexasMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustTenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNinteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">vnrx:CollaborativeArrangementCoPromotionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnivercityOfTexasMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustTenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnSeptemberSixteenTwohousandtwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:BioinformaticAnalyticsOfCellFreeDNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnSeptemberSixteenTwohousandtwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:BioinformaticAnalyticsOfCellFreeDNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FiveFebruaryTwoThounsendTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vnrx:FirstInsuranceFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FiveFebruaryTwoThounsendTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vnrx:FirstInsuranceFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:NamurInnovationAndGrowthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:NamurInnovationAndGrowthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SixteenAugustTwoThounsendTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SixteenAugustTwoThounsendTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:EighteenNovemberTwoThounsendTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:EighteenNovemberTwoThounsendTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:SOFINEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:NamurInvestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:WalloonRegionGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vnrx:INGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:In2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OperatingLeaseRightofUseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vnrx:VestIn2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vnrx:VestIn2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ManagingDirectorsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_ManagingDirectorsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:ManagingDirectorsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:BNPParibasLeasingSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:InTwoThousandsEightteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:BNPParibasLeasingSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2020-11-01to2020-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-03</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OutstandingAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:AwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_GrantsRepayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:GrantsRepayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vnrx:OperatingLeaseRightofUseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">vnrx:FinanceLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-27_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-27</instant>
        </period>
    </context>
    <context id="AsOf2018-03-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-27</instant>
        </period>
    </context>
    <context id="AsOf2018-06-15_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-15</instant>
        </period>
    </context>
    <context id="AsOf2018-06-15_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-15</instant>
        </period>
    </context>
    <context id="AsOf2017-06-13_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-13</instant>
        </period>
    </context>
    <context id="AsOf2016-08-05_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-05</instant>
        </period>
    </context>
    <context id="AsOf2016-08-05_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-05</instant>
        </period>
    </context>
    <context id="From2019-01-01to2019-09-30_vnrx_AprilThirteenTwoThousandTwentyMember_vnrx_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="From2022-11-01to2022-11-29_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RestrictedStockUnitsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-05-05to2021-05-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilFourTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-20</instant>
        </period>
    </context>
    <context id="From2019-05-01to2019-05-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-27</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilFourTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-05to2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OnTwoZeroMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-07</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-04</instant>
        </period>
    </context>
    <context id="From2022-08-01to2022-08-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="From2022-11-01to2022-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-04-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="From2021-08-01to2021-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="From2022-04-01to2022-04-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-04</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionFiveteenTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionFourteenTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThirteenTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:EquityIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:CompensationExpenseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_vnrx_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vnrx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:TotalStockOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OptionFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OptionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_TotalStockOptionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:TotalStockOptionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OptionFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OptionFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OptionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_OptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:StockOptionsAmendmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2021-12-31_vnrx_OptionFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_OptionFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:OptionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_WarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-10_vnrx_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="AsOf2022-07-29_vnrx_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-07</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-20</endDate>
        </period>
    </context>
    <context id="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-24</endDate>
        </period>
    </context>
    <context id="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-29</endDate>
        </period>
    </context>
    <context id="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnrx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilTwentyOneTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryTwentyTwentyThusandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilTwentyOneTwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryTwentyTwentyThusandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnrx:RSUSettlementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:DecemberFifteenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:NovemberOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OctoberFourTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SeptemberSevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustThreeTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MayOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MarchTwentyFiveTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AugustThreeTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:NovemberOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:OctoberFourTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:SeptemberSevenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:DecemberFifteenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MayOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:AprilThirteenTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:MarchTwentyFiveTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightFebruaryNineTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightFebruaryNineTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryEightTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryTwoTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:FebruaryTwoTwentyThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vnrx:JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">vnrx:StockOptionExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_ForeignMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:ForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_UnitedStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vnrx:UnitedStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">vnrx:NetDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">vnrx:NetDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MaximumMember_vnrx_PatentsAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:PatentsAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MinimumMember_vnrx_PatentsAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">vnrx:PatentsAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_vnrx_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_vnrx_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vnrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_DilutiveWarrantsAndOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vnrx:DilutiveWarrantsAndOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_DilutiveWarrantsAndOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vnrx:DilutiveWarrantsAndOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_UKDepositProtectionSchemeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:UKDepositProtectionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_UKDepositProtectionSchemeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:UKDepositProtectionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_SingaporeDepositInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:SingaporeDepositInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_SingaporeDepositInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:SingaporeDepositInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_vnrx_BelgianDepositGuaranteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:BelgianDepositGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_vnrx_BelgianDepositGuaranteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">vnrx:BelgianDepositGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-01to2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0000093314</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="0" unitRef="Shares">57873379</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">53772261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">155803</us-gaap:InterestExpenseOther>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <vnrx:SharesWithheldForTax
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="Shares">0</vnrx:SharesWithheldForTax>
    <vnrx:NumberOfWarrantsOutstandingBeginningBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      unitRef="Shares">485000</vnrx:NumberOfWarrantsOutstandingBeginningBalance>
    <vnrx:NumberOfWarrantsExercised
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="0"
      unitRef="Shares">0</vnrx:NumberOfWarrantsExercised>
    <vnrx:NumberOfWarrantsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      unitRef="Shares">0</vnrx:NumberOfWarrantsExercised>
    <vnrx:NumberOfWarrantsExpired
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="0"
      unitRef="Shares">0</vnrx:NumberOfWarrantsExpired>
    <vnrx:NumberOfWarrantsExpired
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      unitRef="Shares">0</vnrx:NumberOfWarrantsExpired>
    <vnrx:WeightedAverageExercisePriceOutstandingBalanceOne
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</vnrx:WeightedAverageExercisePriceOutstandingBalanceOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <vnrx:NumberOfOptionsOutstandingBeginningBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      unitRef="Shares">5027518</vnrx:NumberOfOptionsOutstandingBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      unitRef="Shares">0</vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised>
    <vnrx:WeightedAverageExercisePriceOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      unitRef="USDPShares">3.87</vnrx:WeightedAverageExercisePriceOutstandingBalance>
    <vnrx:NumberOfRsusOutstandingBeginingBalance
      contextRef="AsOf2021-12-31_vnrx_StockOptionsMember"
      decimals="0"
      unitRef="Shares">810750</vnrx:NumberOfRsusOutstandingBeginingBalance>
    <vnrx:SharePriceBeginningBalance
      contextRef="AsOf2021-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      unitRef="USDPShares">3.33</vnrx:SharePriceBeginningBalance>
    <vnrx:StockCompensationExpenses
      contextRef="From2019-01-01to2019-09-30_vnrx_AprilThirteenTwoThousandTwentyMember_vnrx_RestrictedStockUnitsMember"
      decimals="0"
      unitRef="USD">0</vnrx:StockCompensationExpenses>
    <vnrx:MaturityTerm contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">P10Y</vnrx:MaturityTerm>
    <vnrx:MaturityTerm contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember">P10Y</vnrx:MaturityTerm>
    <vnrx:LoanAgreementTerm contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember">P3Y5M30D</vnrx:LoanAgreementTerm>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-36833</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">VOLITIONRX LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">91-1949078</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">1489 West Warm Springs Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Henderson</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">89014</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">650&#x2013;1351</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">VNRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">73353231</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-08" decimals="INF" unitRef="Shares">63096766</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">3627</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Sadler, Gibb &amp; Associates, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Draper, UT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_2"
      unitRef="USD">10867050</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_3"
      unitRef="USD">20581313</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_4"
      unitRef="USD">72609</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_5"
      unitRef="USD">12510</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_6"
      unitRef="USD">784920</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_7"
      unitRef="USD">598367</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_8"
      unitRef="USD">447566</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_9"
      unitRef="USD">786642</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_10"
      unitRef="USD">12172145</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_11"
      unitRef="USD">21978832</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_12"
      unitRef="USD">5393012</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_13"
      unitRef="USD">4911077</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_14"
      unitRef="USD">619392</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_15"
      unitRef="USD">383551</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_16"
      unitRef="USD">110505</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_17"
      unitRef="USD">216876</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_18"
      unitRef="USD">18295054</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_19"
      unitRef="USD">27490336</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_22"
      unitRef="USD">3043008</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_23"
      unitRef="USD">1542457</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_24"
      unitRef="USD">2872247</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_25"
      unitRef="USD">3828501</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_26"
      unitRef="USD">10000000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_27"
      unitRef="USD">12512</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_28"
      unitRef="USD">71119</us-gaap:ManagementFeePayable>
    <us-gaap:ManagementFeePayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_29"
      unitRef="USD">71303</us-gaap:ManagementFeePayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_30"
      unitRef="USD">1066700</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_31"
      unitRef="USD">797855</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_32"
      unitRef="USD">46014</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_33"
      unitRef="USD">48958</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_34"
      unitRef="USD">245163</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_35"
      unitRef="USD">171166</us-gaap:OperatingLeaseLiabilityCurrent>
    <vnrx:CurrentPortionOfGrantRepayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_36"
      unitRef="USD">41836</vnrx:CurrentPortionOfGrantRepayable>
    <vnrx:CurrentPortionOfGrantRepayable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_37"
      unitRef="USD">43100</vnrx:CurrentPortionOfGrantRepayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_38"
      unitRef="USD">17386087</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_39"
      unitRef="USD">6515852</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_40"
      unitRef="USD">2779240</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_41"
      unitRef="USD">2270767</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_42"
      unitRef="USD">436132</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_43"
      unitRef="USD">511086</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_44"
      unitRef="USD">400091</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_45"
      unitRef="USD">217305</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <vnrx:GrantRepayableNetOfCurrentPortion
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_46"
      unitRef="USD">420466</vnrx:GrantRepayableNetOfCurrentPortion>
    <vnrx:GrantRepayableNetOfCurrentPortion
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_47"
      unitRef="USD">253221</vnrx:GrantRepayableNetOfCurrentPortion>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_48"
      unitRef="USD">21422016</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_49"
      unitRef="USD">9768231</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_69"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_71"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_72"
      unitRef="Shares">57873379</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_73"
      unitRef="Shares">53772261</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_52"
      unitRef="USD">57873</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_53"
      unitRef="USD">53772</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_54"
      unitRef="USD">164397468</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_55"
      unitRef="USD">154730938</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_56"
      unitRef="USD">227097</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_57"
      unitRef="USD">148326</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_58"
      unitRef="USD">-167257429</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_59"
      unitRef="USD">-136988636</us-gaap:RetainedEarningsAccumulatedDeficit>
    <vnrx:TotalVolitionrxLimitedStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_60"
      unitRef="USD">-2574991</vnrx:TotalVolitionrxLimitedStockholdersEquity>
    <vnrx:TotalVolitionrxLimitedStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_61"
      unitRef="USD">17944400</vnrx:TotalVolitionrxLimitedStockholdersEquity>
    <vnrx:MinorityInterests
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_62"
      unitRef="USD">-551971</vnrx:MinorityInterests>
    <vnrx:MinorityInterests
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_63"
      unitRef="USD">-222295</vnrx:MinorityInterests>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_64"
      unitRef="USD">-3126962</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_65"
      unitRef="USD">17722105</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_66"
      unitRef="USD">18295054</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_67"
      unitRef="USD">27490336</us-gaap:LiabilitiesAndStockholdersEquity>
    <vnrx:RoyaltyRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_77"
      unitRef="USD">2911</vnrx:RoyaltyRevenue>
    <vnrx:RoyaltyRevenue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_78"
      unitRef="USD">0</vnrx:RoyaltyRevenue>
    <vnrx:ServiceRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_79"
      unitRef="USD">92488</vnrx:ServiceRevenue>
    <vnrx:ServiceRevenue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_80"
      unitRef="USD">0</vnrx:ServiceRevenue>
    <vnrx:ProductRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_81"
      unitRef="USD">210993</vnrx:ProductRevenue>
    <vnrx:ProductRevenue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_82"
      unitRef="USD">90035</vnrx:ProductRevenue>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_83"
      unitRef="USD">306392</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_84"
      unitRef="USD">90035</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_86"
      unitRef="USD">14572532</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_87"
      unitRef="USD">13022411</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_88"
      unitRef="USD">10937686</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_89"
      unitRef="USD">11676446</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_90"
      unitRef="USD">6576246</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_91"
      unitRef="USD">3724257</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_92"
      unitRef="USD">32086464</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_93"
      unitRef="USD">28423114</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_94"
      unitRef="USD">-31780072</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_95"
      unitRef="USD">-28333079</us-gaap:OperatingIncomeLoss>
    <vnrx:IncomeFromGrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_97"
      unitRef="USD">1229425</vnrx:IncomeFromGrants>
    <vnrx:IncomeFromGrants
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_98"
      unitRef="USD">1522533</vnrx:IncomeFromGrants>
    <vnrx:LossOnDisposalOfFixedAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_99"
      unitRef="USD">0</vnrx:LossOnDisposalOfFixedAssets>
    <vnrx:LossOnDisposalOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_100"
      unitRef="USD">-26166</vnrx:LossOnDisposalOfFixedAssets>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_101"
      unitRef="USD">125265</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_102"
      unitRef="USD">2734</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_103"
      unitRef="USD">173087</us-gaap:InterestExpenseOther>
    <us-gaap:OtherIncome
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_105"
      unitRef="USD">1181603</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_106"
      unitRef="USD">1343298</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_107"
      unitRef="USD">-30598469</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_108"
      unitRef="USD">-26989781</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_109"
      unitRef="USD">329676</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_110"
      unitRef="USD">175116</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_111"
      unitRef="USD">-30268793</vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest>
    <vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_112"
      unitRef="USD">-26814665</vnrx:IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_114"
      unitRef="USD">78771</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_115"
      unitRef="USD">208304</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <vnrx:OthersComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_116"
      unitRef="USD">-30519698</vnrx:OthersComprehensiveIncomeLossNetOfTax>
    <vnrx:OthersComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_117"
      unitRef="USD">-26781477</vnrx:OthersComprehensiveIncomeLossNetOfTax>
    <vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_118"
      unitRef="USDPShares">-0.55</vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited>
    <vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_119"
      unitRef="USDPShares">-0.51</vnrx:NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited>
    <vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_121"
      unitRef="Shares">55350401</vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted>
    <vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_122"
      unitRef="Shares">52655885</vnrx:WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_360"
      unitRef="Shares">48607017</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_361"
      unitRef="USD">48607</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_362"
      unitRef="USD">126526239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_363"
      unitRef="USD">-59978</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_364"
      unitRef="USD">-110173971</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_365"
      unitRef="USD">-47179</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_366"
      unitRef="USD">16293718</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_367"
      unitRef="Shares">77451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_368"
      unitRef="USD">77</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_369"
      unitRef="USD">-77</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_370"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_371"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_372"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_373"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <vnrx:CommonStockIssuedForSettlementOfRsuSShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_374"
      unitRef="Shares">24712</vnrx:CommonStockIssuedForSettlementOfRsuSShares>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_375"
      unitRef="USD">25</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_376"
      unitRef="USD">-25</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_377"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_378"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_379"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_380"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedInPublicOfferingsNetShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_381"
      unitRef="Shares">5063081</vnrx:CommonStockIssuedInPublicOfferingsNetShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_382"
      unitRef="USD">5063</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_383"
      unitRef="USD">23214581</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_384"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_385"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_386"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_387"
      unitRef="USD">23219644</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_388"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_389"
      unitRef="USD">-130426</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_390"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_391"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_392"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_393"
      unitRef="USD">-130426</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_394"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_395"
      unitRef="USD">2670297</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_396"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_397"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_398"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_399"
      unitRef="USD">2670297</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_400"
      unitRef="USD">0</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_401"
      unitRef="USD">2450349</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_402"
      unitRef="USD">0</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_403"
      unitRef="USD">0</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_404"
      unitRef="USD">0</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <vnrx:StockBasedCompensationInRelationToModificationOfOptions
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_405"
      unitRef="USD">2450349</vnrx:StockBasedCompensationInRelationToModificationOfOptions>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_406"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_407"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_408"
      unitRef="USD">208304</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_409"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_410"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_411"
      unitRef="USD">208304</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_412"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_413"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_414"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_415"
      unitRef="USD">-26814665</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_416"
      unitRef="USD">-175116</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_417"
      unitRef="USD">-26989781</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_418"
      unitRef="Shares">53772261</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_419"
      unitRef="USD">53772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_420"
      unitRef="USD">154730938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_421"
      unitRef="USD">148326</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_422"
      unitRef="USD">-136988636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_423"
      unitRef="USD">-222295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_424"
      unitRef="USD">17722105</us-gaap:StockholdersEquity>
    <vnrx:CommonStockIssuedForSettlementOfRsuSShares
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_425"
      unitRef="Shares">297289</vnrx:CommonStockIssuedForSettlementOfRsuSShares>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_426"
      unitRef="USD">297</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_427"
      unitRef="USD">-297</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_428"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_429"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_430"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedForSettlementOfRsuSAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_431"
      unitRef="USD">0</vnrx:CommonStockIssuedForSettlementOfRsuSAmount>
    <vnrx:CommonStockIssuedInPublicOfferingsNetShares
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_432"
      unitRef="Shares">3803829</vnrx:CommonStockIssuedInPublicOfferingsNetShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_433"
      unitRef="USD">3804</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_434"
      unitRef="USD">6732640</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_435"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_436"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_437"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_438"
      unitRef="USD">6736444</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_439"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_440"
      unitRef="USD">-180472</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_441"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_442"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_443"
      unitRef="USD">0</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_444"
      unitRef="USD">-180472</vnrx:TaxWithholdingsPaidRelatedToStockBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_445"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_446"
      unitRef="USD">3114659</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_447"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_448"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_449"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_450"
      unitRef="USD">3114659</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_451"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_452"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_453"
      unitRef="USD">78771</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_454"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_455"
      unitRef="USD">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_456"
      unitRef="USD">78771</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_457"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_458"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_459"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_460"
      unitRef="USD">-30268793</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_461"
      unitRef="USD">-329676</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_462"
      unitRef="USD">-30598469</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_463"
      unitRef="Shares">57873379</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_464"
      unitRef="USD">57873</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_465"
      unitRef="USD">164397468</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="fid_466"
      unitRef="USD">227097</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_467"
      unitRef="USD">-167257429</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="fid_468"
      unitRef="USD">-551971</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_469"
      unitRef="USD">-3126962</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_226"
      unitRef="USD">-30598469</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_227"
      unitRef="USD">-26989781</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_229"
      unitRef="USD">936084</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_230"
      unitRef="USD">945367</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_231"
      unitRef="USD">253864</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_232"
      unitRef="USD">199793</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <vnrx:OperatingLossOnDisposalOfFixedAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_233"
      unitRef="USD">0</vnrx:OperatingLossOnDisposalOfFixedAssets>
    <vnrx:OperatingLossOnDisposalOfFixedAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_234"
      unitRef="USD">26166</vnrx:OperatingLossOnDisposalOfFixedAssets>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_235"
      unitRef="USD">3114659</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_236"
      unitRef="USD">2670297</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_237"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_238"
      unitRef="USD">2450349</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_240"
      unitRef="USD">433995</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_241"
      unitRef="USD">-295189</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_242"
      unitRef="USD">-72609</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_243"
      unitRef="USD">-12510</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_244"
      unitRef="USD">351514</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_245"
      unitRef="USD">-202801</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_246"
      unitRef="USD">9987488</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_247"
      unitRef="USD">12512</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_248"
      unitRef="USD">548611</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_249"
      unitRef="USD">522220</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <vnrx:ManagementAndDirectorsFeesPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_250"
      unitRef="USD">-184</vnrx:ManagementAndDirectorsFeesPayable>
    <vnrx:ManagementAndDirectorsFeesPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_251"
      unitRef="USD">16129</vnrx:ManagementAndDirectorsFeesPayable>
    <vnrx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_252"
      unitRef="USD">-232695</vnrx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vnrx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_253"
      unitRef="USD">-196471</vnrx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_254"
      unitRef="USD">-15277742</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_255"
      unitRef="USD">-20853919</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_257"
      unitRef="USD">1570182</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_258"
      unitRef="USD">973559</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_259"
      unitRef="USD">-1570182</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_260"
      unitRef="USD">-973559</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_262"
      unitRef="USD">6736444</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_263"
      unitRef="USD">23219644</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_264"
      unitRef="USD">180472</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_265"
      unitRef="USD">130426</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vnrx:ProceedsFromGrantsRepayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_266"
      unitRef="USD">218445</vnrx:ProceedsFromGrantsRepayable>
    <vnrx:ProceedsFromGrantsRepayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_267"
      unitRef="USD">37631</vnrx:ProceedsFromGrantsRepayable>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_268"
      unitRef="USD">1523098</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_269"
      unitRef="USD">592423</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_270"
      unitRef="USD">-1268386</us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_271"
      unitRef="USD">-755721</us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt>
    <vnrx:PaymentsOnGrantsRepayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_272"
      unitRef="USD">-45664</vnrx:PaymentsOnGrantsRepayable>
    <vnrx:PaymentsOnGrantsRepayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_273"
      unitRef="USD">-47789</vnrx:PaymentsOnGrantsRepayable>
    <vnrx:PaymentsOnFinancingLeasesLeaseAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_274"
      unitRef="USD">45433</vnrx:PaymentsOnFinancingLeasesLeaseAmount>
    <vnrx:PaymentsOnFinancingLeasesLeaseAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_275"
      unitRef="USD">58210</vnrx:PaymentsOnFinancingLeasesLeaseAmount>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_276"
      unitRef="USD">6938032</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_277"
      unitRef="USD">22857552</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_278"
      unitRef="USD">195629</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_279"
      unitRef="USD">106502</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_280"
      unitRef="USD">-9714263</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_281"
      unitRef="USD">1136576</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_282"
      unitRef="USD">20581313</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_283"
      unitRef="USD">19444737</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_284"
      unitRef="USD">10867050</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_285"
      unitRef="USD">20581313</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_287"
      unitRef="USD">173087</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_288"
      unitRef="USD">155803</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_289"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_290"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_292"
      unitRef="Shares">297</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_293"
      unitRef="Shares">102</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <vnrx:OfferingCostsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_294"
      unitRef="USD">427443</vnrx:OfferingCostsFromIssuanceOfCommonStock>
    <vnrx:OfferingCostsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_295"
      unitRef="USD">218459</vnrx:OfferingCostsFromIssuanceOfCommonStock>
    <vnrx:NonCashNotePayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_2071"
      unitRef="USD">620549</vnrx:NonCashNotePayable>
    <vnrx:NonCashNotePayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_2072"
      unitRef="USD">0</vnrx:NonCashNotePayable>
    <us-gaap:NatureOfOperations contextRef="From2022-01-01to2022-12-31" id="fid_305">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 1 - Nature of Operations &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with the Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of &#x201c;VolitionRX Limited&#x201d; and the name change became effective on October 11, 2011. On October 7, 2016, the Company amended its Certificate of Incorporation to reflect a name change to &#x201c;VolitionRx Limited.&#x201d;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On October&#160;6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited, a Singapore corporation incorporated on August 5, 2010 (&#x201c;Singapore Volition&#x201d;), and the shareholders of Singapore Volition.&#160; Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company.&#160; The issuance was deemed to be a reverse acquisition for accounting purposes and as such, Singapore Volition is regarded as the predecessor of the Company. The number of shares outstanding and per share amounts of the Company have been restated to recognize the foregoing recapitalization.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood tests designed to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics&lt;sup style="vertical-align:super"&gt;TM&lt;/sup&gt;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid &#x2013; an indication that disease is present.&#160; The Company has two wholly owned subsidiaries, Volition Global Services SRL (&#x201c;Volition Global&#x201d;) which was formed in August 2021 and Singapore Volition. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL, a Belgium private limited liability company (&#x201c;Belgian Volition&#x201d;), which it acquired in September 2010.&#160; Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (&#x201c;Volition Diagnostics&#x201d;), which was formed in November&#160;2015, Volition America, Inc. (&#x201c;Volition America&#x201d;), which was formed in February 2017, Volition Germany GmbH (&#x201c;Volition Germany&#x201d;), which was acquired in January 2020, as well as its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (&#x201c;Volition Vet&#x201d;), which was formed in June 2019.&#160; Following the acquisition of Singapore Volition in 2011, the Company&#x2019;s fiscal year end was changed from August 31 to December 31.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <vnrx:LiquidityAndGoingConcernAssessment contextRef="From2022-01-01to2022-12-31" id="fid_306">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;No&lt;/strong&gt;&lt;strong&gt;te 2 &lt;/strong&gt;&lt;strong&gt;&#x2013; Liquidity and &lt;/strong&gt;&lt;strong&gt;Go&lt;/strong&gt;&lt;strong&gt;ing Concern Assessment&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company&#x2019;s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $167.3 million, has negative cash flows from operations, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period at least one year from the date of issuance of these consolidated financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions; (c) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.&lt;/p&gt;</vnrx:LiquidityAndGoingConcernAssessment>
    <vnrx:NetIncomeLossSinceInception
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      id="fid_550"
      unitRef="USD">167300000</vnrx:NetIncomeLossSinceInception>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_296">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 3 - Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company&#x2019;s fiscal year end is December 31.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), &lt;em&gt;Commitments and Contingencies &#x2013; Other Commitments&lt;/em&gt;, for more information regarding Volition Vet, Volition Germany and Volition America. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Reclassification&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative amounts of research and development, sales and marketing and general and administrative expenses to be consistent with the current year classification.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Accounts Receivable &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company&#x2019;s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.&#160; The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company computes net loss per share in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 260, &lt;em&gt;&#x201c;Earnings Per Share,&#x201d;&lt;/em&gt; which requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of December 31, 2022, and December 31, 2021, 7,787,013 and 6,323,268, respectively, of potential common shares equivalents from stock options, RSUs and warrants were excluded from the diluted EPS calculations as their effect is anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, &lt;em&gt;&#x201c;Foreign Currency Matters &#x2013; Foreign Currency Transactions&#x201d;&lt;/em&gt;. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Pursuant to ASC 820, &#x201c;&lt;em&gt;Fair Value Measurements and Disclosures,&#x201d;&lt;/em&gt; an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 1&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 2&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 3&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on &#x201c;Level 1&#x201d; inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;ASC 220, &#x201c;&lt;em&gt;Other Comprehensive Income/(Loss)&#x201d;,&lt;/em&gt; establishes standards for the reporting and display of other comprehensive loss and its components in the financial statements. As of December 31, 2022, the Company had $227,097 of accumulated other comprehensive income, relating to foreign currency translation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, &lt;em&gt;&#x201c;Accounting for Income Taxes&#x201d;&lt;/em&gt; as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Refer to Note 9 for further details.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company adopted ASC 606, &#x201c;&lt;em&gt;Revenue from Contracts with Customers,&#x201d;&lt;/em&gt; effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company generates product revenues from the sale of its Nu.Q&lt;sup style="vertical-align:super"&gt;&#xae;&lt;/sup&gt; Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Royalty &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under &#x201c;Royalty&#x201d; under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Product&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in &#x201c;Product&#x201d; in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Service &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue recognized from laboratory services performed in the Company&#x2019;s laboratory on behalf of third parties under &#x201c;Service&#x201d; under the consolidated statements of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Licensing&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue recognized from the licensing of certain rights to third parties in &#x201c;Licensing&#x201d; in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue from Heska License Agreement &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the &#x201c;License Agreement&#x201d;) with Heska Corporation (&#x201c;Heska&#x201d;), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q&#xae; Vet Cancer Test at the point of care (&#x201c;POC&#x201d;) initially for the screening of lymphoma and hemangiosarcoma in dogs (&#x201c;Canine Lymphoma &amp;amp; HSA&#x201d;), and non-exclusive rights to sell its Nu.Q&#xae; Vet Cancer Test in kit format (&#x201c;Kits&#x201d;) through Heska&#x2019;s network of central reference laboratories (&#x201c;Central Lab&#x201d;) initially for Canine Lymphoma &amp;amp; HSA.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp;amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well.&#160; Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (&#x201c;Key Components&#x201d;) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska&#x2019;s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party&#x2019;s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;According to ASC Topic 606, &#x201c;&lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;&#x201d;, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Deferred Revenue (Contract Liabilities) and Contract Assets&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC 360, &lt;em&gt;&#x201c;Property Plant and Equipment&#x201d;,&lt;/em&gt; the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company records stock-based compensation in accordance with ASC 718, &#x201c;&lt;em&gt;Compensation &#x2013; Stock Compensation&#x201d;&lt;/em&gt;. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. The estimated fair value of RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation model. Refer to Note 8 for further details.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &#x201c;Leases.&#x201d; The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (&#x201c;ROU&#x201d;) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (&#x201c;IBR&#x201d;) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Grant Income&#160; &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;COVID-19 Pandemic Impact &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company&#x2019;s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Recent&#160;Accounting&#160;Pronouncements&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"/&gt;&lt;/strong&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_308">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company&#x2019;s fiscal year end is December 31.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31" id="fid_309">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_310">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), &lt;em&gt;Commitments and Contingencies &#x2013; Other Commitments&lt;/em&gt;, for more information regarding Volition Vet, Volition Germany and Volition America. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_311">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_552"
      unitRef="USD">10867050</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_551"
      unitRef="USD">20581313</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_554"
      unitRef="USD">10079089</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_553"
      unitRef="USD">19753878</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2022-12-31_vnrx_BelgianDepositGuaranteeMember"
      decimals="0"
      id="fid_568"
      unitRef="USD">1725981</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2021-12-31_vnrx_BelgianDepositGuaranteeMember"
      decimals="0"
      id="fid_561"
      unitRef="USD">134134</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2022-12-31_vnrx_SingaporeDepositInsuranceMember"
      decimals="0"
      id="fid_563"
      unitRef="USD">100601</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2021-12-31_vnrx_SingaporeDepositInsuranceMember"
      decimals="0"
      id="fid_562"
      unitRef="USD">102514</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2022-12-31_vnrx_UKDepositProtectionSchemeMember"
      decimals="0"
      id="fid_565"
      unitRef="USD">326631</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2021-12-31_vnrx_UKDepositProtectionSchemeMember"
      decimals="0"
      id="fid_564"
      unitRef="USD">142410</us-gaap:CashUninsuredAmount>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2022-01-01to2022-12-31" id="fid_312">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company&#x2019;s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.&#160; The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_560"
      unitRef="USD">72609</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_322">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_315">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company computes net loss per share in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 260, &lt;em&gt;&#x201c;Earnings Per Share,&#x201d;&lt;/em&gt; which requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of December 31, 2022, and December 31, 2021, 7,787,013 and 6,323,268, respectively, of potential common shares equivalents from stock options, RSUs and warrants were excluded from the diluted EPS calculations as their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <vnrx:PotentiallyDilutiveWarrantsAndOptions
      contextRef="AsOf2022-12-31_vnrx_DilutiveWarrantsAndOptionsMember"
      decimals="0"
      id="fid_567"
      unitRef="Shares">7787013</vnrx:PotentiallyDilutiveWarrantsAndOptions>
    <vnrx:PotentiallyDilutiveWarrantsAndOptions
      contextRef="AsOf2021-12-31_vnrx_DilutiveWarrantsAndOptionsMember"
      decimals="0"
      id="fid_566"
      unitRef="Shares">6323268</vnrx:PotentiallyDilutiveWarrantsAndOptions>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_316">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, &lt;em&gt;&#x201c;Foreign Currency Matters &#x2013; Foreign Currency Transactions&#x201d;&lt;/em&gt;. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_323">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Pursuant to ASC 820, &#x201c;&lt;em&gt;Fair Value Measurements and Disclosures,&#x201d;&lt;/em&gt; an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 1&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 2&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Level 3&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on &#x201c;Level 1&#x201d; inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. &lt;/p&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_324">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;ASC 220, &#x201c;&lt;em&gt;Other Comprehensive Income/(Loss)&#x201d;,&lt;/em&gt; establishes standards for the reporting and display of other comprehensive loss and its components in the financial statements. As of December 31, 2022, the Company had $227,097 of accumulated other comprehensive income, relating to foreign currency translation.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_555"
      unitRef="USD">227097</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_331">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, &lt;em&gt;&#x201c;Accounting for Income Taxes&#x201d;&lt;/em&gt; as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these consolidated financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Refer to Note 9 for further details.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_313">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company adopted ASC 606, &#x201c;&lt;em&gt;Revenue from Contracts with Customers,&#x201d;&lt;/em&gt; effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company generates product revenues from the sale of its Nu.Q&lt;sup style="vertical-align:super"&gt;&#xae;&lt;/sup&gt; Vet Cancer Test, from the sale of nucleosomes, and from the sale of research use only kits. In addition, revenue is received from external third parties for services the Company performs for them in its laboratory.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Royalty &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under &#x201c;Royalty&#x201d; under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Product&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in &#x201c;Product&#x201d; in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Service &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue recognized from laboratory services performed in the Company&#x2019;s laboratory on behalf of third parties under &#x201c;Service&#x201d; under the consolidated statements of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Licensing&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company includes revenue recognized from the licensing of certain rights to third parties in &#x201c;Licensing&#x201d; in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue from Heska License Agreement &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the &#x201c;License Agreement&#x201d;) with Heska Corporation (&#x201c;Heska&#x201d;), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q&#xae; Vet Cancer Test at the point of care (&#x201c;POC&#x201d;) initially for the screening of lymphoma and hemangiosarcoma in dogs (&#x201c;Canine Lymphoma &amp;amp; HSA&#x201d;), and non-exclusive rights to sell its Nu.Q&#xae; Vet Cancer Test in kit format (&#x201c;Kits&#x201d;) through Heska&#x2019;s network of central reference laboratories (&#x201c;Central Lab&#x201d;) initially for Canine Lymphoma &amp;amp; HSA.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp;amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well.&#160; Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (&#x201c;Key Components&#x201d;) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska&#x2019;s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party&#x2019;s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;According to ASC Topic 606, &#x201c;&lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;&#x201d;, a performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <vnrx:TermsOfLicenseAgreement contextRef="From2022-01-01to2022-12-31" id="fid_569">Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma &amp; HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines</vnrx:TermsOfLicenseAgreement>
    <vnrx:InitialTermForPoc contextRef="From2022-01-01to2022-12-31" id="fid_570">P22Y</vnrx:InitialTermForPoc>
    <vnrx:InitialTermForCentralLab contextRef="From2022-01-01to2022-12-31" id="fid_571">P5Y</vnrx:InitialTermForCentralLab>
    <vnrx:UpfrontPayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      id="fid_572"
      unitRef="USD">10000000.0</vnrx:UpfrontPayment>
    <vnrx:MilestoneAmountRecognized
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      id="fid_573"
      unitRef="USD">18000000.0</vnrx:MilestoneAmountRecognized>
    <vnrx:DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_314">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.&lt;/p&gt;</vnrx:DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2022-12-31"
      decimals="-5"
      id="fid_574"
      unitRef="USD">10000000.0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2021-12-31"
      decimals="-6"
      id="fid_575"
      unitRef="USD">12512000000</us-gaap:DeferredRevenue>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31" id="fid_317">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <vnrx:ResearchAndDevelopmentExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      id="fid_556"
      unitRef="USD">14600000</vnrx:ResearchAndDevelopmentExpenses>
    <vnrx:ResearchAndDevelopmentExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      id="fid_557"
      unitRef="USD">13000000.0</vnrx:ResearchAndDevelopmentExpenses>
    <vnrx:ImpairmentofLongLivedAssetsPolixyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_328">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC 360, &lt;em&gt;&#x201c;Property Plant and Equipment&#x201d;,&lt;/em&gt; the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value. Impairment losses of $nil and $nil were recognized during the years ended December 31, 2022 and December 31, 2021, respectively.&lt;/p&gt;</vnrx:ImpairmentofLongLivedAssetsPolixyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31" id="fid_318">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company records stock-based compensation in accordance with ASC 718, &#x201c;&lt;em&gt;Compensation &#x2013; Stock Compensation&#x201d;&lt;/em&gt;. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. The estimated fair value of RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation model. Refer to Note 8 for further details.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_330">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &#x201c;Leases.&#x201d; The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (&#x201c;ROU&#x201d;) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (&#x201c;IBR&#x201d;) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_320">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <vnrx:COVID19PandemicImpactPolicyTextblock contextRef="From2022-01-01to2022-12-31" id="fid_321">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company&#x2019;s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.&lt;/p&gt;</vnrx:COVID19PandemicImpactPolicyTextblock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_298">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 4 - Property and Equipment&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s property and equipment consist of the following amounts as of December 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;656,759&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;497,306&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;159,453&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,190,289&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,951,387&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,238,902&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;358,575&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;239,436&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;119,139&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;30 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,054,332&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;298,397&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,755,935&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Building improvements&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5-15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,317,132&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;326,337&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;990,795&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Not amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;128,788&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;128,788&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;8,705,875&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;3,312,863&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;5,393,012&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;599,944&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;474,169&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;125,775&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,032,108&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,434,347&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,597,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;293,427&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;213,244&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;80,183&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;30 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,177,641&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;243,750&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,933,891&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Building improvements&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5-15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,293,258&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;256,309&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,036,949&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Not amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;136,518&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;136,518&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;7,532,896&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2,621,819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4,911,077&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the years ended December 31, 2022 and December 31, 2021, the total capital expenditure was $1.6 million and $1.1 million, respectively, the majority of which was from purchases of laboratory equipment. For further details refer to Note 10 (a) for Finance Leases included in &lt;em&gt;Property, Plant and Equipment.&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the years ended December 31, 2022 and December 31, 2021, the Company recognized $865,262 and $812,109, respectively, in depreciation expense.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_332">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;656,759&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;497,306&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;159,453&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,190,289&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,951,387&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,238,902&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;358,575&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;239,436&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;119,139&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;30 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,054,332&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;298,397&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,755,935&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Building improvements&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5-15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,317,132&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;326,337&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;990,795&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Not amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;128,788&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;128,788&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;8,705,875&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;3,312,863&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;5,393,012&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Useful Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;599,944&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;474,169&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;125,775&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,032,108&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,434,347&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,597,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;293,427&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;213,244&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;80,183&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Buildings&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;30 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,177,641&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;243,750&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,933,891&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Building improvements&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;5-15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,293,258&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;256,309&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,036,949&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;Not amortized&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;136,518&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;136,518&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;7,532,896&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2,621,819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4,911,077&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_us-gaap_ComputerEquipmentMember"
      id="fid_508">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_470"
      unitRef="USD">656759</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_482"
      unitRef="USD">497306</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_496"
      unitRef="USD">159453</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_vnrx_LaboratoryEquipmentMember"
      id="fid_509">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_471"
      unitRef="USD">4190289</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_483"
      unitRef="USD">1951387</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_497"
      unitRef="USD">2238902</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_us-gaap_OfficeEquipmentMember"
      id="fid_510">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_472"
      unitRef="USD">358575</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_484"
      unitRef="USD">239436</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_498"
      unitRef="USD">119139</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_us-gaap_BuildingMember"
      id="fid_511">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_473"
      unitRef="USD">2054332</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_485"
      unitRef="USD">298397</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_499"
      unitRef="USD">1755935</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember"
      id="fid_512">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-01to2022-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember"
      id="fid_513">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_474"
      unitRef="USD">1317132</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_486"
      unitRef="USD">326337</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_500"
      unitRef="USD">990795</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_475"
      unitRef="USD">128788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_487"
      unitRef="USD">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_501"
      unitRef="USD">128788</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_530"
      unitRef="USD">8705875</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_528"
      unitRef="USD">3312863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_494"
      unitRef="USD">5393012</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember"
      id="fid_514">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_531"
      unitRef="USD">599944</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_488"
      unitRef="USD">474169</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="fid_502"
      unitRef="USD">125775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_vnrx_LaboratoryEquipmentMember"
      id="fid_515">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_477"
      unitRef="USD">3032108</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_489"
      unitRef="USD">1434347</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_vnrx_LaboratoryEquipmentMember"
      decimals="0"
      id="fid_503"
      unitRef="USD">1597761</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_us-gaap_OfficeEquipmentMember"
      id="fid_516">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_478"
      unitRef="USD">293427</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_490"
      unitRef="USD">213244</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_504"
      unitRef="USD">80183</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_us-gaap_BuildingMember"
      id="fid_517">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_479"
      unitRef="USD">2177641</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_491"
      unitRef="USD">243750</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_505"
      unitRef="USD">1933891</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_srt_MinimumMember_us-gaap_BuildingImprovementsMember"
      id="fid_518">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2021-01-01to2021-12-31_srt_MaximumMember_us-gaap_BuildingImprovementsMember"
      id="fid_519">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_480"
      unitRef="USD">1293258</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_492"
      unitRef="USD">256309</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_us-gaap_BuildingImprovementsMember"
      decimals="0"
      id="fid_506"
      unitRef="USD">1036949</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_481"
      unitRef="USD">136518</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_493"
      unitRef="USD">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_507"
      unitRef="USD">136518</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_532"
      unitRef="USD">7532896</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_529"
      unitRef="USD">2621819</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_495"
      unitRef="USD">4911077</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      id="fid_535"
      unitRef="USD">1600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      id="fid_536"
      unitRef="USD">1100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_533"
      unitRef="USD">865262</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_534"
      unitRef="USD">812109</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_299">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 5 - Intangible Assets&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company&#x2019;s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets&#x2019; estimated useful lives, which range from 8 to 20 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,104,103&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;993,598&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;110,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,178,135&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;961,259&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;216,876&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the years ended December 31, 2022 and December 31, 2021, the Company recognized $75,558 and $91,645, respectively, in amortization expense.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,636&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;24,869&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Intangible Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;110,505&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2022. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2022.&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_333">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,104,103&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;993,598&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;110,505&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Accumulated&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Net Carrying&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,178,135&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;961,259&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;216,876&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_539"
      unitRef="USD">1104103</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_541"
      unitRef="USD">993598</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_537"
      unitRef="USD">110505</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_540"
      unitRef="USD">1178135</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_542"
      unitRef="USD">961259</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="fid_538"
      unitRef="USD">216876</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_546"
      unitRef="USD">75558</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_547"
      unitRef="USD">91645</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2022-01-01to2022-12-31_srt_MinimumMember_vnrx_PatentsAndIntellectualPropertyMember"
      id="fid_548">P8Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2022-01-01to2022-12-31_srt_MaximumMember_vnrx_PatentsAndIntellectualPropertyMember"
      id="fid_549">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_334">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,636&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;24,869&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Intangible Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;110,505&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_543"
      unitRef="USD">85636</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_544"
      unitRef="USD">24869</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_545"
      unitRef="USD">110505</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_300">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 6 - Related Party Transactions&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;See Note 7 for common stock issued to related parties and Note 8 for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under accruals and management and directors&#x2019; fees payable (see consolidated balance sheets). &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_301">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 7 - Common Stock&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which 57,873,379 and 53,772,261 shares were issued as of December 31, 2022 and December 31, 2021, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Stock Option Exercises&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2022 no shares of common stock were issued pursuant to the exercise of stock options.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Stock Option Exercises&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2021 we issued a total of 77,451 shares of common stock from the cashless exercise of options, as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock Incentive Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 13 - March 19, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,634&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;948&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 2, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,181&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,769&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,446&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8 - February 9, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,357&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;18,750&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;277,634&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;77,451&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;RSU Settlements&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2022 we issued a total of 297,289 shares of common stock from the settlement of RSUs, as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Restricted Stock Units Vested&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Settled &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Withheld for Tax&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;March 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;April 13, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.95&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.79&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;August 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,102&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;191,992&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,110&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;September 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,038&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,962&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,905&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.46&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,022&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,883&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;November 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,406&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,181&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;377,007&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;297,289&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;79,718&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2021 we issued a total of 24,712 shares of common stock from the settlement of RSUs, as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Restricted Stock Units Vested&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Settled&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Withheld for Tax&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.10&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;April 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.44&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;31,250&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;24,712&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;6,538&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Equity&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt;&lt;em&gt; &lt;/em&gt;&lt;/strong&gt;&lt;strong&gt;&lt;em&gt;Capital Raises&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On July 29, 2022, the Company entered into an underwriting agreement with Newbridge Securities Corporation (&#x201c;Newbridge&#x201d;) in connection with an underwritten public offering of 3,450,000 shares of the Company&#x2019;s common stock, which includes Newbridge&#x2019;s exercise in full of its overallotment option (of 450,000 shares), pursuant to the Company&#x2019;s &#x201c;shelf&#x201d; registration statement on Form S-3 (declared effective by the SEC on November 8, 2021, File No. 333-259783) (as amended and supplemented from time to time, the &#x201c;2021 Form S-3&#x201d;). Newbridge purchased the shares from the Company at a weighted average&#160;price of $1.87 per share.&#160;The offering closed on August 2, 2022. The Company received net proceeds of approximately $6.4 million from the offering before deducting offering expenses of $0.2 million paid by the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;&lt;strong&gt;Equity&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/em&gt;&lt;strong&gt;&lt;em&gt;Capital Raises &lt;/em&gt;(continued)&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February 10, 2021, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) in connection with an underwritten public offering of 3,809,524 shares of the Company&#x2019;s common stock, pursuant to the Company&#x2019;s &#x201c;shelf&#x201d; registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248) (the &#x201c;2018 Form S-3&#x201d;). Cantor purchased the shares from the Company at a price of $4.9533 per share, and elected not to exercise an option to purchase up to an additional 571,428 shares of common stock at the same price per share. The offering closed on February 12, 2021. The Company received net proceeds of approximately $18.9 million from the offering before deducting offering expenses. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Equity&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt;&lt;em&gt; &lt;/em&gt;&lt;/strong&gt;&lt;strong&gt;&lt;em&gt;Distribution Agreements&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On May 20, 2022, the Company entered into an equity distribution agreement (the &#x201c;2022 EDA&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) to sell shares of the Company&#x2019;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#x201c;at the market&#x201d; offering pursuant to the Company&#x2019;s 2021 Form S-3 through Jefferies acting as the Company&#x2019;s agent and/or principal.&#160;The Company is not obligated to sell any shares under the 2022 EDA.&#160; As of December 31, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.8 million under the 2022 EDA through the sale of 350,829 shares of common stock, before deducting offering expenses.&#160;See Note 11 for additional details regarding the Company&#x2019;s equity distribution agreements subsequent to December 31, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;From January 1, 2022 through May 7, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $9,500 under the 2021 EDA (as defined below) through the sale of 3,000 shares of its common stock. The Company terminated the 2021 EDA effective May 7, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On September 24, 2021, the Company entered into an equity distribution agreement (the &#x201c;2021 EDA&#x201d;) with Cantor and Oppenheimer &amp;amp; Co. Inc. (&#x201c;Oppenheimer&#x201d;) to sell shares of the Company&#x2019;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#x201c;at the market&#x201d; offering pursuant to the Company&#x2019;s 2021 Form S-3 through Cantor and Oppenheimer acting as the Company&#x2019;s agents and/or principals. From the 2021 EDA&#x2019;s effectiveness on November 8, 2021 through December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.7 million through the sale of 190,600 shares of its common stock. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 10, 2020, the Company entered into an equity distribution agreement (the &#x201c;2020 EDA&#x201d;) with Cantor and Oppenheimer to sell shares of the Company&#x2019;s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an &#x201c;at the market&#x201d; offering pursuant to the 2018 Form S-3 through Cantor and Oppenheimer acting as the Company&#x2019;s agents and/or principals. During the year ended December 31, 2021 (and from inception of the 2020 EDA), the Company raised aggregate net proceeds (net of broker commissions and fees) of $2.7 million under the 2020 EDA through the sale of 754,348 shares of its common stock. The Company terminated the 2020 EDA effective November 8, 2021.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the &#x201c;2018 EDA&#x201d;) with Oppenheimer to sell shares of the Company&#x2019;s common stock, with an aggregate offering price of up to $10.0 million, from time to time through an &#x201c;at the market&#x201d; offering pursuant to the 2018 Form S-3 through Oppenheimer acting as the Company&#x2019;s agent and/or principal. The Company utilized the 2018 EDA in full during the three months ended March 31, 2021, and raised aggregate net proceeds (net of broker commissions and fees) of approximately $9.7&#160;million under the 2018 EDA since inception through the sale of&#160;2,539,606&#160;shares of its common stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of $1.2 million under the 2018 EDA through the sale of 308,609 shares of its common stock. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022 and 2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Issuances Upon Warrant Exercises&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;&#160;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the years ended December 31, 2022 and December 31, 2021 no warrants were exercised. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vnrx:CommonStockShareAuthorized
      contextRef="AsOf2022-12-31"
      decimals="-6"
      id="fid_763"
      unitRef="Shares">100000000</vnrx:CommonStockShareAuthorized>
    <vnrx:CommonStockPricePerSahres
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="fid_761"
      unitRef="USDPShares">0.001</vnrx:CommonStockPricePerSahres>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_752"
      unitRef="Shares">57873379</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_797"
      unitRef="Shares">53772261</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_799"
      unitRef="Shares">77451</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_347">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock Incentive Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 13 - March 19, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,634&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;948&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 2, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,181&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,769&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,446&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8 - February 9, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,357&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;18,750&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;277,634&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;77,451&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      id="fid_663">2011</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_630"
      unitRef="Shares">7634</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="INF"
      id="fid_683"
      unitRef="USDPShares">3.35</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_645"
      unitRef="Shares">948</us-gaap:ExcessStockSharesIssued>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      id="fid_664">2011</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_631"
      unitRef="Shares">20000</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="INF"
      id="fid_684"
      unitRef="USDPShares">3.80</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_FebruaryTwoTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_646"
      unitRef="Shares">6181</us-gaap:ExcessStockSharesIssued>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"
      id="fid_665">2011</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"
      decimals="0"
      id="fid_632"
      unitRef="Shares">15000</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"
      decimals="INF"
      id="fid_685"
      unitRef="USDPShares">4.00</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesOneMember"
      decimals="0"
      id="fid_647"
      unitRef="Shares">5769</us-gaap:ExcessStockSharesIssued>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"
      id="fid_666">2015</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"
      decimals="0"
      id="fid_633"
      unitRef="Shares">100000</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"
      decimals="INF"
      id="fid_686"
      unitRef="USDPShares">5.00</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesTwoMember"
      decimals="0"
      id="fid_648"
      unitRef="Shares">19446</us-gaap:ExcessStockSharesIssued>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      id="fid_667">2015</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_634"
      unitRef="Shares">85000</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="INF"
      id="fid_687"
      unitRef="USDPShares">4.00</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_649"
      unitRef="Shares">26357</us-gaap:ExcessStockSharesIssued>
    <vnrx:StockIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      id="fid_668">2015</vnrx:StockIncentivePlan>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_635"
      unitRef="Shares">50000</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="INF"
      id="fid_688"
      unitRef="USDPShares">3.25</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_FebruaryEightTwentyThousandTwentyOneMember_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_650"
      unitRef="Shares">18750</us-gaap:ExcessStockSharesIssued>
    <vnrx:CommonStockShareIssuedUponCashlessExercise
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_636"
      unitRef="Shares">277634</vnrx:CommonStockShareIssuedUponCashlessExercise>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2021-12-31_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_651"
      unitRef="Shares">77451</us-gaap:ExcessStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-01to2022-12-31_vnrx_UnderwritingAgreementMember"
      decimals="0"
      id="fid_800"
      unitRef="Shares">297289</us-gaap:StockIssuedDuringPeriodSharesOther>
    <vnrx:ScheduleOfShareIssuedFromTheSettlementOfRsus contextRef="From2022-01-01to2022-12-31" id="fid_348">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Restricted Stock Units Vested&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Settled &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Withheld for Tax&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;March 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;April 13, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.95&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.79&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;August 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,102&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;191,992&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,110&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;September 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,038&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,962&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,905&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.46&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,022&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,883&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;November 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,344&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,406&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.97&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,181&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;377,007&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;297,289&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;79,718&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Restricted Stock Units Vested&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price Settled&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Per Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares Withheld for Tax&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.10&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;April 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.44&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;31,250&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;24,712&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;6,538&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfShareIssuedFromTheSettlementOfRsus>
    <vnrx:RestrictedStockUnitsVested
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_637"
      unitRef="Shares">15000</vnrx:RestrictedStockUnitsVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_689"
      unitRef="USDPShares">3.01</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_652"
      unitRef="Shares">15000</us-gaap:ExcessStockSharesIssued>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_748"
      unitRef="Shares">26250</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_706"
      unitRef="USDPShares">2.95</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_705"
      unitRef="Shares">21712</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AprilThirteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_704"
      unitRef="Shares">4538</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_747"
      unitRef="Shares">50000</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_710"
      unitRef="USDPShares">2.79</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_709"
      unitRef="Shares">35000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_MayOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_708"
      unitRef="Shares">15000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_746"
      unitRef="Shares">230102</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_714"
      unitRef="USDPShares">1.97</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_713"
      unitRef="Shares">191992</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_AugustThreeTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_712"
      unitRef="Shares">38110</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_743"
      unitRef="Shares">12000</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_718"
      unitRef="USDPShares">1.65</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_717"
      unitRef="Shares">7038</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_SeptemberSevenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_716"
      unitRef="Shares">4962</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_744"
      unitRef="Shares">19905</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_722"
      unitRef="USDPShares">1.46</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_721"
      unitRef="Shares">13022</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_OctoberFourTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_720"
      unitRef="Shares">6883</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_745"
      unitRef="Shares">21750</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_726"
      unitRef="USDPShares">1.97</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_725"
      unitRef="Shares">12344</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_NovemberOneTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_724"
      unitRef="Shares">9406</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_742"
      unitRef="Shares">2000</vnrx:RestrictedStockUnitVested>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"
      decimals="INF"
      id="fid_730"
      unitRef="USDPShares">1.97</us-gaap:SharePrice>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_729"
      unitRef="Shares">1181</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember_vnrx_DecemberFifteenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_728"
      unitRef="Shares">819</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_749"
      unitRef="Shares">377007</vnrx:RestrictedStockUnitVested>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_659"
      unitRef="Shares">297289</us-gaap:ExcessStockSharesIssued>
    <vnrx:SharesWithheldForTax
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionExercisesMember"
      decimals="0"
      id="fid_733"
      unitRef="Shares">79718</vnrx:SharesWithheldForTax>
    <vnrx:IssuedOfCommonStockFromSettlementOfRSU
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_798"
      unitRef="Shares">24712</vnrx:IssuedOfCommonStockFromSettlementOfRSU>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_734"
      unitRef="Shares">5000</vnrx:RestrictedStockUnitVested>
    <vnrx:SaleOfStockPriceSettledPerShare
      contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="INF"
      id="fid_736"
      unitRef="USDPShares">4.10</vnrx:SaleOfStockPriceSettledPerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_738"
      unitRef="Shares">3000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_740"
      unitRef="Shares">2000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_735"
      unitRef="Shares">26250</vnrx:RestrictedStockUnitVested>
    <vnrx:SaleOfStockPriceSettledPerShare
      contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="INF"
      id="fid_737"
      unitRef="USDPShares">3.44</vnrx:SaleOfStockPriceSettledPerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_739"
      unitRef="Shares">21712</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31_vnrx_AprilTwentyOneTwentyTwentyOneMember_vnrx_RSUSettlementsMember"
      decimals="0"
      id="fid_741"
      unitRef="Shares">4538</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <vnrx:RestrictedStockUnitVested
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_2073"
      unitRef="Shares">31250</vnrx:RestrictedStockUnitVested>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_2074"
      unitRef="Shares">24712</us-gaap:ExcessStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_2075"
      unitRef="Shares">6538</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember"
      decimals="0"
      id="fid_760"
      unitRef="Shares">3450000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <vnrx:PurchasePricePerShare
      contextRef="AsOf2022-07-29_vnrx_UnderwritingAgreementMember"
      decimals="INF"
      id="fid_793"
      unitRef="USDPShares">1.87</vnrx:PurchasePricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember"
      decimals="-4"
      id="fid_794"
      unitRef="USD">640000</us-gaap:StockIssuedDuringPeriodValueOther>
    <vnrx:OfferingExpenses
      contextRef="From2022-07-01to2022-07-29_vnrx_UnderwritingAgreementMember"
      decimals="-5"
      id="fid_795"
      unitRef="USD">200000</vnrx:OfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember"
      decimals="0"
      id="fid_801"
      unitRef="Shares">3809524</us-gaap:StockIssuedDuringPeriodSharesOther>
    <vnrx:PurchasePricePerShare
      contextRef="AsOf2021-02-10_vnrx_UnderwritingAgreementMember"
      decimals="INF"
      id="fid_805"
      unitRef="USDPShares">4.9533</vnrx:PurchasePricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember"
      decimals="0"
      id="fid_802"
      unitRef="USD">571428</us-gaap:StockIssuedDuringPeriodValueOther>
    <vnrx:OfferingExpenses
      contextRef="From2021-02-01to2021-02-10_vnrx_UnderwritingAgreementMember"
      decimals="-4"
      id="fid_803"
      unitRef="USD">1890000</vnrx:OfferingExpenses>
    <vnrx:AggeregateShareOfCommonStockOfferingPrice
      contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember"
      decimals="-4"
      id="fid_808"
      unitRef="USD">2500000.0</vnrx:AggeregateShareOfCommonStockOfferingPrice>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember"
      decimals="-4"
      id="fid_810"
      unitRef="USD">80000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-01to2022-05-20_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_809"
      unitRef="Shares">350829</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vnrx:BrokerageFees
      contextRef="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_817"
      unitRef="USD">9500</vnrx:BrokerageFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-01to2022-05-07_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_816"
      unitRef="Shares">3000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vnrx:AggeregateShareOfCommonStockOfferingPrice
      contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember"
      decimals="-4"
      id="fid_777"
      unitRef="USD">2500000.0</vnrx:AggeregateShareOfCommonStockOfferingPrice>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_781"
      unitRef="USD">700000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-09-01to2021-09-24_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_806"
      unitRef="Shares">190600</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vnrx:AggeregateShareOfCommonStockOfferingPrice
      contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_778"
      unitRef="USD">25000000.0</vnrx:AggeregateShareOfCommonStockOfferingPrice>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_782"
      unitRef="USD">2700000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-11-01to2020-11-10_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_771"
      unitRef="Shares">754348</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vnrx:AggeregateShareOfCommonStockOfferingPrice
      contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_779"
      unitRef="USD">10000000.0</vnrx:AggeregateShareOfCommonStockOfferingPrice>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_783"
      unitRef="USD">9700000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2018-09-01to2018-09-07_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_772"
      unitRef="Shares">2539606</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember"
      decimals="-5"
      id="fid_819"
      unitRef="USD">1200000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityDistributionAgreementMember"
      decimals="0"
      id="fid_818"
      unitRef="Shares">308609</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2022-01-01to2022-12-31" id="fid_302">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;No&lt;/strong&gt;&lt;strong&gt;te 8 - &lt;/strong&gt;&lt;strong&gt;Stock-Based Compensation&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;a&lt;/strong&gt;&lt;strong&gt;) Warrants&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table summarizes the changes in warrants outstanding of the Company during the year ended December 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;175,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;310,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;485,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;539,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;485,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Effective April 4, 2022, the Company granted a warrant to purchase 54,000 shares of common stock to a Company employee for services to the Company and/or its subsidiaries. This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share. The Company has calculated the estimated fair market value of this warrant at $80,901, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $2.95, exercise price $3.05, 71.07% volatility, 2.53% risk-free rate, and no forfeiture rate.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective January 1, 2021, the Company granted warrants to purchase 125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share. The Company has calculated the estimated fair market value of these warrants at $242,877, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.80, exercise price $3.95, 74.53% volatility, 0.50% risk free rate, and no forfeiture rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vested on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.80, exercise price $4.90, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the warrants issued and outstanding as of December 31, 2022. The warrants outstanding have a weighted average price of $3.80 per share and an aggregate weighted average remaining contractual life of 3.24 years. The warrants exercisable have a weighted average price of&#160; $3.88 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Proceeds to&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Company if&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercised &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;($)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Life (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;2.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;0.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;308,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;54,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;5.76&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;164,700&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.45&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.17&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;172,500&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.01&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;493,750&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;185,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.90&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;906,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;539,000&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;485,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,046,200&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Stock-based compensation expense related to warrants of $84,102 and $701,781 was recorded for the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately $35,812 and is expected to be recognized over a period of 1.26 years. As of December 31, 2022, the total intrinsic value of warrants was $0.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;b) Options&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company currently has options outstanding under both its 2011 Equity Incentive Plan (the &#x201c;2011 Plan&#x201d;) (for option issuances prior to 2016,) and its 2015 Stock Incentive Plan (the &#x201c;2015 Plan&#x201d;) (for option issuances commencing in 2016). Effective as of January 1, 2016, no additional awards were or may be made under the 2011 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The 2015 Plan was adopted by the Board of Directors on August 18, 2015 and approved by the stockholders at an annual meeting held on October 30, 2015. On August 5, 2016, the Board of Directors adopted an amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 1,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on October 7, 2016. On June&#160;13, 2017, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 2,500,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 8, 2017. On June 15, 2018, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 3,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 7, 2018.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On March 27, 2019, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 1,000,000 shares to an aggregate maximum of 4,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 14, 2019. On March 31, 2021, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such&#160; Plan by 1,750,000 shares to an aggregate maximum of 6,000,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 17, 2021.&lt;/p&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On April 4, 2022, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such plan by 1,750,000 shares to an aggregate maximum of 7,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 13, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The 2015 Plan permits the grant of incentive stock options, non-statutory stock options, restricted stock awards, stock bonus awards, stock appreciation rights, restricted stock units and performance awards. The primary purpose of the 2015 Plan is to enhance the Company&#x2019;s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company&#x2019;s business largely depends, and to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company that is tied to the Company&#x2019;s performance, thereby giving them an interest in the success and increased value of the Company. &#160;The 2015 Plan is administered by the Compensation Committee comprised solely of members of the Board of Directors or by the Board of Directors as a whole.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table summarizes the changes in options outstanding of the Company during the years ended December 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,278,619&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,090,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(277,634&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(63,467&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.64&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,027,518&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.87&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(42,413&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.43&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,985,105&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.87&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,495,011&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2022, no options were granted.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On August 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 18, 2022, 5,000 Options previously granted to an employee on April 13, 2020 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 18, 2022, 32,383 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee.&lt;/p&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Effective May 20, 2021, the Company granted stock options to purchase 40,000 shares of common stock to a Company employee in exchange for services provided to the Company. These options vested on May 20, 2022 and were initially scheduled to expire six years after the grant date, with an exercise price of $3.60 per share. The Company extended the expiration date to ten years after the original grant date. The Company has calculated the estimated fair market value of these options at $73,641, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.50, exercise price $3.60, 76.16% volatility, 0.58% risk free rate, and no forfeiture rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the year ended December 31, 2021, the Company modified a total of 3,342,518 options to extend their expiration dates to ten years from the original dates of grant. This resulted in $2,450,349 of expense.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table summarizes the amendments to the expiration dates of various options approved during the year ended December 31, 2021. Except as otherwise noted, the expiration dates for all options in the table below were extended from six years to ten years from the original date of grant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amendment &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;New Expiration &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Option Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;292,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 23, 2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 23, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;442,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,367&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 20, 2013&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 20, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8,151&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 2, 2013&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 2, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;335,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;163,945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2018&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;308,066&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 13, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 13, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;127,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;760,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 15, 2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 15, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;984,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 23, 2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 23, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;32,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;387,934&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 30, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;224,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;615,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2018&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;213,646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;425,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;180,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 1, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;40,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 20, 2031&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,342,518&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,450,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The expiration date of these options were extended from five and a half years to ten years from the original date of grant.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;These options were previously amended on December 16, 2019 and amended again on September 21, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Effective August 3, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted stock options to purchase an aggregate of 926,640 shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with options to purchase up to 463,328 shares vesting on August 3, 2022, and options to purchase up to 463,312 shares vesting on August 3, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $1,811,216, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.31, exercise price $3.40, 69.13% volatility, 1.19% risk free rate, and no forfeiture rate. &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Effective September 7, 2021, the Company granted stock options to purchase 50,000 shares of common stock to two employees in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 25,000 shares vesting on September 7, 2022, and 25,000 shares vesting on September 7, 2023 subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The Company has calculated the estimated fair market value of these options at $98,322, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.32, exercise price $3.40, 68.98% volatility, 1.38% risk free rate, and no forfeiture rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Effective October 4, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval the Company granted stock options to purchase 73,360 shares of common stock to an employee in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 36,680 shares vesting on October 4, 2022, and 36,680 shares vesting on October 4, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $128,003, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.04 exercise price $3.40, 68.80% volatility, 1.49% risk free rate, and no forfeiture rate. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the options issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2011 Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016)and which have a weighted average exercise price of $3.87 per share and an aggregate weighted average remaining contractual life of 5.22 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Proceeds to&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Company if&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercised &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;($)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;635,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;635,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.25&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.12&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,063,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,717&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,717&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.35&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;0.67&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;9,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,022,587&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;532,493&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.40&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8.32&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,476,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;795,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;795,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.60&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6.94&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,862,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,682,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,682,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.76&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,731,348&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;11,801&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;11,801&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;0.44&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;51,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.38&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5.07&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;390,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.80&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.01&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;696,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;696,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5.00&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.24&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,480,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;4,985,105&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;4,495,011&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;19,304,864&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Stock-based compensation expense related to stock options of $1,127,502 and $1,069,605 was recorded for the year ended December 31, 2022 and December 31, 2021 respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately $287,363 and is expected to be recognized over a period of 0.76 years. As of December 31, 2022, the total intrinsic value of stock options was $nil.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, an aggregate of 417,318 shares of common stock remained available for future issuance under the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;c&lt;/strong&gt;&lt;strong&gt;) Restricted Stock Units (RSUs)&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;67,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;789,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(31,250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.55&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.3&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;810,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,892,102&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(377,007&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(62,937&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.88&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Outstanding at December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,262,908&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2.05&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs granted during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan. These RSUs vest equally over periods stated on the dates noted, subject to continued service, and will result in the compensation expense stated. The exception to this is specified in note (iv) which is described in detail below.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:5%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;First&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Second&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSU&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Incentive&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Period&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;22,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;84,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;32,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;94,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;104,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;306,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;33,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;80,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;63,102&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;126,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;25,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;42,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(iii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,144,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,670,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(iv)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;450,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Up to 42 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;321,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(v)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;1,892,102&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2,755,843&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(iii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;These RSUs vest upon the achievement of corporate goals focused around product development and commercialization with further time-based vesting, subject to continued service of the award recipient to the Company through the applicable vesting dates. On October 13, 2022, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals previously established by the Compensation Committee, which resulted in the vesting of the rights with respect to an aggregate of 198,275 RSUs. The RSUs are further subject to a three-year time based vesting schedule, vesting in three equal installments on the dates set forth in the table above, and conditioned upon the recipient&#x2019;s continued service through the applicable vesting date. On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain additional corporate goals, which resulted in the vesting of the rights with respect to an aggregate of an additional 424,875 RSUs, subject to the foregoing time-based vesting and conditioned upon the recipient&#x2019;s continued service through the applicable vesting date.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(iv)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;These RSUs vest upon the share price closing above $5.00 per share for a minimum of ten consecutive trading days within a period of three years from the date of grant, with further time-based vesting in a single installment six months after the timely achievement of the target, if at all, and subject to continued service. The estimated fair value of the RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation of a Geometric Brownian Motion stock path model and incorporating the probability of vesting occurring. The estimated fair value of these awards will be recognized over the derived service period (as determined by the valuation model), with such recognition occurring regardless of whether the market condition is met.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(v)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company granted an aggregate of 3,000 RSUs on November 29, 2022 as an employment inducement award. These RSUs are subject to time-based vesting and subject to the continued service of each recipient.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Below is a table summarizing the RSUs vested during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Withheld for &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Taxes&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;26,250&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,712&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;35,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;230,102&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;191,992&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;38,110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;12,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7,038&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,905&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;13,022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,750&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;12,344&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;9,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,181&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;377,007&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;297,289&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;79,718&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs cancelled during the year ended December 31, 2022, all of which were originally issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Cancellation &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Cancelled&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:24%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:23%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,365&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,365&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;17,572&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;17,572&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 21, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;62,937&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;62,937&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs granted during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;First Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Second Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Third Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSU Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Period&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;107,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;150,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;496,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;460,191&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,523,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;38,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;126,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;39,809&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;121,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;43,500&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;152,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;23,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;77,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;789,500&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2,624,486&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective August 3, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 460,191 shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective October 4, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 39,809 shares of common stock to an employee of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs vested during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;#&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Issued&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Withheld for Taxes&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;5,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;31,250&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;24,712&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;6,538&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs cancelled during the year ended December 31, 2021, all of which were originally issued pursuant to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Equity Incentive Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs Cancelled&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;15,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;15,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022 of which the last to vest have a remaining contractual life of 3.26 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;(Years)&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:31%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"&gt;0.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,133,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.46&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.76&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;63,102&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.01&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.08&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.15&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.91&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;33,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.45&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.81&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.67&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.83&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;136,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.95&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.97&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;19,904&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.04&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.38&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;311,152&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.31&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.32&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.68&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.38&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.48&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;21,750&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.51&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;0.23&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;2,262,908&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Stock-based compensation expense related to RSUs of $1,903,054 and $898,910 was recorded in the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $2,214,593.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_335">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;175,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;310,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;485,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;539,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.80&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;485,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <vnrx:NumberOfWarrantsOutstandingBeginningBalance
      contextRef="From2020-01-01to2020-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_822"
      unitRef="Shares">175000</vnrx:NumberOfWarrantsOutstandingBeginningBalance>
    <vnrx:WeightedAverageExercisePriceOutstandingBalanceOne
      contextRef="From2020-01-01to2020-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_833"
      unitRef="USDPShares">2.75</vnrx:WeightedAverageExercisePriceOutstandingBalanceOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_825"
      unitRef="Shares">310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_834"
      unitRef="USDPShares">4.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <vnrx:WeightedExercisePriceExercised
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_836"
      unitRef="USDPShares">0</vnrx:WeightedExercisePriceExercised>
    <vnrx:WeightedExercisePriceExpired
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_838"
      unitRef="USDPShares">0</vnrx:WeightedExercisePriceExpired>
    <vnrx:NumberOfWarrantsOutstandingEndingBalance
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_829"
      unitRef="Shares">485000</vnrx:NumberOfWarrantsOutstandingEndingBalance>
    <vnrx:WeightedAverageExercisePriceEndingBalanceOne
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_840"
      unitRef="USDPShares">3.88</vnrx:WeightedAverageExercisePriceEndingBalanceOne>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_826"
      unitRef="Shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_835"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <vnrx:WeightedExercisePriceExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_837"
      unitRef="USDPShares">0</vnrx:WeightedExercisePriceExercised>
    <vnrx:WeightedExercisePriceExpired
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_839"
      unitRef="USDPShares">0</vnrx:WeightedExercisePriceExpired>
    <vnrx:NumberOfWarrantsOutstandingEndingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_830"
      unitRef="Shares">539000</vnrx:NumberOfWarrantsOutstandingEndingBalance>
    <vnrx:WeightedAverageExercisePriceEndingBalanceOne
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_841"
      unitRef="USDPShares">3.80</vnrx:WeightedAverageExercisePriceEndingBalanceOne>
    <vnrx:NumberOfWarrantsExercisable
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_831"
      unitRef="Shares">485000</vnrx:NumberOfWarrantsExercisable>
    <vnrx:WeightedAverageExercisePriceExercisable
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_842"
      unitRef="USDPShares">3.88</vnrx:WeightedAverageExercisePriceExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1725"
      unitRef="Shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription
      contextRef="From2022-01-01to2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      id="fid_1726">This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share</us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2057"
      unitRef="USDPShares">3.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1727"
      unitRef="USD">80901</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      id="fid_2061">P3Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2062"
      unitRef="USDPShares">2.95</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2054"
      unitRef="USDPShares">3.05</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2063"
      unitRef="Pure">0.7107</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31_vnrx_AprilFourTwoThousandTwentyTwoMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2064"
      unitRef="Pure">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1590"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      id="fid_1692">These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share.</us-gaap:MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1701"
      unitRef="USD">242877</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      id="fid_2044">P3Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2036"
      unitRef="USDPShares">3.80</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2038"
      unitRef="USDPShares">3.95</vnrx:ExercisePrice>
    <vnrx:VolatilityRate
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2039"
      unitRef="Pure">0.7453</vnrx:VolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2043"
      unitRef="Pure">0.0050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1591"
      unitRef="Shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2052"
      unitRef="USDPShares">4.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1702"
      unitRef="USD">459352</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      id="fid_2051">P3Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_1565"
      unitRef="USDPShares">4.80</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_2049"
      unitRef="USDPShares">4.90</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_1575"
      unitRef="Pure">0.7503</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31_vnrx_FebruaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="INF"
      id="fid_1582"
      unitRef="Pure">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <vnrx:SummarizingTheWarrantsIssuedAndOutstanding contextRef="From2022-01-01to2022-12-31" id="fid_336">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Proceeds to&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Company if&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercised &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;($)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Life (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;2.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;0.15&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:17%;vertical-align:bottom;text-align:right;"&gt;308,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;54,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;5.76&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;164,700&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;50,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.45&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.17&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;172,500&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.01&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;493,750&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;185,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.90&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;906,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;539,000&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;485,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,046,200&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:SummarizingTheWarrantsIssuedAndOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantOneMember"
      decimals="0"
      id="fid_854"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantOneMember"
      decimals="0"
      id="fid_851"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_WarrantOneMember"
      decimals="INF"
      id="fid_869"
      unitRef="USDPShares">2.47</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantOneMember"
      id="fid_846">P0Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantOneMember"
      decimals="0"
      id="fid_859"
      unitRef="USD">308750</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember"
      decimals="0"
      id="fid_855"
      unitRef="Shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_WarrantTwoMember"
      decimals="INF"
      id="fid_870"
      unitRef="USDPShares">3.05</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember"
      id="fid_847">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantTwoMember"
      decimals="0"
      id="fid_860"
      unitRef="USD">164700</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember"
      decimals="0"
      id="fid_856"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember"
      decimals="0"
      id="fid_873"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_WarrantThreeMember"
      decimals="INF"
      id="fid_871"
      unitRef="USDPShares">3.45</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember"
      id="fid_848">P3Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantThreeMember"
      decimals="0"
      id="fid_861"
      unitRef="USD">172500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember"
      decimals="0"
      id="fid_857"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember"
      decimals="0"
      id="fid_850"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_WarrantsFourMember"
      decimals="INF"
      id="fid_872"
      unitRef="USDPShares">3.95</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember"
      id="fid_2027">P4Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFourMember"
      decimals="0"
      id="fid_862"
      unitRef="USD">493750</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember"
      decimals="0"
      id="fid_876"
      unitRef="Shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember"
      decimals="0"
      id="fid_877"
      unitRef="Shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_WarrantsFiveMember"
      decimals="INF"
      id="fid_874"
      unitRef="USDPShares">4.90</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember"
      id="fid_878">P4Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsFiveMember"
      decimals="0"
      id="fid_875"
      unitRef="USD">906500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_858"
      unitRef="Shares">539000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_853"
      unitRef="Shares">485000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_863"
      unitRef="USD">2046200</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1728"
      unitRef="USD">84102</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1729"
      unitRef="USD">701781</us-gaap:ShareBasedCompensation>
    <vnrx:CompensationCostRelatedToNonVestedWarrants
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1730"
      unitRef="USD">35812</vnrx:CompensationCostRelatedToNonVestedWarrants>
    <vnrx:MaturityTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_WarrantsMember"
      id="fid_1731">P1Y3M3D</vnrx:MaturityTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-12-31_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1733"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2016-08-05_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1677"
      unitRef="Shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2016-08-05_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1678"
      unitRef="Shares">1750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2065"
      unitRef="USD">750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2017-06-13_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1680"
      unitRef="Shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-06-15_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1681"
      unitRef="Shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-06-15_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1682"
      unitRef="Shares">3250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-03-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1683"
      unitRef="Shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-03-27_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1684"
      unitRef="Shares">4250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-05-01to2019-05-27_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2066"
      unitRef="USD">1750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-03-31_srt_MaximumMember_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1685"
      unitRef="Shares">6000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vnrx:CommonStockAvailable
      contextRef="From2022-04-01to2022-04-04"
      decimals="0"
      id="fid_1736"
      unitRef="Shares">1750000</vnrx:CommonStockAvailable>
    <vnrx:ShareAggregateMaximum
      contextRef="From2022-04-01to2022-04-04"
      decimals="0"
      id="fid_1738"
      unitRef="Shares">7750000</vnrx:ShareAggregateMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_337">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,278,619&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,090,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(277,634&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(63,467&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.64&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,027,518&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.87&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Expired/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(42,413&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.43&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,985,105&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.87&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,495,011&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.93&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <vnrx:NumberOfOptionsOutstandingBeginningBalance
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_880"
      unitRef="Shares">4278619</vnrx:NumberOfOptionsOutstandingBeginningBalance>
    <vnrx:WeightedAverageExercisePriceOutstandingBalance
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_890"
      unitRef="USDPShares">4.00</vnrx:WeightedAverageExercisePriceOutstandingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_881"
      unitRef="Shares">1090000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <vnrx:WeightedAverageExercisePriceGranted
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_892"
      unitRef="USDPShares">3.41</vnrx:WeightedAverageExercisePriceGranted>
    <vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_883"
      unitRef="Shares">277634</vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised>
    <vnrx:WeightedAverageExercisePriceExercised
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_894"
      unitRef="USDPShares">4.19</vnrx:WeightedAverageExercisePriceExercised>
    <vnrx:NumberOfExpiredCancelled
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_885"
      unitRef="USD">63467</vnrx:NumberOfExpiredCancelled>
    <vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_896"
      unitRef="USDPShares">3.64</vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled>
    <vnrx:NumberOfOptionOutstandingEndingBalance
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_887"
      unitRef="Shares">5027518</vnrx:NumberOfOptionOutstandingEndingBalance>
    <vnrx:WeightedAverageExercisePriceEndingBalance
      contextRef="From2020-01-01to2021-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_900"
      unitRef="USDPShares">3.87</vnrx:WeightedAverageExercisePriceEndingBalance>
    <vnrx:WeightedAverageExercisePriceGranted
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_893"
      unitRef="USDPShares">0</vnrx:WeightedAverageExercisePriceGranted>
    <vnrx:WeightedAverageExercisePriceExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_895"
      unitRef="USDPShares">0</vnrx:WeightedAverageExercisePriceExercised>
    <vnrx:NumberOfExpiredCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_886"
      unitRef="USD">42413</vnrx:NumberOfExpiredCancelled>
    <vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_897"
      unitRef="USDPShares">3.43</vnrx:WeightedAverageExercisePriceExercisedExpiresCancelled>
    <vnrx:NumberOfOptionOutstandingEndingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_888"
      unitRef="Shares">4985105</vnrx:NumberOfOptionOutstandingEndingBalance>
    <vnrx:WeightedAverageExercisePriceEndingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_898"
      unitRef="USDPShares">3.87</vnrx:WeightedAverageExercisePriceEndingBalance>
    <vnrx:NumberOfOptionsExercisable
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_889"
      unitRef="Shares">4495011</vnrx:NumberOfOptionsExercisable>
    <vnrx:WeightedAverageExercisePriceExercisableBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_899"
      unitRef="USDPShares">3.93</vnrx:WeightedAverageExercisePriceExercisableBalance>
    <vnrx:OptionGranted
      contextRef="From2022-08-01to2022-08-18"
      decimals="0"
      id="fid_1747"
      unitRef="Shares">2515</vnrx:OptionGranted>
    <vnrx:OptionGranted
      contextRef="From2020-04-01to2020-04-13"
      decimals="0"
      id="fid_1743"
      unitRef="Shares">5000</vnrx:OptionGranted>
    <vnrx:OptionGranted
      contextRef="From2022-11-01to2022-11-18"
      decimals="0"
      id="fid_1745"
      unitRef="Shares">32383</vnrx:OptionGranted>
    <vnrx:OptionGranted
      contextRef="From2021-08-01to2021-08-03"
      decimals="0"
      id="fid_1741"
      unitRef="Shares">2515</vnrx:OptionGranted>
    <vnrx:StockOptionsPurchaseSharesOfCommonStock
      contextRef="From2021-01-01to2021-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"
      decimals="0"
      id="fid_1707"
      unitRef="Shares">40000</vnrx:StockOptionsPurchaseSharesOfCommonStock>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"
      decimals="INF"
      id="fid_2048"
      unitRef="USDPShares">3.60</vnrx:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-01-01to2021-12-31_vnrx_JanuaryOneTwoThousandTwentyOneMember_vnrx_WarrantsMember"
      decimals="0"
      id="fid_1708"
      unitRef="USD">73641</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-05-05to2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"
      id="fid_2047">P3Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-05-05to2021-05-20"
      decimals="INF"
      id="fid_1567"
      unitRef="USDPShares">3.50</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2021-05-20_vnrx_OnTwoZeroMayTwoThousandTwentyOneMember_us-gaap_OptionMember"
      decimals="INF"
      id="fid_2045"
      unitRef="USDPShares">3.60</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2021-05-05to2021-05-20"
      decimals="INF"
      id="fid_1577"
      unitRef="Pure">0.7616</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-05-05to2021-05-20"
      decimals="INF"
      id="fid_1584"
      unitRef="Pure">0.0058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <vnrx:ApprovedStockOptions
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1519"
      unitRef="Shares">3342518</vnrx:ApprovedStockOptions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1710"
      unitRef="USD">2450349</us-gaap:ShareBasedCompensation>
    <vnrx:SummaryOfAmendmentsToExpirationDatesOfOptions contextRef="From2022-01-01to2022-12-31" id="fid_2085">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amendment &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;New Expiration &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:13%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Option Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;292,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 23, 2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 23, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;442,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,367&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 20, 2013&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 20, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jul 14, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8,151&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 2, 2013&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 2, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;335,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;163,945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2018&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Sep 21, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;308,066&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 13, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 13, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;127,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;760,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 15, 2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 15, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;984,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 23, 2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 23, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;32,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;387,934&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 30, 2017&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;224,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;615,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2018&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 23, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;213,646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;425,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;180,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 1, 2030&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 8, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;40,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 20, 2031&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,342,518&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,450,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:SummaryOfAmendmentsToExpirationDatesOfOptions>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      id="fid_959">2021-07-14</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      id="fid_931">2011</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      decimals="0"
      id="fid_902"
      unitRef="Shares">292000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      id="fid_945">2015-07-23</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      id="fid_973">2025-07-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentOneMember"
      decimals="0"
      id="fid_917"
      unitRef="USD">442273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      id="fid_960">2021-07-14</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      id="fid_932">2011</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      decimals="0"
      id="fid_903"
      unitRef="Shares">6367</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      id="fid_946">2013-03-20</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      id="fid_974">2023-03-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwoMember"
      decimals="0"
      id="fid_918"
      unitRef="USD">4151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      id="fid_961">2021-07-14</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      id="fid_933">2011</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      decimals="0"
      id="fid_904"
      unitRef="Shares">8151</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      id="fid_947">2013-09-02</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      id="fid_975">2023-09-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThreeMember"
      decimals="0"
      id="fid_919"
      unitRef="USD">6009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      id="fid_962">2021-09-21</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      id="fid_934">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      decimals="0"
      id="fid_905"
      unitRef="Shares">335000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      id="fid_948">2020-04-13</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      id="fid_976">2030-04-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourMember"
      decimals="0"
      id="fid_920"
      unitRef="USD">163945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      id="fid_963">2021-09-21</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      id="fid_935">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      decimals="0"
      id="fid_906"
      unitRef="Shares">89163</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      id="fid_949">2018-01-23</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      id="fid_977">2028-01-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFiveMember"
      decimals="0"
      id="fid_921"
      unitRef="USD">24194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      id="fid_964">2021-09-21</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      id="fid_936">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      decimals="0"
      id="fid_907"
      unitRef="Shares">308066</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      id="fid_950">2017-02-13</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      id="fid_978">2027-02-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSixMember"
      decimals="0"
      id="fid_922"
      unitRef="USD">127719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      id="fid_965">2021-11-03</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      id="fid_937">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      decimals="0"
      id="fid_908"
      unitRef="Shares">760000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      id="fid_951">2016-04-15</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      id="fid_979">2026-04-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentSevenMember"
      decimals="0"
      id="fid_923"
      unitRef="USD">984511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      id="fid_966">2021-11-03</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      id="fid_938">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      decimals="0"
      id="fid_909"
      unitRef="Shares">15000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      id="fid_952">2016-06-23</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      id="fid_980">2026-06-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentEightMember"
      decimals="0"
      id="fid_924"
      unitRef="USD">19582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      id="fid_967">2021-11-03</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      id="fid_939">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      decimals="0"
      id="fid_910"
      unitRef="Shares">50000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      id="fid_953">2017-01-01</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      id="fid_981">2027-01-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentNineMember"
      decimals="0"
      id="fid_925"
      unitRef="USD">32456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      id="fid_968">2021-11-03</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      id="fid_940">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      decimals="0"
      id="fid_911"
      unitRef="Shares">387934</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      id="fid_954">2017-03-30</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      id="fid_982">2027-03-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTenMember"
      decimals="0"
      id="fid_926"
      unitRef="USD">224901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      id="fid_969">2021-11-03</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      id="fid_941">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      decimals="0"
      id="fid_912"
      unitRef="Shares">615837</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      id="fid_955">2018-01-23</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      id="fid_983">2028-01-23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentElevenMember"
      decimals="0"
      id="fid_927"
      unitRef="USD">213646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      id="fid_970">2021-12-08</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      id="fid_942">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      decimals="0"
      id="fid_913"
      unitRef="Shares">425000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      id="fid_956">2020-04-13</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      id="fid_984">2030-04-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentTwelveMember"
      decimals="0"
      id="fid_928"
      unitRef="USD">180267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      id="fid_971">2021-12-08</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      id="fid_943">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      decimals="0"
      id="fid_914"
      unitRef="Shares">10000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      id="fid_957">2020-12-01</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      id="fid_985">2030-12-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentThirteenMember"
      decimals="0"
      id="fid_929"
      unitRef="USD">5209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:stockoptionamendmentdate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      id="fid_972">2021-12-08</vnrx:stockoptionamendmentdate>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      id="fid_944">2015</vnrx:EquityIncentivePlan>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      decimals="0"
      id="fid_915"
      unitRef="Shares">40000</vnrx:ApprovedStockOptions>
    <vnrx:StockOptionGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      id="fid_958">2021-05-20</vnrx:StockOptionGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      id="fid_986">2031-05-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsAmendmentFourteenMember"
      decimals="0"
      id="fid_930"
      unitRef="USD">21486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vnrx:ApprovedStockOptions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_901"
      unitRef="Shares">3342518</vnrx:ApprovedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_916"
      unitRef="USD">2450349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1686"
      unitRef="Shares">926640</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vnrx:CommonStockSharesIssuableUponExerciseOfStockOption
      contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1546"
      unitRef="Shares">463328</vnrx:CommonStockSharesIssuableUponExerciseOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1593"
      unitRef="Shares">463312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <vnrx:FairValueOfOptions
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1537"
      unitRef="USD">1811216</vnrx:FairValueOfOptions>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      id="fid_1560">P5Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1568"
      unitRef="USDPShares">3.31</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1555"
      unitRef="USDPShares">3.40</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1578"
      unitRef="Pure">0.6913</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-08-01to2021-08-03_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1585"
      unitRef="Pure">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1687"
      unitRef="Shares">50000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vnrx:CommonStockSharesIssuableUponExerciseOfStockOption
      contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1547"
      unitRef="Shares">25000</vnrx:CommonStockSharesIssuableUponExerciseOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1594"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <vnrx:FairValueOfOptions
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1538"
      unitRef="USD">98322</vnrx:FairValueOfOptions>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      id="fid_1561">P5Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1569"
      unitRef="USDPShares">3.32</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1556"
      unitRef="USDPShares">3.40</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1579"
      unitRef="Pure">0.6898</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-09-01to2021-09-07_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1586"
      unitRef="Pure">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1688"
      unitRef="Shares">73360</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1595"
      unitRef="Shares">36680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <vnrx:NumberOfSharesVesting
      contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2067"
      unitRef="Shares">36680</vnrx:NumberOfSharesVesting>
    <vnrx:FairValueOfOptions
      contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1539"
      unitRef="USD">128003</vnrx:FairValueOfOptions>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1570"
      unitRef="USDPShares">3.04</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <vnrx:ExercisePrice
      contextRef="AsOf2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1557"
      unitRef="USDPShares">3.40</vnrx:ExercisePrice>
    <vnrx:Volatility
      contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1580"
      unitRef="Pure">0.6880</vnrx:Volatility>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-01to2021-10-04_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1587"
      unitRef="Pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <vnrx:ExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="INF"
      id="fid_1748"
      unitRef="USDPShares">3.87</vnrx:ExercisePrice>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      id="fid_1749">P5Y2M19D</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_338">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Proceeds to&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Company if&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercised &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;($)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;635,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;635,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.25&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.12&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,063,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,717&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,717&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.35&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;0.67&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;9,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,022,587&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;532,493&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.40&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8.32&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,476,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;795,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;795,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.60&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6.94&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,862,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,682,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,682,837&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3.76&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,731,348&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;11,801&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;11,801&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;0.44&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;51,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;89,163&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.38&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5.07&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;390,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.80&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.01&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;696,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;696,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5.00&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4.24&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,480,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;4,985,105&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;4,495,011&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;19,304,864&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_OptionsOneMember"
      decimals="0"
      id="fid_997"
      unitRef="Shares">635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_OptionsOneMember"
      decimals="0"
      id="fid_987"
      unitRef="Shares">635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_OptionsOneMember"
      decimals="INF"
      id="fid_1017"
      unitRef="USDPShares">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"
      id="fid_1026">P2Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"
      decimals="0"
      id="fid_1007"
      unitRef="USD">2063750</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_OptionTwoMember"
      decimals="0"
      id="fid_998"
      unitRef="Shares">2717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_OptionTwoMember"
      decimals="0"
      id="fid_988"
      unitRef="Shares">2717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_OptionTwoMember"
      decimals="INF"
      id="fid_1018"
      unitRef="USDPShares">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"
      id="fid_1027">P0Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"
      decimals="0"
      id="fid_1008"
      unitRef="USD">9102</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember"
      decimals="0"
      id="fid_999"
      unitRef="Shares">1022587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember"
      decimals="0"
      id="fid_989"
      unitRef="Shares">532493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionThreeMember"
      decimals="INF"
      id="fid_1019"
      unitRef="USDPShares">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"
      id="fid_1028">P8Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"
      decimals="0"
      id="fid_1009"
      unitRef="USD">3476796</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_1000"
      unitRef="Shares">795000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_990"
      unitRef="Shares">795000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_1020"
      unitRef="USDPShares">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      id="fid_1029">P6Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_1010"
      unitRef="USD">2862000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_OptionFiveMember"
      decimals="0"
      id="fid_1001"
      unitRef="Shares">1682837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_OptionFiveMember"
      decimals="0"
      id="fid_991"
      unitRef="Shares">1682837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_OptionFiveMember"
      decimals="INF"
      id="fid_1021"
      unitRef="USDPShares">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"
      id="fid_1030">P3Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"
      decimals="0"
      id="fid_1011"
      unitRef="USD">6731348</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember"
      decimals="0"
      id="fid_1002"
      unitRef="Shares">11801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember"
      decimals="0"
      id="fid_992"
      unitRef="Shares">11801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionSixMember"
      decimals="INF"
      id="fid_1022"
      unitRef="USDPShares">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"
      id="fid_1031">P0Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"
      decimals="0"
      id="fid_1012"
      unitRef="USD">51334</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember"
      decimals="0"
      id="fid_1003"
      unitRef="Shares">89163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember"
      decimals="0"
      id="fid_993"
      unitRef="Shares">89163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionSevenMember"
      decimals="INF"
      id="fid_1023"
      unitRef="USDPShares">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"
      id="fid_1032">P5Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"
      decimals="0"
      id="fid_1013"
      unitRef="USD">390534</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember"
      decimals="0"
      id="fid_1004"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember"
      decimals="0"
      id="fid_994"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionEightMember"
      decimals="INF"
      id="fid_1024"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"
      id="fid_1033">P4Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"
      decimals="0"
      id="fid_1014"
      unitRef="USD">240000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember"
      decimals="0"
      id="fid_1005"
      unitRef="Shares">696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember"
      decimals="0"
      id="fid_995"
      unitRef="Shares">696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_vnrx_StockOptionNineMember"
      decimals="INF"
      id="fid_1025"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"
      id="fid_1034">P4Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"
      decimals="0"
      id="fid_1015"
      unitRef="USD">3480000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_vnrx_TotalStockOptionOneMember"
      decimals="0"
      id="fid_1006"
      unitRef="Shares">4985105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_vnrx_TotalStockOptionOneMember"
      decimals="0"
      id="fid_996"
      unitRef="Shares">4495011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember"
      decimals="0"
      id="fid_1016"
      unitRef="USD">19304864</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember"
      decimals="0"
      id="fid_1750"
      unitRef="USD">1127502</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31_us-gaap_OptionMember"
      decimals="0"
      id="fid_1713"
      unitRef="USD">1069605</us-gaap:AllocatedShareBasedCompensationExpense>
    <vnrx:FairValueOfOptions
      contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1751"
      unitRef="USD">287363</vnrx:FairValueOfOptions>
    <vnrx:MaturityTerm
      contextRef="From2022-01-01to2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      id="fid_1752">P0Y9M3D</vnrx:MaturityTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_1753"
      unitRef="Shares">417318</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vnrx:SummarizingTheRsusIssuedAndOutstandingMaturityLife contextRef="From2022-01-01to2022-12-31" id="fid_339">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Exercise Price &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;67,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.47&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;789,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(31,250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.55&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3.3&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;810,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,892,102&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(377,007&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(62,937&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2.88&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Outstanding at December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2,262,908&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;2.05&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:SummarizingTheRsusIssuedAndOutstandingMaturityLife>
    <vnrx:NumberOfRsusOutstandingBeginingBalance
      contextRef="AsOf2020-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1035"
      unitRef="Shares">67500</vnrx:NumberOfRsusOutstandingBeginingBalance>
    <vnrx:SharePriceBeginningBalance
      contextRef="AsOf2020-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1044"
      unitRef="USDPShares">3.47</vnrx:SharePriceBeginningBalance>
    <vnrx:GrantedShares
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1037"
      unitRef="Shares">789500</vnrx:GrantedShares>
    <vnrx:SharePriceGranted
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1045"
      unitRef="USDPShares">3.33</vnrx:SharePriceGranted>
    <vnrx:NumberOfStockVested
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1050"
      unitRef="Shares">31250</vnrx:NumberOfStockVested>
    <vnrx:SharePriceVested
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1054"
      unitRef="USDPShares">3.55</vnrx:SharePriceVested>
    <vnrx:NumberOfStockCancelled
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1051"
      unitRef="Shares">15000</vnrx:NumberOfStockCancelled>
    <vnrx:Cancelled
      contextRef="From2021-01-01to2021-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1055"
      unitRef="USDPShares">3.3</vnrx:Cancelled>
    <vnrx:NumberOfRsusOutstandingEndingBalance
      contextRef="AsOf2021-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1041"
      unitRef="Shares">810750</vnrx:NumberOfRsusOutstandingEndingBalance>
    <vnrx:SharePriceEndingBalance
      contextRef="AsOf2021-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1049"
      unitRef="USDPShares">3.33</vnrx:SharePriceEndingBalance>
    <vnrx:GrantedShares
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1038"
      unitRef="Shares">1892102</vnrx:GrantedShares>
    <vnrx:SharePriceGranted
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1046"
      unitRef="USDPShares">1.64</vnrx:SharePriceGranted>
    <vnrx:NumberOfStockVested
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1039"
      unitRef="Shares">377007</vnrx:NumberOfStockVested>
    <vnrx:SharePriceVested
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1047"
      unitRef="USDPShares">3.33</vnrx:SharePriceVested>
    <vnrx:NumberOfStockCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1040"
      unitRef="Shares">62937</vnrx:NumberOfStockCancelled>
    <vnrx:Cancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1048"
      unitRef="USDPShares">2.88</vnrx:Cancelled>
    <vnrx:NumberOfRsusOutstandingEndingBalance
      contextRef="AsOf2022-12-31_vnrx_StockOptionsMember"
      decimals="0"
      id="fid_1053"
      unitRef="Shares">2262908</vnrx:NumberOfRsusOutstandingEndingBalance>
    <vnrx:SharePriceEndingBalance
      contextRef="AsOf2022-12-31_vnrx_StockOptionsMember"
      decimals="INF"
      id="fid_1057"
      unitRef="USDPShares">2.05</vnrx:SharePriceEndingBalance>
    <vnrx:ScheduleOfRsusGrantedDuringPeriod contextRef="From2022-01-01to2022-12-31" id="fid_355">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:5%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;First&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Second&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Third &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSU&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Incentive&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Period&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Feb 8, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;22,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;84,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;32,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;94,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;104,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 4, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;306,800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;33,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jun 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;80,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;63,102&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 15, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;126,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;25,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 21, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;42,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(iii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,144,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,670,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(iv)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;450,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Up to 42 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;Variable&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;321,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;(v)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;3,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 29, 2025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;1,892,102&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2,755,843&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;First Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Second Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Third Vesting &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSU Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Period&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;5,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;107,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;150,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;36 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;496,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;460,191&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,523,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;38,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;126,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;39,809&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;121,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;43,500&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;152,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;23,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2021&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;24 Months&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;77,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;789,500&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2,624,486&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfRsusGrantedDuringPeriod>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1143">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      decimals="0"
      id="fid_1114"
      unitRef="Shares">8000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1157">2022-02-08</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1129">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1171">2023-02-08</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1185">2024-02-08</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseOneMember"
      decimals="0"
      id="fid_1196"
      unitRef="USD">22640</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1204">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      decimals="0"
      id="fid_1203"
      unitRef="Shares">30000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1202">2022-03-01</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1201">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1200">2023-03-01</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1199">2024-03-01</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTwoMember"
      decimals="0"
      id="fid_1197"
      unitRef="USD">84300</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1212">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      decimals="0"
      id="fid_1211"
      unitRef="Shares">32000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1210">2022-04-04</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1209">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1208">2023-04-04</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1207">2024-04-04</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseThreeMember"
      decimals="0"
      id="fid_1205"
      unitRef="USD">94400</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1220">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      decimals="0"
      id="fid_1219"
      unitRef="Shares">104000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1218">2022-04-04</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1217">36 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1216">2023-04-04</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1215">2024-04-04</vnrx:SecondVestingDate>
    <vnrx:ThirdVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1214">2025-04-04</vnrx:ThirdVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFourMember"
      decimals="0"
      id="fid_1213"
      unitRef="USD">306800</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1228">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      decimals="0"
      id="fid_1227"
      unitRef="Shares">33000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1226">2022-06-01</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1225">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1224">2023-06-01</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1223">2024-06-01</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseFiveMember"
      decimals="0"
      id="fid_1221"
      unitRef="USD">80850</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1236">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      decimals="0"
      id="fid_1235"
      unitRef="Shares">63102</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1234">2022-08-15</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1233">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1232">2023-08-15</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1231">2024-08-15</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSixMember"
      decimals="0"
      id="fid_2028"
      unitRef="USD">126835</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1244">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      decimals="0"
      id="fid_1243"
      unitRef="Shares">25000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1242">2022-09-21</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1241">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1240">2023-09-21</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1239">2024-09-21</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseSevenMember"
      decimals="0"
      id="fid_1237"
      unitRef="USD">42250</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1252">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      decimals="0"
      id="fid_1251"
      unitRef="Shares">1144000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1250">2022-10-04</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1249">36 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1248">2023-10-04</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1247">2024-10-04</vnrx:SecondVestingDate>
    <vnrx:ThirdVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1246">2025-10-04</vnrx:ThirdVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseEightMember"
      decimals="0"
      id="fid_1245"
      unitRef="USD">1670240</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"
      id="fid_1260">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"
      decimals="0"
      id="fid_1259"
      unitRef="Shares">450000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"
      id="fid_1258">2022-10-04</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"
      id="fid_1834">Up to 42 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseNineMember"
      decimals="0"
      id="fid_1253"
      unitRef="USD">321078</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1268">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      decimals="0"
      id="fid_1267"
      unitRef="Shares">3000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1266">2022-11-29</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1265">36 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1264">2023-11-29</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1263">2024-11-29</vnrx:SecondVestingDate>
    <vnrx:ThirdVestingDate
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      id="fid_1262">2025-11-29</vnrx:ThirdVestingDate>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_CompensationExpenseTenMember"
      decimals="0"
      id="fid_1261"
      unitRef="USD">6450</vnrx:RsuExpense>
    <vnrx:CompensationExpenseRsus
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1270"
      unitRef="Shares">1892102</vnrx:CompensationExpenseRsus>
    <vnrx:RsuExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1269"
      unitRef="USD">2755843</vnrx:RsuExpense>
    <vnrx:VestingAggregate
      contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1756"
      unitRef="Shares">198275</vnrx:VestingAggregate>
    <vnrx:AggregrateAggregate
      contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1758"
      unitRef="Shares">424875</vnrx:AggregrateAggregate>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="INF"
      id="fid_1760"
      unitRef="USDPShares">5.00</us-gaap:SharePrice>
    <vnrx:GrantedAggregate
      contextRef="From2022-11-01to2022-11-29_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1763"
      unitRef="Shares">3000</vnrx:GrantedAggregate>
    <vnrx:ScheduleOfRsusVestedDuringPeriod contextRef="From2022-01-01to2022-12-31" id="fid_356">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:19%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Withheld for &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Plan&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Taxes&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Mar 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;26,250&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,712&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;35,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;230,102&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 3, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;191,992&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;38,110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;12,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Sep 7, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7,038&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;4,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;19,905&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Oct 4, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;13,022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6,883&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;21,750&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;12,344&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;9,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1,181&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;377,007&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;297,289&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;79,718&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;#&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Issued&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Shares&#160;Withheld for Taxes&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;5,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Jan 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;26,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Apr 13, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;21,712&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4,538&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;31,250&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;24,712&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;6,538&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfRsusVestedDuringPeriod>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1271">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1279"
      unitRef="Shares">15000</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1286">2022-03-25</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1317"
      unitRef="Shares">15000</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1318"
      unitRef="USD">0</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1323">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1322"
      unitRef="Shares">26250</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1321">2022-04-13</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1320"
      unitRef="Shares">21712</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1319"
      unitRef="USD">4538</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      id="fid_1328">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      decimals="0"
      id="fid_1327"
      unitRef="Shares">50000</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      id="fid_1326">2022-05-01</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      decimals="0"
      id="fid_1325"
      unitRef="Shares">35000</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      decimals="0"
      id="fid_1324"
      unitRef="USD">15000</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      id="fid_1338">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      decimals="0"
      id="fid_1337"
      unitRef="Shares">230102</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      id="fid_1336">2022-08-03</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      decimals="0"
      id="fid_1335"
      unitRef="Shares">191992</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      decimals="0"
      id="fid_1334"
      unitRef="USD">38110</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"
      id="fid_1343">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"
      decimals="0"
      id="fid_1342"
      unitRef="Shares">12000</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"
      id="fid_1341">2022-09-07</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"
      decimals="0"
      id="fid_1340"
      unitRef="Shares">7038</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFiveMember"
      decimals="0"
      id="fid_1339"
      unitRef="USD">4962</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"
      id="fid_1348">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"
      decimals="0"
      id="fid_1347"
      unitRef="Shares">19905</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"
      id="fid_1346">2022-10-04</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"
      decimals="0"
      id="fid_1345"
      unitRef="Shares">13022</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSixMember"
      decimals="0"
      id="fid_1344"
      unitRef="USD">6883</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"
      id="fid_1353">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"
      decimals="0"
      id="fid_1352"
      unitRef="Shares">21750</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"
      id="fid_1351">2022-11-01</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"
      decimals="0"
      id="fid_1350"
      unitRef="Shares">12344</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanSevenMember"
      decimals="0"
      id="fid_1349"
      unitRef="USD">9406</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"
      id="fid_1358">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"
      decimals="0"
      id="fid_1357"
      unitRef="Shares">2000</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"
      id="fid_1356">2022-12-15</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"
      decimals="0"
      id="fid_1355"
      unitRef="Shares">1181</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanEightMember"
      decimals="0"
      id="fid_1354"
      unitRef="USD">819</vnrx:RsusHeldForTaxes>
    <vnrx:EquityIncentiveRsu
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1362"
      unitRef="Shares">377007</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveRsuIssued
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1361"
      unitRef="Shares">297289</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1360"
      unitRef="USD">79718</vnrx:RsusHeldForTaxes>
    <vnrx:ScheduleOfRsusCancelledDuringPeriod contextRef="From2022-01-01to2022-12-31" id="fid_357">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Equity Incentive &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Cancellation &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Cancelled&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:24%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:23%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;May 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:23%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,365&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Aug 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,365&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;17,572&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;17,572&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Nov 21, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;62,937&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;62,937&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Equity Incentive Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vest Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;RSUs Cancelled&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:18%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;Dec 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;15,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;15,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfRsusCancelledDuringPeriod>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1410">2015</vnrx:IncentivePlan>
    <vnrx:IncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1409"
      unitRef="Shares">33000</vnrx:IncentiveRsu>
    <vnrx:CancellationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1408">2022-05-31</vnrx:CancellationDate>
    <vnrx:RsuCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1407"
      unitRef="Shares">33000</vnrx:RsuCancelled>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1426">2015</vnrx:IncentivePlan>
    <vnrx:IncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1425"
      unitRef="Shares">1365</vnrx:IncentiveRsu>
    <vnrx:CancellationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1424">2022-08-18</vnrx:CancellationDate>
    <vnrx:RsuCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1423"
      unitRef="Shares">1365</vnrx:RsuCancelled>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      id="fid_1430">2015</vnrx:IncentivePlan>
    <vnrx:IncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      decimals="0"
      id="fid_1429"
      unitRef="Shares">17572</vnrx:IncentiveRsu>
    <vnrx:CancellationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      id="fid_1428">2022-11-18</vnrx:CancellationDate>
    <vnrx:RsuCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanThreeMember"
      decimals="0"
      id="fid_1427"
      unitRef="Shares">17572</vnrx:RsuCancelled>
    <vnrx:IncentivePlan
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      id="fid_1434">2015</vnrx:IncentivePlan>
    <vnrx:IncentiveRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      decimals="0"
      id="fid_1433"
      unitRef="Shares">11000</vnrx:IncentiveRsu>
    <vnrx:CancellationDate
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      id="fid_1432">2022-11-21</vnrx:CancellationDate>
    <vnrx:RsuCancelled
      contextRef="From2022-01-01to2022-12-31_vnrx_EquityIncentivePlanFourMember"
      decimals="0"
      id="fid_1431"
      unitRef="Shares">11000</vnrx:RsuCancelled>
    <vnrx:RsuCancelled
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1439"
      unitRef="Shares">62937</vnrx:RsuCancelled>
    <vnrx:IncentiveRsu
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1440"
      unitRef="Shares">62937</vnrx:IncentiveRsu>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1442">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"
      decimals="0"
      id="fid_1441"
      unitRef="Shares">5000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1459">2021-01-01</vnrx:CompensationExpenseGrantDate>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"
      id="fid_1475">2021-01-01</vnrx:FirstVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseOneMember"
      decimals="0"
      id="fid_1491"
      unitRef="USD">19450</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1443">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      decimals="0"
      id="fid_1452"
      unitRef="Shares">30000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1460">2021-03-25</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1468">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1476">2022-03-25</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      id="fid_1483">2023-03-25</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseTwoMember"
      decimals="0"
      id="fid_1492"
      unitRef="USD">107700</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1444">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      decimals="0"
      id="fid_1453"
      unitRef="Shares">150000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1461">2021-05-01</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1469">36 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1477">2022-05-01</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1484">2023-05-01</vnrx:SecondVestingDate>
    <vnrx:ThirdVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      id="fid_1490">2024-05-01</vnrx:ThirdVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseThreeMember"
      decimals="0"
      id="fid_1493"
      unitRef="USD">496500</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1445">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      decimals="0"
      id="fid_1454"
      unitRef="Shares">460191</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1462">2021-08-03</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1470">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1478">2022-08-03</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      id="fid_1485">2023-08-03</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFourMember"
      decimals="0"
      id="fid_1494"
      unitRef="USD">1523232</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1446">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      decimals="0"
      id="fid_1455"
      unitRef="Shares">38000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1463">2021-09-07</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1471">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1479">2022-09-07</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      id="fid_1486">2023-09-07</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseFiveMember"
      decimals="0"
      id="fid_1495"
      unitRef="USD">126160</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1447">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      decimals="0"
      id="fid_1456"
      unitRef="Shares">39809</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1464">2021-10-04</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1472">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1480">2022-10-04</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      id="fid_1487">2023-10-04</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSixMember"
      decimals="0"
      id="fid_1496"
      unitRef="USD">121019</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1448">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      decimals="0"
      id="fid_1457"
      unitRef="Shares">43500</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1465">2021-11-01</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1473">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1481">2022-11-01</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      id="fid_1488">2023-11-01</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseSevenMember"
      decimals="0"
      id="fid_1497"
      unitRef="USD">152685</vnrx:RsuExpense>
    <vnrx:EquityIncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1449">2015</vnrx:EquityIncentivePlan>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      decimals="0"
      id="fid_1458"
      unitRef="Shares">23000</vnrx:CompensationExpenseRsus>
    <vnrx:CompensationExpenseGrantDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1466">2021-12-15</vnrx:CompensationExpenseGrantDate>
    <vnrx:CompensationExpenseVestingPeriod
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1474">24 Months</vnrx:CompensationExpenseVestingPeriod>
    <vnrx:FirstVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1482">2022-12-15</vnrx:FirstVestingDate>
    <vnrx:SecondVestingDate
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      id="fid_1489">2023-12-15</vnrx:SecondVestingDate>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31_vnrx_CompensationExpenseEightMember"
      decimals="0"
      id="fid_1498"
      unitRef="USD">77740</vnrx:RsuExpense>
    <vnrx:CompensationExpenseRsus
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1501"
      unitRef="Shares">789500</vnrx:CompensationExpenseRsus>
    <vnrx:RsuExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1500"
      unitRef="USD">2624486</vnrx:RsuExpense>
    <vnrx:GrantedRsu
      contextRef="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1766"
      unitRef="Shares">460191</vnrx:GrantedRsu>
    <vnrx:DescriptionOfVestingShall
      contextRef="From2021-08-01to2021-08-03_vnrx_RestrictedStockUnitsOneMember"
      id="fid_1769">The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232</vnrx:DescriptionOfVestingShall>
    <vnrx:GrantedRsu
      contextRef="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1771"
      unitRef="Shares">39809</vnrx:GrantedRsu>
    <vnrx:DescriptionOfVestingShall
      contextRef="From2021-10-01to2021-10-04_vnrx_RestrictedStockUnitsOneMember"
      id="fid_1772">These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019</vnrx:DescriptionOfVestingShall>
    <vnrx:IncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1499">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1503"
      unitRef="Shares">5000</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1505">2021-01-01</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1507"
      unitRef="Shares">3000</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1509"
      unitRef="USD">2000</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1502">2015</vnrx:IncentivePlan>
    <vnrx:EquityIncentiveRsu
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1504"
      unitRef="Shares">26250</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveVestDate
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"
      id="fid_1506">2021-04-13</vnrx:IncentiveVestDate>
    <vnrx:IncentiveRsuIssued
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1508"
      unitRef="Shares">21712</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanTwoMember"
      decimals="0"
      id="fid_1510"
      unitRef="USD">4538</vnrx:RsusHeldForTaxes>
    <vnrx:EquityIncentiveRsu
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1511"
      unitRef="Shares">31250</vnrx:EquityIncentiveRsu>
    <vnrx:IncentiveRsuIssued
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1512"
      unitRef="Shares">24712</vnrx:IncentiveRsuIssued>
    <vnrx:RsusHeldForTaxes
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_1513"
      unitRef="USD">6538</vnrx:RsusHeldForTaxes>
    <vnrx:IncentivePlan
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1515">2015</vnrx:IncentivePlan>
    <vnrx:IncentiveRsu
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_2070"
      unitRef="Shares">15000</vnrx:IncentiveRsu>
    <vnrx:VestDate
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      id="fid_1517">2020-12-31</vnrx:VestDate>
    <vnrx:RsuCancelled
      contextRef="From2021-01-01to2021-12-31_vnrx_EquityIncentivePlanOneMember"
      decimals="0"
      id="fid_1514"
      unitRef="Shares">15000</vnrx:RsuCancelled>
    <vnrx:IncentiveRsu
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_2069"
      unitRef="Shares">15000</vnrx:IncentiveRsu>
    <vnrx:RsuCancelled
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      id="fid_2068"
      unitRef="Shares">15000</vnrx:RsuCancelled>
    <vnrx:summarizingtheRSUsissuedandoutstandingtabletextblock contextRef="From2022-01-01to2022-12-31" id="fid_340">&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Grant date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Remaining &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Number&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;strong&gt;(Years)&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:31%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"&gt;0.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:31%;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,133,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.46&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.76&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;63,102&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.01&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.08&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.15&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.91&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;33,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.45&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.81&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.67&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.83&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;136,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.95&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.97&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;19,904&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.04&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.38&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;311,152&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.31&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.32&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.68&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.38&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.48&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;21,750&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.51&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;0.23&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;2,262,908&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:summarizingtheRSUsissuedandoutstandingtabletextblock>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"
      decimals="0"
      id="fid_1058"
      unitRef="Shares">450000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"
      decimals="INF"
      id="fid_1066"
      unitRef="USDPShares">0.69</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionsOneMember"
      id="fid_1073">P3Y3M3D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"
      decimals="0"
      id="fid_1059"
      unitRef="Shares">1133000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"
      decimals="INF"
      id="fid_1067"
      unitRef="USDPShares">1.46</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionTwoMember"
      id="fid_1074">P1Y9M3D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"
      decimals="0"
      id="fid_1060"
      unitRef="Shares">25000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"
      decimals="INF"
      id="fid_1068"
      unitRef="USDPShares">1.69</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThreeMember"
      id="fid_1075">P1Y2M19D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="0"
      id="fid_1061"
      unitRef="Shares">63102</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      decimals="INF"
      id="fid_1069"
      unitRef="USDPShares">2.01</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFourMember"
      id="fid_1076">P1Y29D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"
      decimals="0"
      id="fid_1062"
      unitRef="Shares">3000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"
      decimals="INF"
      id="fid_1070"
      unitRef="USDPShares">2.15</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_OptionFiveMember"
      id="fid_1077">P1Y10M28D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"
      decimals="0"
      id="fid_1063"
      unitRef="Shares">33000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"
      decimals="INF"
      id="fid_1071"
      unitRef="USDPShares">2.45</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSixMember"
      id="fid_1078">P0Y11M1D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"
      decimals="0"
      id="fid_1064"
      unitRef="Shares">30000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"
      decimals="INF"
      id="fid_1072"
      unitRef="USDPShares">2.81</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionSevenMember"
      id="fid_1079">P0Y8M1D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"
      decimals="0"
      id="fid_1090"
      unitRef="Shares">8000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"
      decimals="INF"
      id="fid_1089"
      unitRef="USDPShares">2.83</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionEightMember"
      id="fid_1088">P0Y7M9D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"
      decimals="0"
      id="fid_1093"
      unitRef="Shares">136000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"
      decimals="INF"
      id="fid_1092"
      unitRef="USDPShares">2.95</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionNineMember"
      id="fid_1091">P0Y11M19D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember"
      decimals="0"
      id="fid_1105"
      unitRef="Shares">19904</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember"
      decimals="INF"
      id="fid_1104"
      unitRef="USDPShares">3.04</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTenMember"
      id="fid_1103">P0Y4M17D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember"
      decimals="0"
      id="fid_1102"
      unitRef="Shares">311152</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember"
      decimals="INF"
      id="fid_1101"
      unitRef="USDPShares">3.31</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionElevenMember"
      id="fid_1100">P0Y7M2D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember"
      decimals="0"
      id="fid_1096"
      unitRef="Shares">12000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember"
      decimals="INF"
      id="fid_1095"
      unitRef="USDPShares">3.32</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionTwelveMember"
      id="fid_1094">P0Y8M4D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember"
      decimals="0"
      id="fid_1112"
      unitRef="Shares">2000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember"
      decimals="INF"
      id="fid_1111"
      unitRef="USDPShares">3.38</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionThirteenTenMember"
      id="fid_1110">P0Y5M23D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember"
      decimals="0"
      id="fid_1099"
      unitRef="Shares">21750</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember"
      decimals="INF"
      id="fid_1098"
      unitRef="USDPShares">3.51</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFourteenTenMember"
      id="fid_1097">P0Y5M1D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember"
      decimals="0"
      id="fid_1108"
      unitRef="Shares">15000</vnrx:NumberOfStockOutstandingBalance>
    <vnrx:SharesPriceRsu
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember"
      decimals="INF"
      id="fid_1107"
      unitRef="USDPShares">3.59</vnrx:SharesPriceRsu>
    <vnrx:WeightedAverageRemainingContractualLifeYears
      contextRef="From2022-01-01to2022-12-31_vnrx_StockOptionFiveteenTenMember"
      id="fid_1106">P0Y2M23D</vnrx:WeightedAverageRemainingContractualLifeYears>
    <vnrx:NumberOfStockOutstandingBalance
      contextRef="From2022-01-01to2022-12-31_vnrx_TotalStockOptionOneMember"
      decimals="0"
      id="fid_1065"
      unitRef="Shares">2262908</vnrx:NumberOfStockOutstandingBalance>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1774"
      unitRef="USD">1903054</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1773"
      unitRef="USD">898910</us-gaap:ShareBasedCompensation>
    <vnrx:UnrecognizedCompensationCost
      contextRef="From2022-01-01to2022-12-31_vnrx_RestrictedStockUnitsOneMember"
      decimals="0"
      id="fid_1776"
      unitRef="USD">2214593</vnrx:UnrecognizedCompensationCost>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_307">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 9 - Income Taxes&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has estimated net operating losses for the years ended December 31, 2022 and 2021 of $28.6 million and $24.4 million, respectively, available to offset taxable income in future years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The significant components of deferred income taxes and assets as of December 31, 2022 and December 31, 2021 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Net Deferred Tax Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Excess of tax over book depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(46,001&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,330&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;ROU Asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(117,134&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(28,657&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;122,279&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;47,301&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,655&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,199&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Unrealized Gain/Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;103,106&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Capitalized research expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,237,122&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;321,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses carry-forward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,556,992&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,390,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;769,317&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;606,729&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,850,186&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,297,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(30,850,186&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,297,640&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,552,546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Summary Rate Reconciliation&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;State income taxes, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Permanent Differences &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4.8&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Stock based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal Research &amp;amp; Development Credits &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.7&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Foreign taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.1&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal Deferred Rate Decrease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14.4&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Change in Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3.2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Disclosure Amounts&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses - United States &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,072,965&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,614,447&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Credit Carryforward - United States &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Credit Carryforward - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;769,317&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Increase in Valuation Allowance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,552,546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <vnrx:NetOperatingLosses
      contextRef="AsOf2022-12-31"
      decimals="-4"
      id="fid_628"
      unitRef="USD">2860000</vnrx:NetOperatingLosses>
    <vnrx:NetOperatingLosses
      contextRef="AsOf2021-12-31"
      decimals="-4"
      id="fid_629"
      unitRef="USD">2440000</vnrx:NetOperatingLosses>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_358">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Net Deferred Tax Liability&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Excess of tax over book depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(46,001&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,330&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;ROU Asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(117,134&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(28,657&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;122,279&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;47,301&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,655&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,199&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Unrealized Gain/Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;103,106&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Capitalized research expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,237,122&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;321,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,252&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses carry-forward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,556,992&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,390,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:15px"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;769,317&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;606,729&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,850,186&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,297,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(30,850,186&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,297,640&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,552,546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Summary Rate Reconciliation&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;State income taxes, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Permanent Differences &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4.8&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Stock based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal Research &amp;amp; Development Credits &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.7&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Foreign taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.1&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Federal Deferred Rate Decrease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14.4&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;Change in Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3.2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Disclosure Amounts&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;December 31, 2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses - United States &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,072,965&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net Operating Losses - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,614,447&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Credit Carryforward - United States &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Credit Carryforward - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;769,317&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Increase in Valuation Allowance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,552,546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <vnrx:ExcessOfTaxOverBookDepreciationAndAmortization
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_578"
      unitRef="USD">-46001</vnrx:ExcessOfTaxOverBookDepreciationAndAmortization>
    <vnrx:ExcessOfTaxOverBookDepreciationAndAmortization
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_577"
      unitRef="USD">-8330</vnrx:ExcessOfTaxOverBookDepreciationAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_580"
      unitRef="USD">117134</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_579"
      unitRef="USD">28657</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_582"
      unitRef="USD">122279</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_581"
      unitRef="USD">47301</us-gaap:FinanceLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_584"
      unitRef="USD">5655</us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_583"
      unitRef="USD">1199</us-gaap:DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals>
    <vnrx:UnrealizedGainLoss
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_585"
      unitRef="USD">103106</vnrx:UnrealizedGainLoss>
    <vnrx:CapitalizedResearchExpenses
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_599"
      unitRef="USD">1237122</vnrx:CapitalizedResearchExpenses>
    <vnrx:CapitalizedResearchExpenses
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_600"
      unitRef="USD">0</vnrx:CapitalizedResearchExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_588"
      unitRef="USD">321956</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_587"
      unitRef="USD">186252</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_590"
      unitRef="USD">28556992</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_589"
      unitRef="USD">24390040</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_592"
      unitRef="USD">769317</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_591"
      unitRef="USD">606729</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_594"
      unitRef="USD">30850186</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_593"
      unitRef="USD">25297640</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_596"
      unitRef="USD">30850186</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_595"
      unitRef="USD">25297640</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_598"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_597"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <vnrx:ChangeInValuationAllowance
      contextRef="AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember"
      decimals="0"
      id="fid_601"
      unitRef="USD">-5552546</vnrx:ChangeInValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_604"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_603"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_605"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_606"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_607"
      unitRef="Pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_608"
      unitRef="Pure">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_609"
      unitRef="Pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_610"
      unitRef="Pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_612"
      unitRef="Pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_611"
      unitRef="Pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_613"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_614"
      unitRef="Pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_616"
      unitRef="Pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_615"
      unitRef="Pure">-0.144</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_617"
      unitRef="Pure">-0.212</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_618"
      unitRef="Pure">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_619"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="fid_620"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_vnrx_UnitedStateMember"
      decimals="0"
      id="fid_624"
      unitRef="USD">35072965</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_vnrx_ForeignMember"
      decimals="0"
      id="fid_626"
      unitRef="USD">90614447</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2022-12-31_vnrx_UnitedStateMember"
      decimals="0"
      id="fid_625"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2022-12-31_vnrx_ForeignMember"
      decimals="0"
      id="fid_627"
      unitRef="USD">769317</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <vnrx:IncreaseInValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_623"
      unitRef="USD">5552546</vnrx:IncreaseInValuationAllowance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_303">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Note 10 - Commitments and Contingencies&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;a) &lt;/strong&gt;&lt;strong&gt;Finance Lease Obligations&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (&#x201c;ING&#x201d;) to purchase a property located in Belgium for &#x20ac;1.12 million, maturing May 2031, with implicit interest of 2.62%. As of December 31, 2022, the balance payable was $482,146.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for &#x20ac;25,000, maturing January 2022, with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of December 31, 2022, the balance payable was $0. The following is a schedule showing the future minimum lease payments under financing leases by years and the present value of the minimum payments as of December 31, 2022. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,725&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,725&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,534&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;541,162&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,016&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Present value of minimum lease payments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;482,146&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;b) &lt;/strong&gt;&lt;strong&gt;Operating Lease Right-of-Use Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, operating lease right-of-use assets and liabilities arising from operating leases were $619,392 and $645,254, respectively. During the year ended December 31, 2022, cash paid for amounts included for the measurement of lease liabilities was $245,354 and the Company recorded operating lease expense of $267,434. Our weighted average discount rate is 2.38% and the weighted average remaining lease term is 25 months.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of December 31, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;264,799&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;164,225&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,209&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;25,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Operating Lease Obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;669,633&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(24,379&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Present Value of minimum lease payments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;645,254&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company&#x2019;s office space leases are short term, and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the year ended December 31, 2022, $76,955 was recognized in short-term lease costs associated with the office space leases in Singapore and Nevada. The annual payments remaining for such short-term office leases as of December 31, 2022, were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,069&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024 - 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Operating Lease Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;27,069&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;c) Grants Repayable &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#x20ac;1,048,020. Per the terms of the agreement, &#x20ac;314,406 of the grant is to be repaid by installments over the period from June 30, 2014 to June 30, 2023. The Company has recorded the balance of &#x20ac;733,614 to other income in previous years as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;314,406 and the 6% royalty on revenue, is twice the amount of funding received. As of December 31, 2022, the grant balance repayable was $26,831. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for &#x20ac;605,000.&#160; Per the terms of the agreement, &#x20ac;181,500 of the grant is to be repaid by instalments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $107,280. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#x20ac;495,000.&#160; Per the terms of the agreement, &#x20ac;148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $97,799. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for &#x20ac;929,433.&#160; Per the terms of the agreement, &#x20ac;278,830 of the grant is to be repaid by instalments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $230,392.&lt;/p&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2022, the balance repayable was $462,302 and the annual payments remaining were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;49,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,541&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;34,581&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,026&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,978&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;263,893&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Grants Repayable &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;462,302&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;d) Long-Term Debt&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2016, the Company entered into a 7-year loan agreement with Namur Invest for &#x20ac;440,000 with a fixed interest rate of 4.85%, maturing December 2023. As of December 31, 2022, the principal balance payable was $82,659.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2016, the Company entered into a 15-year loan agreement with ING for &#x20ac;270,000 with a fixed interest rate of 2.62%, maturing December 2031. As of December 31, 2022, the principal balance payable was $188,806. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to &#x20ac;1 million with a fixed interest rate of 4.50%, maturing September 2024.&#160; As of December 31, 2022, &#x20ac;1 million has been drawn down under this agreement and the principal balance payable was $482,954. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for &#x20ac;500,000 with fixed interest rate of 4.00%, maturing June 2022. As of December 31, 2022, the principal balance payable was $0.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for &#x20ac;500,000 with fixed interest rate of 4.80%, maturing September 2024. As of December 31, 2022, the principal balance payable was $279,548.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of &#x20ac;830,000 with fixed interest rate of 4.00%, maturing March 2031. As of December 31, 2022, the amount that has been drawn down under this agreement was &#x20ac;707,599, representing a principal balance payable of $759,419.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 23, 2021, the Company entered into a 3 &#xbd; year loan agreement with SOFINEX for a maximum of &#x20ac;450,000 with fixed interest rate of 5.00%, maturing June 2025. As of December 31, 2022, the amount that has been drawn down under this agreement was &#x20ac;450,000, representing a principal balance payable of $442,708.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February 5, 2022 the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $620,549 with fixed interest rate of 3.57%, maturing November 2022. As of December 31, 2022, the principal balance payable was $0.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On August 16, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of &#x20ac;1,000,000 with fixed interest rate of 6.00%, maturing July 2026. As of December 31, 2022, the amount that has been drawn down under this agreement was &#x20ac;1,000,000, representing a principal balance payable of $1,073,231.&lt;/p&gt;&#160; &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 18, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of &#x20ac;500,000 with fixed interest rate of 5.45%, maturing December 2027. As of December 31, 2022, the amount that has been drawn down under this agreement was &#x20ac;500,000, representing a principal balance payable of $536,615.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the total balance for long-term debt payable was $3,845,940 and the payments remaining were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,268,528&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,138,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;704,312&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;480,358&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;281,602&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;446,799&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,319,826&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(473,886&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Long-Term Debt&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;3,845,940&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;e) Collaborative Agreement Obligations&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a 3-year period for a cost to the Company of up to $2.55 million payable over such period. As of December 31, 2022, $510,000 is still to be paid by the Company under this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2019, the Company entered into a funded sponsored research agreement with the Texas A&amp;amp;M University (&#x201c;TAMU&#x201d;) in consideration for the license granted to the Company for a 5-year period for a cost to the Company of up to $400,000 payable over such period. As of December 31, 2022, $0 is still to be paid by the Company under this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of &#x20ac;54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of &#x20ac;100,236. In the year ended December 31, 2022, the parties entered into agreements for an additional cost to the Company of &#x20ac;39,000. As of December 31, 2022, $23,018 is still to be paid by the Company under the amended agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On August 2, 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (&#x201c;NETs&#x201d;) in cancer patients with sepsis for a cost to the Company of $346,787. As of December 31, 2022, $346,787 is still to be paid by the Company under this agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the total amount to be paid for future research and collaboration commitments was approximately $879,805 and the annual payments remaining were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;798,032&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024 - 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;81,773&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Collaborative Agreement Obligations&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;879,805&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;f) Other Commitments&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Volition Vet &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On October 25, 2019, the Company entered into an agreement with TAMU for provision of in-kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of December 31, 2022, TAMU has a 12.5 % equity interest in Volition Vet.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Volition Germany &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (&#x201c;Octamer&#x201d;), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or &#x201c;Volition Germany&#x201d;). &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany&#x2019;s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, $210 is payable under the 6% royalty agreement on sales to date towards the Company&#x2019;s aggregate minimum royalty obligation of&#160; $118,055.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Volition America &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 3, 2020, the Company entered into a professional services master agreement (the &#x201c;Master Agreement&#x201d;) with Diagnostic Oncology CRO, LLC (&#x201c;DXOCRO&#x201d;) to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. On August 8, 2022, the Company and DXOCRO amended and restated the Master Agreement to expand the scope of DXOCRO&#x2019;s consultant services provided thereunder (the &#x201c;A&amp;amp;R Master Agreement&#x201d;). The A&amp;amp;R Master Agreement requires DXOCRO to support development and clinical validation studies for the Company&#x2019;s Nu.Q&#xae; product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q&#xae; NETs and Nu.Q&#xae; Cancer tests to determine clinical utility in sepsis and non-Hodgkin&#x2019;s lymphoma. The Company anticipates DXOCRO&#x2019;s services under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million. The Company&#x2019;s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days&#x2019; prior written notice. Unless earlier terminated, the A&amp;amp;R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of December 31, 2022, $ 264,692 is payable under the A&amp;amp;R Master Agreement, and up $3,435,165 may be payable by Company in future periods for services rendered. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;g) Legal Proceedings&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;h) Commitments in Respect of Corporate Goals and Performance-Based Awards&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In August 2021 and October 2021, the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals related to the awards in August 2021 and October 2021 resulting in the payment of the cash bonus awards and the vesting of the remaining rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company has paid compensation expense of $737,137 in relation to the July 1, 2022 specified corporate goals based on the actual outcomes related to the prescribed performance targets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In October 2022, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around product development, manufacturing, financing and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Conditional upon the achievement by January 1, 2023 and July 1, 2023 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company has accrued compensation expense of $905,856 in relation to the January 1, 2023 and July 1, 2023 specified corporate goals based on the actual outcomes related to the prescribed performance targets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As discussed in detail in Note 8, - &lt;em&gt;Stock-Based Compensation,&lt;/em&gt; an aggregate of 1,144,000 RSUs were issued under the 2015 Stock Incentive Plan in connection with the October 2022 grants and an aggregate of 1,000,000 stock options and 500,000 RSUs were issued under the 2015 Stock Incentive Plan in connection with the August 2021 and October 2021 grants. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company has recognized compensation expense of $969,593 in relation to the options vested in 2022 and $630,863 in relation to the options that will vest in 2023. The Company has unrecognized compensation expense of $270,550 to such stock options, based on the outcomes related to the prescribed performance targets on the outstanding awards.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:25%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Award&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;969,593&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;580,411&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;389,182&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;630,863&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450,090&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;180,773&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;270,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;h) Commitments in Respect of Corporate Goals and Performance-Based Awards (continued)&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company has recognized compensation expense of $822,149 in relation to the RSUs fully vested in 2022 and $530,930 in relation to RSUs that will vest in 2023. The Company has unrecognized compensation expense of $228,491 to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:25%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Award&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;822,149 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;493,207&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;328,942 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;530,930 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;379,191 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;151,739 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;228,491 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of December 31, 2022, the Company has recognized total compensation expense of $245,861 of which $134,087 in relation to RSUs that will vest in 2023, $65,088 in relation to RSUs that will vest in 2024, and $46,686 in relation to RSUs that will vest in 2025. The Company has unrecognized compensation expense of $1,408,319 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:32%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:32%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:34%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Year&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;134,087 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;417,327 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;65,088 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;470,244 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;46,686 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;520,748 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;245,861 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;1,408,319 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vnrx:MaturityDate
      contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember"
      id="fid_1873">May 2031</vnrx:MaturityDate>
    <vnrx:FixedInterestRateOnLease
      contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember"
      decimals="INF"
      id="fid_1879"
      unitRef="Pure">0.0262</vnrx:FixedInterestRateOnLease>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember"
      decimals="0"
      id="fid_1880"
      unitRef="USD">482146</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments
      contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1872"
      unitRef="EUR">25000</us-gaap:BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments>
    <vnrx:MaturityDate
      contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"
      id="fid_1874">January 2022</vnrx:MaturityDate>
    <vnrx:ImplicitInterest
      contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"
      decimals="INF"
      id="fid_1875"
      unitRef="Pure">0.0135</vnrx:ImplicitInterest>
    <vnrx:LeasedEquipmentAmortizedPeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"
      id="fid_1876">P5Y</vnrx:LeasedEquipmentAmortizedPeriod>
    <vnrx:AmountPayable
      contextRef="AsOf2022-12-31_vnrx_InTwoThousandsEightteenMember_vnrx_BNPParibasLeasingSolutionsMember_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1850"
      unitRef="USD">0</vnrx:AmountPayable>
    <vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_341">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,725&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,725&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,726&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,534&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;541,162&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,016&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Present value of minimum lease payments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;482,146&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1777"
      unitRef="USD">57726</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1778"
      unitRef="USD">57725</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1779"
      unitRef="USD">57725</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1780"
      unitRef="USD">57726</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1781"
      unitRef="USD">57726</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1782"
      unitRef="USD">252534</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1783"
      unitRef="USD">541162</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <vnrx:LessAmountRepresentingInterest
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1784"
      unitRef="USD">-59016</vnrx:LessAmountRepresentingInterest>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember"
      decimals="0"
      id="fid_1785"
      unitRef="USD">482146</us-gaap:FinanceLeaseLiability>
    <vnrx:OperatingLeaseRightOfUseAssets
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1963"
      unitRef="USD">619392</vnrx:OperatingLeaseRightOfUseAssets>
    <vnrx:OperatingLeasesLiability1
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1964"
      unitRef="USD">645254</vnrx:OperatingLeasesLiability1>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1870"
      unitRef="USD">245354</us-gaap:ShortTermLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1871"
      unitRef="USD">267434</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="INF"
      id="fid_1869"
      unitRef="Pure">0.0238</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <vnrx:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_342">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;264,799&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;164,225&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,209&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;25,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Operating Lease Obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;669,633&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(24,379&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Present Value of minimum lease payments&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;645,254&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock>
    <vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1786"
      unitRef="USD">264799</vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo>
    <vnrx:FiniteLivedIntangibleAssetAmortizationExpenseYearTwo
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1787"
      unitRef="USD">164225</vnrx:FiniteLivedIntangibleAssetAmortizationExpenseYearTwo>
    <vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFour
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1788"
      unitRef="USD">120209</vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFour>
    <vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFive
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1789"
      unitRef="USD">94600</vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearFive>
    <vnrx:OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1793"
      unitRef="USD">25800</vnrx:OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix>
    <vnrx:OperatingLeaseObligations
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1790"
      unitRef="USD">669633</vnrx:OperatingLeaseObligations>
    <vnrx:LessAmountRepresentingInterest
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1791"
      unitRef="USD">-24379</vnrx:LessAmountRepresentingInterest>
    <vnrx:OperatingLeasesFutureMinimumPaymentDue
      contextRef="AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1792"
      unitRef="USD">645254</vnrx:OperatingLeasesFutureMinimumPaymentDue>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-01-01to2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember"
      decimals="0"
      id="fid_1965"
      unitRef="USD">76955</us-gaap:ShortTermLeaseCost>
    <vnrx:ScheduleOfRecognizedInShortTermLeaseCosts contextRef="From2022-01-01to2022-12-31" id="fid_343">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,069&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024 - 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Operating Lease Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;27,069&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfRecognizedInShortTermLeaseCosts>
    <vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1794"
      unitRef="USD">27069</vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent>
    <vnrx:OperatingLeasesFutureMinimumPaymentDueInTwoYears
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1796"
      unitRef="USD">0</vnrx:OperatingLeasesFutureMinimumPaymentDueInTwoYears>
    <vnrx:OperatingLeasesFutureMinimumLeasePaymentDue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1795"
      unitRef="USD">27069</vnrx:OperatingLeasesFutureMinimumLeasePaymentDue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      decimals="0"
      id="fid_2023"
      unitRef="EUR">1048020</us-gaap:GrantsReceivableCurrent>
    <vnrx:RepaymentOfGrants
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      decimals="0"
      id="fid_1890"
      unitRef="EUR">314406</vnrx:RepaymentOfGrants>
    <us-gaap:OtherIncome
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      decimals="0"
      id="fid_1966"
      unitRef="USD">733614</us-gaap:OtherIncome>
    <vnrx:TermsOfAgreementDescription
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      id="fid_1886">it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;314,406 and the 6% royalty on revenue, is twice the amount of funding received</vnrx:TermsOfAgreementDescription>
    <vnrx:RoyalityOnRevenuePercentange
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      decimals="INF"
      id="fid_1897"
      unitRef="Pure">0.06</vnrx:RoyalityOnRevenuePercentange>
    <vnrx:AmountRepayable
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_In2010Member"
      decimals="0"
      id="fid_1882"
      unitRef="USD">26831</vnrx:AmountRepayable>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1898"
      unitRef="EUR">605000</us-gaap:GrantsReceivableCurrent>
    <vnrx:RepaymentOfGrants
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1891"
      unitRef="EUR">181500</vnrx:RepaymentOfGrants>
    <vnrx:GrantRepaidByInstallments
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      id="fid_1901">over 12 years</vnrx:GrantRepaidByInstallments>
    <vnrx:TermsOfAgreementDescription
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      id="fid_1887">it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received</vnrx:TermsOfAgreementDescription>
    <vnrx:RoyalityOnRevenuePercentange
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="INF"
      id="fid_1894"
      unitRef="Pure">0.0353</vnrx:RoyalityOnRevenuePercentange>
    <vnrx:AmountRepayable
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsEightteenMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1883"
      unitRef="USD">107280</vnrx:AmountRepayable>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      decimals="0"
      id="fid_1900"
      unitRef="EUR">495000</us-gaap:GrantsReceivableCurrent>
    <vnrx:RepaymentOfGrants
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      decimals="0"
      id="fid_1893"
      unitRef="EUR">148500</vnrx:RepaymentOfGrants>
    <vnrx:GrantRepaidByInstallments
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      id="fid_1903">over 10 years</vnrx:GrantRepaidByInstallments>
    <vnrx:TermsOfAgreementDescription
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      id="fid_1889">it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received</vnrx:TermsOfAgreementDescription>
    <vnrx:RoyalityOnRevenuePercentange
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      decimals="INF"
      id="fid_1896"
      unitRef="Pure">0.0289</vnrx:RoyalityOnRevenuePercentange>
    <vnrx:AmountRepayable
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember"
      decimals="0"
      id="fid_1885"
      unitRef="USD">97799</vnrx:AmountRepayable>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1899"
      unitRef="EUR">929433</us-gaap:GrantsReceivableCurrent>
    <vnrx:RepaymentOfGrants
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1892"
      unitRef="EUR">278830</vnrx:RepaymentOfGrants>
    <vnrx:GrantRepaidByInstallments
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      id="fid_1902">over 15 years</vnrx:GrantRepaidByInstallments>
    <vnrx:TermsOfAgreementDescription
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      id="fid_1888">it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of &#x20ac;278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received</vnrx:TermsOfAgreementDescription>
    <vnrx:RoyalityOnRevenuePercentange
      contextRef="From2022-01-01to2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="INF"
      id="fid_1895"
      unitRef="Pure">0.0434</vnrx:RoyalityOnRevenuePercentange>
    <vnrx:AmountRepayable
      contextRef="AsOf2022-12-31_vnrx_WalloonRegionGovernmentMember_vnrx_InTwoThousandsTwentyTwentyMember_us-gaap_AdditionalFundingAgreementTermsMember"
      decimals="0"
      id="fid_1884"
      unitRef="USD">230392</vnrx:AmountRepayable>
    <vnrx:GrantRepyable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1857"
      unitRef="USD">462302</vnrx:GrantRepyable>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_344">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;49,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,541&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;34,581&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,026&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,978&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;263,893&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Grants Repayable &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;462,302&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1797"
      unitRef="USD">49283</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1798"
      unitRef="USD">26541</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1799"
      unitRef="USD">34581</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1800"
      unitRef="USD">42026</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1801"
      unitRef="USD">45978</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven>
    <vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1802"
      unitRef="USD">263893</vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter>
    <vnrx:GrantsRepayable
      contextRef="AsOf2022-12-31_vnrx_GrantsRepayableMember"
      decimals="0"
      id="fid_1803"
      unitRef="USD">462302</vnrx:GrantsRepayable>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1934">P7Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1923"
      unitRef="EUR">440000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1913"
      unitRef="Pure">0.0485</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1904">December 2023</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1940"
      unitRef="USD">82659</us-gaap:OtherLongTermDebt>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1933">P15Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1922"
      unitRef="EUR">270000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1914"
      unitRef="Pure">0.0262</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1905">December 2031</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_INGMember_vnrx_In2016Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1948"
      unitRef="USD">188806</us-gaap:OtherNotesPayable>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1932">P7Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="-6"
      id="fid_1924"
      unitRef="EUR">1000000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1915"
      unitRef="Pure">0.0450</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1908">September 2024</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_In2017Member_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1941"
      unitRef="USD">482954</us-gaap:OtherLongTermDebt>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"
      id="fid_1936">P4Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1925"
      unitRef="EUR">500000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1916"
      unitRef="Pure">0.0400</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"
      id="fid_1907">June 2022</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2022-12-31_vnrx_In2018Member_us-gaap_LongTermDebtMember_vnrx_NamurInnovationAndGrowthMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1946"
      unitRef="USD">0</us-gaap:OtherLongTermDebt>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1935">P4Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1926"
      unitRef="EUR">500000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1917"
      unitRef="Pure">0.0480</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1906">September 2024</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandNineteenMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1942"
      unitRef="USD">279548</us-gaap:OtherLongTermDebt>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1968">P10Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1969"
      unitRef="EUR">830000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1970"
      unitRef="Pure">0.0400</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1971">March 2031</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <vnrx:AgreementUnderAmount
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1973"
      unitRef="EUR">707599</vnrx:AgreementUnderAmount>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_NamurInvestMember_vnrx_InTwoThousandTwentyMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1972"
      unitRef="USD">759419</us-gaap:OtherNotesPayable>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1975"
      unitRef="EUR">450000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1919"
      unitRef="Pure">0.0500</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1910">June 2025</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <vnrx:AgreementUnderAmount
      contextRef="From2022-01-01to2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1950"
      unitRef="EUR">450000</vnrx:AgreementUnderAmount>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_SOFINEXMember_vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1974"
      unitRef="USD">442708</us-gaap:OtherNotesPayable>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"
      id="fid_1938">P9M</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"
      decimals="0"
      id="fid_1928"
      unitRef="USD">620549</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"
      decimals="INF"
      id="fid_1920"
      unitRef="Pure">0.0357</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"
      id="fid_1911">November 2022</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember_vnrx_FirstInsuranceFundingMember"
      decimals="0"
      id="fid_1976"
      unitRef="USD">0</us-gaap:OtherNotesPayable>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1979">P4Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1978"
      unitRef="EUR">1000000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1980"
      unitRef="Pure">0.0600</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1981">July 2026</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <vnrx:AgreementUnderAmount
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1982"
      unitRef="EUR">1000000</vnrx:AgreementUnderAmount>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_SixteenAugustTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1983"
      unitRef="USD">1073231</us-gaap:OtherNotesPayable>
    <vnrx:LoanAgreementTerm
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1986">P4Y</vnrx:LoanAgreementTerm>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1985"
      unitRef="EUR">500000</vnrx:RepaymentsOfLongtermLoans>
    <vnrx:FixedInterestRate
      contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="INF"
      id="fid_1987"
      unitRef="Pure">0.0545</vnrx:FixedInterestRate>
    <vnrx:LineOfCreditFacilityExpirationDatesOne
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      id="fid_1988">December 2027</vnrx:LineOfCreditFacilityExpirationDatesOne>
    <vnrx:AgreementUnderAmount
      contextRef="From2022-01-01to2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1989"
      unitRef="EUR">500000</vnrx:AgreementUnderAmount>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2022-12-31_vnrx_NamurMember_vnrx_EighteenNovemberTwoThounsendTwentyTwoMember_us-gaap_LongTermDebtMember_vnrx_LoanAgreementMember"
      decimals="0"
      id="fid_1990"
      unitRef="USD">536615</us-gaap:OtherNotesPayable>
    <vnrx:LongTermDebtPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1858"
      unitRef="USD">3845940</vnrx:LongTermDebtPayable>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_345">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,268,528&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,138,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;704,312&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;480,358&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;281,602&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Greater than 5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;446,799&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,319,826&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(473,886&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Total Long-Term Debt&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;strong&gt;3,845,940&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1804"
      unitRef="USD">1268528</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1805"
      unitRef="USD">1138227</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1806"
      unitRef="USD">704312</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1807"
      unitRef="USD">480358</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1808"
      unitRef="USD">281602</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturingInYearsFourAndFive
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1809"
      unitRef="USD">446799</us-gaap:LongTermDebtMaturingInYearsFourAndFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1810"
      unitRef="USD">4319826</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <vnrx:LongTermDebtLessAmountRepresentingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1811"
      unitRef="USD">-473886</vnrx:LongTermDebtLessAmountRepresentingInterest>
    <us-gaap:LongTermDebt
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1812"
      unitRef="USD">3845940</us-gaap:LongTermDebt>
    <vnrx:LeaseAgreementExpirePeriod
      contextRef="From2022-01-01to2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember"
      id="fid_1958">P3Y</vnrx:LeaseAgreementExpirePeriod>
    <vnrx:CollaborativeObligationsAmount
      contextRef="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember"
      decimals="-1"
      id="fid_1961"
      unitRef="USD">2550</vnrx:CollaborativeObligationsAmount>
    <vnrx:CollaborativeObligationsAmountDue
      contextRef="AsOf2022-12-31_vnrx_UniversityOfTaiwanMember_vnrx_InTwoThousandsEightteenMember_vnrx_ClinicalStudyResearchAgreementMember"
      decimals="0"
      id="fid_1955"
      unitRef="USD">510000</vnrx:CollaborativeObligationsAmountDue>
    <vnrx:LeaseAgreementExpirePeriods
      contextRef="From2022-01-01to2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember"
      id="fid_1956">5</vnrx:LeaseAgreementExpirePeriods>
    <vnrx:CollaborativeObligationsAmount
      contextRef="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember"
      decimals="0"
      id="fid_1960"
      unitRef="USD">400000</vnrx:CollaborativeObligationsAmount>
    <vnrx:CollaborativeObligationsAmountDue
      contextRef="AsOf2022-12-31_vnrx_InTwoThousandNinteenMember_vnrx_CollaborativeArrangementCoPromotionMember"
      decimals="0"
      id="fid_1953"
      unitRef="USD">0</vnrx:CollaborativeObligationsAmountDue>
    <vnrx:RepaymentsOfLongtermLoans
      contextRef="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"
      decimals="0"
      id="fid_1930"
      unitRef="EUR">54879</vnrx:RepaymentsOfLongtermLoans>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"
      decimals="0"
      id="fid_1947"
      unitRef="USD">100236</us-gaap:OtherLongTermDebt>
    <vnrx:AdditionalCostOfCompany
      contextRef="From2022-01-01to2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"
      decimals="0"
      id="fid_1951"
      unitRef="USD">39000</vnrx:AdditionalCostOfCompany>
    <vnrx:CollaborativeObligationsAmountDue
      contextRef="AsOf2022-12-31_vnrx_OnSeptemberSixteenTwohousandtwentyMember_vnrx_BioinformaticAnalyticsOfCellFreeDNAMember"
      decimals="0"
      id="fid_2024"
      unitRef="USD">23018</vnrx:CollaborativeObligationsAmountDue>
    <vnrx:AdditionalCostOfCompany
      contextRef="From2022-01-01to2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_1952"
      unitRef="USD">346787</vnrx:AdditionalCostOfCompany>
    <vnrx:CollaborativeObligationsAmountDue
      contextRef="AsOf2022-12-31_vnrx_UnivercityOfTexasMDMember_vnrx_AugustTenTwoThousandTwentyTwoMember"
      decimals="0"
      id="fid_2025"
      unitRef="USD">346787</vnrx:CollaborativeObligationsAmountDue>
    <vnrx:PaymentsForFutureResearchAndCollobration
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1855"
      unitRef="USD">879805</vnrx:PaymentsForFutureResearchAndCollobration>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_346">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;798,032&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024 - 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;81,773&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total Collaborative Agreement Obligations&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;879,805&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1813"
      unitRef="USD">798032</vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour>
    <vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1815"
      unitRef="USD">81773</vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive>
    <vnrx:CollaborativeAgreementObligations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1814"
      unitRef="USD">879805</vnrx:CollaborativeAgreementObligations>
    <vnrx:RoyalityOnRevenuePercentange
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="fid_1992"
      unitRef="Pure">0.06</vnrx:RoyalityOnRevenuePercentange>
    <vnrx:AmountPayable
      contextRef="AsOf2022-12-31_vnrx_ManagingDirectorsAgreementMember"
      decimals="0"
      id="fid_1851"
      unitRef="USD">210</vnrx:AmountPayable>
    <vnrx:Royality
      contextRef="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember"
      decimals="INF"
      id="fid_1878"
      unitRef="Pure">0.06</vnrx:Royality>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2022-01-01to2022-12-31_vnrx_ManagingDirectorsAgreementMember"
      decimals="0"
      id="fid_1877"
      unitRef="USD">118055</us-gaap:PaymentsForRoyalties>
    <vnrx:AggerateAmountPayableDescription contextRef="From2020-11-01to2020-11-03" id="fid_1856">under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million</vnrx:AggerateAmountPayableDescription>
    <vnrx:AmountPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1991"
      unitRef="USD">264692</vnrx:AmountPayable>
    <vnrx:PayableByCompanyForServicesRendered
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1854"
      unitRef="USD">3435165</vnrx:PayableByCompanyForServicesRendered>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1868"
      unitRef="USD">737137</us-gaap:SalariesWagesAndOfficersCompensation>
    <vnrx:AccruedCompensationExpense
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_1852"
      unitRef="USD">905856</vnrx:AccruedCompensationExpense>
    <vnrx:RestrictedStockUnit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1993"
      unitRef="Shares">1144000</vnrx:RestrictedStockUnit>
    <us-gaap:DilutiveSecurities
      contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember"
      decimals="0"
      id="fid_1867"
      unitRef="USD">1000000</us-gaap:DilutiveSecurities>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember"
      decimals="0"
      id="fid_1866"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-01to2022-12-31_vnrx_StockIncentivePlanMember"
      decimals="0"
      id="fid_1864"
      unitRef="USD">969593</us-gaap:CostsAndExpenses>
    <vnrx:UnrecognizedCompensationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1859"
      unitRef="USD">270550</vnrx:UnrecognizedCompensationExpense>
    <vnrx:ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets contextRef="From2022-01-01to2022-12-31" id="fid_359">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:24%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:25%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Award&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;969,593&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;580,411&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;389,182&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;630,863&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450,090&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;180,773&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;270,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:24%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:25%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Award&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;822,149 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;493,207&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;328,942 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;530,930 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;379,191 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;151,739 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;228,491 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:32%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Vesting&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:32%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:34%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;Year&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;Un-Amortised&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;134,087 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;417,327 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;65,088 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;470,244 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;46,686 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&#160;520,748 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;245,861 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;&lt;strong&gt;&#160;1,408,319 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</vnrx:ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1816"
      unitRef="USD">969593</us-gaap:WarrantsAndRightsOutstanding>
    <vnrx:AmortisedOfOutstandingAward2022
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1820"
      unitRef="USD">580411</vnrx:AmortisedOfOutstandingAward2022>
    <vnrx:AmortisedOfOutstandingAward2021
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1821"
      unitRef="USD">389182</vnrx:AmortisedOfOutstandingAward2021>
    <vnrx:UnAmortisedOfOutstandingAward2023
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1822"
      unitRef="USD">0</vnrx:UnAmortisedOfOutstandingAward2023>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1823"
      unitRef="USD">630863</us-gaap:WarrantsAndRightsOutstanding>
    <vnrx:AmortisedOfOutstandingAward2022
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1824"
      unitRef="USD">450090</vnrx:AmortisedOfOutstandingAward2022>
    <vnrx:AmortisedOfOutstandingAward2021
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1825"
      unitRef="USD">180773</vnrx:AmortisedOfOutstandingAward2021>
    <vnrx:UnAmortisedOfOutstandingAward2023
      contextRef="From2022-01-01to2022-12-31_us-gaap_StockOptionMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1819"
      unitRef="USD">270550</vnrx:UnAmortisedOfOutstandingAward2023>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member"
      decimals="0"
      id="fid_2076"
      unitRef="USD">822149</us-gaap:ShareBasedCompensation>
    <vnrx:RSuVested
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member"
      decimals="0"
      id="fid_2077"
      unitRef="USD">530930</vnrx:RSuVested>
    <vnrx:UnrecognizedCompensationExpenses
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2023Member"
      decimals="0"
      id="fid_2078"
      unitRef="USD">228491</vnrx:UnrecognizedCompensationExpenses>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1826"
      unitRef="USD">822149</us-gaap:WarrantsAndRightsOutstanding>
    <vnrx:AmortisedOfOutstandingAward2022
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1828"
      unitRef="USD">493207</vnrx:AmortisedOfOutstandingAward2022>
    <vnrx:AmortisedOfOutstandingAward2021
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1829"
      unitRef="USD">328942</vnrx:AmortisedOfOutstandingAward2021>
    <vnrx:UnAmortisedOfOutstandingAward2023
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1830"
      unitRef="USD">0</vnrx:UnAmortisedOfOutstandingAward2023>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1831"
      unitRef="USD">530930</us-gaap:WarrantsAndRightsOutstanding>
    <vnrx:AmortisedOfOutstandingAward2022
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1832"
      unitRef="USD">379191</vnrx:AmortisedOfOutstandingAward2022>
    <vnrx:AmortisedOfOutstandingAward2021
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1833"
      unitRef="USD">151739</vnrx:AmortisedOfOutstandingAward2021>
    <vnrx:UnAmortisedOfOutstandingAward2023
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1827"
      unitRef="USD">228491</vnrx:UnAmortisedOfOutstandingAward2023>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"
      decimals="0"
      id="fid_2084"
      unitRef="USD">245861</us-gaap:ShareBasedCompensation>
    <vnrx:RSuVested
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"
      decimals="0"
      id="fid_2081"
      unitRef="USD">134087</vnrx:RSuVested>
    <vnrx:RSuVestedIn2024
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"
      decimals="0"
      id="fid_2082"
      unitRef="USD">65088</vnrx:RSuVestedIn2024>
    <vnrx:RSuVestedIn2025
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"
      decimals="0"
      id="fid_2083"
      unitRef="USD">46686</vnrx:RSuVestedIn2025>
    <vnrx:UnrecognizedCompensationExpenses
      contextRef="From2022-01-01to2022-12-31_vnrx_PerformanceBasedAwardMember_vnrx_VestIn2024Member"
      decimals="0"
      id="fid_2079"
      unitRef="USD">1408319</vnrx:UnrecognizedCompensationExpenses>
    <vnrx:OutstandingAwardVestingPeriod
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      id="fid_1835">2023</vnrx:OutstandingAwardVestingPeriod>
    <vnrx:AmortisedOfOutstandingAwardAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1837"
      unitRef="USD">134087</vnrx:AmortisedOfOutstandingAwardAmount>
    <vnrx:UnAmortisedOfOutstandingAward
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember"
      decimals="0"
      id="fid_1839"
      unitRef="USD">417327</vnrx:UnAmortisedOfOutstandingAward>
    <vnrx:OutstandingAward
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      id="fid_1840">2024</vnrx:OutstandingAward>
    <vnrx:AmortisedOfOutstandingAwardAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1841"
      unitRef="USD">65088</vnrx:AmortisedOfOutstandingAwardAmount>
    <vnrx:UnAmortisedOfOutstandingAward
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardTwoMember"
      decimals="0"
      id="fid_1836"
      unitRef="USD">470244</vnrx:UnAmortisedOfOutstandingAward>
    <vnrx:OutstandingAward
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember"
      id="fid_1843">2025</vnrx:OutstandingAward>
    <vnrx:AmortisedOfOutstandingAwardAmount
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember"
      decimals="0"
      id="fid_1844"
      unitRef="USD">46686</vnrx:AmortisedOfOutstandingAwardAmount>
    <vnrx:UnAmortisedOfOutstandingAward
      contextRef="From2022-01-01to2022-12-31_us-gaap_RestrictedStockMember_vnrx_OutstandingAwardThreeMember"
      decimals="0"
      id="fid_1845"
      unitRef="USD">520748</vnrx:UnAmortisedOfOutstandingAward>
    <vnrx:AmortisedOfOutstandingAwardAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1847"
      unitRef="USD">245861</vnrx:AmortisedOfOutstandingAwardAmount>
    <vnrx:UnAmortisedOfOutstandingAward
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="fid_1848"
      unitRef="USD">1408319</vnrx:UnAmortisedOfOutstandingAward>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31" id="fid_304">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Note 11 - Subsequent Events&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Common Stock Issuances and Repurchases&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;From January 1 to January 19, 2023, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $656,000 under the 2022 EDA through the sale of 279,703 shares of its common stock.&#160; No additional shares have been sold under the 2022 EDA through March 8, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January&#160;5, 2023, the Company purchased from a former officer 13,264 shares of its common stock at $2.39 per share, for a total cost to the Company of $31,772.66.&#160; These shares were subsequently retired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;RSU Vesting&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals established by the Compensation Committee on October 4, 2022, which resulted in the vesting of rights with respect to an aggregate of 424,875 RSUs.&#160; The RSUs are further subject to a 3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively, and conditioned upon the recipient&#x2019;s continued service through the applicable vesting date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February 8, 2023, 4,000 RSUs previously granted to an employee vested and resulted in the issuance of 2,369 shares of common stock and the remaining 1,631 shares of common stock were withheld as taxes and returned to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On March 1, 2023, 15,000 RSUs previously granted to employees vested and resulted in the issuance of 9,609 shares of common stock. An aggregate of 5,391 shares of common stock were withheld as taxes and returned to the 2015 Plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Capital Raise&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February&#160;17, 2023, the Company entered into an underwriting agreement with Newbridge in connection with an underwritten public offering of&#160;4,945,000&#160;shares of the Company&#x2019;s common stock, which includes Newbridge&#x2019;s exercise in full of its overallotment option, pursuant to the Company&#x2019;s 2021 Form S-3. Newbridge purchased the shares from the Company at a price of $1.6275 per share.&#160; The offering closed on February 22, 2023. &#160;The Company received net proceeds of approximately $8.0 million from the offering before deducting offering expenses payable by the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;Commercial Product Launches&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 12, 2023, the Company announced the availability of its Nu.Q&#xae; Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February 16, 2023, the Company announced that its Nu.Q&#xae; Vet Cancer Test was available for pre-order to veterinarians at the point of care through Heska.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember"
      decimals="0"
      id="fid_2016"
      unitRef="USD">656000</us-gaap:Revenues>
    <vnrx:SaleOfCommonStock
      contextRef="From2023-01-01to2023-01-19_vnrx_CommonStockIssuancesAndRepurchasesMember"
      decimals="0"
      id="fid_2019"
      unitRef="USD">279703</vnrx:SaleOfCommonStock>
    <vnrx:CommonStockSharePurchase
      contextRef="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember"
      decimals="0"
      id="fid_2020"
      unitRef="Shares">13264</vnrx:CommonStockSharePurchase>
    <vnrx:CommonStockPerShare
      contextRef="AsOf2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember"
      decimals="INF"
      id="fid_2021"
      unitRef="USDPShares">2.39</vnrx:CommonStockPerShare>
    <vnrx:CostOfTheCompany
      contextRef="From2023-01-01to2023-01-05_vnrx_CommonStockIssuancesAndRepurchasesMember"
      decimals="0"
      id="fid_2022"
      unitRef="USD">31772</vnrx:CostOfTheCompany>
    <vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
      contextRef="AsOf2023-01-12_vnrx_RsuVestingEventMember"
      decimals="0"
      id="fid_2012"
      unitRef="Shares">424875</vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested>
    <vnrx:RsuVestingDescription
      contextRef="From2023-01-01to2023-01-12_vnrx_RsuVestingEventMember"
      id="fid_2015">3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025</vnrx:RsuVestingDescription>
    <vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
      contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2002"
      unitRef="Shares">4000</vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2007"
      unitRef="Shares">2369</us-gaap:CommonStockSharesIssued>
    <vnrx:CommonStockSharesWithheldForTaxes
      contextRef="AsOf2023-02-08_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2010"
      unitRef="Shares">1631</vnrx:CommonStockSharesWithheldForTaxes>
    <vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
      contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2001"
      unitRef="Shares">15000</vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2006"
      unitRef="Shares">9609</us-gaap:CommonStockSharesIssued>
    <vnrx:CommonStockSharesWithheldForTaxes
      contextRef="AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember"
      decimals="0"
      id="fid_2009"
      unitRef="Shares">5391</vnrx:CommonStockSharesWithheldForTaxes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember"
      decimals="0"
      id="fid_1994"
      unitRef="Shares">4945000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-02-17_vnrx_CapitalRaiseMember"
      decimals="INF"
      id="fid_1995"
      unitRef="USDPShares">1.6275</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-02-01to2023-02-17_vnrx_CapitalRaiseMember"
      decimals="-5"
      id="fid_1996"
      unitRef="USD">8000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&P/X^U(I_71A7BSM7B0N_@=02P,$%     @ .8)O5OR]C EN @  )0<  !@
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM55UOTS 4_2M60 BD4>>C249)
M(VV=$'M 5*L8SVYRVUAS[& [[>#78SM9U(X,6HD^-+[V/>>>X\37V5[(!U4!
M:/18,Z[F7J5U,\-8%1741$U$ ]RL;(2LB3:AW&+52""E ]4,A[Z?X)I0[N69
MFUO*/!.M9I3#4B+5UC61/Z^!B?W<"[RGB3NZK;2=P'G6D"VL0']KEM)$>& I
M:0U<4<&1A,W<NPIFB\3FNX1["GMU,$;6R5J(!QO<EG//MX* 0:$M S&/'2R
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MGV9#VG<?3J2A=9PU?0"E43H\9KI$<:2;0!"/3)"X)U/L)].N@N[TKGM84<'
M&;BFLLB: ?BF*#>F>$Y17RV0Y- +>!X.*6Y$;*SA]2R,8V]=_6CNZ#3.MUL]
M@BY9ZZP$7S=**NWJR)"/O=S^RY5U(FO',>AY'OMYWI%9I\\V@X<A"6$ K3IR
M2.JI)4R281^<'MPZ5DPLF\M8"3*^J55[;=>][2Y\WS;7G(/WU^ABWE[;]F;:
M6^3/5"R+6H*2+;1)>!YK6**]F&T?%%\W=YN/7"E>-3]7C.K]:@3T_PO.U?[!
M+-!=C\_^!U!+ P04    "  Y@F]61U](Z$0'  "4+   &    'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;+5:T9*;-A3]%8W;Z:0S<8P$2)#N[DSB!9J9-LUD
MDW;Z2+"\9@+( 7DW^?M*V&L;219VHN8A:^QSSQ5']\HZ,E>/K/W<K2CEX&M=
M-=WU9,7Y^N5LUA4K6N?="[:FC?ADR=HZY^*RO9]UZY;FBSZHKF;(\_"LSLMF
M<G/5O_>NO;EB&UZ5#7W7@FY3UWG[[36MV./U!$Z>WGA?WJ^X?&-V<[7.[^D=
MY1_7[UIQ-=NS+,J:-EW)&M#2Y?7D%7R9(2P#>L3?)7WLCEX#>2N?&/LL+]XL
MKB>>'!&M:,$E12[^/- YK2K)),;Q94<ZV>>4@<>OG]C3_N;%S7S*.SIGU3_E
M@J^N)]$$+.@RWU3\/7O\G>YN*)1\!:NZ_G_PN,5B,@'%IN.LW@6+$=1EL_V;
M?]T)<10 _1,!:!> S@WP=P&^$H!.#2G8!01*0(!/!(2[@% -\$X$X%T 5H<4
MG @@NP#23]96W7YJ;G.>WURU[!&T$BW8Y(M^?OMH,2-E(TOQCK?BTU+$\9LY
M:SI6E8N<TP6XX^*/J#,.V%)<L.+SBE4+VG8@^;(I^3?P[)8NRZ+DOX(I^'AW
M"Y[]_.O5C(MA2+)9L4OY>IL2G4CY@?&\,H3-[6%S5M>B=CLY+$/TK3WZU6)1
MRMK/*_ N+Q?3L@'S?%V:1Y*,<!7%IMY4O61_\15M@1B;6 A6LD,?*'C3%*RF
MX-D?K.M,^J1V^O>4BR5$<"=YVY3-?0>>'6=\F@(#<68G?LO$P!K>LDI\<B^&
MR6E+.SXDFHD"VE<1VE<1ZIF#$\RO\RIO"OH<=*M<4(*<BV$6+X /GP/D(<]4
M)%9&N0*_[-9Y0:\G0MF.M@]T<O/+3Q![OYE*9TL6]F1R]7VX"2+L$0^2J]G#
M<96XS)JX)$M=DF6.R ;%X.^+P3^O&/*:;<1:<DXQ;!GQT?Q!C&*?P&@X?W,=
MV$^T,LL&.H1#A)$?#Y&)CIR&<4R4M*D!!J&H+C\F< C-#-" 0')(/! UV(L:
M6$4]7OU V74;L1*(C0@H\FY5T:X#]"MMB[*C<NG>HMA:+GC=4U.:9+?FO+0'
M ZT'"0E"19Y;ERD3EV2I2[+,$=F@5L)]K83_6ZUL>]94*Z$VO9[2FZ%6^41M
M3)UDJF*2T43I*"*S(0::XKVF^+LT[2CGU7[/]/[NH[7?K#DN[3>LW2,2"PU2
M%'>9,G%)EKHDRQR1#6J#[&N#.*N-T_U%1ON+:/V%0F6V=9*IBDE&$Z6CB,R&
M&&@8[36,+M90[-'7FT]560CYEK256^'GH*'<UF'6+)=V6*3=9>AAWXO4[S27
M21.79*E+LLP1V: ^XGU]Q [KXW27Q?JBZ2,8XR!0FBW6FDW.O3+Q9K8@5"LD
MT8%JSXTB,AMBH"GT#N;?LZKZ(?\*'DN^DC:_=YIKX8U!2[=.D[.MWE-YUK,
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M77;?2G076FS;SPV>A-:B;H<;S@HNC0#\OA*P'H<+\X#^BY7E_P%02P,$%
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M)<<"N%]9?"2[#1L89N#YOU!+ P04    "  Y@F]6:40;+",%  #!"P  &
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*U6VW(4-Q#]E:XE1=E59F\VAN!+
ME0T)H2JD7#@DSQJI9T=!(PV2QO;R]3FMF5U? /.0O.R.+MTZY_1%.KX.\5-J
MF#/=M,ZGDTF3<_=J-DNZX5:E:>C88Z4.L549P[B:I2ZR,L6H=;/E?'XX:Y7U
MD]/C,G<13X]#GYWU?!$I]6VKXOJ<7;@^F2PFFXD/=M5DF9B='G=JQ9></W87
M$:/9UHNQ+?MD@Z?(]<GD;/'J_$#VEPU_6;Y.=[Y)F%0A?)+!.W,RF0L@=JRS
M>%#XN^+7[)PX HS/H\_)]D@QO/N]\?YKX0XNE4K\.KB_K<G-R>3EA S7JG?Y
M0[C^C4<^S\6?#BZ57[H>]N[_/"'=IQS:T1@(6NN'?W4SZG#'X.7\.P;+T6!9
M< \'%91O5%:GQS%<4Y3=\"8?A6JQ!CCK)2B7.6+5PBZ?_FX_]];8O";E#;T-
MUJ_H=?":HZ>SE#@E1" ?SS+.$HN9'OV>#WZ7W_&[6-+[X'.3Z!=OV-QW, /(
M+=+E!NGY\E&/;UA/:7^Q1\OY<OF(O_TM\_WB;_]_9S[X/?BV7ZFB5ZE3FD\F
M*)/$\8HGIT^?+ [G1X^@/MBB/GC,^W] _;C?/P)EIB4]??)RN5@<T<-SZ-L'
MT9\-8[KME%\7TQ='B73P*3AK5&9#M?7*:ZL<I8P),4JD(A/$Z?!OJ$_B6VD=
M>I_ELXL6%IWC1"OV')5S:UGG3AQ:3QF'?O161I?B-%&HZ:SE:+6B'<&QG!]]
MG%Y.Z>W9V449+XYV]TAUG<.6RC'E0(I613X]LKINK&YD!)2=*V[E(+0Z9[^H
MTD-PC )W80!57-%HN^*LJJRSV<)P!.FE<3CX[&-BV5,)66@WO2L<-4HL=!]%
M#A=$7<(^S3(+UN,!/RT.7TSWT06<P\Q>,?.\4M+72*O44(T>FZB.H26T[5B@
MI;T"5C:C?UC!$_F*?<]8&3F#H]!-?84@(0C88T)?95(5&CE9(5RXK44XD<C"
M'EI\)2*N"<SA;!L,J4R.5<H4/-.:51R@B3*2',+)IM0K88IOS$.E'V;/H%W=
MYSYNS+9*"B*_X0Y8&[W151TX,>XR S0/&84JX_X"_[JVVDI>:]797$+G<[15
M/RHYXI%\]68&KD."9MYJ*A!:M:9*II ?$E*<D-#*Y0@Y^#8T4WJO/.Z^4DK(
M.9]*8AH3!;,00P"NBM">&7V4JO4>[:A=2HQT*3@,JA2^@'45$3L(XPV0[E2[
M(ZT'NVXIY":&?M5 %D0:7 2NZ $W295+,QW1CMX='(L%J@?W,:<->V/35AV*
M<@$6 KFQT1"J>U,+?*,;Y5=<TB-UK&UMI?*[9T@(8![=54I_>B81ZM2ZA'I(
MW1VS"XQ7>$!TH_((2XMRE\2P7V1.9.UB,+T6?;TD@30,5V*# . =(1WOGMZ;
M-"Z0^4;<(?VRL,!:&C9$W*]CSI=67NILR,!-_CQ(P1\4B$UC&@J$OOLZ%U,/
MX"G5_=CUX-99U+:<,:2(X:2A^FTO1"O5;$KK5%$A6EU35!)>R,K<#QTTEPR$
M3#526YK@W40LC,II(#$"_D$7-P$-+DN/<KV!M=2?^0>)/BSG!O7?%CE1#)Z%
M%=Y]9._K!4%ZO^G)CR@WI7>/&(X5K R26,IQK-\]J"OMUQG!@.S30SEJM*5[
M_+]U-<_N/*N0;:OR>)3K#??4\,+:SF[?IV?#L^QV^_"X?:_BRB)TCFN8SJ<O
MGD^&>MD,<NC*(ZT*&4^^\MG@C<U1-F"]#B%O!G+ ]M5^^B]02P,$%     @
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M_$#R3_Y#9S?\N##Y^L0O_.>*;)]N,(!^7UC;^0_8(+PV_?S_ %!+ P04
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M&P1POS68_MTD&-CWF(N_ 5!+ P04    "  Y@F]6B U /A,$  !;"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RM5FUOXC@0_BNC;+6?4D@"H= %
M)$KO="O=KJIVK_?9)!-BU;&SME/*_OH;.R%0T58GW:EJB.V99Y[QO&6^4_K)
ME(@67BHAS2(HK:VOAT.3E5@Q,U U2CHIE*Z8I:7>#DVMD>5>J1+#)(HFPXIQ
M&2SG?N].+^>JL8)+O--@FJIB>G^#0NT601P<-N[YMK1N8[B<UVR+#VC_JN\T
MK88]2LXKE(8K"1J+1;"*KV_&3MX+/'+<F9-W<)YLE'IRBZ_Y(H@<(12868?
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MK3^N&(67%0&^7S0X*=@')6#XKXG3_P)02P,$%     @ .8)O5GO&H>'>%P
MZEX  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL[3QI;]RXDG^%\/@]
MV( B2Z+.F21 ,M?.PR833.; ?I2[V=UZ44L].NSX_?JM@Y2H;MEN)_8@LUC
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M!C-16]8- P+EE83>$"P%J&!08XT04M_ZQM:D%/K(@@+B_R^GFF"^NH?MB]7
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MZ7*C<C";L ,\7]5@X.@;G&#XO/W+_P502P,$%     @ .8)O5G6"W-//!
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M^!D%UBFPP+L]*+"\Y([/3HS>@/'2B.8'P=2@C>2D\D&Y=09W)>JYV2=5Z%K
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M:RD<6YR+@ZH1\9EXI;(X2Z1X(^$'XFJ:JD5,OE6)GS/8QPDM42\ET2GB[%:
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MG-U12VJL&<OW[.BT'%J1YQQ5I?^5#A;:7*8?[5Y.Y%@!,MAQ[C7P+C1&&MT
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MA3J_B<M9-;1?I[%^3\N<\^OVJ/IC0]RVH[VQ@V#@P9? (G2YUL5[.SQX$RL
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MF7B#W).*]V6>2$DN6)$Y*=GB_RR'1>CK8O"U5L$0=%,@1=))$\8TZX.6?B$
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MOAQ3RYRSH+#DO]K)_\"VLXMG?M<Z<6$AR& D> T<&N6-B<I!TJ/R:%N5!OF
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M=^>3,[]D6SKSH*NZB3P%3E\M=FAF.K$B\S#I"N"TB)\:/,%1PB6P_U\.P,;
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M/@"_+XUIW ?<P/__&;S\7U!+ P04    "  Y@F]6AKW8C90#   S"   &0
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MPB9^X&-UN^CTP/3\=%/>JBO5?=Y<-NA->RWS:J76;56O2:-NSB87[/D+)K2
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MSE6C'\#]FQKYW77T!/U?69S_#U!+ P04    "  Y@F]6/L(U'%D$  "N"0
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M Y%84S\,^LX)<7]('Q=T.!%T$HNL6".]I]9%\)VH-N_)QD,,K]KX!?T!_25
M]PO='G5;WH1C"R*T&RU65W?.'^0NY:K ZIZ%<=]6R/\$@)S"+<?(?>XEY;DS
M_+K062GU5B',*KFU?>=E?$YF<8_*J3#$R;F:4BQAP8"S49J\)K\WDU(\#6,6
MQX/6$U1Y5!'[@O@O<.\5J3W<O@JHPS=N><4'AQP\U;+]HSNT0K5R+P6J5>N3
MYCKM5KO'R*RY@P_BS4OFJU"KHM90XI)4*<B)!ZIY'303(S?N1EY(0_>[&Z[I
M087*"M#^4DJSG]@#NB?:]!]02P,$%     @ .8)O5AJ?(0 '!0  =0X  !D
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M C8':03P]X7 7&ENS +MD?'H/U!+ P04    "  Y@F]6Q*5)HXH%   2'@
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M8:C3 BJF1[(&@6]RJ2IF<*BVH:X5L,R!JC*,HV@65HR+(%FXN0>5+.3.E%S
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M'@62RSRGXOV.97P]=GQG<^$IG<V5N>!.1@LZ8\],?5T\"GWF-BI)FK-"IKQ
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M:;N';(,&W1X6>Z"EL2U$$K4D;:?_?DE*EF6]DB YQ!0UCV_(X0PU.U+VR'<
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MGA1OURQ<,I'OH/Z_XES6&WF#9A'6_#]02P,$%     @ .8)O5FWE;' Q P
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M.KJ8=-U?.Z6(ZQT7SV#H-P [K$[2."%TG=<WO7,QXZZWC"J1_N@E8[=9$/1
M'GV.W,OJ"%&0G7QN.S >1,T+>3#S3]/HP<.O>/CB,WR[>BJQZ 35"9JH;:N.
MQVT??>-SX&O3^@@4LRV5Y1>R7JW;JQO35#369[KM,KW#JTS9L]T1KFI,H Q6
M2M(9A*J>>=D&E1/)"M-)+)E4?8D9;E3K"%P;J/T58_(PT0'J9G3Z#U!+ P04
M    "  Y@F]6]^*M5TH)   =2@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6RU7&MOXS86_2N"NRA:H!N+%/7P- DPR4RP+9 V&,]T/RSZ0;&9Q!A;
M<B4YF?GW*\FRKQA1]U*,C $F?O >\9#R/4?DE<Y?TNQK_B1EX7S;K)/\8O)4
M%-MWTVF^>)*;.#]+MS(IOWE(LTU<E&^SQVF^S62\K(,VZREWW6"ZB5?)Y/*\
M_NPNNSQ/=\5ZE<B[S,EWFTV<?;^2Z_3E8L(FAP\^K1Z?BNJ#Z>7Y-GZ4<UE\
MV=YEY;OI$66YVL@D7Z6)D\F'B\E[]NXZ"JJ NL5?*_F2MUX[%97[-/U:O?EM
M>3%QJQ[)M5P4%41<_GF6UW*]KI#*?OS3@$Z.QZP"VZ\/Z#<U^9+,?9S+ZW3]
MW]6R>+J81!-G*1_BW;KXE+[\1S:$_ IOD:[S^G_G9=]6!!-GL<N+=-,$ESW8
MK)+]W_A;,Q"M -87P)L ;AK@-0%>373?LYK6A[B(+\^S],7)JM8E6O6B'ILZ
MNF2S2JIIG!=9^>VJC"LNYT6Z^'I5CL/2N4XWY<F1Q_7P_O1!%O%JG3O!S\Z_
MG2_S#\Y/__KY?%J4AZP"IXL&_FH/SWO@&7=NTZ1XRIV/R5(N58!IV==CA_FA
MPU<<1?P@%V>.QWYQN,NYID/7YN$,Z8YW'#^OQA,]>,J@??Q6O9;.I_F77#=6
M>RB_AJI^7\^7+)IQYI8\GML4NNW":.:[[K&9TE5Q[*I NUKVZM!#7>?VP4'K
MH#ST_4AXKSJG:1=P(:) WSO_V#M_^$#^439R_G<K-_<R^UO7:12S2H'O\FV\
MD!>3,L?E,GN6D\L??V"!^ZONS!D)3*$?'.D'XYU'0>?\$.79T3H_]GS0(UKR
M"8]\0I3/QW]VJ^*[\UNRD$F5J)V[=9SHN. PW&6^;JK0*$MJT9%:-'RJ'K,X
M*9QE7&A_6SC@GXOBS'%<\8O3F]10 $N^LR/?V7"^?\F\6"6/SIW,5NE2QQD'
M_;)UBM01!WG0<48!+#DS%W31?4NV;*+;:= K,WD8O?H-XD>Q9=%2=S9\[C[+
M!$VJ..;0K#H6FCH"'$: CY=8&ZQV9O6Z>14_HBTC<!P,MQS&J97 Z<NM>)@M
M/7 I#+<I%NF50/PC?3YS^ Q)KSB +66P/LS"^] 9ED#U B2YXK&VC,'M,-SN
MW*RRO#A2[)U7'$295T_+\A06B($'8KA[F<M%FBR=9XHFCJ+0%%J:I[!##/P0
MP_W+YZ=59L 2!U%8ZO/2*4P0 Q?$<,="&8)9QQ $I2M_+1VG,#4<3 W'38TV
MT?Q)7&/AF$/MP%AHZ@B (>(6AJC/#C18;3L0=>V II7O]EVL<S N'#<NQC)/
MX/3)_. PE0?8%6ZQ0H+K.8%X(^^KZZ4($70"X?<XJ1#8'@%;!^+@6[B%;Z%%
MG$#E A%Q/-;VMP2VA>,&PTS$*1!E,K4J3B ,F$SP)QRW%H;*3:"HW+32C2/8
M3B$X%(Y["T+4FFAEL8\'HI,!N\W8K"U^:N_ 6'"+E9;/+RDN5R/9A(;:*4P'
M!]/!+=9>>N5JIKUZ[<P6U4Q=" =SX>'FPEBP")P^P1H<IO( B^!96 1<L C$
MVSAK92BM8)D@<)].<1[X"\]B8836*P(5U2N[6)5?:V.&< E&ZD2 J#.G52<3
MA,/,<8P9. T/]P2&XD2@J-2TXF2"<*#F8=3 4GBXEA-ZU$2WA2827B?#:9HQ
M-PQ[4QS8 L]BE^;S4R;Q*R@<=:@DC86FC@%8!@^W#,-V/,.NUO"N)&F:,1_1
M)' 0'NX@S#4)Q^G5I*%A*@_P 9Z%#R T"4=\O\VH32<"X3;^;F:[!5@(8;$^
M06L2@8IJ$A';LXBJ\@-K(7 9-],D D2=.:TF$0C*S&&:),!-"%R[#36)0%&I
M:36)0%"H89HDP$@(7,'-EC=QD*$YGNB2PE)@+%O%(6^K#NF6?<R$Z"1R33,Q
M"_I+5\ 8"(LMDIMTEZ'"BX,.GI13[)D(,!]BQ!(1T:T18:[H*J^FG0A<-F,]
M$P8V08Q4 $+@]"GOX#"5!S@(,7JU!X%HH+P4PNZQ0O ,I!<<ACA)E0>!BNY!
M$K$FEX,^6 L?%W(SZ25 #*270E"F#M->'UR%C\NYH?82* ;:2R$HW##Q]<%7
M^+B>FXDO :)2TZ83',$RM_O@,7Q<T GU;:*5:B,WB#K97-..^=PK__449X(]
M\"UV-VZJO(Z69XZT0=&P.\5VA]\J4+6P('WZVV I%[Z:4B)=LZCWNM<'K^#C
M7L%8?0F</O4='*;R !?A6RPVX.I+(/Z^2ZBU6 )A+K<50DBKKP\NP[=P&;3Z
M$JCHA:]=K,H/W(6/:[FA^N(@ZM3IU1='4*<.4]\ C$6 *[JA^A(H*C>M^I+]
M:'/#U#< 9Q'@BD[(4A.M+,>Z4:?H1=.,\:#,R_HL%X Y""RV,.:K;Z@FX9A#
M-6DL-'4$P#<$(]Y^$G3O*PF\[MTGFF;>+')G/;,%%B+ +82Q)A$X?9HT.$SE
M 3X@L/ !N"81B+5Q9OH]HH8;#J#>08!)4M"Z(<5BN8&6) (5E22[6)4?6(L
MEW$S22) E)G3*A(!@-[[H3(#,Q'@TFVJ2 :+# =J>D$:<EL+*DC@(X(W%6$&
MW2+,4FDBSW^=XG3MF,MZ<EP(9B"TV,"8RV?BC@L<=:@FC86FC@&8AG#$$LNP
M6SS)_>YUDJ:9\'J7E4-P$.%(198$3N]]:F\JL@S!!X2C%UD2B+6=Y-AE$@%0
M%W0;[0^&8"%"BU4(6I,(5%23[&)5?F MPC$J*@D09>:TFD0 J#.':5((;B(<
MI:"21&E1TVH2 :!2PS0I;-WI^J8:RK!;'"DX[UPD:9HQO]0NOR?%@1L(+986
M/E9/-\ E:=0RRK'0U#$ VQ".6$89=NLC&1.:O3--0^[U+MY%8"*BD0HI"9P^
M41H<IO( (Q"-7DA)()K<*8TCU,]_8 :%E!%XB.@DA90$*KIS1L2:B%($WB(:
MHY"2 $$O!AI2.((R<Y@H16 G(ER\#46)0%&I:56)0%"H8:(4@9.(< TWVS<C
M0%1F^EQRBIJ("&Q%A.LYH;U-M"*J05A.TNM4KFD8AJ%XG<JGK0?M;&3V6#]_
M*'<6Z2XI]H^P.7YZ?,;1^_K)/J\^OV+OKO=/*@*8_8.3;N/L<97DSEH^E)#N
M6>75LOVSB/9OBG1;/\[G/BV*=%._?)+Q4F95@_+[AS0M#F^J QR?"'7Y?U!+
M P04    "  Y@F]60BH@OET&  #]+0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6RU6MENVT84_96!6A0)D)J<A:+DR@*\)(@#N#&B)'TH^D!+8XL(
M%X4<2?;?EYLY7"^7C%YLD9I[YMPA=>XA[RR.?O CW'(NT+/K>.'%9"O$[ES3
MPO66NU9XYN^X%WWSZ >N):+#X$D+=P&W-DF0ZVA$UZ>::]G>9+E(SMT'RX6_
M%X[M\?L A7O7M8*7*^[XQXL)GKR>^&(_;45\0ELN=M837W'Q;7<?1$=:CK*Q
M7>Z%MN^A@#]>3"[Q^;5!XX!DQ'>;'\/"9Q2G\N#[/^*#V\W%1(\9<8>O10QA
M1?\._)H[3HP4\?B9@4[R.>/ XN=7] ])\E$R#U;(KWWG'WLCMA>3V01M^*.U
M=\07__B19PD9,=[:=\+D+SJF8]ET@M;[4/AN%APQ<&TO_6\]9PM1",!M 20+
M('T#:!:0K)R6,DO2NK&$M5P$_A$%\>@(+?Z0K$T2'65C>_%E7(D@^M:.XL1R
M)?SUCZMH'3;HVG>CFR.TDN5]<\.%93LA,M^B/]&WU0UZ\_O;A2:B*>- ;9W!
M7Z7PI 4>$W3G>V(;HO?>AF_* %K$-2=,7@E?$1#QAJ_/$,7O$-$):2!TW3\<
M W1HOGXTP6,M>.]_[FWQ@FZ]-??B&Q)]67UK6J84Q4A0XI_684E-4]?-A78H
MDF\8AHFAYZ-*'%G.D8$<2^30;1CNJU<BY<AJDY.Y26;S"L>&8<S$I)FCD7,T
M0(X1LQ!]Y,X&1=*$OEK//&RBF(),"W.;<Q//*@SKHZ8&G343G.8$I\,N]+UC
M>>BSQ]&_=]Q]X,%_37Q!S%BBS\.=M>87DTB#0QX<^&3YQV]XJO_5=&<K BNE
M;^;IFSWOH3COIE3A>*)CHRFGH5$E\K.<_$S)CW16N[.QH>MZY>ZJCRH-*C&<
MYPSG/9?W.P\%BJ2<-Q&$0>ZLX P1XQUJU48X_I/EG2&DXQ0 4D>LR_*B*]&>
M#*9K[1N&T=;%QX4BB%6H3X92%)8:P?H0TDZ02()DA/I\/?J@^L"@0^5'%5IY
M"62AQ7"E[5:@#H V"1H<5DY 5F$,E^&^*H0;"NRT: (RVEW#RC1E(<9P)>XI
M11THE[M(BS %M&@( *A%LH)CN(3WUJ)I?65QT>%D"70-*].4E1;#1:^O&)DU
MI6%%EY.1[!A5YB@+*AY845,]V@8<]D,P[&!%4H167@19LW'?HMVJ2#! JR*!
M82/S(K)F$[AF]Q4J4B_&<<FN"A4\V]AL9&TG<&WOJ6<=*'?6B[1&S<^=(,#8
M-*5#(+!#Z"MN&4S)0348+7BVL=G(8D_@HMM3 S.4HKHUN49XLK')R,)/!A;^
M1"P_^/L U$H8=:A6JD(KKX%T%:2OJVC3R@Z -JV$P\;F)3T%&?A:H$TK&\P"
MU;%>-17P=&/3D=Z#]'W,A\421KG</\4/DI#[@Q'&YBG]"X']2V^U;'@E,,?S
M>>VRG<*)$.E$"&PD^LKEO":7=(9Q32Y/83^HM!]TH/U(Y3+^!,DEC#I4+E6A
ME== FA;:U[2TR64'0)M<PF%C\Y(NA0Y\C]'VNKSN4C"I%W9XMK'9%-[]]WTE
M :IE!\J*[V*U- &UA!'&YBD-#%730*#U5Q*F7GLDA2<;FXQT(E1)IX'6FPAL
M/JWJ/CS7V%RD^Z!CFA(K^QE62J5="55HY260CH7^:F.B Z!5*4_A4*AT*%1-
MSX(V.92Y;E1OU%,8%"H-"E72W^A ^;P6L5(R2"E/X5V8]"Y,3;N#-;0[:))2
MN=5Z"A?"I MA2MHBK-[SF,YFM)K+*9P'D\Z#C>F@K/B!>Z!8PK!#Q5(56GD1
MI&%AO]I#Z0!H$TLX;&Q>A0T.:EHKK*%G@LU::P6>;6PVTJ$P)1V8#I2__<-9
MQRM+&&%LGM*],#7]&%9_=X()9:QZU4YA1)@T(DQ)VX;5&S)SID^KN9S"?#!I
M/MB8]L[[>$L<+)9*VSNJT,J+(#T+^]7V3@= JUB>PJ,8TJ,8:MH[1MVC-#R"
MPY.-349:%$-)=Z<#)=D5B*&=,S# V#2E>S'4='>,AO<F>(:KU^P4+L20+L10
MTMPQZLV=&:YN1H2G&IJ*5MA(Z_+@*=E?'**UO_=$ND4U/YOO8;Y,=NY6SE_A
M\^MT)[*$23=&WUG!D^V%R.&/$:1^9D;7*DCW&J<'PM\EVW4??"%\-_FXY=:&
M!_& Z/M'WQ>O!_$$^8[OY?]02P,$%     @ .8)O5O_Z)3X)!   O!8  !D
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MO"OD*% %[20K[O+PS064,80%!3ZAHP@+VA06<RWB:*WH-)RJH$U5H1!'-2%
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M^O)(E1LGNV;H7'U4"]I>6RVOFK!E.KG7.Y\P0A<OOKYX]92K:F*JN";V0[?
M*:;RDM\7J]U*>%<<\:P[IQ]:&D,U#=5T5#-0S40U"]5L5'-0S44U#]5FJ.:C
M6H!J(:I%J!936OV-H&J@J>(&&G*XBW;44&V*:AJJZ:AFH)J):A:JV:CFH)J+
M:AZJS5#-5\^?]#EL.R0.6B94E=:#[)9GA[9-&+5,>)RN,6'<,F'S2NQZ;E9M
M-%7<A/E'DNV?Y;H5'PFCC314FZ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVHS5/-1
M+4"U$-4B5(LIK9[H555-Y1]F)R8[!SS:4T,U#=5T5#-0S40U"]5L5'-0S44U
M3STOLXW[\MFMVELF&_7DT;C1!_+1A0M0+42U"-5B2JME<K]JJ?7%+35KG6>+
M]78Q/]X0LBV"Q4+7"$:U*:IIJ*:CFH%J)JI9J&:CFH-J+JIYI7::K<TJ,3I#
M']4"5 M1+4*UF-+J(5W5WOI7:F]7+F83#^^<T.@CZU!-0S4=U0Q4,U'-0C4;
MU1Q4<U'-N_+"E \79TKJ]2O?T,7R42U M1#5(E2+*:V>XTJ5X^):W:?FHZ*E
M+%TF>?HHY1MIO5G_=?_HC.*[;^6I[]:L1XMWJ#9%-0W5=%0S4,U$-0O5;%1S
M4,U%-:_43H_&U<&X66>:H3/U42U M1#5(E2+*:V>Y%6!KR\N\/W\DBV64O]>
M4GJ*<GKYWDV?6HKQSAF./M4.U314TU'-0#43U2Q4LU'-0347U3Q4FZ&:CVH!
MJH6H%J%:3&GUJ*^:A,67HJB_?@=Y,= YSDEMBFH:JNFH9J":B6H6JMFHYJ":
MBVI>J35N:SAH'I&3\_11+4"U$-4B5(LIK1[35:NP+VX57KUYO7A\YY0FM2FJ
M::BFHYJ!:B:J6:AFHYJ#:BZJ>5=>F>KUYR;,T 7R42U M1#5(E2+*:T>X55E
MLB^N3%ZY8[)X=.< 1UN/J*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:5VNEAMO)N<G:8
MC;8942U M1#5(E2+*:V>T56;L2]N,[Z=WTZOGQ9!2XNH-D4U#=5T5#-0S40U
M"]5L5'-0S44UK]_V3+_STR)H&1'5 E0+42U"M9C2ZGE=M2C[XA:E^([YXL&=
M(QJM3Z*:AFHZJAFH9J*:A6HVJCFHYJ*:5VJ-^X^/Y%[SR:OH;'U4"U M1+4(
MU6)*JZ=TU8SLBYN1U^^W+P8Z)S7:@T0U#=5T5#-0S40U"]5L5'-0S44UK]2:
M3XI0!FHSJ=&G^J%:@&HAJD6H%E-:+:D'55]R(.Y+ZNGG;)=DWR7Y<.V?W/G:
M/['?-<A1;8IJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JK-4,U'M0#50E2+4"VFM'K:
M5\7+@;C?=?W:/S'0.<[1ZB6J::BFHYJ!:B:J6:AFHYJ#:BZJ>:5V>I*[_Z[Q
M]+89.DL?U0)4"U$M0K68TNHIK50I+:Y57KWT3SR^<TBCG4E4TU!-1S4#U4Q4
MLU#-1C4'U5Q4\U!M=N5U?L.%A#ZZ0 &JA:@6H5I,:?4(K_J4@UL>B'CY*!LM
M3*+:%-4T5--1S4 U$]4L5+-1S4$U%]4\5)N56OV8O?&T&A^=98!J(:I%J!93
M6CVBJQYD\:4HHCM<^2>6.L<UJ4U134,U'=4,5#-1S4(U&]4<5'-1S2NU*R=%
MR%GZJ!:@6HAJ$:K%E%:/ZZH/.1"WKL07_HD'=TYHM R):AJJZ:AFH)J):A:J
MV:CFH)J+:AZJS4JM>1GAH*<V#ZK1RB.JA:@6H5I,:?64KBJ/ W'E\?J%?V*@
M<U*CK4=4TU!-1S4#U4Q4LU#-1C4'U5Q4\U!M5FK-RPA[@TDSJ='B(ZJ%J!:A
M6DQI]:2NBH\#<?'Q>(9Z<WRJ[\LNFS\G[4^L$3N= QNM/:*:AFHZJAFH9J*:
MA6HVJCFHYJ*:AVJS0<N3"\>#LR<<^NA< U0+42U"M9C2ZGE=%1\'XN*C]OO+
M(DNEQW0[SQ:'U&X-:[0 B6I35--034<U ]5,5+-0S48U!]5<5/.NO#S_]KS8
MOM[G?O]4[.52VM_\7EJLI?S;1DK_M4N6Q3?;O/B;5;K_V"G))5EY?=!"LGZ4
ME/[K=U^RS4K*GU/IZ< ]%O^4OI>VN\__3.?Y_M;Z\V*RQ7J7/DK[Q5[,T\/X
M])@0Q>'<Z=V<QX>_._W)Y'[_O.Z7PEI\39??[Z5OB_RYF*KQ09BT^2+]:5_#
MEU[2[/B@[]:WG6O;I=BT;P\ .&Z38@GM9'W2.E&D/[>N7;IZ66Z^[S=7L36R
MS>[IN=@*\^?#!OE+8YWKXNC*6DU.UNI=ZZ<$:/$4U4)4BU MIK3ZNV15/!V(
MBZ?EA[JO3^!L?>*$F.C\'HE63U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0[79X/Q)
MG?W!1!THS7_0H,U35 M1+4*UF-)J43VLFJ=#<?/T]0V[]Z/-4['?-<=1;8IJ
M&JKIJ&:@FHEJ%JK9J.:@FHMJ'JK-4,U'M0#50E2+4"VFM'K:5\W3X1]MGHJ!
MSG&.-D]134,U'=4,5#-1S4(U&]4<5'-1S1N>-T_5\]OAHO/T42U M1#5(E2+
M*:T>TTH5TW^P>BH>WSFET>HIJFFHIJ.:@6HFJEFH9J.:@VHNJGE77IFW/'4"
M72 ?U0)4"U$M0K68TNH17E5/AW^H>BH>W3G T>HIJFFHIJ.:@6HFJEFH9J.:
M@VHNJGG#\[*HVBR+SM!9^J@6H%J(:A&JQ916C^BJ>EI\*8KHJLMT\3)YL= Y
MIDEMBFH:JNFH9J":B6H6JMFHYJ":BVI>J34K2/VS^^.BL_51+4"U$-4B5(LI
MK1[55>UT**Z=7B\TB8'.28U63U%-0S4=U0Q4,U'-0C4;U1Q4<U'-&[:617MG
M#P9"Y^JC6H!J(:I%J!936CVHJ^;I\):';=[09Q([G?,:+:"BFH9J.JH9J&:B
MFH5J-JHYJ.:BFE=JIPVD0?^L@#1KF4Q66HI*Z,(%J!:B6H1J,:75@[@JE@YO
M>J*F\!)L,=$Y@]%.*:IIJ*:CFH%J)JI9J&:CFH-J+JIYI79ZT?2X-^G)S0P^
MGTSI*^/1J)G!:%D4U4)4BU MIK1Z!E=ET:&X=:4GBTQ:)=EO:2Y]39:[0^WI
M>&S<GL=H;135IJBFH9J.:@:JF:AFH9J-:@ZJN:CFH=JLU$YC>Z0.^W(SM='R
M(JJ%J!:A6DQI]=2NRHM#<7GQ6-*5U7NEI_1.ZS!1NLVSQ3Q/'Z7C:8Y?UXMK
MY1BTY(AJ4U334$U'-0/53%2S4,U&-0?57%3S4&V&:CZJ!:@6HEJ$:C&EU8)_
M5%4A1^(JY#'4YYO5_HQ)<CB#+3I[(M:Z9CNJ35%-0S4=U0Q4,U'-0C4;U1Q4
M<TOM](BX<1[90V<X0S4?U0)4"U$M0K68TNJ!7;491^(VH[^6E-Z]Y"7?SZKK
M_O$32-&QN1COG-]HTQ'5-%334<U -1/5+%2S4<U!-1?5/%2;H9J/:@&JA:@6
MH5I,:?6H5ZJH%_>NKA?7Q4#G.$<KD:BFH9J.:@:JF:AFH9I=:O6>R;!^T.N@
MLW11S;ME!6;H+'U4"U M1+4(U6)*JX=OU64<B;N,5^OHXO&=LQ=M,Z*:AFHZ
MJAFH9J*:A6KVE=_7&TK:#KI +JIYJ#9#-1_5 E0+42U"M9C2ZA%>=1V++Z^?
MVRZO/7F[,/MXY]WM_K*4^695O%BD[7ZZUH@7^ITCGM2FJ*:AFHYJ!JJ9J&:A
MFHUJ#JJYJ.:AVJS43B_KWE_\W;RJ&YUI@&HAJD6H%E/:,<8?ML]IFD^3//GX
M?I5F3^FG=+G<%EF\6Q?\_OC\[:=2EGXI8E[^Z6?E[N'LYX;\DR.W_-R3?YH=
M?OY0\1_?OR1/J9=D3XOBK6"9?BEFM7_XWYV4+9Z>W[[)-R\?[N0[Z?,FSS>K
MPY?/:?*89OL)BK__LMGDK]_L9_!MD_UV6)V/_P]02P,$%     @ .8)O5@:F
M6OV= @  0 <  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULE95=;]HP
M%(;_BA7MHI6V)C'Y@"I$:D'=)K4::M?M8MJ%"0=BU1_,-M#^^]D.S5@)H-X0
M?[WG.>>$O"XV4CWI&L"@9\Z$'@:U,<O+,-15#9SH"[D$87?F4G%B[%0M0KU4
M0&9>Q%F(HR@+.:$B* N_-E%E(5>&40$3A?2*<Z)>KH')S3"(@]>%>[JHC5L(
MRV))%O  YG$Y4786ME%FE(/05 JD8#X,KN++ZSAR G_B!X6-WADC5\I4RB<W
M^3H;!I'+"!A4QH4@]K&&$3#F(MD\_FR#!BW3"7?'K]%O?/&VF"G1,)+L)YV9
M>ACT S2#.5DQ<R\W7V!;4.KB59)I_XLVS=D\#U"UTD;RK=AFP*EHGN1YVX@=
M <8'!'@KP#[O!N2S'!-#RD+)#5+NM(WF!KY4K[;)4>'>RH-1=I=:G2E'DG-J
M;)N-1D3,T$@*0\4"1$5!H[,Q&$*9/D>?T T51%2 ;L$V 7V;,KH@KK$:_;H#
M/@7UNPB-S<C%#:LM_;JAXP/T,507J!=_1#C"&#T^C-'9A_/_PX2VH+8JW%:%
M?=SD0%P;KM>53:/*O,K]7]=EFN<X*\)U!ZS7PGJG8$D7K%&E;V!I-RQI8<DI
M6-H%2]X#2UM8>@J6=<'23MB!-F8M+#L%R[M@V7M@>0O+C\(^6P<SH)"IB4 I
M>@&B=!<\WX/C%*>]I)O>;^G]H_3OTA#6A>OOUYK$<8:[<8,6-SB*NP6M+]$5
MERMAK)-:]];@OW)$A6T":-.5RV OET_I((H/-#Z._AE.=#2;28-':\)6@.3<
MN1KE*XZ8-Y8E>?%NU&DFT=[WF_1QG+S-*=SQ0W>WW!&UH-:H&,RM,+K(;56J
ML>MF8N326^14&FNX?EC;*PZ4.V#WYU*:UXESW?;2+/\"4$L#!!0    ( #F"
M;U:GJKGUG (  .X&   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;(65
M76_;(!2&_PJR=M%*:^S@K[AR++6)IDUJU:A=MXMI%\0Y25#!>$"2]M\/L&ME
ML]/<V!S@G.<]?!SR@Y O:@N@T2MGE9IZ6ZWK:]]7Y18X42-10V5&UD)RHHTI
M-[ZJ)9"5<^+,QT&0^)S0RBMRU[>012YVFM$*%A*I'>=$OMT"$X>I-_;>.Q[I
M9JMMAU_D-=G $^CG>B&-Y7=15I1#I:BHD(3UU+L97]]F=KZ;\(/"01VUD<UD
M*<2+-;ZMIEY@!0&#4ML(Q/SV, /&;" CXT\;T^N0UO&X_1[]B\O=Y+(D"F:"
M_:0KO9UZ$P^M8$UV3#^*PU=H\XEMO%(PY;[HT,X-/%3NE!:\=38*.*V:/WEM
MU^'( >,3#KAUP$YW W(JYT23(I?B@*2=;:+9ADO5>1MQM+*;\J2E&:7&3Q<S
MP3G59I6U0J1:H9FH-*TV4)44%+J8@R:4*32^1%?HH09)["BZ [,0R.T@$FOT
M;(R'):,;8E=:H5_WP)<@?^>^-A(MR"];.;>-''Q"SAS*$0K'GQ$.,$;/3W-T
M\>GRWS"^R;!+$W=I8A<W.A'7A N'U#1>B?.RYW=?X"1*LRSW]P.TL*.%YVC1
M$*WQBH]HXR3".!ZF11TM.D>+AVA1GV:F!B=RBSM:?(Z6#-'B'BV+DB 8AB4=
M+#D'2X=@20^&X\DI6-K!T@]AWX4FK'?(C\[UD)*TIR1)LB0,AZ5,.BF3#Z7<
M@5+7Z(:+7:5-Z3/E5H&[EXA6&HREA[1,>EJN<!2F)S8\Z[1D'VI9-'"T)VP'
M]K:;*D3YCB/FUJ<F;ZYZ# G*>K<KB6(<1_\)\H_*EWT)[HG<4%-&&*R-8S!*
M34JRJ:Z-H47M*MI2:%,?77-K'B20=H(97PNAWPU;)+LGKO@+4$L#!!0    (
M #F";U9""5R3&P(   (%   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM
M;)U4VX[3,!#]%<L@M$A0I^X-2A*);846:1'5EH5G-YDVUOH2;+=9_A[;::,*
MI07QDGCL.9>Q/4X;;9YL!>#0LQ3*9KARKIX38HL*)+,#78/R*UMM)',^-#MB
M:P.LC" I"$V2*9&,*YRG<6YE\E3OG> *5@;9O93,_+H%H9L,#_%IXH'O*A<F
M2)[6; =K<(_UROB(="PEEZ LUPH9V&;XXW!^.PGY,>$[A\:>C5&H9*/U4P@^
MEQE.@B$04+C P/SO  L0(A!Y&S^/G+B3#,#S\8G]4ZS=U[)A%A9:_."EJS+\
M#J,2MFPOW(-N[N!83S18:&'C%S5M[IAB5.RMT_((]@XD5^V?/1_WX0Q +P'H
M$4"C[U8HNEPRQ_+4Z :9D.W9PB"6&M'>'%?A4-;.^%7N<2Y?:"FY\[OL+&*J
M1 NM'%<[4 4'BVZ6X!@7%M'7*7%>+H!(<:2^;:GI!>HE% ,T&KY!-*$4/:Z7
MZ.;E'S3$N^TLT\XRC;RC_['<9[.E&_?3A5L_MS4K(,/^6ELP!\#YJQ?#:?+A
MBME19W9TC3WWM8_Z/+6H:42%QCGD=)9,WZ?DT",V[L3&?Q,;H[=AOV=]FBUX
M<J:9].M-.KW)5;UOVC&!OM9@6#@!= ^^/] ]9QLNN+MP&I-_JIR<7>GP.GQA
M9L>510*V'I<,9I[&M!W7!D[7\99OM/,]$X>5?Z3 A 2_OM7:G8+0.-VSE_\&
M4$L#!!0    ( #F";U:T'0?B4P(  "D&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;(6576_:,!2&_XH5[:*5MB8XGU00:06MVT4EU*[;Q;0+$P[$
MJC\RVY3R[V<[(6(CE)O$'^=]GW,2YV2RD^I%UP &O7$F]#2HC6ENPU!7-7"B
M;V0#PNZLI>+$V*G:A+I10%9>Q%F(HR@+.:$B*"=^;:'*B=P:1@4L%-);SHG:
MWP&3NVDP"@X+CW13&[<0EI.&;. )S'.S4'86]BXKRD%H*@52L)X&GT>W=X6+
M]P$_*.STT1BY2I92OKC)M]4TB%Q"P* RSH'8VRO,@#%G9-/XTWD&/=()C\<'
M]R^^=EO+DFB82?:3KDP]#8H K6!-MLP\RMU7Z.I)G5\EF?97M&MC\RA U58;
MR3NQS8!3T=[)6_<<C@08GQ'@3H!]WBW(9SDGAI03)7=(N6CKY@:^5*^VR5'A
M7LJ347:76ITI9Y)S:NQ3-AH1L4(S*0P5&Q 5!8VNYF (91K%U^@3NE?$A3U"
M0_9DR0#]>@"^!/5[$AJ;BC,,JPY[UV+Q&>P<JAL4CSXB'&&,GI_FZ.K#];\V
MH:VD+P?WY6#OFYSQM7;Q4#:M*O,J=TY?RV2,"QOZ.@"+>UA\"98,P5I5>@3#
M69J,AF%)#TLNP=(A6'("BY.T. -+>UAZ"98-P=(36-*&#L&R'I9=@N5#L.P4
MEH[S8AB6][#\7=B][5P&%#(U$2A%>R!*#\'S@7<8%^,S)Z;HZ<6[]._2$';R
M'0WQB],#F^$XPO_QPZ,OWS71!Z(V5&C$8&V%T4UN*U!M8VHG1C:^&2REL:W%
M#VO;RT&Y +N_EM(<)JZ_]'^'\B]02P,$%     @ .8)O5M%V^4:O @  Q <
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M50'OA3;UM&JNS0T&I%U@YI="Z'W'.FCO1,DO4$L#!!0    ( #F";U;$#OJ
MTP(  "H)   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;+66;6_;(!#'
MOPKRIJF5UMK@)(Z[Q%(>-FTOJE6MNKVF]B5!M<$#DG3??H =QUV<[*'J&QLP
M][_?'8=AM!7R4:T -'HJ<J[&WDKK\LKW5;J"@JI+40(W7Q9"%E2;KESZJI1
M,V=4Y#X)@H%?4,:]9.3&;F0R$FN=,PXW$JEU45#Y<PJYV(X][.T&;MERI>V
MGXQ*NH0[T/?EC30]OU')6 %<,<&1A,78F^"K*2;6P,WXQF"K6FUD0WD0XM%V
MOF1C+[!$D$.JK00UKPW,(,^MDN'X48MZC4]KV&[OU#^YX$TP#U3!3.3?6:97
M8V_HH0P6=)WK6[']#'5 ?:N7BERY)]I6<P=F<KI66A2UL2$H&*_>]*E.1,N
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M8Q:B7]8K$];%8J,>[](L8SCFQ":Z0,9- 'KI%93&H#2.HJD-13I3X:DW7]$
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MZ/+\LEG4F\K<L+?_G)"882O"83A-NI;I%-"FDYES2,/,9>P>8^38$\_MW">
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M4$L! A0#%     @ .8)O5I72"T7N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ .8)O5IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  Y@F]6!64?D)8'  #:,0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ .8)O5GZR^I;<!@  5!P
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M965T-BYX;6Q02P$"% ,4    "  Y@F]6YRSW/<T$   /"P  &
M    @(%"+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M.8)O5FE$&RPC!0  P0L  !@              ("!130  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #F";U;RP./Z1AP  'E:   8
M          " @9XY  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  Y@F]6G2)PRW,$  !O"@  &0              @($:5@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #F";U:(#4 ^$P0  %L)
M   9              " @<1:  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ .8)O5G6L<O:M @  ,@8  !D              ("!#E\
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  Y@F]6@)S[
M@E4)  !!(0  &0              @('R80  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( #F";U9[QJ'AWA<  .I>   9
M  " @7YK  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M.8)O5G6"W-//!   S@H  !D              ("!DX,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  Y@F]6HQ^<Q>84  #32@  &0
M            @(&9B   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( #F";U8@&6[9( 8  (\.   9              " @;:=  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ .8)O5K<+1MS['
MVV   !D              ("!#:0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  Y@F]6AKW8C90#   S"   &0              @($_
MP0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #F";U;-
MPPT-WP,  ',)   9              " @0K%  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ .8)O5F0M&)FF @  FP8  !D
M     ("!(,D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F";U8!T&M/U 4  #X6   9              "
M@<3B  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ .8)O
M5L2E2:.*!0  $AX  !D              ("!S^@  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  Y@F]6W.H6WFP"  !$!@  &0
M        @(&0[@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( #F";U8T<2&O< (  ,4&   9              " @3/Q  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ .8)O5C'UXOTU @  7@8
M !D              ("!VO,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  Y@F]6+]/R1,X"  #9"   &0              @(%&]@
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #F";U9"U1Q8
M^P,  &X-   9              " @4OY  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ .8)O5BFM1)=N P  = L  !D
M ("!??T  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  Y
M@F]6TH.GTG<"  "B!@  &0              @($B 0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #F";U8Q2#H<$@(  / $   9
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M970S.2YX;6Q02P$"% ,4    "  Y@F]6]6N'/Y@$   '%P  &0
M    @($Y' $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M #F";U8=C5GEF@,   8-   9              " @0@A 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ .8)O5D:<>&0>"@  >5T  !D
M             ("!V20! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  Y@F]6IUZ7GA(&  "0)0  &0              @($N+P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #F";U9MY6QP,0,
M )@*   9              " @7<U 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ .8)O5O?BK5=*"0  '4H  !D              ("!
MWS@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  Y@F]6
M0BH@OET&  #]+0  &0              @(%@0@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( #F";U;_^B4^"00  +P6   9
M      " @?1( 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ .8)O5E]6$7P9!@  HRD  !D              ("!-$T! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  Y@F]60+(ZP4X9  ".I $
M&0              @(&$4P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( #F";U8&IEK]G0(  $ '   9              " @0EM 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ .8)O5J>JN?6<
M @  [@8  !D              ("!W6\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  Y@F]60@E<DQL"   "!0  &0
M@(&P<@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #F"
M;U:T'0?B4P(  "D&   9              " @0)U 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ .8)O5M%V^4:O @  Q <  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( #F";U8@V25\^!D   <I 0 9
M  " @3.& 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M.8)O5D)321BB!@  @CD  !D              ("!8J ! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    "  Y@F]6LHW75VL#  #,%@  #0
M            @ $[IP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #F";U:7
MBKL<P    !,"   +              "  =&J 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( #F";U9F/]AR:@0  . G   /              "  ;JK 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  Y@F]6F!M:GOL!  #+(P  &@
M        @ %1L $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  Y@F]6=-+&8MX!  !:(P  $P              @ &$L@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     1 !$ ),2  "3M $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>319</ContextCount>
  <ElementCount>454</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>153</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - Liquidity and Going Concern Assessment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/LiquidityAndGoingConcernAssessment</Role>
      <ShortName>Liquidity and Going Concern Assessment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - StockBased Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensation</Role>
      <ShortName>StockBased Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vnrx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/PropertyAndEquipment</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommonStock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/IntangibleAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - StockBased Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationTables</Role>
      <ShortName>StockBased Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative</Role>
      <ShortName>Liquidity and Going Concern Assessment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/LiquidityAndGoingConcernAssessment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IntangibleAssetsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - Intangible Assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>Intangible Assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IntangibleAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IntangibleAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IncomeTaxesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommonStockTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - Common Stock (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommonStockDetails1</Role>
      <ShortName>Common Stock (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommonStockTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommonStockDetailsNarrative</Role>
      <ShortName>Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommonStockTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - StockBased Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails</Role>
      <ShortName>StockBased Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - StockBased Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails1</Role>
      <ShortName>StockBased Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - StockBased Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails2</Role>
      <ShortName>StockBased Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - StockBased Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails3</Role>
      <ShortName>StockBased Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - StockBased Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails4</Role>
      <ShortName>StockBased Compensation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - StockBased Compensation (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails5</Role>
      <ShortName>StockBased Compensation (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - StockBased Compensation (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails6</Role>
      <ShortName>StockBased Compensation (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - StockBased Compensation (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails7</Role>
      <ShortName>StockBased Compensation (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - StockBased Compensation (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails8</Role>
      <ShortName>StockBased Compensation (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - StockBased Compensation (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetails9</Role>
      <ShortName>StockBased Compensation (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - StockBased Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/StockbasedCompensationDetailsNarrative</Role>
      <ShortName>StockBased Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000056 - Disclosure - Commitments and Contingencies (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails6</Role>
      <ShortName>Commitments and Contingencies (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>000057 - Disclosure - Commitments and Contingencies (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails7</Role>
      <ShortName>Commitments and Contingencies (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>000058 - Disclosure - Commitments and Contingencies (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetails8</Role>
      <ShortName>Commitments and Contingencies (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>000059 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="vnrx_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>000060 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vnrx.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 26 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:GoodwillImpairmentLoss, us-gaap:InterestExpenseOther, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber, vnrx:LoanAgreementTerm, vnrx:MaturityTerm, vnrx:NumberOfOptionsOutstandingBeginningBalance, vnrx:NumberOfRsusOutstandingBeginingBalance, vnrx:NumberOfWarrantsExercised, vnrx:NumberOfWarrantsExpired, vnrx:NumberOfWarrantsOutstandingBeginningBalance, vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised, vnrx:SharePriceBeginningBalance, vnrx:SharesWithheldForTax, vnrx:StockCompensationExpenses, vnrx:WeightedAverageExercisePriceOutstandingBalance, vnrx:WeightedAverageExercisePriceOutstandingBalanceOne -  vnrx_10k.htm 1</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="vnrx_10k.htm">vnrx_10k.htm</File>
    <File>vnrx-20221231.xsd</File>
    <File>vnrx-20221231_cal.xml</File>
    <File>vnrx-20221231_def.xml</File>
    <File>vnrx-20221231_lab.xml</File>
    <File>vnrx-20221231_pre.xml</File>
    <File>vnrx_ex1027.htm</File>
    <File>vnrx_ex211.htm</File>
    <File>vnrx_ex231.htm</File>
    <File>vnrx_ex311.htm</File>
    <File>vnrx_ex312.htm</File>
    <File>vnrx_ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vnrx_10kimg1.jpg</File>
    <File>vnrx_10kimg2.jpg</File>
    <File>vnrx_10kimg3.jpg</File>
    <File>vnrx_10kimg4.jpg</File>
    <File>vnrx_10kimg5.jpg</File>
    <File>vnrx_10kimg6.jpg</File>
    <File>vnrx_10kimg7.jpg</File>
    <File>vnrx_10kimg8.jpg</File>
    <File>vnrx_10kimg9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="657">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnrx_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 657,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 319,
   "dts": {
    "calculationLink": {
     "local": [
      "vnrx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnrx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vnrx_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnrx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnrx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vnrx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 691,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://vnrx.com/20221231": 16,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 30
   },
   "keyCustom": 213,
   "keyStandard": 241,
   "memberCustom": 135,
   "memberStandard": 18,
   "nsprefix": "vnrx",
   "nsuri": "http://vnrx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://vnrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://vnrx.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://vnrx.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://vnrx.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://vnrx.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - StockBased Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://vnrx.com/role/StockbasedCompensation",
     "shortName": "StockBased Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://vnrx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://vnrx.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://vnrx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://vnrx.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://vnrx.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://vnrx.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://vnrx.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - StockBased Compensation (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://vnrx.com/role/StockbasedCompensationTables",
     "shortName": "StockBased Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://vnrx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "vnrx:LiquidityAndGoingConcernAssessment",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vnrx:NetIncomeLossSinceInception",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - Liquidity and Going Concern Assessment (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative",
     "shortName": "Liquidity and Going Concern Assessment (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "vnrx:LiquidityAndGoingConcernAssessment",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vnrx:NetIncomeLossSinceInception",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "vnrx:TermsOfLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://vnrx.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - Property and Equipment (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "Property and Equipment (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://vnrx.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_PatentsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - Intangible Assets (Details 1)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://vnrx.com/role/IntangibleAssetsDetails1",
     "shortName": "Intangible Assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - Intangible Assets (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "Intangible Assets (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:ExcessOfTaxOverBookDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://vnrx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_NetDeferredTaxAssetsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:ExcessOfTaxOverBookDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000033 - Disclosure - Income Taxes (Details 1)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://vnrx.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:IncreaseInValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000034 - Disclosure - Income Taxes (Details 2)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://vnrx.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:IncreaseInValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "vnrx:NetOperatingLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000035 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://vnrx.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "vnrx:NetOperatingLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ExcessStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000036 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://vnrx.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2021-01-01to2021-12-31_vnrx_StockOptionExercisesMember",
      "decimals": "0",
      "lang": null,
      "name": "vnrx:CommonStockShareIssuedUponCashlessExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:RestrictedStockUnitVested",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000037 - Disclosure - Common Stock (Details 1)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://vnrx.com/role/CommonStockDetails1",
     "shortName": "Common Stock (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_JanuaryTwentyTwentyThusandTwentyOneMember_vnrx_RSUSettlementsMember",
      "decimals": "0",
      "lang": null,
      "name": "vnrx:RestrictedStockUnitVested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000038 - Disclosure - Common Stock (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://vnrx.com/role/CommonStockDetailsNarrative",
     "shortName": "Common Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "vnrx:IssuedOfCommonStockFromSettlementOfRSU",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2020-01-01to2020-12-31_vnrx_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfWarrantsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000039 - Disclosure - StockBased Compensation (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails",
     "shortName": "StockBased Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2020-01-01to2020-12-31_vnrx_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfWarrantsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:RoyaltyRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:RoyaltyRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummarizingTheWarrantsIssuedAndOutstanding",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000040 - Disclosure - StockBased Compensation (Details 1)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails1",
     "shortName": "StockBased Compensation (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummarizingTheWarrantsIssuedAndOutstanding",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_WarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2020-01-01to2021-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfOptionsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000041 - Disclosure - StockBased Compensation (Details 2)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails2",
     "shortName": "StockBased Compensation (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2020-01-01to2021-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfOptionsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummaryOfAmendmentsToExpirationDatesOfOptions",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:ApprovedStockOptions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000042 - Disclosure - StockBased Compensation (Details 3)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails3",
     "shortName": "StockBased Compensation (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummaryOfAmendmentsToExpirationDatesOfOptions",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000043 - Disclosure - StockBased Compensation (Details 4)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails4",
     "shortName": "StockBased Compensation (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummarizingTheRsusIssuedAndOutstandingMaturityLife",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2020-12-31_vnrx_StockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfRsusOutstandingBeginingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000044 - Disclosure - StockBased Compensation (Details 5)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails5",
     "shortName": "StockBased Compensation (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:SummarizingTheRsusIssuedAndOutstandingMaturityLife",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2020-12-31_vnrx_StockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfRsusOutstandingBeginingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusGrantedDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:CompensationExpenseRsus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000045 - Disclosure - StockBased Compensation (Details 6)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails6",
     "shortName": "StockBased Compensation (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusGrantedDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:CompensationExpenseRsus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusVestedDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:EquityIncentiveRsu",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000046 - Disclosure - StockBased Compensation (Details 7)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails7",
     "shortName": "StockBased Compensation (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusVestedDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:EquityIncentiveRsu",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusCancelledDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:RsuCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000047 - Disclosure - StockBased Compensation (Details 8)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails8",
     "shortName": "StockBased Compensation (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRsusCancelledDuringPeriod",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:RsuCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:summarizingtheRSUsissuedandoutstandingtabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfStockOutstandingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000048 - Disclosure - StockBased Compensation (Details 9)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://vnrx.com/role/StockbasedCompensationDetails9",
     "shortName": "StockBased Compensation (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:summarizingtheRSUsissuedandoutstandingtabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31_vnrx_OptionFourMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:NumberOfStockOutstandingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-04-01to2022-04-04",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:CommonStockAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000049 - Disclosure - StockBased Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
     "shortName": "StockBased Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-04-01to2022-04-04",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:CommonStockAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - Consolidated Statement of Stockholders Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
     "shortName": "Consolidated Statement of Stockholders Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000050 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_FinanceLeaseObligationsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000051 - Disclosure - Commitments and Contingencies (Details 1)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_OperatingLeaseRightofUseObligationsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRecognizedInShortTermLeaseCosts",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000052 - Disclosure - Commitments and Contingencies (Details 2)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfRecognizedInShortTermLeaseCosts",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:OperatingLeasesFutureMinimumPaymentDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_GrantsRepayableMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000053 - Disclosure - Commitments and Contingencies (Details 3)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_vnrx_GrantsRepayableMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000054 - Disclosure - Commitments and Contingencies (Details 4)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000055 - Disclosure - Commitments and Contingencies (Details 5)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails5",
     "shortName": "Commitments and Contingencies (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000056 - Disclosure - Commitments and Contingencies (Details 6)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
     "shortName": "Commitments and Contingencies (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "vnrx:ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember_vnrx_AwardOneMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000057 - Disclosure - Commitments and Contingencies (Details 7)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
     "shortName": "Commitments and Contingencies (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockMember_vnrx_AwardOneMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:AmortisedOfOutstandingAwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000058 - Disclosure - Commitments and Contingencies (Details 8)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
     "shortName": "Commitments and Contingencies (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:AmortisedOfOutstandingAwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:GrantRepyable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000059 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vnrx:GrantRepyable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000060 - Disclosure - Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://vnrx.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "AsOf2023-03-01_us-gaap_OptionMember_vnrx_TwoThousandFifteenEquityIncentivePlanMember",
      "decimals": "0",
      "lang": null,
      "name": "vnrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://vnrx.com/role/NatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnrx:LiquidityAndGoingConcernAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - Liquidity and Going Concern Assessment",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://vnrx.com/role/LiquidityAndGoingConcernAssessment",
     "shortName": "Liquidity and Going Concern Assessment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnrx:LiquidityAndGoingConcernAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://vnrx.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "vnrx_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 153,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r263",
      "r385",
      "r392",
      "r413",
      "r414",
      "r428",
      "r431",
      "r436",
      "r470",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r263",
      "r385",
      "r392",
      "r413",
      "r414",
      "r428",
      "r431",
      "r436",
      "r470",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r183",
      "r386",
      "r429",
      "r434",
      "r465",
      "r466",
      "r472",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service Axis"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r183",
      "r386",
      "r429",
      "r434",
      "r465",
      "r466",
      "r472",
      "r520"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r262",
      "r263",
      "r289",
      "r290",
      "r291",
      "r361",
      "r385",
      "r392",
      "r413",
      "r414",
      "r428",
      "r431",
      "r436",
      "r464",
      "r470",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Axis"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r262",
      "r263",
      "r289",
      "r290",
      "r291",
      "r361",
      "r385",
      "r392",
      "r413",
      "r414",
      "r428",
      "r431",
      "r436",
      "r464",
      "r470",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r430",
      "r435",
      "r472"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r430",
      "r435",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r459",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual Axis"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r60",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r133",
      "r391",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "vnrx_TotalVolitionrxLimitedStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r98",
      "r346",
      "r393",
      "r394",
      "r449",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFundingAgreementTermsMember": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of commitments to provide additional funding under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Colorectal Cancer Research Agreement [Member]"
       }
      }
     },
     "localname": "AdditionalFundingAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "vnrx_TotalVolitionrxLimitedStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r456",
      "r457",
      "r458",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "[Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation]",
        "negatedLabel": "Tax withholdings paid related to stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r32",
      "r50",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r113",
      "r131",
      "r149",
      "r174",
      "r177",
      "r181",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r319",
      "r321",
      "r327",
      "r433",
      "r468",
      "r469",
      "r511"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r136",
      "r149",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r319",
      "r321",
      "r327",
      "r433",
      "r468",
      "r469",
      "r511"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date Axis"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type Axis"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetails6",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingImprovementsMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building Improvements [Member]"
       }
      }
     },
     "localname": "BuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.",
        "label": "Purchase Price For The Property"
       }
      }
     },
     "localname": "BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital expenditure"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r127",
      "r415"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r27",
      "r34",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]",
        "periodEndLabel": "Cash and Cash Equivalents - End of Year",
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of Year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r27",
      "r108"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]",
        "totalLabel": "Net Change in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Amount in excess of FDIC limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Deposits/cash in excess of insured limits"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollectiveBargainingArrangementAxis": {
     "auth_ref": [
      "r431",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement collectively bargained between employer and its employees represented by union.",
        "label": "Collective Bargaining Arrangement Axis"
       }
      }
     },
     "localname": "CollectiveBargainingArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollectiveBargainingArrangementDomain": {
     "auth_ref": [
      "r431",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement collectively bargained between employer and its employees represented by union."
       }
      }
     },
     "localname": "CollectiveBargainingArrangementDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r228",
      "r229",
      "r400",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r456",
      "r457",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Shares Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative",
      "http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "vnrx_TotalVolitionrxLimitedStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 57,873,379 shares and 53,772,261 shares, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax Assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Hardware And Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles Of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Stock Option Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maturity Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "[Deferred Revenue]",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r90",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r90",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net Operating Losses carry-forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r88",
      "r90",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Credit Carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r90",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "[Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation Expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r32",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails2",
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8",
      "http://vnrx.com/role/StockbasedCompensationDetails9",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument Risk Axis"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails2",
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8",
      "http://vnrx.com/role/StockbasedCompensationDetails9",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Total Of Stock Option"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic And Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "[Effective Income Tax Rate Reconciliation, Percent]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Rate Reconciliation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r150",
      "r302",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "[Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent]",
        "verboseLabel": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r314",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Federal Deferred Rate Decrease"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Permanent Differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent]",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Federal Research &amp;amp;amp; Development Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign": {
     "auth_ref": [
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.",
        "label": "Foreign taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r123",
      "r140",
      "r141",
      "r142",
      "r152",
      "r153",
      "r154",
      "r156",
      "r161",
      "r163",
      "r165",
      "r192",
      "r261",
      "r295",
      "r296",
      "r297",
      "r311",
      "r312",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r346",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Shares Issued",
        "verboseLabel": "Shares Issued"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r32",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Warrant expenses"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r337",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Lease Liability",
        "verboseLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current portion of financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "[Finance Lease, Liability, to be Paid]",
        "terseLabel": "Lease Payable",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Greater than 5 years"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year One]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finance Lease, Liability, to be Paid, Year Two]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "[Finance Lease, Right-of-Use Asset, after Accumulated Amortization]",
        "negatedLabel": "ROU Asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r197",
      "r198",
      "r199",
      "r200",
      "r205",
      "r213",
      "r214",
      "r215",
      "r245",
      "r258",
      "r323",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r424",
      "r460",
      "r461",
      "r462",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument Axis"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/StockbasedCompensationDetails5",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r130",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Schedule Of Annual Estimated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r221",
      "r223",
      "r224",
      "r226",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class Axis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r54",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "[Finite-Lived Intangible Assets, Gross]",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r54",
      "r387"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Intangible assets, net",
        "terseLabel": "Total Intangible Assets",
        "verboseLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/IntangibleAssetsDetails",
      "http://vnrx.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization Of Long-lived Asset On Straight Line Basis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r32",
      "r218",
      "r219",
      "r220",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grant Receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r22",
      "r451"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 17.0,
       "parentTag": "vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Net Loss attributable to Non-Controlling Interest"
       }
      }
     },
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r303",
      "r304",
      "r309",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r300",
      "r301",
      "r304",
      "r305",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r28",
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income tax paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "[Increase (Decrease) in Deferred Revenue]",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "[Increase (Decrease) in Other Current Assets]",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r52",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "[Interest Expense, Other]",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r144",
      "r146",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r149",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r320",
      "r321",
      "r322",
      "r327",
      "r422",
      "r468",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r111",
      "r116",
      "r433",
      "r455",
      "r463",
      "r507"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r126",
      "r149",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r320",
      "r321",
      "r322",
      "r327",
      "r433",
      "r468",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r0",
      "r110",
      "r114",
      "r243",
      "r246",
      "r426",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Total Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturingInYearsFourAndFive": {
     "auth_ref": [
      "r64",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year Four and Five]",
        "verboseLabel": "Greater than 5 years"
       }
      }
     },
     "localname": "LongTermDebtMaturingInYearsFourAndFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r64",
      "r151",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, after Year Five]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r64",
      "r151",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year One]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r64",
      "r151",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year Five]",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r64",
      "r151",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year Four]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r64",
      "r151",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year Three]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r64",
      "r151",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Long-Term Debt, Maturity, Year Two]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type Axis"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r13",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeePayable": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.",
        "label": "Management and directors' fees payable"
       }
      }
     },
     "localname": "ManagementFeePayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the significant collective-bargaining arrangements within the range of expiration dates for collective-bargaining arrangements requiring contributions to a multiemployer plan as well as other information to help investors understand the significance of the collective-bargaining agreements and when they expire. A multiemployer plan is a pension or postretirement benefit plan to which two or more unrelated employers contribute where assets contributed by one participating employer may be used to provide benefits to employees of other participating employers.",
        "label": "Expire description"
       }
      }
     },
     "localname": "MultiemployerPlansCollectiveBargainingArrangementExpirationDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r166",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/NatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r27",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net Cash Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r33",
      "r112",
      "r118",
      "r124",
      "r137",
      "r138",
      "r142",
      "r149",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r174",
      "r176",
      "r180",
      "r182",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r326",
      "r327",
      "r423",
      "r468"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 16.0,
       "parentTag": "vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss for the Year"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r93",
      "r261",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Furniture and Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r174",
      "r176",
      "r180",
      "r182",
      "r423"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r340",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net Operating Losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "auth_ref": [
      "r67",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.",
        "label": "Stock price"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Option [Member]",
        "verboseLabel": "Option [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r135",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments Axis"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r94",
      "r95",
      "r97"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 19.0,
       "parentTag": "vnrx_OthersComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "[Other Income]",
        "totalLabel": "Total Other Income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expenses)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r0",
      "r110",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Total Long-term Debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r0",
      "r110",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Principal Balance Payable"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Royalty Payment"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name Axis"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetailsNarrative",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetailsNarrative",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r134",
      "r216",
      "r217",
      "r416"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceed from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from issuance of common shares",
        "verboseLabel": "Common stock available for issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from other long-term debt.",
        "label": "Payments on long-term debt"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from long-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "[Proceeds from Stock Options Exercised]",
        "verboseLabel": "Proceeds to Company if Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds to Company if Exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type Axis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r59",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r117",
      "r390",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "verboseLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Accounts Receivables"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RegulatoryAgencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of regulatory agency.",
        "label": "Regulatory Agency [Axis]"
       }
      }
     },
     "localname": "RegulatoryAgencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryAgencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization that establishes and ensures compliance with rules or regulations."
       }
      }
     },
     "localname": "RegulatoryAgencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r122",
      "r349",
      "r350",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction Axis"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type Axis"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r121",
      "r519"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted stock option"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Shares Withheld for Tax",
        "verboseLabel": "Shares Withheld for tax"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r70",
      "r115",
      "r396",
      "r398",
      "r433"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "vnrx_TotalVolitionrxLimitedStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r152",
      "r153",
      "r154",
      "r156",
      "r161",
      "r163",
      "r192",
      "r295",
      "r296",
      "r297",
      "r311",
      "r312",
      "r325",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r143",
      "r149",
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r191",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r327",
      "r389",
      "r468"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "[Revenues]",
        "totalLabel": "Total Revenues",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern Assessment"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Compensation"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Common stock shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Commissions and fee"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of annual payments Of Collaborative Agreement Obligations"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Shedule of components of deferred income taxes and assets"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule Of Grants Repayable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule Of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Long-term Debt Payable"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock": {
     "auth_ref": [
      "r68",
      "r104",
      "r105",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.",
        "label": "Schedule Of share issued from the cashless exercise of options"
       }
      }
     },
     "localname": "ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.",
        "label": "Schedule Of Property And Equipment"
       }
      }
     },
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Summarizing The Options Issued And Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r77",
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summarizes The Changes In Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r71",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Summary Of Changes In Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "[Share-Based Payment Arrangement, Noncash Expense]",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation in relation to modification of options"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.",
        "label": "Stock option expiration date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number Exercisable",
        "verboseLabel": "Number Exercisable, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Stock option purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number Outstanding",
        "verboseLabel": "Number Outstanding, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Option expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetails6",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Price per shares",
        "terseLabel": "Share price",
        "verboseLabel": "share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Fair market value of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r339",
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeasePayments": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.",
        "label": "Payment Of Lease Liabilities"
       }
      }
     },
     "localname": "ShortTermLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r69",
      "r123",
      "r140",
      "r141",
      "r142",
      "r152",
      "r153",
      "r154",
      "r156",
      "r161",
      "r163",
      "r165",
      "r192",
      "r261",
      "r295",
      "r296",
      "r297",
      "r311",
      "r312",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r346",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/CommonStockDetailsNarrative",
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://vnrx.com/role/IncomeTaxesDetails",
      "http://vnrx.com/role/IncomeTaxesDetails2",
      "http://vnrx.com/role/IntangibleAssetsDetails",
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails2",
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails5",
      "http://vnrx.com/role/StockbasedCompensationDetails6",
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8",
      "http://vnrx.com/role/StockbasedCompensationDetails9",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative",
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statement of Stockholders Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r165",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1",
      "http://vnrx.com/role/CommonStockDetailsNarrative",
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://vnrx.com/role/IncomeTaxesDetails",
      "http://vnrx.com/role/IncomeTaxesDetails2",
      "http://vnrx.com/role/IntangibleAssetsDetails",
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative",
      "http://vnrx.com/role/PropertyAndEquipmentDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetails2",
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails5",
      "http://vnrx.com/role/StockbasedCompensationDetails6",
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8",
      "http://vnrx.com/role/StockbasedCompensationDetails9",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative",
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r74",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock issued for cashless exercise of stock options, shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r69",
      "r70",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common Stock issued on exercises of stock options and warrants and settlement of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Common stock issued in public offerings, net, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Proceeds from Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Restricted Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued for cashless exercise of stock options, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r49",
      "r433",
      "r455",
      "r463",
      "r507"
     ],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets",
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r148",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r261",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward Axis"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.",
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r245",
      "r258",
      "r323",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r460",
      "r461",
      "r462",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://vnrx.com/role/StockbasedCompensationDetails5",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockBased Compensation"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Outstanding award",
        "verboseLabel": "Outstanding award"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_AccruedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation expense"
       }
      }
     },
     "localname": "AccruedCompensationExpense",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AdditionalCostOfCompany": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cost Of Company"
       }
      }
     },
     "localname": "AdditionalCostOfCompany",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AggerateAmountPayableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggerate Amount Payable, Description"
       }
      }
     },
     "localname": "AggerateAmountPayableDescription",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_AggeregateShareOfCommonStockOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggeregate share of common stock offering price"
       }
      }
     },
     "localname": "AggeregateShareOfCommonStockOfferingPrice",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AggregrateAggregate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregrate aggregate"
       }
      }
     },
     "localname": "AggregrateAggregate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_AgreementUnderAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Under Amount"
       }
      }
     },
     "localname": "AgreementUnderAmount",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AmortisedOfOutstandingAward2021": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortised of outstanding award 2021",
        "verboseLabel": "Amortised of outstanding award 2021"
       }
      }
     },
     "localname": "AmortisedOfOutstandingAward2021",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AmortisedOfOutstandingAward2022": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortised of outstanding award 2022",
        "verboseLabel": "Amortised of outstanding award 2022"
       }
      }
     },
     "localname": "AmortisedOfOutstandingAward2022",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AmortisedOfOutstandingAwardAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Amortised of outstanding award 2022]",
        "verboseLabel": "Amortised of outstanding award 2022"
       }
      }
     },
     "localname": "AmortisedOfOutstandingAwardAmount",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AmountPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount payable"
       }
      }
     },
     "localname": "AmountPayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_AmountRepayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Repayable"
       }
      }
     },
     "localname": "AmountRepayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ApprovedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approved Stock options",
        "verboseLabel": "Stock options approved amount"
       }
      }
     },
     "localname": "ApprovedStockOptions",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_AprilFourTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 4, 2022 [Member]"
       }
      }
     },
     "localname": "AprilFourTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AprilThirteenTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 13,2020 [Member]"
       }
      }
     },
     "localname": "AprilThirteenTwoThousandTwentyMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AprilThirteenTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 13, 2022 [Member]"
       }
      }
     },
     "localname": "AprilThirteenTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AprilTwentyOneTwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 21, 2021"
       }
      }
     },
     "localname": "AprilTwentyOneTwentyTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AugustTenTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Ten Two Thousand Twenty Two [Member]"
       }
      }
     },
     "localname": "AugustTenTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AugustThreeTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 3, 2022 [Member]"
       }
      }
     },
     "localname": "AugustThreeTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_AwardOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Award 1",
        "verboseLabel": "Outstanding Award 1"
       }
      }
     },
     "localname": "AwardOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_BNPParibasLeasingSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BNP Paribas leasing solutions [Member]"
       }
      }
     },
     "localname": "BNPParibasLeasingSolutionsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_BelgianDepositGuaranteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belgian Deposit Guarantee [Member]"
       }
      }
     },
     "localname": "BelgianDepositGuaranteeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_BioinformaticAnalyticsOfCellFreeDNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bioinformatic Analytics Of Cell Free DNA [Member]"
       }
      }
     },
     "localname": "BioinformaticAnalyticsOfCellFreeDNAMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_BrokerageFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Brokerage fees"
       }
      }
     },
     "localname": "BrokerageFees",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_COVID19PandemicImpactPolicyTextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Covid-19 Pandemic Impact"
       }
      }
     },
     "localname": "COVID19PandemicImpactPolicyTextblock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_CancellationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation Date"
       }
      }
     },
     "localname": "CancellationDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_Cancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled net"
       }
      }
     },
     "localname": "Cancelled",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_CapitalRaiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Raise [Member]"
       }
      }
     },
     "localname": "CapitalRaiseMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CapitalizedResearchExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research expenses"
       }
      }
     },
     "localname": "CapitalizedResearchExpenses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ChangeInValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "ChangeInValuationAllowance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ClinicalStudyResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Study Research Agreement [Member]"
       }
      }
     },
     "localname": "ClinicalStudyResearchAgreementMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CollaborativeAgreementObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Collaborative Agreement Obligations"
       }
      }
     },
     "localname": "CollaborativeAgreementObligations",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CollaborativeArrangementCoPromotionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Co-promotion [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementCoPromotionMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CollaborativeObligationsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Obligations Amount"
       }
      }
     },
     "localname": "CollaborativeObligationsAmount",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CollaborativeObligationsAmountDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Obligations Amount Due"
       }
      }
     },
     "localname": "CollaborativeObligationsAmountDue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Common Stock]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_CommonStockAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock available"
       }
      }
     },
     "localname": "CommonStockAvailable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockIssuancesAndRepurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuances And Repurchases [Member]"
       }
      }
     },
     "localname": "CommonStockIssuancesAndRepurchasesMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CommonStockIssuedForSettlementOfRsuSAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for settlement of RSUs, amount"
       }
      }
     },
     "localname": "CommonStockIssuedForSettlementOfRsuSAmount",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CommonStockIssuedForSettlementOfRsuSShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for settlement of RSUs, shares"
       }
      }
     },
     "localname": "CommonStockIssuedForSettlementOfRsuSShares",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockIssuedInPublicOfferingsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in public offerings, net, shares"
       }
      }
     },
     "localname": "CommonStockIssuedInPublicOfferingsNetShares",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, per share"
       }
      }
     },
     "localname": "CommonStockPerShare",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_CommonStockPricePerSahres": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock price per sahres"
       }
      }
     },
     "localname": "CommonStockPricePerSahres",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_CommonStockShareAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockShareAuthorized",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockShareIssuedUponCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, share issued upon cashless exercise"
       }
      }
     },
     "localname": "CommonStockShareIssuedUponCashlessExercise",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockSharePurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, share purchase"
       }
      }
     },
     "localname": "CommonStockSharePurchase",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockSharesIssuableUponExerciseOfStockOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares issuable upon exercise of stock option"
       }
      }
     },
     "localname": "CommonStockSharesIssuableUponExerciseOfStockOption",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CommonStockSharesWithheldForTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares withheld for taxes"
       }
      }
     },
     "localname": "CommonStockSharesWithheldForTaxes",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CompensationCostRelatedToNonVestedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Compensation cost related to non-vested warrants"
       }
      }
     },
     "localname": "CompensationCostRelatedToNonVestedWarrants",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CompensationExpenseEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Eight [Member]"
       }
      }
     },
     "localname": "CompensationExpenseEightMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Five [Member]"
       }
      }
     },
     "localname": "CompensationExpenseFiveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Four [Member]"
       }
      }
     },
     "localname": "CompensationExpenseFourMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense grant date"
       }
      }
     },
     "localname": "CompensationExpenseGrantDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_CompensationExpenseNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Nine [Member]"
       }
      }
     },
     "localname": "CompensationExpenseNineMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense One [Member]"
       }
      }
     },
     "localname": "CompensationExpenseOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseRsus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense RSUs"
       }
      }
     },
     "localname": "CompensationExpenseRsus",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_CompensationExpenseSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Seven [Member]"
       }
      }
     },
     "localname": "CompensationExpenseSevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Six [Member]"
       }
      }
     },
     "localname": "CompensationExpenseSixMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Ten [Member]"
       }
      }
     },
     "localname": "CompensationExpenseTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Three [Member]"
       }
      }
     },
     "localname": "CompensationExpenseThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Two [Member]"
       }
      }
     },
     "localname": "CompensationExpenseTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_CompensationExpenseVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense Vesting Period"
       }
      }
     },
     "localname": "CompensationExpenseVestingPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_CostOfTheCompany": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cost of the company"
       }
      }
     },
     "localname": "CostOfTheCompany",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_CurrentPortionOfGrantRepayable": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of grant repayable"
       }
      }
     },
     "localname": "CurrentPortionOfGrantRepayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_DecemberFifteenTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 15, 2022 [Member]"
       }
      }
     },
     "localname": "DecemberFifteenTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue (contract Liabilities) And Contract Assets"
       }
      }
     },
     "localname": "DeferredRevenueContractLiabilitiesAndContractAssetsPolicyTextBlock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_DescriptionOfVestingShall": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting shall"
       }
      }
     },
     "localname": "DescriptionOfVestingShall",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_DilutiveWarrantsAndOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Options [Member]"
       }
      }
     },
     "localname": "DilutiveWarrantsAndOptionsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EighteenNovemberTwoThounsendTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 18, 2022 [Member]"
       }
      }
     },
     "localname": "EighteenNovemberTwoThounsendTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan",
        "verboseLabel": "Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3",
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_EquityIncentivePlanEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Eight [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanEightMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Five [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanFiveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Four [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanFourMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan One [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Seven [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanSevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Six [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanSixMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Three [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentivePlanTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Two [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_EquityIncentiveRsu": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive RSU"
       }
      }
     },
     "localname": "EquityIncentiveRsu",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_ExcessOfTaxOverBookDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of tax over book depreciation and amortization"
       }
      }
     },
     "localname": "ExcessOfTaxOverBookDepreciationAndAmortization",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Exercise Price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_FairValueOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of options"
       }
      }
     },
     "localname": "FairValueOfOptions",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FebruaryEightFebruaryNineTwentyThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 8 - February 9, 2021"
       }
      }
     },
     "localname": "FebruaryEightFebruaryNineTwentyThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FebruaryEightTwentyThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 8, 2021"
       }
      }
     },
     "localname": "FebruaryEightTwentyThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FebruaryOneTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 1, 2021 [Member]"
       }
      }
     },
     "localname": "FebruaryOneTwoThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FebruaryTwoTwentyThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2, 2021"
       }
      }
     },
     "localname": "FebruaryTwoTwentyThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FinanceLeaseObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Obligations [Member]",
        "verboseLabel": "Finance Lease Obligations [Member]"
       }
      }
     },
     "localname": "FinanceLeaseObligationsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FiniteLivedIntangibleAssetAmortizationExpenseYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2024]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetAmortizationExpenseYearTwo",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FirstInsuranceFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Insurance Funding [Member]"
       }
      }
     },
     "localname": "FirstInsuranceFundingMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FirstVestingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Vesting date"
       }
      }
     },
     "localname": "FirstVestingDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_FiveFebruaryTwoThounsendTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 5, 2022 [Member]"
       }
      }
     },
     "localname": "FiveFebruaryTwoThounsendTwentyTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Interest Rate"
       }
      }
     },
     "localname": "FixedInterestRate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_FixedInterestRateOnLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Interest Rate On Lease"
       }
      }
     },
     "localname": "FixedInterestRateOnLease",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_ForeignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "2022"
       }
      }
     },
     "localname": "FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2024 - 2027]",
        "verboseLabel": "2024 - 2027"
       }
      }
     },
     "localname": "FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Greater than 5 years]",
        "verboseLabel": "Greater than 5 years"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableThearafter",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2025 1]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFive",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2024 1]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearFour",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2027 1]",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSeven",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2026 1]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearSix",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2023 2]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FutureMinimumPaymentsRemainderOfFiscalYearGrantsRepayableYearThree",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_GrantRepaidByInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Repaid By Installments"
       }
      }
     },
     "localname": "GrantRepaidByInstallments",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_GrantRepayableNetOfCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant repayable, net of current portion"
       }
      }
     },
     "localname": "GrantRepayableNetOfCurrentPortion",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_GrantRepyable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Repyable"
       }
      }
     },
     "localname": "GrantRepyable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_GrantedAggregate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted aggregate"
       }
      }
     },
     "localname": "GrantedAggregate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_GrantedRsu": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted RSU"
       }
      }
     },
     "localname": "GrantedRsu",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_GrantedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Granted]",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "GrantedShares",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_GrantsRepayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Total Grants Repayable"
       }
      }
     },
     "localname": "GrantsRepayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_GrantsRepayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Repayable [Member]"
       }
      }
     },
     "localname": "GrantsRepayableMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_INGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ING [Member]"
       }
      }
     },
     "localname": "INGMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_ImpairmentofLongLivedAssetsPolixyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentofLongLivedAssetsPolixyTextBlock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ImplicitInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Implicit Interest"
       }
      }
     },
     "localname": "ImplicitInterest",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_In2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2010 [Member]"
       }
      }
     },
     "localname": "In2010Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_In2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2016 [Member]"
       }
      }
     },
     "localname": "In2016Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_In2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2017 [Member]"
       }
      }
     },
     "localname": "In2017Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_In2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2018 [Member]"
       }
      }
     },
     "localname": "In2018Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_InTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2019 [Member]"
       }
      }
     },
     "localname": "InTwoThousandNineteenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_InTwoThousandNinteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[In 2019 [Member]]",
        "verboseLabel": "In 2019 [Member]"
       }
      }
     },
     "localname": "InTwoThousandNinteenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_InTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[In 2020 [Member]]",
        "verboseLabel": "In 2020 [Member]"
       }
      }
     },
     "localname": "InTwoThousandTwentyMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_InTwoThousandsEightteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[In 2018 [Member]]",
        "verboseLabel": "In 2018 [Member]"
       }
      }
     },
     "localname": "InTwoThousandsEightteenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_InTwoThousandsTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In 2020 [Member]"
       }
      }
     },
     "localname": "InTwoThousandsTwentyTwentyMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_IncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Plan",
        "verboseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "IncentivePlan",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7",
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_IncentiveRsu": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive RSU"
       }
      }
     },
     "localname": "IncentiveRsu",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_IncentiveRsuIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive RSU Issued"
       }
      }
     },
     "localname": "IncentiveRsuIssued",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_IncentiveVestDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Vest Date"
       }
      }
     },
     "localname": "IncentiveVestDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_IncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "IncomeFromGrants",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 18.0,
       "parentTag": "vnrx_OthersComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net Loss attributable to VolitionRx Limited Stockholders]",
        "totalLabel": "Net Loss attributable to VolitionRx Limited Stockholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_IncreaseInValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in Valuation Allowance"
       }
      }
     },
     "localname": "IncreaseInValuationAllowance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_InitialTermForCentralLab": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial term for Central Lab"
       }
      }
     },
     "localname": "InitialTermForCentralLab",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_InitialTermForPoc": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial term for POC"
       }
      }
     },
     "localname": "InitialTermForPoc",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_IssuedOfCommonStockFromSettlementOfRSU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued of common stock from settlement of RSU"
       }
      }
     },
     "localname": "IssuedOfCommonStockFromSettlementOfRSU",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_JanuaryOneTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 01, 2021 [Member]"
       }
      }
     },
     "localname": "JanuaryOneTwoThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 13 - March 19, 2021"
       }
      }
     },
     "localname": "JanuaryThirteenMarchNinteenTwoThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_JanuaryTwentyTwentyThusandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 20, 2021"
       }
      }
     },
     "localname": "JanuaryTwentyTwentyThusandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_LeaseAgreementExpirePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Lease Agreement Expire Period]",
        "verboseLabel": "Lease Agreement Expire Period"
       }
      }
     },
     "localname": "LeaseAgreementExpirePeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_LeaseAgreementExpirePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement Expire Period"
       }
      }
     },
     "localname": "LeaseAgreementExpirePeriods",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_LeasedEquipmentAmortizedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leased Equipment Amortized Term"
       }
      }
     },
     "localname": "LeasedEquipmentAmortizedPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_LessAmountRepresentingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Amount representing interest",
        "verboseLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LessAmountRepresentingInterest",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_LineOfCreditFacilityExpirationDatesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Maturity Date]",
        "verboseLabel": "Maturity Date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDatesOne",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_LiquidityAndGoingConcernAssessment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Liquidity and Going Concern Assessment]",
        "verboseLabel": "Liquidity and Going Concern Assessment"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernAssessment",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/LiquidityAndGoingConcernAssessment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_LoanAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement Term"
       }
      }
     },
     "localname": "LoanAgreementTerm",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_LongTermDebtLessAmountRepresentingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Less: Amount representing interest]",
        "verboseLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LongTermDebtLessAmountRepresentingInterest",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_LongTermDebtPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt payable"
       }
      }
     },
     "localname": "LongTermDebtPayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_LossOnDisposalOfFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "LossOnDisposalOfFixedAssets",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ManagementAndDirectorsFeesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Management and directors' fees payable]",
        "verboseLabel": "Management and directors' fees payable"
       }
      }
     },
     "localname": "ManagementAndDirectorsFeesPayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ManagingDirectorsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Managing Director's Agreement [Member]"
       }
      }
     },
     "localname": "ManagingDirectorsAgreementMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_MarchTwentyFiveTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 25, 2022 [Member]"
       }
      }
     },
     "localname": "MarchTwentyFiveTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_MaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Date"
       }
      }
     },
     "localname": "MaturityDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_MaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen da",
        "label": "Vesting term"
       }
      }
     },
     "localname": "MaturityTerm",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_MayOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 1, 2022 [Member]"
       }
      }
     },
     "localname": "MayOneTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_MilestoneAmountRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone amount recognized"
       }
      }
     },
     "localname": "MilestoneAmountRecognized",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_MinorityInterests": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterests",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_NamurInnovationAndGrowthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Namur Innovation and Growth [Member]"
       }
      }
     },
     "localname": "NamurInnovationAndGrowthMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_NamurInvestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Namur Invest [Member]"
       }
      }
     },
     "localname": "NamurInvestMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_NamurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Namur [Member]"
       }
      }
     },
     "localname": "NamurMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_NetDeferredTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Deferred Tax Assets [Member]"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_NetIncomeLossSinceInception": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Since Inception"
       }
      }
     },
     "localname": "NetIncomeLossSinceInception",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/LiquidityAndGoingConcernAssessmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_NetOperatingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses"
       }
      }
     },
     "localname": "NetOperatingLosses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_NonCashNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Note Payable"
       }
      }
     },
     "localname": "NonCashNotePayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_NovemberOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 1, 2022 [Member]"
       }
      }
     },
     "localname": "NovemberOneTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_NumberOfExpiredCancelled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of Expired/Cancelled]",
        "negatedLabel": "Number of Expired/Cancelled"
       }
      }
     },
     "localname": "NumberOfExpiredCancelled",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_NumberOfOptionOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of option outstanding ending balance"
       }
      }
     },
     "localname": "NumberOfOptionOutstandingEndingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfOptionsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercisable"
       }
      }
     },
     "localname": "NumberOfOptionsExercisable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfOptionsOutstandingBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding beginning balance"
       }
      }
     },
     "localname": "NumberOfOptionsOutstandingBeginningBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfRsusOutstandingBeginingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of RSUs outstanding begining balance]",
        "periodStartLabel": "Number of RSUs outstanding begining balance"
       }
      }
     },
     "localname": "NumberOfRsusOutstandingBeginingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfRsusOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of RSUs outstanding ending balance]",
        "periodEndLabel": "Number of RSUs outstanding ending balance"
       }
      }
     },
     "localname": "NumberOfRsusOutstandingEndingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfSharesVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares vesting"
       }
      }
     },
     "localname": "NumberOfSharesVesting",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfStockCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Cancelled]",
        "negatedLabel": "Cancelled"
       }
      }
     },
     "localname": "NumberOfStockCancelled",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfStockOutstandingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock Outstanding balance"
       }
      }
     },
     "localname": "NumberOfStockOutstandingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfStockVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Vested]",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "NumberOfStockVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants"
       }
      }
     },
     "localname": "NumberOfWarrantsAbstract",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_NumberOfWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Exercisable"
       }
      }
     },
     "localname": "NumberOfWarrantsExercisable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of warrants exercised]",
        "negatedLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Number of warrants Expired]",
        "negatedLabel": "Number of warrants Expired"
       }
      }
     },
     "localname": "NumberOfWarrantsExpired",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfWarrantsOutstandingBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants Outstanding beginning balance"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandingBeginningBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_NumberOfWarrantsOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding ending balance"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandingEndingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_OctoberFourTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 4, 2022 [Member]"
       }
      }
     },
     "localname": "OctoberFourTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OfferingCostsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs from issuance of common stock"
       }
      }
     },
     "localname": "OfferingCostsFromIssuanceOfCommonStock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "offering expenses"
       }
      }
     },
     "localname": "OfferingExpenses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OnSeptemberSixteenTwohousandtwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "On September 16, 2020 [Member]"
       }
      }
     },
     "localname": "OnSeptemberSixteenTwohousandtwentyMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OnTwoZeroMayTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "On 20, May 2021 [Member]"
       }
      }
     },
     "localname": "OnTwoZeroMayTwoThousandTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Operating Lease Obligations"
       }
      }
     },
     "localname": "OperatingLeaseObligations",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right-of-use Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssets",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeaseRightofUseObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right of Use Obligations [Member]"
       }
      }
     },
     "localname": "OperatingLeaseRightofUseObligationsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumLeasePaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumLeasePaymentDue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Present value of minimum lease payments]",
        "verboseLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2023 1]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2026]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInRollingYearFive",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2025]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInRollingYearFour",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2023]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentDueInTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 - 2027"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInTwoYears",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2027]",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingYearSix",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLeasesLiability1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeasesLiability1",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OperatingLossOnDisposalOfFixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Loss on disposal of fixed assets]",
        "verboseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "OperatingLossOnDisposalOfFixedAssets",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OptionFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Five [Member]"
       }
      }
     },
     "localname": "OptionFiveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OptionFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Four [Member]"
       }
      }
     },
     "localname": "OptionFourMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2",
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Granted"
       }
      }
     },
     "localname": "OptionGranted",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_OptionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Two [Member]"
       }
      }
     },
     "localname": "OptionTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OptionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options One [Member]"
       }
      }
     },
     "localname": "OptionsOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OthersComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Net Comprehensive Loss]",
        "totalLabel": "Net Comprehensive Loss"
       }
      }
     },
     "localname": "OthersComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_OutstandingAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Outstanding award]",
        "verboseLabel": "Outstanding award"
       }
      }
     },
     "localname": "OutstandingAward",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_OutstandingAwardThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Award 3"
       }
      }
     },
     "localname": "OutstandingAwardThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OutstandingAwardTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Award 2",
        "verboseLabel": "Outstanding Award 2"
       }
      }
     },
     "localname": "OutstandingAwardTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_OutstandingAwardVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period"
       }
      }
     },
     "localname": "OutstandingAwardVestingPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_PatentsAndIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Intellectual Property [Member]"
       }
      }
     },
     "localname": "PatentsAndIntellectualPropertyMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_PayableByCompanyForServicesRendered": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable By Company For Services Rendered"
       }
      }
     },
     "localname": "PayableByCompanyForServicesRendered",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_PaymentsForFutureResearchAndCollobration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments For Future Research And Collobration"
       }
      }
     },
     "localname": "PaymentsForFutureResearchAndCollobration",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_PaymentsOnFinancingLeasesLeaseAmount": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Payments on financing leases]",
        "negatedLabel": "Payments on financing leases"
       }
      }
     },
     "localname": "PaymentsOnFinancingLeasesLeaseAmount",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_PaymentsOnGrantsRepayable": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments on grants repayable"
       }
      }
     },
     "localname": "PaymentsOnGrantsRepayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_PerformanceBasedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Award [Member]"
       }
      }
     },
     "localname": "PerformanceBasedAwardMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_PotentiallyDilutiveWarrantsAndOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially dilutive securities excluded from the computation of EPS"
       }
      }
     },
     "localname": "PotentiallyDilutiveWarrantsAndOptions",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_ProceedsFromGrantsRepayable": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from grants repayable"
       }
      }
     },
     "localname": "ProceedsFromGrantsRepayable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ProductRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product"
       }
      }
     },
     "localname": "ProductRevenue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_PurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_RSUSettlementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Settlements [Member]"
       }
      }
     },
     "localname": "RSUSettlementsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_RSuVested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RSu Vested"
       }
      }
     },
     "localname": "RSuVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RSuVestedIn2024": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RSu Vested in 2024"
       }
      }
     },
     "localname": "RSuVestedIn2024",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RSuVestedIn2025": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RSu Vested in 2025"
       }
      }
     },
     "localname": "RSuVestedIn2025",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RepaymentOfGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment Of Grants"
       }
      }
     },
     "localname": "RepaymentOfGrants",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RepaymentsOfLongtermLoans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment Of Long-term Loan Amount"
       }
      }
     },
     "localname": "RepaymentsOfLongtermLoans",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit"
       }
      }
     },
     "localname": "RestrictedStockUnit",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_RestrictedStockUnitVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Restricted Stock Units Vested]",
        "terseLabel": "Restricted Stock Units Vested",
        "verboseLabel": "Restricted Stock Units Vested"
       }
      }
     },
     "localname": "RestrictedStockUnitVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails",
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_RestrictedStockUnitsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member] | One"
       }
      }
     },
     "localname": "RestrictedStockUnitsOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_RestrictedStockUnitsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Vested"
       }
      }
     },
     "localname": "RestrictedStockUnitsVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_Royality": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royality"
       }
      }
     },
     "localname": "Royality",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_RoyalityOnRevenuePercentange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RoyalityOnRevenuePercentange"
       }
      }
     },
     "localname": "RoyalityOnRevenuePercentange",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_RoyaltyRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty"
       }
      }
     },
     "localname": "RoyaltyRevenue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RsuCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Cancelled"
       }
      }
     },
     "localname": "RsuCancelled",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_RsuExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Expense"
       }
      }
     },
     "localname": "RsuExpense",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_RsuVestingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of rsu vesting"
       }
      }
     },
     "localname": "RsuVestingDescription",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_RsuVestingEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Vesting [Member]"
       }
      }
     },
     "localname": "RsuVestingEventMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_RsusHeldForTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RSUs Held for Taxes"
       }
      }
     },
     "localname": "RsusHeldForTaxes",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_SOFINEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOFINEX [Member]"
       }
      }
     },
     "localname": "SOFINEXMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_SaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock"
       }
      }
     },
     "localname": "SaleOfCommonStock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_SaleOfStockPriceSettledPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Settled Per Share"
       }
      }
     },
     "localname": "SaleOfStockPriceSettledPerShare",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Future Minimum Lease Payments Under Financing Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForLeasesTableTextBlock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Future Minimum Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outcomes related to the prescribed performance targets"
       }
      }
     },
     "localname": "ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfRecognizedInShortTermLeaseCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Recognized In Short-term Lease Costs"
       }
      }
     },
     "localname": "ScheduleOfRecognizedInShortTermLeaseCosts",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfRsusCancelledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSUs cancelled during period"
       }
      }
     },
     "localname": "ScheduleOfRsusCancelledDuringPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfRsusGrantedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSUs granted during period"
       }
      }
     },
     "localname": "ScheduleOfRsusGrantedDuringPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfRsusVestedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSUs vested during period"
       }
      }
     },
     "localname": "ScheduleOfRsusVestedDuringPeriod",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_ScheduleOfShareIssuedFromTheSettlementOfRsus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of share issued from the settlement of RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareIssuedFromTheSettlementOfRsus",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_SecondVestingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second vesting date"
       }
      }
     },
     "localname": "SecondVestingDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_SeptemberSevenTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 7, 2022 [Member]"
       }
      }
     },
     "localname": "SeptemberSevenTwoThousandTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_ServiceRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Service"
       }
      }
     },
     "localname": "ServiceRevenue",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_ShareAggregateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share aggregate maximum"
       }
      }
     },
     "localname": "ShareAggregateMaximum",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSUs, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "[Exercised]",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentExercised",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_SharePriceBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Share price beginning balance]",
        "periodStartLabel": "Share price beginning balance"
       }
      }
     },
     "localname": "SharePriceBeginningBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_SharePriceEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Share price ending balance]",
        "periodEndLabel": "Share price ending balance"
       }
      }
     },
     "localname": "SharePriceEndingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_SharePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price granted"
       }
      }
     },
     "localname": "SharePriceGranted",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_SharePriceVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price vested"
       }
      }
     },
     "localname": "SharePriceVested",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_SharesPriceRsu": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price"
       }
      }
     },
     "localname": "SharesPriceRsu",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_SharesWithheldForTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Shares Withheld for Tax]",
        "verboseLabel": "Shares Withheld for Tax"
       }
      }
     },
     "localname": "SharesWithheldForTax",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_SingaporeDepositInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore Deposit Insurance [Member]"
       }
      }
     },
     "localname": "SingaporeDepositInsuranceMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_SixteenAugustTwoThounsendTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 16, 2022 [Member]"
       }
      }
     },
     "localname": "SixteenAugustTwoThounsendTwentyTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockBasedCompensationInRelationToModificationOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation in relation to modification of options"
       }
      }
     },
     "localname": "StockBasedCompensationInRelationToModificationOfOptions",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_StockCompensationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expenses"
       }
      }
     },
     "localname": "StockCompensationExpenses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_StockIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Eight [Member]"
       }
      }
     },
     "localname": "StockOptionEightMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Eleven [Member]"
       }
      }
     },
     "localname": "StockOptionElevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionExercisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Exercises [Member]"
       }
      }
     },
     "localname": "StockOptionExercisesMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionExercisesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Exercises 1 [Member]"
       }
      }
     },
     "localname": "StockOptionExercisesOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionExercisesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Exercises Two [Member]"
       }
      }
     },
     "localname": "StockOptionExercisesTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionFiveteenTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Fiveteen [Member]"
       }
      }
     },
     "localname": "StockOptionFiveteenTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionFourteenTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Fourteen [Member]"
       }
      }
     },
     "localname": "StockOptionFourteenTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option grant date"
       }
      }
     },
     "localname": "StockOptionGrantDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_StockOptionNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Nine [Member]"
       }
      }
     },
     "localname": "StockOptionNineMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Seven [Member]"
       }
      }
     },
     "localname": "StockOptionSevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Six [Member]"
       }
      }
     },
     "localname": "StockOptionSixMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Ten [Member]"
       }
      }
     },
     "localname": "StockOptionTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionThirteenTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Thirteen [Member]"
       }
      }
     },
     "localname": "StockOptionThirteenTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Three [Member]"
       }
      }
     },
     "localname": "StockOptionThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Twelve [Member]"
       }
      }
     },
     "localname": "StockOptionTwelveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Eight [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentEightMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Eleven [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentElevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Five [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentFiveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Four [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentFourMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Fourteen [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentFourteenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Nine [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentNineMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment One [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Seven [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentSevenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Six [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentSixMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Ten [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentTenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Thirteen [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentThirteenMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Three [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Twelve [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentTwelveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsAmendmentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Amendment Two [Member]"
       }
      }
     },
     "localname": "StockOptionsAmendmentTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_StockOptionsPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options purchase shares of common stock"
       }
      }
     },
     "localname": "StockOptionsPurchaseSharesOfCommonStock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_SummarizingTheRsusIssuedAndOutstandingMaturityLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summarizing The Rsus Issued And Outstanding Maturity Life"
       }
      }
     },
     "localname": "SummarizingTheRsusIssuedAndOutstandingMaturityLife",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_SummarizingTheWarrantsIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summarizing The Warrants Issued And Outstanding"
       }
      }
     },
     "localname": "SummarizingTheWarrantsIssuedAndOutstanding",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_SummaryOfAmendmentsToExpirationDatesOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Amendments to Expiration Dates of Options"
       }
      }
     },
     "localname": "SummaryOfAmendmentsToExpirationDatesOfOptions",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnrx_TaxWithholdingsPaidRelatedToStockBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax withholdings paid related to stock-based compensation"
       }
      }
     },
     "localname": "TaxWithholdingsPaidRelatedToStockBasedCompensation",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_TermsOfAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Terms Of Agreement Description"
       }
      }
     },
     "localname": "TermsOfAgreementDescription",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_TermsOfLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Terms of license Agreement"
       }
      }
     },
     "localname": "TermsOfLicenseAgreement",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_ThirdVestingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third vesting date"
       }
      }
     },
     "localname": "ThirdVestingDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails6"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_TotalStockOptionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Option [Member]"
       }
      }
     },
     "localname": "TotalStockOptionOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails4",
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_TotalVolitionrxLimitedStockholdersEquity": {
     "auth_ref": [],
     "calculation": {
      "http://vnrx.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Total VolitionRx Limited Stockholders' Equity (Deficit)]",
        "totalLabel": "Total VolitionRx Limited Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "TotalVolitionrxLimitedStockholdersEquity",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 23, 2021 [Member]"
       }
      }
     },
     "localname": "TwentyTreeNovemberTwoThounsendTwentyTwentyOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Equity Incentive Plan [Member]",
        "verboseLabel": "2015 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative",
      "http://vnrx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UKDepositProtectionSchemeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UK Deposit Protection Scheme [Member]"
       }
      }
     },
     "localname": "UKDepositProtectionSchemeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UnAmortisedOfOutstandingAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Un-amortised of outstanding award"
       }
      }
     },
     "localname": "UnAmortisedOfOutstandingAward",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UnAmortisedOfOutstandingAward2023": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Un-amortised of outstanding award 2023",
        "verboseLabel": "Un-amortised of outstanding award 2023"
       }
      }
     },
     "localname": "UnAmortisedOfOutstandingAward2023",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails6",
      "http://vnrx.com/role/CommitmentsAndContingenciesDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UnitedStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]"
       }
      }
     },
     "localname": "UnitedStateMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UnivercityOfTexasMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Univercity Of Texas MD [Member]"
       }
      }
     },
     "localname": "UnivercityOfTexasMDMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UniversityOfTaiwanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Taiwan [Member]"
       }
      }
     },
     "localname": "UniversityOfTaiwanMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_UnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain/Loss"
       }
      }
     },
     "localname": "UnrealizedGainLoss",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UnrecognizedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "unrecognized compensation cost"
       }
      }
     },
     "localname": "UnrecognizedCompensationCost",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpense",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UnrecognizedCompensationExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Unrecognized compensation expense]",
        "verboseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpenses",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnrx_VestDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vest date"
       }
      }
     },
     "localname": "VestDate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails8"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_VestIn2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vest In 2023 [Member]"
       }
      }
     },
     "localname": "VestIn2023Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_VestIn2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vest In 2024 [Member]"
       }
      }
     },
     "localname": "VestIn2024Member",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_VestingAggregate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting aggregate"
       }
      }
     },
     "localname": "VestingAggregate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_Volatility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility"
       }
      }
     },
     "localname": "Volatility",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_VolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility rate"
       }
      }
     },
     "localname": "VolatilityRate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "vnrx_WalloonRegionGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Walloon Region Government [Member]"
       }
      }
     },
     "localname": "WalloonRegionGovernmentMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]"
       }
      }
     },
     "localname": "WarrantThreeMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]"
       }
      }
     },
     "localname": "WarrantTwoMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantsFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Five [Member]"
       }
      }
     },
     "localname": "WarrantsFiveMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantsFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Four [Member]"
       }
      }
     },
     "localname": "WarrantsFourMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails",
      "http://vnrx.com/role/StockbasedCompensationDetails1",
      "http://vnrx.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "vnrx_WeightedAverageExercisePriceEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price ending balance]",
        "verboseLabel": "Weighted Average Exercise Price ending balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceEndingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceEndingBalanceOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price ending balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceEndingBalanceOne",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price exercisable"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisable",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceExercisableBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price exercisable balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisableBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercised",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceExercisedExpiresCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price expires/cancelled"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisedExpiresCancelled",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Granted]",
        "verboseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceGranted",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceOutstandingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Weighted Average Exercise Price Outstanding balance]",
        "verboseLabel": "Weighted Average Exercise Price Outstanding balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstandingBalance",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageExercisePriceOutstandingBalanceOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstandingBalanceOne",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnrx_WeightedAverageRemainingContractualLifeYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYears",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails9"
     ],
     "xbrltype": "durationItemType"
    },
    "vnrx_WeightedExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Exercise Price"
       }
      }
     },
     "localname": "WeightedExercisePriceAbstract",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vnrx_WeightedExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Exercise Price Exercised"
       }
      }
     },
     "localname": "WeightedExercisePriceExercised",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_WeightedExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Exercise Price Expired"
       }
      }
     },
     "localname": "WeightedExercisePriceExpired",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vnrx_stockoptionamendmentdate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option amendment date"
       }
      }
     },
     "localname": "stockoptionamendmentdate",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "dateItemType"
    },
    "vnrx_summarizingtheRSUsissuedandoutstandingtabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "summarizing the RSUs issued and outstanding"
       }
      }
     },
     "localname": "summarizingtheRSUsissuedandoutstandingtabletextblock",
     "nsuri": "http://vnrx.com/20221231",
     "presentation": [
      "http://vnrx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.18)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r441": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r442": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r443": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001477932-23-001497-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-23-001497-xbrl.zip
M4$L#!!0    ( #F";U9.0"':E1X  &*. 0 1    =FYR>"TR,#(R,3(S,2YX
M<V3M/=MRXSAV[ZG*/S!^R6Q5W+;L=M^J>[?<=KOCQ&V[+/7,)"];, 5)J*$
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MM:=1"K6MYW_"&7B$E9FO"ZS\/M$MO&@=R>8CDU5[@E(9U<I<EO3\(*[]SSX
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M&:9&3)E-&H5!JE"!WN<GL8<#X"<^%*:0;E$L7K\3Z8)Z'[,;:)B6P?#H0C5
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M!&.<C2QPH=%@DD(_6 "KEHW3AJ:IM1\L- J,A\UZP8*CP!@5V0!#H\*8T[?
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M>B01"@_QSIQ*<%'1]4].3O;D7^=#:R,_GFD\?\9@;PZ'#V?D"Y./NTE#J5P
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MLL4( H.D)6@[UL/@F*G<1#@8,@AMB]$.JBX-@</(!_<K$ /W->0%S@(2L]N
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M35GO)0A>]X1Q]W"<L?EOI+FEJ8M?_)DO09Y/*2UU9,3!,X[E$_\LQE6&[7E
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MA8=="E,*']92.% :YQL@JUOT %&.ZA/EZI:]'G[1#">^B$KHE_\!4$L#!!0
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MMC[[V*4S6DC5?\:@?X*9]RS_M!A-=> 1I)DESA;!["-%NWZ%#UV!M+]%ND_
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M4^O:6P&9:9!3#L)F[^#;49HNM&)(PN#>83Z@A6%XN-,KS2<S*PTG]^($A,O
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M.?>J(K7V,IJ[ (-8 KO7W10JP. 4YVN03A<S[UG@^&G;D4/(M9;-Q&6X6Y
M)!_>@)Z!1Q#&60;3^3/.9^'>)I41N0""BAQV+[1]B^/Y4Q"&EZNU%\!,&.&]
M!UY[%]"0B-#O9I@.<X:M:H*6.8#.9_<A0!]E?EE&L+:(J1Q"12R(Y8M?9V !
M$"?S6_0!1R+'0:.A0P@T>+=\$PMO.GY$@?H>J]'8(>4S^6_<S=*Q&-_$*>('
MG?S"%[X;C[,F*]*ZH/<6XA 8R@/Q;J[(J;Q'325*-O+\>7GC11]C*N28"KD/
MJ9!DFM^$.,>8^E9.7F9H6'$>D!*Q4_D\2A)9SIOD\H@YE*5I*!$/(CNGQ<Q4
M!9&6T7*VI6D0!Y1N8Q1(:SF:"4PIG-%/6XS1#QC?^<9/I_ .P,? YQE2U)3=
MT@VKR67?1.JBFL;QWK-@)>%^1UN^6<WMFC^N3GFJ9XE@(HUP1_H?@N72@,$.
M4OHZP73K14N!-:+^[(P)HGBF%+Y3A7+SF A[.\E84K$M#?SKBJSE('T>J"H'
M8B84U4E;@R\#O4J2)ST#6.ZR%%Z581/8]V"UV%XW7YIA"T5,B];LKBOO/H99
MYJ9<ZYA T-Y)I4MD(CJWY$.?+A9H05?^'CC-G01&+!+!Q5(9^9--D-4\E0%2
M;^<R$G59" 264H0).Y>K-8P?\\IQJG"P:/8!&I9<!"9++\)<>=%<!@O=QB(,
MX@,M4_$TYT31.I/:)-O5[T@YJ\U*M&&M-;&K7L;VFMJMUE@E^M29GB;3I_<L
MU6>UR:#U6665Z+-;:I@Y?_,W*,Q8DM'9M]O* 3N9*'8?E*)2#<_ &@(_R*Z?
MHG^'H*C_=KR*81K\*_L]5QAALI.F$1P"79_0=I^\XC)V#020BZD<@E$LB-U'
MK;B\_4C 8A->!0M!VH,2\3X 1<M3OR)C/2-(6$.M4313DAIDN#A<O7RC(*FI
M40R34;]QS&<:\YGV*)_I JL57*&/;U[_4$Y>OGO_B.%IZ"62^D:M.G$C3-9%
M,LMY3@)>MYRJE*9IW=$@\I\ZS&1UL-ER6\Z)L@7X$$*)MD!WH<;=C9>JN)=K
MS>QOFCO.Y_J.NBH6,<J6W!0"F22>)#FE?<24-TMR8>QZDP3\41X1VO/1"3AN
M7_L!)5<\N[X@ <=";Y",;C] 8WJ$=N-AX!S-#QAG\Z/&^P_\L_GD8)>.!)$O
MY$CE18BQ;/SH6W#'MS"FRVJ^M/^ZTV6U.DO&=-G"&S'$4^EE5"BPK[>Q=4=N
M6)JNTEEV0DGX;>>(ZM39(+R/'6=W._"%7DA;9>]M3X A6&K;DX"V_Q\'='GJ
M-63\'6F]X%!X+X\CC#L(0^"G&R\D$73A70<U4OM.BQX&HU).14E< I).U].8
MEOGFR%+N$.U6G"YXCTDS<ODD=/:_"O4,/8DH@W6DWP*LAR!:5A(( 0SB^0$?
MN<X=.@1I9QGK?O5=N6W+)UOYR51'C==EJV^VCGE4HZ]SZ+[.%O"@67T*P3S(
MGSA8Q/#)@W.Q'T- XI3'0B"'Y8PH)F<JQU IX2!\#M(YIP+4@/*93,$U( ^!
M9LAVD(W$.:=>@Y14<$4\%B<WT>E41&!_JZ8X]>CSIT@@RTE'N"9#'.'3\731
MX!$=F*\"[SX(\T?X[I,4>KZHUFV7SNPCJEX+MXM\)EXN.G_V09)DA?&GCP">
MQ/%?]!6LVLTKSF?6MA,7@.HBE_6,(_PZWQ7P$G ;+!_2Z>)'DI_HA"==/I$+
M.*G(8??J&<T:^:Y?U!"AFCN*!25!KS>7M-6W1]\R95S);XNW*O!#%O 18 M\
M[/MPXX6"HU3W'AW"LKN0)EZ(^A%!X(7X?:1O2$C.,Q[9<U6,ABYHG<=[K\>@
M.,H\]=9!F@]$'G"1O%<CI'!%O4(A[#[WU-@)HG_4/C6\<43_3_8?)R!"BDZ3
M\]4ZC%] Y<]*EDO+."Y ;TCT7F])Z9\PTS7 Z;S1$IL-^EBIMH[).W$9:I%<
M=I^H:K!ZB8M<X,,'^VFM%F!*>W(94:EPEA^\:C LN7[%:^\R1K6K5I:?MRK9
MPJ]!YR8^#.,G?%YI 0N+V&6,6/)8?AJKP:/PUA2[M<N0T#>D]+Z.=?J <V\N
M(Z4O(-LQ"PA<4+%,!DN/7S4S&IAWT(Z44AJ,73^K\WC(XO&#&H^'8^+%F'@Q
MV,0+289ER?DW$"^AMWX(?"_D7SH3-'<CT4(L@X6;5'?Y-*!Y$;U=(FAN_<*:
M="[1(/#E,)$ZL2,0AI >H0L(>PD1/W *YSP30I@'P6AG-_U;.HVJ#O$&]_UR
M'3C:O(@A"):14).U-@YIL<8YT6"WXQU'@VC;!W'4K\7A0DSBRO%"+(7=[/@N
M/N$]<0$K>'R'XMY@)H.U<17R.G (+F69;%6.J1^&A658/JH=BLT6HCV-5ZLX
MNDMC_R_!M8E/=59SLDE&-UZ;&$_OPS^]MX#G&%N1,R2)^*I$K9D;IW8V[Y:O
M1)3<R'+J&PT'<>6!.5]X"A_(M8:N*A_"N;R[VETHE'H&8/"8+?B748*,(.;D
M-DC^$ALC,953MDDLBN7"(EOF3M&DP7GWLQ?Y6^]BJD$8,95IQP6*)96)UZNM
M C4@TZ<9K!T\<\USJ8%[N/'@RSE.R9\]H=Y?9@_Q)O&B>?[3-!)[+MMT8/^D
MRUEU*VZX%@(16ZC5RYF=Z:9KK)CS9V39@P0DLZ=8B(*$QK[B5:P!C8)$(*)X
MK<[1"O+DAVMTXNK]7;3HS#Y4;;^1%L(1V+2FR["F2NN/93CJU_&EU/7=[4H/
M1]__Z448[ME# %, HN\XK1-AC_^-OM!V7TG'ONRCI/"1=)2-8*;U7@[Y1O'
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M[:9=WL#8!V">X (WQ9)-?/ZBRH5"*H?P% MB(J-1ENJ05>1R+Q.!P78]6W$
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MC A'@70#5U1'\US/J!M "M-G5@K3I]8I3)_'%*8QA6D?4IC&PO!C8?BQ,/P
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MY)4>>.92V==]AP>U68*8R&3*GY?/'O#D9^/4&[FBT3K?)I*9?@)\Y@3SXT<
MO26X!9A]A!KYRC9>>!4LP'\!#_)NL;7KPA7EMY.JGBPU@+25:P_"S&"RTE>^
MMDY?*;L;TUC&-)9]2&/)W@' 26<*K\=NFSF5J%+CW7)F2LF-+,>AT7 0^2?,
M^<)3^$!R3+JJ?$"9)!W4OH-LD3&);B=)=/N3FS40(V8JB>YH;X :D.DSF$3W
M8:!F\2*(O,@/O' KL=@B<@F<,H9<*2Q_7C/H1<D"P.0XFM\!^!CXZ 0\73#8
M3? \2]A_DGV.>D<9A)V5S.,:_'H50'WBXYQ1&65 )M_>O*%7AX\#71W(<WWB
M):':RJEUH,JZY0^9_3@B7]^#,L"LJ<)1=LUN?G1*W0.R7:U53IN<3P,U.=O7
M0N5>PFTSIXQ.C7?+GX')AUT9OG<CHPW" C)G;MV3;T1\ZI,>9U"7T09DU&W-
M(GIM^+S+M2&!*37)T$_;"89^^/,6R\19"]#?J3^[L094>3;QY:HHE)N:1-C;
M22*2U+)6E<569"W%Z/- 53D$$Z.N3MH:?-GI_=^?..T!63!A\ER]D?T<E[;I
M<G4)B"'0FJQUO(9!B#-/9T_Q["'>)%XTGSTAP%YD=U>5*.UKG1-NI16M) G1
M?K=,K]X;J#QMD@M(T:S:RK[R3?@=:QN=JL@$):UIZM2TN @6.&V545M/?*.H
M30_V86/OLRNWBMH(1$#1^P(\N(<;#[Y,(]#X;&47O!1I[0.A8+P492$8:,UI
M_T\OZ@J!&JD3"*B)0@#0FMZ>K5QE+GU]=/GR+25U @ U40@ >M^K!VB5"OP4
MS+-DW1](.^)MJ8C OK)-NFDJY50%6B X=;MCW>F0]MU[#E:;E>B85FMB$:KZ
MH;9Q1JNQ2O2I]4KU%']G_P_ ^+OWTMKVJQ+;_QX4C(^J,/U\#RW,CTS[$AK[
M2K=IA!B :3UN(XE6<92-=_SH!2'G%D)6MI;9= #PJ!7=97)O[+K9\7()P1(Q
M5A@_CDXY;5U1*H=]$W?0\F/U-^R XI9RK[5Q18LUMDW4U#Y>KV'\6!B6HN(<
M=Q_.:NJ*+MG<FZBO75YES2Y@XN+40;3DZ)33UA6E<MBOE^'6XD7Q OB'%V[
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MDA"?6$)\ZBC$I]&1/CK2]\&1GE\P";QP6ZA:[$OG$CCE3N=*8=FC/D/K6K(
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M0Q=4S.*[W[U<7F9'LBE*CV=N':$R.6U=T">']7Y78KF>YM4JCLH+.CB9&IO
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MXTZ!\Y?\SU5;%\GS6QH]/.;@9_]/ #\&7)U]^WP//NZS*$99!NZ2W1Y#R3Z
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M:COQ&ZWNL.U.TFZ_LZ)5TF*&_#\_)"^_!"@J6I[-\!_P_#DC72[^\N\72;$
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MZ%I5 7YKQ2K0<(!*RB!YJU>B"8@JH+J@IFR!83=[;Q?YE[L$LH)O&#(F^<,
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M3_<BFF]Z+!#VOYEQ7Z_*IS<. EIS:KM8(!<"W6WVO5/MD3ZSK'#FOX'\^!P
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MXCVZ17[R$$?JAZX*>B8/!Q0[T?3X2Y2H)VJS72Y<./;2A-O->$'404U_E+H
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MD); L2E V\*Q9J0U0)IS(>CD!N;2DY>6C,&5' M<8\U6%Z!A/K/U9NN"PUP
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M3]MN!A)!AV2I11BJ-%I@.9D%KB8.D8+N^%B[V>O'2ES?^';8R;Q84N82U7,
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M=#K*TTVW%TR,!=+HL8F'5)5,6-^&?T![MKMW8Z[K )=X!AJ3Q]S;(-]-'G&
M*GL%[,QQNQ[+IJ:2U5F. 5\RS>U:RY&MC^8K-QG%QZH\T>TLK9WN?Z"=MH>@
MJ637$]Z%+W.&'S7H#<"Y-QF_%FU/?S@/J[I+'+=@Q2L>I3G2G_I::G9]XZPN
MR-SC=1V::7>VF<_<]!^(T*H[R6D;EOSD/3C65K/M+]?E6%.'C)J_"=9K-SDF
M0JOC.Q^?8^?/SVGR@H)Z-UC=9,L98I$(9$4;EA"]W31?+#SK82IR>&UB'#0
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MLK:>G4X=IIK%&3MQ'0NO.(&=3,,B>00)[<3B93W88!YN7200#Z@:A<9/=\?
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M$0%4)2J5^H V, J=+J,TR\OG\"Q/5\8077C@*GJT!6A1IHT?;JQ78!9#ZR:
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M2DV-'F"M9I.E=5/4!W!G8Q@7D]L'4+1@8))C?0U"8DD4+!HE/HV$TO0X:Q5
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M#E\_F!LK*3[*AZ;0-]%1(G@N>O$(1RHU6)YC5:$$S,F[(V,PDQL+7".C6UV
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M[V(.!%\E4#\MFR)!I"%IS)58TJ_[71ZAI^==\H92G$PLNTAV.^3CY&(?8?I
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M?L!N17QU^[YXSOEKQ-N9L47-64(1U+K=8\G1!">;8(YLWAM21]AFU4$#8!6
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MA/8%9=DYJ=9QBYYQO'6,+Q(<<F&Q#AQD&H9.<]2 5\<Y8O&RO $,-]8+->H
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MCS@)LE ?DX'#,&"R^/2160,*B;M,\S0CN<+8]HLN,KA]Q_\O[Y(O:+N]Q@K
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M\JUS?3P3*0+C9BN"Y0O^I)-M_I.%-?%[J0K\:>ZQ\L=-#_6Y4:UBB\ATDG6
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MI!$A<[>U&*E5/"3[$"H2^ZXV3Q%?\]1N)49>=2_'+B(%9"4^XB5F;4V7.@G
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M@*+$234)U!O#4!JF5B:B9<F 5V@M(M8?-0.VA^]131+KC>$D'54K:]&R>'G
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M10,(I=95H#OAFQ(]PRSI%5;[>@+D65&JB;)D %\$^<L /;C&@XX'QGD<$^_
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MJFK')K2W>W"ZW??#G,$\.:L'.MN-=-8:2D69W*SZO<+@OI')D%JQ8O[/W&[
MBGW+&+9A&1>A.!].+L;^CB2-@JE+21DQNG8O1PF8R]R(=YNG)UB^7J=WV4->
M%\#(U[NP9B)>X[,L;CD8M#=C>+H9=T.1R[<UV-EAM+/]<"K<E3N@!#+&,OL
M"$T+*O*\_@"KK+I.VW<+7IY<!M[C)?%AQ76['S,J2!,3>9I$  IPC7K)3D*
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MQ\]T9^S8.N -\"WM[0^,($90$Q&0=71VW\_R^!HV3>J@<'OWK97_E\L16E,
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M//OZ^T?7Y#4I5D\.6D804VWA%.T/H)-XNB2KD]I[\A!'529F,.I#6?R.2OB
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M!2.<-L/'6Q+&VEV50X[L+J990@Y:S.T+-: U!5%H)0L_4[BX9@DM:'^Q-Z2
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M+I/8B8,\SUX*TWT#^*YG.$MSR9Z/#,WB4>06<[!E)/_85&LRYX-ADKT>N-V
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M+A'\<>P2<6I9ZCRM!MDE8B-&RPQ_;X@M8I=H4"[<+F$$7F#H=J0>4UC4+M%
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M;PU'PHN0H([#>'$JNFT]]\7G>RSEOD>SZ%+PYMUC8/_PDL% ^L#!HHZX6?1
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M48&B5G>MJ-7JOGLM&$=@7U#MLR_'9RO;5F%<J3#N96VG4Y'Y%<:5'N->(G'
M* "5[%9>+,LI #EQ;!E!\!^SRQ'^;GPL6FCBQN)DI7:P1-%A(A^GB*=SO]26
M)9X.(F+6]Q+^;A2P[R4M<9'343MX2B&@:*?SHIEN&>[PWUM%.YV-Q7%'[>#I
M/5561XDCN&XH#UX6_-I>P"=TV[;*J" L M^2P?75P_/0EU?E JF]H]<*58Q%
M*R,7GMS6:X5OYUKZ5P5/_;TG([9V]&JAJFL(E8MJI[951OC.#4R=88HI?*/*
M!>![V[:>TI19N-X9,P[B$+MVE1'"UL;*2,/W@7&[%&+S[1M[]3#V;DH)8;VM
MUPY?-.J4$<#9OEX]A$%A+"6$S;Y>.X0[@TB6DHBMC;UZ&%?Z4JGA6_@J=@^#
M[^NL:5?!MQ3VCKGPW0^'(S@_ZG1]>(-_RA6P=\RJ0WG[3EX[4%? P+$@4)_#
MHK$J0"VZ16-1D#ZY"6-% %I\$\:"$'T&F\6J@+3P-HM%0?KT1HH5 >D*&"D6
MA.ES6"56!:A%MTHL"M)7Z;:==1 ED7=+'6=Q'X">>D4W/"P(T6PCKQVDE:FA
MA$"M3 UE!&IE:B@70"M30_E 6ID:R@;2POO:%H1HJ9VG]])**]M1"8%:V8Z*
M#]#[& ,KMEMD8^"LICM6@E+!ZR;/+3 SF6BU(BV0[I$15T%F=;ED!<95XHT5
MZ![#&QO+XHT*&O4*&H^ 1OVY;JI.F C?VE;AI< % EWG[JF,E]<B,DCQO8CW
M2\=_I<Y$NT),\9V(]RQY\TI]B=81K( /\7XP?:VN1/L(BNY"O"=$7Z4G,:N?
MM_*PG-S*JX)CKJ!/X5T2]ZU0]#H]$[KT5L&=$0N39JG=$7= ,2Z#\CFYE5+!
M<987HK(@%,@Q<8>;J#($%!0PE3Y?6-!4:GEQ05-IUX4!2Z4D%Q$<A8^.71P<
M3Q(?^P),JS(]% LTE06A<,"H# $O ([[Q+0U8:4NKE:W,R@VM&9%CBZPG5*9
M;AX$7EWWOB3@S6^G N\J].!8'+A5^PWK-%:A*=+"H*WZ(>40O31P?9UE/F8>
M1?$M\PM#M8K.LSA7\>WZBW/A*D0O.XP5\ HL#-@J3L\^C*+[%!8'ZZL,UINM
MUQ?>+;&XB>+5Q^[ES35E >OK+/\QQTQ3> _)/4Q.KS,N<XZ)IN!.EGL8FUYC
MF.;,HRB\KV9AH)8S9E,!M3XOR;V*%+@_'.LOD.6^8)9*!<>"T^,LM_</$44B
M2 J>&[\ Y/(;62;<GBL"0>^@^"KC/<"QVK%L:A<KH!8L#I(5#YK2NRBZ0'\/
M@*QRV)3:0^%%\<7!L3)A4[?>(640QJ8W4W20W"4I5U?\ZDC+"\*RD@W* \N*
M;98'EI6 6 XX5I+E:L!Q;BG3RL)T/QB^8,,WVU)?KV#X+%;Z^G/+.!4,B\M+
M33WA.@Q99[A]#UP974=>X@7]9A_D<]Q.L8%X[HO@5 QMM^<MNW@BI5X=XA+M
M+/6=M8W="BB/ 8HZQ&596AH?U^J[BMNIOW<80(?_26$]!Q[P$*^;HE-O=<%T
MYUZ>B@?JXUV !^K37Z(LTK!ED8;AAQ5DER.A-.XAH30L1KH,"64[DU#P[XIF
MERNW;"\LM]#I/[T.6$%VQ37#*9K=J+CQ"]+LQO*X<2.3H/COC:T*LDNEV04E
M*'WZRZ39'8MF*^5E*72ZLSB=VIK.,NATPZ+3RCZP%-K<6)PV-Y8L \^VTE70
M7"5[W5W0;(XBS^]<PQ[&9X'D/\Q'WC@_>-'^WI9)XM-!%=Q$2UD->& 6P!?8
MZ%S WV_BB72*60?WJE#LGR)(132VC[PS2&,1N*5$M(6W6Z';TG($*BZVZFCU
M7.&G%3,J$S-ZX5J/AS<RZGFQC&V4.9 ]^G3D76(]O<YUV!F$UI&7(>QK_ADL
M"8\FT'CA,RW53?=83#P-K^@3W105%CX:"Q<ZSPH#+0P\ZR4ADFV81A4&+@$#
M%SK/"@,M#&S+44(?J9!7A81+0,)%C[3"0PL/FVD_C3E[I4+")2#A0N=98:"%
M@2=B7 F"RT&^NXZRPCN;\Y')2E67K]!O&;QOL1.ML/ 5(M8JPO:N_H^S;[.H
M-V"$Q^SNBJ\LY5I;\$R+;L)]"$)5 OJ*"^A%0:3*ZKKB5M>B(%)E/%UQXVE1
M$*FR@9;"!EH4=*H<W"5Q<!<%H2K+Y$I:)HN"/I6!L00&QB)&<E4VII+8F%;,
MPOFZT*D@S,(4MJE M/0R-\OEYW-S^"MP+8=#OD06_RSR.Y+="*/7J;FF#EZW
M+XN)8/W5@_^L&W+Q73_^ABX,_KT$NZC0Z]6@5_'9F_Z #:)?)RXN? (EPLL7
M9WL5VKU&M"L^.WP@+A;>(K.B-_)3F_Q62N:KD&R%D*RTK*[P70=6% N?NKG6
M2K&Z"LE6",D*S>K0T?/:](N[]EPBC>(E&5R%6J5&K4*R-5U71\5(D%?[U MF
MQDN4$A$?=  EPLJ78'@5TKURI"L**\S%L1R%D?3Z03&Q*8X2@ UL%I__*L-^
M)$8#KR=\^TZU-[ B82H3%7F]1+JTS=6%PM0F5A$2IS(YD)<RBJ3;$3?-.)9%
M+QH(R]R'U7K)OHBB\648(=NULZ_F[FA%X-.HX%-H:6=6="[PBW^?B!MOF YM
M(>8<>$.0Q,W ;<$POB][22K\\RB$29-Q,>&(K.]"!'TEQN#'W,X>+YVT E=>
M>L@]CT%"P:.!Z;RN+QD9OHQ/Q%]AM.^+.+;P9I&S?#+1I6 %) C=X 1+BF[V
MSBIT>YF(;W5Z&J>*B3P:Q$?W :_IL6#O;,5D@PHZ190,9ME!IB4##;LOJ0=;
M"OJMX2C"B@'%!>33BP2:KV+?DP1X+C:7&N'JOHRS MWZX?D'5RK3Q5U(E;O_
MRX%4R[WX*Z2Z%U)-HE QT>91P'V= #V[O/1ZTAQ0B> Z<V>O!;RD\AV+;AB)
M)(S&98(O:6!SM_9: *SI=S\<CM)$1F6"L'YXSM[*".+%[(;E$.1>EW90>.M@
M.9#J=6D'!4.J2CLH*4 K[:"4X*VT@Y(#N-(.R@'B.9Z=8Q&XQ80DRF( 13?M
M)6=16T97P&3S8,O67G3'S9S#7QTYN<#2[ O JX0P6FFX5+)ED:%4B8C%AM.D
MI%>)!"\0)5V)!*L-KQ+":*7A4HD$1892)1(4&TZ5:WA5A;<*4D6EJ1SO._#\
M%/-F?X@H$AS_STFR!1?VFC""J];>EKTT\A)/QH<W/3]UI8MF9 :2P+V<71Z*
M* !)(CZ747L@(OEE/'L N^'+'2>S(M!N5- N,+2?B@MSUO%O!W(4QEX"S"V1
M/=Q-F\!7;&!?R'[JD\S2[,N@-[93D&_?T2J29 6D%:"D-G 3,0HCJ7;6"N(4
MV$1O=8%TQXY6D9(J(*T )7V1?M\3@=K0UU3@;2M7%T2W[F<5J:@"4'$I2.O6
MIV& 3T6A[Z,)&YZ/9%QP!=M4ET&E.1FCO!X&:'7/J]:W;6U%R&D26A<R$5X@
M7:V5E ).LS>UHA!J]GKI$!F(=,^2@8QPTY$<X-%@1;%>6'1I?$&@+;S/586C
MZWJH;@C_7'AN*]@7(R\1?CE@=]O>5A1>L-<A*(=8F:\4,)K:3]'ALD"X;25K
MK'[([0)@KH24TH*VDFZ>4+I9"02HQ*+7 >A*GEHE@,X)<:D$KB*;XB:A5<E-
M18=0)?X\CW'GR>%823$K!:]*&"END<Y*UG@:,;*@!;4J(:6TH*VDF^<R[A05
M 2JQZ'4 NI*G5@F@2BBN\WA/#:K[29CU)4O^]4JJ?$)]X*FA50F'18=0)>,]
MCP7KR>%8B6HK!:]*XGIAN,R7B@L@4!5%Q"S.B3Q]!'RQ-KGL\,C-M3K\[V.Q
M-JD6M41(UC^L;=:+M4FUJ(=M,@T\WN'W]H'9UE"*.(WD9R\.MS8:.WOPFWY=
M_Z0_X_M38U'><CPUG&(O]..]QH/YSR?&=+TK.#'[R=-T**E:R -W,?4^?GD@
M@W#H!;.&770WN2'>YU=_VZ;/8: Y1SB"/^]U@(??+^8"%WZ[?:SWWLT>[#%,
MHYZ,^>- "I<0%3;R^9=$='WIQ,G8!XR_!/Q:B[W_RKW&Z.;3M><F@[U&O?X_
M,'_2#5U YP1>3%S]_)>SBX/#B[4O9YW.V<F>LSVZ<>+0]]Q/\,+[!/&6GK_M
MG8W9[[Q7\[VG]7W^9:1?/SH[[:RU6__O<,]IU$?))X>^.&J>M([_W',2$%%B
M)Y#7#ES@(OCDG#0OOK9.]YPZ[,=!VED3OM</]OY*8R#8,4SZOW]K?*A_^N7]
M:/F3]"2JZ;BQ&!3WH/_Y%V_8=^*H]^L;RGAKU'_"%XWUOT;]-X[PDUE?O__\
M_;35.3QPVIUFY[#]RWL]U+,LN'VX__VBU6D=MIWFZ8%S^,?^M^;IUT-G_^SD
MI-5NM\Y.GWE!/T0\ +4Z"8.:<["^O^YLU+>W=I]I$<^**O%(!#/H\N,H>?/Y
MZ.SBQ/D%:#D( V)]7L]1=\.%O+PM8N^-$PB\VUSI[1V$H/7"O%AFYLWG1GWM
M-^(/V9APG+B*S\]_O#FNU TC8%AKL)0>@'ZO_LDZ#IS7&LN7EXG-MYR>]/V1
M<+&8VZ]OZC8?TZ,/I-<?)'L-8%YO;#[%HVS^#\)D- ,0.#-]O!1#SQ_O3>YW
M***^%^S5:=AE@:H9!*GP+^0HC)(WSF48#05P#0_V#Q+*7C<,_:[P_1 V>8/G
MN;NS]>'3-%!'BM/B_Q^]-84:S=/3[\UCY^+P_.RBXYQ_OVA_;YYVG,Z9 SRD
M XS":6PZ9Q=.8_NM^\XY.W(ZWPX=B[T8UM+<[^#/C=W-K3S>E?UR. JS_:K_
M1DXRD,Z1%_>$[_PI1>0<!JYTET?ZYR1?'K(FF$.H/1<U>QAXX(KQ&*:6P9O/
M![+'IH#-1LW!D6<PC(I3%()3="(1Q&08NP^WV'HF;M&Y:)ZV6\06EL,QIDCG
M;.J;E^4I+R)$S&(I4]],GUTR]<U@ZAOYH'$0*:>^!"R=^FYZX<$"$XZFESF]
MWT4F<Q>8[!*@,?W8O_4_BQS'],39^R64:=$,/ V.&$W*<,D!&P>F [?+WN/O
MMT.RON"8/"0:;1IKFQ\^;FZN^)7%W'0-_]X3:1+J+R*ZF^@;OH\^/.Y2FU#3
M_T9&K[K3L-7UEU6"EH0D%[+OP70B2$[AES>??S\[IHOIX@_GN'6"JO="6I%M
M[IAWMD]X8F\/;T0OH<TYX:43F4TY(G;BD>RA==)UO,#QDMCI#40$[[TKP!WX
M4&+0,OK"]/!Q^VGI@6?9VOZ?YZ&,Y2 _^K:C$19JQEIYZ,S;#],@B<;[H2NG
M1<88G\"R]3@.*P2^N!9HT+R-J2KQ,2\O-^I/>U(6CDW,7TY0=L1-2[DA>@1.
M??/M-M8:NUN[]9V/"T#I#@ZFO[^240+3^&I/23A:TE%E__>".9R.T-0)(R?$
M4 WGKS3R8M>C:H_ ^I9UB]^]$,^F'5I/U!>!]U_Z_,Y9KN(T'YM?$A2M]8OU
M]KIS.!SYX1A%[><Z^SRF.Z?A>A'NLE5A%4W7C60<J_\<>X%LO/G<V/JXZ_R0
M<>+\$-'0:8\B#%]S+D+AUB89Q[($].F%;+SYW$X]H.]&H_Y"DOI,X9,>=&5/
MD?M>&H"@XL."ER:'JD/8AS_/HDYX#;?K-XFSQ&$P>1*U)0. 6.I9= XW.W"U
M12[^4WDE7/'$>'$>PKS^__-&)(U\_KA;1Y?[2[HHWJJ5H8R-!-+S1L)WY(WL
M40UO^!H[D\3O5DEGOYO;WI<B_D_#>?MH3$!":$92,.P_;'V8A/R[QV/;<0@7
MY_D@#(R9X,-V_7__]G&CT?C4V-QNO#"R9:HIK6GG4PS/^7*$"W8"6G$-5#JL
M10^\V@$Y7, AN+*DZ)>5SU?ZK8Q I1VE49RBHIN$3IN+?CN-C;?==TBCZ#YI
M]I*]IX783'_1O13;Y3@B%E1L-D'S>D&IL>,E/ADI#D5OX.S[(H[WYJN)VTMQ
MJSQ:&7SI,XL$D7A[/.R&_MOX775B=YS8J;*$$9(=WO0&(NC#%X'S8^#!-Q>&
M@>RMDO*[-$5 \=)Q8Z-+]/CF,\=H.Q2D77-&(G*NA)]*Y^_U]7J]X8PP,'*P
MJ*FGI KOTHY?T3.3\YO/OY]>_%&=ZQ+16A,\F?2GM!D)OQI%YL_VH=.D^410
M<XZ/]Q>UDJVHA>&)Y*U^3MYR3D%$?0&AZRG/)YNP%;AH>9).=^ST!K+WTP$*
M^^EXO'_+]^+%CG"N09Y;^QF 1N_$4H VCWZ8.$Y1>!>QX\I++V#7S$4*@M%6
M?5N?I 4 .-1UYT_X0X5I+$O3_@&+^PW7UE9+:]'*@"["*>7>Q).]7F@&80+?
M_"?UD!*  "[1:QU1@$T\FS(VT3)L/E$H2T8G3P+2WT,_#1(1D?L[BBM0.M<#
M2:Z""7B^;;QS!D"!"$37$;YO(&F#N"O5 S!F'JHY:%JT:J1-@##^C&%'CINB
M/94>'46R)TF<;VPX%&(7.V]A/+BFG#@%X30>A.B>=3C[ ]X1R>3:KT4\C8CT
MLMK#.T<$KO-V@[?8A;L.?N[^!1O Q^E)> <7H8;!H+&8UD!K%''B[-8=5XSC
M]65AYGX:13 +!Z2A^).() 4$_1.3,&9C*%PDCHE,>\W(BE $  Z]) &(2Q\
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M),9YXL-8<, 5D1L[&-_AN;--?'R@C<VWXMTLD66]$HHU\)0U0?%I]#BA:"A
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M&.]Y ;_2(8P'7K&/MS_<%UD*S]-G\A0E+X1'V7V2=/:9>YQV:CS#;%.[+4)
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M<PQ2**["+5BHUVN(#4!&V/])^'&-RHK+"!?B_3<[+=5- /OHC1)8I_PT<?K
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M);2,X7JY1N0-<))^*K# /S<[]B*DR!0XS5BOZ^AV63C7^[V+S2&(0?P,PNM
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M4V_/EVA,Z+&!V!A^60)0-DB9,[56X%HJ_\MLZ)J#\4&/?-&3VII:'?CR#GP
MYZ/Z)Z,[ &5>1.\(5!87OT=W-=X=@: S5X9?UQ/]((QAV%@!J +"(YA4)'V/
M<)[Z''N1RYX]&>>], R:.!V-D(TI68W\^)H4U$6"[N6<%T75)(1+:(0O3$TU
MYE$]65W^CP+D_/.U75C5$3_PB,^C,&'WA;X*T"<:(-XC*?C8.!Q#H8 <0"A.
MV&6![>0EMH6/9*+\:-7Q/^CXOVBW$"!SE(XRMY($S2(<>CW+193WD<1I1''%
MVC&[?_9[ZV"ML>N@V4;"F^LO'0SI/+.SX0CER\Q$:+E$:^SUU([=6"$\JM<)
M-I?6 7I>_-,Y8@^%UNA K,66T+PCU16:/S2:IBWT9.P'PROSP>;4^HE^UM_7
MV^N+-+7.Q=<=[NM0MRR@JK1.I%9@P%K#>)/4<LRA(J]<>1@?J+Y'P%B8,,_-
M"$]QG"" !MU(RN$+DD :B&O\!C#*/*$<L-E#5Q[L2L29Y4>%QV@/Y3KZ256<
M$;M>*21'N!2#$9E0 < &'!C>9I$<B#J5.0'F5N]B7%[(_QFF#@>=T;GE(A^
M,#'8!&D8;J%<H!&)TU/$AW2'X)(W Z^+KTX&+BKBS=Z\SG6+OSWNL991-,6*
MH-?;-28]2\6R,;<K;0<TXS'ZB\E\=*W6G2$<F^BML-3;G*1DY?H)S&XDQ4]
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MTL#$(BDI 36[$%0Z53^V?'8B\(; +]<KS^@SP18NR!A8NP&F=>]1GN1PF 9
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M4G.F ]0P:]>C((Z0$X!QF]0*Y4H&GO;=39C4A8:;PF%C0*K=ZL1P/:0YR^U
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ME$RX=[(7V*6;E8\V"T8Q-2K(HH*-1+E#%<+0-P6+.8/AZ*!I),\OJ&IH;?E
M4B\)=1JEP_"."3O'\@/&GLOG1I(6UYQ6YXP)872)Z=)WKLHQ?LB9GO.9(@YQ
MKRF.6NI*+#0^])*$XTNRR/B!\"]QA4",FZ6#1,X2G)51NU>I=_66#I)5!4(/
M%JL+6E*SL*F^9JJ)S0L5FZQ"K!E*%HLI<!B!7<VL*FQ*H0C3WH 2?0-MM#6U
M4NB$[] (&G6C8DSI%%9LXV15>A4@VJ5(-"X2I0,841(,@ZP:#$;FJ9H[<1I=
M>5;DX"?@F"HA6<6"6)ZQ-5I#%OO&INJW.G%D*(9#=5-P9(V51_*.CIXS4G26
MBDJ.UNDK9/X=9^&7^2!$E-=Q3NM4J0X6J)RFU)Q9&0VE8BZ#T-K!U.(%Y:\2
M%$A>-F9K78@G"R$3?197V3TPS)K_*>#K8P@QQ!(V0>8#JN"39$%I(-YCP9LD
M#0C8JIB$D;U5WZ&(,X&R^%8TH:"$1M4I=<2MHF%*S?51 1\K&Z_JG&IJ WFJ
M !#:W%%UYCPB727J44%:BB+8O\*)4).T-%T(D"O9ZMM_ZLA)RR"R4H64*)A4
M8J&;2ZK6(]&T[G3#&W@4K>.DL;!U?D;50572<! "'8( $8*BK2OMPO^H7 \F
M[U+;X"L/9)'UQYX&3\LY&VE$Z\IZ0UC7([LYM2P3:M&Q*\>AD6(RJ1ZU5DX6
M9-0G+3E+8+,+*;$)(1TBZT+_A&8_MN^ 54*B- I7M;2Z6*K(3<5.,DRB*A'(
M@Q3&UB9T.Z/#F>Z?T\I>Z>[KJ=@Y8'!H9.KSY9!O#?+@F(49&)8W1MH-3[*8
M8$FEJLIG@WRLNUPG#JVI\MP/+KT-(QR'O0S4@92N+QDV S$&$:'WL[PRU3?,
MK%#<EIL9>3=TKM,>82Y*1LS^T@_YP%2Y3BX*$X< QCO*=MH7LLW-5!$FLC"S
M2Y:CX[$H _5USYR=EA2,$ I<#/HU](.&>^/K-89J'I)6.UE5D_?.B,*E!+'D
M!C:-Q**>I"+1!:258 RP1E]%%[G!3&29%RW_J)Y/>:Q72BRMEXRE7-(5#H/%
MFBQ+6]5-].@\@(&;<J61'(:4_PQ+[O,1!Z&'14U)@$%+/SI9N+\0:9*P1+SF
M(@>; M.M;F(;K-_I+((0[8[76'*22GBHXY4!G.M %:0,?;,&SA >YRVX@!!7
MZIKG]Z0!$QK<-6AM+.IR&6JD=GUQFZ)9*%("[\Y?H6PXIIMVS93XP$(ARN@#
MZ!YF[6*G4]IK%HY;%7/9KX^2'DW_7ZGCU.UZL5T*@"-%.>N8E14:04JSTM\-
M3E/]2D1I77ZRYO13E.NS6Y[O?QT*-U5K-B]<ZIM]W3FC\2TT6CK:VI71@JO0
MOY*J0AK".:O4JPLU74:BSTVO9S,-U1 TJQZC?(&*>8Q\$0\%:V@*"Y"]# 6F
M.*"5(L+0H(BK8 ?('1&Z''QL5Y]$A:1L?/] COQPG*4 +!'(NLXF&7IRW%5%
M3[$I48ZF::*(B03Z[?FQ'!R@N889!WLB34+]1421"_1-E6[PU"&LAP$91?@F
M4LE%*N$3FQT2)3]$35:IA<H/1[E$2G+4;?>R@,T9T7.:YV;&\;Q3<KIZI+:8
M5Q'F]X)_TU,*J^4'P0@/-J'ERJ7D63M<J,D@=*N(_ON==SL+T]2YU2JKDD6[
MK P,)Z,D+,QHO9;-2,+S4RSR&+.D1XG*NNRD5/XSD)3($ZIK->IBW%03F88!
MZ27U=6M-,K%HN8IM*LJV842>"M(/HRQ59H-X*JX@$WBKE(O[GRJ%8NBBB]1[
M*NLWE0\3?BT9%)W'I 3=HF@H<11;):!N/%-A0$7:9Z9!$D1*I5G1LJ 4%%7N
M@&RR("MR=/:,H=;P=E$6$5T7SQ:"02KH)MPLA7Y3ZIWV('"IZAGCFF*4L$*<
M@GOZZ,)H*G)/*X\UKMI@G<(0"UE@ZB4(*CV/7&9X,7JJF4)7H'*$[-4VO&>N
M,WR5E2/?+I8YT?TY9P[@"$*T+*NH0G(H* N/\L<=6)<U!;=0HG+IE*UFP*H[
M6T58WN#0A_\^)@G;KITTK=1BC%&NNL-&?:/!E>,DR*P40":US&0''DU4'L?:
M)*H([3!TS??Q9#N/>;7-<\'"F3TC0_A)5Q8*R903P<8XTWS!Q$FQ9ID)"WIY
MWS::C8M-6$@2I3YEC7@Q(ST9 FI..E)1,7P@Z*Z)8.-H3,DOBNO8AG9Q@2PR
MYQJFQ>"81-F9" 8/A:&E7=BBZ[ISQ/:K(17!?E2R9!Y9L")#.)(!%C9DSP96
MH/9T<1SMI)W$ID"W0R<>8<XBDPE$G,<K KNG4%"ADNF63F(C!2BJ0))1FF2A
M0N3,M6L=O@_MMGTQ6]9(QN,ROL :>0)R)"I;IR7AJR$>$Y+)^E_I.%-GXII
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MUUNQ"@CFO/$Y&UCIH#-IN=T/AR/03_!4RFVMS:/E)5WZY!%2NT>Q!)BKA^D
MF([.I8,((]9T&Y_,7U1S5.J03(F!*IW U#K,HDBT%?3P!IUF;4)P^-H*/*@Y
M7U,14=OF;S0!?''1;!V3*Z_F'*&<BEC^+?2Y* 5\7W/V0>XX$3?.L7<)JVE&
M/5SNP1_Z)4SG8N9S@H6+48?E7[#35F\,1Y!;P=GHMU#-KIX[P6I7.'BV9C.
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MT05WX$5*5.0TK) E$Q&YNCDEF4YS30LR78^-R=V("VG[-#UR"%A9S.5DE)6
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M:?Q>JN*%#5^:FM:(P9X1XG2!?M6I@MHD>,1>S3"* E1SH?)EB79"NGY0W9_
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MCH6UR3;?6<R*:C*72<RJ1B(3E+&88#%OE-OZ$:4+U52D"7LX*)@([;VHN8"
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MQ6F@>2<Q!1@F?C0@ HBG([+1TL_4(<L1)..9*N.2.F$3;+6;6YD#?15KI#[
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MSD1?U+0)ECS'.B@B7Q^-;DV.:<!/%.TD7<I155)=K.):,9+?9)SG4(3'!31
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MVM=^/5KH,@%4\9FWD&L!H:)G$R)EQ=;6]K,U59I!RT\1&2$X$.\M4+D%@JN
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M=(J,R]#(#YD,^' <LDP-,\;Y;^"D2S5Z"AP64T6:3BL!H_N!$)=-GGK$8+O
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MR,UB(T;*C+(D3#>_CJ[CEA<N3@K(9$$NDN0%L:*$Z6P<&7*+)>GM@3$*74(
MO@(:-*@G1OSMBG5:/>7 >_*]ZW7.=^UP&\+X[]*K1)'CL1DAPB5(\PD(8H+5
MPY0X=S\IU(ZZ<VJF68V(%!IY,/^4X0;F,/OUJ@Y6@\=B)*Y-J38%;/L+J?U
M';>6WGR^ &FZD,+D:AFV@C(5L P28(A N,M90EC%\O<.A15=45:UZ G;@=:+
MN>+QFT(- PP7G7^PK9B;*%M0RYP+5;TRL?D,OZ!FH1I[I-JJ2"H@8J&E%W<2
MCVUM.D,&3&9V,]OGS04^E,"]"? (^U.LY0]2C(<D*J1,>;W$@XL%VI2M43>5
MKRC+**I4_B,L'U,YNG06W,9U0"S!K89Z6>HL<NT 7C([[/13"QE7^>GXECN
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M"]&VT]L4%DT[<%H@E C:L3K-H0RXXM=TN<4NS0&]F^[:S/)-&7WLA$(3RN]
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MYVC#I (C=%8.DM.K F#CK]2%R/VC+L/<CGA!\!+O*;'(J^RB_@2/,[1I0X'
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MXJ3D$>C.6(RE-:CK"NW9VMD=!JC']!KX%O*2:_K3>$FO$>T;#JV<GR!-9FX
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MO&1A+2I4HV%<.Z<;GM&U&YJ!;F=HXK$7HD6?2^V58PN'8-,/B4NBPI9HW7\
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M3E3V 3#CIG7;Z:9>! ".L:E=E5=5?YO>/ X]-*'&0)K+/0(420QTS)DNGU'
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M),2)1 44U#V;&_1]L$4<;BCNWBMR";:ZU,:="H!@/ER0%!_)^Z*SED:O((^
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MNUW<O&D^>=A\YU5Y"41=7?+>#YX#T^?_7>7!;1^\$3QU6^2,J5@1?SKEI/0
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M3O!;&6=U3I&\&4*OK-:/Z1(Z"*8 T8JLOMVS"XR?&,I)XJ]'=(G?M__8QW_
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M>"]^N3=NQ6]\%I\>Q$\?/_G:;[31Z3[#_WSAT_V= VCU3G="NL[+JJ%.1?S
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MM2?E$!9=* *IG767BT#TLW9912#QX-DBD,<7)OUR&8@5L;)>QWNBJ.2MJ>J
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M;A2B;L15/'$&F4/&$@P?[.#@*ENL.QVMJ#_'W1G!KO=&(R]R6<3L#IAL9(M
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M73),:/>77_H/@\O[RPOM[MOGZ_ZYUCL_O_UV,^C??-&N^O=?4Z_4<3BGV.7
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M3H#H(Q@MN@UDV$N90?OZRVFWSIZX\=S1:VM$VNTN,1HJ@4*2D4L'V]8)%+L
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M0$5'+AUOVW40WAW>F@:6B+S<7D]J02U'$B>[: MHBS=X>8'IX,U<8_LGM33
M$,7[UJ2 ]!$STW:=AI%NM^Z%H-KM^ IIUF,D.XI>L!4=>5=H6^L^U&O;M1O>
M&&_;.!%;1&\52,G?H[/P#25S'^\5HH'2HO<DB/5:X8[!L6<])A77<)A[9FOE
MQF@2HZ54:4E&+A]TA9O^E@ Z@[3K+V<-'9HVO7#=,?M9^2[:1&A3[I65!,8J
M@KK <UNW\XS)*WSNKY/T[3JI=5Y91Z)"^0< 1+W9))U:707$JZTL'-MRJSAR
ME4@LNS=SI=@G$Q97L?#]63#Y"6F;Y$@BP3B]MH\%Z!V=M&KRQ0(J.G+Y<,MO
M6+9)_N,NX%9OU(G1E>]R/J7\'9M]4>H&R5 !IH"B@')DBN@-#64NZI$&U#OU
MYA7.?HH5 J#6+JMS:J39[9!&Z^52B$-WWQTGC@IG-96#(Z-%NITN:7<*=" ]
MPHCXJE#5S##T[6$4FD.':J&GW7CNZ3F\V/=8ER<M]LY+*GV/0=?8@?U6.-\I
M#;[$/ 9_<R(+2'[G^?CV7@88 P]@,4I1$8-B^XX@76P:>1 ]%13*94&Y7CC+
MZFU1KK>;1-</ ^6'9PZLG%Q_ MYP?^]_:M?V%';-TAY";_1]XCD6]64U'RK%
MVNL517V[F^53QL8?H-YBNQ&PKBC+]MP]\ON"U6*T.J3]VLOJ#]2249#FD-[N
MZGDY(0T&5$=OD-8&690J!>/(1JY2?+ZB(U>)Q(>CZO+DBW-O.O/IA+J!_8,F
M'0KP@%#="2H)X(J.7"42R^Y(SBFMNO)\F*6KC2+?I^YHKH6^Z08.4UDUT_I7
M%(1XE9ADQ:^5LE76FRK;M^3#(VKAA!(5Z1P-YP(, \0"'[7G6H,4&;T$&)\I
MF"AT8/[,-6ON3'C/UIZX-ACC[9=#/S(XXA132,,4VS<%/ BF,&H=4J\=86/K
M-W=/+VKL$N>N5(K1G_'4%;ZOEWGJ&)L'.7R.% <<W(Z!<7>2 J-W26N#_%CE
M3#Y>B!:^T7>/$#5:F%E#&NW]%UXJY["RRJNQT8K$2M',S8.XH[[V, %30/OK
M+QU#US]JG\W 'K%+9"]L)\)$")4K<4RZ0.%;R)DN (!!O !<&%H82,#N%!!9
MM"QC?/@_!3PVU!'Z-U>+6L(=&RO(* NUL^;^8\@*O?*@M_ %YI*A]Y5^1*7D
M'M[(5=* *CIRE4A\.$KNW]G40#OMP9CF(^6*;J#=1F$0@H)KNX^2ZJH*PL>[
MT8K$TDDI.7(@8K&UUA"75%A5RC19:YD8V]4@Q&>4.*)NHNF0^K?C<V\Z]5QV
M7F5.JR6[90O7NS!)/C6;I-ZLD49-Y34HF!>"^79U"6\%<X.TL-5CYY5.HWT>
M6K^'0\^:XY_HC\@,<G5[,SA]Z/_O)4P.1]'8!U>]K_WK?W[0EL?1OO;NO_1O
M/FC+!X^6(?>(8HG'QX69[&6\=X,)U<S1R)O.3'>.I>*N%\+[T!%M MS@L4??
M=+29Z8=X 48XH0%%X#% FZC4CVW7=$<V/ 2X"2E+#WR_OQ5D=HP[QL680\^W
MJ,^P LOZ4&-@8+!8&5# JU;["_ 4,/+,M!#^"&5X*4=!K@ISDA4"D]EPXJ?S
M>5[Y.7E&H@T=4(PR4D-;:-<,F_$Q;Q^N3NO=C49-Z?+;#$3 Z="GYO=3<PRO
M^:"9SI,Y#W[[M(D")]Y&IY_^,+6)C_S^R^#V_*IW<_)IP$@!@,'2)YXP:L*[
M\-E2.6P!(YA_98_G.V>K?"#&:N.?M]>I@BC^[ _ZMS?W_]"N^U_[@\N+106R
M]!G] 4S@QC U0_,Q.:GP;AO'G'\ 1G=LEYZP\^7A\N33>9;#'V*^1H)F(TQ,
M0VY_U"[_'=GA'%8%XXB]?G=!Q_;(#M_O?*TOBX1XW5>>CP)+^R<U_4"[!!T?
M5'@ZHGCF:76=:*@+,L4>3\LWG"C>5 GG9 #SLUWMFVLGNQYH%Y[CP/2)1G^.
M* BO@ 4)779P+]>.R"5P,S]VZ#@L30"7JN;N6Y6<6%R5!(L8N>EO)\:2@Z!5
MMH-@[Y:$VN)*;O&+-E J)O<JC'L@>] R 87V>4>/HJ+,5!R-HFGDH/["%RB:
M8+\%25.'(M]I.6>P7^EX&'OR]C,X E:\\5S%=HKM-IW!QNZ+(]Z#55QLYEHN
M(@52J+7V+1&XNYF[$F3=_[>?P1X18.P; 7>F;9W:+YP+N:$ A8B#5@86JIAD
MW>>WG\$14#IC@<FZRV\_@R.@<[;/M*S;_/8S4&J^4O.W5O)^J;'_.U1ECV>!
MO&%\C1/@%UDQ\/8SJ (*>U,O<D/M#6'XJ]P@>/L95 &&Y^;,#DWGS:7AK[*"
MX.UG4 48/M.!5(%1IAE4 8PB5TS!4,'P;65BWBU92D64:095P"&[M+V:PO#P
MBISYC#^;CNF.*%G)+Z[)53PE38W4Y@SY4BE4O;5THU@ON!WCSO/RI_\3_5S_
M3]0X8<SY*R/1<L-7[J;J!T'TJEJG1H>T:FU2TU_NHU<I'!PS O4=(3!36\%K
M*K9M"\Q!J  HQ\CE ]#8"(!I:C/F7_1=X8LJ&XRZT2)-^,^H%[@ N@JX.'Q$
MKNT05F_5-X-DFB6PKN%ZR?!,VX(UNZ3;?KE!\Z&WL#M.N#4V@ML]#4W;I=:E
MZ;NV^QCL#5NZ7B-ZNPX *_?R<@6PL@#6W A@^3<W[@UFC3:@K, IJQ FCP[7
M>@Y@)6IGH)AUZZ2M%SCY9/3^J):9>P?]L2VWBB,K$A_]R(K$1S^R(O'1CZQ(
M?/0C*Q(?_<A5(K'\P7M1B!R@,:W9+/*+5K0V,H.)0X- HS^I/[(#ULJ./^7-
MT#26[ )D^8"\ W_(QI?E%0RP\@C_1>3;[N,=]6W/XJ'[&_K$O@I>$?QOMTEC
M@[M%*H648\9H_B5.96#T3].)*/ONEDN@2R&:MLE5X?=IJ_P 24;>0_1BX_N:
M7I$LL ?0II&.(NA540YI)&:[5AR(KTH1V!Z4_Z&^9X$B^*P0/54R5(Z1RT=N
M_L42SR&W0+:!@FDU1BX?IAM?#+%]SH(":S5&+A^L]4W!JG#XFH2(M_>H!30,
MG>02@?N';\J#5CYW-7;GG6"W!V6^Y:QWY?D/"6%OQ_=!]!!?MKNU"\UHD+9N
M2,=Z%1VY?) VWP"DO!?,MHXSX^5;K"J%D<-'YWK'6;M5CN-L/U!-W65%,*O<
M9?)(Q^)!L,+NLE=!\4 5Z8J.7#Y>BP?$GG>2*7!69N3RP5D\"+:):TQ!M#(C
MEP[1SL;AL2JC[S 3RVQ7FT5#QQYIWGA,T6<9$'A5* FVCYFKBH?N"OH8^NX=
M(^UM3-D;&K[:$]8DM5:=U#HJGTR2D<L':O'@W:ORR5Z3\LC.!@91!4\Y1BX?
MGAN'ZW:?1?9JJ!IU8N@-TE3B5):1R\=K\0!8*<EF:[![H-IW14<N'ZW%(V&O
M3S!3T#R"D<N'9O$HV*Z2RA1 CV#D\@&Z<9QL_SIGE[0:#>F0*'\JV<#\J3W9
MX02['.'AILW @M!\RI0S+?2X=^UT: ;P3U#,9J"DF;BWDH#^\-GM5(*U5''D
M\L7E#NL6F4,4>/7O&59%6_^>,^K 8[_YC%QZGF%2=9P?[LCEIUUU2JI7W E8
MMVG_6:^1AM%2.5CR@G$M%KM[*%E40K1R(Y>/VUT7+"J05F[D\D%:3KFB@FKE
M1BY?*>T6KE8\9G53_B2L!^4?4OZA8QRY_%-YAY6CL:.]9_TK"D+,1PT&WAIC
MG66^#9?%8<^UXC+NVW&VN%L=UX<[<OD8+AY.+Y2L5#J>"X292*M=(T97-723
M9.3RP;U%6>JVF4U*<$N(L&/&=O&:U\WRH!20)833,0.Y>)2U2-:4@K.$H#IF
M.&\<DU6J\E$F9*WSIV%E(TO+PK^'GC;U+'L,4V'_]L:J9;YRNQW%R&5+V$:M
M>*;!\VE9^>&%OGLON'7@?<WPZNU8J0$'/W+Y("V>5K!Y:M9. %M$&V@T:Z3>
M4/?22S)R^>@MGF^P73*7$KV5&[E\\!:OO]X@HTLAM7(CEX_4X@'DC=.Z%%XK
M-W+Y>-TX6*S4U</LR'7E^3 I5QM%OD_=T5P+?=,-')40ICQ3AS]R^?*Q>+[!
MBPEA SJ=>;[ISR__'=GA7##HN>#/0<J>F?"!.L0/=^3R0;I%L^PB&5\*L-4:
MN7S %D\0V#J+Z_7@+:"GUCJD7I.OYT5%1RX?Q\6KM3?+V%(2MUHCEXY4O7B$
MM4A*EL)KM48N'Z\;!UO5>7^(*54W--0<+PC8'8F@SVG_I*8O";C%"S_?WE]<
MWI]^OAT,;K]^T(8.[)RFPP("S[&MC])PW4;S?)4SZZYW<=&_^9(, 2]_B^4K
M1+P5(M:+Z1+ZMH-HX/;<-<B'4I0$A6>%YS5X+KG1N\*VPO:;87N/3>$5SA7.
M2\;YVG8U#;VL?O+/H'J;FVE;I*,W2*OU\@VUSX+]0#LF*N"N K?<;O.[A:_>
M;A)=?[G5DL)N-;"[=2/ZG4O5;J=+VAO<=K1K9&Z;"W:<BHDT3)"@_-B66\61
M%8F/?F1%XJ,?69'XZ$=6)#[ZD16)CW[D*I%8_J0)/N//IF.Z(TJT"SIB?AZM
MKA,-[6L9=E%FN.X@AK*4N-P+;L=;W4W.;KKGM^]MX?+@/S_YU*R3=ML@1DM=
M[2S)R.4CL+LC!.)7V)J?^@'/E-LV"8Z#4 %0CI%+!Z!1VPB A=(B=@=&O=D@
M[7J-=.L=A4@Y1BX?D?IFB'S5#?>[06>C0^I%KB>I CX.'YGKHV*&L1$T"UQG
MOPL<9N_+P7!9A[3JZHK&PP18?2. %;Z4?K<P,PPP4KHOY[DHB$EXNC:>0UB)
M9V6;M $V>JT ;&3T%*E OW)+JI$5B=7(BL25&UF1^.A'5B0^^I$5B8]^Y"J1
M6/Y /X_>P0O!F-9L%B5FC1("&H8.Q985>+W,_<,W=;=,^?Z/_&HR(U/88!2Z
MFR3S+4\ N/+\AX2PM^/[('H0 ?[M,P.,;IL8'?GZY59TY/)1FE\Z5BY*>U.0
ME.'6S7,DO(NLHB/O(4Z17Q[V'#XWOSRG=*QF(AE%0*NB&/+(Q_R.H\_B;ZOK
M;[;%HNI_=T@CEX_7_,ZBS^%U@QMO%#BK,'+IX*SG-Q-]#IP;7W*C(%J%D<N'
M:'[_T!R(5AE]\M]>D^<)LUUM%@T=>Z1YXS'U\:PC\*I0$FP?,U?EMWO<H9>A
M[]XQTM[&E+VAX:N=8772J<%_AG*'23)R^4#-[^.X%5 74MLX2B\BQ.8=(-2S
M_C2=B-[0)_;-UIVD$:+R]9&NZ,CEPS._%>.KO6%[@6J+M.L&:35J"JYRC%P^
M7(N'P%Y7;%,,N@>J?%=TY/+16CP45J#^1D'S>$<N'YK%HV"%*W<40(]WY/(!
MNG&8;.\J9XLT&O)92/+GD@W,G]J3'4ZP* O/-FT&]H/F4Z:;::''?6NG0[S,
M&VB?WN8M">8/G]O4Y="'3;_UTK)XD/9Y=RCPZM\SK(J6_CUGU(''?O,9N?0\
MPZ3J-#_<D<O/NFH4#]1NGG7U6K!NTZZ@4R.-(KV&5 :6-,*RL7%$]I496$J(
M5FGD\G%;/.:Y02:6 FF51BX?I,7CG1MG9"FH5FGD/2BE&P<_JZ!NRI^"]:#\
M0\H_=(PCEW\J[[!T-/:S9VZM'WAKC'66]S9<%H<]U[K\2?V1'=#;,1OA=H:?
MJXC0 8]</H:+1],+I2J5CN<B.7@ZWL?95&FBDHQ</KBWJ$K=-K%)"6X)$7;,
MV"Y>\;I9&I0"LH1P.F8@%X^R%DF:4G"6$%1'#.?FQC%9I2H?94+6E>?#I%QM
M%/D^=4=S+?1--W"43TWYU Y_Y/+%9_$T@A=]:@,ZG7F^Z<]YQWK!H.>"/P<I
M>V8DL#KC#W?D\D%:/&>@D--, ;9:(Y</V.+Y UL[PEX/WLWUU':'M-OJ<DQ)
M1BX?QL7KJC?S>2F!6ZV1RT=J\=!P$:>6PFNU1BX?KQN'@=5Q?X!MMFYHJ#E>
M$+ N\Z#-:?^DIB\)ML4+/]_>7US>GWZ^'0QNOW[0=)AZX#FV]5$:=GMAAJ]R
M7]WU+B[Z-U^R+W^+A2L4[!,%ZZ5Q\;R%%YU@( *XU78-<J 474!A6&$X@^$M
M.G(7\9$I/"L\[Q7/Q=,4MG:A*6PK;)> [?4U.ZWBA>2;.=:>0?(6!3OU&C%:
M8 -VZZ\#^(&6C2NP<K 6#Q$7\:WM&+)&E[3:+877"N-UXVAQZ=*SV>V01NOE
MK*Y=HU'^K"T.F<^F8[HC2K0+.F+"0:OK1$,"2:VVU&$5EA<-'2HM:ZU,<2=*
M>6LIKMT+;L=;]?YFG>1Y>[M7-*)OMDFG72?U=G$.JRL%O-I(;NP(R?@5%M%3
M/^ 1F6V#+1S,"L@*R,6 W-P(R,7[W>\$U'JK0>K=-BA!'85LA>QBR&YMANQ7
MM<;?"<H-HTUJ&]QDJA!>280_8ZJV-X)X@7[ZN\!SIF-/JTT,4$P:&]SU]"RX
MC\.C4F&@=C8":N'N^KN%:[.ID^X&"4L*JL<,U>YS4-T#"NM$-UJDVWJYT=FN
M<<C<?K^'0\^:XY\F;&V&O%>W-X/3A_[_7G[0&'TU]L%5[VO_^I\?M&4*:U][
M]U_Z-Q^T)=?=1RU#C1%%%O^X@(&]C/=N,*&:.<+^::8[!UD#>Q'"^TP?/@8P
MP&./ONEH,],/-6^,.7@!15@P=S-KU3^V7=,=V?!0$,('+%'R_?Y6D-DQ1JAX
MS*'G Q89A6%9'VJ,#1E#K@PHH%*K_040#XPV,RWLY8?8A)=R%.0Z@4^R3#J9
M#2=^.I_GW<<GSXB<H6..OF=\^MK@\A^#T_[-Q>7-@&W*Q[Q]N#K%F\\V&#6E
MRV\S\Y&>#GUJ?C\UQ_":#YKI/)GSX+=/FR2)BK?1Z:<_3&WB(P/_,K@]O^K=
MX.T.2 H S#E*$$#$'[^;\"Y\ME0.6\ (YNW:X_G.V2H?B'\$<%Z[CY_^O+W^
MXW?Q]_BS_J!_>W/_#^VZ_[4_N+Q(O]_+C/X )G!CF)JA^9B<))8=S!QS_@$8
M'10->L*D__D5WF^;X?"'A*\91<U@HETYWE.@P3K@S9_VO)QWES_!, T"?N7N
M-S@\XCD&V@5H3*:/\F<O4]I8^&1^[-!Q6)HP*M7.W;?:,[&>4WM^J;'_6PE^
M=C?0?F("PDGF((3_=M(ZV=-Y%:/X2F2TSZGI:]2UJ+6(V;?9_(W/#@6O0O R
M]@VOG$#PCB7BYG/Y]5EDY\;L]^[#4^ K$7RZ M\A5E_=SJAOAF@4]L#N_F&'
M-@T^2.(!7_*,9+"^."G@F"-U_JM-E[-0\DW2P.)"21EV2R:(+L/R]7Y1P]BZ
MY/C-TB(/W2=_G#C*+Y;4,SC2]X$C]+%WNJ3=*5"@?I07BF0*_?'^69\"=4:V
M0^&GH@H=/L6_C] #%@G_DY<H2:9T2I*T['-LRZWBR%4BL>P*(#]Y;->B;NRM
MNZ SD& V:V&BF:ZEF5,/)O$?U<]UE\?[^M-]X[+;Y=,]2[B>:_4R9-LVKZY;
M;Y%:1[Y;ZBLZ<NG@J^>7Q6Z@6I8!OD:3U%LO)W5*+=/?0"'-D>E9<F H-M4]
M'6H&5&/ ./7&IZ"<:H Q&BJ'0/G,MG%9[S*S)?[5:Z3>/0YT._X6T!Y2+DOK
MRY_8,I]NG5;=K)-.2XE_248N'Y'YA;L;B/]](5+O=C?JAB#UF2"'GH\^( VH
MCZD\7F Z>"Z,[9_44@? OMAMXR;5"Q<'I[P&%+QU+P3];L=72#W&<:KWZ0&/
M7#[N\KM*/R/FM\1= 4VC1?36RTU#I!;K<JCZ+)]>4[=;OP%;;=P".[<&XHMO
MPF^MB\@'%KNCONU9?YI.1/-OP#J^BZXJ.G+YL,P/.V^@U.\1E@9IM6O$V*"$
M5^HCX$U2.!B93E<E/@89?<I[D6,$<NI9]ABFDCJ!V)5YDO#!,7/@QMV-<]OT
M?'Z>R91R?T@CEP^V_#;$FXC[#<!61*(WFC52;\BG:,BNU)]\.I^8[B,\N9@E
MP@PL%I%U;'-H.RICI'+I!!4=N4HDEEW?S'$YW/ET9MJ61KEO7VF4I1_RC:WO
MW.Z[(Q]#-!>4_]EW!?5>&9AIU.NDVVU*=]A7=.3RLY ;^='K#?3,DB"824SN
M-HG>*3>[778E,B\)9#2"28$*Z=,1M7]@V;DD:#UJ/MFZ&?8JG\04O$\(^&I>
M:1ND55.%((<)K?SX\58BN 1HZ09IZC5YI+ <RC)KD:F-V'61H4JUV)?"O/%%
MRB^S"F]RR@GXNJAWO:D#BZC\.DE&WH/$S@\1;R6Q=P;#C.)<,TBG5NUROMR*
MF#&%;;9 <?Y!W4AIS>6+ZZU+I5?Y)*;>/2?>UM4(I-MIDT;GY3;JE8+",8-P
MZSKKTD#(5.J7VYHJG_7FSI"9.6<-^%BEXVCD1W0AOB8)V(^9S3:^-W=S*_:.
M$Q4+T3A)KU.*;GT]3*-#6GH!Y:@*Z#AF7.87XK[*NU(*+@V#&$8!/XN,AX(<
MBOY7TS4?6<-:=AQ8MD]'H><'?_VE8^CMC]J8TN3 D(0-#I\!UUO+S<)13E:G
MD%(1^.PBIN$5T$ZPW^L]FT5*XI7'7!J1WBP<LRP54)_T%M$WN-A%:LDMASI_
MNU30+JT&OV&_5@GX;H>=93<0]86CI(PS<[RB"X7(KU>O,L[1ND%:13)<#E3P
M*X3F([1PL'7O"-6[+=+8X/:E8W;?GR3]F[&S*;MRXAL6QO1=+:\K\?.M\Q4/
M2L:#6T=Q 0R(A3O?^V%;U/H\1U!D>#%%Q.NYL$F,=INT&P7\M.JH."J8;AWE
MW2-,C1KI-.NDJTN4)YFQ)8[,M)76J#ZVY59QY"J16'[]L^_^H(&DEU\HC![]
M1BL22R>&Y'"1WD7^:&(&E-W%./.QL#B<LS@7_7=DS]"]+</.*NOB)>MBZVX2
M=^:<75(P\'HC(+E/[P0*[AR3Q38N8R!L'= @S7:-Z!UE^E85G%MWGR@?G-UV
MG32+-+ZJEGLT3V]5[M&#8KZMKPY8XW=*(+%+]Z@Z(JJ-TM;6=PSL$:72G15O
MTEGNRG9-=Z1<&=6U<RLZ<I5(++O*FN/*0-UUYGLP%RO0QO!CS0Z""$051=_&
MR)M.X< )L)V=9-E?\D'Y]4F5K:T;7-P)$N(O^H* M^-S1C[6U'1;2Z]%VO46
M:3149;4D(Y</PJU;890&0J-.#+U+6A*B4';-,T?D#\R?VI,=3B:>8X%"BF48
MML7;&U,+NQL':[H@2\(!A\][SUAT6Z=E96[.O>>D''A Z;^GA+[R_-WVI=4[
M-=)H'[_WX3B1MG5FU5L@K0Y(,PI<:G*$_N;<;J%9Q?T1KQ? EG2JK&Y?JE+A
MWAHLD3VK)[$[(8"/9J\K?S+T#BCIJF>H)".7C[S"#37*0EZ]35IU^4KY#U O
M7Y3FCN<^GH;4G\+F#R5+)SE*CMJZ=T:6J1XFGA\.@&H70+17I'Z Q5OKJOY(
MDHQ</OBV;I"Q<_ UNP:HV@=^+:PDZKG(P\&K894XW[-]V]ZZKW^6I9AZQ(AX
M.V9=(J^!CJ]DL6P"!QP[I-XIU[!5$"L+8EOW[=\?Q-K-)FD;$A4R2Z)K9T2S
M\IOLGW.VZU$14^W6W8WQFK))HTE:+=6)Z##!M%T[B1+!U"9M=6?*<R)WG&3#
ML1Y#DJ66J&S3?#XK')M<XK,D!Y*U:PG8__:FV,UQZZNRFJ11+V"K'JC85H#,
M!V3A$&;I@&QVB%'QBUIRZF+B-'/M\US+2X16M3'RL=UZKMOZ0H$U10<)(EY=
M=/"I1;KU#JG5Y>OK+L/("L^Y>-[Z;H+R\6P8I--LDV93/D#+;H&<?+H<C^DH
MQ#1VV'R8GJO1GR-V'3B:(",\F+!DG_T%Z_9_F ZJ!8IG#X!GMP[6<E#<CB\%
M%.[-D-ZZR,;XWV4*@WL*.HD]"JF%7_1<:_&#S)-;AWF[3=*2L&>Q#",KV.?"
M?NLPL4RPK[5(LW;@!YIJK[=W3_&Q+;>*(U>)Q/(KR,P_PQ5BV^6>&E2(V5\N
M956(Y4/M#CR9G:V355YUA-]1W_:LU;[J(R?",HZLLL 5B-<W@R!MO4&,UO'[
M[ \8I^MANG7"RT' ])-.]#HHI^T"^5@R'B9OXO1?>WQH[,HO_:/VF<(/7?3\
M>V/MG]3T)6$;97(^Q_)+F3J]X'9<$IMO[22MD69')W5=OJ1E&496N,[%=3T7
MUS6)<*UWL>\&:=?;TN%:?MLFCD&_?"Q=PI?)@:3BT(?#P8U<#B[#3MK>U4DZ
MK3:I->6[4E:&D16N<W'=5!J7\N(?[,A5<O%6=.0JD5A^3?<AFLT<=J6RZ6@7
M=C!RO"#R^=T43.F]<KPGK>]R40\R6K6=K1* *SIRE4@LNW,XIQBH#_HMR*B0
M]1Z480]E!NL.;(JM+[J)"74'=+JAVT=6VG52Z\CGR*KHR.4#;NO+:W8%N&:3
M=&H';I_*4;C9=T?>E&JA^5-"::U\2+GLM_7U-9S8 _,G#9 #%]GO/]3W+# I
MGN6\4^EX3H:1%4[S<-K=^@*;8\2I\EW*K18=VW*K.'*52"R[KGGRZ<9S3[F/
M4EV/57&P5G3D*I'X /V4_/(:C=U>PV[&HA86#].?U!_9X@)P=EV*YLU0APQ8
MKM&3Z?.><OB/@(8AC\_@P_</WU1!1>GNI^[6%VDQ2O<9H2\B'PXDGGS.KK,(
MV)>WG-"7 @+6%AXJ_K:33T97>40E&;E\2&Y]K=9>(:D?>F6N'#[3V_&8(JF
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MUH?CS>(= W[%"2VO4YN8/U B4%?#*@2&!<:P(^_1!9LUWGGZZ.$KX7-S9H>
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M8>!(OHE/)3O5 UP, SGPS@AU=G@F5N[.5LYR6'+DXW8X'J(&%#?49/!_9O$
MOZX+736;A?M;\\@5#7F=US6,^8!C]>/Q-@R:GC976E&##(3WMTX^Z:WVV6KR
MC#:U'0?^0MBJ7; _F [*(NQC$,8BF<M+O%/<ZL.'I[:+PS(;R(WP!!8D Q(A
MM? L 5LD1+!97C2$LWX(]@D[=F*% >B.&V7#[_%$6L8 ,Z70B+%!(P9=#*]/
M#9GRPL0ZFQH2UA*>AVS.V881HL,R8384 >,H=BLNN&R03V)2PBXGILT38 !0
M-,-C$G&\2"!O&)K 0$$T'MNHT8>:, (9Z7Q[& E@I-?< D1^!])Q<1'2!"(X
MA:DY1]O9IT)#@1$"F#P.@0.G2#O3OIJN^<A]'2 !7&9=F9:%WFNN(0Q!,=,8
M;BE:S4-07M^9[\%0&7%; $-I^"Z8*[OV'#;&M6"F[X;OQ;*6GDJ7$!MY%@7@
MPEIPNK@?\)J \T[P47LW>L]?S.[V!67>%88^KAX,AV1W-!;N#KC;P_8M%L<4
MDBEQ>"#:@QDP\]A&.3P[!7S#G,7K, GG%"DT$Q=Z<DY\9[V/+<[8%D+'!J;&
MHJ#$SW!;9[YG12-^'3&  ,6W0[GO!_&&@9>%_8ZYDDTYSO^'1V$5W%YEM/><
M0+!P ,8,%QM'R5 Q.RQQU OBRPX$5^&.1K-5U@++&KT[XT@<J?!:QPZXMYDC
MW@(%#4"4'K1P3H\H,^0!0B: ;\8;OB*9@,G"B!_/(6,HH/K8YH'I+%^MQ-I?
M5A$L#P/RPHV W@<8P\(]XE\S2WG*T#%$%S6N"@T&>W&_8$,B-S[PG]FY,ZW_
MS ^%0#(MX$F4+D(<$30GX6QW+)P#,-.(2Y<1,]\SZR]+O]\ 2RI?(,D7,%2^
M@,H76#^90I%_%?(_RI"_T=WZ\N7/9F 'M^,[[K%E@K_G6@\P/@M4NF$O,7#O
M %V@UP8#&.6SPS*[%[PBR4%E]<#^PG_\G]'0.WKK;=(&ZMJI]A!-IW$<.EV2
MEJY)BQ=UM)Z.Q;PB,2)[$LQA$>/\P*+F+*GH$P,$;E@6$F4E#6WOZ=OZIE<!
M^"58S_G_KH/V/E7HEW7,M:')Q#=E,\L%="4>C\4@5>)7XO%5%D#."KL'4%V9
MA%OP\:SU$MN!)*Y@.;GH&_>;7<+OIWA\R,= 6[<"@Z7=CI.%O2&C<+0G?LQ<
M5@%DPRK1)XB6Y!(C"-<*NEH2>YZ%H+\#<\0+%.D(0305E?S,A#/Y)>+<T3KS
M?.353.; @K<U<:_R^(N5]&+F%9],".'0^3]"=U[6=<<2#7*=TR+))&\^J5\)
M'@*^Y_X7BSM_TA\Q:YDY$1<=O:838*[#8P3R 8QF^L-T(K8WZW?)ITZ<)&'1
M,?6Y5$HZ!K*U:OP]2#\3 UHHK&"3HH""H0][\(-[R,$XATF)6 :2C,?2\%\V
MG$_NHXU6"=\]HH&%Z//8&/.H14*^I=X\AYFYS,]TZHU/HT#\=F'CY^G<,"D
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M"!'XA=],0._"' [,7"%+'I5@:2K,W+2!\9B\9DSB\PR0!2LK@&]'/,YHI9*
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M8X9<IH<MWQIL08KMJ>"!)Q"\?'6SW'W-_3UKO(5[&S??6MS@3:X%2TSR[-)
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M1(:)AP3U0N:B<)B?9ZJB-]FQ%<>:16(],NVU7'65!W(P<L6\GICF\>5J,KN
MWY4G;*#HQ1OS,=B9F2H.>;*2-L4"FEX*1B7PH0@TU3CNTK(B#?3,T\&BS".*
MQYZNLA\O:JGG^MWUGD^P,S!HA"_,LIZ\=N#9W8F<4YF*<,4V:H$!8YHM,K/G
M<Q:#R!AOL8X@CW20#6W)D]44F2^+U84=9REPAB59"L4514X'[_R.-*7?ZQ=@
MFKKCC^_XN^J.7]WQJSM^=<>OVL7(T%Q"%/"5-,>!9S((8K)3TNU-\*HJ][L\
M:BOZ;G]@3?OUY4> =>&CDD[?>UW!IRDP2H%B$MY)XD+<K4ON]98S=5-?\C#/
M?68Y4^:'I6--&5^44WQ77_34>(3VBU@ ^U-3:=!D_4KK AX?L<=#<GEJ/?B$
M3T-ED7DVCL]V8_=SZ2:3A;)IZ:WCY+GIX$\$M/TH<Q@\>F?(,];MQVAZ8)2I
MC&5;T?@S*_*8$2;@E"KJ?:"3G.D6A.YM8^8]Z]E=8G0MGL.(&Z:A<*;XDC_2
M4 $%YW&KUOP .[N_X%%1FM4/5%C,86?H[;-^K5D2)?&#E$,%,H>#+7F7T_2-
M!T^GQDXB)$[8CT+Q&K'IE2:[,$UJF^=T*F*4+(ZU)5AVQVY;^1M9N8"^TIB)
MC>!DGE5Z4";/(7F*;PNB-62C-;AX;!+ELNUE@B4Y.Z3E/-$ 3YO&QN]9WQ<J
M$YD:!I0Z/[#XI5(\4BJE6R)U0R^2,6Q$XS%17]AH8F>ZR56RD7_AY46Z48J=
MO^A9U&LWWC'&TE+C@Y-1-\\SPHN?HH*.:&PI<M6>$*&JBZ[/*!78Q$MV_*C$
MY5*%[Y\*,1]9RB)9F$D0!+Q_<+C$,K901AF0$GOF>1,^I J1 1X]3#=*910(
MW\D\_=1T3SK"L\%>35L)T?Y#V0'#FI6D/YR<NJ4E1U1EP8:5T4]BGE3C3+4Q
M'QI'AS '*Y&G5)PHIF*9D2)-F4-E#NLQAV] O2W@FV^5852&41G&E<2E_TN"
M[Y;VB>NSBUC3GJ31O'.USS3%PAQ$:>HKPXYIS(RZPG2PPF<KP!D)$8%0!K\M
MYG,XY FMWJ"@9NQEBI)QIT9Z]\G(_='SYSP5,&[J2/\2?5C'5(,X>Y59H)65
M/M A8!/^S&?/=R;/>'IIKS9J;!/S'H"-HN<)DUM8ZLIRTDJDY.>>S6S!.-US
M\LM=T@#3QJ@5JVWG=0;!&';K<G#AO#S.9\ >2JP9 3X]V%Y@X61CB_9$]!Z"
M^+FP #1KGZ+O_(_U./]-^[_?+A)2X&-<SVWD[BM*VLG9%[SRNQWR.H#XQ?\/
M?"O>432_(F8"57DN"8&JWQE@0J7LL"ZXM-%+'!.A,<MH-_QCGZS['&KE[O?D
M5 W+:$3F!0O:)R>RV6C/XFO\E?,2MZ9<3D+M]H;;)J'2MHPC?-W=E+\H?L^K
M]RL'*LZH@E\NH2=<[FNCU6QICV#(::#3U9(&FYC7 =NW>=_4*"4RRGV&[X @
MXF#S:)8,/@_S%5_WFMWXD7''GJGM!V$*"+,<L?L71%&9 !P[^M04P@%-'<,0
M!7^MO.DL"[+<!3QZ(.R>GUD!RW%[),G$'GZSS5(I7W=31-UK 2DEY M7$BLF
M3%PGF'X=+-]7,QRY:@Y1[EC'N&0$$)Z/!DM0"4$C/2!DB=O-)6)# ?:]]T0:
MDSAS-18(VB[S&918-#/H A!0)#8 H=$S2$8<K:Z+UBU@*W%>A\347J0Q^8\V
MT'T<994&Z>/HD@</E!.5_BC]A2W?/[[6$P5TTLJ1I[#<<@*P),RJIS2XAB:"
M]4+%3T6'VD*DWZ ^*6_>0%LTAS3O,\X(LEQW$2M]VYWR2B]6()+Y$OT$'I[O
MY"5==A<;*OCUQ_C7B5D)V+HG=D#OT%@""4_B9M#9>Z:E:0%E]<K6V<CS9* 5
M(.+'>^>%?H$),CU;>B2A^-^LTQ%_)K:8D=9DW=J6E5XS@BJV$[^/.1O9/=('
M8Q8L1R1 G%C-)BNF?E8PQQ5%S8NRL]TG.,O=OE]D)U?11A6L=H_N-$E;R::I
MJ(84!TE6Z:ED%96LHI)55+**2E;9+LM1):ZDDD]X>HH@^638F=[WI^L25VI.
M3Q'[&[QI*B\(X-,Z>)P=P3G#E98675-H: ''LV@BAY=\4,_@?4#[? 3GF";T
MXT32@+ED20H[\CEV75*/BF&>C;KW"=L81)".0M$9:_W/APE0=S]:/X:N63A]
MX4;31:R)-0_7P3\$J109SP&O8?@&RR1I)T=0KHY-\7-$'SW'0:)8,Q(#6J/(
MIA)0\KE1<(8^"'><%WOHMW:*/=RPQV,( HS"%V^<:4?1",CXW63A8_4T=IQ8
M=D99677L'Z2F6:RN;^NF!(+U<=\'7)\UR^RN667*>=)9O),&]E,N%:5SB/<:
MG"?\SL>"P^,X[ ?2P"?2D3B)0XT$P"\?ETN:U_>%5L3PSB!8#C/RYL#-G2J,
M*2"->L*@<RJ\[:2N$XVGV&$4.(C&$5O44[)=.!58E) JUM6HCH$?;'9CEOG<
M4E7O/U@] X;[DGI#?IV*]U[Q=_$7]PMWXI )VPK3,"N/7"Z Y4TF+/YE7,_J
M=Z*NUO';<. 1UO5AS_^+E?W%%=(TUA_74F<>,,W66;-.K[2O0W*YOOQ<KJD]
M5E+I/>-5+KSC@5V\I78-^,M;^!EBP6HG-EZ1IB<Q9980E86P?NJQ5N:;H1_'
M&^(IS[A;7MSRXS D1$#! Y&<Y/(\J2WA%H ]?84MQW4@"QAD.O[)_3>?]I&H
M,4&D.G.CSGK"HE#S^U5L&N*%:VN\HRN<)#U28,'PEC8Y/32C(IHQ$?7]?&&?
MRIZS@-MF=EGK>N&JW$9Y#+C)Z"Z:!\+>P&H7>#%,2YC>+M7O\P_%YPX%=P9>
M-?YN3ECR!F%7MOBGN&=^=+_/O\\Q1E0_%:^+$Y6VE\+[>+T<*H+^N[?=J-V+
M"X0*L>,+WEZ[#T[>"^+S%G>%B-K>Q+73V,<F>LC)'HS+I)B-A>?_LP!4R*:9
MK?;\2BY3UK3^ZF\](Y3"EC]8F/$+BRL6;/'5Z"[U^-*"L85$Z[UZCS<[JZV^
MDEN)[%W0&CF+TH7L(!D$8V'9'BAC/Y4.XB4-E"BYZ!R@=$@C.PG'$G=9RV:]
M1.TFF+ N+YH>1?B4X"Z*:I%8@:022")3L?YX+!N$S**RC4)XWPK\>/8V;?-J
MHP;.RTM<=^C9D%60>CZ""$PW:#F<?L$2CY+RXB4/!%]/H_]43]F,$E2;;NAX
MYY-'B^7JK!'ZK9OI4*'_')'B@E+B:YQC5(;\#];)/S;?7Y6:=81G9 @RC(HO
M4I@E>K!=/O0PE2W%(!Z;-, RQ%CE-+XM]:R34ZTWJY,B!4E^&1OD6L[+?_E9
MS\O:<U? ""5MSL>?K0S#LN>87X&QU"F-EOKGYPKFY%71"R?<=&X6([9) S@1
M6#B?&%\?>B%XCGFG,VY[+M V"7PAR455,G99E'''-GE/EM+9_KV8/%"IMI,6
M;;BM1)>/L]W7J'"S]!0&<R)\$RN1G#NG$Y+H;=N@7486,G)ZWT0.+ZB7N+7_
M6\K[^"\7M">^?-W2MNY72Q5\1 ).@6B7J>U?N)/HMVSK<C22O%Q&-^DI!Y'=
MSDS8R': =)EVCZ^B:7H7-0YP'O4H37KU01%8P(=$#109YGS#P!>=;.RY#9],
M0=2HKN)/>:O=+\+\]HM6DDN?;J\83XW(<428JT-8)1TB.X?@!,-"/7+CR0UK
M@$-GFT:Y2^)4.4H6P5RJ,6F#)9:BL\2,B($QW^CG^>1%&I))JA;PX,=]-IA:
MM5)17E%N91[EC>TI+VY1;)1*^=X:RIMZUS % XY7:7YRV"C6]GPZ3E2%P?)4
M,@%'^!-K N2YL5'G\5)O#B<\Y]Q&B>+CI3=1ER@I!<GUPE1+T^66IKR3'9L]
M'M>^R&>H^[NW-65;!(N<VN 5FTS+K/*!C'%.PZU^>ZG[,6]6QU.^<<$HW&RV
M+JTUH3.*4XQ,%S&QL[>NXQ4?A4N/8]:3B ]I[M.C ;\TZ3:_;?S6DZ@IREK+
MN:+CV==:R4ZSM\9*NFM;X8L%TDCMR3C(GMKK+'^JRQ6["R0;TEZR\^I5XRA)
M<_'Z*A=/Y>*I7#R5BZ=R\?;(1>,99X)<M#:Q3-.2=E#4#> UVX_*6#[!5QN?
MJ)<N:=C-'.R6 Q5OTYOB)ND>D_#:CX.'UW(0?;N7'9;R)>H]\,6Q^ W:U7\6
M]CQ5A,IG1J7= *Q "30'F>NPZ]IX!BT;@O+@>XLYB[IAH.2)^"P<^<*:SM-<
M0?IQUOJ?>@79FGU>?D3B<#W.%K5\GUYZ1HT K!<>B$O>XI"F]C'SI&B&*N8S
M\)(KS!PC3S;0EL<%=!K9B[*.'/O19J4Q[S(Q?9!XO,Q(TEGX &96FI,>Q_M;
MYGO6!,O,27JS^,E[O%_$BY&QPR:H8K49>0 CR$OK?TN&1O%Z+N9"I9Z-N3=T
MA (^)UH!;\P >[59R4O<5B$>UCT&)O/V$;1[!IWI.HY>D]I'-,^5^VMTE.T4
M?$!:4[<RZR5*E>##$V9VP/I_3:-/T-PP'&L%#V+UPDE&7S0Y* @\@ )A]!AZ
M+QTLTY=GH_J1ZS<.>0 PNMUA@D@O9X0#;$!H '_0'"<<<>;1.]WI$FWO":Z5
MYTU-HE[_28-G6-=TX=![H29-<4Y)NAUH<<^ ^,J8WAPMB7%Z8_$HM=0$X3@Y
M@,TD0(:*)@FS#)G'Z'&@DY,BKYAM02(+]'*=]F*(,V@6O%@]SN?%]B2,.JQ)
M0KS.3($73=X!FM%QP)8=T"'!<;L8G!=,3V)3NX"?$OM 1\?9F=;'R822)1K9
M03Q-BA]SUFH;!)],TM1J:C?9-_"(@&NSYMST'S1&)^ZXO-D7%02&-SNF1^]5
M[(X(OH5@!1L?J)BB 2%N0#\C'10PMH8"46#OVPQ,!]UA>H-W-*/]PIW<N(B-
M03K0R 8'#?2-5JXP< (D,HCID7%J_6RZN" J: PR&<?I/=/?&\9O&N5ZAM_I
MH4;1Z"*>Q\?+"?"@QB_(716M3<6Q9&"*Z90RKO!I0A^=':YGE6)V&#M583B)
M+*X.32F"^*:?/,X=[X60.$^6-G<!BTF2-&!J$761>J;I%6@EXCP&%LW,K@2'
MJ]-=\MH'7C8,FL^B$S2SAH8J0^T#AF4:W\8S#YO&\YH)ED2*_Z+3CM 281'K
MF'79PA=@B([=--*W+QLDT)/X>/99CF;8GR84ETP9<=DFDD5EM_/UVQ]1*G7<
M\HH#I(@6\7UMG#01,Y&_+V%BO.7/>"2UCY;O>.#-Q6@HWFIZ>MQ 38\KH)$_
M41 KG?YM;UTN$^G?3X"R/)]M2X[LADR*93KSUXD=")%J924=@XX9*UBVJ6;4
M2"_]W!@$)MVYK.0ZDM9NT+=I5ICZ=33K$H$O+P?S)MCW;I*ZRF0:E?V!-8&@
M9Q(0W-(3TA_)'T"'T=J&-VTL> NO5*."KW=_Q-T)TF7V;.5.DL82:8ALCBO=
M :@23M8'6K7A,Y2/B8>T*,BFMPW\=O_3RH.3N4[ $-8=@":!P-*BU;*+J:@E
MS[+EX:,RLC9FX0(,C?81YS]:L9?&_D";E<!V*%QE)+[)_CUJ(0*4 6ED(V9H
M T!>Q489,4_H3WY@\Y/$7^(V(IU;S/W/J'PM>1LO6\G,.K4"#XOO7F(\SSO:
M1<L1+B76[]%J)C2M(O7PI$TTX]R$UADFY4744\ 8'8!^:M+3"UM0/]%-F2+8
MFT^)B%6-P$4V"A"_&4O:S8>OL:1ES)_MLJLN>M,6U\]PWJXP**)8:@88(]Y*
MQ\45L8@&(L6=+? TP[+2<YQXT2;;&.[AF3<5?*8!#-:8(QV*\?A^Z=EW\/#X
M41T%<YT N&"M(F^C1%,CEX0RR6]D&T&YR ($KA@6O.AQ28@CEY%FDJ=""/2O
M/#AT<ADF=TGP8^F(9WU+EJO&;Z=9U2)-ED65B.:8ERR*>("1'<J\*(N-MBE,
M[KI!1EFO$N;-TP1:'J=)>;0KQQS]U0< P Z/&5&GFW,WLXM':T+[(6:P;::1
M:FHMF3 4C3?$STHM!FMP7[B339.[$@G*/,UA"<- N>RCX"U4Q*/AP7B")O$X
MKK@=4>99:69@-C';J<^41?)D>-_+'$<VTDTFXX]X?7(PQQJ[3,.CV$#0YV8M
MUND-0J2-18$\XT4TH%ZDXS 9_7'QN'0HP$N*!W^G81":0S<N%8E-(LO91G,4
M"0C-UO0 )27R@FF![*>I_8,WYDFU0FIJ?T:IYJ+O+'V:RCL7&,KR. WEY-A(
M(EN;E-:DD<Z*),<306>>'S:H-N'<HTB IL.FBN)3^@O$P3"QJ5HX"UAP&]LX
M_RMU(E,:+P61LO'?U??NKE)5UHBD62,#E36BLD94ULCY98TX9!I*G,*Q:=WL
M=!;)Z) \;^,?-/!Z@P4HA'<5E2Y :.X<(+PESXGD?('=P#^93\_CA>NCAH(T
MG,[$:+?&A[JW8<.FL20&3P(;)[NXART 2)Y$@,VBDR6PG#)QR5D" =YS1W>V
M\!EL](3S->!QL?L:E]900$6!&( %^Y%V@GVTPTPV 6MK2@'9Q,881S9Y.Q4*
M9/%]6N?$:R!7GDIG),\Q$,0=MNG*NIK:/Y@_B@W,Z7@ 8):-[EQ$DJ21@"",
MPZ8 L'U3OX_U>LD4QO EIJZ(?!XZ S?&QRN4-#YF)<AVJJJ,S;5($2E%';9G
MW,;U\G*C5C3@@%HO%(A@HY49-H.A[2+*=R^WPZGU2SM2%$.!E'7()"P&AP=;
MB2689PZTE@QDB1IWY4PIOR>.39Z2%",^V (_P]K7%'@/=7\HQ^T@6$0<?*3%
MB,PU2MJM8>[#.(P:_$QC]#+WDE2<*+PBF&RG;K!B:_7Q[L^;RX8QU+[  26/
MH,9N&&WELUF[]5BC&S2&T?;8[A(C=7_ JZV+./J;A,.QYYJ-G=AT?H[BYGFL
M6P..F. !-.Q#1'PWX$'(*) $S/)H!1'=:1#U8O87_&J<UM-.HE:%,?_G$?_Y
MG08\E'4L=P5UP^Q T40D=J%"LY_X9J(7\Q]7WI"]@4"MA!K=M]&J1&-F7C+[
M3OZ>V0F.?PIITI^+T4;,2;2<0->2ZN,YR#L-8+K8WRYN;1)8J :C,>[T3HXX
MX/*>7(CJPL'&4@^K1=^A]9V@>B!SUJT!M.8#RQ$MRC]X'4G/1Z$QS$B&Z*45
M5]+(HBA!4T_IZCB%0>=!:X&ZIJ,"^%T/#<?3Z#+O=(7V@UVDQ;U-L'D$M5-,
MP"W-75"_$:^,EH8L>9D;NN4Y2U%-:I2 00_I(M78@V]_/8W2577>E+*1=NUP
M!=1]LOT%MX2\^RA-MJ37E@\XV IM&G[(X9/8W'CDE89)L:R+*(VOCX& -((,
MBZ%PC"</(W";\-MI(%M\'#CW:2X(NY#E3^+-.FFK/W@'^T804N#TWX06/)?P
M)>KRKL?W6,%B'%UD/('Y1P"<:0L/. !P[..1F^72ZG;'-%<<EY;X6.SGK*=5
MLVW>=B/+RROBU)?I!>8G\M^!#D!]D'0AN+[X]B$"G!??_M!8N>= USY$.>4?
M:2HVUT=O>%Y)J_OV73J$0MNO9ONB9'NE?$K? :QK*,JO"7$M%I[7@*:SP M9
MFC$=C,:RSNE5(&U":;.0GL4&8\''>ZU>MN47/>;L;*_4V?.>ANQW:5\,-&N2
M69^B N]!&*)Z\=GT':HHZ,P=[J1QO?H+PADL9&7Y([0U#^VQ]$\+1 !4!@OH
MM7F_6G:I:4UX[L,<+_+#,"IACG\?(:7T$M -26=D+[L,D2YS:;;@JLN@BRT0
M;<R<)'W+,*ZBQ..H9FK4<",S5#<RZD9&W<B<WXV,J(Y7'-PPASM73$1UA[3L
M\,*=Q$6'EV!W'0\M_J%3>#-74AVMH7U)SVF.%WR 4%-U+QD)?,O,>&H2;3MJ
MUQ9YA*PS3%*Q%>0U/A+74+T[>*"NO757X;CZ9SPC$W!P[Z9?Z!W,'R&-T.>*
M>+Y@K\<<R[>/56&0%!_P%8T H#A]#WUC8VH]VL[+N^5W/EH^H.1W+7Q(BMK4
M0%?SS.B!SS-0F)1.Y!T ZF??FO_VJI(71N!L@D1%<7$0H_Z?5^:K RY*44$R
M*D3O>H+3CQ%>?F;OO1!\92'<KM2BT>H+VG!S61,?D("%W0JE@M3A.X'#=Q$U
M<B"3PU).L6H3JV[I)'C6?D!I2"5PE0O<1R\(E5*0FT>76! TMGGC"L4KF7GU
M)]8BR:RYEY:U%+'_J47_+Q6SK^!^,:(56_L?K(W1)WMZ2+HELC:=,ED3$R@A
MS$;!X]O,PN1]U_U:1*,O%Y>7-[?_2"_RM]-7"HI1BE$GR*A\#?[;O37^CMT-
MW4D#2.#Y[WX:CPF93C-WL$M4#+T25IDV>Z]HSZ4%UD'/+'_RS+*6X?7>-,0?
MA"+'8\(_5V].\N8-MPI?%_W-8^M_1_N,@^>?:0RK\'42LVQHV-9,)VZ+IQ.O
MH>+/!U 9];]9K#O80H8_%]85[_,ZUW>6!V1G9].4)@3_\+V@:$/[UE(_^_>]
M;D_O=X<KC>PEX,\YOKERF1R89<ID*NZ7=B'AWP[AW0$O'K%$BR6FYHKPKM+;
M&?;U=FMUM(0$G#S'-U<NO<->+1KUENPLD49WJ'>Z;>DD<BO,-Z7_5S/F^V3=
M8YXD-E0F2?:),'Q;+ZP;%H9U6-OT=[*/2E%==PM4=V[^7PG0S5BK:$IB]%[(
MK:,;PY9N#@I@M]/E_\D(W*!=HL =&I89^K!KZ.U!7XGF"8CFL%^'+MP#<YFZ
MV1[HP];J,%#IKDAD";#=3:?8!GNZ\%W6LR&3_2H#[#(*=T.)83_;E$)=1ZMI
M^L6"$_OQ>2_0U>X.]&Z_*XNB.8L75@:YUHX.WT[:#HVXS/90[[0+!,).5TQ.
M1BZ7RXXJT8+[A+B,H6ZTI7$[Y8]L?5C8#A:H!%+@JL(=>V))B]9?R>5D2R&J
M*A'5^K#"GAS>"TJ9>JO;T=MM:;RVLWAA96"J6X*@'1Q%#0=Z>ZBB5J<@D,-A
ME9IO'_BD][M=?=B6QHF4/UH5,0F[EV'C5-YX00(P5;BJ^N_ #__^S*9',%E;
M$<&;U.9JB5TU<K?5WFY;UH\#;LM0,;E*$62Q*$D)W-X+31IZV^B#6ZK0Y"D(
MW:!8GD]QH3LTLFR;/7!U%+(\ >'LMHJE]9:@$?= F<-A2^\/CQ-C'BC]S)W4
M"2EOO1![":'*D:1H/K=JYM!'=N]RGC7HIEC8 H6C5C1C#O3^8+#Q])Y9M=<9
M"^I@?1+.9D&M!@']E_C>Q IF:Z6YH>18R7$$GM8GUNZA</<)R<FO;G<-TJE&
M*NH0KAS"]EH/IAZ( R>NU=4'!7*IE'$X%[DTUV:^2!?3T=N&J0]ZFXN]E 2?
MB01WAFNCY75@F:[>'K;UEK$Y$'YH-'.0EO:J!['<ND,U %54V$R%PL'\P_8@
M-F1NTZ8TD#I[)W3V5 OBHV&5:D&L!$ZU(%8\4BV(CY17J@6Q:D%\3@U3%:,4
MHQ2C9+C.SC&(J@4Q+]SH" LWC%3AAJ%:$)]/P\QN6YQN4[80[)4)T!T.]6&G
M(UW+S#-]<_4MB,6W_#O*Y*&S #K]CF[T5 -M2=Y<N49MB7M4E:U1]\IF[.K]
M(CVJ5 OB(VE!;'0+PSK5@E@._Z^$TA1QQG_)C-ZO&Y[>:INZT=J<.7W"_#\9
M@1N(.V;L)G"'AF6&WFEW]'9'E=R>@&AV6^(V5B7KPKV:NG2'?;W?,V01-_D#
M;$?0@KBW=31-M2 ^;DW3Z1<+3ARP!;$Y;.L=4]FU4Y"VH;@0:R=I.S3B,HVV
M;A8)XYZNF)R*7'9;XC*6<K7@'G!KT-*-08$A6Q)B+=6!V.AO#:M4!^)C526=
M_OJHPF$[$!O]OM[K2..TG<4+*\-2Q:ZZ)>] W&GK_6Y+">3Q"V2W)>XM59+F
MVRM8-6RW]<%0&KTG?[!*W@[$XJ'S(C!U5!V(Q4-7<[>E.A"?K![M#(H%20[?
M@1@C<V9778:>@M -BZ7Y'$\'8K/;T]LM::8VG<4+*T.6XO;8%6C$O5!FJ]W3
MAQUI1$[^,)WJ07R./:,&Q0(7M?<@AM,+[H7,;:24H-;;W&Q]%H[J0:SD^!CD
MN-M:GUE[H![$\JM;U8-8'<+R>A"O=;#K@3A]'9:A#X:;YV8KXW N<FFNO:^6
M+JJC]TQ#'QB;G6PEP6<BP9WAVGO'.K!,1Q\:AM[J;TY2/32:6>Y!O'2/4WE/
M8HVNI\J>3<D;+Q<^WF"&,\*NIS3B3LA$6VY::M)$_)56ICK]8NB%EJ.-K;F-
M_R4_YO ,EKW_; 7:ZWQK+ZY@%$P479;/C^Q=5\FK@AMWO/!],OFP"&^]\'])
M^,6R)P5EM=%=$E8M@,,&[^L!!&^N @$-Y,K!K2!1UNRO<*G 0?>W>N,?[4_7
MX,5S K]\(LX+8_:C]6_/M\,7S9MJ<"C',\KD*6Q-FR_\\<P*0!SA;XZ@;+:I
M77L^%G? @WQ87VC93@#OF,)/H:?!O@B(N/;&>HO[TJYMUW+'1/M$Z$-M=^PL
M4#AM5_N=/+Z/E)2N435%F1$KJN;OO\)'RCI(FUN('\]IQ2)TRWT!LH^]!Q>#
MO.M$N/#0WV413B.?G3-Z>UW=[*TVK=]T[@HWO*EDT096OZYBK^7#!%(\2;V.
MZ<V -)DQ*M_D%!"OPBWQT;Q6T0(_[GHXOY_YR7H*M/?+@5#WCC7^G@)2VNCJ
MKU'CYO;RZG;$3K:H7^)U [/M"C45C!CSR]QZ((U[GUC?&]84'O-.LYQGZR7X
MY?T6+0I195G:S$=A^FET]_'ZXO;5^Q%E!:C4CRC3-,7(>L_56RYF.7JEES2O
M#$+?<Q_>_WGWZ69T<W?[]2_MT\WGF]'5Y>^_\C_5OQ@T50':+. )E2QT]KC!
ML@$$?0OA%SP?[&"+1&/[O]1,7*TQ$ZPE_<$6^>8U:CY0C0&S['^ ,H5_40(&
MVJ7G.+"!MP=88$K.Q?EHYE"<CU; .-ZXH>4^V'!2+V#?87!I!V/'"P#GC>!A
M'QQO_/V51@"DS>%+H;\@%?=P34YW6L"UKM;0DJ5J;*VELT(6<#5*P-'__#0P
MC?YOB#GCW5MT]\CPP Y"U,=SBZIC'3"Q[3HOFC4&].DS,4:D17\.;&K=X>,?
MB/-@6Z[V)^@+_%U3PS?RAVC83/">(+J++]\U[PF!\2QZ-U\5" ;LE"J<!>L@
MZP"D@&4P..[#@@D#Y /44&:+8<5F??P2GY?V[F#RVWA&)@N'W$U!Q8)^^ 0;
MGBP?(FHG\\]/N4-^!EUI9OP<+(5I36_JN+?6J\.'^Q1=CH@NDC4U7X%,,C<X
M/S-144?H*(Z0FL%S?#P[WV$\2DK4!)V39%8ZXT Q[4B8)OU,G3-H$[UQ3M#6
M?:1KF.*AVGLKOBF^G2[?Y&^.\,4*E]LA'%[(\S/_))7^/:1^39:U.)O57"IU
MX!P45SNLB</O63!OM#KP_S?W<1-F"9Z3^E0RG9+ICKA>LBR93@6QTH[4KE(^
M'+;U[G#'NAXEXV<JXVUQB5I9,KY/G9K1TKNMS=-E9)#GPZ5+J1MH=4VDZ"([
M720+ :YD<9]I.%!&45%'Z"B.D+J!/CZ>J1MH)27J!OJDF*5NH(^0:>H&6KK8
MDKH14WQ3?%-\4S?0Z@;Z2&\R.L6ZMQ_J!KH_T(WV<=QF*)F61J:+-8>7Y0:Z
M9^AF=\<.84K&SU3&V\4&X1[@!MHT>OJ@OV//1AENH%63L1+;%G7$G;<*5)JG
M=>O==%E =^XIVM6[@ADP&_H8=0K/Q*QG%T-#[W5689&@L9&5>G^VL=%I]HN(
M>S8$5%8=SWUH8%.&2=0U GO%P:)\"S4L_,DEVKT5V('V;(<S>+S_&-#&#7A,
M:.N&O!E8'?%H+X%D"T9[/;G^CT@Y7[BH?L&  .,6EA,U4]M:9W\EV/T"UIUI
M:0J+]B;&FO%8@Y7I6*&7O^G"C58$@[\DVK29,U66=0*Q7'>!_1/C[AZ94Q3P
M%AA)4Q 7R*%-87E<J8(T82<^SW&\Y^#=X;M]B+NP%=#!ZU!PBB173*^HMA_J
M%F/3+49\7N6]R=@(X\4D+3EF%A-*P_&&4HE;>6Y.)'LY4=D*Y9#M<M-%Z*'[
M'TL=U06ST98K-!"_62QXXO6\WN#-EQF8$D_H*<7X8GO!:V_A[]PLM:OWVIN]
M=JDO-PXR%0X8V)'K&&R.D)5Y/FJ)Z'8J/CCPV=UGPNN#WG&$;^6W*2/:P%[0
MZ5+B\]6&Q4^\!:QVMP,6-?I\G>KGN<V)6WG_5D<N>F7NT1./J]C^Z%52U+1,
ML)S#UC[7V/*!@G!S&H!! 70P3OQDD^= L\- $(\+/0VT,(ZH"&=6B.$4V]?&
M/-]8>\*D-Y!N7)@7:N0'**4)_]#4@O\!#GPG(?L<"]Y$:\!GV-BZ=1%JP6(\
MTRR^$AH6'8\]?T)G&M"XW\6WCUJ[U\*PC3==#8>S)_LD6#BTWVPXLX/H:7 X
MIK;_2)?%-J#!)KUD]?3S27M9'-* >[%AF;1';=X[F2@=0F!RXDBMUJYQI*^$
M7I=^L?SP9>1;;L .L*S=EGM:0^-+UNB:M?2B3[;M\C="V.2//AWZ,?8>'S'<
M&0)7-#L(%BCB'H@](\P<"&/#Z_#FA'YK0+_%/N[-*:ETD'8?2!>RCWW]]D>0
M_Z3L\9W!L; >?,)ZM[-3NOQJ?!\]6GS<"6T%[7N3Q9B_$%M$PY&%<_ZB!<1_
MLL?P+=:<&;L\@Q;P<2V >N#@T9_  -%O OFL!_IN^N,$3NHX]/RX\_.4P)/F
MU@N-:;X)@'+C=/_Y>\NARB68$5!R;YO:X0[SN<^/,+9,7U;S(]3\"#4_XJSF
M1[1;QJ[(YAN:NYGG@%8-<.15^(("M1G7T-?9+EB?"W"'\(>_Q]9XT+4.@WCZ
M@'@^,GM/=W2R&.="#+:SF2T(T:U%./-\FMT"RH&"%BW/2>[W"@5V\?[[':,R
M)?*W&8"0B_@]14?(]5+N,7U$D)DBUVKE3\D+Z,>1 AEP!WB*^RJY*3#]WMJV
M/GE;_ +'C'PA_C=K1M=9:(<WM]?9", 7OLWWK6:K)1B2!^XFVYJ>S,++W4A7
MG!V:-]]PB5W!#86O.T0RHCUT^_J@W];;_=68(=7BN0L?KIV+7L/"VWJ_;^IF
M3\ !+EC/!% U!_@Y;FU>9EDZ<ZE96DJ<+&HG#K/A+6?T1OI)H#E.9P0JOJ-N
M"&8DT4L%$W0P?/C]R:KBF": ?ZF<:G?4:]2N?A!_; <DX-#X1/>_E(N9FXKI
M>GEZ.WW<P <.%CA\$ZP5/I)P(N*7,C[YR67_[7"V#'6VU-D",8 3%)LK/CP9
MCDN^!19G/Q9( Z8\8!:8+8VE*#+3>H=#>/<PS/V^WNGF&^5EK4&S6I$R8RN8
M.>"N971%'+F3*8,Q)_]ZJWEE[  $-R )/\ADY%%N1$Y;75F+.X?3Q#>PU:2>
M1<KC$ASWK(:0+ --MB3'E9 (4[TW+OX!TX-Q/+:<%#VB%-(L<?FQEH2JBHU;
MLY&&"#2PAQJU9XJ1Q\I(!D<TAG)D8..^>=ZG5D"[:_Z>HL,A>XS\5#@Q_?!Y
MUXJ'X@V(4OP44X^<J=(>3/G3?/]IN0O+?]&,MM;0/EO^>*89PS5-E6L7Q9J0
MDSC<T5N^3LR/,[&:6D[.T<SV0T)<2M!;V\5_CYZ]T<Q;!)8[&3T#+'RY<TFZ
M')<Z4<R'BD.#V2)<>J7'XE>1'XMN+,91#6,EI4D*[DFGPLHKA>BUQ4F8!Y2-
MY9M&Y@#\,??<CSS &'U[GQBGWFMWI*M..M,W5R[D W$^17V"'8>/4?QHA&+O
MW(5VLT CL[,2HQ,6X)RJF?H%^.K'&!1PF6D@P\[F:5E2(]Z#5(E>DWN?0EY3
MP=P8YHK[DN1"F8B&>#KHJ5#(]I1T9EN<A%NO.-0"9LV6WA*D:4K Y'-\<_5H
M5ER]7JDP5P)@!TIF)7ES]0"V=SB9+1^S]G1CL)H@=6@^RA^GC5'K0*'6&+5V
M=X,I5_C<'<])_!$%7:74EFU3%IFH!;\:785?Y7ES]?BU0#"K$HFN ,1VFDIP
M97ES]2!V;<5<#8);/I+MZOT"S<:D1K*'C;\J))L@67%O_DI1"_B*Q9%L5R'9
MVI'LEJDGU<E$/4BVI4*Q$KVY>BB[15BK5)&N ,IV%925YLW50]GU\YZJ%]SR
MH:PQU#N=(^\X?>"HK-;0XA]4_FP"; N/:Q(<G.B'6]LEE:<9*(1;/\+=,>ND
M0N&H!>H.5-!6HC=7CW2WC7V5+MHJ>GO2;ZX>\@YED>#RL:_9T]O=OG2BK.*X
M1PEWQ9,H*XW9G0S$5>.D*2@^0%++H8!PMUC(5X9*7AD.B#3GH$QP7%,TK8:<
M7%,5E2FUGB?GW=8AY;R"D/% [W>/0W7O&D8^L>.X096?A_8138@[- M*'2*7
M"RNWS#"1"2::_6(]!V28-2>#S$LCV:>N7)1:.[1:ZXIG86RIRJJ#23D-H674
M7(6F9*JY:;NWL]QY;II9Z*T),]3<-#4W3<U-.]&Y:=4=IK5CR+0W\9BT\@E0
M:!H!?[\5 X#TJ#;!$+>IT;',WJMJ.22>\_'UVQ_:-Q*&3G3L3GG AQJHM/M
MH:V&G@R*3WUFP/</)/JS;\/!>+B(!OCF!,*KG(IB#ONZ.1 ,6=LT%B6(SQ!^
M!F<62S8,17S=NV88"KN>C2>AI&(F^-W1C"1JXV[Z-5@$FX=5DGY[;+9?;8+)
M:CZ*FAY0;'K 5P+_L,<,^>!Y1!@4:'_"K^68)J#8NOMT#Z9?)EI]('9E'6J^
MR+&+DG3S110;]V#CO^QP-B/.! &>-K)^R,!0-3!&S6-0/#PD#U\K'AX]#]4Y
M5#R4+JTJ)T!0084"&V=C=EFP31+IDTWNR\PQ*CP;>-/%//L[Y1_+?+RVG\A*
M*WYQMY(D?$&?3X,7+':A^NR=R)NKSTH7%[Q5*[V5)*6WY&NV>Z9OKEQHN^8!
MA;:"#'.E<B5Z<UG2VSCT7N0OK+V8^[:C&6T%6VO1F_V<ADY;Z4W*LVA^U.Y
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M7#H\Y2>(1F>'OSKG!)FM_MHA,=57A!DY^/KX6'H*8G*$)#H%LN>?SK6W934
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MQ;^-/PQO"XCC;'?9P=&=]0 +>@"MF&B#V((S@[5&5^;VMN^F8J#=ALEU)3N
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MEO-LO02_O"^2W,R?AG.-+6WFHRS]-+K[>'UQ^^K]B+("X,E'/$UT\I'UGL]
MSLU4.Q87JO@0]C_O/MV,;NYNO_ZE?;KY?#.ZNCS@1'@<%$J=!N )E2P**J]M
MUW+'MN6PT?"/I(J1M,47B2.E_Y>.D[Y:,]R5WS4=:I%O7J,G!*H5!QG;KO8'
MZ%+X%R5@H%T"K(0-E#].?O,"#W9)B+)%9SZS$<_W*R.>M3>QGUDC822X/ETW
M^KE2HA0:4YP>L$YQ4'J2N&#&N-$;FQU2\?2\ W+M P&/4+/!CUX:6!WYD[&C
M;:-?,J':*#VQVJ*1G!6MQ;Q\X8SKF?5$,!$WFCEKL6SVS&7:H)4$#.@K+5>S
M'AY\\@ :9_6K/GED-XB4@PCA,'W2L:?T>>VFV6'.X-*J2*I*:-.J&&?HV@:9
MB[Y#S]@N?(F3\36^)6P&DD3GD_J>DPMWDJH-KWBB]JXH]#1F0M;^POQIM8H*
MB@K+DXLE'5@LX[ARQ< M&/C%]\:$3- YDX%W9S%M6B+I5%0X@C,:A>!E.*"*
M<5LP[FOD#"G.'1GGHDMQ>RH#ZPH&\\6TK)ERK.&##%13 J_8=NILH[?RFF+;
MD;'M8Q(;5;P[,M[%'<VE.':[W?,G-_Q28(94C'LM386-;L[FB.S&2L%YR08
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MP<<:(JT_7+O:;E/O=%M JM5.@;@QH B\@#2CF<0G=A@*3"",A]@&D>>P(B5
MIR?X!IBC!#=&PVXGQ8Y;4[OZ,2;S$./Q="+I,YI-UP,YTL4O1><&_)#XC7S>
M)=O#/8$M,8<EAM54?!,'I8!HIR2[/L;GX;V<]GYK9B,RMY5R\^5N>A'S<>1=
MQ<2\1%K&^7Y;SD!<2D$2[&ROV8>B;."\%+URIM8()]5L3!#LE/7ZPD-S8EYN
M&+AUGM1A^%Z[B8=&*R*M$HF"C"@4*S^!VK43B-YD'X'HU$^96_AZ8D$4B7)G
MV"&5$#T**+3;'7AR^RW.KJZ0R.GK+2''#Y(/?S R(&Z*R;"Z\$,(NWQ$PKR9
M8R%2S0KBITUGZ%0H4M(IJD^E2+7M4Y&"PN="- YTU[K)>E;^QGY[*.;5Q!IQ
M1&+8W;(\*QW6C!W8^-HB$[2@%T,LL!.'GR8TZIV.\>%O:"KFQ'K!, YQ7[W_
MY\+1C$[41'RIC.DLV=06I_.6P:9H1!#WL]'<8X*+<9Z4%_2P%H]-*X/T)=\5
MF$,S9Z#?8<W2AI+W"IG*UY1SJ'(K+/;G;.JC- 1Q65COF33?W5BY;J\+4LG*
MK/Z6+9*+,6OOJ]YL$'X;%IM%67SJ"M;8LE-?39Q%0_B9WAB/+9: ,O;I%RPG
M_:2/7A#NW*2R8^IF7U1B+F/WHG/4.CWQ_?9VLCEZ]A0\KA8>EX'1Q&Q2\'@#
M/"[#+HM)7S(\[NEMX? Z!8Z%X'C+[LY;\'4W</S9\GDF>]+768%C#H[%.8Y[
M,JMV<)RPV"S*XE-7K\:6[4%KXFP=X%@WNJ)F8R4&E!4TW@<:EQ&2'&$IO@+'
MU8+C4A!:#J,4/-X CTNQS#G$+QD@#S9H7 60,P"YC+!5'F=W@\C?R%PS%4(6
M(N0R8OT";M6.D6,>*X@<0>0RKK"K8&T-(+FGMUJK-2\J?BR+VNF5$9C,:8:[
M.T:F.L10&#F%D<N :3E\RH/(ZOZ/0^0R3',.[<NNQFR+6VTJC)R#D<N(7N6P
M=C>(?#'WXR:G"B,O8>0R0OZKW*H=(B<\;A?E\:GK6+.,>^P*6%L#1#9Z;7W8
M$8UE.Y;4Y,/E)A]>8^4"ZS*"FM< QQ2PKA98EP+NQ'Q2P'H#L"[%GHMI7W;H
M>:B#GE:XNBBN+B/DE</9'5.7+3=*71[(<OQDYV).#ZU]N5A_3G/,>U,:WA\:
M;Y=Q.5X!:VO VV9'-X:=:F/2"F[7#;?+B(]^LW\HM%TMVBX#\8G9I,#V!K!=
MAC$7D[[L('9KH+=ZJPTUSU?KK8=IW3)B9V+.[H:UK\D]CV\:?5E.G^Q,[)=Q
M$['"Q-JA=L)Z4QK6'QIJEW'%7CYGZXALFWV];Y26_J%RI,M/_R@C^OF-/!%1
M!_#=@?.M]Q2-53M+);**FTL!;SE\4LAY W(NQ33G$+]D[-SOB<>[*-B5@YW+
MB(/E\7:/#) N1<\]64Z@[&SLEW'?(&#C85)#*/--:9A_:/Q<QDUZ%;RM 4$/
M!QV]:Y169:@2J,M'T&5$-*_P50I!5XJ@RP!Q>7Q2"'H#@B[#/.<1OV0$;:@,
MZJT =!G1K3S6[MJE+D[U*(JASL9<#<JX*Q"PZP!]ZN*<#@64.5 NXPZ\"M[6
M$6H>ZMV!J2+-TBJ>G/&:VPGGK5UR(V<%DY=A<AE(+8=-"B5OJ!,OPS;GT+YD
MD-Q54>:M0'(9(:P<SNZ>#FULE:%Q-I9J4,:5P"JS#I+U;*A,C#1 +N.VNP+.
MUH"/VSB =EU*G8HC'Q@?E])'4>5A5 N/.Z6TVU99&+N@XU+:.=:1@]$>]/5A
M>UV%B4+'&71<2@O"$C,PL,UONZ70L1 =E]+)_N!Y%@F+%3J.T'$I#=6/,<O"
M-#OZL*5Z.<NK=7JE7" [*E&Y<H!<!DK+993"R!LP<BF7\7G4+WO<B='5!VTU
M\*0P3"XC>I7+W-JZ:IR-S1J4$?07\4OUSSB\IC7+N,ZNA+EUX&6CK?<Z*IHL
MK^[IES,6D#@E]Y^[)&-MH/!R"B^7,Q@PAU$*+V_ R^7,!LRA?LEXN6.JS.2M
M\'(Y P)SF*NZ.Y>.E\N9$;C*+]7?^?":UBQG3& %S*TC.7G0TLVUHUU5?/G
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M8@)BP^)!+MJUJ;P-NZJ6K\OS\BJ7HF5QF?ODR?86@?.BT2 F" [(UR494X]
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M#-LP9AULD=>>K_TO-5E75 W%2JK-E(])E10+%AYLD6]>HYT&GPBPH@9:\@^
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MHN&LY?2\*KF2,_/0Z(AG=^;F; HF<:Y,LZ6WOH()=Y@68717TD3.A?BK.4E
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M-"092L\PJLV(DBP1)7&&@ [/ )@'OV' AJ\0^A\/["W=!+09!K.XB,]!C,R
M<EV\%D#?QP^7>=H "$;R><0<Z7A:>&'(?B%M_]<O747N?'1BF"$%F3,J_Y<&
M"@"(459XXFM75([B%9\.\%DA^')I5UMZU09*SE@CDYZ2.0GC_<H@YJ;2E+I)
MQ+PD(!%(\!KZ;"'4UJ5I]?25P;DLIJJX-:"#(P$6@+JSD%-*M[\J6^"E#J:
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M7(CLI !"A5N(18I%A&BISYMW0955&338HO0[F*TWELV,UOPE_'4DR)(GZ=?
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M+\4E'*_LCI><W_%ZFNBV2^G.8X9"?QVN2(FCP/R^UV8*+%^)=842.SB*6W?
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M-R6WR*SN7"U9NH=(O0APNDM1+WJQ:D1HI50J[8#0\@CQ'?;!'AGA'9&G6RF
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M*=/MI1B_40+IU"HTU5-Z4C.F\[D\PZ>L*'$50"W73%(Z7:FK5A:=2CV!L@Y
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M07<)ZC+# $F<7%H0H)<GJK<C:)8>!VBI;:DMK[/[T>4?-K*IRZ:Z!F2"NM5
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M"]D9?DMG.JA)BJ558)@_(\,-@Z>#3 !WU"9?IH/?PQRN_\L@C2N1@>:;)=_
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M+@WS\Y\M@!!S<H)8*V](>_%C-FRRC9\?X2GU,YZSU'C<>.%8* VY1>X-K!0
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M$V7GW,U]:D>2U;A><Y,S+%["YY1_><:<!*8NZGI]K-/1&I]S5O#C?IC-!SX
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MWB#KK)F?0HL9),;[+</<],7BO?U0 '%\!HG7^\N+_N=%YO76#*4I3W.OWC^
M;[8+L_C&XGJ9'Q#)E ?? OF&"3%.$LL-92-67I*<^P_ [TOWH+-\4>87P0P
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MX:DZZSNN;?FC\$,59@[($,$0P1"/9Z9*O7@\$P$4 30M#CC*1_F[+#^-@(@
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MI<U56H#+,Z5M .A2(% V/L?]$+#\"%SGA2,C\M"^IEV0;U#!'BEW.6N3ZC-
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MY!)3,7FH^A'D-;#/B/-8$UD^@WL,X:];##S,C,#(8Q9DL&?XK=>EL8#__TT
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M[QQ6,65$JG%3@R"DQQ^]J526PC> 2L^D!4FJC"M#?[T-,2K:W?,[PA5\86Y
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MZF_4'G?V\?0S3BIW%'>7^REAQJ1MRT7'*J0+X4X:H4.V7W4J<\!2MQ3(BS>
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M[B_2<9Z'-..:4YNI6XD@3U2J(6OM] O2%OL$Q:XJGZY6'$.QJU^E061>:?V
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M[VY(>E-N7+H,UYT5JC*GH>O+(7B*&XEMZAC^O0 J2KE+[R]+X&,MR\D,D;I
MRL.T&@M=#:#>! 2!90#-$"V[@M.<_U[XUA7#D&$TU G'0NZ#H626E9V=Z\^4
M0K9^3$/]O&0WWI1D<_%FRGG?.!N?HRI[<MI>K7 A3K\/X.V,S1;K^B?C)O,&
MB^.K:[ ,H.X*ES>V+<SS9NZ50:!N/$9T-:GY15QYOCOZ1/Y$</KX4(^/$&#\
M&>B!H>/.)VY\@87_>YZ_<_+([MKX"UWVJ2OI=Z: T_D&JT)Q.^:1.4\'ZW8#
M0"KG8ZLM54Q&C/9![+#U]5%BJW! 12JZ"=6?,WM?V5 6AV'M'V7KN,0+]4$+
M92V)<7(B]WYM95;S68?&NF0%6\?16ZI(4]YN+SDOXJ](0VW$GYA<E_R_(_75
M0+G3<PZU\%]]]]&WIF?_[?,7S/+[D[A(PG(<XE6I 60AB!U-M:\D7.R:X<_&
M\/Z:!F]W5E_@[')?")F/R:YB89T[V6880#3D0W9I R@+<PE1$TND8I>PJ'F^
M#>&"?&Y >Y+Y>.56FHG,P3VH]ZG #(.50<S(X[-'+6<:,$+Y>,'"BX3O%8[1
MYKHE4L!<IJBL'H(]5/!AG"XHP\W!GI<9P5-U7)+O;@:<?(B<J+[?H<;-T<J8
M2J@^7?V=G!=DIH^FLV(X<2-IX>+E^(BH]YW\(YZ2AY<\IC6=C@L=M&+JKW^G
MJ7R_'7?T39+43(3*X#2A-DO*L5P^VO2;F#IE'*I,+,5DL/>2(>7OH>TU 1TM
M!VZ%B DD_C!=XPM%J-]O':7B?3AL^I=G\Z7Z'D>>['X_,756743M3UBYSLC;
MRO>C_$S.W]TAJ>%Y&#$+[\I=U7YO&W ?;1>;)M/Y=4M5AU+T\C9>_?ZKR7#=
MR?)'@-P30)XCJ+_3/91=Q0056/C1N,4LM#=!#7,G;\CS\--V,(J9B_<D3?Y-
M"]\ZL4WINK1RRMNM%Y:<YSOZ$_B6@&Q)0#&.9%EJ\P+X:.3]WE^9V7%..HT
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MU/??2,2,WN$W:(G?[,(V3!GS?2O.#O>&@;Y4J(:@W^%V):%?CWTM0"Y2 6[
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MXXB#G&"0&76XJJ;^-2RH!P?NT!^*U@@K*H^FG@*,H!!8=,T0IA]L.*H7BG%
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M4^/6#PW&@,W^4NIFO_[O_P1)4@Y>>5&WU<0!::%E^F]>J2?_-:=I#()B#Z]
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M.0VN<#X5T.@\S@?Y#DLL<T\V9\&J*--!)BQ^(MCY]=';<T$NO+Z@RULQT%.
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M_EN!(!Q]D7'U(M8T*<"1> GH@(OF0$0Z@F6##%#RZS!SQ9W)WU:_I99N_;#
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MJM7'E(_[C\,,#7V.>#'MB\<#VR8@?R)OY\5B#;C5EN!+_&POQ9J[M];9WZ]
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M"QP!(\'M QID00;X =>-6FK)@MOFO\>.5ZD_9/W7D9H[!.4Q=OY'-U_ Q"Z
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MVTMG03'$^KP2@[P+HE,U<1QF[%3CE/H6+9 $+7J4YY?VIJVM3;0?,'-&IS&
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MV-A!T_J'VA(+%355#)#EM7J]5(Q!_]/, ]S4O2D77R4L[X@S[?8H?2F[O'N
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MV$D8.NRZP^]GWXV]F-AW;E2.4I\M8!"6-'\>"@M.C7U21P=.1KVX[=38]9T
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MC2BI7DW3"1_;:^].-G59"7*15"1JW5YBXE!$3I&21)X*0D["J7J:$/O>E^V
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M"9C+O"LBNMLLZ"#_YOB;#@$LXA(\QM\H]%:(L@;LBSD"FP5E:7O2R;^QQB5
M '0FI/58N2BRLJ08/#@+>LT^<6L&_XF*ICMIUB,7JWV8(@F[]G M0R6OORM!
M3J\#[ V4%L.2K\8JI60VN=WB!V=]F\9J8?18;4%O=X[6/L%L;#*;BK@"6%LZ
M ;AD=]'HU'W]F1A*Z=_J;YB=*(@<WU$CFAI#A=&6(A59_OA_CO/.=AVZ._(0
MTP I;;IL0$QDHV.3U11_7XVWY OXV97I=IN?I04W".@.3*T9'D"NY"92&ROV
M1+J#4O(L\ B@$-DQ" XO0Z\$CZMU";$.@2FOL.3O4FFNHO%WU;;K=X\W[2LL
MC2^<!3%/?&),A>MJ+W'N.)V'QL>D[F,Q'7?&,,H0_,J(4H:2NB"OA[<R %X$
M=N[DK6T-?HN!#6CQPU -:9X76R]0 U"ZB/?I6E7&.L?&<S! L.R&47-@Z?R*
M-R2>/L3-^"0MD&$QVN&ZW\>?!$41B&5Y%YQ#2H?+_,N99;L?O3^-RKF HAG
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M5C_55#J=MNE[],>'/;UU5Y,=U)RI]?/L1:CC)@4+DX"_(LUY4&#XT_F_!29
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MK )*81<"XX3#N;FX!;FY!15$A445_N> 7@$$-[ &8>PP1<"&@+$C8% KD <
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M&$,B2[W!3$C!_TF]M,,C!8$_Y X$XV1K)KET^^GV/ 02\1_'&<)Z$-@6LX%
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M:<9XC1GSOU/W=#N=====Y]ZU[G>O_W_M[]Y[??_[LW[_M3?4!?4!N4UVCG8
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M2@F;_,^_U^].*;$N,"^3(D8DOB10DX<M[E*35YUPML6<$#GP_=&9:FP06G5
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M<)#<3)H_SRVQ*'R8A>X[*O2F\[LA$'>4CIN"=1+82J*?A31K8[X- I9J-A"
M>?/UIW)$*;$D/=QG*5%6_,Q;"-S@X$QQO]DLEE14RA)4X4;YCB]_*:W[2^<&
M6_Y="%3K?DL=#ZDFA#+G" I??'\M_E-K2CMA#>XST?Q;)B_S\_]#9>$ER#JS
M?/:R/4>+>=EDTO2TJ7AER,G TMT,S:LOC/H<U4%^Q,9^AATOI>7N_8;.S.R'
M01V[KR0-'PA'%>&?YT ]?P)02P,$%     @ .8)O5C=?*BX&"@  9@L  !
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MC)5-ZA@[_QD<Y)JG@+1:"!2N%Y=.JN60.6ZVA+"_W<$IB,*,RBX?H'TE^^_
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M ^?&YFQB*B6*DOR]?];.O&G+7>8\4?&X$B=RL>\,N7Z/0FAQO+2ZFNO\?(9
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MU1'$0KB5^=4B7PN2P)U;C$]_!U!+ P04    "  Y@F]6F3,QRGPD   CO@
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M,>IJ 2*J (T7Y-X2%&64869 R$$JTC(&V!K\]<.6VK9,9=-$MQ\PM8XV4^O
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MSA)H VR=B\&___!\K_-L;V\;S1"Q4C(/O?&OL$,_I+K3/?C1CV8A5W2X="J
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M;.FM>;P[UUEH=%!9*+LXD8;Z20'&! MT,+R.BQ:!W)]0YF+J_I@$OG2?=XG
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M&VTXPK=<0][,;-P?9;S,!9 -)=SMFQNJVNI:-OS.= K(GF(C$8>'*"'B?,:
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M*I^ 'L0UK=T=,E-@]=!?"2CT"%BB&,&"0IQ&;I6YYFVKSB5>[(J!^]STG_,
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ML4([B(#!F/J_\-=%_Y?>+]VWE,H5]=]]XYE8#57:^G@XF(2M,U,4EU /,*K
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M;6_:,!#'O\J-BJF3%AXJ59U"&@D&I5EYF""MNKV9G.0(UAP[<@R%?OHYX:%
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M"*7V]1GTBW7AB-W>L*LC(P_D^*9Y<,#=H18 Y2D'JVM?'<?(1)SM";9:7W>
MXFG*XI>+POF1Q0T679R0Y CB@8'81*G[3:$9>=?'A6]OL,W3?L3MT'!CPB,,
M^BC'U->/[G6GY<#W-5_<7-&G],/1YB;^:CAO_0DK^Y)I_P%02P,$%     @
M.8)O5KJS3G&R @  7PD   X   !V;G)X7V5X,C,Q+FAT;=56;6_:,!#^*[=*
MJU:)$)(0H)!%2B&P:! J2*=N7R:3&/"4V)'MK+!?/X< I9OVIK65^B&6[;M[
M[GG.SB7.6F:IZZPQ2EQ'$IEB]ROEF\]X8UI&71D=O=IU7FG:@,5%AJF$F&,D
M<0*%('0%_F#DS29(2,PUS77T"FS!DBT(N4WQV[/(OXTT;QR,PBZD>"E[,)R&
M41>,1BY!D@P+H/@..,L0[<'$FXT"Y=G(-]!^?>8Z^0%GR:C4!/F&NV5D;[=<
MHHRDV^Z/*!GB*T*["N/,/:<+D?? T7,7[L%*"MH\^.17/"I.VM";!../W=^S
M.CY$&23>2 VE9$6[G*S6LJ<8"\D97;G^[;O@*HC M.J&H^\W'XW&@]1?"B')
M<ML[J'UZL;&Z"9B?J'4*MS\-YWX8P70(03CPKWTUJ.7,'P7SR)_Y [B^N1H'
M??#Z_>E-& 7A"(;!;.+HA?NK OW7H3]]&>X+'S&0:PQ>D1 )?99E1$J,GY/!
M!Y8221B=;6!,5'J<O-1:>@((37".U: :#L<K4O87U7/R8I&2&% <LX)*1*6H
MP1V&M3(NMA S*LH 69T%H3'C.>.HK HH.\=+Y4AC#&P)K.!J0YDE)+M^-D$\
M7H-AU\!LF%:M1).(4&4A5.$1 8C2 J6'*(4Y9#RKRF,TM/=P1^1:646.XR.)
MDI,ZF"K%DE!$8Z(PA%0;93L5)9>?CZY6)B7*6HG?:SB-.LT^URQX,SOUG!\\
M(62B#I9E:<:E;1I*5SDWS;;9[!SG;<O8SZV69=E*:%(M[<MVQ[K8K?^!3.?/
M9,Q&QS;,?5*C:1A',D;#;AZ)V2W[A%AK/[<[AF7=DVRU6Y?F1?VEWG8'9ZXN
M=)BC),6\!B.R6, YRM1'RQ."J>LBL;KFXW'?T97K2Y7Y-_*>C\W#E_VQ:[K[
M_W&_ U!+ P04    "  Y@F]6Y%)R?(P'   G)@  #@   '9N<GA?97@S,3$N
M:'1M[5IM;R(Y$OXKOJQFE9%@ F&C70&+1)+.#+I)6!%F-7M?3J;;#;ZXV[UV
M-R_[Z^\I=P.= !-R":O,*1]"TNURN<I^JNHID_8DC52G/1$\Z+13F2K1F<9F
M_F\Q;]3K'S#8/LG?MO]1K5YJ/XM$G#+?")Z*@&56QF/F77[L#JZY386I5COM
MDUS92 <+9M.%$K\>#;VOPVKW<^_C39,I$:8M=M6_&399O9:D+)61L"P6,V9T
MQ.,6N^X./O8@64OF[.=W1YUVLM03ZCBM6OF7:-+,EGL,>235HOE02\3-6,9-
MZ#CJ_!B/;-)B[9.DP];*R(3J;>]?7FY';E/UJGO=^_Q'\]M6K7XD!E(Q3ZM<
MR7'<-'(\25NPV*9&Q^..]_53[[PW9(WZAWK[I'CYP(QG^?1B+MUSP\<9"U/R
MX\(;#'M7O8ONL->_8?TK=O&IYUTQ[ZMW\678^]W#*XQZ [;+R4,9]MN7P>V7
M[LV0#?OLUKL@\_*-:=1.R<[A)X_==@?GW1OOMMK_^MG[@W4OAC1R6JN=KJQ]
M"(W7<28[8?:?S*8R7& ?>A5VP2,!)]A +&*M EMAOC TS-()3YLO[UG*1THL
M]8VT"1#V-N$^4D&SUBJ9Z2*=5FANC?.9#-()AFKOCF"R4@D/ NCX]:AV1*N8
MY1(305'5K)^1(1@(E@.Y@I_>M:;DL,]5L6ZJD]91V>FR)_4/Y 6R6G!/UV,J
M=B&R=!1LPJ>"&3&58H;<F$ZD93R.,Z[P,M$F93BE*VTBX*#Z3Z9#]KM6,I4Z
M'LS99QE)9-36RCA\F&]OPT[S7+;MW5QZE&(;NRU>'^IJ.Y[F\@,%CYO\<KM]
M>JAC/.<6AX>3BA;L+M8S)8*QJ.2G61QCH G'&F40V.8RQBDO6!:G)J.P0&%T
M-1+GRUF$)R.!@)#[>&68QC&S5.=R&P*Q\(6UW"Q().)W NN6=%J\"V ,EE2T
ML[0&"?C2H#!#+,9T6(*(9+.)]"?,9O2QGC\31A1*R(%(6H5B345\)M,)'+2)
M\)V!I#>!:3J F]A6;,IH4=Z&-ZCNN73C;X>J8*&, 0;"U?KP*\ IQ#%L2N,R
M#I&2.*4A_.VK+(!. *QTTA6 4QJU8 GP0= FR"NUQFX!&_M@:81'X/);A20R
M!0$ 5@-5;CGK[/&YG;!0Z9E=HMF(L41=YEB(T\O<;EA9*8'2+HW9L/8-EWLN
M_=.A<#F\=X@__O#+:?WGEBV05Y 32CDZ#"4>W?'V&#?" 0G D$0P<.!,6"(;
MTDY(G,0BI%M*N?0<2.LK;3/,HT1LM,H1E1CMBP"O+3L&@ (!1.8H\>;^A,=C
MP;K(<8-,0:+>X-7ZV;%X[Z;6SX+\*7^4Q#;C',FDGU$B+ $\!QS9LO="X;V%
M0BQ$?CZ$/22(3#3OXP(?1+U6[<SK(V([6=>6.'D6BSOF[P\$WDMA\0+'Z$KG
MXQBK4%7W>6;WGT+E=22 EV*EO& CB=L,R6TJK4N9$!*Q4T,\?IULRPG;",4=
M_HJ"O<90I4CF-"B1>&&*!=L,7-MNLY&5@>1&DOTRIQ6NA,2D*;-4ZEVX6L<+
M7(+55L"@% F=)B6<-CI3G.H"O')&K"D#9N0$I,R;\-=(D"!2-^:_$-M]=EY^
MO;G^V3Z_7%@<C_Z>@-L[Y6[$W?[)>FOXZ<QLQ!]"=BH#"BMN=>RR+;<(2>+9
M%&O<!$O<(Q(E'TGT<POB,=N6I23@0L2A/P_@>Z(EGNZ*W[QP*,E,@NBSCG?Y
M/A*],\ Q]K&(0:<4@A C(J'H)A%T(WF@(0O(!/7G+=2^GU#S#Q5JWI2KS%4
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M9;PH+\,[5/<<^O2;0U6P0,8  ^%JO?D5X!3F:#:E=AD'H"1.-(2_/97Y\ F
ME7:Z G!*HQ8L 3X(V@1YI=;8+6!C'PR-]/ =OU7((E,P & U4.6&LRX>C]N0
M!4K/[!+-1DPD:C+'0)Q>YG$CRDH)E'89S*-HWW&YY] _'0J7HXU-_/&'?S;J
M/[=L@;Q"G!#EZ""0>'3;VV?<" <D $.2P,"&,V%);$@;DCF91:!;HEQZ]J7U
ME+89^A$1&ZUR1"5&>\+':\N. 2!? )$Y2GIS+^3Q1+ N.&Z8*5C43WFU?G8L
M/KJN]3,_?\H?)2G-.$<R^6=$A"6 YX"C6/8>*-@8*,! -,^'L(<%B8GF)B[P
M0=*KP,Q;%&([5=>6/'F1BCOF'P\$WDMA\0+;Z$KGTQBK4%7W>&;W[T+E=2R
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MME#ZZ +H 1B57)Y8:!.;15A(^9=PDREJR-;[UG?I\7U)CX,=@;M0&($!\U4
M4.'(&A!W7] 4N5#)"[2,IUI-!57IF$^*[YE,P>\B2I1>"+3.0IV3.M_(-&3&
MJTB83R]AS8.SY%F-:/(2"]<L(KKA!DE?/ZNP1JUQNH,?3ZG7^:+YJ/E\,+SL
M#:OG@]%H<--D8\6]>U9/YLS=IQ51GYY1][:(.B?V9./K^/8)7NX8L]YPO9Z?
M"4\P_]\T?:4?:)3DR,8ZE$==1K+?S$O66Y\/.8>+4(J 7:VR8%"23B,J(CB1
M&O;UV2TSY#5_A^%^$]7Y/U!+ P04    "  Y@F]6^IL&QV($  ">$@  #@
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MD86@XMNOF/+OH\$_4$L! A0#%     @ .8)O5DY (=J5'@  8HX! !$
M         ( !     '9N<G@M,C R,C$R,S$N>'-D4$L! A0#%     @ .8)O
M5E*";+IY$   @,@  !4              ( !Q!X  '9N<G@M,C R,C$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( #F";U;IN>BBH3\   :*!  5
M  "  7 O  !V;G)X+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  Y@F]6
M"G#7O>^*  !O40< %0              @ %$;P  =FYR>"TR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ .8)O5GK _T6F<   PEX& !4
M ( !9OH  '9N<G@M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( #F";U;]
MH:$._5(" /=;'@ ,              "  3]K 0!V;G)X7S$P:RYH=&U02P$"
M% ,4    "  Y@F]6UH*%;K<!  !W @  $               @ %FO@, =FYR
M>%\Q,&MI;6<Q+FIP9U!+ 0(4 Q0    ( #F";U8ZDN- )$$  +!$   0
M          "  4O  P!V;G)X7S$P:VEM9S(N:G!G4$L! A0#%     @ .8)O
M5K)+I"IC+   ##   !               ( !G0$$ '9N<GA?,3!K:6UG,RYJ
M<&=02P$"% ,4    "  Y@F]6FFYG%4A"   <2   $               @ $N
M+@0 =FYR>%\Q,&MI;6<T+FIP9U!+ 0(4 Q0    ( #F";U8!&-@P! T   0.
M   0              "  :1P! !V;G)X7S$P:VEM9S4N:G!G4$L! A0#%
M  @ .8)O5NCI>_?8"   'PH  !               ( !UGT$ '9N<GA?,3!K
M:6UG-BYJ<&=02P$"% ,4    "  Y@F]6P>I$1A4)  ##"@  $
M    @ '<A@0 =FYR>%\Q,&MI;6<W+FIP9U!+ 0(4 Q0    ( #F";U9>4R+X
MS @  &$*   0              "  1^0! !V;G)X7S$P:VEM9S@N:G!G4$L!
M A0#%     @ .8)O5C=?*BX&"@  9@L  !               ( !&9D$ '9N
M<GA?,3!K:6UG.2YJ<&=02P$"% ,4    "  Y@F]6F3,QRGPD   CO@  #P
M            @ %-HP0 =FYR>%]E>#$P,C<N:'1M4$L! A0#%     @ .8)O
M5DF!S.$B P  *1T   X              ( !]L<$ '9N<GA?97@R,3$N:'1M
M4$L! A0#%     @ .8)O5KJS3G&R @  7PD   X              ( !1,L$
M '9N<GA?97@R,S$N:'1M4$L! A0#%     @ .8)O5N12<GR,!P  )R8   X
M             ( !(LX$ '9N<GA?97@S,3$N:'1M4$L! A0#%     @ .8)O
M5@M=O,MS!P  <R4   X              ( !VM4$ '9N<GA?97@S,3(N:'1M
M4$L! A0#%     @ .8)O5OJ;!L=B!   GA(   X              ( !>=T$
E '9N<GA?97@S,C$N:'1M4$L%!@     5 !4 ' 4   ?B!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
